<!DOCTYPE html> <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease - Lo, C - 2018 | Cochrane Library</title> <meta property="og:title" content="Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease - Lo, C - 2018 | Cochrane Library" /> <meta property="og:url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011798.pub2/references" /> <meta property="og:type" content="article" /> <meta property=”og:image” content=”https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png” /> <meta content="initial-scale=1.0, width=device-width" name="viewport" /> <meta name="dc.identifier" scheme="DOI" content="10.1002/14651858.CD011798.pub2" /> <meta name="citation_title" content="Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease" /> <meta name="citation_author" content="Clement Lo" /> <meta name="citation_author" content="Tadashi Toyama" /> <meta name="citation_author" content="Ying Wang" /> <meta name="citation_author_institution" content="The George Institute for Global Health, UNSW Sydney" /> <meta name="citation_author" content="Jin Lin" /> <meta name="citation_author_institution" content="Beijing Friendship Hospital, Capital Medical University" /> <meta name="citation_author" content="Yoichiro Hirakawa" /> <meta name="citation_author_institution" content="The George Institute for Global Health, UNSW Sydney" /> <meta name="citation_author" content="Min Jun" /> <meta name="citation_author_institution" content="The George Institute for Global Health, UNSW Sydney" /> <meta name="citation_author" content="Alan Cass" /> <meta name="citation_author_institution" content="Menzies School of Health Research" /> <meta name="citation_author" content="Carmel M Hawley" /> <meta name="citation_author_institution" content="Princess Alexandra Hospital" /> <meta name="citation_author" content="Helen Pilmore" /> <meta name="citation_author" content="Sunil V Badve" /> <meta name="citation_author_institution" content="St George Hospital" /> <meta name="citation_author" content="Vlado Perkovic" /> <meta name="citation_author_institution" content="The George Institute for Global Health, UNSW Sydney" /> <meta name="citation_author" content="Sophia Zoungas" /> <meta name="citation_author_email" content="szoungas@georgeinstitute.org.au" /> <meta name="citation_journal_title" content="Cochrane Database of Systematic Reviews" /> <meta name="citation_publisher" content="John Wiley &amp; Sons, Ltd" /> <meta name="citation_issue" content="9" /> <meta name="citation_doi" content="10.1002/14651858.CD011798.pub2" /> <meta name="citation_date" content="2018" /> <meta name="citation_online_date" content="2018/09/24" /> <meta name="citation_abstract_html_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011798.pub2/abstract" /> <meta name="citation_fulltext_html_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011798.pub2/full" /> <meta name="citation_pdf_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011798.pub2/pdf/CDSR/CD011798/CD011798.pdf" /> <meta name="citation_issn" content="1465-1858" /> <meta name="citation_language" content="en" /> <meta name="citation_keywords" content="Cause of Death; Diabetes Mellitus [blood, *drug therapy, mortality]; Diabetic Nephropathies [blood, *drug therapy, mortality]; Dipeptidyl‐Peptidase IV Inhibitors [therapeutic use]; Glipizide [adverse effects, therapeutic use]; Glucagon‐Like Peptide 1 [agonists]; Glycated Hemoglobin A [drug effects]; Hypoglycemic Agents [adverse effects, *therapeutic use]; Insulin [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic [blood, *drug therapy, mortality]; Sitagliptin Phosphate [adverse effects, therapeutic use]; Sodium‐Glucose Transporter 2; Sodium‐Glucose Transporter 2 Inhibitors; Thiazolidinediones [therapeutic use]" /> <script type="text/javascript" src="//script.crazyegg.com/pages/scripts/0056/6375.js" async="async"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <script type="text/javascript">var o={auth:{customerIds:["P#DRAAEAC","EAL00000056729","DRAA3TITLES","TSINGH009S","EAL0001468","EAL00000045347"],individualId:null,brandedCustomer:"EAL0001468",roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=UTF-8" http-equiv="content-type" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/favicon.ico" rel="Shortcut Icon" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" rel="canonical" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;zh&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="zh-CN" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;zh_TW&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="zh-TW" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;hr&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="hr-HR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="x-default" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="en-US" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;fr&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="fr-FR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;de&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="de-DE" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ja&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ja-JP" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ko&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ko-KR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ms&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ms-MY" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;fa&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="fa-IR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;pl&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="pl-PL" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;pt&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="pt-PT" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ru&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ru-RU" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;es&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="es-ES" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ta&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ta-IN" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;th&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="th-TH" rel="alternate" /> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;main&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;aui&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <link href="&#x2f;html&#x2f;css&#x2f;main&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1513680834000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718256000" rel="stylesheet" type="text/css" /> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 13},getRevision:function(){return"605.1"},getVersion:function(){return"13.0"},isAir:function(){return false},isChrome:function(){return false},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return false},isMac:function(){return true},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="EfT7x5RD";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dreferences\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011798\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011798\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011798\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011798\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article References"},article:{availableLanguage:["en","es","de","ru","pt","ms","za","fr","pl","zh"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011798.pub2",title:"Insulin and glucose\\u2010lowering agents for treating people with diabetes and chronic kidney disease",firstPublishedDate:"Sep 24, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;custom&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <style type="text/css"></style> <script src="//assets.adobedtm.com/6e626c9ec247e474f6b98eb15a79a185cf7e26a5/satelliteLib-b0f13d7a13ebe8b0b1b00a9f0730a084926e292f.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1581422282000" type="text/javascript"></script> <![endif]--> </head> <body class=" yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div id="js-cookie-message" class="cookie-message cookie-message--hidden system-message-container"> <div class="container"> <a href="#" class="fa fa-times js-cookie-close pull-right" aria-label="Close cookies message"></a> <div class="system-message-wrapper container"> <i class="fa fa-exclamation-triangle" aria-hidden="true"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/N7XGCZUQPW4C675JNSTYTLUDN7XB/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a href="#" class="btn secondary js-cookie-close js-cookie-accept">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/"> <span class="brand-name">The Cochrane Library</span> <img class="brand-logo" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/en-US_logo.png" alt="Cochrane Library logo" title="Cochrane Library" /> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end " id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img id="owel__null__null" src="/scolaris-search/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_auth=EfT7x5RD&p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=1&p_p_state=normal&p_p_mode=view&_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input type="hidden" name="searchType" value="basic" /> <input type="hidden" name="facetDisplayName" value="" /> <input type="hidden" name="facetQueryTerm" value="" /> <input type="hidden" name="facetQueryField" value="" /> <input type="hidden" name="facetCategory" value="" /> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select title="Search by options" aria-label="Search by options" name="searchBy" class="custom-select-enabled search-type"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" style="display: none;" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=topics-list&p_p_cacheability=cacheLevelPage"> <select class="search-select-topic-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input type="text" size="30" class="field browser-search search-text ui-autocomplete-input" value="" aria-label="Enter search term" id="searchText" name="searchText" placeholder="Search">
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button type="submit" class="searchByBtn" aria-label="Search">
<i class="fa fa-search" aria-hidden="true"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=references&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011798.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011798.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a href="/en/browse-by-topic" class="btn secondary">Browse</a>
<a href="/en/advanced-search" class="btn primary advanced-search-button">Advanced search</a>
</div>
</div>
<a href="#" class="toggle-menu-switch"><i class="fa fa-bars" aria-hidden="true"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<p class="auxiliary-menu-item access">Access provided by: <strong>Tsinghua University</strong></p>
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img id="bvrs__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hr, ja, ko, ms, pl, pt, ru, ta, th, zh, za]"> <a title="Select your preferred language" class="open-language-modal" href="#"> <i class="fa fa-file-text"></i> English </a> <a title="Select your preferred language" class="open-language-modal" href="#"> <i class="fa fa-globe"></i> English </a> </div> <div class="language-selector-modal-content" style="display: none;" data-modal-title="Language selection" data-size="large"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane Review language</h3> <p>Select your preferred language for Cochrane Reviews. You will see translated Review sections in your preferred language. Sections without translation will be in English.</p> <div> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de" class="content-language-selector " data-languagecode="de">Deutsch</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en" class="content-language-selector is-active" data-languagecode="en">English</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es" class="content-language-selector " data-languagecode="es">Español</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa" class="content-language-selector " data-languagecode="fa">فارسی</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr" class="content-language-selector " data-languagecode="fr">Français</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr" class="content-language-selector " data-languagecode="hr">Hrvatski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja" class="content-language-selector " data-languagecode="ja">日本語</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko" class="content-language-selector " data-languagecode="ko">한국어</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms" class="content-language-selector " data-languagecode="ms">Bahasa Malaysia</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl" class="content-language-selector " data-languagecode="pl">Polski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt" class="content-language-selector " data-languagecode="pt">Português</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru" class="content-language-selector " data-languagecode="ru">Русский</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta" class="content-language-selector " data-languagecode="ta">தமிழ்</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th" class="content-language-selector " data-languagecode="th">ภาษาไทย</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh" class="content-language-selector " data-languagecode="zh">简体中文</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=za" class="content-language-selector " data-languagecode="za">繁體中文</a> </div> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div> <a href="/en/cdsr/doi/10.1002/14651858.CD011798.pub2/references/en" class="portal-language-selector is-active" data-portallanguage="en">English</a> <a href="/es/cdsr/doi/10.1002/14651858.CD011798.pub2/references/es" class="portal-language-selector " data-portallanguage="es">Español</a> </div> </div> <button class="btn primary btn-cancel" type="button">Cancel</button> <a class="btn secondary ok-btn pull-right" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/c/portal/login?p_l_id=20757&redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011798.pub2%2Freferences" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
</a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
<div class="access-provider-mobile">
<p class="access">Access provided by: <strong>Tsinghua University</strong></p>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class=" nav-root-item parent">
<a href="#">Cochrane Reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_14" role="presentation">
<a aria-labelledby="layout_14" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;reviews" role="menuitem">
Search Reviews (CDSR)
</a>
</li>
<li class=" child-nav-item" id="layout_15" role="presentation">
<a aria-labelledby="layout_15" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;reviews&#x2f;topics" role="menuitem">
Browse Reviews
</a>
</li>
<li class=" child-nav-item" id="layout_18" role="presentation">
<a aria-labelledby="layout_18" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;table-of-contents" role="menuitem">
Issues
</a>
</li>
<li class=" child-nav-item" id="layout_17" role="presentation">
<a aria-labelledby="layout_17" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;editorials" role="menuitem">
Editorials
</a>
</li>
<li class=" child-nav-item" id="layout_19" role="presentation">
<a aria-labelledby="layout_19" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;special-collections" role="menuitem">
Special Collections
</a>
</li>
<li class=" child-nav-item" id="layout_20" role="presentation">
<a aria-labelledby="layout_20" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;supplements" role="menuitem">
Supplements
</a>
</li>
<li class=" child-nav-item" id="layout_13" role="presentation">
<a aria-labelledby="layout_13" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;about-cdsr" role="menuitem">
About the CDSR
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_22" role="presentation">
<a aria-labelledby="layout_22" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;central" role="menuitem">
Search Trials (CENTRAL)
</a>
</li>
<li class=" child-nav-item" id="layout_114" role="presentation">
<a aria-labelledby="layout_114" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;central&#x2f;about-central" role="menuitem">
About CENTRAL
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_29" role="presentation">
<a aria-labelledby="layout_29" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cca" role="menuitem">
Browse Clinical Answers
</a>
</li>
<li class=" child-nav-item" id="layout_91" role="presentation">
<a aria-labelledby="layout_91" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cca&#x2f;about" role="menuitem">
About Clinical Answers
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_116" role="presentation">
<a aria-labelledby="layout_116" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;about-cochrane-library" role="menuitem">
About the Cochrane Library
</a>
</li>
<li class=" child-nav-item" id="layout_34" role="presentation">
<a aria-labelledby="layout_34" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochrane&#x2e;org&#x2f;about-us" role="menuitem">
About Cochrane
</a>
</li>
<li class=" child-nav-item" id="layout_121" role="presentation">
<a aria-labelledby="layout_121" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;about-cochrane-reviews" role="menuitem">
About Cochrane Reviews
</a>
</li>
<li class=" child-nav-item" id="layout_92" role="presentation">
<a aria-labelledby="layout_92" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;author-information" role="menuitem">
Information for authors
</a>
</li>
<li class=" child-nav-item" id="layout_188" role="presentation">
<a aria-labelledby="layout_188" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;releases" role="menuitem">
What&#039;s new
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_177" role="presentation">
<a aria-labelledby="layout_177" href="https&#x3a;&#x2f;&#x2f;www&#x2e;wiley&#x2e;com&#x2f;network&#x2f;cochranelibrarytraining" role="menuitem">
Cochrane Library Training
</a>
</li>
<li class=" child-nav-item" id="layout_44" role="presentation">
<a aria-labelledby="layout_44" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;access" role="menuitem">
Access options
</a>
</li>
<li class=" child-nav-item" id="layout_150" role="presentation">
<a aria-labelledby="layout_150" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;permissions" role="menuitem">
Permissions and reprints
</a>
</li>
<li class=" child-nav-item" id="layout_93" role="presentation">
<a aria-labelledby="layout_93" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;media" role="menuitem">
Media information
</a>
</li>
<li class=" child-nav-item" id="layout_97" role="presentation">
<a aria-labelledby="layout_97" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;contact-us" role="menuitem">
Contact us
</a>
</li>
<li class=" child-nav-item" id="layout_125" role="presentation">
<a aria-labelledby="layout_125" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;terms-and-conditions" role="menuitem">
Terms and conditions
</a>
</li>
<li class=" child-nav-item" id="layout_176" role="presentation">
<a aria-labelledby="layout_176" href="https&#x3a;&#x2f;&#x2f;hub&#x2e;wiley&#x2e;com&#x2f;docs&#x2f;cochrane-library&#x2f;cochrane-library-known-issues-DOC-16221&#x3f;referrer&#x3d;cochrane" role="menuitem">
Known issues
</a>
</li>
</ul>
</li>
<li class="about-link"><a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img id="etlj__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <section class="content-language-banner system-message-container" data-content-language="en" data-portal-language="en" style="display: none"> <div class="container"> <a href="#0" class="fa fa-times content-language-banner-close pull-right" aria-label="Close"></a> <i class="fa fa-globe" aria-hidden="true"></i> <div class="system-message-title">Content Language Selection</div> <div class="system-message-description">Your language preference is set to <strong class="language">English</strong>. Where translations are available, article sections will display in this language. Return to <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=reset-content-language&p_p_cacheability=cacheLevelPage" class="language secondary">English</a>.</div> </div> </section> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<div id="content" class="">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="rjus__column1__0" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools"> <li class="cdsr-nav-link pulldown-menu readcube-menu closed"> <a href="#0" class="pulldown-menu-trigger"> <i class="icon fa fa-file-pdf-o"></i>View PDF <i aria-hidden="true" class="fa fa-caret-up"></i> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/pdf/full/en" class="download media pdf-link-full pdf-link" title="Article in PDF format"> <span class="readcube-label "> Full </span> <span class="readcube-description "> All content </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/epdf/full/en" class="download media pdf-link-full readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Full </span> <span class="readcube-description "> All content </span> </a> </li> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/pdf/standard/en" class="download media pdf-link-standard pdf-link" title="Article in PDF format"> <span class="readcube-label "> Standard </span> <span class="readcube-description "> Excludes data and analyses, and appendices </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/epdf/standard/en" class="download media pdf-link-standard readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Standard </span> <span class="readcube-description "> Excludes data and analyses, and appendices </span> </a> </li> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/pdf/abstract/en" class="download media pdf-link-abstract pdf-link" title="Article in PDF format"> <span class="readcube-label "> Summary </span> <span class="readcube-description "> Abstract and plain language summary only </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/epdf/abstract/en" class="download media pdf-link-abstract readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Summary </span> <span class="readcube-description "> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="cdsr-nav-link cite-article-link" data-article-id="CD011798.PUB2" data-modal-title="Cite this Review"> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/#"> <i class="icon fa fa-share"></i>Cite this Review </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-english-only-message="Please note, that requesting permissions is available in English only. Apologies for any inconvenience." href="/cdsr/doi/10.1002/14651858.CD011798.pub2/#" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false"> <span class="request-permissions-icon"></span> Request Permissions </a> </li> <li class="cdsr-nav-link comment-on-review"> <a id="comment-on-review" class="js-old-version-modal-trigger" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/comment" data-new-version="" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience."> <i class="icon fa fa-comment"></i>Comment on Review </a> </li> <li class="cdsr-nav-link comment-on"> <span>Read comments on this Review(0)</span> </li> </ul> <ul class="share clearfix"> <li class="cdsr-nav-link print-cdsr-link" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011798.pub2/print" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh&quot;,&quot;title&quot;:&quot;概要&quot;},{&quot;language&quot;:&quot;za&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Data and analysis&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;}]}]"> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/#"> <i class="icon fa fa-print"></i>Print </a> </li> <li class="cdsr-nav-link share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011798.pub2/full"> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/#"> <i class="icon fa fa-share-alt"></i>Share </a> </li> <li class="cdsr-nav-link"> <a href="/c/portal/login" class="article-not-followed cochrane-link signin"> <span class="article-follow-display"><i class="icon fa fa-plus"></i>Follow</span> </a> </li> </ul> <ul id="linked-articles" data-type="cdsr" class="linked-content tools clearfix linked-content-trigger"> <li> <a href="#0"> <span class="linked-to-this"> Linked to this Review <span class="linked-content-count"></span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> </li> </ul> <ul class="linked-content-dropdown"> <li data-type="cca" class="linked-cca"> <p>Cochrane Clinical Answers</p> </li> <li data-type="editorial" class="linked-editorials"> <p>Editorials</p> </li> <li data-type="podcast" class="linked-podcasts"> <p>Podcasts</p> </li> <li data-type="sc" class="linked-sc"> <p>Special Collections</p> </li> </ul> <ul class="nav-long-form"> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/full#CD011798-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/full#CD011798-sec1-0007"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/full#CD011798-sec1-0001"> Summary of findings </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/full#CD011798-sec1-0002"> Background </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/full#CD011798-sec1-0003"> Objectives </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/full#CD011798-sec1-0004"> Methods </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/full#CD011798-sec1-0005"> Results </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/full#CD011798-sec1-0006"> Discussion </a> </li> </ul> <ul class="tools"> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/appendices#CD011798-sec1-0012"> Appendices </a> </li> </ul> <ul> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/information"> Information </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/information#authors"> Authors </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/information#history"> History </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/information#keywords"> Keywords </a> </li> </ul> <ul> <li class="cdsr-nav-link bold-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/#"> <i class="icon fa fa-globe"></i>Translation notes </a> </li> </ul> <ul> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references"> References </a> </li> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#dataAndAnalyses"> Data and analyses </a> </li> </ul> <ul class="tools"> <li class="cdsr-nav-link "> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/#"> <i class="icon fa fa-line-chart"></i>Figures and tables </a> </li> <li class="cdsr-nav-link download-stats-data-link " data-download-href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/table_n/CD011798StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/table_n/CD011798StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <i class="icon fa fa-download"></i>Download statistical data </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i>Related content <span class="note podcast-indicator">Podcast available</span> </a> </li> </ul> </nav> </div> <article class="information" data-article-id="CD011798.PUB2"> <header> <h1 class="publication-title"><h1 lang="en" class="publication-title">Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease </h1></h1> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div><h2 class="title section-collapse-title"> References <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <section class="references bibliographies" id="references"> <section> <div class="section-header" id="CD011798-bbs1-0001"> <h3 class="title">References to studies included in this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD011798-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0003">studies awaiting assessment</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0004">ongoing studies</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0005">additional references</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0006">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0001"> <div class="reference-title-banner"> <h4 class="title">Abe 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0001"> <div class="citation-journal">Abe M, Kikuchi F, Kaizu K, Matsumoto K. <span class="citation-title">Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2‐diabetic patients on hemodialysis</span>. <span class="citation"> Clinical Nephrology </span><span class="pubYear">2007</span>;<span class="volume">68</span>(5):287‐94. [MEDLINE: 18044260]<a class="crsref citation-link central-link" data-crsref="9140630" href="" ref="info:x-wiley/crsRef/9140630" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18044260" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Combination+therapy+of+pioglitazone+with+voglibose+improves+glycemic+control+safely+and+rapidly+in+Japanese+type+2%E2%80%90diabetic+patients+on+hemodialysis+&author=M+Abe&author=F+Kikuchi&author=K+Kaizu&author=K+Matsumoto&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0002"> <div class="reference-title-banner"> <h4 class="title">Abe 2008a {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0002"> <div class="citation-journal">Abe M, Okada K, Kikuchi F, Matsumoto K. <span class="citation-title">Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2‐diabetic patients undergoing hemodialysis</span>. <span class="citation"> Clinical Nephrology </span><span class="pubYear">2008</span>;<span class="volume">70</span>(3):220‐8. [MEDLINE: 18793563]<a class="crsref citation-link central-link" data-crsref="9140632" href="" ref="info:x-wiley/crsRef/9140632" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18793563" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Clinical+investigation+of+the+effects+of+pioglitazone+on+the+improvement+of+insulin+resistance+and+blood+pressure+in+type+2%E2%80%90diabetic+patients+undergoing+hemodialysis+&author=M+Abe&author=K+Okada&author=F+Kikuchi&author=K+Matsumoto&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0003"> <div class="reference-title-banner"> <h4 class="title">Abe 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0003"> <div class="citation-journal">Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K. <span class="citation-title">Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis</span>. <span class="citation"> Expert Opinion on Pharmacotherapy </span><span class="pubYear">2010</span>;<span class="volume">11</span>(2):169‐76. [MEDLINE: 20025554]<a class="crsref citation-link central-link" data-crsref="9140634" href="" ref="info:x-wiley/crsRef/9140634" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20025554" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Combination+therapy+with+mitiglinide+and+voglibose+improves+glycemic+control+in+type+2+diabetic+patients+on+hemodialysis+&author=M+Abe&author=K+Okada&author=T+Maruyama&author=N+Maruyama&author=K+Matsumoto&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0004"> <div class="reference-title-banner"> <h4 class="title">Abe 2010a {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0004"> <div class="citation-journal">Abe M, Okada K, Maruyama T, Maruyama N, Soma M, Matsumoto K. <span class="citation-title">Clinical effectiveness and safety evaluation of long‐term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis</span>. <span class="citation"> Expert Opinion on Pharmacotherapy </span><span class="pubYear">2010</span>;<span class="volume">11</span>(10):1611‐20. [MEDLINE: 20540652]<a class="crsref citation-link central-link" data-crsref="9140636" href="" ref="info:x-wiley/crsRef/9140636" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20540652" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Clinical+effectiveness+and+safety+evaluation+of+long%E2%80%90term+pioglitazone+treatment+for+erythropoietin+responsiveness+and+insulin+resistance+in+type+2+diabetic+patients+on+hemodialysis+&author=M+Abe&author=K+Okada&author=T+Maruyama&author=N+Maruyama&author=M+Soma&author=K+Matsumoto&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0005"> <div class="reference-title-banner"> <h4 class="title">Abe 2016 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0005"> <div class="citation-journal">Abe M, Higuchi T, Moriuchi M, Okamura M, Tei R, Nagura C, et al. <span class="citation-title">Efficacy and safety of saxagliptin, a dipeptidyl peptidase‐4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open‐label prospective trial</span>. <span class="citation"> Diabetes Research &amp; Clinical Practice </span><span class="pubYear">2016</span>;<span class="volume">116</span>:244‐52. [MEDLINE: 27321342]<a class="crsref citation-link central-link" data-crsref="9140638" href="" ref="info:x-wiley/crsRef/9140638" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+saxagliptin,+a+dipeptidyl+peptidase%E2%80%904+inhibitor,+in+hemodialysis+patients+with+diabetic+nephropathy:+A+randomized+open%E2%80%90label+prospective+trial+&author=M+Abe&author=T+Higuchi&author=M+Moriuchi&author=M+Okamura&author=R+Tei&author=C+Nagura&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0006"> <div class="citation-journal">Abe M, Okada K, Oikawa O, Maruyama N, Furukawa T. <span class="citation-title">Efficacy and safety of dipeptidyl peptidase‐4 (DPP‐4) inhibitor in hemodialysis patients with type 2 diabetes [abstract]</span>. <span class="citation"> Nephrology Dialysis Transplantation </span><span class="pubYear">2016</span>;<span class="volume">31</span>(Suppl 1):i216. [EMBASE: 72326481]<a class="crsref citation-link central-link" data-crsref="9140639" href="" ref="info:x-wiley/crsRef/9140639" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+dipeptidyl+peptidase%E2%80%904+(DPP%E2%80%904)+inhibitor+in+hemodialysis+patients+with+type+2+diabetes+[abstract]+&author=M+Abe&author=K+Okada&author=O+Oikawa&author=N+Maruyama&author=T+Furukawa&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0007"> <div class="citation-journal">Abe M, Otsuki T, Maruyama N, Oikawa O, Okada K. <span class="citation-title">Efficacy and safety of saxagliptin, dipeptidyl peptidase‐4 inhibitor, in hemodialysis patients with type 2 diabetes [abstract]</span>. <span class="citation"> Nephrology </span><span class="pubYear">2016</span>;<span class="volume">21</span>(Suppl 2):65. [EMBASE: 612312682]<a class="crsref citation-link central-link" data-crsref="9140640" href="" ref="info:x-wiley/crsRef/9140640" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+saxagliptin,+dipeptidyl+peptidase%E2%80%904+inhibitor,+in+hemodialysis+patients+with+type+2+diabetes+[abstract]+&author=M+Abe&author=T+Otsuki&author=N+Maruyama&author=O+Oikawa&author=K+Okada&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0006"> <div class="reference-title-banner"> <h4 class="title">AleNephro 2014 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0008"> <div class="citation-other">Herz M, Ruilope L, Hanefeld M, Lincoff AM, Viberti G, Reigner SM, et al. <span class="citation-title">Effects of aleglitazar on renal function in patients with stage 3 chronic kidney disease and type‐2 diabetes [abstract no: O22]</span>. British Transplantation Society &amp; the Renal Association Joint Congress; 2013 Mar 13‐15; Bournemouth, UK. <span class="pubYear">2013</span>. <a class="crsref citation-link central-link" data-crsref="9140642" href="" ref="info:x-wiley/crsRef/9140642" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+aleglitazar+on+renal+function+in+patients+with+stage+3+chronic+kidney+disease+and+type%E2%80%902+diabetes+[abstract+no:+O22]+&author=M+Herz&author=L+Ruilope&author=M+Hanefeld&author=AM+Lincoff&author=G+Viberti&author=SM+Reigner&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0009"> <div class="citation-journal">Malmberg K, Hanefeld M, Ruilope L, Lincoff A, Viberti G, Mudie N, et al. <span class="citation-title">Effects of aleglitazar on cardiovascular risk factors in patients with stage 3 chronic kidney disease and type II diabetes [abstract]</span>. <span class="citation"> Journal of the American College of Cardiology </span><span class="pubYear">2013</span>;<span class="volume">10</span>(Suppl 1):E1173. [EMBASE: 71020536]<a class="crsref citation-link central-link" data-crsref="9140643" href="" ref="info:x-wiley/crsRef/9140643" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+aleglitazar+on+cardiovascular+risk+factors+in+patients+with+stage+3+chronic+kidney+disease+and+type+II+diabetes+[abstract]+&author=K+Malmberg&author=M+Hanefeld&author=L+Ruilope&author=A+Lincoff&author=G+Viberti&author=N+Mudie&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0010"> <div class="citation-journal">Ruilope L, Hanefeld M, Lincoff AM, Viberti G, Meyer‐Reigner S, Mudie N, et al. <span class="citation-title">Effects of the dual peroxisome proliferator‐activated receptor‐alpha/gamma agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study</span>. <span class="citation"> BMC Nephrology </span><span class="pubYear">2014</span>;<span class="volume">15</span>(1):180. [MEDLINE: 25407798]<a class="crsref citation-link central-link" data-crsref="9140644" href="" ref="info:x-wiley/crsRef/9140644" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25407798" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+the+dual+peroxisome+proliferator%E2%80%90activated+receptor%E2%80%90alpha/gamma+agonist+aleglitazar+on+renal+function+in+patients+with+stage+3+chronic+kidney+disease+and+type+2+diabetes:+a+Phase+IIb,+randomized+study+&author=L+Ruilope&author=M+Hanefeld&author=AM+Lincoff&author=G+Viberti&author=S+Meyer%E2%80%90Reigner&author=N+Mudie&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0007"> <div class="reference-title-banner"> <h4 class="title">Arjona Ferreira 2013 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0011"> <div class="citation-journal">Arjona Ferreira JC, Engel SS, Guo H, Golm GT, Johnson‐Levonas AO, Kaufman KD, et al. <span class="citation-title">Consistency of the A1C‐lowering effects of sitagliptin versus glipizide in patients with type 2 diabetes and chronic renal insufficiency across a variety of baseline characteristics [abstract]</span>. <span class="citation"> Diabetes </span><span class="pubYear">2012</span>;<span class="volume">61</span>:A281. [EMBASE: 70797683]<a class="crsref citation-link central-link" data-crsref="9140646" href="" ref="info:x-wiley/crsRef/9140646" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Consistency+of+the+A1C%E2%80%90lowering+effects+of+sitagliptin+versus+glipizide+in+patients+with+type+2+diabetes+and+chronic+renal+insufficiency+across+a+variety+of+baseline+characteristics+[abstract]+&author=JC+ArjonaFerreira&author=SS+Engel&author=H+Guo&author=GT+Golm&author=AO+Johnson%E2%80%90Levonas&author=KD+Kaufman&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0012"> <div class="citation-journal">Arjona Ferreira JC, Engel SS, Guo H, Golm GT, Sisk CM, Kaufman KD, et al. <span class="citation-title">Sitagliptin more effectively achieves a composite endpoint of a1c reduction, no body weight gain, and lack of hypoglycemia in patients with type 2 diabetes and renal insufficiency compared to glipizide [abstract]</span>. <span class="citation"> Diabetes </span><span class="pubYear">2012</span>;<span class="volume">61</span>:A258. [EMBASE: 70797604]<a class="crsref citation-link central-link" data-crsref="9140647" href="" ref="info:x-wiley/crsRef/9140647" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Sitagliptin+more+effectively+achieves+a+composite+endpoint+of+a1c+reduction,+no+body+weight+gain,+and+lack+of+hypoglycemia+in+patients+with+type+2+diabetes+and+renal+insufficiency+compared+to+glipizide+[abstract]+&author=JC+ArjonaFerreira&author=SS+Engel&author=H+Guo&author=GT+Golm&author=CM+Sisk&author=KD+Kaufman&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0013"> <div class="citation-journal">Arjona Ferreira JC, Marre M, Barzilai N, Guo H, Golm GT, Sisk CM, et al. <span class="citation-title">Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate‐to‐severe chronic renal insufficiency</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2013</span>;<span class="volume">36</span>(5):1067‐73. [MEDLINE: 23248197]<a class="crsref citation-link central-link" data-crsref="9140648" href="" ref="info:x-wiley/crsRef/9140648" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23248197" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+sitagliptin+versus+glipizide+in+patients+with+type+2+diabetes+and+moderate%E2%80%90to%E2%80%90severe+chronic+renal+insufficiency+&author=JC+ArjonaFerreira&author=M+Marre&author=N+Barzilai&author=H+Guo&author=GT+Golm&author=CM+Sisk&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0014"> <div class="citation-journal">Arjona Ferreira JC, Marre M, Rabelink TJ, Barzilai N, Bakris GL, Guo H, et al. <span class="citation-title">Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate to severe chronic renal insufficiency [abstract]</span>. <span class="citation"> Diabetes, Stoffwechsel und Herz </span><span class="pubYear">2011</span>;<span class="volume">20</span>(6):419. [EMBASE: 70696902]<a class="crsref citation-link central-link" data-crsref="9140649" href="" ref="info:x-wiley/crsRef/9140649" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+sitagliptin+versus+glipizide+in+patients+with+type+2+diabetes+and+moderate+to+severe+chronic+renal+insufficiency+[abstract]+&author=JC+ArjonaFerreira&author=M+Marre&author=TJ+Rabelink&author=N+Barzilai&author=GL+Bakris&author=H+Guo&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0015"> <div class="citation-journal">Arjona Ferreira JCA, Marre M, Bakris GL, Rabelink TJ. <span class="citation-title">Efficacy and safety of sitagliptin vs. glipizide in patients with type 2 diabetes and moderate to severe chronic renal insufficiency [abstract no: LB‐PO3166]</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">2011</span>;<span class="volume">22</span>(Abstracts):8B. <a class="crsref citation-link central-link" data-crsref="9140650" href="" ref="info:x-wiley/crsRef/9140650" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+sitagliptin+vs.+glipizide+in+patients+with+type+2+diabetes+and+moderate+to+severe+chronic+renal+insufficiency+[abstract+no:+LB%E2%80%90PO3166]+&author=JCA+ArjonaFerreira&author=M+Marre&author=GL+Bakris&author=TJ+Rabelink&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0016"> <div class="citation-journal">Engel S, Arjona Ferreira JC, Guo H, Golm G, Johnson‐Levonas AO, Kaufman K, et al. <span class="citation-title">Consistency of HbA1c‐lowering effects of sitagliptin vs glipizide in patients with type 2 diabetes and chronic renal insufficiency across a variety of baseline characteristics [abstract]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2012</span>;<span class="volume">55</span>(1 Suppl):S342. [EMBASE: 70888848]<a class="crsref citation-link central-link" data-crsref="9140651" href="" ref="info:x-wiley/crsRef/9140651" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Consistency+of+HbA1c%E2%80%90lowering+effects+of+sitagliptin+vs+glipizide+in+patients+with+type+2+diabetes+and+chronic+renal+insufficiency+across+a+variety+of+baseline+characteristics+[abstract]+&author=S+Engel&author=JC+ArjonaFerreira&author=H+Guo&author=G+Golm&author=AO+Johnson%E2%80%90Levonas&author=K+Kaufman&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0008"> <div class="reference-title-banner"> <h4 class="title">Arjona Ferreira 2013a {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0017"> <div class="citation-journal">Arjona Ferreira JC, Corry D, Mogensen CE, Sloan L, Xu L, Golm GT, et al. <span class="citation-title">Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54‐week randomized trial</span>. <span class="citation"> American Journal of Kidney Diseases </span><span class="pubYear">2013</span>;<span class="volume">61</span>(4):579‐87. [MEDLINE: 23352379]<a class="crsref citation-link central-link" data-crsref="9140653" href="" ref="info:x-wiley/crsRef/9140653" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23352379" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+sitagliptin+in+patients+with+type+2+diabetes+and+ESRD+receiving+dialysis:+a+54%E2%80%90week+randomized+trial+&author=JC+ArjonaFerreira&author=D+Corry&author=CE+Mogensen&author=L+Sloan&author=L+Xu&author=GT+Golm&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0018"> <div class="citation-journal">Arjona Ferreira JC, Corry D, Mogensen CE, Slone L, Xii L, Gonzalez EJ, et al. <span class="citation-title">Efficacy and safety of sitagliptin vs. glipizide in patients with type 2 diabetes mellitus and end‐stage renal disease on dialysis: A 54‐week randomised trial [abstract]</span>. <span class="citation"> Diabetes, Stoffwechsel und Herz </span><span class="pubYear">2011</span>;<span class="volume">20</span>(6):430. [EMBASE: 70696927]<a class="crsref citation-link central-link" data-crsref="9140654" href="" ref="info:x-wiley/crsRef/9140654" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+sitagliptin+vs.+glipizide+in+patients+with+type+2+diabetes+mellitus+and+end%E2%80%90stage+renal+disease+on+dialysis:+A+54%E2%80%90week+randomised+trial+[abstract]+&author=JC+ArjonaFerreira&author=D+Corry&author=CE+Mogensen&author=L+Slone&author=L+Xii&author=EJ+Gonzalez&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0019"> <div class="citation-journal">Arjona Ferreira JC, Corry DB, Mogensen CE. <span class="citation-title">Efficacy and safety of sitagliptin vs. glipizide in patients with type 2 diabetes and end‐stage renal disease on dialysis [abstract no: LB‐PO3167]</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">2011</span>;<span class="volume">22</span>(Abstracts):8B. <a class="crsref citation-link central-link" data-crsref="9140655" href="" ref="info:x-wiley/crsRef/9140655" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+sitagliptin+vs.+glipizide+in+patients+with+type+2+diabetes+and+end%E2%80%90stage+renal+disease+on+dialysis+[abstract+no:+LB%E2%80%90PO3167]+&author=JC+ArjonaFerreira&author=DB+Corry&author=CE+Mogensen&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0009"> <div class="reference-title-banner"> <h4 class="title">Baldwin 2012 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0020"> <div class="citation-journal">Baldwin D, Zander J, Munoz C, Raghu P, DeLange‐Hudec S, Lee H, et al. <span class="citation-title">A randomized trial of two weight‐based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2012</span>;<span class="volume">35</span>(10):1970‐4. [MEDLINE: 22699288]<a class="crsref citation-link central-link" data-crsref="9140657" href="" ref="info:x-wiley/crsRef/9140657" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22699288" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+randomized+trial+of+two+weight%E2%80%90based+doses+of+insulin+glargine+and+glulisine+in+hospitalized+subjects+with+type+2+diabetes+and+renal+insufficiency+&author=D+Baldwin&author=J+Zander&author=C+Munoz&author=P+Raghu&author=S+DeLange%E2%80%90Hudec&author=H+Lee&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0021"> <div class="citation-journal">Zander J, Raghu P, Lee H, Molitch M, Glossop V, Smallwood K, et al. <span class="citation-title">Initial insulin doses should be decreased in hospitalized patients with renal insufficiency and type 2 diabetes [abstract]</span>. <span class="citation"> Diabetes </span><span class="pubYear">2011</span>;<span class="volume">60</span>:A297. [EMBASE: 70628849]<a class="crsref citation-link central-link" data-crsref="9140658" href="" ref="info:x-wiley/crsRef/9140658" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Initial+insulin+doses+should+be+decreased+in+hospitalized+patients+with+renal+insufficiency+and+type+2+diabetes+[abstract]+&author=J+Zander&author=P+Raghu&author=H+Lee&author=M+Molitch&author=V+Glossop&author=K+Smallwood&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0010"> <div class="reference-title-banner"> <h4 class="title">Barnett 2013 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0023"> <div class="citation-journal">Barnett AH, Huisman H, Jones R. <span class="citation-title">Efficacy and safety of linagliptin in elderly patients (.70 years) with type 2 diabetes mellitus [abstract no: OCS‐05‐3]</span>. <span class="citation"> Journal of Diabetes Investigation </span><span class="pubYear">2012</span>;<span class="volume">3</span>(Suppl 1):102. <a class="crsref citation-link central-link" data-crsref="9140661" href="" ref="info:x-wiley/crsRef/9140661" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+linagliptin+in+elderly+patients+(.70+years)+with+type+2+diabetes+mellitus+[abstract+no:+OCS%E2%80%9005%E2%80%903]+&author=AH+Barnett&author=H+Huisman&author=R+Jones&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0022"> <div class="citation-journal">Barnett AH, Huisman H, Jones R, Eynatten M, Patel S, Woerle HJ. <span class="citation-title">Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double‐blind, placebo‐controlled trial</span>. <span class="citation"> Lancet </span><span class="pubYear">2013</span>;<span class="volume">382</span>(9902):1413‐23. [MEDLINE: 23948125]<a class="crsref citation-link central-link" data-crsref="9140660" href="" ref="info:x-wiley/crsRef/9140660" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23948125" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Linagliptin+for+patients+aged+70+years+or+older+with+type+2+diabetes+inadequately+controlled+with+common+antidiabetes+treatments:+a+randomised,+double%E2%80%90blind,+placebo%E2%80%90controlled+trial+&author=AH+Barnett&author=H+Huisman&author=R+Jones&author=M+Eynatten&author=S+Patel&author=HJ+Woerle&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0024"> <div class="citation-journal">McGill JB, Barnett AH, Lewin AJ, Patel S, Neubacher D, Eynatten M, et al. <span class="citation-title">Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate‐to‐severe renal impairment</span>. <span class="citation"> Diabetes &amp; Vascular Disease Research </span><span class="pubYear">2014</span>;<span class="volume">11</span>(1):34‐40. [MEDLINE: 24169807]<a class="crsref citation-link central-link" data-crsref="9140662" href="" ref="info:x-wiley/crsRef/9140662" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24169807" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Linagliptin+added+to+sulphonylurea+in+uncontrolled+type+2+diabetes+patients+with+moderate%E2%80%90to%E2%80%90severe+renal+impairment+&author=JB+McGill&author=AH+Barnett&author=AJ+Lewin&author=S+Patel&author=D+Neubacher&author=M+Eynatten&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0011"> <div class="reference-title-banner"> <h4 class="title">Bellante 2016 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0025"> <div class="citation-journal">Bellante R, Lucchesi D, Giusti L, Garofolo M, Sancho‐Bornez V, Caprioli R, et al. <span class="citation-title">Sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes and advanced chronic kidney disease [abstract]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2016</span>;<span class="volume">59</span>(1 Suppl 1):S360‐1. [EMBASE: 612313307]<a class="crsref citation-link central-link" data-crsref="9140664" href="" ref="info:x-wiley/crsRef/9140664" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Sitagliptin+increases+circulating+endothelial+progenitor+cells+in+patients+with+type+2+diabetes+and+advanced+chronic+kidney+disease+[abstract]+&author=R+Bellante&author=D+Lucchesi&author=L+Giusti&author=M+Garofolo&author=V+Sancho%E2%80%90Bornez&author=R+Caprioli&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0012"> <div class="reference-title-banner"> <h4 class="title">Chan 2008a {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0026"> <div class="citation-journal">Chan JC, Scott R, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, et al. <span class="citation-title">Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency</span>. <span class="citation"> Diabetes, Obesity &amp; Metabolism </span><span class="pubYear">2008</span>;<span class="volume">10</span>(7):545‐55. [MEDLINE: 18518892]<a class="crsref citation-link central-link" data-crsref="9140666" href="" ref="info:x-wiley/crsRef/9140666" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18518892" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Safety+and+efficacy+of+sitagliptin+in+patients+with+type+2+diabetes+and+chronic+renal+insufficiency+&author=JC+Chan&author=R+Scott&author=JC+ArjonaFerreira&author=D+Sheng&author=E+Gonzalez&author=MJ+Davies&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0013"> <div class="reference-title-banner"> <h4 class="title">Diez 1987 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0027"> <div class="citation-journal">Diez JJ, Alvaro F, Munoz J, Miguelez C, P‐Diaz V, Jabari NS, et al. <span class="citation-title">Comparative randomized study of insulin administration through two different routes in CAPD diabetic patients [abstract]</span>. <span class="citation"> Nephrology Dialysis Transplantation </span><span class="pubYear">1987</span>;<span class="volume">2</span>(5):452‐3. <a class="crsref citation-link central-link" data-crsref="9140668" href="" ref="info:x-wiley/crsRef/9140668" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparative+randomized+study+of+insulin+administration+through+two+different+routes+in+CAPD+diabetic+patients+[abstract]+&author=JJ+Diez&author=F+Alvaro&author=J+Munoz&author=C+Miguelez&author=V+P%E2%80%90Diaz&author=NS+Jabari&publication_year=1987&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0028"> <div class="citation-journal">Diez JJ, Alvaro F, Munoz J, Miguelez C, P‐Diaz V, Jabari NS, et al. <span class="citation-title">Comparative randomized study of insulin administration through two different routes in CAPD diabetic patients. [abstract]</span>. <span class="citation"> Kidney International </span><span class="pubYear">1988</span>;<span class="volume">34</span>(2):296. <a class="crsref citation-link central-link" data-crsref="9140669" href="" ref="info:x-wiley/crsRef/9140669" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparative+randomized+study+of+insulin+administration+through+two+different+routes+in+CAPD+diabetic+patients.+[abstract]+&author=JJ+Diez&author=F+Alvaro&author=J+Munoz&author=C+Miguelez&author=V+P%E2%80%90Diaz&author=NS+Jabari&publication_year=1988&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0014"> <div class="reference-title-banner"> <h4 class="title">EMPA‐REG BP 2015 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0029"> <div class="citation-journal">Cherney D, Cooper M, Tikkanen I, Crowe S, Johansen OE, Lund SS, et al. <span class="citation-title">Contrasting influences of renal function on blood pressure and HbA1c reductions with empagliflozin in patients with type 2 diabetes and hypertension [abstract no: 16709]</span>. <span class="citation"> Circulation </span><span class="pubYear">2014</span>;<span class="volume">130</span>(Suppl 1):n/a. <a class="crsref citation-link central-link" data-crsref="9140671" href="" ref="info:x-wiley/crsRef/9140671" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Contrasting+influences+of+renal+function+on+blood+pressure+and+HbA1c+reductions+with+empagliflozin+in+patients+with+type+2+diabetes+and+hypertension+[abstract+no:+16709]+&author=D+Cherney&author=M+Cooper&author=I+Tikkanen&author=S+Crowe&author=OE+Johansen&author=SS+Lund&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0030"> <div class="citation-journal">Cherney D, Cooper M, Tikkanen I, Crowe S, Johansen OE, Lund SS, et al. <span class="citation-title">Contrasting influences of renal function on blood pressure and hba1c reductions with empagliflozin in patients with type 2 diabetes and hypertension [abstract no: 4B.01]</span>. <span class="citation"> Journal of Hypertension </span><span class="pubYear">2015</span>;<span class="volume">33</span>(Suppl 1):e53. [MEDLINE: 26102847]<a class="crsref citation-link central-link" data-crsref="9140672" href="" ref="info:x-wiley/crsRef/9140672" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Contrasting+influences+of+renal+function+on+blood+pressure+and+hba1c+reductions+with+empagliflozin+in+patients+with+type+2+diabetes+and+hypertension+[abstract+no:+4B.01]+&author=D+Cherney&author=M+Cooper&author=I+Tikkanen&author=S+Crowe&author=OE+Johansen&author=SS+Lund&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0031"> <div class="citation-journal">Mancia G, Cannon CP, Tikkanen I, Zeller C, Ley L, Woerle HJ, et al. <span class="citation-title">Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication</span>. <span class="citation"> Hypertension </span><span class="pubYear">2016</span>;<span class="volume">68</span>(6):1355‐64. [MEDLINE: 27977392]<a class="crsref citation-link central-link" data-crsref="9140673" href="" ref="info:x-wiley/crsRef/9140673" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27977392" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Impact+of+empagliflozin+on+blood+pressure+in+patients+with+type+2+diabetes+mellitus+and+hypertension+by+background+antihypertensive+medication+&author=G+Mancia&author=CP+Cannon&author=I+Tikkanen&author=C+Zeller&author=L+Ley&author=HJ+Woerle&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0032"> <div class="citation-journal">Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, et al. <span class="citation-title">Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2015</span>;<span class="volume">38</span>(3):420‐8. [MEDLINE: 25271206]<a class="crsref citation-link central-link" data-crsref="9140674" href="" ref="info:x-wiley/crsRef/9140674" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25271206" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Empagliflozin+reduces+blood+pressure+in+patients+with+type+2+diabetes+and+hypertension&author=I+Tikkanen&author=K+Narko&author=C+Zeller&author=A+Green&author=A+Salsali&author=UC+Broedl&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0015"> <div class="reference-title-banner"> <h4 class="title">EMPA‐REG OUTCOME 2013 {published and unpublished data} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0033"> <div class="citation-journal">Cherney DZI, Zinman B, Inzucchi SE, Koitka‐Weber A, Mattheus M, von EM, et al. <span class="citation-title">Effects of empagliflozin on the urinary albumin‐to‐creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA‐REG OUTCOME randomised, placebo‐controlled trial</span>. <span class="citation"> Lancet Diabetes &amp; Endocrinology </span><span class="pubYear">2017</span>;<span class="volume">5</span>(8):610‐21. [MEDLINE: 28666775]<a class="crsref citation-link central-link" data-crsref="9140676" href="" ref="info:x-wiley/crsRef/9140676" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+empagliflozin+on+the+urinary+albumin%E2%80%90to%E2%80%90creatinine+ratio+in+patients+with+type+2+diabetes+and+established+cardiovascular+disease:+an+exploratory+analysis+from+the+EMPA%E2%80%90REG+OUTCOME+randomised,+placebo%E2%80%90controlled+trial+&author=DZI+Cherney&author=B+Zinman&author=SE+Inzucchi&author=A+Koitka%E2%80%90Weber&author=M+Mattheus&author=EM+von&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0034"> <div class="citation-journal">D'Emden M, Bergenstal R, Maldonado Lutomirsky M, Wanner C. <span class="citation-title">Effect of empagliflozin on nephropathy in subgroups by age: Results from EMPA‐REG OUTCOME [abstract]</span>. <span class="citation"> Nephrology </span><span class="pubYear">2016</span>;<span class="volume">21</span>(Suppl 2):59. [EMBASE: 612313031]<a class="crsref citation-link central-link" data-crsref="9140677" href="" ref="info:x-wiley/crsRef/9140677" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+empagliflozin+on+nephropathy+in+subgroups+by+age:+Results+from+EMPA%E2%80%90REG+OUTCOME+[abstract]+&author=M+D'Emden&author=R+Bergenstal&author=M+MaldonadoLutomirsky&author=C+Wanner&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0035"> <div class="citation-journal">Daacke I, Kandaswamy P, Tebboth A, Kansal A, Reifsnider O. <span class="citation-title">Impact of empagliflozin (jardiance) to the NHS: Estimation of budget and event impact based on EMPA‐REG OUTCOME data [abstract]</span>. <span class="citation"> Value in Health </span><span class="pubYear">2016</span>;<span class="volume">19</span>(7):A668. [EMBASE: 613236982]<a class="crsref citation-link central-link" data-crsref="9140678" href="" ref="info:x-wiley/crsRef/9140678" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Impact+of+empagliflozin+(jardiance)+to+the+NHS:+Estimation+of+budget+and+event+impact+based+on+EMPA%E2%80%90REG+OUTCOME+data+[abstract]+&author=I+Daacke&author=P+Kandaswamy&author=A+Tebboth&author=A+Kansal&author=O+Reifsnider&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0036"> <div class="citation-journal">Inzucchi SE, Zinman B, Lachin JM, Wanner C, Ferrari R, Bluhmki E, et al. <span class="citation-title">Design of the empagliflozin cardiovascular outcome event trial in type 2 diabetes mellitus [abstract]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2013</span>;<span class="volume">56</span>(Suppl 1):S378. [EMBASE: 71439366]<a class="crsref citation-link central-link" data-crsref="9140679" href="" ref="info:x-wiley/crsRef/9140679" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Design+of+the+empagliflozin+cardiovascular+outcome+event+trial+in+type+2+diabetes+mellitus+[abstract]+&author=SE+Inzucchi&author=B+Zinman&author=JM+Lachin&author=C+Wanner&author=R+Ferrari&author=E+Bluhmki&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0037"> <div class="citation-journal">Langslet G, Zinman B, Wanner C, Hantel S, Espadero R, Johansen O, et al. <span class="citation-title">Cardiovascular (CV) outcomes according to LDL cholesterol (LDLC) levels in EMPA‐REG OUTCOME [abstract]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2016</span>;<span class="volume">59</span>(1 Suppl 1):S537. [EMBASE: 612313836]<a class="crsref citation-link central-link" data-crsref="9140680" href="" ref="info:x-wiley/crsRef/9140680" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cardiovascular+(CV)+outcomes+according+to+LDL+cholesterol+(LDLC)+levels+in+EMPA%E2%80%90REG+OUTCOME+[abstract]+&author=G+Langslet&author=B+Zinman&author=C+Wanner&author=S+Hantel&author=R+Espadero&author=O+Johansen&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0038"> <div class="citation-journal">Langslet G, Zinman B, Wanner C, Hantel S, Espadero R, Johansen OE, et al. <span class="citation-title">Cardiovascular outcomes according to LDL cholesterol levels in EMPA‐REG OUTCOME [abstract]</span>. <span class="citation"> European Heart Journal </span><span class="pubYear">2016</span>;<span class="volume">37</span>(Suppl 1):1192. [EMBASE: 612285725]<a class="crsref citation-link central-link" data-crsref="9140681" href="" ref="info:x-wiley/crsRef/9140681" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cardiovascular+outcomes+according+to+LDL+cholesterol+levels+in+EMPA%E2%80%90REG+OUTCOME+[abstract]&author=G+Langslet&author=B+Zinman&author=C+Wanner&author=S+Hantel&author=R+Espadero&author=OE+Johansen&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0039"> <div class="citation-journal">Perkovic V, Levin A, Wheeler D, Koitka‐Weber A, Mattheus M, George J, et al. <span class="citation-title">Effects of empagliflozin on cardiovascular outcomes across KDIGO risk categories: results from the EMPA‐REG OUTCOME trial [abstract]</span>. <span class="citation"> Nephrology Dialysis Transplantation </span><span class="pubYear">2017</span>;<span class="volume">32</span>(Suppl 3):iii12. [EMBASE: 617302721]<a class="crsref citation-link central-link" data-crsref="9140682" href="" ref="info:x-wiley/crsRef/9140682" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+empagliflozin+on+cardiovascular+outcomes+across+KDIGO+risk+categories:+results+from+the+EMPA%E2%80%90REG+OUTCOME+trial+[abstract]+&author=V+Perkovic&author=A+Levin&author=D+Wheeler&author=A+Koitka%E2%80%90Weber&author=M+Mattheus&author=J+George&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0040"> <div class="citation-journal">Wanner C, Heerspink HJL, Koitka‐Weber A, Mattheus M, Eynatten M, Groop PH. <span class="citation-title">Empagliflozin and progression of kidney disease in patients at high renal risk: Slope analyses from EMPA‐REG OUTCOME [abstract]</span>. <span class="citation"> Diabetes </span><span class="pubYear">2017</span>;<span class="volume">66</span>:A314. [EMBASE: 616962744]<a class="crsref citation-link central-link" data-crsref="9140683" href="" ref="info:x-wiley/crsRef/9140683" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Empagliflozin+and+progression+of+kidney+disease+in+patients+at+high+renal+risk:+Slope+analyses+from+EMPA%E2%80%90REG+OUTCOME+[abstract]+&author=C+Wanner&author=HJL+Heerspink&author=A+Koitka%E2%80%90Weber&author=M+Mattheus&author=M+Eynatten&author=PH+Groop&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0041"> <div class="citation-journal">Wanner C, Inzucchi S, Lachin JM, Fitchett D, Eynatten M, Mattheus M, et al. <span class="citation-title">Reduced progression of kidney disease with empagliflozin: Results from EMPA‐REG OUTCOME [abstract]</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2017</span>;<span class="volume">34</span>(Suppl 1):80‐1. [EMBASE: 614845117]<a class="crsref citation-link central-link" data-crsref="9140684" href="" ref="info:x-wiley/crsRef/9140684" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Reduced+progression+of+kidney+disease+with+empagliflozin:+Results+from+EMPA%E2%80%90REG+OUTCOME+[abstract]+&author=C+Wanner&author=S+Inzucchi&author=JM+Lachin&author=D+Fitchett&author=M+Eynatten&author=M+Mattheus&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0042"> <div class="citation-journal">Wanner C, Inzucchi SE, Lachin JM, Fitchett D, Eynatten M, Mattheus M, et al. <span class="citation-title">Empagliflozin and progression of kidney disease in type 2 diabetes</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2016</span>;<span class="volume">375</span>(4):323‐34. [MEDLINE: 27299675]<a class="crsref citation-link central-link" data-crsref="9140685" href="" ref="info:x-wiley/crsRef/9140685" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27299675" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Empagliflozin+and+progression+of+kidney+disease+in+type+2+diabetes&author=C+Wanner&author=SE+Inzucchi&author=JM+Lachin&author=D+Fitchett&author=M+Eynatten&author=M+Mattheus&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0043"> <div class="citation-journal">Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George JT, et al. <span class="citation-title">Empagliflozin and clinical outcomes in patients with type 2 diabetes, established cardiovascular disease and chronic kidney disease</span>. <span class="citation"> Circulation </span><span class="pubYear">2018</span>;<span class="volume">137</span>(2):119‐29. [MEDLINE: 28904068]<a class="crsref citation-link central-link" data-crsref="9140686" href="" ref="info:x-wiley/crsRef/9140686" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/28904068" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Empagliflozin+and+clinical+outcomes+in+patients+with+type+2+diabetes,+established+cardiovascular+disease+and+chronic+kidney+disease+&author=C+Wanner&author=JM+Lachin&author=SE+Inzucchi&author=D+Fitchett&author=M+Mattheus&author=JT+George&publication_year=2018&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0044"> <div class="citation-journal">Wanner C, Levin A, Perkovic V, Koitka‐Weber A, Mattheus M, Eynatten M, et al. <span class="citation-title">Effects of empagliflozin on renal outcomes across KDIGO risk categories: Results from the EMPA‐REG OUTCOME trial [abstract]</span>. <span class="citation"> Nephrology Dialysis Transplantation </span><span class="pubYear">2017</span>;<span class="volume">32</span>(Suppl 3):iii193‐iii. [EMBASE: 617290043]<a class="crsref citation-link central-link" data-crsref="9140687" href="" ref="info:x-wiley/crsRef/9140687" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+empagliflozin+on+renal+outcomes+across+KDIGO+risk+categories:+Results+from+the+EMPA%E2%80%90REG+OUTCOME+trial+[abstract]+&author=C+Wanner&author=A+Levin&author=V+Perkovic&author=A+Koitka%E2%80%90Weber&author=M+Mattheus&author=M+Eynatten&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0045"> <div class="citation-journal">Zinman B, Inzucchi S, Lachin J, Wanner C, Ferrari R, Fitchett D, et al. <span class="citation-title">Baseline characteristics of participants enrolled in the empagliflozin cardiovascular outcome trial (EMPA‐REG OUTCOME) in patients with type 2 diabetes [abstract]</span>. <span class="citation"> Diabetologie und Stoffwechsel </span><span class="pubYear">2014</span>;<span class="volume">9</span>:n/a. <a class="crsref citation-link central-link" data-crsref="9140688" href="" ref="info:x-wiley/crsRef/9140688" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Baseline+characteristics+of+participants+enrolled+in+the+empagliflozin+cardiovascular+outcome+trial+(EMPA%E2%80%90REG+OUTCOME)+in+patients+with+type+2+diabetes+[abstract]+&author=B+Zinman&author=S+Inzucchi&author=J+Lachin&author=C+Wanner&author=R+Ferrari&author=D+Fitchett&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0046"> <div class="citation-journal">Zinman B, Inzucchi SE, Lachin JM, Wanner C, Ferrari R, Bluhmki E, et al. <span class="citation-title">Design of the empagliflozin cardiovascular (CV) outcome event trial in type 2 diabetes (T2D) [abstract]</span>. <span class="citation"> Diabetes </span><span class="pubYear">2013</span>;<span class="volume">62</span>(Suppl 1):A600. [EMBASE: 71288750]<a class="crsref citation-link central-link" data-crsref="9140689" href="" ref="info:x-wiley/crsRef/9140689" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Design+of+the+empagliflozin+cardiovascular+(CV)+outcome+event+trial+in+type+2+diabetes+(T2D)+[abstract]+&author=B+Zinman&author=SE+Inzucchi&author=JM+Lachin&author=C+Wanner&author=R+Ferrari&author=E+Bluhmki&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0047"> <div class="citation-journal">Zinman B, Inzucchi SE, Lachin JM, Wanner C, Ferrari R, Fitchett D, et al. <span class="citation-title">Rationale, design, and baseline characteristics of a randomized, placebo‐controlled cardiovascular outcome trial of empagliflozin (EMPA‐REG OUTCOME)</span>. <span class="citation"> Cardiovascular Diabetology </span><span class="pubYear">2014</span>;<span class="volume">13</span>:102. [MEDLINE: 24943000]<a class="crsref citation-link central-link" data-crsref="9140690" href="" ref="info:x-wiley/crsRef/9140690" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24943000" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rationale,+design,+and+baseline+characteristics+of+a+randomized,+placebo%E2%80%90controlled+cardiovascular+outcome+trial+of+empagliflozin+(EMPA%E2%80%90REG+OUTCOME)+&author=B+Zinman&author=SE+Inzucchi&author=JM+Lachin&author=C+Wanner&author=R+Ferrari&author=D+Fitchett&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0048"> <div class="citation-journal">Zinman B, Inzucchi SE, Lachin JM, Wanner C, Fitchett D, Kohler S, et al. <span class="citation-title">Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk</span>. <span class="citation"> Stroke </span><span class="pubYear">2017</span>;<span class="volume">48</span>(5):1218‐25. [MEDLINE: 28386035]<a class="crsref citation-link central-link" data-crsref="9140691" href="" ref="info:x-wiley/crsRef/9140691" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/28386035" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Empagliflozin+and+cerebrovascular+events+in+patients+with+type+2+diabetes+mellitus+at+high+cardiovascular+risk+&author=B+Zinman&author=SE+Inzucchi&author=JM+Lachin&author=C+Wanner&author=D+Fitchett&author=S+Kohler&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0049"> <div class="citation-journal">Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. <span class="citation-title">Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2015</span>;<span class="volume">373</span>(22):2117‐28. [MEDLINE: 26378978]<a class="crsref citation-link central-link" data-crsref="9140692" href="" ref="info:x-wiley/crsRef/9140692" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26378978" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Empagliflozin,+cardiovascular+outcomes,+and+mortality+in+type+2+diabetes&author=B+Zinman&author=C+Wanner&author=JM+Lachin&author=D+Fitchett&author=E+Bluhmki&author=S+Hantel&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0050"> <div class="citation-journal">Eynatten M, Bergenstal RM, Calabro P, Maldonado‐Lutomirsky M, Mattheus M, Lachin JM, et al. <span class="citation-title">Effect of empagliflozin on nephropathy in subgroups by age: Results from EMPA‐REG OUTCOME [abstract]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2016</span>;<span class="volume">59</span>(1 Suppl 1):S483. [EMBASE: 612313304]<a class="crsref citation-link central-link" data-crsref="9140693" href="" ref="info:x-wiley/crsRef/9140693" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+empagliflozin+on+nephropathy+in+subgroups+by+age:+Results+from+EMPA%E2%80%90REG+OUTCOME+[abstract]+&author=M+Eynatten&author=RM+Bergenstal&author=P+Calabro&author=M+Maldonado%E2%80%90Lutomirsky&author=M+Mattheus&author=JM+Lachin&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0016"> <div class="reference-title-banner"> <h4 class="title">EMPA‐REG RENAL 2014 {published and unpublished data} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0051"> <div class="citation-journal">Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, et al. <span class="citation-title">Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double‐blind, placebo‐controlled trial</span>. <span class="citation"> The Lancet Diabetes &amp; Endocrinology </span><span class="pubYear">2014</span>;<span class="volume">2</span>(5):369‐84. [MEDLINE: 24795251]<a class="crsref citation-link central-link" data-crsref="9140695" href="" ref="info:x-wiley/crsRef/9140695" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24795251" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+empagliflozin+added+to+existing+antidiabetes+treatment+in+patients+with+type+2+diabetes+and+chronic+kidney+disease:+a+randomised,+double%E2%80%90blind,+placebo%E2%80%90controlled+trial+&author=AH+Barnett&author=A+Mithal&author=J+Manassie&author=R+Jones&author=H+Rattunde&author=HJ+Woerle&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0017"> <div class="reference-title-banner"> <h4 class="title">GUARD 2017 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0052"> <div class="citation-journal">Yoon S, Han B, Kim S, Han S, Jo Y, Jeong K, et al. <span class="citation-title">Efficacy and safety of gemigliptin in type 2 diabetes patients with moderate to severe renal impairment [abstract no:804]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2015</span>;<span class="volume">58</span>(1 Suppl 1):S387. [EMBASE: 72031048]<a class="crsref citation-link central-link" data-crsref="9140697" href="" ref="info:x-wiley/crsRef/9140697" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+gemigliptin+in+type+2+diabetes+patients+with+moderate+to+severe+renal+impairment+[abstract+no:804]+&author=S+Yoon&author=B+Han&author=S+Kim&author=S+Han&author=Y+Jo&author=K+Jeong&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0053"> <div class="citation-journal">Yoon S, Han B, Kim S, Han S, Jo YI, Jeong K, et al. <span class="citation-title">Efficacy and safety of gemigliptin in type 2 diabetes patients with moderate to severe renal impairment (GUARD study) [abstract no: 760]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2016</span>;<span class="volume">59</span>(1 Suppl 1):S361. [EMBASE: 612313344]<a class="crsref citation-link central-link" data-crsref="9140698" href="" ref="info:x-wiley/crsRef/9140698" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+gemigliptin+in+type+2+diabetes+patients+with+moderate+to+severe+renal+impairment+(GUARD+study)+[abstract+no:+760]+&author=S+Yoon&author=B+Han&author=S+Kim&author=S+Han&author=YI+Jo&author=K+Jeong&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0054"> <div class="citation-journal">Yoon SA, Han BG, Kim SG, Han SY, Jo YI, Jeong KH, et al. <span class="citation-title">Efficacy, safety and albuminuria‐reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12‐week, double‐blind randomized study (the GUARD Study)</span>. <span class="citation"> Diabetes, Obesity &amp; Metabolism </span><span class="pubYear">2017</span>;<span class="volume">19</span>(4):590‐8. [MEDLINE: 28019072]<a class="crsref citation-link central-link" data-crsref="9140699" href="" ref="info:x-wiley/crsRef/9140699" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/28019072" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy,+safety+and+albuminuria%E2%80%90reducing+effect+of+gemigliptin+in+Korean+type+2+diabetes+patients+with+moderate+to+severe+renal+impairment:+A+12%E2%80%90week,+double%E2%80%90blind+randomized+study+(the+GUARD+Study)+&author=SA+Yoon&author=BG+Han&author=SG+Kim&author=SY+Han&author=YI+Jo&author=KH+Jeong&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0018"> <div class="reference-title-banner"> <h4 class="title">Haneda 2016 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0055"> <div class="citation-journal">Haneda M, Seino Y, Inagaki N, Kaku K, Sasaki T, Fukatsu A, et al. <span class="citation-title">Influence of renal function on the 52‐week efficacy and safety of the sodium glucose cotransporter 2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus</span>. <span class="citation"> Clinical Therapeutics </span><span class="pubYear">2016</span>;<span class="volume">38</span>(1):66‐88. [MEDLINE: 26718606]<a class="crsref citation-link central-link" data-crsref="9140701" href="" ref="info:x-wiley/crsRef/9140701" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26718606" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Influence+of+renal+function+on+the+52%E2%80%90week+efficacy+and+safety+of+the+sodium+glucose+cotransporter+2+inhibitor+luseogliflozin+in+Japanese+patients+with+type+2+diabetes+mellitus+&author=M+Haneda&author=Y+Seino&author=N+Inagaki&author=K+Kaku&author=T+Sasaki&author=A+Fukatsu&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0019"> <div class="reference-title-banner"> <h4 class="title">Idorn 2013 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0056"> <div class="citation-journal">Idorn T, Knop FK, Jorgensen M, Jensen T, Resuli M, Hansen PM, et al. <span class="citation-title">Safety and efficacy of liraglutide in patients with type 2 diabetes and end‐stage renal disease: protocol for an investigator‐initiated prospective, randomised, placebo‐controlled, double‐blinded, parallel intervention study</span>. <span class="citation"> BMJ Open </span><span class="pubYear">2013</span>;<span class="volume">3</span>(4):1. [MEDLINE: 23624993]<a class="crsref citation-link central-link" data-crsref="9140703" href="" ref="info:x-wiley/crsRef/9140703" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Safety+and+efficacy+of+liraglutide+in+patients+with+type+2+diabetes+and+end%E2%80%90stage+renal+disease:+protocol+for+an+investigator%E2%80%90initiated+prospective,+randomised,+placebo%E2%80%90controlled,+double%E2%80%90blinded,+parallel+intervention+study+&author=T+Idorn&author=FK+Knop&author=M+Jorgensen&author=T+Jensen&author=M+Resuli&author=PM+Hansen&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0057"> <div class="citation-journal">Idorn T, Knop FK, Jorgensen MB, Jensen T, Resuli M, Hansen PM, et al. <span class="citation-title">Safety and efficacy of liraglutide in patients with type 2 diabetes and end‐stage renal disease: An investigator‐initiated, randomised, placebo controlled trial [abstract]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2014</span>;<span class="volume">57</span>(1 Suppl):S370‐1. [EMBASE: 71595559]<a class="crsref citation-link central-link" data-crsref="9140704" href="" ref="info:x-wiley/crsRef/9140704" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Safety+and+efficacy+of+liraglutide+in+patients+with+type+2+diabetes+and+end%E2%80%90stage+renal+disease:+An+investigator%E2%80%90initiated,+randomised,+placebo+controlled+trial+[abstract]+&author=T+Idorn&author=FK+Knop&author=MB+Jorgensen&author=T+Jensen&author=M+Resuli&author=PM+Hansen&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0058"> <div class="citation-journal">Idorn T, Knop FK, Jorgensen MB, Jensen T, Resuli M, Hansen PM, et al. <span class="citation-title">Safety and efficacy of liraglutide in patients with type 2 diabetes and end‐stage renal disease: an investigator‐initiated, placebo‐controlled, double‐blind, parallel‐group, randomized trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2016</span>;<span class="volume">39</span>(2):206‐13. [MEDLINE: 26283739]<a class="crsref citation-link central-link" data-crsref="9140705" href="" ref="info:x-wiley/crsRef/9140705" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26283739" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Safety+and+efficacy+of+liraglutide+in+patients+with+type+2+diabetes+and+end%E2%80%90stage+renal+disease:+an+investigator%E2%80%90initiated,+placebo%E2%80%90controlled,+double%E2%80%90blind,+parallel%E2%80%90group,+randomized+trial+&author=T+Idorn&author=FK+Knop&author=MB+Jorgensen&author=T+Jensen&author=M+Resuli&author=PM+Hansen&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0020"> <div class="reference-title-banner"> <h4 class="title">Ito 2011a {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0059"> <div class="citation-journal">Ito M, Abe M, Okada K, Sasaki H, Maruyama N, Tsuchida M, et al. <span class="citation-title">The dipeptidyl peptidase‐4 (DPP‐4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis</span>. <span class="citation"> Endocrine Journal </span><span class="pubYear">2011</span>;<span class="volume">58</span>(11):979‐87. [MEDLINE: 21921362]<a class="crsref citation-link central-link" data-crsref="9140707" href="" ref="info:x-wiley/crsRef/9140707" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21921362" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+dipeptidyl+peptidase%E2%80%904+(DPP%E2%80%904)+inhibitor+vildagliptin+improves+glycemic+control+in+type+2+diabetic+patients+undergoing+hemodialysis+&author=M+Ito&author=M+Abe&author=K+Okada&author=H+Sasaki&author=N+Maruyama&author=M+Tsuchida&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0021"> <div class="reference-title-banner"> <h4 class="title">Jin 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0060"> <div class="citation-journal">Jin HM, Pan Y. <span class="citation-title">Angiotensin type‐1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy</span>. <span class="citation"> Nephrology Dialysis Transplantation </span><span class="pubYear">2007</span>;<span class="volume">22</span>(7):1943‐9. [MEDLINE: 17308317]<a class="crsref citation-link central-link" data-crsref="9140709" href="" ref="info:x-wiley/crsRef/9140709" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Angiotensin+type%E2%80%901+receptor+blockade+with+losartan+increases+insulin+sensitivity+and+improves+glucose+homeostasis+in+subjects+with+type+2+diabetes+and+nephropathy+&author=HM+Jin&author=Y+Pan&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0061"> <div class="citation-journal">Jin HM, Pan Y. <span class="citation-title">Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy</span>. <span class="citation"> Kidney &amp; Blood Pressure Research </span><span class="pubYear">2007</span>;<span class="volume">30</span>(4):203‐11. [MEDLINE: 17575467]<a class="crsref citation-link central-link" data-crsref="9140710" href="" ref="info:x-wiley/crsRef/9140710" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17575467" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Renoprotection+provided+by+losartan+in+combination+with+pioglitazone+is+superior+to+renoprotection+provided+by+losartan+alone+in+patients+with+type+2+diabetic+nephropathy+&author=HM+Jin&author=Y+Pan&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0022"> <div class="reference-title-banner"> <h4 class="title">Kaku 2014 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0062"> <div class="citation-journal">Kaku K, Kiyosue A, Inoue S, Ueda N, Tokudome T, Yang J, et al. <span class="citation-title">Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise</span>. <span class="citation"> Diabetes, Obesity and Metabolism </span><span class="pubYear">2014</span>;<span class="volume">16</span>(11):1102‐1110. [MEDLINE: 24909293]<a class="crsref citation-link central-link" data-crsref="9140712" href="" ref="info:x-wiley/crsRef/9140712" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+dapagliflozin+monotherapy+in+Japanese+patients+with+type+2+diabetes+inadequately+controlled+by+diet+and+exercise+&author=K+Kaku&author=A+Kiyosue&author=S+Inoue&author=N+Ueda&author=T+Tokudome&author=J+Yang&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0023"> <div class="reference-title-banner"> <h4 class="title">Kohan 2014 {published and unpublished data} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0063"> <div class="citation-journal">Kohan DE, Fioretto P, Tang W, List JF. <span class="citation-title">Long‐term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control</span>. <span class="citation"> Kidney International </span><span class="pubYear">2014</span>;<span class="volume">85</span>(4):962‐71. [MEDLINE: 24067431]<a class="crsref citation-link central-link" data-crsref="9140714" href="" ref="info:x-wiley/crsRef/9140714" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24067431" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+study+of+patients+with+type+2+diabetes+and+moderate+renal+impairment+shows+that+dapagliflozin+reduces+weight+and+blood+pressure+but+does+not+improve+glycemic+control+&author=DE+Kohan&author=P+Fioretto&author=W+Tang&author=JF+List&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0064"> <div class="citation-journal">Kohan DE, Firescu C, List JF, Tang W. <span class="citation-title">Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment [abstract no:TH‐PO524]</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">2011</span>;<span class="volume">22</span>(Abstracts):232A‐3A. <a class="crsref citation-link central-link" data-crsref="9140715" href="" ref="info:x-wiley/crsRef/9140715" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+dapagliflozin+in+patients+with+type+2+diabetes+and+moderate+renal+impairment+[abstract+no:TH%E2%80%90PO524]+&author=DE+Kohan&author=C+Firescu&author=JF+List&author=W+Tang&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0024"> <div class="reference-title-banner"> <h4 class="title">Kothny 2015 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0065"> <div class="citation-journal">Kothny W, Lukashevich V, Foley JE, Rendell MS, Schweizer A. <span class="citation-title">Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2015</span>;<span class="volume">58</span>(9):2020‐6. [MEDLINE: 26067186]<a class="crsref citation-link central-link" data-crsref="9140717" href="" ref="info:x-wiley/crsRef/9140717" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26067186" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparison+of+vildagliptin+and+sitagliptin+in+patients+with+type+2+diabetes+and+severe+renal+impairment:+a+randomised+clinical+trial+&author=W+Kothny&author=V+Lukashevich&author=JE+Foley&author=MS+Rendell&author=A+Schweizer&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0025"> <div class="reference-title-banner"> <h4 class="title">Laakso 2015 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0066"> <div class="citation-journal">Groop P, Perkovic V, Cooper M, Crowe S, Lee J, Patel S, et al. <span class="citation-title">Long‐term efficacy and safety of linagliptin in type 2 diabetes patients with moderate to severe renal disease</span>. <span class="citation"> Diabetes </span><span class="pubYear">2014</span>;<span class="volume">63</span>(Suppl 1):A264. [EMBASE: 71559411]<a class="crsref citation-link central-link" data-crsref="9140719" href="" ref="info:x-wiley/crsRef/9140719" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+efficacy+and+safety+of+linagliptin+in+type+2+diabetes+patients+with+moderate+to+severe+renal+disease+&author=P+Groop&author=V+Perkovic&author=M+Cooper&author=S+Crowe&author=J+Lee&author=S+Patel&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0067"> <div class="citation-journal">Groop PH, Laakso M, Rosenstock J, Hehnke U, Tamminen I, Patel S, et al. <span class="citation-title">Linagliptin versus placebo followed by glimepiride in type 2 diabetes patients with moderate to severe renal impairment [abstract no:P13‐11527]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2016</span>;<span class="volume">56</span>(Suppl 1):S364‐5. <a class="crsref citation-link central-link" data-crsref="9140720" href="" ref="info:x-wiley/crsRef/9140720" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Linagliptin+versus+placebo+followed+by+glimepiride+in+type+2+diabetes+patients+with+moderate+to+severe+renal+impairment+[abstract+no:P13%E2%80%9011527]+&author=PH+Groop&author=M+Laakso&author=J+Rosenstock&author=U+Hehnke&author=I+Tamminen&author=S+Patel&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0068"> <div class="citation-journal">Laakso M, Rosenstock J, Groop P, Hehnke U, Tamminen I, Patel S, et al. <span class="citation-title">Linagliptin vs. placebo followed by glimepiride in type 2 diabetes patients with moderate to severe renal impairment</span>. <span class="citation"> Diabetes </span><span class="pubYear">2013</span>;<span class="volume">62</span>(Suppl 1):A281‐A2. [EMBASE: 71287521]<a class="crsref citation-link central-link" data-crsref="9140721" href="" ref="info:x-wiley/crsRef/9140721" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Linagliptin+vs.+placebo+followed+by+glimepiride+in+type+2+diabetes+patients+with+moderate+to+severe+renal+impairment+&author=M+Laakso&author=J+Rosenstock&author=P+Groop&author=U+Hehnke&author=I+Tamminen&author=S+Patel&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0069"> <div class="citation-journal">Laakso M, Rosenstock J, Groop PH, Barnett AH, Gallwitz B, Hehnke U, et al. <span class="citation-title">Treatment with the dipeptidyl peptidase‐4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52‐week, randomized, double‐blind clinical trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2015</span>;<span class="volume">38</span>(2):e15‐7. [MEDLINE: 25614693]<a class="crsref citation-link central-link" data-crsref="9140722" href="" ref="info:x-wiley/crsRef/9140722" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25614693" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Treatment+with+the+dipeptidyl+peptidase%E2%80%904+inhibitor+linagliptin+or+placebo+followed+by+glimepiride+in+patients+with+type+2+diabetes+with+moderate+to+severe+renal+impairment:+a+52%E2%80%90week,+randomized,+double%E2%80%90blind+clinical+trial+&author=M+Laakso&author=J+Rosenstock&author=PH+Groop&author=AH+Barnett&author=B+Gallwitz&author=U+Hehnke&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0026"> <div class="reference-title-banner"> <h4 class="title">LANTERN 2015 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0070"> <div class="citation-journal">Kashiwagi A, Takahashi H, Ishikawa H, Yoshida S, Kazuta K, Utsuno A, et al. <span class="citation-title">A randomized, double‐blind, placebo‐controlled study on long‐term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long‐term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study</span>. <span class="citation"> Diabetes, Obesity and Metabolism </span><span class="pubYear">2015</span>;<span class="volume">17</span>(2):152‐60. [MEDLINE: 25347938]<a class="crsref citation-link central-link" data-crsref="9140724" href="" ref="info:x-wiley/crsRef/9140724" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+randomized,+double%E2%80%90blind,+placebo%E2%80%90controlled+study+on+long%E2%80%90term+efficacy+and+safety+of+ipragliflozin+treatment+in+patients+with+type+2+diabetes+mellitus+and+renal+impairment:+results+of+the+long%E2%80%90term+ASP1941+safety+evaluation+in+patients+with+type+2+diabetes+with+renal+impairment+(LANTERN)+study+&author=A+Kashiwagi&author=H+Takahashi&author=H+Ishikawa&author=S+Yoshida&author=K+Kazuta&author=A+Utsuno&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0027"> <div class="reference-title-banner"> <h4 class="title">Leiter 2014 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0071"> <div class="citation-journal">Leiter LA, Carr MC, Stewart M, Jones‐Leone A, Scott R, Yang F, et al. <span class="citation-title">Efficacy and safety of the once‐weekly GLP‐1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2014</span>;<span class="volume">37</span>(10):2723‐30. [MEDLINE: 25048383]<a class="crsref citation-link central-link" data-crsref="9140726" href="" ref="info:x-wiley/crsRef/9140726" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25048383" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+the+once%E2%80%90weekly+GLP%E2%80%901+receptor+agonist+albiglutide+versus+sitagliptin+in+patients+with+type+2+diabetes+and+renal+impairment:+a+randomized+phase+III+study+&author=LA+Leiter&author=MC+Carr&author=M+Stewart&author=A+Jones%E2%80%90Leone&author=R+Scott&author=F+Yang&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0028"> <div class="reference-title-banner"> <h4 class="title">Lewin 2012 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0072"> <div class="citation-journal">Lewin AJ, Arvay L, Liu D, Patel S, Eynatten M, Woerle HJ. <span class="citation-title">Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18‐week, multicenter, randomized, double‐blind, placebo‐controlled trial</span>. <span class="citation"> Clinical Therapeutics </span><span class="pubYear">2012</span>;<span class="volume">34</span>(9):1909‐19. [MEDLINE: 22939034]<a class="crsref citation-link central-link" data-crsref="9140728" href="" ref="info:x-wiley/crsRef/9140728" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22939034" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+tolerability+of+linagliptin+added+to+a+sulfonylurea+regimen+in+patients+with+inadequately+controlled+type+2+diabetes+mellitus:+an+18%E2%80%90week,+multicenter,+randomized,+double%E2%80%90blind,+placebo%E2%80%90controlled+trial+&author=AJ+Lewin&author=L+Arvay&author=D+Liu&author=S+Patel&author=M+Eynatten&author=HJ+Woerle&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0073"> <div class="citation-journal">McGill JB, Barnett AH, Lewin AJ, Patel S, Neubacher D, Eynatten M, et al. <span class="citation-title">Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate‐to‐severe renal impairment</span>. <span class="citation"> Diabetes &amp; Vascular Disease Research </span><span class="pubYear">2014</span>;<span class="volume">11</span>(1):34‐40. [MEDLINE: 24169807]<a class="crsref citation-link central-link" data-crsref="9140729" href="" ref="info:x-wiley/crsRef/9140729" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24169807" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Linagliptin+added+to+sulphonylurea+in+uncontrolled+type+2+diabetes+patients+with+moderate%E2%80%90to%E2%80%90severe+renal+impairment+&author=JB+McGill&author=AH+Barnett&author=AJ+Lewin&author=S+Patel&author=D+Neubacher&author=M+Eynatten&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0029"> <div class="reference-title-banner"> <h4 class="title">LIRA‐RENAL 2016 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0074"> <div class="citation-journal">Davies MJ, Bain SC, Atkin SL, Rossing P, Scott D, Shamkhalova MS, et al. <span class="citation-title">Efficacy and safety of liraglutide versus placebo as add‐on to glucose‐lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA‐RENAL): a randomized clinical trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2016</span>;<span class="volume">39</span>(2):222‐30. [MEDLINE: 26681713]<a class="crsref citation-link central-link" data-crsref="9140731" href="" ref="info:x-wiley/crsRef/9140731" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26681713" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+liraglutide+versus+placebo+as+add%E2%80%90on+to+glucose%E2%80%90lowering+therapy+in+patients+with+type+2+diabetes+and+moderate+renal+impairment+(LIRA%E2%80%90RENAL):+a+randomized+clinical+trial+&author=MJ+Davies&author=SC+Bain&author=SL+Atkin&author=P+Rossing&author=D+Scott&author=MS+Shamkhalova&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0075"> <div class="citation-journal">Mathieu C, Umpierrez G, Atkin S, Bain S, Rossing P, Scott D, et al. <span class="citation-title">Efficacy and safety of liraglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment (LIRA‐RENAL): a randomised trial [abstract no: OP60]</span>. <span class="citation"> Diabetes Research &amp; Clinical Practice </span><span class="pubYear">2014</span>;<span class="volume">106</span>(Suppl 1):S31. [EMBASE: 71824748]<a class="crsref citation-link central-link" data-crsref="9140732" href="" ref="info:x-wiley/crsRef/9140732" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+liraglutide+versus+placebo+in+subjects+with+type+2+diabetes+and+moderate+renal+impairment+(LIRA%E2%80%90RENAL):+a+randomised+trial+[abstract+no:+OP60]+&author=C+Mathieu&author=G+Umpierrez&author=S+Atkin&author=S+Bain&author=P+Rossing&author=D+Scott&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0076"> <div class="citation-journal">Ngo P, Davies M, Atkin S, Bain S, Rossing P, Scott D, et al. <span class="citation-title">Efficacy and safety of liraglutide vs. placebo as add‐on to existing diabetes medication in subjects with type 2 diabetes and moderate renal impairment (LIRA‐RENAL) [abstract no: 18]</span>. <span class="citation"> Canadian Journal of Diabetes </span><span class="pubYear">2014</span>;<span class="volume">38</span>(5 Suppl):S9‐S10. [EMBASE: 72003971]<a class="crsref citation-link central-link" data-crsref="9140733" href="" ref="info:x-wiley/crsRef/9140733" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+liraglutide+vs.+placebo+as+add%E2%80%90on+to+existing+diabetes+medication+in+subjects+with+type+2+diabetes+and+moderate+renal+impairment+(LIRA%E2%80%90RENAL)+[abstract+no:+18]+&author=P+Ngo&author=M+Davies&author=S+Atkin&author=S+Bain&author=P+Rossing&author=D+Scott&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0077"> <div class="citation-journal">Umpierrez G, Atkin S, Bain S, Rossing P, Scott D, Shamkhalova M, et al. <span class="citation-title">Efficacy and safety of liraglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment (LIRA‐RENAL): a randomised trial [abstract]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2014</span>;<span class="volume">57</span>(Suppl 1):S84. [EMBASE: 71594832]<a class="crsref citation-link central-link" data-crsref="9140734" href="" ref="info:x-wiley/crsRef/9140734" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+liraglutide+versus+placebo+in+subjects+with+type+2+diabetes+and+moderate+renal+impairment+(LIRA%E2%80%90RENAL):+a+randomised+trial+[abstract]+&author=G+Umpierrez&author=S+Atkin&author=S+Bain&author=P+Rossing&author=D+Scott&author=M+Shamkhalova&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0030"> <div class="reference-title-banner"> <h4 class="title">Lukashevich 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0078"> <div class="citation-journal">Kothny W, Schweizer A, Naik R, Groop P, Shao Q, Lukashevich V. <span class="citation-title">Comparison of vildagliptin with placebo in a 24‐week study of 221 patients with type 2 diabetes and severe renal impairment (eGFR&lt;30) [abstract]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2011</span>;<span class="volume">54</span>:S332. [EMBASE: 70562964]<a class="crsref citation-link central-link" data-crsref="9140736" href="" ref="info:x-wiley/crsRef/9140736" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="https://scholar.google.com/scholar_lookup?title=Comparison+of+vildagliptin+with+placebo+in+a+24‐week+study+of+221+patients+with+type+2+diabetes+and+severe+renal+impairment+(eGFR<30)+[abstract]+&author=W+Kothny&author=A+Schweizer&author=R+Naik&author=P+Groop&author=Q+Shao&author=V+Lukashevich&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0079"> <div class="citation-journal">Kothny W, Shao Q, Groop PH, Lukashevich V. <span class="citation-title">One‐year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment</span>. <span class="citation"> Diabetes, Obesity &amp; Metabolism </span><span class="pubYear">2012</span>;<span class="volume">14</span>(11):1032‐9. [MEDLINE: 22690943]<a class="crsref citation-link central-link" data-crsref="9140737" href="" ref="info:x-wiley/crsRef/9140737" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22690943" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=One%E2%80%90year+safety,+tolerability+and+efficacy+of+vildagliptin+in+patients+with+type+2+diabetes+and+moderate+or+severe+renal+impairment+&author=W+Kothny&author=Q+Shao&author=PH+Groop&author=V+Lukashevich&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0080"> <div class="citation-journal">Kothny W, Wang M, Shao Q, Groop P, Lukashevich V. <span class="citation-title">One‐year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes mellitus and moderate or severe renal insufficiency [abstract]</span>. <span class="citation"> Diabetes </span><span class="pubYear">2012</span>;<span class="volume">61</span>:A253. [EMBASE: 70797589]<a class="crsref citation-link central-link" data-crsref="9140738" href="" ref="info:x-wiley/crsRef/9140738" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=One%E2%80%90year+safety,+tolerability+and+efficacy+of+vildagliptin+in+patients+with+type+2+diabetes+mellitus+and+moderate+or+severe+renal+insufficiency+[abstract]+&author=W+Kothny&author=M+Wang&author=Q+Shao&author=P+Groop&author=V+Lukashevich&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0081"> <div class="citation-journal">Lukashevich V, Schweizer A, Foley J, Shao Q, Groop P, Kothny W. <span class="citation-title">Efficacy of vildagliptin therapy in combination with insulin in patients with type 2 diabetes and severe renal impairment [abstract]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2011</span>;<span class="volume">54</span>:S332‐3. [EMBASE: 70562965]<a class="crsref citation-link central-link" data-crsref="9140739" href="" ref="info:x-wiley/crsRef/9140739" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+of+vildagliptin+therapy+in+combination+with+insulin+in+patients+with+type+2+diabetes+and+severe+renal+impairment+[abstract]+&author=V+Lukashevich&author=A+Schweizer&author=J+Foley&author=Q+Shao&author=P+Groop&author=W+Kothny&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0082"> <div class="citation-journal">Lukashevich V, Schweizer A, Foley JE, Dickinson S, Groop PH, Kothny W. <span class="citation-title">Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment</span>. <span class="citation"> Vascular Health &amp; Risk Management </span><span class="pubYear">2013</span>;<span class="volume">9</span>:21‐8. [MEDLINE: 23378769]<a class="crsref citation-link central-link" data-crsref="9140740" href="" ref="info:x-wiley/crsRef/9140740" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+of+vildagliptin+in+combination+with+insulin+in+patients+with+type+2+diabetes+and+severe+renal+impairment+&author=V+Lukashevich&author=A+Schweizer&author=JE+Foley&author=S+Dickinson&author=PH+Groop&author=W+Kothny&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0083"> <div class="citation-journal">Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. <span class="citation-title">Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24‐week randomized placebo‐controlled trial</span>. <span class="citation"> Diabetes, Obesity &amp; Metabolism </span><span class="pubYear">2011</span>;<span class="volume">13</span>(10):947‐54. [MEDLINE: 21733061]<a class="crsref citation-link central-link" data-crsref="9140741" href="" ref="info:x-wiley/crsRef/9140741" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21733061" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Safety+and+efficacy+of+vildagliptin+versus+placebo+in+patients+with+type+2+diabetes+and+moderate+or+severe+renal+impairment:+a+prospective+24%E2%80%90week+randomized+placebo%E2%80%90controlled+trial+&author=V+Lukashevich&author=A+Schweizer&author=Q+Shao&author=PH+Groop&author=W+Kothny&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0031"> <div class="reference-title-banner"> <h4 class="title">McGill 2013 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0084"> <div class="citation-journal">McGill JB, Barnett AH, Lewin AJ, Patel S, Neubacher D, Eynatten M, et al. <span class="citation-title">Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate‐to‐severe renal impairment</span>. <span class="citation"> Diabetes &amp; Vascular Disease Research </span><span class="pubYear">2014</span>;<span class="volume">11</span>(1):34‐40. [MEDLINE: 24169807]<a class="crsref citation-link central-link" data-crsref="9140743" href="" ref="info:x-wiley/crsRef/9140743" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24169807" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Linagliptin+added+to+sulphonylurea+in+uncontrolled+type+2+diabetes+patients+with+moderate%E2%80%90to%E2%80%90severe+renal+impairment+&author=JB+McGill&author=AH+Barnett&author=AJ+Lewin&author=S+Patel&author=D+Neubacher&author=M+Eynatten&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0085"> <div class="citation-journal">McGill JB, Sloan L, Newman J, Patel S, Sauce C, Eynatten M, et al. <span class="citation-title">Long‐term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: A 1‐year, randomized, double‐blind, placebo‐controlled study</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2013</span>;<span class="volume">36</span>(2):237‐44. [MEDLINE: 23033241]<a class="crsref citation-link central-link" data-crsref="9140744" href="" ref="info:x-wiley/crsRef/9140744" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23033241" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+efficacy+and+safety+of+linagliptin+in+patients+with+type+2+diabetes+and+severe+renal+impairment:+A+1%E2%80%90year,+randomized,+double%E2%80%90blind,+placebo%E2%80%90controlled+study+&author=JB+McGill&author=L+Sloan&author=J+Newman&author=S+Patel&author=C+Sauce&author=M+Eynatten&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0086"> <div class="citation-journal">McGill JB, Yki‐Jarvinen H, Crowe S, Woerle HJ, Eynatten M. <span class="citation-title">Combination of the dipeptidyl peptidase‐4 inhibitor linagliptin with insulin‐based regimens in type 2 diabetes and chronic kidney disease</span>. <span class="citation"> Diabetes &amp; Vascular Disease Research </span><span class="pubYear">2015</span>;<span class="volume">12</span>(4):249‐57. [MEDLINE: 25941160]<a class="crsref citation-link central-link" data-crsref="9140745" href="" ref="info:x-wiley/crsRef/9140745" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25941160" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Combination+of+the+dipeptidyl+peptidase%E2%80%904+inhibitor+linagliptin+with+insulin%E2%80%90based+regimens+in+type+2+diabetes+and+chronic+kidney+disease+&author=JB+McGill&author=H+Yki%E2%80%90Jarvinen&author=S+Crowe&author=HJ+Woerle&author=M+Eynatten&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0032"> <div class="reference-title-banner"> <h4 class="title">Mohideen 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0087"> <div class="citation-journal">Mohideen P, Bornemann M, Sugihara J, Genadio V, Sugihara V, Arakaki R. <span class="citation-title">The metabolic effects of troglitazone in patients with diabetes and end‐stage renal disease</span>. <span class="citation"> Endocrine </span><span class="pubYear">2005</span>;<span class="volume">28</span>(2):181‐6. [MEDLINE: 16388091]<a class="crsref citation-link central-link" data-crsref="9140747" href="" ref="info:x-wiley/crsRef/9140747" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16388091" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+metabolic+effects+of+troglitazone+in+patients+with+diabetes+and+end%E2%80%90stage+renal+disease+&author=P+Mohideen&author=M+Bornemann&author=J+Sugihara&author=V+Genadio&author=V+Sugihara&author=R+Arakaki&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0033"> <div class="reference-title-banner"> <h4 class="title">Mori 2016 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0088"> <div class="citation-journal">Mori K, Emoto M, Shoji T, Inaba M. <span class="citation-title">Linagliptin monotherapy compared with voglibose monotherapy in patients with type 2 diabetes undergoing hemodialysis: a 12‐week randomized trial</span>. <span class="citation"> BMJ Open Diabetes Research &amp; Care </span><span class="pubYear">2016</span>;<span class="volume">4</span>(1):e000265. [MEDLINE: 27547421]<a class="crsref citation-link central-link" data-crsref="9140749" href="" ref="info:x-wiley/crsRef/9140749" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27547421" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Linagliptin+monotherapy+compared+with+voglibose+monotherapy+in+patients+with+type+2+diabetes+undergoing+hemodialysis:+a+12%E2%80%90week+randomized+trial+&author=K+Mori&author=M+Emoto&author=T+Shoji&author=M+Inaba&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0034"> <div class="reference-title-banner"> <h4 class="title">Nakamura 2001 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0089"> <div class="citation-journal">Nakamura T, Ushiyama C, Osada S, Shimada N, Ebihara I, Koide H. <span class="citation-title">Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes</span>. <span class="citation"> Renal Failure </span><span class="pubYear">2001</span>;<span class="volume">23</span>(6):863‐4. [MEDLINE: 11777327]<a class="crsref citation-link central-link" data-crsref="9140751" href="" ref="info:x-wiley/crsRef/9140751" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11777327" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+pioglitazone+on+dyslipidemia+in+hemodialysis+patients+with+type+2+diabetes&author=T+Nakamura&author=C+Ushiyama&author=S+Osada&author=N+Shimada&author=I+Ebihara&author=H+Koide&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0035"> <div class="reference-title-banner"> <h4 class="title">Nowicki 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0090"> <div class="citation-journal">Nowicki M, Rychlik I, Haller H, Warren M, Suchower L, Gause‐Nilsson I, et al. <span class="citation-title">Long‐term treatment with the dipeptidyl peptidase‐4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52‐week efficacy and safety study</span>. <span class="citation"> International Journal of Clinical Practice </span><span class="pubYear">2011</span>;<span class="volume">65</span>(12):1230‐9. [MEDLINE: 21977965]<a class="crsref citation-link central-link" data-crsref="9140753" href="" ref="info:x-wiley/crsRef/9140753" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21977965" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+treatment+with+the+dipeptidyl+peptidase%E2%80%904+inhibitor+saxagliptin+in+patients+with+type+2+diabetes+mellitus+and+renal+impairment:+a+randomised+controlled+52%E2%80%90week+efficacy+and+safety+study+&author=M+Nowicki&author=I+Rychlik&author=H+Haller&author=M+Warren&author=L+Suchower&author=I+Gause%E2%80%90Nilsson&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0091"> <div class="citation-journal">Nowicki M, Rychlik I, Haller H, Warren ML, Suchower L, Gause‐Nilsson I, et al. <span class="citation-title">Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment</span>. <span class="citation"> Diabetes, Obesity &amp; Metabolism </span><span class="pubYear">2011</span>;<span class="volume">13</span>(6):523‐32. [MEDLINE: 21332627]<a class="crsref citation-link central-link" data-crsref="9140754" href="" ref="info:x-wiley/crsRef/9140754" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21332627" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Saxagliptin+improves+glycaemic+control+and+is+well+tolerated+in+patients+with+type+2+diabetes+mellitus+and+renal+impairment+&author=M+Nowicki&author=I+Rychlik&author=H+Haller&author=ML+Warren&author=L+Suchower&author=I+Gause%E2%80%90Nilsson&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0036"> <div class="reference-title-banner"> <h4 class="title">Pfutzner 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0092"> <div class="citation-journal">Pfutzner AH, Schondorf T, Dikta G, Krajewski V, Fuchs W, Forst T, et al. <span class="citation-title">Use of pioglitazone vs. placebo in addition to standard insulin treatment in patients with type 2 diabetes mellitus requiring hemodialysis treatment [abstract]</span>. <span class="citation"> Diabetes </span><span class="pubYear">2011</span>;<span class="volume">60</span>(Suppl 1):A315‐6. [EMBASE: 70628912]<a class="crsref citation-link central-link" data-crsref="9140756" href="" ref="info:x-wiley/crsRef/9140756" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Use+of+pioglitazone+vs.+placebo+in+addition+to+standard+insulin+treatment+in+patients+with+type+2+diabetes+mellitus+requiring+hemodialysis+treatment+[abstract]+&author=AH+Pfutzner&author=T+Schondorf&author=G+Dikta&author=V+Krajewski&author=W+Fuchs&author=T+Forst&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0037"> <div class="reference-title-banner"> <h4 class="title">Ruggenenti 2003a {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0093"> <div class="citation-journal">Ruggenenti P, Flores C, Aros C, Ene‐Iordache B, Trevisan R, Ottomano C, et al. <span class="citation-title">Renal and metabolic effects of insulin lispro in type 2 diabetic subjects with overt nephropathy</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2003</span>;<span class="volume">26</span>(2):502‐9. [MEDLINE: 12547889]<a class="crsref citation-link central-link" data-crsref="9140758" href="" ref="info:x-wiley/crsRef/9140758" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12547889" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Renal+and+metabolic+effects+of+insulin+lispro+in+type+2+diabetic+subjects+with+overt+nephropathy+&author=P+Ruggenenti&author=C+Flores&author=C+Aros&author=B+Ene%E2%80%90Iordache&author=R+Trevisan&author=C+Ottomano&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0038"> <div class="reference-title-banner"> <h4 class="title">SAVOR‐TIMI 53 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0094"> <div class="citation-journal">Cahn A, Raz I, Mosenzon O, Leibowitz G, Yanuv I, Rozenberg A, et al. <span class="citation-title">Predisposing factors for any and major hypoglycemia with saxagliptin versus placebo and overall: analysis from the SAVOR‐TIMI 53 trial</span>. <span class="citation"> Diabetes care </span><span class="pubYear">2016</span>;<span class="volume">39</span>(8):1329‐37. [MEDLINE: 27222508]<a class="crsref citation-link central-link" data-crsref="9140760" href="" ref="info:x-wiley/crsRef/9140760" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27222508" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Predisposing+factors+for+any+and+major+hypoglycemia+with+saxagliptin+versus+placebo+and+overall:+analysis+from+the+SAVOR%E2%80%90TIMI+53+trial+&author=A+Cahn&author=I+Raz&author=O+Mosenzon&author=G+Leibowitz&author=I+Yanuv&author=A+Rozenberg&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0095"> <div class="citation-journal">Kalra S, Gupta Y, Baruah MP, Gupta A. <span class="citation-title">Comment on Udell et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR‐TIMI 53 Trial. Diabetes Care 2015;38:696‐705</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2015</span>;<span class="volume">38</span>(6):e88‐9. [MEDLINE: 25998303]<a class="crsref citation-link central-link" data-crsref="9140761" href="" ref="info:x-wiley/crsRef/9140761" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25998303" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comment+on+Udell+et+al.+Saxagliptin+and+cardiovascular+outcomes+in+patients+with+type+2+diabetes+and+moderate+or+severe+renal+impairment:+observations+from+the+SAVOR%E2%80%90TIMI+53+Trial.+Diabetes+Care+2015;38:696%E2%80%90705+&author=S+Kalra&author=Y+Gupta&author=MP+Baruah&author=A+Gupta&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0096"> <div class="citation-journal">Krempf M. <span class="citation-title">Study on the risk reduction of cardiovascular events with saxagliptin in type 2 diabetic patients (SAVOR‐TIMI 53): Study and patients description</span>. <span class="citation"> Medecine des Maladies Metaboliques </span><span class="pubYear">2013</span>;<span class="volume">7</span>(4):354‐9. [EMBASE: 2014082407]<a class="crsref citation-link central-link" data-crsref="9140762" href="" ref="info:x-wiley/crsRef/9140762" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Study+on+the+risk+reduction+of+cardiovascular+events+with+saxagliptin+in+type+2+diabetic+patients+(SAVOR%E2%80%90TIMI+53):+Study+and+patients+description+&author=M+Krempf&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0097"> <div class="citation-journal">Leiter LA, Teoh H, Mosenzon O, Cahn A, Hirshberg B, Stahre CA, et al. <span class="citation-title">Frequency of cancer events with saxagliptin in the SAVOR‐TIMI 53 trial</span>. <span class="citation"> Diabetes, Obesity &amp; Metabolism </span><span class="pubYear">2016</span>;<span class="volume">18</span>(2):186‐90. [MEDLINE: 26443993]<a class="crsref citation-link central-link" data-crsref="9140763" href="" ref="info:x-wiley/crsRef/9140763" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26443993" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Frequency+of+cancer+events+with+saxagliptin+in+the+SAVOR%E2%80%90TIMI+53+trial&author=LA+Leiter&author=H+Teoh&author=O+Mosenzon&author=A+Cahn&author=B+Hirshberg&author=CA+Stahre&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0098"> <div class="citation-journal">Mosenzon O, Leibowitz G, Bhatt DL, Cahn A, Hirshberg B, Wei C, et al. <span class="citation-title">Effect of saxagliptin on renal outcomes in the SAVOR‐TIMI 53 trial</span>. <span class="citation"> Diabetes care </span><span class="pubYear">2017</span>;<span class="volume">40</span>(1):69‐76. [MEDLINE: 27797925]<a class="crsref citation-link central-link" data-crsref="9140764" href="" ref="info:x-wiley/crsRef/9140764" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27797925" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+saxagliptin+on+renal+outcomes+in+the+SAVOR%E2%80%90TIMI+53+trial&author=O+Mosenzon&author=G+Leibowitz&author=DL+Bhatt&author=A+Cahn&author=B+Hirshberg&author=C+Wei&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0099"> <div class="citation-journal">Mosenzon O, Raz I, Scirica BM, Hirshberg B, Stahre CI, Steg PG, et al. <span class="citation-title">Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)‐TIMI 53 trial</span>. <span class="citation"> Diabetes/Metabolism Research Reviews </span><span class="pubYear">2013</span>;<span class="volume">29</span>(5):417‐26. [MEDLINE: 23564755]<a class="crsref citation-link central-link" data-crsref="9140765" href="" ref="info:x-wiley/crsRef/9140765" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Baseline+characteristics+of+the+patient+population+in+the+Saxagliptin+Assessment+of+Vascular+Outcomes+Recorded+in+patients+with+diabetes+mellitus+(SAVOR)%E2%80%90TIMI+53+trial+&author=O+Mosenzon&author=I+Raz&author=BM+Scirica&author=B+Hirshberg&author=CI+Stahre&author=PG+Steg&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0100"> <div class="citation-journal">Mosenzon O, Scirica BM, Rozenberg A, Yanuv I, Cahn A, KyungAh I, et al. <span class="citation-title">Clinically significant change in albumin creatinine ratio with saxagliptin: A post hoc analysis from the SAVOR‐TIMI 53 trial [abstract]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2017</span>;<span class="volume">60</span>(1 Suppl 1):S355. [EMBASE: 618052611]<a class="crsref citation-link central-link" data-crsref="9140766" href="" ref="info:x-wiley/crsRef/9140766" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Clinically+significant+change+in+albumin+creatinine+ratio+with+saxagliptin:+A+post+hoc+analysis+from+the+SAVOR%E2%80%90TIMI+53+trial+[abstract]+&author=O+Mosenzon&author=BM+Scirica&author=A+Rozenberg&author=I+Yanuv&author=A+Cahn&author=I+KyungAh&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0101"> <div class="citation-journal">Mosenzon O, Wei C, Davidson J, Scirica BM, Yanuv I, Rozenberg A, et al. <span class="citation-title">Incidence of fractures in patients with type 2 diabetes in the SAVOR‐TIMI 53 trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2015</span>;<span class="volume">38</span>(11):2142‐50. [MEDLINE: 26358285]<a class="crsref citation-link central-link" data-crsref="9140767" href="" ref="info:x-wiley/crsRef/9140767" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26358285" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Incidence+of+fractures+in+patients+with+type+2+diabetes+in+the+SAVOR%E2%80%90TIMI+53+trial&author=O+Mosenzon&author=C+Wei&author=J+Davidson&author=BM+Scirica&author=I+Yanuv&author=A+Rozenberg&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0102"> <div class="citation-journal">Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. <span class="citation-title">Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2013</span>;<span class="volume">369</span>(14):1317‐26. [MEDLINE: 23992601]<a class="crsref citation-link central-link" data-crsref="9140768" href="" ref="info:x-wiley/crsRef/9140768" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23992601" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Saxagliptin+and+cardiovascular+outcomes+in+patients+with+type+2+diabetes+mellitus&author=BM+Scirica&author=DL+Bhatt&author=E+Braunwald&author=PG+Steg&author=J+Davidson&author=B+Hirshberg&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0103"> <div class="citation-journal">Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. <span class="citation-title">The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus‐thrombolysis in myocardial infarction (SAVOR‐TIMI) 53 study</span>. <span class="citation"> American Heart Journal </span><span class="pubYear">2011</span>;<span class="volume">162</span>(5):818‐25. [MEDLINE: 22093196]<a class="crsref citation-link central-link" data-crsref="9140769" href="" ref="info:x-wiley/crsRef/9140769" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22093196" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+design+and+rationale+of+the+saxagliptin+assessment+of+vascular+outcomes+recorded+in+patients+with+diabetes+mellitus%E2%80%90thrombolysis+in+myocardial+infarction+(SAVOR%E2%80%90TIMI)+53+study+&author=BM+Scirica&author=DL+Bhatt&author=E+Braunwald&author=PG+Steg&author=J+Davidson&author=B+Hirshberg&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0104"> <div class="citation-journal">Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. <span class="citation-title">Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR‐TIMI 53 randomized trial</span>. <span class="citation"> Circulation </span><span class="pubYear">2014</span>;<span class="volume">130</span>(18):1579‐88. [MEDLINE: 25189213]<a class="crsref citation-link central-link" data-crsref="9140770" href="" ref="info:x-wiley/crsRef/9140770" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25189213" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Heart+failure,+saxagliptin,+and+diabetes+mellitus:+observations+from+the+SAVOR%E2%80%90TIMI+53+randomized+trial+&author=BM+Scirica&author=E+Braunwald&author=I+Raz&author=MA+Cavender&author=DA+Morrow&author=P+Jarolim&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0105"> <div class="citation-journal">Scirica BM, Raz I, Cavender MA, Steg P, Hirshberg B, Davidson J, et al. <span class="citation-title">Outcomes of patients with type 2 diabetes and known congestive heart failure treated with saxagliptin: Analyses of the SAVOR‐TIMI 53 study [abstract]</span>. <span class="citation"> Circulation </span><span class="pubYear">2013</span>;<span class="volume">128</span>(22 Suppl 1):n/a. [EMBASE: 71339453]<a class="crsref citation-link central-link" data-crsref="9140771" href="" ref="info:x-wiley/crsRef/9140771" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Outcomes+of+patients+with+type+2+diabetes+and+known+congestive+heart+failure+treated+with+saxagliptin:+Analyses+of+the+SAVOR%E2%80%90TIMI+53+study+[abstract]+&author=BM+Scirica&author=I+Raz&author=MA+Cavender&author=P+Steg&author=B+Hirshberg&author=J+Davidson&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0106"> <div class="citation-journal">Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg PG, et al. <span class="citation-title">Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR‐TIMI 53 Trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2015</span>;<span class="volume">38</span>(4):696‐705. [MEDLINE: 25552421]<a class="crsref citation-link central-link" data-crsref="9140772" href="" ref="info:x-wiley/crsRef/9140772" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25552421" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Saxagliptin+and+cardiovascular+outcomes+in+patients+with+type+2+diabetes+and+moderate+or+severe+renal+impairment:+observations+from+the+SAVOR%E2%80%90TIMI+53+Trial+&author=JA+Udell&author=DL+Bhatt&author=E+Braunwald&author=MA+Cavender&author=O+Mosenzon&author=PG+Steg&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0039"> <div class="reference-title-banner"> <h4 class="title">Scarpioni 1994 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0107"> <div class="citation-journal">Scarpioni L, Ballocchi S, Castelli A, Scarpioni R. <span class="citation-title">Insulin therapy in uremic diabetic patients on continuous ambulatory peritoneal dialysis; comparison of intraperitoneal and subcutaneous administration</span>. <span class="citation"> Peritoneal Dialysis International </span><span class="pubYear">1994</span>;<span class="volume">14</span>(2):127‐31. [MEDLINE: 8043664]<a class="crsref citation-link central-link" data-crsref="9140774" href="" ref="info:x-wiley/crsRef/9140774" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8043664" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Insulin+therapy+in+uremic+diabetic+patients+on+continuous+ambulatory+peritoneal+dialysis;+comparison+of+intraperitoneal+and+subcutaneous+administration+&author=L+Scarpioni&author=S+Ballocchi&author=A+Castelli&author=R+Scarpioni&publication_year=1994&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0040"> <div class="reference-title-banner"> <h4 class="title">TECOS 2013 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0108"> <div class="citation-journal">Bethel MA, Engel SS, Green JB, Huang Z, Josse RG, Kaufman KD, et al. <span class="citation-title">Assessing the safety of sitagliptin in older participants in the trial evaluating cardiovascular outcomes with sitagliptin (TECOS)</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2017</span>;<span class="volume">40</span>(4):494‐501. [MEDLINE: 28057693]<a class="crsref citation-link central-link" data-crsref="9140776" href="" ref="info:x-wiley/crsRef/9140776" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/28057693" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Assessing+the+safety+of+sitagliptin+in+older+participants+in+the+trial+evaluating+cardiovascular+outcomes+with+sitagliptin+(TECOS)+&author=MA+Bethel&author=SS+Engel&author=JB+Green&author=Z+Huang&author=RG+Josse&author=KD+Kaufman&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0109"> <div class="citation-journal">Buse JB, Bethel MA, Green JB, Stevens SR, Lokhnygina Y, Aschner P, et al. <span class="citation-title">Pancreatic safety of sitagliptin in the TECOS study</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2017</span>;<span class="volume">40</span>(2):164‐70. [MEDLINE: 27630212]<a class="crsref citation-link central-link" data-crsref="9140777" href="" ref="info:x-wiley/crsRef/9140777" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27630212" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pancreatic+safety+of+sitagliptin+in+the+TECOS+study&author=JB+Buse&author=MA+Bethel&author=JB+Green&author=SR+Stevens&author=Y+Lokhnygina&author=P+Aschner&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0110"> <div class="citation-journal">Cornel JH, Bakris GL, Stevens SR, Alvarsson M, Bax WA, Chuang LM, et al. <span class="citation-title">Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS</span>. <span class="citation"> Diabetes care </span><span class="pubYear">2017</span>;<span class="volume">39</span>(12):2304‐10. [MEDLINE: 27742728]<a class="crsref citation-link central-link" data-crsref="9140778" href="" ref="info:x-wiley/crsRef/9140778" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+sitagliptin+on+kidney+function+and+respective+cardiovascular+outcomes+in+type+2+diabetes:+outcomes+from+TECOS+&author=JH+Cornel&author=GL+Bakris&author=SR+Stevens&author=M+Alvarsson&author=WA+Bax&author=LM+Chuang&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0111"> <div class="citation-journal">Engel SS, Suryawanshi S, Josse RG, Peterson ED, Holman RR. <span class="citation-title">Assessing the safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) [abstract]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2016</span>;<span class="volume">59</span>(1 Suppl 1):S361. [EMBASE: 612313326]<a class="crsref citation-link central-link" data-crsref="9140779" href="" ref="info:x-wiley/crsRef/9140779" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Assessing+the+safety+of+sitagliptin+in+patients+with+type+2+diabetes+and+chronic+kidney+disease+in+the+Trial+Evaluating+Cardiovascular+Outcomes+with+Sitagliptin+(TECOS)+[abstract]+&author=SS+Engel&author=S+Suryawanshi&author=RG+Josse&author=ED+Peterson&author=RR+Holman&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0112"> <div class="citation-journal">Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. <span class="citation-title">Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes.[Erratum appears in N Engl J Med. 2015 Aug 6;373(6):586; PMID: 26182233]</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2015</span>;<span class="volume">373</span>(3):232‐42. [MEDLINE: 26052984]<a class="crsref citation-link central-link" data-crsref="9140780" href="" ref="info:x-wiley/crsRef/9140780" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26052984" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+sitagliptin+on+cardiovascular+outcomes+in+type+2+diabetes.[Erratum+appears+in+N+Engl+J+Med.+2015+Aug+6;373(6):586;+PMID:+26182233]+&author=JB+Green&author=MA+Bethel&author=PW+Armstrong&author=JB+Buse&author=SS+Engel&author=J+Garg&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0113"> <div class="citation-journal">Green JB, Bethel MA, Paul SK, Ring A, Kaufman KD, Shapiro DR, et al. <span class="citation-title">Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease</span>. <span class="citation"> American Heart Journal </span><span class="pubYear">2013</span>;<span class="volume">166</span>(6):983‐9. [MEDLINE: 24268212]<a class="crsref citation-link central-link" data-crsref="9140781" href="" ref="info:x-wiley/crsRef/9140781" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24268212" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rationale,+design,+and+organization+of+a+randomized,+controlled+Trial+Evaluating+Cardiovascular+Outcomes+with+Sitagliptin+(TECOS)+in+patients+with+type+2+diabetes+and+established+cardiovascular+disease+&author=JB+Green&author=MA+Bethel&author=SK+Paul&author=A+Ring&author=KD+Kaufman&author=DR+Shapiro&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0114"> <div class="citation-journal">McGuire DK, Werf F, Armstrong PW, Standl E, Koglin J, Green JB, et al. <span class="citation-title">Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial</span>. <span class="citation"> JAMA Cardiology </span><span class="pubYear">2016</span>;<span class="volume">1</span>(2):126‐35. [MEDLINE: 27437883]<a class="crsref citation-link central-link" data-crsref="9140782" href="" ref="info:x-wiley/crsRef/9140782" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27437883" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Association+between+sitagliptin+use+and+heart+failure+hospitalization+and+related+outcomes+in+type+2+diabetes+mellitus:+secondary+analysis+of+a+randomized+clinical+trial+&author=DK+McGuire&author=F+Werf&author=PW+Armstrong&author=E+Standl&author=J+Koglin&author=JB+Green&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0115"> <div class="citation-journal">Pagidipati NJ, Navar AM, Pieper KS, Green JB, Bethel MA, Armstrong PW, et al. <span class="citation-title">Secondary prevention of cardiovascular disease in patients with type 2 diabetes mellitus: international insights from the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin)</span>. <span class="citation"> Circulation </span><span class="pubYear">2017</span>;<span class="volume">136</span>(13):1193‐203. [MEDLINE: 28626088]<a class="crsref citation-link central-link" data-crsref="9140783" href="" ref="info:x-wiley/crsRef/9140783" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/28626088" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Secondary+prevention+of+cardiovascular+disease+in+patients+with+type+2+diabetes+mellitus:+international+insights+from+the+TECOS+Trial+(Trial+Evaluating+Cardiovascular+Outcomes+With+Sitagliptin)+&author=NJ+Pagidipati&author=AM+Navar&author=KS+Pieper&author=JB+Green&author=MA+Bethel&author=PW+Armstrong&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0041"> <div class="reference-title-banner"> <h4 class="title">Wong 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0116"> <div class="citation-journal">Wong TY, Szeto CC, Chow KM, Leung CB, Lam CW, Li PK. <span class="citation-title">Rosiglitazone reduces insulin requirement and C‐reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis</span>. <span class="citation"> American Journal of Kidney Diseases </span><span class="pubYear">2005</span>;<span class="volume">46</span>(4):713‐9. [MEDLINE: 16183427]<a class="crsref citation-link central-link" data-crsref="9140785" href="" ref="info:x-wiley/crsRef/9140785" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16183427" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rosiglitazone+reduces+insulin+requirement+and+C%E2%80%90reactive+protein+levels+in+type+2+diabetic+patients+receiving+peritoneal+dialysis+&author=TY+Wong&author=CC+Szeto&author=KM+Chow&author=CB+Leung&author=CW+Lam&author=PK+Li&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0042"> <div class="reference-title-banner"> <h4 class="title">Yale 2013 {published and unpublished data} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0117"> <div class="citation-journal">Bakris G, Yale JF, Wajs E, Li X, Usiskin K, Meininger G. <span class="citation-title">Efficacy and safety of canagliflozin (CANA) in subjects with type 2 diabetes mellitus (t2dm) and moderate renal impairment [abstract no:TH‐PO536]</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">2012</span>;<span class="volume">23</span>(Abstracts):220A. <a class="crsref citation-link central-link" data-crsref="9140787" href="" ref="info:x-wiley/crsRef/9140787" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+canagliflozin+(CANA)+in+subjects+with+type+2+diabetes+mellitus+(t2dm)+and+moderate+renal+impairment+[abstract+no:TH%E2%80%90PO536]+&author=G+Bakris&author=JF+Yale&author=E+Wajs&author=X+Li&author=K+Usiskin&author=G+Meininger&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0118"> <div class="citation-journal">Nieto Iglesias J, Yale JF, Bakris G, Cariou B, Wajs E, Figueroa K, et al. <span class="citation-title">Efficacy and safety of canagliflozin in subjects with type 2 diabetes mellitus and chronic kidney disease over 52 weeks [abstract no: 951]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2013</span>;<span class="volume">56</span>(Suppl 1):S381. <a class="crsref citation-link central-link" data-crsref="9140788" href="" ref="info:x-wiley/crsRef/9140788" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+canagliflozin+in+subjects+with+type+2+diabetes+mellitus+and+chronic+kidney+disease+over+52+weeks+[abstract+no:+951]+&author=J+NietoIglesias&author=JF+Yale&author=G+Bakris&author=B+Cariou&author=E+Wajs&author=K+Figueroa&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0119"> <div class="citation-journal">Yale J, Bakris G, Cariou B, Iglesias JN, Wajs E, Figueroa K, et al. <span class="citation-title">Efficacy and safety of canagliflozin (CANA) in subjects with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) over 52 weeks [abstract]</span>. <span class="citation"> Diabetes </span><span class="pubYear">2013</span>;<span class="volume">62</span>(Suppl 1):A277‐8. [EMBASE: 71287507]<a class="crsref citation-link central-link" data-crsref="9140789" href="" ref="info:x-wiley/crsRef/9140789" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+canagliflozin+(CANA)+in+subjects+with+type+2+diabetes+mellitus+(T2DM)+and+chronic+kidney+disease+(CKD)+over+52+weeks+[abstract]+&author=J+Yale&author=G+Bakris&author=B+Cariou&author=JN+Iglesias&author=E+Wajs&author=K+Figueroa&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0120"> <div class="citation-journal">Yale JF, Bakris G, Cariou B, Nieto Iglesias J, Wajs E, Figueroa K, et al. <span class="citation-title">Efficacy and safety of canagliflozin (CANA) in subjects with type 2 diabetes mellitus T2DM) and chronic kidney disease (CKD) over 52 weeks [abstract no: 71]</span>. <span class="citation"> Canadian Journal of Diabetes </span><span class="pubYear">2015</span>;<span class="volume">37</span>(Suppl 4):S27. <a class="crsref citation-link central-link" data-crsref="9140790" href="" ref="info:x-wiley/crsRef/9140790" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+canagliflozin+(CANA)+in+subjects+with+type+2+diabetes+mellitus+T2DM)+and+chronic+kidney+disease+(CKD)+over+52+weeks+[abstract+no:+71]+&author=JF+Yale&author=G+Bakris&author=B+Cariou&author=J+NietoIglesias&author=E+Wajs&author=K+Figueroa&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0121"> <div class="citation-journal">Yale JF, Bakris G, Cariou B, Nieto J, David‐Neto E, Yue D, et al. <span class="citation-title">Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease</span>. <span class="citation"> Diabetes, Obesity &amp; Metabolism </span><span class="pubYear">2014</span>;<span class="volume">16</span>(10):1016‐27. [MEDLINE: 24965700]<a class="crsref citation-link central-link" data-crsref="9140791" href="" ref="info:x-wiley/crsRef/9140791" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24965700" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+canagliflozin+over+52+weeks+in+patients+with+type+2+diabetes+mellitus+and+chronic+kidney+disease+&author=JF+Yale&author=G+Bakris&author=B+Cariou&author=J+Nieto&author=E+David%E2%80%90Neto&author=D+Yue&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0122"> <div class="citation-journal">Yale JF, Bakris G, Cariou B, Yue D, David‐Neto E, Xi L, et al. <span class="citation-title">Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease</span>. <span class="citation"> Diabetes, Obesity &amp; Metabolism </span><span class="pubYear">2013</span>;<span class="volume">15</span>(5):463‐73. [MEDLINE: 23464594]<a class="crsref citation-link central-link" data-crsref="9140792" href="" ref="info:x-wiley/crsRef/9140792" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23464594" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+canagliflozin+in+subjects+with+type+2+diabetes+and+chronic+kidney+disease+&author=JF+Yale&author=G+Bakris&author=B+Cariou&author=D+Yue&author=E+David%E2%80%90Neto&author=L+Xi&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0123"> <div class="citation-journal">Yale JF, Bakris G, Wajs E, Xi L, Figueroa K, Usiskin K, et al. <span class="citation-title">Canagliflozin, a sodium glucose co‐transporter 2 inhibitor, improves glycaemic control and is well tolerated in type 2 diabetes subjects with moderate renal impairment [abstract no:759]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2012</span>;<span class="volume">55</span>(Suppl 1):S312. <a class="crsref citation-link central-link" data-crsref="9140793" href="" ref="info:x-wiley/crsRef/9140793" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Canagliflozin,+a+sodium+glucose+co%E2%80%90transporter+2+inhibitor,+improves+glycaemic+control+and+is+well+tolerated+in+type+2+diabetes+subjects+with+moderate+renal+impairment+[abstract+no:759]+&author=JF+Yale&author=G+Bakris&author=E+Wajs&author=L+Xi&author=K+Figueroa&author=K+Usiskin&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0124"> <div class="citation-journal">Yale JF, Bakris G, Xi L, Figueroa K, Wajs E, Usiskin K, et al. <span class="citation-title">Canagliflozin (CANA), a sodium glucose co‐transporter 2 (SGLT2) inhibitor, improves glycemia and is well tolerated in type 2 diabetes mellitus (T2DM) subjects with moderate renal impairment [abstract no:139]</span>. <span class="citation"> Canadian Journal of Diabetes </span><span class="pubYear">2012</span>;<span class="volume">36</span>(5 Suppl):S40‐1. <a class="crsref citation-link central-link" data-crsref="9140794" href="" ref="info:x-wiley/crsRef/9140794" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Canagliflozin+(CANA),+a+sodium+glucose+co%E2%80%90transporter+2+(SGLT2)+inhibitor,+improves+glycemia+and+is+well+tolerated+in+type+2+diabetes+mellitus+(T2DM)+subjects+with+moderate+renal+impairment+[abstract+no:139]+&author=JF+Yale&author=G+Bakris&author=L+Xi&author=K+Figueroa&author=E+Wajs&author=K+Usiskin&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0125"> <div class="citation-other">Yale JF, Bakris GL, Cariou B, Nieto Iglesias J, Wajs E, Figueroa K, et al. <span class="citation-title">Efficacy and safety of canagliflozin (CANA) in subjects with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) over 52 weeks [abstract no: 0175‐P]</span>. 73rd Scientific Sessions of the American Diabetes Association; 21‐25 June 2013; Chicago, IL. <span class="pubYear">2013</span>. <a class="crsref citation-link central-link" data-crsref="9140795" href="" ref="info:x-wiley/crsRef/9140795" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+canagliflozin+(CANA)+in+subjects+with+type+2+diabetes+mellitus+(T2DM)+and+chronic+kidney+disease+(CKD)+over+52+weeks+[abstract+no:+0175%E2%80%90P]+&author=JF+Yale&author=GL+Bakris&author=B+Cariou&author=J+NietoIglesias&author=E+Wajs&author=K+Figueroa&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0043"> <div class="reference-title-banner"> <h4 class="title">Yki‐Järvinen 2013 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0126"> <div class="citation-journal">Sheu WH, Park SW, Gong Y, Pinnetti S, Bhattacharya S, Patel S, et al. <span class="citation-title">Linagliptin improves glycemic control after 1 year as add‐on therapy to basal insulin in Asian patients with type 2 diabetes mellitus</span>. <span class="citation"> Current Medical Research &amp; Opinion </span><span class="pubYear">2015</span>;<span class="volume">31</span>(3):503‐12. [MEDLINE: 25629790]<a class="crsref citation-link central-link" data-crsref="9140797" href="" ref="info:x-wiley/crsRef/9140797" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Linagliptin+improves+glycemic+control+after+1+year+as+add%E2%80%90on+therapy+to+basal+insulin+in+Asian+patients+with+type+2+diabetes+mellitus+&author=WH+Sheu&author=SW+Park&author=Y+Gong&author=S+Pinnetti&author=S+Bhattacharya&author=S+Patel&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0127"> <div class="citation-journal">Yki‐Järvinen H, Rosenstock J, Durán‐Garcia S, Pinnetti S, Bhattacharya S, Thiemann S, et al. <span class="citation-title">Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52‐week randomized, double‐blind study</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2013</span>;<span class="volume">36</span>(12):3875‐81. [MEDLINE: 24062327]<a class="crsref citation-link central-link" data-crsref="9140798" href="" ref="info:x-wiley/crsRef/9140798" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24062327" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+adding+linagliptin+to+basal+insulin+regimen+for+inadequately+controlled+type+2+diabetes:+a+%E2%89%A552%E2%80%90week+randomized,+double%E2%80%90blind+study+&author=H+Yki%E2%80%90J%C3%A4rvinen&author=J+Rosenstock&author=S+Dur%C3%A1n%E2%80%90Garcia&author=S+Pinnetti&author=S+Bhattacharya&author=S+Thiemann&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011798-bbs2-0044"> <div class="reference-title-banner"> <h4 class="title">Zambrowicz 2015 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0128"> <div class="citation-journal">Zambrowicz B, Lapuerta P, Strumph P, Banks P, Wilson A, Ogbaa I, et al. <span class="citation-title">LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion</span>. <span class="citation"> Clinical Therapeutics </span><span class="pubYear">2015</span>;<span class="volume">37</span>(1):71‐82. [MEDLINE: 25529979]<a class="crsref citation-link central-link" data-crsref="9140800" href="" ref="info:x-wiley/crsRef/9140800" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25529979" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=LX4211+therapy+reduces+postprandial+glucose+levels+in+patients+with+type+2+diabetes+mellitus+and+renal+impairment+despite+low+urinary+glucose+excretion+&author=B+Zambrowicz&author=P+Lapuerta&author=P+Strumph&author=P+Banks&author=A+Wilson&author=I+Ogbaa&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD011798-bbs1-0002"> <h3 class="title">References to studies excluded from this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD011798-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0003">studies awaiting assessment</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0004">ongoing studies</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0005">additional references</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0006">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0045"> <div class="reference-title-banner"> <h4 class="title">ACCORD 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0129"> <div class="citation-journal">ACCORD Study Group, ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, et al. <span class="citation-title">Effects of medical therapies on retinopathy progression in type 2 diabetes.[Erratum appears in N Engl J Med. 2011 Jan 13;364(2):190], [Erratum appears in N Engl J Med. 2012 Dec 20;367(25):2458]</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2010</span>;<span class="volume">363</span>(3):233‐44. [MEDLINE: 20587587]<a class="crsref citation-link central-link" data-crsref="9140802" href="" ref="info:x-wiley/crsRef/9140802" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20587587" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+medical+therapies+on+retinopathy+progression+in+type+2+diabetes.[Erratum+appears+in+N+Engl+J+Med.+2011+Jan+13;364(2):190],+[Erratum+appears+in+N+Engl+J+Med.+2012+Dec+20;367(25):2458]+&author=EY+Chew&author=WT+Ambrosius&author=MD+Davis&author=RP+Danis&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0130"> <div class="citation-journal">ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, et al. <span class="citation-title">Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2007</span>;<span class="volume">99</span>(12A):21i‐33i. [MEDLINE: 17599422]<a class="crsref citation-link central-link" data-crsref="9140803" href="" ref="info:x-wiley/crsRef/9140803" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17599422" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Action+to+Control+Cardiovascular+Risk+in+Diabetes+(ACCORD)+trial:+design+and+methods&author=JB+Buse&author=JT+Bigger&author=RP+Byington&author=LS+Cooper&author=WC+Cushman&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0131"> <div class="citation-journal">ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, et al. <span class="citation-title">Effects of intensive blood‐pressure control in type 2 diabetes mellitus</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2010</span>;<span class="volume">362</span>(17):1575‐85. [MEDLINE: 20228401]<a class="crsref citation-link central-link" data-crsref="9140804" href="" ref="info:x-wiley/crsRef/9140804" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20228401" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+intensive+blood%E2%80%90pressure+control+in+type+2+diabetes+mellitus&author=WC+Cushman&author=GW+Evans&author=RP+Byington&author=DC+Goff&author=RH+Grimm&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0132"> <div class="citation-journal">ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, Ismail‐Beigi F, Buse JB, et al. <span class="citation-title">Long‐term effects of intensive glucose lowering on cardiovascular outcomes</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2011</span>;<span class="volume">364</span>(9):818‐28. [MEDLINE: 21366473]<a class="crsref citation-link central-link" data-crsref="9140805" href="" ref="info:x-wiley/crsRef/9140805" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21366473" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+effects+of+intensive+glucose+lowering+on+cardiovascular+outcomes&author=HC+Gerstein&author=ME+Miller&author=S+Genuth&author=F+Ismail%E2%80%90Beigi&author=JB+Buse&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0133"> <div class="citation-journal">ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, et al. <span class="citation-title">Effects of combination lipid therapy in type 2 diabetes mellitus.[Erratum appears in N Engl J Med. 2010 May 6;362(18):1748]</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2010</span>;<span class="volume">362</span>(17):1563‐74. [MEDLINE: 20228404]<a class="crsref citation-link central-link" data-crsref="9140806" href="" ref="info:x-wiley/crsRef/9140806" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20228404" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+combination+lipid+therapy+in+type+2+diabetes+mellitus.[Erratum+appears+in+N+Engl+J+Med.+2010+May+6;362(18):1748]+&author=HN+Ginsberg&author=MB+Elam&author=LC+Lovato&author=JR+Crouse&author=LA+Leiter&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0134"> <div class="citation-journal">Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, et al. <span class="citation-title">Effects of intensive glucose lowering in type 2 diabetes</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2008</span>;<span class="volume">358</span>(24):2545‐59. [MEDLINE: 18539917]<a class="crsref citation-link central-link" data-crsref="9140807" href="" ref="info:x-wiley/crsRef/9140807" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18539917" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+intensive+glucose+lowering+in+type+2+diabetes&author=HC+Gerstein&author=ME+Miller&author=RP+Byington&author=DC+Goff&author=JT+Bigger&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0135"> <div class="citation-journal">Barzilay JI, Howard AG, Evans GW, Fleg JL, Cohen RM, Booth GL, et al. <span class="citation-title">Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2012</span>;<span class="volume">35</span>(7):1401‐5. [MEDLINE: 22723577]<a class="crsref citation-link central-link" data-crsref="9140808" href="" ref="info:x-wiley/crsRef/9140808" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22723577" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensive+blood+pressure+treatment+does+not+improve+cardiovascular+outcomes+in+centrally+obese+hypertensive+individuals+with+diabetes:+the+Action+to+Control+Cardiovascular+Risk+in+Diabetes+(ACCORD)+Blood+Pressure+Trial+&author=JI+Barzilay&author=AG+Howard&author=GW+Evans&author=JL+Fleg&author=RM+Cohen&author=GL+Booth&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0136"> <div class="citation-journal">Barzilay JI, Lovato JF, Murray AM, Williamson J, Ismail‐Beigi F, Karl D, et al. <span class="citation-title">Albuminuria and cognitive decline in people with diabetes and normal renal function</span>. <span class="citation"> Clinical Journal of the American Society of Nephrology: CJASN </span><span class="pubYear">2013</span>;<span class="volume">8</span>(11):1907‐14. [MEDLINE: 23990163]<a class="crsref citation-link central-link" data-crsref="9140809" href="" ref="info:x-wiley/crsRef/9140809" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23990163" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Albuminuria+and+cognitive+decline+in+people+with+diabetes+and+normal+renal+function&author=JI+Barzilay&author=JF+Lovato&author=AM+Murray&author=J+Williamson&author=F+Ismail%E2%80%90Beigi&author=D+Karl&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0137"> <div class="citation-journal">Bonds DE, Kurashige EM, Bergenstal R, Brillon D, Domanski M, Felicetta JV, et al. <span class="citation-title">Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2007</span>;<span class="volume">99</span>(12A):80i‐9i. [MEDLINE: 17599428]<a class="crsref citation-link central-link" data-crsref="9140810" href="" ref="info:x-wiley/crsRef/9140810" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17599428" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Severe+hypoglycemia+monitoring+and+risk+management+procedures+in+the+Action+to+Control+Cardiovascular+Risk+in+Diabetes+(ACCORD)+trial+&author=DE+Bonds&author=EM+Kurashige&author=R+Bergenstal&author=D+Brillon&author=M+Domanski&author=JV+Felicetta&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0138"> <div class="citation-journal">Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, et al. <span class="citation-title">The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study</span>. <span class="citation"> BMJ </span><span class="pubYear">2010</span>;<span class="volume">340</span>:b4909. [MEDLINE: 20061358]<a class="crsref citation-link central-link" data-crsref="9140811" href="" ref="info:x-wiley/crsRef/9140811" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20061358" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+association+between+symptomatic,+severe+hypoglycaemia+and+mortality+in+type+2+diabetes:+retrospective+epidemiological+analysis+of+the+ACCORD+study+&author=DE+Bonds&author=ME+Miller&author=RM+Bergenstal&author=JB+Buse&author=RP+Byington&author=JA+Cutler&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0139"> <div class="citation-journal">Bonds DE, Miller ME, Dudl J, Feinglos M, Ismail‐Beigi F, Malozowski S, et al. <span class="citation-title">Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data</span>. <span class="citation"> BMC Endocrine Disorders </span><span class="pubYear">2012</span>;<span class="volume">12</span>:5. [MEDLINE: 22646230]<a class="crsref citation-link central-link" data-crsref="9140812" href="" ref="info:x-wiley/crsRef/9140812" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22646230" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Severe+hypoglycemia+symptoms,+antecedent+behaviors,+immediate+consequences+and+association+with+glycemia+medication+usage:+Secondary+analysis+of+the+ACCORD+clinical+trial+data+&author=DE+Bonds&author=ME+Miller&author=J+Dudl&author=M+Feinglos&author=F+Ismail%E2%80%90Beigi&author=S+Malozowski&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0140"> <div class="citation-journal">Chew EY, Ambrosius WT, Howard LT, Greven CM, Johnson S, Danis RP, et al. <span class="citation-title">Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD‐EYE)</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2007</span>;<span class="volume">99</span>(12A):103i‐11i. [MEDLINE: 17599420]<a class="crsref citation-link central-link" data-crsref="9140813" href="" ref="info:x-wiley/crsRef/9140813" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17599420" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rationale,+design,+and+methods+of+the+Action+to+Control+Cardiovascular+Risk+in+Diabetes+Eye+Study+(ACCORD%E2%80%90EYE)+&author=EY+Chew&author=WT+Ambrosius&author=LT+Howard&author=CM+Greven&author=S+Johnson&author=RP+Danis&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0141"> <div class="citation-journal">Cushman WC, Grimm RH, Cutler JA, Evans GW, Capes S, Corson MA, et al. <span class="citation-title">Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2007</span>;<span class="volume">99</span>(12A):44i‐55i. [MEDLINE: 17599425]<a class="crsref citation-link central-link" data-crsref="9140814" href="" ref="info:x-wiley/crsRef/9140814" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17599425" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rationale+and+design+for+the+blood+pressure+intervention+of+the+Action+to+Control+Cardiovascular+Risk+in+Diabetes+(ACCORD)+trial+&author=WC+Cushman&author=RH+Grimm&author=JA+Cutler&author=GW+Evans&author=S+Capes&author=MA+Corson&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0142"> <div class="citation-journal">Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, et al. <span class="citation-title">Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study)</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2014</span>;<span class="volume">114</span>(8):1217‐22. [MEDLINE: 25159234]<a class="crsref citation-link central-link" data-crsref="9140815" href="" ref="info:x-wiley/crsRef/9140815" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25159234" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Impact+of+intensive+glycemic+control+on+the+incidence+of+atrial+fibrillation+and+associated+cardiovascular+outcomes+in+patients+with+type+2+diabetes+mellitus+(from+the+Action+to+Control+Cardiovascular+Risk+in+Diabetes+Study)+&author=O+Fatemi&author=E+Yuriditsky&author=C+Tsioufis&author=D+Tsachris&author=T+Morgan&author=J+Basile&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0143"> <div class="citation-journal">Fonseca V, McDuffie R, Calles J, Cohen RM, Feeney P, Feinglos M, et al. <span class="citation-title">Determinants of weight gain in the action to control cardiovascular risk in diabetes trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2013</span>;<span class="volume">36</span>(8):2162‐8. [MEDLINE: 23412077]<a class="crsref citation-link central-link" data-crsref="9140816" href="" ref="info:x-wiley/crsRef/9140816" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23412077" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Determinants+of+weight+gain+in+the+action+to+control+cardiovascular+risk+in+diabetes+trial+&author=V+Fonseca&author=R+McDuffie&author=J+Calles&author=RM+Cohen&author=P+Feeney&author=M+Feinglos&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0144"> <div class="citation-journal">Genuth S, Ismail‐Beigi F. <span class="citation-title">Clinical implications of the ACCORD trial. [Review]</span>. <span class="citation"> Journal of Clinical Endocrinology &amp; Metabolism </span><span class="pubYear">2012</span>;<span class="volume">97</span>(1):41‐8. [MEDLINE: 22049171]<a class="crsref citation-link central-link" data-crsref="9140817" href="" ref="info:x-wiley/crsRef/9140817" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Clinical+implications+of+the+ACCORD+trial.+[Review]&author=S+Genuth&author=F+Ismail%E2%80%90Beigi&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0145"> <div class="citation-journal">Gerstein HC, Ambrosius WT, Danis R, Ismail‐Beigi F, Cushman W, Calles J, et al. <span class="citation-title">Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2013</span>;<span class="volume">36</span>(5):1266‐71. [MEDLINE: 23238658]<a class="crsref citation-link central-link" data-crsref="9140818" href="" ref="info:x-wiley/crsRef/9140818" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23238658" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Diabetic+retinopathy,+its+progression,+and+incident+cardiovascular+events+in+the+ACCORD+trial+&author=HC+Gerstein&author=WT+Ambrosius&author=R+Danis&author=F+Ismail%E2%80%90Beigi&author=W+Cushman&author=J+Calles&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0146"> <div class="citation-journal">Gerstein HC, Miller ME, Ismail‐Beigi F, Largay J, McDonald C, Lochnan HA, et al. <span class="citation-title">Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial</span>. <span class="citation"> Lancet </span><span class="pubYear">2014</span>;<span class="volume">384</span>(9958):1936‐41. [MEDLINE: 25088437]<a class="crsref citation-link central-link" data-crsref="9140819" href="" ref="info:x-wiley/crsRef/9140819" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25088437" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+intensive+glycaemic+control+on+ischaemic+heart+disease:+analysis+of+data+from+the+randomised,+controlled+ACCORD+trial+&author=HC+Gerstein&author=ME+Miller&author=F+Ismail%E2%80%90Beigi&author=J+Largay&author=C+McDonald&author=HA+Lochnan&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0147"> <div class="citation-journal">Gerstein HC, Riddle MC, Kendall DM, Cohen RM, Goland R, Feinglos MN, et al. <span class="citation-title">Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2007</span>;<span class="volume">99</span>(12A):34i‐43i. [MEDLINE: 17599423]<a class="crsref citation-link central-link" data-crsref="9140820" href="" ref="info:x-wiley/crsRef/9140820" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17599423" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Glycemia+treatment+strategies+in+the+Action+to+Control+Cardiovascular+Risk+in+Diabetes+(ACCORD)+trial+&author=HC+Gerstein&author=MC+Riddle&author=DM+Kendall&author=RM+Cohen&author=R+Goland&author=MN+Feinglos&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0148"> <div class="citation-journal">Ginsberg HN, Bonds DE, Lovato LC, Crouse JR, Elam MB, Linz PE, et al. <span class="citation-title">Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2007</span>;<span class="volume">99</span>(12A):56i‐67i. [MEDLINE: 17599426]<a class="crsref citation-link central-link" data-crsref="9140821" href="" ref="info:x-wiley/crsRef/9140821" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17599426" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Evolution+of+the+lipid+trial+protocol+of+the+Action+to+Control+Cardiovascular+Risk+in+Diabetes+(ACCORD)+trial+&author=HN+Ginsberg&author=DE+Bonds&author=LC+Lovato&author=JR+Crouse&author=MB+Elam&author=PE+Linz&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0149"> <div class="citation-journal">Goff DC, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, et al. <span class="citation-title">Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2007</span>;<span class="volume">99</span>(12A):4i‐20i. [MEDLINE: 17599424]<a class="crsref citation-link central-link" data-crsref="9140822" href="" ref="info:x-wiley/crsRef/9140822" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17599424" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Prevention+of+cardiovascular+disease+in+persons+with+type+2+diabetes+mellitus:+current+knowledge+and+rationale+for+the+Action+to+Control+Cardiovascular+Risk+in+Diabetes+(ACCORD)+trial+&author=DC+Goff&author=HC+Gerstein&author=HN+Ginsberg&author=WC+Cushman&author=KL+Margolis&author=RP+Byington&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0150"> <div class="citation-journal">Isakova T, Craven TE, Scialla JJ, Nickolas TL, Schnall A, Barzilay J, et al. <span class="citation-title">Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial</span>. <span class="citation"> Bone </span><span class="pubYear">2015 Sep</span>;<span class="volume">78</span>:23‐7. [MEDLINE: 25937184]<a class="crsref citation-link central-link" data-crsref="9140823" href="" ref="info:x-wiley/crsRef/9140823" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25937184" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Change+in+estimated+glomerular+filtration+rate+and+fracture+risk+in+the+Action+to+Control+Cardiovascular+Risk+in+Diabetes+Trial+&author=T+Isakova&author=TE+Craven&author=JJ+Scialla&author=TL+Nickolas&author=A+Schnall&author=J+Barzilay&publication_year=2015Sep&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0151"> <div class="citation-journal">Ismail‐Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. <span class="citation-title">Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial</span>. <span class="citation"> Lancet </span><span class="pubYear">2010</span>;<span class="volume">376</span>(9739):419‐30. [MEDLINE: 20594588]<a class="crsref citation-link central-link" data-crsref="9140824" href="" ref="info:x-wiley/crsRef/9140824" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20594588" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+intensive+treatment+of+hyperglycaemia+on+microvascular+outcomes+in+type+2+diabetes:+an+analysis+of+the+ACCORD+randomised+trial+&author=F+Ismail%E2%80%90Beigi&author=T+Craven&author=MA+Banerji&author=J+Basile&author=J+Calles&author=RM+Cohen&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0152"> <div class="citation-other">Ismail‐Beigi F, Craven TE, O'Connor PJ, Karl D, Calles‐Escandon J, Hramiak I, et al. <span class="citation-title">Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients</span>. Kidney International<span class="pubYear">2012</span>; Vol. 81, issue 6:586‐94. [MEDLINE: 22166848]<a class="crsref citation-link central-link" data-crsref="9140825" href="" ref="info:x-wiley/crsRef/9140825" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Combined+intensive+blood+pressure+and+glycemic+control+does+not+produce+an+additive+benefit+on+microvascular+outcomes+in+type+2+diabetic+patients+&author=F+Ismail%E2%80%90Beigi&author=TE+Craven&author=PJ+O'Connor&author=D+Karl&author=J+Calles‐Escandon&author=I+Hramiak&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0153"> <div class="citation-journal">Kingry C, Bastien A, Booth G, Geraci TS, Kirpach BR, Lovato LC, et al. <span class="citation-title">Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2007</span>;<span class="volume">99</span>(12A):68i‐79i. [MEDLINE: 17599427]<a class="crsref citation-link central-link" data-crsref="9140826" href="" ref="info:x-wiley/crsRef/9140826" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17599427" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Recruitment+strategies+in+the+Action+to+Control+Cardiovascular+Risk+in+Diabetes+(ACCORD)+trial+&author=C+Kingry&author=A+Bastien&author=G+Booth&author=TS+Geraci&author=BR+Kirpach&author=LC+Lovato&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0154"> <div class="citation-journal">Linz PE, Lovato LC, Byington RP, O'Connor PJ, Leiter LA, Weiss D, et al. <span class="citation-title">Paradoxical reduction in HDL‐C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2014</span>;<span class="volume">37</span>(3):686‐93. [MEDLINE: 24296848]<a class="crsref citation-link central-link" data-crsref="9140827" href="" ref="info:x-wiley/crsRef/9140827" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24296848" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Paradoxical+reduction+in+HDL%E2%80%90C+with+fenofibrate+and+thiazolidinedione+therapy+in+type+2+diabetes:+the+ACCORD+Lipid+Trial+&author=PE+Linz&author=LC+Lovato&author=RP+Byington&author=PJ+O'Connor&author=LA+Leiter&author=D+Weiss&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0155"> <div class="citation-journal">Margolis KL, O'Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, et al. <span class="citation-title">Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2014</span>;<span class="volume">37</span>(6):1721‐8. [MEDLINE: 24595629]<a class="crsref citation-link central-link" data-crsref="9140828" href="" ref="info:x-wiley/crsRef/9140828" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24595629" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Outcomes+of+combined+cardiovascular+risk+factor+management+strategies+in+type+2+diabetes:+the+ACCORD+randomized+trial+&author=KL+Margolis&author=PJ+O'Connor&author=TM+Morgan&author=JB+Buse&author=RM+Cohen&author=WC+Cushman&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0156"> <div class="citation-journal">Meier M, Hummel M. <span class="citation-title">Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence‐based strategies</span>. <span class="citation"> Vascular Health &amp; Risk Management </span><span class="pubYear">2009</span>;<span class="volume">5</span>:859‐71. [MEDLINE: 19898642]<a class="crsref citation-link central-link" data-crsref="9140829" href="" ref="info:x-wiley/crsRef/9140829" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cardiovascular+disease+and+intensive+glucose+control+in+type+2+diabetes+mellitus:+moving+practice+toward+evidence%E2%80%90based+strategies+&author=M+Meier&author=M+Hummel&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0157"> <div class="citation-journal">Miller ME, Bonds DE, Gerstein HC, Seaquist ER, Bergenstal RM, Calles‐Escandon J, et al. <span class="citation-title">The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study</span>. <span class="citation"> BMJ </span><span class="pubYear">2010</span>;<span class="volume">340</span>:b5444. [MEDLINE: 20061360]<a class="crsref citation-link central-link" data-crsref="9140830" href="" ref="info:x-wiley/crsRef/9140830" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20061360" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+effects+of+baseline+characteristics,+glycaemia+treatment+approach,+and+glycated+haemoglobin+concentration+on+the+risk+of+severe+hypoglycaemia:+post+hoc+epidemiological+analysis+of+the+ACCORD+study+&author=ME+Miller&author=DE+Bonds&author=HC+Gerstein&author=ER+Seaquist&author=RM+Bergenstal&author=J+Calles%E2%80%90Escandon&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0158"> <div class="citation-journal">Miller ME, Williamson JD, Gerstein HC, Byington RP, Cushman WC, Ginsberg HN, et al. <span class="citation-title">Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2014</span>;<span class="volume">37</span>(3):634‐43. [MEDLINE: 24170759]<a class="crsref citation-link central-link" data-crsref="9140831" href="" ref="info:x-wiley/crsRef/9140831" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24170759" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+randomization+to+intensive+glucose+control+on+adverse+events,+cardiovascular+disease,+and+mortality+in+older+versus+younger+adults+in+the+ACCORD+Trial+&author=ME+Miller&author=JD+Williamson&author=HC+Gerstein&author=RP+Byington&author=WC+Cushman&author=HN+Ginsberg&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0159"> <div class="citation-journal">Mottl AK, Pajewski N, Fonseca V, Ismail‐Beigi F, Chew E, Ambrosius WT, et al. <span class="citation-title">The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial</span>. <span class="citation"> Journal of Diabetes &amp; its Complications </span><span class="pubYear">2014</span>;<span class="volume">28</span>(6):874‐9. [MEDLINE: 25123755]<a class="crsref citation-link central-link" data-crsref="9140832" href="" ref="info:x-wiley/crsRef/9140832" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+degree+of+retinopathy+is+equally+predictive+for+renal+and+macrovascular+outcomes+in+the+ACCORD+Trial+&author=AK+Mottl&author=N+Pajewski&author=V+Fonseca&author=F+Ismail%E2%80%90Beigi&author=E+Chew&author=WT+Ambrosius&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0160"> <div class="citation-other">Mychaleckyj JC, Craven T, Nayak U, Buse J, Crouse JR, Elam M, et al. <span class="citation-title">Reversibility of fenofibrate therapy‐induced renal function impairment in ACCORD type 2 diabetic participants</span>. Diabetes Care<span class="pubYear">2012</span>; Vol. 35, issue 5:1008‐14. [MEDLINE: 22432114]<a class="crsref citation-link central-link" data-crsref="9140833" href="" ref="info:x-wiley/crsRef/9140833" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Reversibility+of+fenofibrate+therapy%E2%80%90induced+renal+function+impairment+in+ACCORD+type+2+diabetic+participants+&author=JC+Mychaleckyj&author=T+Craven&author=U+Nayak&author=J+Buse&author=JR+Crouse&author=M+Elam&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0161"> <div class="citation-journal">Mychaleckyj JC, Farber EA, Chmielewski J, Artale J, Light LS, Bowden DW, et al. <span class="citation-title">Buffy coat specimens remain viable as a DNA source for highly multiplexed genome‐wide genetic tests after long term storage</span>. <span class="citation"> Journal of Translational Medicine </span><span class="pubYear">2011</span>;<span class="volume">9</span>:91. [MEDLINE: 21663644]<a class="crsref citation-link central-link" data-crsref="9140834" href="" ref="info:x-wiley/crsRef/9140834" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21663644" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Buffy+coat+specimens+remain+viable+as+a+DNA+source+for+highly+multiplexed+genome%E2%80%90wide+genetic+tests+after+long+term+storage+&author=JC+Mychaleckyj&author=EA+Farber&author=J+Chmielewski&author=J+Artale&author=LS+Light&author=DW+Bowden&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0162"> <div class="citation-journal">Nadkarni GN, Rao V, Ismail‐Beigi F, Fonseca VA, Shah SV, Simonson MS, et al. <span class="citation-title">Association of Urinary Biomarkers of Inflammation, Injury, and Fibrosis with Renal Function Decline: The ACCORD Trial</span>. <span class="citation"> Clinical Journal of the American Society of Nephrology: CJASN </span><span class="pubYear">2016</span>;<span class="volume">11</span>(8):1343‐52. [MEDLINE: 27189318]<a class="crsref citation-link central-link" data-crsref="9140835" href="" ref="info:x-wiley/crsRef/9140835" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27189318" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Association+of+Urinary+Biomarkers+of+Inflammation,+Injury,+and+Fibrosis+with+Renal+Function+Decline:+The+ACCORD+Trial+&author=GN+Nadkarni&author=V+Rao&author=F+Ismail%E2%80%90Beigi&author=VA+Fonseca&author=SV+Shah&author=MS+Simonson&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0163"> <div class="citation-journal">Papademetriou V, Lovato L, Doumas M, Nylen E, Mottl A, Cohen RM, et al. <span class="citation-title">Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes</span>. <span class="citation"> Kidney International </span><span class="pubYear">2015</span>;<span class="volume">87</span>(3):649‐59. [MEDLINE: 25229335]<a class="crsref citation-link central-link" data-crsref="9140836" href="" ref="info:x-wiley/crsRef/9140836" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25229335" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Chronic+kidney+disease+and+intensive+glycemic+control+increase+cardiovascular+risk+in+patients+with+type+2+diabetes+&author=V+Papademetriou&author=L+Lovato&author=M+Doumas&author=E+Nylen&author=A+Mottl&author=RM+Cohen&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0164"> <div class="citation-journal">Papademetriou V, Zaheer M, Doumas M, Lovato L, Applegate WB, Tsioufis C, et al. <span class="citation-title">Cardiovascular outcomes in action to control cardiovascular risk in diabetes: impact of blood pressure level and presence of kidney disease</span>. <span class="citation"> American Journal of Nephrology </span><span class="pubYear">2016</span>;<span class="volume">43</span>(4):271‐80. [MEDLINE: 27161620]<a class="crsref citation-link central-link" data-crsref="9140837" href="" ref="info:x-wiley/crsRef/9140837" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27161620" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cardiovascular+outcomes+in+action+to+control+cardiovascular+risk+in+diabetes:+impact+of+blood+pressure+level+and+presence+of+kidney+disease+&author=V+Papademetriou&author=M+Zaheer&author=M+Doumas&author=L+Lovato&author=WB+Applegate&author=C+Tsioufis&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0165"> <div class="citation-journal">Pop‐Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, et al. <span class="citation-title">Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2010</span>;<span class="volume">33</span>(7):1578‐84. [MEDLINE: 20215456]<a class="crsref citation-link central-link" data-crsref="9140838" href="" ref="info:x-wiley/crsRef/9140838" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20215456" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+cardiac+autonomic+dysfunction+on+mortality+risk+in+the+Action+to+Control+Cardiovascular+Risk+in+Diabetes+(ACCORD)+trial+&author=R+Pop%E2%80%90Busui&author=GW+Evans&author=HC+Gerstein&author=V+Fonseca&author=JL+Fleg&author=BJ+Hoogwerf&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0166"> <div class="citation-journal">Punthakee Z, Miller ME, Launer LJ, Williamson JD, Lazar RM, Cukierman‐Yaffee T, et al. <span class="citation-title">Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2012</span>;<span class="volume">35</span>(4):787‐93. [MEDLINE: 22374637]<a class="crsref citation-link central-link" data-crsref="9140839" href="" ref="info:x-wiley/crsRef/9140839" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22374637" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Poor+cognitive+function+and+risk+of+severe+hypoglycemia+in+type+2+diabetes:+post+hoc+epidemiologic+analysis+of+the+ACCORD+trial+&author=Z+Punthakee&author=ME+Miller&author=LJ+Launer&author=JD+Williamson&author=RM+Lazar&author=T+Cukierman%E2%80%90Yaffee&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0167"> <div class="citation-journal">Raisch DW, Feeney P, Goff DC, Narayan KM, O'Connor PJ, Zhang P, et al. <span class="citation-title">Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial</span>. <span class="citation"> Cardiovascular Diabetology </span><span class="pubYear">2012</span>;<span class="volume">11</span>:35. [MEDLINE: 22515638]<a class="crsref citation-link central-link" data-crsref="9140840" href="" ref="info:x-wiley/crsRef/9140840" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22515638" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Baseline+comparison+of+three+health+utility+measures+and+the+feeling+thermometer+among+participants+in+the+Action+to+Control+Cardiovascular+Risk+in+Diabetes+trial+&author=DW+Raisch&author=P+Feeney&author=DC+Goff&author=KM+Narayan&author=PJ+O'Connor&author=P+Zhang&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0168"> <div class="citation-journal">Reyes‐Soffer G, Ngai CI, Lovato L, Karmally W, Ramakrishnan R, Holleran S, et al. <span class="citation-title">Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2013</span>;<span class="volume">36</span>(2):422‐8. [MEDLINE: 23033246]<a class="crsref citation-link central-link" data-crsref="9140841" href="" ref="info:x-wiley/crsRef/9140841" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23033246" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+combination+therapy+with+fenofibrate+and+simvastatin+on+postprandial+lipemia+in+the+ACCORD+lipid+trial+&author=G+Reyes%E2%80%90Soffer&author=CI+Ngai&author=L+Lovato&author=W+Karmally&author=R+Ramakrishnan&author=S+Holleran&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0169"> <div class="citation-journal">Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, et al. <span class="citation-title">Epidemiologic relationships between A1C and all‐cause mortality during a median 3.4‐year follow‐up of glycemic treatment in the ACCORD trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2010</span>;<span class="volume">33</span>(5):983‐90. [MEDLINE: 20427682]<a class="crsref citation-link central-link" data-crsref="9140842" href="" ref="info:x-wiley/crsRef/9140842" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20427682" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Epidemiologic+relationships+between+A1C+and+all%E2%80%90cause+mortality+during+a+median+3.4%E2%80%90year+follow%E2%80%90up+of+glycemic+treatment+in+the+ACCORD+trial+&author=MC+Riddle&author=WT+Ambrosius&author=DJ+Brillon&author=JB+Buse&author=RP+Byington&author=RM+Cohen&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0170"> <div class="citation-journal">Samaropoulos XF, Light L, Ambrosius WT, Marcovina SM, Probstfield J, Jr DC. <span class="citation-title">The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers</span>. <span class="citation"> Diabetes Research &amp; Clinical Practice </span><span class="pubYear">2012</span>;<span class="volume">95</span>(3):389‐98. [MEDLINE: 22019270]<a class="crsref citation-link central-link" data-crsref="9140843" href="" ref="info:x-wiley/crsRef/9140843" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+effect+of+intensive+risk+factor+management+in+type+2+diabetes+on+inflammatory+biomarkers+&author=XF+Samaropoulos&author=L+Light&author=WT+Ambrosius&author=SM+Marcovina&author=J+Probstfield&author=DC+Jr&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0171"> <div class="citation-journal">Seaquist ER, Miller ME, Bonds DE, Feinglos M, Goff DC, Peterson K, et al. <span class="citation-title">The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2012</span>;<span class="volume">35</span>(2):409‐14. [MEDLINE: 22179956]<a class="crsref citation-link central-link" data-crsref="9140844" href="" ref="info:x-wiley/crsRef/9140844" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22179956" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+impact+of+frequent+and+unrecognized+hypoglycemia+on+mortality+in+the+ACCORD+study&author=ER+Seaquist&author=ME+Miller&author=DE+Bonds&author=M+Feinglos&author=DC+Goff&author=K+Peterson&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0172"> <div class="citation-journal">Strylewicz G, Doctor J. <span class="citation-title">Evaluation of an automated method to assist with error detection in the ACCORD central laboratory</span>. <span class="citation"> Clinical Trials </span><span class="pubYear">2010</span>;<span class="volume">7</span>(4):380‐9. [MEDLINE: 20571135]<a class="crsref citation-link central-link" data-crsref="9140845" href="" ref="info:x-wiley/crsRef/9140845" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20571135" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Evaluation+of+an+automated+method+to+assist+with+error+detection+in+the+ACCORD+central+laboratory+&author=G+Strylewicz&author=J+Doctor&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0173"> <div class="citation-journal">Sullivan MD, Anderson RT, Aron D, Atkinson HH, Bastien A, Chen GJ, et al. <span class="citation-title">Health‐related quality of life and cost‐effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2007</span>;<span class="volume">99</span>(12A):90i‐102i. [MEDLINE: 17599429]<a class="crsref citation-link central-link" data-crsref="9140846" href="" ref="info:x-wiley/crsRef/9140846" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17599429" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Health%E2%80%90related+quality+of+life+and+cost%E2%80%90effectiveness+components+of+the+Action+to+Control+Cardiovascular+Risk+in+Diabetes+(ACCORD)+trial:+rationale+and+design+&author=MD+Sullivan&author=RT+Anderson&author=D+Aron&author=HH+Atkinson&author=A+Bastien&author=GJ+Chen&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0174"> <div class="citation-journal">Sullivan MD, O'Connor P, Feeney P, Hire D, Simmons DL, Raisch DW, et al. <span class="citation-title">Depression predicts all‐cause mortality: epidemiological evaluation from the ACCORD HRQL substudy</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2012</span>;<span class="volume">35</span>(8):1708‐15. [MEDLINE: 22619083]<a class="crsref citation-link central-link" data-crsref="9140847" href="" ref="info:x-wiley/crsRef/9140847" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22619083" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Depression+predicts+all%E2%80%90cause+mortality:+epidemiological+evaluation+from+the+ACCORD+HRQL+substudy+&author=MD+Sullivan&author=P+O'Connor&author=P+Feeney&author=D+Hire&author=DL+Simmons&author=DW+Raisch&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0175"> <div class="citation-journal">Thethi T, Rajapurkar M, Walker P, McDuffie R, Goff DC, Probstfield J, et al. <span class="citation-title">Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria‐‐a substudy of the ACCORD Trial</span>. <span class="citation"> Clinical Chemistry </span><span class="pubYear">2011</span>;<span class="volume">57</span>(2):341‐4. [MEDLINE: 21159897]<a class="crsref citation-link central-link" data-crsref="9140848" href="" ref="info:x-wiley/crsRef/9140848" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21159897" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Urinary+catalytic+iron+in+patients+with+type+2+diabetes+without+microalbuminuria%E2%80%90%E2%80%90a+substudy+of+the+ACCORD+Trial+&author=T+Thethi&author=M+Rajapurkar&author=P+Walker&author=R+McDuffie&author=DC+Goff&author=J+Probstfield&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0176"> <div class="citation-journal">Williamson JD, Launer LJ, Bryan RN, Coker LH, Lazar RM, Gerstein HC, et al. <span class="citation-title">Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial</span>. <span class="citation"> JAMA Internal Medicine </span><span class="pubYear">2014</span>;<span class="volume">174</span>(3):324‐33. [MEDLINE: 24493100]<a class="crsref citation-link central-link" data-crsref="9140849" href="" ref="info:x-wiley/crsRef/9140849" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24493100" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cognitive+function+and+brain+structure+in+persons+with+type+2+diabetes+mellitus+after+intensive+lowering+of+blood+pressure+and+lipid+levels:+a+randomized+clinical+trial+&author=JD+Williamson&author=LJ+Launer&author=RN+Bryan&author=LH+Coker&author=RM+Lazar&author=HC+Gerstein&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0177"> <div class="citation-journal">Williamson JD, Miller ME, Bryan RN, Lazar RM, Coker LH, Johnson J, et al. <span class="citation-title">The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD‐MIND): rationale, design, and methods</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2007</span>;<span class="volume">99</span>(12A):112i‐22i. [MEDLINE: 17599421]<a class="crsref citation-link central-link" data-crsref="9140850" href="" ref="info:x-wiley/crsRef/9140850" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17599421" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+Action+to+Control+Cardiovascular+Risk+in+Diabetes+Memory+in+Diabetes+Study+(ACCORD%E2%80%90MIND):+rationale,+design,+and+methods+&author=JD+Williamson&author=ME+Miller&author=RN+Bryan&author=RM+Lazar&author=LH+Coker&author=J+Johnson&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0046"> <div class="reference-title-banner"> <h4 class="title">ADOPT 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0178"> <div class="citation-journal">Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. <span class="citation-title">Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.[erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387‐8]</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2006</span>;<span class="volume">355</span>(23):2427‐43. [MEDLINE: 17145742]<a class="crsref citation-link central-link" data-crsref="9140852" href="" ref="info:x-wiley/crsRef/9140852" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17145742" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Glycemic+durability+of+rosiglitazone,+metformin,+or+glyburide+monotherapy.[erratum+appears+in+N+Engl+J+Med.+2007+Mar+29;356(13):1387%E2%80%908]+&author=SE+Kahn&author=SM+Haffner&author=MA+Heise&author=WH+Herman&author=RR+Holman&author=NP+Jones&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0179"> <div class="citation-journal">Kahn SE, Zinman B, Haffner SM, O'Neill MC, Kravitz BG, Yu D, et al. <span class="citation-title">Obesity is a major determinant of the association of C‐reactive protein levels and the metabolic syndrome in type 2 diabetes</span>. <span class="citation"> Diabetes </span><span class="pubYear">2006</span>;<span class="volume">55</span>(8):2357‐64. [MEDLINE: 16873701]<a class="crsref citation-link central-link" data-crsref="9140853" href="" ref="info:x-wiley/crsRef/9140853" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16873701" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Obesity+is+a+major+determinant+of+the+association+of+C%E2%80%90reactive+protein+levels+and+the+metabolic+syndrome+in+type+2+diabetes+&author=SE+Kahn&author=B+Zinman&author=SM+Haffner&author=MC+O'Neill&author=BG+Kravitz&author=D+Yu&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0180"> <div class="citation-journal">Lachin JM, Viberti G, Zinman B, Haffner SM, Aftring RP, Paul G, et al. <span class="citation-title">Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy</span>. <span class="citation"> Clinical Journal of the American Society of Nephrology: CJASN </span><span class="pubYear">2011</span>;<span class="volume">6</span>(5):1032‐40. [MEDLINE: 21454723]<a class="crsref citation-link central-link" data-crsref="9140854" href="" ref="info:x-wiley/crsRef/9140854" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21454723" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Renal+function+in+type+2+diabetes+with+rosiglitazone,+metformin,+and+glyburide+monotherapy&author=JM+Lachin&author=G+Viberti&author=B+Zinman&author=SM+Haffner&author=RP+Aftring&author=G+Paul&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0181"> <div class="citation-journal">Zinman B, Kahn SE, Haffner SM, O'Neill MC, Heise MA, Freed MI, et al. <span class="citation-title">Phenotypic characteristics of GAD antibody‐positive recently diagnosed patients with type 2 diabetes in North America and Europe</span>. <span class="citation"> Diabetes </span><span class="pubYear">2004</span>;<span class="volume">53</span>(12):3193‐200. [MEDLINE: 15561950]<a class="crsref citation-link central-link" data-crsref="9140855" href="" ref="info:x-wiley/crsRef/9140855" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15561950" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Phenotypic+characteristics+of+GAD+antibody%E2%80%90positive+recently+diagnosed+patients+with+type+2+diabetes+in+North+America+and+Europe+&author=B+Zinman&author=SE+Kahn&author=SM+Haffner&author=MC+O'Neill&author=MA+Heise&author=MI+Freed&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0047"> <div class="reference-title-banner"> <h4 class="title">ADVANCE 2001 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0200"> <div class="citation-journal"><span class="citation-title">Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high‐risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified‐Release Controlled Evaluation</span>. <span class="citation"> Journal of Hypertension ‐ Supplement </span><span class="pubYear">2001</span>;<span class="volume">19</span>(4):S21‐8. [MEDLINE: 11848259]<a class="crsref citation-link central-link" data-crsref="9140875" href="" ref="info:x-wiley/crsRef/9140875" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0201"> <div class="citation-journal"><span class="citation-title">Study rationale and design of ADVANCE: action in diabetes and vascular disease‐‐preterax and diamicron MR controlled evaluation</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2001</span>;<span class="volume">44</span>(9):1118‐20. [MEDLINE: 11596665]<a class="crsref citation-link central-link" data-crsref="9140876" href="" ref="info:x-wiley/crsRef/9140876" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11596665" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0183"> <div class="citation-journal">ADVANCE Collaborative Group. <span class="citation-title">ADVANCE‐‐Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2005</span>;<span class="volume">22</span>(7):882‐8. [MEDLINE: 15975103]<a class="crsref citation-link central-link" data-crsref="9140858" href="" ref="info:x-wiley/crsRef/9140858" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15975103" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0182"> <div class="citation-journal">ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. <span class="citation-title">Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2008</span>;<span class="volume">358</span>(24):2560‐72. [MEDLINE: 18539916]<a class="crsref citation-link central-link" data-crsref="9140857" href="" ref="info:x-wiley/crsRef/9140857" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18539916" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensive+blood+glucose+control+and+vascular+outcomes+in+patients+with+type+2+diabetes&author=A+Patel&author=S+MacMahon&author=J+Chalmers&author=B+Neal&author=L+Billot&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0185"> <div class="citation-journal">Chalmers J. <span class="citation-title">[ADVANCE study: objectives, design and current status]. [French]</span>. <span class="citation"> Drugs </span><span class="pubYear">2003</span>;<span class="volume">63</span>(Spec No 1):39‐44. [MEDLINE: 12708881]<a class="crsref citation-link central-link" data-crsref="9140860" href="" ref="info:x-wiley/crsRef/9140860" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12708881" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=[ADVANCE+study:+objectives,+design+and+current+status].+[French]&author=J+Chalmers&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0184"> <div class="citation-journal">Chalmers J, Marre M, de GB, Zoungas S, Hamet P, Neal B, et al. <span class="citation-title">The efficacy of lowering HbAlc with a gliclazide modified release‐based intensive glucose lowering regimen in the ADVANCE trial [abstract]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2009</span>;<span class="volume">52</span>(Suppl 1):S354. [EMBASE: 70068392]<a class="crsref citation-link central-link" data-crsref="9140859" href="" ref="info:x-wiley/crsRef/9140859" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+efficacy+of+lowering+HbAlc+with+a+gliclazide+modified+release%E2%80%90based+intensive+glucose+lowering+regimen+in+the+ADVANCE+trial+[abstract]+&author=J+Chalmers&author=M+Marre&author=GB+de&author=S+Zoungas&author=P+Hamet&author=B+Neal&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0186"> <div class="citation-journal">Cooper ME, Zoungas S, Jardine M, Hata J, Perkovic V, Ninomiya T, et al. <span class="citation-title">Risk of major renal events in people with type 2 diabetes: Prediction models based on the ADVANCE study population [abstract]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2011</span>;<span class="volume">54</span>(1 Suppl):S442. [EMBASE: 70563236]<a class="crsref citation-link central-link" data-crsref="9140861" href="" ref="info:x-wiley/crsRef/9140861" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Risk+of+major+renal+events+in+people+with+type+2+diabetes:+Prediction+models+based+on+the+ADVANCE+study+population+[abstract]+&author=ME+Cooper&author=S+Zoungas&author=M+Jardine&author=J+Hata&author=V+Perkovic&author=T+Ninomiya&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0187"> <div class="citation-journal">Hata J, Arima H, Rothwell PM, Woodward M, Zoungas S, Anderson C, et al. <span class="citation-title">Effects of visit‐to‐visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial</span>. <span class="citation"> Circulation </span><span class="pubYear">2013</span>;<span class="volume">128</span>(12):1325‐34. [MEDLINE: 23926207]<a class="crsref citation-link central-link" data-crsref="9140862" href="" ref="info:x-wiley/crsRef/9140862" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23926207" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+visit%E2%80%90to%E2%80%90visit+variability+in+systolic+blood+pressure+on+macrovascular+and+microvascular+complications+in+patients+with+type+2+diabetes+mellitus:+the+ADVANCE+trial+&author=J+Hata&author=H+Arima&author=PM+Rothwell&author=M+Woodward&author=S+Zoungas&author=C+Anderson&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0188"> <div class="citation-journal">Heerspink HJ, Ninomiya T, Perkovic V, Woodward M, Zoungas S, Cass A, et al. <span class="citation-title">Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease</span>. <span class="citation"> European Heart Journal </span><span class="pubYear">2010</span>;<span class="volume">31</span>(23):2888‐96. [MEDLINE: 20501479]<a class="crsref citation-link central-link" data-crsref="9140863" href="" ref="info:x-wiley/crsRef/9140863" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20501479" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+a+fixed+combination+of+perindopril+and+indapamide+in+patients+with+type+2+diabetes+and+chronic+kidney+disease+&author=HJ+Heerspink&author=T+Ninomiya&author=V+Perkovic&author=M+Woodward&author=S+Zoungas&author=A+Cass&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0189"> <div class="citation-journal">Jardine M, Ninomiya T, Perkovic V, Woodward M, Pillai A, Cass A, et al. <span class="citation-title">Predictive baseline factors for major renal events: a proportional hazards model based on the Advance Study [abstract no: F‐PO1916]</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">2008</span>;<span class="volume">19</span>(Abstracts Issue):543A. <a class="crsref citation-link central-link" data-crsref="9140864" href="" ref="info:x-wiley/crsRef/9140864" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Predictive+baseline+factors+for+major+renal+events:+a+proportional+hazards+model+based+on+the+Advance+Study+[abstract+no:+F%E2%80%90PO1916]+&author=M+Jardine&author=T+Ninomiya&author=V+Perkovic&author=M+Woodward&author=A+Pillai&author=A+Cass&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0190"> <div class="citation-journal">Jardine MJ, Hata J, Woodward M, Perkovic V, Ninomiya T, Arima H, et al. <span class="citation-title">Prediction of kidney‐related outcomes in patients with type 2 diabetes</span>. <span class="citation"> American Journal of Kidney Diseases </span><span class="pubYear">2012</span>;<span class="volume">60</span>(5):770‐8. [MEDLINE: 22694950]<a class="crsref citation-link central-link" data-crsref="9140865" href="" ref="info:x-wiley/crsRef/9140865" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22694950" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Prediction+of+kidney%E2%80%90related+outcomes+in+patients+with+type+2+diabetes&author=MJ+Jardine&author=J+Hata&author=M+Woodward&author=V+Perkovic&author=T+Ninomiya&author=H+Arima&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0191"> <div class="citation-journal">Mohammedi K, Woodward M, Zoungas S, Li Q, Harrap S, Patel A, et al. <span class="citation-title">Absence of peripheral pulses and risk of major vascular outcomes in patients with type 2 diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2016</span>;<span class="volume">39</span>(12):2270‐7. [MEDLINE: 27679583]<a class="crsref citation-link central-link" data-crsref="9140866" href="" ref="info:x-wiley/crsRef/9140866" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27679583" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Absence+of+peripheral+pulses+and+risk+of+major+vascular+outcomes+in+patients+with+type+2+diabetes+&author=K+Mohammedi&author=M+Woodward&author=S+Zoungas&author=Q+Li&author=S+Harrap&author=A+Patel&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0192"> <div class="citation-journal">Ninomiya T, Zoungas S, Neal B, Woodward M, Patel A, Perkovic V, et al. <span class="citation-title">Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial</span>. <span class="citation"> Journal of Hypertension </span><span class="pubYear">2010</span>;<span class="volume">28</span>(6):1141‐9. [MEDLINE: 20486273]<a class="crsref citation-link central-link" data-crsref="9140867" href="" ref="info:x-wiley/crsRef/9140867" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20486273" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+routine+blood+pressure+lowering+in+older+patients+with+diabetes:+results+from+the+ADVANCE+trial+&author=T+Ninomiya&author=S+Zoungas&author=B+Neal&author=M+Woodward&author=A+Patel&author=V+Perkovic&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0193"> <div class="citation-journal">Patel A, Chalmers J, Poulter N. <span class="citation-title">ADVANCE: Action in diabetes and vascular disease</span>. <span class="citation"> Journal of Human Hypertension </span><span class="pubYear">2005</span>;<span class="volume">19</span>(Suppl 1):S27‐32. [EMBASE: 2005306507]<a class="crsref citation-link central-link" data-crsref="9140868" href="" ref="info:x-wiley/crsRef/9140868" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16075030" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=ADVANCE:+Action+in+diabetes+and+vascular+disease&author=A+Patel&author=J+Chalmers&author=N+Poulter&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0194"> <div class="citation-journal">Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. <span class="citation-title">Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial</span>. <span class="citation"> Lancet </span><span class="pubYear">2007</span>;<span class="volume">370</span>(9590):829‐40. [MEDLINE: 17765963]<a class="crsref citation-link central-link" data-crsref="9140869" href="" ref="info:x-wiley/crsRef/9140869" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17765963" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+a+fixed+combination+of+perindopril+and+indapamide+on+macrovascular+and+microvascular+outcomes+in+patients+with+type+2+diabetes+mellitus+(the+ADVANCE+trial):+a+randomised+controlled+trial+&author=A+Patel&author=S+MacMahon&author=J+Chalmers&author=B+Neal&author=M+Woodward&author=L+Billot&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0195"> <div class="citation-journal">Perkovic V, Heerspink HL, Chalmers J, Woodward M, Jun M, Li Q, et al. <span class="citation-title">Intensive glucose control improves kidney outcomes in patients with type 2 diabetes</span>. <span class="citation"> Kidney International </span><span class="pubYear">2013</span>;<span class="volume">83</span>(3):517‐23. [MEDLINE: 23302714]<a class="crsref citation-link central-link" data-crsref="9140870" href="" ref="info:x-wiley/crsRef/9140870" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23302714" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensive+glucose+control+improves+kidney+outcomes+in+patients+with+type+2+diabetes&author=V+Perkovic&author=HL+Heerspink&author=J+Chalmers&author=M+Woodward&author=M+Jun&author=Q+Li&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0196"> <div class="citation-other">Perkovic V, Ninomiya T, Galan BE, Zoungas S, Cass A, Patel A, et al. <span class="citation-title">Joint effects of routine blood pressure lowering and intensive glucose control in the ADVANCE trial [abstract no: LB‐002]</span>. American Society of Nephrology (ASN) Renal Week; 2008 Nov 4‐9; Philadelphia, PA. <span class="pubYear">2008</span>. <a class="crsref citation-link central-link" data-crsref="9140871" href="" ref="info:x-wiley/crsRef/9140871" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Joint+effects+of+routine+blood+pressure+lowering+and+intensive+glucose+control+in+the+ADVANCE+trial+[abstract+no:+LB%E2%80%90002]+&author=V+Perkovic&author=T+Ninomiya&author=BE+Galan&author=S+Zoungas&author=A+Cass&author=A+Patel&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0197"> <div class="citation-journal">Perkovic V, Zoungas S, Heerspink HL, Woodward M, Jun M, Cass A, et al. <span class="citation-title">Intensive glucose lowering and end stage kidney disease ‐ new data from the ADVANCE trial [abstract no: 071]</span>. <span class="citation"> Nephrology </span><span class="pubYear">2011</span>;<span class="volume">16</span>(Suppl 1):42. <a class="crsref citation-link central-link" data-crsref="9140872" href="" ref="info:x-wiley/crsRef/9140872" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensive+glucose+lowering+and+end+stage+kidney+disease+%E2%80%90+new+data+from+the+ADVANCE+trial+[abstract+no:+071]+&author=V+Perkovic&author=S+Zoungas&author=HL+Heerspink&author=M+Woodward&author=M+Jun&author=A+Cass&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0198"> <div class="citation-journal">Perkovic V, Galan B, Chalmers J, Ninomiya T, Patel A, Cass A, et al. <span class="citation-title">Renoprotection with perindopril‐indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: results of the ADVANCE trial [abstract no: 085]</span>. <span class="citation"> Nephrology </span><span class="pubYear">2008</span>;<span class="volume">13</span>(Suppl 3):A121. <a class="crsref citation-link central-link" data-crsref="9140873" href="" ref="info:x-wiley/crsRef/9140873" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Renoprotection+with+perindopril%E2%80%90indapamide+below+current+recommended+blood+pressure+targets+in+patients+with+type+2+diabetes+mellitus:+results+of+the+ADVANCE+trial+[abstract+no:+085]+&author=V+Perkovic&author=B+Galan&author=J+Chalmers&author=T+Ninomiya&author=A+Patel&author=A+Cass&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0199"> <div class="citation-journal">Poulter NR. <span class="citation-title">Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE</span>. <span class="citation"> Journal of Hypertension </span><span class="pubYear">2009</span>;<span class="volume">27 Suppl 1</span>:S3‐8. [MEDLINE: 19483505]<a class="crsref citation-link central-link" data-crsref="9140874" href="" ref="info:x-wiley/crsRef/9140874" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Blood+pressure+and+glucose+control+in+subjects+with+diabetes:+new+analyses+from+ADVANCE&author=NR+Poulter&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0202"> <div class="citation-journal">Wong G, Zoungas S, Lo S, Chalmers J, Cass A, Neal B, et al. <span class="citation-title">The risk of cancer in people with diabetes and chronic kidney disease</span>. <span class="citation"> Nephrology Dialysis Transplantation </span><span class="pubYear">2012</span>;<span class="volume">27</span>(8):3337‐44. [MEDLINE: 22357699]<a class="crsref citation-link central-link" data-crsref="9140877" href="" ref="info:x-wiley/crsRef/9140877" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+risk+of+cancer+in+people+with+diabetes+and+chronic+kidney+disease&author=G+Wong&author=S+Zoungas&author=S+Lo&author=J+Chalmers&author=A+Cass&author=B+Neal&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0203"> <div class="citation-journal">Wong MG, Perkovic V, Chalmers J, Woodward M, Li Q, Cooper ME, et al. <span class="citation-title">Long‐term benefits of intensive glucose control for preventing end‐stage kidney disease: ADVANCE‐ON</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2016 May</span>;<span class="volume">39</span>(5):694‐700. [MEDLINE: 27006512]<a class="crsref citation-link central-link" data-crsref="9140878" href="" ref="info:x-wiley/crsRef/9140878" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27006512" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+benefits+of+intensive+glucose+control+for+preventing+end%E2%80%90stage+kidney+disease:+ADVANCE%E2%80%90ON+&author=MG+Wong&author=V+Perkovic&author=J+Chalmers&author=M+Woodward&author=Q+Li&author=ME+Cooper&publication_year=2016May&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0204"> <div class="citation-journal">Zoungas S, Chalmers J, Ninomiya T, Li Q, Cooper ME, Colagiuri S, et al. <span class="citation-title">Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2012</span>;<span class="volume">55</span>(3):636‐43. [MEDLINE: 22186981]<a class="crsref citation-link central-link" data-crsref="9140879" href="" ref="info:x-wiley/crsRef/9140879" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22186981" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Association+of+HbA1c+levels+with+vascular+complications+and+death+in+patients+with+type+2+diabetes:+evidence+of+glycaemic+thresholds+&author=S+Zoungas&author=J+Chalmers&author=T+Ninomiya&author=Q+Li&author=ME+Cooper&author=S+Colagiuri&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0205"> <div class="citation-journal">Zoungas S, Lambers Heerspink HJ, Chalmers J, Woodward M, Jun M, Cass A, et al. <span class="citation-title">Intensive glucose lowering and end stage kidney disease: New data from the ADVANCE trial [abstract]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2011</span>;<span class="volume">54</span>(1 Suppl):S23. [EMBASE: 70562184]<a class="crsref citation-link central-link" data-crsref="9140880" href="" ref="info:x-wiley/crsRef/9140880" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensive+glucose+lowering+and+end+stage+kidney+disease:+New+data+from+the+ADVANCE+trial+[abstract]+&author=S+Zoungas&author=HJ+LambersHeerspink&author=J+Chalmers&author=M+Woodward&author=M+Jun&author=A+Cass&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0206"> <div class="citation-journal">Zoungas S, Patel A, Chalmers J, Galan BE, Li Q, Billot L, et al. <span class="citation-title">Severe hypoglycemia and risks of vascular events and death</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2010</span>;<span class="volume">363</span>(15):1410‐8. [MEDLINE: 20925543]<a class="crsref citation-link central-link" data-crsref="9140881" href="" ref="info:x-wiley/crsRef/9140881" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20925543" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Severe+hypoglycemia+and+risks+of+vascular+events+and+death&author=S+Zoungas&author=A+Patel&author=J+Chalmers&author=BE+Galan&author=Q+Li&author=L+Billot&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0207"> <div class="citation-journal">Zoungas S, Perkovic V, Ninomiya T, de GB, Pillai I, Patel A, et al. <span class="citation-title">Joint effects of blood pressure lowering and glucose control in the ADVANCE trial [abstract]</span>. <span class="citation"> Hypertension </span><span class="pubYear">2009</span>;<span class="volume">53</span>(6):1103. [EMBASE: 70036220]<a class="crsref citation-link central-link" data-crsref="9140882" href="" ref="info:x-wiley/crsRef/9140882" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Joint+effects+of+blood+pressure+lowering+and+glucose+control+in+the+ADVANCE+trial+[abstract]+&author=S+Zoungas&author=V+Perkovic&author=T+Ninomiya&author=GB+de&author=I+Pillai&author=A+Patel&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0208"> <div class="citation-journal">Zoungas S, Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, et al. <span class="citation-title">Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2009</span>;<span class="volume">32</span>(11):2068‐74. [MEDLINE: 19651921]<a class="crsref citation-link central-link" data-crsref="9140883" href="" ref="info:x-wiley/crsRef/9140883" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19651921" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Combined+effects+of+routine+blood+pressure+lowering+and+intensive+glucose+control+on+macrovascular+and+microvascular+outcomes+in+patients+with+type+2+diabetes:+New+results+from+the+ADVANCE+trial+&author=S+Zoungas&author=BE+Galan&author=T+Ninomiya&author=D+Grobbee&author=P+Hamet&author=S+Heller&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0209"> <div class="citation-journal">Galan BE, Ninomiya T, Perrovic V, Pillai A, Patel A, Neal ACB, et al. <span class="citation-title">Renoprotective effects of blood pressure lowering with perindopril‐indapamide below current targets in people with type 2 diabetes mellitus: Results of the ADVANCE trial [abstract]</span>. <span class="citation"> Diabetes </span><span class="pubYear">2008</span>;<span class="volume">57</span>(Suppl 1):A218‐9. <a class="crsref citation-link central-link" data-crsref="9140884" href="" ref="info:x-wiley/crsRef/9140884" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Renoprotective+effects+of+blood+pressure+lowering+with+perindopril%E2%80%90indapamide+below+current+targets+in+people+with+type+2+diabetes+mellitus:+Results+of+the+ADVANCE+trial+[abstract]+&author=BE+Galan&author=T+Ninomiya&author=V+Perrovic&author=A+Pillai&author=A+Patel&author=ACB+Neal&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0210"> <div class="citation-journal">Galan BE, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A, et al. <span class="citation-title">Lowering blood pressure reduces renal events in type 2 diabetes</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">2009</span>;<span class="volume">20</span>(4):883‐92. [MEDLINE: 19225038]<a class="crsref citation-link central-link" data-crsref="9140885" href="" ref="info:x-wiley/crsRef/9140885" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19225038" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Lowering+blood+pressure+reduces+renal+events+in+type+2+diabetes&author=BE+Galan&author=V+Perkovic&author=T+Ninomiya&author=A+Pillai&author=A+Patel&author=A+Cass&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0048"> <div class="reference-title-banner"> <h4 class="title">Agarwal 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0212"> <div class="citation-journal">Agarwal R. <span class="citation-title">Anti‐inflammatory effects of short‐term pioglitazone therapy in men with advanced diabetic nephropathy</span>. <span class="citation"> American Journal of Physiology ‐ Renal Physiology </span><span class="pubYear">2006</span>;<span class="volume">290</span>(3):F600‐5. [MEDLINE: 16159895]<a class="crsref citation-link central-link" data-crsref="9140888" href="" ref="info:x-wiley/crsRef/9140888" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16159895" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Anti%E2%80%90inflammatory+effects+of+short%E2%80%90term+pioglitazone+therapy+in+men+with+advanced+diabetic+nephropathy+&author=R+Agarwal&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0211"> <div class="citation-journal">Agarwal R, Saha C, Battiwala M, Vasavada N, Curley T, Chase SD, et al. <span class="citation-title">A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy</span>. <span class="citation"> Kidney International </span><span class="pubYear">2005</span>;<span class="volume">68</span>(1):285‐92. [MEDLINE: 15954919]<a class="crsref citation-link central-link" data-crsref="9140887" href="" ref="info:x-wiley/crsRef/9140887" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15954919" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+pilot+randomized+controlled+trial+of+renal+protection+with+pioglitazone+in+diabetic+nephropathy+&author=R+Agarwal&author=C+Saha&author=M+Battiwala&author=N+Vasavada&author=T+Curley&author=SD+Chase&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0049"> <div class="reference-title-banner"> <h4 class="title">Aljabri 2004 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0213"> <div class="citation-journal">Aljabri K, Kozak SE, Thompson DM. <span class="citation-title">Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial</span>. <span class="citation"> American Journal of Medicine </span><span class="pubYear">2004</span>;<span class="volume">116</span>(4):230‐5. [MEDLINE: 14969650]<a class="crsref citation-link central-link" data-crsref="9140890" href="" ref="info:x-wiley/crsRef/9140890" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/14969650" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Addition+of+pioglitazone+or+bedtime+insulin+to+maximal+doses+of+sulfonylurea+and+metformin+in+type+2+diabetes+patients+with+poor+glucose+control:+a+prospective,+randomized+trial+&author=K+Aljabri&author=SE+Kozak&author=DM+Thompson&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0050"> <div class="reference-title-banner"> <h4 class="title">Amador‐Licona 2000 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0214"> <div class="citation-journal">Amador‐Licona N, Guizar‐Mendoza J, Vargas E, Sanchez‐Camargo G, Zamora‐Mata L. <span class="citation-title">The short‐term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus</span>. <span class="citation"> Archives of Medical Research </span><span class="pubYear">2000</span>;<span class="volume">31</span>(6):571‐5. [MEDLINE: 11257323]<a class="crsref citation-link central-link" data-crsref="9140892" href="" ref="info:x-wiley/crsRef/9140892" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11257323" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+short%E2%80%90term+effect+of+a+switch+from+glibenclamide+to+metformin+on+blood+pressure+and+microalbuminuria+in+patients+with+type+2+diabetes+mellitus+&author=N+Amador%E2%80%90Licona&author=J+Guizar%E2%80%90Mendoza&author=E+Vargas&author=G+Sanchez%E2%80%90Camargo&author=L+Zamora%E2%80%90Mata&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0051"> <div class="reference-title-banner"> <h4 class="title">Aoki 1995 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0215"> <div class="citation-journal">Aoki TT, Grecu EO, Prendergast JJ, Arcangeli MA, Meisenheimer R. <span class="citation-title">Effect of chronic intermittent intravenous insulin therapy on antihypertensive medication requirements in IDDM subjects with hypertension and nephropathy</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1995</span>;<span class="volume">18</span>(9):1260‐5. [MEDLINE: 8612440]<a class="crsref citation-link central-link" data-crsref="9140894" href="" ref="info:x-wiley/crsRef/9140894" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8612440" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+chronic+intermittent+intravenous+insulin+therapy+on+antihypertensive+medication+requirements+in+IDDM+subjects+with+hypertension+and+nephropathy+&author=TT+Aoki&author=EO+Grecu&author=JJ+Prendergast&author=MA+Arcangeli&author=R+Meisenheimer&publication_year=1995&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0052"> <div class="reference-title-banner"> <h4 class="title">APRIME 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0216"> <div class="citation-journal">Morikawa A, Ishizeki K, Iwashima Y, Yokoyama H, Muto E, Oshima E, et al. <span class="citation-title">Pioglitazone reduces urinary albumin excretion in renin‐angiotensin system inhibitor‐treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study</span>. <span class="citation"> Clinical &amp; Experimental Nephrology </span><span class="pubYear">2011</span>;<span class="volume">15</span>(6):848‐53. [MEDLINE: 21823043]<a class="crsref citation-link central-link" data-crsref="9140896" href="" ref="info:x-wiley/crsRef/9140896" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone+reduces+urinary+albumin+excretion+in+renin%E2%80%90angiotensin+system+inhibitor%E2%80%90treated+type+2+diabetic+patients+with+hypertension+and+microalbuminuria:+the+APRIME+study+&author=A+Morikawa&author=K+Ishizeki&author=Y+Iwashima&author=H+Yokoyama&author=E+Muto&author=E+Oshima&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0053"> <div class="reference-title-banner"> <h4 class="title">Bakris 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0217"> <div class="citation-journal">Bakris GL, Ruilope LM, McMorn SO, Weston WM, Heise MA, Freed MI, et al. <span class="citation-title">Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria</span>. <span class="citation"> Journal of Hypertension </span><span class="pubYear">2006</span>;<span class="volume">24</span>(10):2047‐55. [MEDLINE: 16957566]<a class="crsref citation-link central-link" data-crsref="9140898" href="" ref="info:x-wiley/crsRef/9140898" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16957566" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rosiglitazone+reduces+microalbuminuria+and+blood+pressure+independently+of+glycemia+in+type+2+diabetes+patients+with+microalbuminuria+&author=GL+Bakris&author=LM+Ruilope&author=SO+McMorn&author=WM+Weston&author=MA+Heise&author=MI+Freed&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0054"> <div class="reference-title-banner"> <h4 class="title">Bangstad 1992 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0220"> <div class="citation-journal">Bangstad HJ. <span class="citation-title">Early glomerulopathy is present in young, type 1 (insulin‐dependent) diabetic patients with microalbuminuria</span>. <span class="citation"> Diabetologia </span><span class="pubYear">1993</span>;<span class="volume">36</span>(6):523‐9. [MEDLINE: 8335174]<a class="crsref citation-link central-link" data-crsref="9140902" href="" ref="info:x-wiley/crsRef/9140902" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8335174" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Early+glomerulopathy+is+present+in+young,+type+1+(insulin%E2%80%90dependent)+diabetic+patients+with+microalbuminuria+&author=HJ+Bangstad&publication_year=1993&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0218"> <div class="citation-journal">Bangstad HJ, Kofoed‐Enevoldsen A, Dahl‐Jorgensen K, Hanssen KF. <span class="citation-title">Glomerular charge selectivity and the influence of improved blood glucose control in type 1 (insulin‐dependent) diabetic patients with microalbuminuria</span>. <span class="citation"> Diabetologia </span><span class="pubYear">1992</span>;<span class="volume">35</span>(12):1165‐9. [MEDLINE: 1478369]<a class="crsref citation-link central-link" data-crsref="9140900" href="" ref="info:x-wiley/crsRef/9140900" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/1478369" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Glomerular+charge+selectivity+and+the+influence+of+improved+blood+glucose+control+in+type+1+(insulin%E2%80%90dependent)+diabetic+patients+with+microalbuminuria+&author=HJ+Bangstad&author=A+Kofoed%E2%80%90Enevoldsen&author=K+Dahl%E2%80%90Jorgensen&author=KF+Hanssen&publication_year=1992&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0219"> <div class="citation-journal">Bangstad HJ, Osterby R, Dahl‐Jorgensen K, Berg KJ, Hartmann A, Hanssen KF. <span class="citation-title">Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy</span>. <span class="citation"> Diabetologia </span><span class="pubYear">1994</span>;<span class="volume">37</span>(5):483‐90. [MEDLINE: 8056186]<a class="crsref citation-link central-link" data-crsref="9140901" href="" ref="info:x-wiley/crsRef/9140901" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8056186" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Improvement+of+blood+glucose+control+in+IDDM+patients+retards+the+progression+of+morphological+changes+in+early+diabetic+nephropathy+&author=HJ+Bangstad&author=R+Osterby&author=K+Dahl%E2%80%90Jorgensen&author=KJ+Berg&author=A+Hartmann&author=KF+Hanssen&publication_year=1994&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0221"> <div class="citation-journal">Berg TJ, Nourooz‐Zadeh J, Wolff SP, Tritschler HJ, Bangstad HJ, Hanssen KF. <span class="citation-title">Hydroperoxides in plasma are reduced by intensified insulin treatment. A randomized controlled study of IDDM patients with microalbuminuria</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1998</span>;<span class="volume">21</span>(8):1295‐300. [MEDLINE: 9702436]<a class="crsref citation-link central-link" data-crsref="9140903" href="" ref="info:x-wiley/crsRef/9140903" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9702436" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Hydroperoxides+in+plasma+are+reduced+by+intensified+insulin+treatment.+A+randomized+controlled+study+of+IDDM+patients+with+microalbuminuria+&author=TJ+Berg&author=J+Nourooz%E2%80%90Zadeh&author=SP+Wolff&author=HJ+Tritschler&author=HJ+Bangstad&author=KF+Hanssen&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0222"> <div class="citation-journal">Hartmann A, Bangstad HJ, Holdass H, Fauchald P, Hanssen KF, Dahl‐Jorgensen K, et al. <span class="citation-title">Effects of glucose control on renal tubular and glomerular functions in incipient IDDM nephropathy [abstract]</span>. <span class="citation"> Nephrology </span><span class="pubYear">1997</span>;<span class="volume">3</span>(Suppl 1):S378. [CENTRAL: CN‐00460903]<a class="crsref citation-link central-link" data-crsref="9140904" href="" ref="info:x-wiley/crsRef/9140904" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+glucose+control+on+renal+tubular+and+glomerular+functions+in+incipient+IDDM+nephropathy+[abstract]+&author=A+Hartmann&author=HJ+Bangstad&author=H+Holdass&author=P+Fauchald&author=KF+Hanssen&author=K+Dahl%E2%80%90Jorgensen&publication_year=1997&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0055"> <div class="reference-title-banner"> <h4 class="title">BARI 2D 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0223"> <div class="citation-journal">Abbott JD, Lombardero MS, Barsness GW, Pena‐Sing I, Buitron LV, Singh P, et al. <span class="citation-title">Ankle‐brachial index and cardiovascular outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial</span>. <span class="citation"> American Heart Journal </span><span class="pubYear">2012</span>;<span class="volume">164</span>(4):585‐90. [MEDLINE: 23067918]<a class="crsref citation-link central-link" data-crsref="9140906" href="" ref="info:x-wiley/crsRef/9140906" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23067918" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Ankle%E2%80%90brachial+index+and+cardiovascular+outcomes+in+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+trial+&author=JD+Abbott&author=MS+Lombardero&author=GW+Barsness&author=I+Pena%E2%80%90Sing&author=LV+Buitron&author=P+Singh&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0224"> <div class="citation-journal">Albu J, Gottlieb SH, August P, Nesto RW, Orchard TJ, Bypass ARI. <span class="citation-title">Modifications of coronary risk factors</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2006</span>;<span class="volume">97</span>(12A):41G‐52G. [MEDLINE: 16813737]<a class="crsref citation-link central-link" data-crsref="9140907" href="" ref="info:x-wiley/crsRef/9140907" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16813737" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Modifications+of+coronary+risk+factors&author=J+Albu&author=SH+Gottlieb&author=P+August&author=RW+Nesto&author=TJ+Orchard&author=ARI+Bypass&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0225"> <div class="citation-journal">Albu JB, Lu J, Mooradian AD, Krone RJ, Nesto RW, Porter MH, et al. <span class="citation-title">Relationships of obesity and fat distribution with atherothrombotic risk factors: baseline results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial</span>. <span class="citation"> Obesity </span><span class="pubYear">2010</span>;<span class="volume">18</span>(5):1046‐54. [MEDLINE: 19875998]<a class="crsref citation-link central-link" data-crsref="9140908" href="" ref="info:x-wiley/crsRef/9140908" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19875998" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Relationships+of+obesity+and+fat+distribution+with+atherothrombotic+risk+factors:+baseline+results+from+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+(BARI+2D)+trial+&author=JB+Albu&author=J+Lu&author=AD+Mooradian&author=RJ+Krone&author=RW+Nesto&author=MH+Porter&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0226"> <div class="citation-journal">Althouse AD, Abbott JD, Sutton‐Tyrrell K, Forker AD, Lombardero MS, Buitron LV, et al. <span class="citation-title">Favorable effects of insulin sensitizers pertinent to peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2013</span>;<span class="volume">36</span>(10):3269‐75. [MEDLINE: 23735723]<a class="crsref citation-link central-link" data-crsref="9140909" href="" ref="info:x-wiley/crsRef/9140909" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23735723" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Favorable+effects+of+insulin+sensitizers+pertinent+to+peripheral+arterial+disease+in+type+2+diabetes:+results+from+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+(BARI+2D)+trial+&author=AD+Althouse&author=JD+Abbott&author=K+Sutton%E2%80%90Tyrrell&author=AD+Forker&author=MS+Lombardero&author=LV+Buitron&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0227"> <div class="citation-journal">August P, Hardison RM, Hage FG, Marroquin OC, McGill JB, Rosenberg Y, et al. <span class="citation-title">Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study</span>. <span class="citation"> Clinical Journal of the American Society of Nephrology: CJASN </span><span class="pubYear">2014</span>;<span class="volume">9</span>(1):64‐71. [MEDLINE: 24178969]<a class="crsref citation-link central-link" data-crsref="9140910" href="" ref="info:x-wiley/crsRef/9140910" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24178969" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Change+in+albuminuria+and+eGFR+following+insulin+sensitization+therapy+versus+insulin+provision+therapy+in+the+BARI+2D+study+&author=P+August&author=RM+Hardison&author=FG+Hage&author=OC+Marroquin&author=JB+McGill&author=Y+Rosenberg&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0228"> <div class="citation-journal">Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber A, et al. <span class="citation-title">Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial</span>. <span class="citation"> Circulation </span><span class="pubYear">2013</span>;<span class="volume">128</span>(8):785‐94. [MEDLINE: 23857320]<a class="crsref citation-link central-link" data-crsref="9140911" href="" ref="info:x-wiley/crsRef/9140911" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23857320" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rosiglitazone+and+outcomes+for+patients+with+diabetes+mellitus+and+coronary+artery+disease+in+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+(BARI+2D)+trial+&author=RG+Bach&author=MM+Brooks&author=M+Lombardero&author=S+Genuth&author=TW+Donner&author=A+Garber&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0229"> <div class="citation-journal">Barsness GW, Gersh BJ, Brooks MM, Frye RL, BARI 2DTI. <span class="citation-title">Rationale for the revascularization arm of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2006</span>;<span class="volume">97</span>(12A):31G‐40G. [MEDLINE: 16813736]<a class="crsref citation-link central-link" data-crsref="9140912" href="" ref="info:x-wiley/crsRef/9140912" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16813736" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rationale+for+the+revascularization+arm+of+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+(BARI+2D)+Trial+&author=GW+Barsness&author=BJ+Gersh&author=MM+Brooks&author=RL+Frye&author=2DTI+BARI&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0230"> <div class="citation-journal">Beohar N, Davidson CJ, Massaro EM, Srinivas VS, Sansing VV, Zonszein J, et al. <span class="citation-title">The impact of race/ethnicity on baseline characteristics and the burden of coronary atherosclerosis in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial</span>. <span class="citation"> American Heart Journal </span><span class="pubYear">2011</span>;<span class="volume">161</span>(4):755‐63. [MEDLINE: 21473976]<a class="crsref citation-link central-link" data-crsref="9140913" href="" ref="info:x-wiley/crsRef/9140913" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21473976" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+impact+of+race/ethnicity+on+baseline+characteristics+and+the+burden+of+coronary+atherosclerosis+in+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+trial+&author=N+Beohar&author=CJ+Davidson&author=EM+Massaro&author=VS+Srinivas&author=VV+Sansing&author=J+Zonszein&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0231"> <div class="citation-journal">Beohar N, Sansing VV, Davis AM, Srinivas VS, Helmy T, Althouse AD, et al. <span class="citation-title">Race/ethnic disparities in risk factor control and survival in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2013</span>;<span class="volume">112</span>(9):1298‐305. [MEDLINE: 23910429]<a class="crsref citation-link central-link" data-crsref="9140914" href="" ref="info:x-wiley/crsRef/9140914" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23910429" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Race/ethnic+disparities+in+risk+factor+control+and+survival+in+the+bypass+angioplasty+revascularization+investigation+2+diabetes+(BARI+2D)+trial+&author=N+Beohar&author=VV+Sansing&author=AM+Davis&author=VS+Srinivas&author=T+Helmy&author=AD+Althouse&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0232"> <div class="citation-journal">Brooks MM, Chaitman BR, Nesto RW, Hardison RM, Feit F, Gersh BJ, et al. <span class="citation-title">Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial</span>. <span class="citation"> Circulation </span><span class="pubYear">2012</span>;<span class="volume">126</span>(17):2115‐24. [MEDLINE: 23008442]<a class="crsref citation-link central-link" data-crsref="9140915" href="" ref="info:x-wiley/crsRef/9140915" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23008442" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Clinical+and+angiographic+risk+stratification+and+differential+impact+on+treatment+outcomes+in+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+(BARI+2D)+trial+&author=MM+Brooks&author=BR+Chaitman&author=RW+Nesto&author=RM+Hardison&author=F+Feit&author=BJ+Gersh&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0233"> <div class="citation-journal">Brooks MM, Chung SC, Helmy T, Hillegass WB, Escobedo J, Melsop KA, et al. <span class="citation-title">Health status after treatment for coronary artery disease and type 2 diabetes mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial</span>. <span class="citation"> Circulation </span><span class="pubYear">2010</span>;<span class="volume">122</span>(17):1690‐9. [MEDLINE: 20937978]<a class="crsref citation-link central-link" data-crsref="9140916" href="" ref="info:x-wiley/crsRef/9140916" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20937978" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Health+status+after+treatment+for+coronary+artery+disease+and+type+2+diabetes+mellitus+in+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+trial+&author=MM+Brooks&author=SC+Chung&author=T+Helmy&author=WB+Hillegass&author=J+Escobedo&author=KA+Melsop&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0234"> <div class="citation-journal">Brooks MM, Frye RL, Genuth S, Detre KM, Nesto R, Sobel BE, et al. <span class="citation-title">Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2006</span>;<span class="volume">97</span>(12A):9G‐19G. [MEDLINE: 16813734]<a class="crsref citation-link central-link" data-crsref="9140917" href="" ref="info:x-wiley/crsRef/9140917" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16813734" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Hypotheses,+design,+and+methods+for+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+(BARI+2D)+Trial+&author=MM+Brooks&author=RL+Frye&author=S+Genuth&author=KM+Detre&author=R+Nesto&author=BE+Sobel&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0235"> <div class="citation-journal">Bypass ARI. <span class="citation-title">Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial</span>. <span class="citation"> American Heart Journal </span><span class="pubYear">2008</span>;<span class="volume">156</span>(3):528‐36. [MEDLINE: 18760137]<a class="crsref citation-link central-link" data-crsref="9140918" href="" ref="info:x-wiley/crsRef/9140918" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18760137" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Baseline+characteristics+of+patients+with+diabetes+and+coronary+artery+disease+enrolled+in+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+(BARI+2D)+trial+&author=ARI+Bypass&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0236"> <div class="citation-journal">Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, et al. <span class="citation-title">The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction.[Erratum appears in Circulation. 2010 Mar 30;121(12):e254]</span>. <span class="citation"> Circulation </span><span class="pubYear">2009</span>;<span class="volume">120</span>(25):2529‐40. [MEDLINE: 19920001]<a class="crsref citation-link central-link" data-crsref="9140919" href="" ref="info:x-wiley/crsRef/9140919" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19920001" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+randomized+trial+of+different+treatment+strategies+in+type+2+diabetes+mellitus+with+stable+ischemic+heart+disease:+impact+of+treatment+strategy+on+cardiac+mortality+and+myocardial+infarction.[Erratum+appears+in+Circulation.+2010+Mar+30;121(12):e254]+&author=BR+Chaitman&author=RM+Hardison&author=D+Adler&author=S+Gebhart&author=M+Grogan&author=S+Ocampo&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0237"> <div class="citation-journal">Chung SC, Hlatky MA, Faxon D, Ramanathan K, Adler D, Mooradian A, et al. <span class="citation-title">The effect of age on clinical outcomes and health status BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes)</span>. <span class="citation"> Journal of the American College of Cardiology </span><span class="pubYear">2011</span>;<span class="volume">58</span>(8):810‐9. [MEDLINE: 21835316]<a class="crsref citation-link central-link" data-crsref="9140920" href="" ref="info:x-wiley/crsRef/9140920" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21835316" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+effect+of+age+on+clinical+outcomes+and+health+status+BARI+2D+(Bypass+Angioplasty+Revascularization+Investigation+in+Type+2+Diabetes)+&author=SC+Chung&author=MA+Hlatky&author=D+Faxon&author=K+Ramanathan&author=D+Adler&author=A+Mooradian&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0238"> <div class="citation-journal">Chung SC, Hlatky MA, Stone RA, Rana JS, Escobedo J, Rogers WJ, et al. <span class="citation-title">Body mass index and health status in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial (BARI 2D)</span>. <span class="citation"> American Heart Journal </span><span class="pubYear">2011</span>;<span class="volume">162</span>(1):184‐92. [MEDLINE: 21742107]<a class="crsref citation-link central-link" data-crsref="9140921" href="" ref="info:x-wiley/crsRef/9140921" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21742107" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Body+mass+index+and+health+status+in+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+Trial+(BARI+2D)+&author=SC+Chung&author=MA+Hlatky&author=RA+Stone&author=JS+Rana&author=J+Escobedo&author=WJ+Rogers&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0239"> <div class="citation-journal">Cresci S, Wu J, Province MA, Spertus JA, Steffes M, McGill JB, et al. <span class="citation-title">Peroxisome proliferator‐activated receptor pathway gene polymorphism associated with extent of coronary artery disease in patients with type 2 diabetes in the bypass angioplasty revascularization investigation 2 diabetes trial</span>. <span class="citation"> Circulation </span> 2011 Sep 27;<span class="volume">124</span>(13):1426‐34. [MEDLINE: 21911782]<a class="crsref citation-link central-link" data-crsref="9140922" href="" ref="info:x-wiley/crsRef/9140922" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21911782" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0240"> <div class="citation-journal">Dagenais GR, Lu J, Faxon DP, Bogaty P, Adler D, Fuentes F, et al. <span class="citation-title">Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in patients with type 2 diabetes and stable coronary artery disease: results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial</span>. <span class="citation"> Journal of the American College of Cardiology </span><span class="pubYear">2013</span>;<span class="volume">61</span>(7):702‐11. [MEDLINE: 23410541]<a class="crsref citation-link central-link" data-crsref="9140923" href="" ref="info:x-wiley/crsRef/9140923" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23410541" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Prognostic+impact+of+the+presence+and+absence+of+angina+on+mortality+and+cardiovascular+outcomes+in+patients+with+type+2+diabetes+and+stable+coronary+artery+disease:+results+from+the+BARI+2D+(Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes)+trial+&author=GR+Dagenais&author=J+Lu&author=DP+Faxon&author=P+Bogaty&author=D+Adler&author=F+Fuentes&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0241"> <div class="citation-journal">Dagenais GR, Lu J, Faxon DP, Kent K, Lago RM, Lezama C, et al. <span class="citation-title">Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease</span>. <span class="citation"> Circulation </span><span class="pubYear">2011</span>;<span class="volume">123</span>(14):1492‐500. [MEDLINE: 21444887]<a class="crsref citation-link central-link" data-crsref="9140924" href="" ref="info:x-wiley/crsRef/9140924" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21444887" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+optimal+medical+treatment+with+or+without+coronary+revascularization+on+angina+and+subsequent+revascularizations+in+patients+with+type+2+diabetes+mellitus+and+stable+ischemic+heart+disease+&author=GR+Dagenais&author=J+Lu&author=DP+Faxon&author=K+Kent&author=RM+Lago&author=C+Lezama&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0242"> <div class="citation-journal">Escobedo J, Rana JS, Lombardero MS, Albert SG, Davis AM, Kennedy FP, et al. <span class="citation-title">Association between albuminuria and duration of diabetes and myocardial dysfunction and peripheral arterial disease among patients with stable coronary artery disease in the BARI 2D study</span>. <span class="citation"> Mayo Clinic Proceedings </span><span class="pubYear">2010</span>;<span class="volume">85</span>(1):41‐6. [MEDLINE: 20042560]<a class="crsref citation-link central-link" data-crsref="9140925" href="" ref="info:x-wiley/crsRef/9140925" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20042560" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Association+between+albuminuria+and+duration+of+diabetes+and+myocardial+dysfunction+and+peripheral+arterial+disease+among+patients+with+stable+coronary+artery+disease+in+the+BARI+2D+study+&author=J+Escobedo&author=JS+Rana&author=MS+Lombardero&author=SG+Albert&author=AM+Davis&author=FP+Kennedy&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0243"> <div class="citation-journal">Farkouh ME, Boden WE, Bittner V, Muratov V, Hartigan P, Ogdie M, et al. <span class="citation-title">Risk factor control for coronary artery disease secondary prevention in large randomized trials</span>. <span class="citation"> Journal of the American College of Cardiology </span><span class="pubYear">2013</span>;<span class="volume">61</span>(15):1607‐15. [MEDLINE: 23500281]<a class="crsref citation-link central-link" data-crsref="9140926" href="" ref="info:x-wiley/crsRef/9140926" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23500281" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Risk+factor+control+for+coronary+artery+disease+secondary+prevention+in+large+randomized+trials+&author=ME+Farkouh&author=WE+Boden&author=V+Bittner&author=V+Muratov&author=P+Hartigan&author=M+Ogdie&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0244"> <div class="citation-journal">Grogan M, Jenkins M, Sansing VV, MacGregor J, Brooks MM, Julien‐Williams P, et al. <span class="citation-title">Health insurance status and control of diabetes and coronary artery disease risk factors on enrollment into the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial</span>. <span class="citation"> Diabetes Educator </span><span class="pubYear">2010 Sep</span>;<span class="volume">36</span>(5):774‐83. [MEDLINE: 20584997]<a class="crsref citation-link central-link" data-crsref="9140927" href="" ref="info:x-wiley/crsRef/9140927" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20584997" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Health+insurance+status+and+control+of+diabetes+and+coronary+artery+disease+risk+factors+on+enrollment+into+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+(BARI+2D)+trial+&author=M+Grogan&author=M+Jenkins&author=VV+Sansing&author=J+MacGregor&author=MM+Brooks&author=P+Julien%E2%80%90Williams&publication_year=2010Sep&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0245"> <div class="citation-journal">Hlatky MA, Boothroyd DB, Melsop KA, Kennedy L, Rihal C, Rogers WJ, et al. <span class="citation-title">Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial</span>. <span class="citation"> Circulation </span><span class="pubYear">2009</span>;<span class="volume">120</span>(25):2550‐8. [MEDLINE: 19920002]<a class="crsref citation-link central-link" data-crsref="9140928" href="" ref="info:x-wiley/crsRef/9140928" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19920002" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Economic+outcomes+of+treatment+strategies+for+type+2+diabetes+mellitus+and+coronary+artery+disease+in+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+trial+&author=MA+Hlatky&author=DB+Boothroyd&author=KA+Melsop&author=L+Kennedy&author=C+Rihal&author=WJ+Rogers&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0246"> <div class="citation-journal">Hlatky MA, Melsop KA, Boothroyd DB, Bypass ARI. <span class="citation-title">Economic evaluation of alternative strategies to treat patients with diabetes mellitus and coronary artery disease</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2006</span>;<span class="volume">97</span>(12A):59G‐65G. [MEDLINE: 16813739]<a class="crsref citation-link central-link" data-crsref="9140929" href="" ref="info:x-wiley/crsRef/9140929" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16813739" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Economic+evaluation+of+alternative+strategies+to+treat+patients+with+diabetes+mellitus+and+coronary+artery+disease+&author=MA+Hlatky&author=KA+Melsop&author=DB+Boothroyd&author=ARI+Bypass&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0247"> <div class="citation-journal">Iskandrian AE, Heo J, Mehta D, Tauxe EL, Yester M, Hall MB, et al. <span class="citation-title">Gated SPECT perfusion imaging for the simultaneous assessment of myocardial perfusion and ventricular function in the BARI 2D trial: an initial report from the Nuclear Core Laboratory</span>. <span class="citation"> Journal of Nuclear Cardiology </span><span class="pubYear">2006</span>;<span class="volume">13</span>(1):83‐90. [MEDLINE: 16464721]<a class="crsref citation-link central-link" data-crsref="9140930" href="" ref="info:x-wiley/crsRef/9140930" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16464721" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Gated+SPECT+perfusion+imaging+for+the+simultaneous+assessment+of+myocardial+perfusion+and+ventricular+function+in+the+BARI+2D+trial:+an+initial+report+from+the+Nuclear+Core+Laboratory+&author=AE+Iskandrian&author=J+Heo&author=D+Mehta&author=EL+Tauxe&author=M+Yester&author=MB+Hall&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0248"> <div class="citation-journal">Kim LJ, King SB, Kent K, Brooks MM, Kip KE, Abbott JD, et al. <span class="citation-title">Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial</span>. <span class="citation"> Jacc: Cardiovascular Interventions </span><span class="pubYear">2009</span>;<span class="volume">2</span>(5):384‐92. [MEDLINE: 19463459]<a class="crsref citation-link central-link" data-crsref="9140931" href="" ref="info:x-wiley/crsRef/9140931" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19463459" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Factors+related+to+the+selection+of+surgical+versus+percutaneous+revascularization+in+diabetic+patients+with+multivessel+coronary+artery+disease+in+the+BARI+2D+(Bypass+Angioplasty+Revascularization+Investigation+in+Type+2+Diabetes)+trial+&author=LJ+Kim&author=SB+King&author=K+Kent&author=MM+Brooks&author=KE+Kip&author=JD+Abbott&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0249"> <div class="citation-journal">Kim LJ, King SB, Kent K, Brooks MM, Kip KE, Abbott JD, et al. <span class="citation-title">Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial</span>. <span class="citation"> Jacc: Cardiovascular Interventions </span><span class="pubYear">2009</span>;<span class="volume">2</span>(5):384‐92. [MEDLINE: 19463459]<a class="crsref citation-link central-link" data-crsref="9140932" href="" ref="info:x-wiley/crsRef/9140932" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19463459" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Factors+related+to+the+selection+of+surgical+versus+percutaneous+revascularization+in+diabetic+patients+with+multivessel+coronary+artery+disease+in+the+BARI+2D+(Bypass+Angioplasty+Revascularization+Investigation+in+Type+2+Diabetes)+trial+&author=LJ+Kim&author=SB+King&author=K+Kent&author=MM+Brooks&author=KE+Kip&author=JD+Abbott&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0250"> <div class="citation-journal">Krishnaswami A, Hardison R, Nesto RW, Sobel B, BARI 2D Investigators. <span class="citation-title">Presentation in patients with angiographically documented coronary artery disease and type II diabetes mellitus (from the BARI 2D Clinical Trial)</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2012</span>;<span class="volume">109</span>(1):36‐41. [MEDLINE: 21958742]<a class="crsref citation-link central-link" data-crsref="9140933" href="" ref="info:x-wiley/crsRef/9140933" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21958742" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Presentation+in+patients+with+angiographically+documented+coronary+artery+disease+and+type+II+diabetes+mellitus+(from+the+BARI+2D+Clinical+Trial)+&author=A+Krishnaswami&author=R+Hardison&author=RW+Nesto&author=B+Sobel&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0251"> <div class="citation-journal">Krishnaswami A, Hardison R, Nesto RW, Sobel B, BARI 2D Investigators. <span class="citation-title">Presentation in patients with angiographically documented coronary artery disease and type II diabetes mellitus (from the BARI 2D Clinical Trial)</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2012</span>;<span class="volume">109</span>(1):36‐41. [MEDLINE: 21958742]<a class="crsref citation-link central-link" data-crsref="9140934" href="" ref="info:x-wiley/crsRef/9140934" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21958742" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Presentation+in+patients+with+angiographically+documented+coronary+artery+disease+and+type+II+diabetes+mellitus+(from+the+BARI+2D+Clinical+Trial)+&author=A+Krishnaswami&author=R+Hardison&author=RW+Nesto&author=B+Sobel&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0252"> <div class="citation-journal">Mafrici A, Briguori C. <span class="citation-title">[The BARI 2D study]. [Italian]</span>. <span class="citation"> Giornale Italiano di Cardiologia </span><span class="pubYear">2010</span>;<span class="volume">11</span>(10):711‐7. [MEDLINE: 21246772]<a class="crsref citation-link central-link" data-crsref="9140935" href="" ref="info:x-wiley/crsRef/9140935" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21246772" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=[The+BARI+2D+study].+[Italian]&author=A+Mafrici&author=C+Briguori&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0253"> <div class="citation-journal">Magee MF, Isley WL, BARI 2D Investigators. <span class="citation-title">Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2006</span>;<span class="volume">97</span>(12A):20G‐30G. [MEDLINE: 16813735]<a class="crsref citation-link central-link" data-crsref="9140936" href="" ref="info:x-wiley/crsRef/9140936" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16813735" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rationale,+design,+and+methods+for+glycemic+control+in+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+(BARI+2D)+Trial+&author=MF+Magee&author=WL+Isley&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0254"> <div class="citation-journal">McBane RD, Hardison RM, Sobel BE, BARI 2D Study Group. <span class="citation-title">Comparison of plasminogen activator inhibitor‐1, tissue type plasminogen activator antigen, fibrinogen, and D‐dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial)</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2010</span>;<span class="volume">105</span>(1):17‐24. [MEDLINE: 20102884]<a class="crsref citation-link central-link" data-crsref="9140937" href="" ref="info:x-wiley/crsRef/9140937" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20102884" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparison+of+plasminogen+activator+inhibitor%E2%80%901,+tissue+type+plasminogen+activator+antigen,+fibrinogen,+and+D%E2%80%90dimer+levels+in+various+age+decades+in+patients+with+type+2+diabetes+mellitus+and+stable+coronary+artery+disease+(from+the+BARI+2D+trial)+&author=RD+McBane&author=RM+Hardison&author=BE+Sobel&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0255"> <div class="citation-journal">Pambianco G, Lombardero M, Bittner V, Forker A, Kennedy F, Krishnaswami A, et al. <span class="citation-title">Control of lipids at baseline in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial</span>. <span class="citation"> Preventive Cardiology </span><span class="pubYear">2009</span>;<span class="volume">12</span>(1):9‐18. [MEDLINE: 19301686]<a class="crsref citation-link central-link" data-crsref="9140938" href="" ref="info:x-wiley/crsRef/9140938" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19301686" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Control+of+lipids+at+baseline+in+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+(BARI+2D)+trial+&author=G+Pambianco&author=M+Lombardero&author=V+Bittner&author=A+Forker&author=F+Kennedy&author=A+Krishnaswami&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0256"> <div class="citation-journal">Pop‐Busui R, Lombardero M, Lavis V, Forker A, Green J, Korytkowski M, et al. <span class="citation-title">Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study)</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2009</span>;<span class="volume">104</span>(1):52‐8. [MEDLINE: 19576321]<a class="crsref citation-link central-link" data-crsref="9140939" href="" ref="info:x-wiley/crsRef/9140939" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19576321" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Relation+of+severe+coronary+artery+narrowing+to+insulin+or+thiazolidinedione+use+in+patients+with+type+2+diabetes+mellitus+(from+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+Study)+&author=R+Pop%E2%80%90Busui&author=M+Lombardero&author=V+Lavis&author=A+Forker&author=J+Green&author=M+Korytkowski&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0257"> <div class="citation-journal">Pop‐Busui R, Lu J, Brooks MM, Albert S, Althouse AD, Escobedo J, et al. <span class="citation-title">Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2013</span>;<span class="volume">36</span>(10):3208‐15. [MEDLINE: 23757426]<a class="crsref citation-link central-link" data-crsref="9140940" href="" ref="info:x-wiley/crsRef/9140940" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23757426" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Impact+of+glycemic+control+strategies+on+the+progression+of+diabetic+peripheral+neuropathy+in+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+(BARI+2D)+Cohort+&author=R+Pop%E2%80%90Busui&author=J+Lu&author=MM+Brooks&author=S+Albert&author=AD+Althouse&author=J+Escobedo&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0258"> <div class="citation-journal">Pop‐Busui R, Lu J, Lopes N, Jones TL, BARI 2D Investigators. <span class="citation-title">Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort</span>. <span class="citation"> Journal of the Peripheral Nervous System </span><span class="pubYear">2009</span>;<span class="volume">14</span>(1):1‐13. [MEDLINE: 19335534]<a class="crsref citation-link central-link" data-crsref="9140941" href="" ref="info:x-wiley/crsRef/9140941" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19335534" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Prevalence+of+diabetic+peripheral+neuropathy+and+relation+to+glycemic+control+therapies+at+baseline+in+the+BARI+2D+cohort+&author=R+Pop%E2%80%90Busui&author=J+Lu&author=N+Lopes&author=TL+Jones&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0259"> <div class="citation-journal">Rana JS, Hardison RM, Pop‐Busui R, Brooks MM, Jones TL, Nesto RW, et al. <span class="citation-title">Resting heart rate and metabolic syndrome in patients with diabetes and coronary artery disease in bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial</span>. <span class="citation"> Preventive Cardiology </span><span class="pubYear">2010</span>;<span class="volume">13</span>(3):112‐6. [MEDLINE: 20626665]<a class="crsref citation-link central-link" data-crsref="9140942" href="" ref="info:x-wiley/crsRef/9140942" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20626665" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Resting+heart+rate+and+metabolic+syndrome+in+patients+with+diabetes+and+coronary+artery+disease+in+bypass+angioplasty+revascularization+investigation+2+diabetes+(BARI+2D)+trial+&author=JS+Rana&author=RM+Hardison&author=R+Pop%E2%80%90Busui&author=MM+Brooks&author=TL+Jones&author=RW+Nesto&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0260"> <div class="citation-journal">Schneider DJ, Hardison RM, Lopes N, Sobel BE, Brooks MM, Pro‐Thrombosis Ancillary Study Group. <span class="citation-title">Association between increased platelet P‐selectin expression and obesity in patients with type 2 diabetes: a BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2009</span>;<span class="volume">32</span>(5):944‐9. [MEDLINE: 19228864]<a class="crsref citation-link central-link" data-crsref="9140943" href="" ref="info:x-wiley/crsRef/9140943" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19228864" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Association+between+increased+platelet+P%E2%80%90selectin+expression+and+obesity+in+patients+with+type+2+diabetes:+a+BARI+2D+(Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes)+substudy+&author=DJ+Schneider&author=RM+Hardison&author=N+Lopes&author=BE+Sobel&author=MM+Brooks&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0261"> <div class="citation-journal">Schwartz L, Bertolet M, Feit F, Fuentes F, Sako EY, Toosi MS, et al. <span class="citation-title">Impact of completeness of revascularization on long‐term cardiovascular outcomes in patients with type 2 diabetes mellitus: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D)</span>. <span class="citation"> Circulation: Cardiovascular Interventions </span><span class="pubYear">2012</span>;<span class="volume">5</span>(2):166‐73. [MEDLINE: 22496082]<a class="crsref citation-link central-link" data-crsref="9140944" href="" ref="info:x-wiley/crsRef/9140944" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22496082" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Impact+of+completeness+of+revascularization+on+long%E2%80%90term+cardiovascular+outcomes+in+patients+with+type+2+diabetes+mellitus:+results+from+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+(BARI+2D)+&author=L+Schwartz&author=M+Bertolet&author=F+Feit&author=F+Fuentes&author=EY+Sako&author=MS+Toosi&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0262"> <div class="citation-journal">Schwartz L, Kip KE, Alderman E, Lu J, Bates ER, Srinivas V, et al. <span class="citation-title">Baseline coronary angiographic findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D)</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2009</span>;<span class="volume">103</span>(5):632‐8. [MEDLINE: 19231325]<a class="crsref citation-link central-link" data-crsref="9140945" href="" ref="info:x-wiley/crsRef/9140945" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19231325" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Baseline+coronary+angiographic+findings+in+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+trial+(BARI+2D)+&author=L+Schwartz&author=KE+Kip&author=E+Alderman&author=J+Lu&author=ER+Bates&author=V+Srinivas&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0263"> <div class="citation-journal">Schwartz L, Kip KE, Alderman E, Lu J, Bates ER, Srinivas V, et al. <span class="citation-title">Baseline coronary angiographic findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D)</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2009</span>;<span class="volume">103</span>(5):632‐8. [MEDLINE: 19231325]<a class="crsref citation-link central-link" data-crsref="9140946" href="" ref="info:x-wiley/crsRef/9140946" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19231325" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Baseline+coronary+angiographic+findings+in+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+trial+(BARI+2D)+&author=L+Schwartz&author=KE+Kip&author=E+Alderman&author=J+Lu&author=ER+Bates&author=V+Srinivas&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0264"> <div class="citation-journal">Shah B, Srinivas VS, Lu J, Brooks MM, Bates ER, Nedeljkovic ZS, et al. <span class="citation-title">Change in enrollment patterns, patient selection, and clinical outcomes with the availability of drug‐eluting stents in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial</span>. <span class="citation"> American Heart Journal </span><span class="pubYear">2013 Sep</span>;<span class="volume">166</span>(3):519‐26. [MEDLINE: 24016502]<a class="crsref citation-link central-link" data-crsref="9140947" href="" ref="info:x-wiley/crsRef/9140947" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24016502" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Change+in+enrollment+patterns,+patient+selection,+and+clinical+outcomes+with+the+availability+of+drug%E2%80%90eluting+stents+in+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+trial+&author=B+Shah&author=VS+Srinivas&author=J+Lu&author=MM+Brooks&author=ER+Bates&author=ZS+Nedeljkovic&publication_year=2013Sep&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0265"> <div class="citation-journal">Shaw LJ, Cerqueira MD, Brooks MM, Althouse AD, Sansing VV, Beller GA, et al. <span class="citation-title">Impact of left ventricular function and the extent of ischemia and scar by stress myocardial perfusion imaging on prognosis and therapeutic risk reduction in diabetic patients with coronary artery disease: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial</span>. <span class="citation"> Journal of Nuclear Cardiology </span><span class="pubYear">2012</span>;<span class="volume">19</span>(4):658‐69. [MEDLINE: 22527794]<a class="crsref citation-link central-link" data-crsref="9140948" href="" ref="info:x-wiley/crsRef/9140948" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22527794" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Impact+of+left+ventricular+function+and+the+extent+of+ischemia+and+scar+by+stress+myocardial+perfusion+imaging+on+prognosis+and+therapeutic+risk+reduction+in+diabetic+patients+with+coronary+artery+disease:+results+from+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+(BARI+2D)+trial+&author=LJ+Shaw&author=MD+Cerqueira&author=MM+Brooks&author=AD+Althouse&author=VV+Sansing&author=GA+Beller&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0266"> <div class="citation-journal">Singh PP, Abbott JD, Lombardero MS, Sutton‐Tyrrell K, Woodhead G, Venkitachalam L, et al. <span class="citation-title">The prevalence and predictors of an abnormal ankle‐brachial index in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2011</span>;<span class="volume">34</span>(2):464‐7. [MEDLINE: 21270200]<a class="crsref citation-link central-link" data-crsref="9140949" href="" ref="info:x-wiley/crsRef/9140949" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21270200" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+prevalence+and+predictors+of+an+abnormal+ankle%E2%80%90brachial+index+in+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+(BARI+2D)+trial+&author=PP+Singh&author=JD+Abbott&author=MS+Lombardero&author=K+Sutton%E2%80%90Tyrrell&author=G+Woodhead&author=L+Venkitachalam&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0267"> <div class="citation-journal">Sobel BE, BARI 2DTI. <span class="citation-title">Ancillary studies in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial: Synergies and opportunities</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2006</span>;<span class="volume">97</span>(12A):53G‐8G. [MEDLINE: 16813738]<a class="crsref citation-link central-link" data-crsref="9140950" href="" ref="info:x-wiley/crsRef/9140950" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16813738" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Ancillary+studies+in+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+(BARI+2D)+Trial:+Synergies+and+opportunities+&author=BE+Sobel&author=2DTI+BARI&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0268"> <div class="citation-journal">Sobel BE, Hardison RM, Genuth S, Brooks MM, McBane RD, Schneider DJ, et al. <span class="citation-title">Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin‐sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial</span>. <span class="citation"> Circulation </span><span class="pubYear">2011</span>;<span class="volume">124</span>(6):695‐703. [MEDLINE: 21768545]<a class="crsref citation-link central-link" data-crsref="9140951" href="" ref="info:x-wiley/crsRef/9140951" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21768545" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Profibrinolytic,+antithrombotic,+and+antiinflammatory+effects+of+an+insulin%E2%80%90sensitizing+strategy+in+patients+in+the+Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes+(BARI+2D)+trial+&author=BE+Sobel&author=RM+Hardison&author=S+Genuth&author=MM+Brooks&author=RD+McBane&author=DJ+Schneider&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0269"> <div class="citation-journal">Tamis‐Holland JE, Lu J, Bittner V, Magee MF, Lopes N, Adler DS, et al. <span class="citation-title">Sex, clinical symptoms, and angiographic findings in patients with diabetes mellitus and coronary artery disease (from the Bypass Angioplasty Revascularization Investigation [BARI] 2 Diabetes trial)</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2011</span>;<span class="volume">107</span>(7):980‐5. [MEDLINE: 21276585]<a class="crsref citation-link central-link" data-crsref="9140952" href="" ref="info:x-wiley/crsRef/9140952" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21276585" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Sex,+clinical+symptoms,+and+angiographic+findings+in+patients+with+diabetes+mellitus+and+coronary+artery+disease+(from+the+Bypass+Angioplasty+Revascularization+Investigation+[BARI]+2+Diabetes+trial)+&author=JE+Tamis%E2%80%90Holland&author=J+Lu&author=V+Bittner&author=MF+Magee&author=N+Lopes&author=DS+Adler&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0270"> <div class="citation-journal">Tamis‐Holland JE, Lu J, Korytkowski M, Magee M, Rogers WJ, Lopes N, et al. <span class="citation-title">Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: a report from the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation 2 Diabetes)</span>. <span class="citation"> Journal of the American College of Cardiology </span><span class="pubYear">2013</span>;<span class="volume">61</span>(17):1767‐76. [MEDLINE: 23500245]<a class="crsref citation-link central-link" data-crsref="9140953" href="" ref="info:x-wiley/crsRef/9140953" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23500245" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Sex+differences+in+presentation+and+outcome+among+patients+with+type+2+diabetes+and+coronary+artery+disease+treated+with+contemporary+medical+therapy+with+or+without+prompt+revascularization:+a+report+from+the+BARI+2D+Trial+(Bypass+Angioplasty+Revascularization+Investigation+2+Diabetes)+&author=JE+Tamis%E2%80%90Holland&author=J+Lu&author=M+Korytkowski&author=M+Magee&author=WJ+Rogers&author=N+Lopes&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0271"> <div class="citation-journal">Thomas SB, Sansing VV, Davis A, Magee M, Massaro E, Srinivas VS, et al. <span class="citation-title">Racial differences in the association between self‐rated health status and objective clinical measures among participants in the BARI 2D trial</span>. <span class="citation"> American Journal of Public Health </span><span class="pubYear">2010</span>;<span class="volume">100 Suppl 1</span>:S269‐76. [MEDLINE: 20147671]<a class="crsref citation-link central-link" data-crsref="9140954" href="" ref="info:x-wiley/crsRef/9140954" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20147671" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Racial+differences+in+the+association+between+self%E2%80%90rated+health+status+and+objective+clinical+measures+among+participants+in+the+BARI+2D+trial+&author=SB+Thomas&author=VV+Sansing&author=A+Davis&author=M+Magee&author=E+Massaro&author=VS+Srinivas&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0272"> <div class="citation-journal">Wall BM, Hardison RM, Molitch ME, Marroquin OC, McGill JB, August PA, et al. <span class="citation-title">High prevalence and diversity of kidney dysfunction in patients with type 2 diabetes mellitus and coronary artery disease: the BARI 2D baseline data</span>. <span class="citation"> American Journal of the Medical Sciences </span><span class="pubYear">2010</span>;<span class="volume">339</span>(5):401‐10. [MEDLINE: 20375690]<a class="crsref citation-link central-link" data-crsref="9140955" href="" ref="info:x-wiley/crsRef/9140955" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20375690" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=High+prevalence+and+diversity+of+kidney+dysfunction+in+patients+with+type+2+diabetes+mellitus+and+coronary+artery+disease:+the+BARI+2D+baseline+data+&author=BM+Wall&author=RM+Hardison&author=ME+Molitch&author=OC+Marroquin&author=JB+McGill&author=PA+August&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0056"> <div class="reference-title-banner"> <h4 class="title">Barnett 1984 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0273"> <div class="citation-journal">Barnett AH, Wakelin K, Leatherdale BA, Britton JR, Polak A, Bennett J, et al. <span class="citation-title">Specific thromboxane synthetase inhibition and albumin excretion rate in insulin‐dependent diabetes</span>. <span class="citation"> Lancet </span><span class="pubYear">1984</span>;<span class="volume">1</span>(8390):1322‐5. [MEDLINE: 6145027]<a class="crsref citation-link central-link" data-crsref="9140957" href="" ref="info:x-wiley/crsRef/9140957" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/6145027" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Specific+thromboxane+synthetase+inhibition+and+albumin+excretion+rate+in+insulin%E2%80%90dependent+diabetes+&author=AH+Barnett&author=K+Wakelin&author=BA+Leatherdale&author=JR+Britton&author=A+Polak&author=J+Bennett&publication_year=1984&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0057"> <div class="reference-title-banner"> <h4 class="title">CANTATA‐SU 2016 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0274"> <div class="citation-journal">Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al. <span class="citation-title">Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial</span>. <span class="citation"> Lancet </span><span class="pubYear">2013</span>;<span class="volume">382</span>(9896):941‐50. [MEDLINE: 23850055]<a class="crsref citation-link central-link" data-crsref="9140959" href="" ref="info:x-wiley/crsRef/9140959" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23850055" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+canagliflozin+versus+glimepiride+in+patients+with+type+2+diabetes+inadequately+controlled+with+metformin+(CANTATA%E2%80%90SU):+52+week+results+from+a+randomised,+double%E2%80%90blind,+phase+3+non%E2%80%90inferiority+trial+&author=WT+Cefalu&author=LA+Leiter&author=KH+Yoon&author=P+Arias&author=L+Niskanen&author=J+Xie&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0275"> <div class="citation-journal">Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. <span class="citation-title">Canagliflozin slows progression of renal function decline independently of glycemic effects</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">2017</span>;<span class="volume">28</span>(1):368‐75. [MEDLINE: 27539604]<a class="crsref citation-link central-link" data-crsref="9140960" href="" ref="info:x-wiley/crsRef/9140960" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27539604" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Canagliflozin+slows+progression+of+renal+function+decline+independently+of+glycemic+effects+&author=HJ+Heerspink&author=M+Desai&author=M+Jardine&author=D+Balis&author=G+Meininger&author=V+Perkovic&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0276"> <div class="citation-journal">Heerspink HJL, Desai M, Jardine M, Meininger G, Perkovic V. <span class="citation-title">Canagliflozin slows progression of renal function decline independent of glycaemic effects [abstract]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2016</span>;<span class="volume">59</span>(1 Suppl 1):S28. [EMBASE: 612313272]<a class="crsref citation-link central-link" data-crsref="9140961" href="" ref="info:x-wiley/crsRef/9140961" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Canagliflozin+slows+progression+of+renal+function+decline+independent+of+glycaemic+effects+[abstract]+&author=HJL+Heerspink&author=M+Desai&author=M+Jardine&author=G+Meininger&author=V+Perkovic&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0058"> <div class="reference-title-banner"> <h4 class="title">Cao 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0277"> <div class="citation-journal">Cao WH, Lan CH, Wang XL, Sun JH. <span class="citation-title">The effects of pioglitazone on urinary albumin in excretion rate of early diabetic nephropathy</span>. <span class="citation"> Chinese General Practice </span><span class="pubYear">2005</span>;<span class="volume">8</span>(18):1484‐5. <a class="crsref citation-link central-link" data-crsref="9140963" href="" ref="info:x-wiley/crsRef/9140963" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+effects+of+pioglitazone+on+urinary+albumin+in+excretion+rate+of+early+diabetic+nephropathy+&author=WH+Cao&author=CH+Lan&author=XL+Wang&author=JH+Sun&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0059"> <div class="reference-title-banner"> <h4 class="title">Chacra 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0278"> <div class="citation-journal">Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R, et al. <span class="citation-title">Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial.[Erratum appears in Int J Clin Pract. 2010 Jan;64(2):277]</span>. <span class="citation"> International Journal of Clinical Practice </span><span class="pubYear">2009</span>;<span class="volume">63</span>(9):1395‐406. [MEDLINE: 19614786]<a class="crsref citation-link central-link" data-crsref="9140965" href="" ref="info:x-wiley/crsRef/9140965" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19614786" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Saxagliptin+added+to+a+submaximal+dose+of+sulphonylurea+improves+glycaemic+control+compared+with+uptitration+of+sulphonylurea+in+patients+with+type+2+diabetes:+a+randomised+controlled+trial.[Erratum+appears+in+Int+J+Clin+Pract.+2010+Jan;64(2):277]+&author=AR+Chacra&author=GH+Tan&author=A+Apanovitch&author=S+Ravichandran&author=J+List&author=R+Chen&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0060"> <div class="reference-title-banner"> <h4 class="title">Chen 2004b {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0279"> <div class="citation-journal">Chen WK. <span class="citation-title">Clinical observation of pioglitazone in diabetic nephropathy</span>. <span class="citation"> International Medical Healthcare Guiding Journal </span><span class="pubYear">2004</span>;<span class="volume">10</span>(1):50‐1. <a class="crsref citation-link central-link" data-crsref="9140967" href="" ref="info:x-wiley/crsRef/9140967" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Clinical+observation+of+pioglitazone+in+diabetic+nephropathy&author=WK+Chen&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0061"> <div class="reference-title-banner"> <h4 class="title">Chen 2006h {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0280"> <div class="citation-journal">Chen H, Song QH, Wang ZS, Tan LL. <span class="citation-title">Observation on the therapeutic effect of rosiglitazone combined with metformin on diabetic nephropathy</span>. <span class="citation"> China Tropical Medicine </span><span class="pubYear">2006</span>;<span class="volume">6</span>(7):1194‐5. <a class="crsref citation-link central-link" data-crsref="9140969" href="" ref="info:x-wiley/crsRef/9140969" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Observation+on+the+therapeutic+effect+of+rosiglitazone+combined+with+metformin+on+diabetic+nephropathy+&author=H+Chen&author=QH+Song&author=ZS+Wang&author=LL+Tan&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0062"> <div class="reference-title-banner"> <h4 class="title">Christensen 1986 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0281"> <div class="citation-journal">Christensen CK, Christiansen JS, Christensen T, Hermansen K, Mogensen CE. <span class="citation-title">The effect of six months continuous subcutaneous insulin infusion on kidney function and size in insulin‐dependent diabetics</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">1986 Jan</span>;<span class="volume">3</span>(1):29‐32. [MEDLINE: 2951131]<a class="crsref citation-link central-link" data-crsref="9140971" href="" ref="info:x-wiley/crsRef/9140971" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2951131" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+effect+of+six+months+continuous+subcutaneous+insulin+infusion+on+kidney+function+and+size+in+insulin%E2%80%90dependent+diabetics+&author=CK+Christensen&author=JS+Christiansen&author=T+Christensen&author=K+Hermansen&author=CE+Mogensen&publication_year=1986Jan&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0063"> <div class="reference-title-banner"> <h4 class="title">Christensen 2001c {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0282"> <div class="citation-journal">Christensen PK, Lund S, Parving HH. <span class="citation-title">The impact of glycaemic control on autoregulation of glomerular filtration rate in patients with non‐insulin dependent diabetes</span>. <span class="citation"> Scandinavian Journal of Clinical &amp; Laboratory Investigation </span><span class="pubYear">2001 Feb</span>;<span class="volume">61</span>(1):43‐50. [MEDLINE: 11300610]<a class="crsref citation-link central-link" data-crsref="9140973" href="" ref="info:x-wiley/crsRef/9140973" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+impact+of+glycaemic+control+on+autoregulation+of+glomerular+filtration+rate+in+patients+with+non%E2%80%90insulin+dependent+diabetes+&author=PK+Christensen&author=S+Lund&author=HH+Parving&publication_year=2001Feb&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0064"> <div class="reference-title-banner"> <h4 class="title">Chu 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0283"> <div class="citation-journal">Chu P, Chiu Y, Lin J, Chen S, Wu K. <span class="citation-title">The effect of low‐flux and high‐flux dialysers on endothelial dysfunction, oxidative stress and insulin resistance [abstract no: SA‐PO774]</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">2006</span>;<span class="volume">17</span>(Abstracts):738A. <a class="crsref citation-link central-link" data-crsref="9140975" href="" ref="info:x-wiley/crsRef/9140975" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+effect+of+low%E2%80%90flux+and+high%E2%80%90flux+dialysers+on+endothelial+dysfunction,+oxidative+stress+and+insulin+resistance+[abstract+no:+SA%E2%80%90PO774]+&author=P+Chu&author=Y+Chiu&author=J+Lin&author=S+Chen&author=K+Wu&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0284"> <div class="citation-journal">Chu PL, Chiu YL, Lin JW, Chen SI, Wu KD. <span class="citation-title">Effects of low‐ and high‐flux dialyzers on oxidative stress and insulin resistance</span>. <span class="citation"> Blood Purification </span><span class="pubYear">2008</span>;<span class="volume">26</span>(2):213‐20. [MEDLINE: 18285698]<a class="crsref citation-link central-link" data-crsref="9140976" href="" ref="info:x-wiley/crsRef/9140976" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18285698" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+low%E2%80%90+and+high%E2%80%90flux+dialyzers+on+oxidative+stress+and+insulin+resistance&author=PL+Chu&author=YL+Chiu&author=JW+Lin&author=SI+Chen&author=KD+Wu&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0065"> <div class="reference-title-banner"> <h4 class="title">Ciavarella 1985 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0285"> <div class="citation-journal">Ciavarella A, Vannini P, Flammini M, Bacci L, Forlani G, Borgnino LC. <span class="citation-title">Effect of long‐term near‐normoglycemia on the progression of diabetic nephropathy</span>. <span class="citation"> Diabete et Metabolisme </span><span class="pubYear">1985 Feb</span>;<span class="volume">11</span>(1):3‐8. [MEDLINE: 3884404]<a class="crsref citation-link central-link" data-crsref="9140978" href="" ref="info:x-wiley/crsRef/9140978" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/3884404" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+long%E2%80%90term+near%E2%80%90normoglycemia+on+the+progression+of+diabetic+nephropathy&author=A+Ciavarella&author=P+Vannini&author=M+Flammini&author=L+Bacci&author=G+Forlani&author=LC+Borgnino&publication_year=1985Feb&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0066"> <div class="reference-title-banner"> <h4 class="title">Dailey 2000 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0286"> <div class="citation-journal">Dailey GE, Boden GH, Creech RH, Johnson DG, Gleason RE, Kennedy FP, et al. <span class="citation-title">Effects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathy</span>. <span class="citation"> Metabolism ‐ Clinical &amp; Experimental </span><span class="pubYear">2000</span>;<span class="volume">49</span>(11):1491‐5. [MEDLINE: 11092517]<a class="crsref citation-link central-link" data-crsref="9140980" href="" ref="info:x-wiley/crsRef/9140980" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+pulsatile+intravenous+insulin+therapy+on+the+progression+of+diabetic+nephropathy&author=GE+Dailey&author=GH+Boden&author=RH+Creech&author=DG+Johnson&author=RE+Gleason&author=FP+Kennedy&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0287"> <div class="citation-journal">Weinrauch LA, Bayliss G, Gleason RE, Lee AT, D'Elia JA. <span class="citation-title">A pilot study to assess utility of changes in elements of the Diabetes Impact Management Scale in evaluating diabetic patients for progressive nephropathy</span>. <span class="citation"> Metabolism ‐ Clinical &amp; Experimental </span><span class="pubYear">2009</span>;<span class="volume">58</span>(4):492‐6. [MEDLINE: 19303969]<a class="crsref citation-link central-link" data-crsref="9140981" href="" ref="info:x-wiley/crsRef/9140981" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+pilot+study+to+assess+utility+of+changes+in+elements+of+the+Diabetes+Impact+Management+Scale+in+evaluating+diabetic+patients+for+progressive+nephropathy+&author=LA+Weinrauch&author=G+Bayliss&author=RE+Gleason&author=AT+Lee&author=JA+D'Elia&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0288"> <div class="citation-journal">Weinrauch LA, Bayliss G, Gleason RE, Lee AT, D'Elia JA. <span class="citation-title">Utilization of an abbreviated diabetes impact management scale to assess change in subjective disability during a trial of pulsatile insulin delivery demonstrates benefit</span>. <span class="citation"> Metabolism ‐ Clinical &amp; Experimental </span><span class="pubYear">2009</span>;<span class="volume">58</span>(4):488‐91. [MEDLINE: 19303968]<a class="crsref citation-link central-link" data-crsref="9140982" href="" ref="info:x-wiley/crsRef/9140982" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Utilization+of+an+abbreviated+diabetes+impact+management+scale+to+assess+change+in+subjective+disability+during+a+trial+of+pulsatile+insulin+delivery+demonstrates+benefit+&author=LA+Weinrauch&author=G+Bayliss&author=RE+Gleason&author=AT+Lee&author=JA+D'Elia&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0289"> <div class="citation-journal">Weinrauch LA, Burger AJ, Aepfelbacher F, Lee AT, Gleason RE, D'Elia JA. <span class="citation-title">A pilot study to test the effect of pulsatile insulin infusion on cardiovascular mechanisms that might contribute to attenuation of renal compromise in type 1 diabetes mellitus patients with proteinuria</span>. <span class="citation"> Metabolism ‐ Clinical &amp; Experimental </span><span class="pubYear">2007 Nov</span>;<span class="volume">56</span>(11):1453‐7. [MEDLINE: 17950093]<a class="crsref citation-link central-link" data-crsref="9140983" href="" ref="info:x-wiley/crsRef/9140983" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+pilot+study+to+test+the+effect+of+pulsatile+insulin+infusion+on+cardiovascular+mechanisms+that+might+contribute+to+attenuation+of+renal+compromise+in+type+1+diabetes+mellitus+patients+with+proteinuria+&author=LA+Weinrauch&author=AJ+Burger&author=F+Aepfelbacher&author=AT+Lee&author=RE+Gleason&author=JA+D'Elia&publication_year=2007Nov&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0067"> <div class="reference-title-banner"> <h4 class="title">Davidson 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0290"> <div class="citation-journal">Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR. <span class="citation-title">A 24‐week, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy</span>. <span class="citation"> Clinical Therapeutics </span><span class="pubYear">2007 Sep</span>;<span class="volume">29</span>(9):1900‐14. [MEDLINE: 18035190]<a class="crsref citation-link central-link" data-crsref="9140985" href="" ref="info:x-wiley/crsRef/9140985" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18035190" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+24%E2%80%90week,+multicenter,+randomized,+double%E2%80%90blind,+placebo%E2%80%90controlled,+parallel%E2%80%90group+study+of+the+efficacy+and+tolerability+of+combination+therapy+with+rosiglitazone+and+sulfonylurea+in+African+American+and+Hispanic+American+patients+with+type+2+diabetes+inadequately+controlled+with+sulfonylurea+monotherapy+&author=JA+Davidson&author=SO+McMorn&author=BR+Waterhouse&author=AR+Cobitz&publication_year=2007Sep&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0068"> <div class="reference-title-banner"> <h4 class="title">DCCT 1986 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0291"> <div class="citation-journal">Al‐Kateb H, Boright AP, Mirea L, Xie X, Sutradhar R, Mowjoodi A, et al. <span class="citation-title">Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study</span>. <span class="citation"> Diabetes </span><span class="pubYear">2008</span>;<span class="volume">57</span>(1):218‐28. [MEDLINE: 17914031]<a class="crsref citation-link central-link" data-crsref="9140987" href="" ref="info:x-wiley/crsRef/9140987" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17914031" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Multiple+superoxide+dismutase+1/splicing+factor+serine+alanine+15+variants+are+associated+with+the+development+and+progression+of+diabetic+nephropathy:+the+Diabetes+Control+and+Complications+Trial/Epidemiology+of+Diabetes+Interventions+and+Complications+Genetics+study+&author=H+Al%E2%80%90Kateb&author=AP+Boright&author=L+Mirea&author=X+Xie&author=R+Sutradhar&author=A+Mowjoodi&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0292"> <div class="citation-journal">Anonymous. <span class="citation-title">Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1990</span>;<span class="volume">13</span>(4):427‐33. [MEDLINE: 2180661]<a class="crsref citation-link central-link" data-crsref="9140988" href="" ref="info:x-wiley/crsRef/9140988" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2180661" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Diabetes+Control+and+Complications+Trial+(DCCT).+Update.+DCCT+Research+Group&author=+Anonymous&publication_year=1990&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0293"> <div class="citation-journal">Anonymous. <span class="citation-title">Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1987</span>;<span class="volume">10</span>(1):1‐19. [MEDLINE: 2882967]<a class="crsref citation-link central-link" data-crsref="9140989" href="" ref="info:x-wiley/crsRef/9140989" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2882967" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Diabetes+Control+and+Complications+Trial+(DCCT):+results+of+feasibility+study.+The+DCCT+Research+Group+&author=+Anonymous&publication_year=1987&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0294"> <div class="citation-journal">Anonymous. <span class="citation-title">Effect of intensive diabetes treatment on the development and progression of long‐term complications in adolescents with insulin‐dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group</span>. <span class="citation"> Journal of Pediatrics </span><span class="pubYear">1994</span>;<span class="volume">125</span>(2):177‐88. [MEDLINE: 8040759]<a class="crsref citation-link central-link" data-crsref="9140990" href="" ref="info:x-wiley/crsRef/9140990" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8040759" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+intensive+diabetes+treatment+on+the+development+and+progression+of+long%E2%80%90term+complications+in+adolescents+with+insulin%E2%80%90dependent+diabetes+mellitus:+Diabetes+Control+and+Complications+Trial.+Diabetes+Control+and+Complications+Trial+Research+Group+&author=+Anonymous&publication_year=1994&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0295"> <div class="citation-journal">Anonymous. <span class="citation-title">Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group</span>. <span class="citation"> Kidney International </span><span class="pubYear">1995</span>;<span class="volume">47</span>(6):1703‐20. [MEDLINE: 7643540]<a class="crsref citation-link central-link" data-crsref="9140991" href="" ref="info:x-wiley/crsRef/9140991" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/7643540" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+intensive+therapy+on+the+development+and+progression+of+diabetic+nephropathy+in+the+Diabetes+Control+and+Complications+Trial.+The+Diabetes+Control+and+Complications+(DCCT)+Research+Group+&author=+Anonymous&publication_year=1995&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0296"> <div class="citation-journal">Anonymous. <span class="citation-title">The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group</span>. <span class="citation"> Diabetes </span><span class="pubYear">1986</span>;<span class="volume">35</span>(5):530‐45. [MEDLINE: 2869996]<a class="crsref citation-link central-link" data-crsref="9140992" href="" ref="info:x-wiley/crsRef/9140992" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2869996" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+Diabetes+Control+and+Complications+Trial+(DCCT).+Design+and+methodologic+considerations+for+the+feasibility+phase.+The+DCCT+Research+Group+&author=+Anonymous&publication_year=1986&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0297"> <div class="citation-journal">DCCT/EDIC Research Group. <span class="citation-title">Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long‐term follow‐up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study</span>. <span class="citation"> Lancet Diabetes &amp; Endocrinology </span><span class="pubYear">2014</span>;<span class="volume">2</span>(10):793‐800. [MEDLINE: 25043685]<a class="crsref citation-link central-link" data-crsref="9140993" href="" ref="info:x-wiley/crsRef/9140993" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0298"> <div class="citation-journal">DCCT/EDIC Research Group, Aiello LP, Sun W, Das A, Gangaputra S, Kiss S, et al. <span class="citation-title">Intensive diabetes therapy and ocular surgery in type 1 diabetes</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2015</span>;<span class="volume">372</span>(18):1722‐33. [MEDLINE: 25923552]<a class="crsref citation-link central-link" data-crsref="9140994" href="" ref="info:x-wiley/crsRef/9140994" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25923552" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensive+diabetes+therapy+and+ocular+surgery+in+type+1+diabetes&author=LP+Aiello&author=W+Sun&author=A+Das&author=S+Gangaputra&author=S+Kiss&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0299"> <div class="citation-journal">DCCT/EDIC Research Group, Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, et al. <span class="citation-title">Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2011</span>;<span class="volume">365</span>(25):2366‐76. [MEDLINE: 22077236]<a class="crsref citation-link central-link" data-crsref="9140995" href="" ref="info:x-wiley/crsRef/9140995" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22077236" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensive+diabetes+therapy+and+glomerular+filtration+rate+in+type+1+diabetes&author=IH+Boer&author=W+Sun&author=PA+Cleary&author=JM+Lachin&author=ME+Molitch&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0300"> <div class="citation-journal">Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, et al. <span class="citation-title">Modern‐day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983‐2005)</span>. <span class="citation"> Archives of Internal Medicine </span><span class="pubYear">2009</span>;<span class="volume">169</span>(14):1307‐16. [MEDLINE: 19636033]<a class="crsref citation-link central-link" data-crsref="9140996" href="" ref="info:x-wiley/crsRef/9140996" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19636033" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Modern%E2%80%90day+clinical+course+of+type+1+diabetes+mellitus+after+30+years'+duration:+the+diabetes+control+and+complications+trial/epidemiology+of+diabetes+interventions+and+complications+and+Pittsburgh+epidemiology+of+diabetes+complications+experience+(1983‐2005)+&author=DM+Nathan&author=B+Zinman&author=PA+Cleary&author=JY+Backlund&author=S+Genuth&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0301"> <div class="citation-journal">Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, Lachin JM, Genuth S, Cleary P, Davis MD, Nathan DM. <span class="citation-title">Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.[Erratum appears in N Engl J Med 2000 May 4;342(18):1376]</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2000</span>;<span class="volume">342</span>(6):381‐9. [MEDLINE: 10666428]<a class="crsref citation-link central-link" data-crsref="9140997" href="" ref="info:x-wiley/crsRef/9140997" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10666428" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Retinopathy+and+nephropathy+in+patients+with+type+1+diabetes+four+years+after+a+trial+of+intensive+therapy.[Erratum+appears+in+N+Engl+J+Med+2000+May+4;342(18):1376]+&author=JM+Lachin&author=S+Genuth&author=P+Cleary&author=MD+Davis&author=DM+Nathan&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0302"> <div class="citation-journal">Gai N, Turkbey EB, Nazarian S, Geest RJ, Liu CY, Lima JA, et al. <span class="citation-title">T1 mapping of the gadolinium‐enhanced myocardium: adjustment for factors affecting interpatient comparison</span>. <span class="citation"> Magnetic Resonance in Medicine </span><span class="pubYear">2011</span>;<span class="volume">65</span>(5):1407‐15. [MEDLINE: 21500267]<a class="crsref citation-link central-link" data-crsref="9140998" href="" ref="info:x-wiley/crsRef/9140998" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21500267" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=T1+mapping+of+the+gadolinium%E2%80%90enhanced+myocardium:+adjustment+for+factors+affecting+interpatient+comparison+&author=N+Gai&author=EB+Turkbey&author=S+Nazarian&author=RJ+Geest&author=CY+Liu&author=JA+Lima&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0303"> <div class="citation-journal">Gubitosi‐Klug RA, DCCT/EDIC Research Group. <span class="citation-title">The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2014</span>;<span class="volume">37</span>(1):44‐9. [MEDLINE: 24356597]<a class="crsref citation-link central-link" data-crsref="9140999" href="" ref="info:x-wiley/crsRef/9140999" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24356597" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+diabetes+control+and+complications+trial/epidemiology+of+diabetes+interventions+and+complications+study+at+30+years:+summary+and+future+directions+&author=RA+Gubitosi%E2%80%90Klug&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0304"> <div class="citation-journal">Hoeldtke RD, Hampe CS, Bekris LM, Hobbs G, Bryner KD, Lernmark A, et al. <span class="citation-title">Antibodies to GAD65 and peripheral nerve function in the DCCT</span>. <span class="citation"> Journal of Neuroimmunology </span><span class="pubYear">2007</span>;<span class="volume">185</span>(1‐2):182‐9. [MEDLINE: 17328966]<a class="crsref citation-link central-link" data-crsref="9141000" href="" ref="info:x-wiley/crsRef/9141000" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17328966" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Antibodies+to+GAD65+and+peripheral+nerve+function+in+the+DCCT&author=RD+Hoeldtke&author=CS+Hampe&author=LM+Bekris&author=G+Hobbs&author=KD+Bryner&author=A+Lernmark&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0305"> <div class="citation-journal">Jacobson AM, Braffett BH, Cleary PA, Gubitosi‐Klug RA, Larkin ME, DCCT/EDIC Research Group. <span class="citation-title">The long‐term effects of type 1 diabetes treatment and complications on health‐related quality of life: a 23‐year follow‐up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2013</span>;<span class="volume">36</span>(10):3131‐8. [MEDLINE: 23835693]<a class="crsref citation-link central-link" data-crsref="9141001" href="" ref="info:x-wiley/crsRef/9141001" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23835693" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+long%E2%80%90term+effects+of+type+1+diabetes+treatment+and+complications+on+health%E2%80%90related+quality+of+life:+a+23%E2%80%90year+follow%E2%80%90up+of+the+Diabetes+Control+and+Complications/Epidemiology+of+Diabetes+Interventions+and+Complications+cohort+&author=AM+Jacobson&author=BH+Braffett&author=PA+Cleary&author=RA+Gubitosi%E2%80%90Klug&author=ME+Larkin&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0306"> <div class="citation-journal">Jenkins AJ, Yu J, Alaupovic P, Basu A, Klein RL, Lopes‐Virella M, et al. <span class="citation-title">Apolipoprotein‐defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort</span>. <span class="citation"> Journal of Diabetes &amp; its Complications </span><span class="pubYear">2013</span>;<span class="volume">27</span>(5):447‐53. [MEDLINE: 23850262]<a class="crsref citation-link central-link" data-crsref="9141002" href="" ref="info:x-wiley/crsRef/9141002" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Apolipoprotein%E2%80%90defined+lipoproteins+and+apolipoproteins:+associations+with+abnormal+albuminuria+in+type+1+diabetes+in+the+diabetes+control+and+complications+trial/epidemiology+of+diabetes+interventions+and+complications+cohort+&author=AJ+Jenkins&author=J+Yu&author=P+Alaupovic&author=A+Basu&author=RL+Klein&author=M+Lopes%E2%80%90Virella&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0307"> <div class="citation-journal">Kilpatrick ES, Rigby AS, Atkin SL. <span class="citation-title">A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2008</span>;<span class="volume">31</span>(11):2198‐202. [MEDLINE: 18650371]<a class="crsref citation-link central-link" data-crsref="9141003" href="" ref="info:x-wiley/crsRef/9141003" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18650371" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A1C+variability+and+the+risk+of+microvascular+complications+in+type+1+diabetes:+data+from+the+Diabetes+Control+and+Complications+Trial+&author=ES+Kilpatrick&author=AS+Rigby&author=SL+Atkin&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0308"> <div class="citation-journal">Kim C, Cleary PA, Cowie CC, Braffett BH, Dunn RL, Larkin ME, et al. <span class="citation-title">Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2014</span>;<span class="volume">37</span>(3):701‐8. [MEDLINE: 24170751]<a class="crsref citation-link central-link" data-crsref="9141004" href="" ref="info:x-wiley/crsRef/9141004" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24170751" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+glycemic+treatment+and+microvascular+complications+on+menopause+in+women+with+type+1+diabetes+in+the+Diabetes+Control+and+Complications+Trial/Epidemiology+of+Diabetes+Interventions+and+Complications+(DCCT/EDIC)+cohort+&author=C+Kim&author=PA+Cleary&author=CC+Cowie&author=BH+Braffett&author=RL+Dunn&author=ME+Larkin&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0309"> <div class="citation-journal">Klein RL, Hammad SM, Baker NL, Hunt KJ, Al Gadban MM, Cleary PA, et al. <span class="citation-title">Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes</span>. <span class="citation"> Metabolism: Clinical &amp; Experimental </span><span class="pubYear">2014</span>;<span class="volume">63</span>(10):1287‐95. [MEDLINE: 25088746]<a class="crsref citation-link central-link" data-crsref="9141005" href="" ref="info:x-wiley/crsRef/9141005" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Decreased+plasma+levels+of+select+very+long+chain+ceramide+species+are+associated+with+the+development+of+nephropathy+in+type+1+diabetes+&author=RL+Klein&author=SM+Hammad&author=NL+Baker&author=KJ+Hunt&author=MM+AlGadban&author=PA+Cleary&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0310"> <div class="citation-journal">Kramer CK, Retnakaran R. <span class="citation-title">Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2013</span>;<span class="volume">30</span>(11):1333‐41. [MEDLINE: 23909911]<a class="crsref citation-link central-link" data-crsref="9141006" href="" ref="info:x-wiley/crsRef/9141006" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23909911" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Concordance+of+retinopathy+and+nephropathy+over+time+in+Type+1+diabetes:+an+analysis+of+data+from+the+Diabetes+Control+and+Complications+Trial+&author=CK+Kramer&author=R+Retnakaran&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0311"> <div class="citation-journal">Ku E, McCulloch CE, Mauer M, Gitelman SE, Grimes BA, Hsu CY. <span class="citation-title">Association between blood pressure and adverse renal events in type 1 diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2016</span>;<span class="volume">39</span>(12):2218‐24. [MEDLINE: 27872156]<a class="crsref citation-link central-link" data-crsref="9141007" href="" ref="info:x-wiley/crsRef/9141007" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27872156" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Association+between+blood+pressure+and+adverse+renal+events+in+type+1+diabetes&author=E+Ku&author=CE+McCulloch&author=M+Mauer&author=SE+Gitelman&author=BA+Grimes&author=CY+Hsu&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0312"> <div class="citation-journal">Lachin JM, Bebu I, Bergenstal RM, Pop‐Busui R, Service FJ, Zinman B, et al. <span class="citation-title">Association of glycemic variability in type 1 diabetes with progression of microvascular outcomes in the diabetes control and complications trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2017</span>;<span class="volume">40</span>(6):777‐83. [MEDLINE: 28404658]<a class="crsref citation-link central-link" data-crsref="9141008" href="" ref="info:x-wiley/crsRef/9141008" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/28404658" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Association+of+glycemic+variability+in+type+1+diabetes+with+progression+of+microvascular+outcomes+in+the+diabetes+control+and+complications+trial+&author=JM+Lachin&author=I+Bebu&author=RM+Bergenstal&author=R+Pop%E2%80%90Busui&author=FJ+Service&author=B+Zinman&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0313"> <div class="citation-journal">Lachin JM, McGee P, Palmer JP, DCCT/EDIC Research Group. <span class="citation-title">Impact of C‐peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial</span>. <span class="citation"> Diabetes </span><span class="pubYear">2014</span>;<span class="volume">63</span>(2):739‐48. [MEDLINE: 24089509]<a class="crsref citation-link central-link" data-crsref="9141009" href="" ref="info:x-wiley/crsRef/9141009" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24089509" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Impact+of+C%E2%80%90peptide+preservation+on+metabolic+and+clinical+outcomes+in+the+Diabetes+Control+and+Complications+Trial+&author=JM+Lachin&author=P+McGee&author=JP+Palmer&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0314"> <div class="citation-journal">Larkin ME, Backlund JY, Cleary P, Bayless M, Schaefer B, Canady J, et al. <span class="citation-title">Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2010</span>;<span class="volume">27</span>(4):451‐8. <a class="crsref citation-link central-link" data-crsref="9141010" href="" ref="info:x-wiley/crsRef/9141010" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20536518" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Disparity+in+management+of+diabetes+and+coronary+heart+disease+risk+factors+by+sex+in+DCCT/EDIC+&author=ME+Larkin&author=JY+Backlund&author=P+Cleary&author=M+Bayless&author=B+Schaefer&author=J+Canady&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0315"> <div class="citation-journal">Lee CC, Sharp SJ, Wexler DJ, Adler AI. <span class="citation-title">Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the Diabetes Control and Complications Trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2010</span>;<span class="volume">33</span>(7):1454‐6. [MEDLINE: 20357378]<a class="crsref citation-link central-link" data-crsref="9141011" href="" ref="info:x-wiley/crsRef/9141011" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20357378" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Dietary+intake+of+eicosapentaenoic+and+docosahexaenoic+acid+and+diabetic+nephropathy:+cohort+analysis+of+the+Diabetes+Control+and+Complications+Trial+&author=CC+Lee&author=SJ+Sharp&author=DJ+Wexler&author=AI+Adler&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0316"> <div class="citation-journal">Levey AS, Greene T, Schluchter MD, Cleary PA, Teschan PE, Lorenz RA, et al. <span class="citation-title">Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">1993</span>;<span class="volume">4</span>(5):1159‐71. [MEDLINE: 8305642]<a class="crsref citation-link central-link" data-crsref="9141012" href="" ref="info:x-wiley/crsRef/9141012" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8305642" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Glomerular+filtration+rate+measurements+in+clinical+trials.+Modification+of+Diet+in+Renal+Disease+Study+Group+and+the+Diabetes+Control+and+Complications+Trial+Research+Group+&author=AS+Levey&author=T+Greene&author=MD+Schluchter&author=PA+Cleary&author=PE+Teschan&author=RA+Lorenz&publication_year=1993&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0317"> <div class="citation-journal">Lin J, Manson J, Schaumberg D. <span class="citation-title">Inflammation and progressive nephropathy in the diabetes complication and control trial (DCCT) [abstract no: F‐PO1015]</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">2007</span>;<span class="volume">18</span>(Abstracts):325‐6A. <a class="crsref citation-link central-link" data-crsref="9141013" href="" ref="info:x-wiley/crsRef/9141013" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Inflammation+and+progressive+nephropathy+in+the+diabetes+complication+and+control+trial+(DCCT)+[abstract+no:+F%E2%80%90PO1015]+&author=J+Lin&author=J+Manson&author=D+Schaumberg&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0318"> <div class="citation-journal">Lopes‐Virella MF, Baker NL, Hunt KJ, Cleary PA, Klein R, Virella G, et al. <span class="citation-title">Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2013</span>;<span class="volume">36</span>(8):2317‐23. [MEDLINE: 23514730]<a class="crsref citation-link central-link" data-crsref="9141014" href="" ref="info:x-wiley/crsRef/9141014" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23514730" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Baseline+markers+of+inflammation+are+associated+with+progression+to+macroalbuminuria+in+type+1+diabetic+subjects+&author=MF+Lopes%E2%80%90Virella&author=NL+Baker&author=KJ+Hunt&author=PA+Cleary&author=R+Klein&author=G+Virella&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0319"> <div class="citation-journal">Lopes‐Virella MF, Carter RE, Baker NL, Lachin J, Virella G, DCCT/EDIC Research Group. <span class="citation-title">High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes</span>. <span class="citation"> Nephrology Dialysis Transplantation </span><span class="pubYear">2012</span>;<span class="volume">27</span>(4):1416‐23. [MEDLINE: 21856760]<a class="crsref citation-link central-link" data-crsref="9141015" href="" ref="info:x-wiley/crsRef/9141015" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=High+levels+of+oxidized+LDL+in+circulating+immune+complexes+are+associated+with+increased+odds+of+developing+abnormal+albuminuria+in+Type+1+diabetes+&author=MF+Lopes%E2%80%90Virella&author=RE+Carter&author=NL+Baker&author=J+Lachin&author=G+Virella&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0320"> <div class="citation-journal">McGee P, Steffes M, Nowicki M, Bayless M, Gubitosi‐Klug R, Cleary P, et al. <span class="citation-title">Insulin secretion measured by stimulated C‐peptide in long‐established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2014</span>;<span class="volume">31</span>(10):1264‐8. [MEDLINE: 24836354]<a class="crsref citation-link central-link" data-crsref="9141016" href="" ref="info:x-wiley/crsRef/9141016" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24836354" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Insulin+secretion+measured+by+stimulated+C%E2%80%90peptide+in+long%E2%80%90established+Type+1+diabetes+in+the+Diabetes+Control+and+Complications+Trial+(DCCT)/+Epidemiology+of+Diabetes+Interventions+and+Complications+(EDIC)+cohort:+a+pilot+study+&author=P+McGee&author=M+Steffes&author=M+Nowicki&author=M+Bayless&author=R+Gubitosi%E2%80%90Klug&author=P+Cleary&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0321"> <div class="citation-journal">Molitch ME, Steffes M, Sun W, Rutledge B, Cleary P, Boer IH, et al. <span class="citation-title">Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2010</span>;<span class="volume">33</span>(7):1536‐43. [MEDLINE: 20413518]<a class="crsref citation-link central-link" data-crsref="9141017" href="" ref="info:x-wiley/crsRef/9141017" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20413518" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Development+and+progression+of+renal+insufficiency+with+and+without+albuminuria+in+adults+with+type+1+diabetes+in+the+diabetes+control+and+complications+trial+and+the+epidemiology+of+diabetes+interventions+and+complications+study+&author=ME+Molitch&author=M+Steffes&author=W+Sun&author=B+Rutledge&author=P+Cleary&author=IH+Boer&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0322"> <div class="citation-journal">Nathan DM, Steffes MW, Sun W, Rynders GP, Lachin JM. <span class="citation-title">Determining stability of stored samples retrospectively: the validation of glycated albumin</span>. <span class="citation"> Clinical Chemistry </span><span class="pubYear">2011</span>;<span class="volume">57</span>(2):286‐90. [MEDLINE: 21030684]<a class="crsref citation-link central-link" data-crsref="9141018" href="" ref="info:x-wiley/crsRef/9141018" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21030684" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Determining+stability+of+stored+samples+retrospectively:+the+validation+of+glycated+albumin+&author=DM+Nathan&author=MW+Steffes&author=W+Sun&author=GP+Rynders&author=JM+Lachin&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0323"> <div class="citation-journal">Polak JF, Backlund JY, Cleary PA, Harrington AP, O'Leary DH, Lachin JM, et al. <span class="citation-title">Progression of carotid artery intima‐media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study</span>. <span class="citation"> Diabetes </span><span class="pubYear">2011</span>;<span class="volume">60</span>(2):607‐13. [MEDLINE: 21270271]<a class="crsref citation-link central-link" data-crsref="9141019" href="" ref="info:x-wiley/crsRef/9141019" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21270271" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Progression+of+carotid+artery+intima%E2%80%90media+thickness+during+12+years+in+the+Diabetes+Control+and+Complications+Trial/Epidemiology+of+Diabetes+Interventions+and+Complications+(DCCT/EDIC)+study+&author=JF+Polak&author=JY+Backlund&author=PA+Cleary&author=AP+Harrington&author=DH+O'Leary&author=JM+Lachin&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0324"> <div class="citation-journal">Siebert C, Clark CM. <span class="citation-title">Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience</span>. <span class="citation"> Controlled Clinical Trials </span><span class="pubYear">1993</span>;<span class="volume">14</span>(1):30‐44. [MEDLINE: 8440093]<a class="crsref citation-link central-link" data-crsref="9141020" href="" ref="info:x-wiley/crsRef/9141020" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8440093" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Operational+and+policy+considerations+of+data+monitoring+in+clinical+trials:+the+Diabetes+Control+and+Complications+Trial+experience+&author=C+Siebert&author=CM+Clark&publication_year=1993&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0325"> <div class="citation-journal">Tello A, Mondress M, Fan Y, Thomas W, Steffes M, Ibrahim H. <span class="citation-title">The utility of serum creatinine based formulas in predicting the glomerular filtration rate in Type 1 diabetics with normal serum creatinine [abstract no: SU‐PO169]</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">2004</span>;<span class="volume">15</span>(Oct):569A. <a class="crsref citation-link central-link" data-crsref="9141021" href="" ref="info:x-wiley/crsRef/9141021" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+utility+of+serum+creatinine+based+formulas+in+predicting+the+glomerular+filtration+rate+in+Type+1+diabetics+with+normal+serum+creatinine+[abstract+no:+SU%E2%80%90PO169]+&author=A+Tello&author=M+Mondress&author=Y+Fan&author=W+Thomas&author=M+Steffes&author=H+Ibrahim&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0326"> <div class="citation-journal">Turkbey EB, Backlund JY, Genuth S, Jain A, Miao C, Cleary PA, et al. <span class="citation-title">Myocardial structure, function, and scar in patients with type 1 diabetes mellitus</span>. <span class="citation"> Circulation </span><span class="pubYear">2011</span>;<span class="volume">124</span>(16):1737‐46. [MEDLINE: 21947298]<a class="crsref citation-link central-link" data-crsref="9141022" href="" ref="info:x-wiley/crsRef/9141022" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21947298" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Myocardial+structure,+function,+and+scar+in+patients+with+type+1+diabetes+mellitus&author=EB+Turkbey&author=JY+Backlund&author=S+Genuth&author=A+Jain&author=C+Miao&author=PA+Cleary&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0327"> <div class="citation-journal">White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, et al. <span class="citation-title">Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">2008</span>;<span class="volume">126</span>(12):1707‐15. [MEDLINE: 19064853]<a class="crsref citation-link central-link" data-crsref="9141023" href="" ref="info:x-wiley/crsRef/9141023" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19064853" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Prolonged+effect+of+intensive+therapy+on+the+risk+of+retinopathy+complications+in+patients+with+type+1+diabetes+mellitus:+10+years+after+the+Diabetes+Control+and+Complications+Trial+&author=NH+White&author=W+Sun&author=PA+Cleary&author=RP+Danis&author=MD+Davis&author=DP+Hainsworth&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0328"> <div class="citation-journal">White NH, Sun W, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP, et al. <span class="citation-title">Effect of prior intensive therapy in type 1 diabetes on 10‐year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents</span>. <span class="citation"> Diabetes </span><span class="pubYear">2010</span>;<span class="volume">59</span>(5):1244‐53. [MEDLINE: 20150283]<a class="crsref citation-link central-link" data-crsref="9141024" href="" ref="info:x-wiley/crsRef/9141024" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20150283" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+prior+intensive+therapy+in+type+1+diabetes+on+10%E2%80%90year+progression+of+retinopathy+in+the+DCCT/EDIC:+comparison+of+adults+and+adolescents+&author=NH+White&author=W+Sun&author=PA+Cleary&author=WV+Tamborlane&author=RP+Danis&author=DP+Hainsworth&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0329"> <div class="citation-journal">Younes N, Cleary PA, Steffes MW, Boer IH, Molitch ME, Rutledge BN, et al. <span class="citation-title">Comparison of urinary albumin‐creatinine ratio and albumin excretion rate in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study</span>. <span class="citation"> Clinical Journal of The American Society of Nephrology: CJASN </span><span class="pubYear">2010</span>;<span class="volume">5</span>(7):1235‐42. [MEDLINE: 20448066]<a class="crsref citation-link central-link" data-crsref="9141025" href="" ref="info:x-wiley/crsRef/9141025" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20448066" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparison+of+urinary+albumin%E2%80%90creatinine+ratio+and+albumin+excretion+rate+in+the+diabetes+control+and+complications+trial/epidemiology+of+diabetes+interventions+and+complications+study+&author=N+Younes&author=PA+Cleary&author=MW+Steffes&author=IH+Boer&author=ME+Molitch&author=BN+Rutledge&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0330"> <div class="citation-journal">Boer IH, Afkarian M, Rue TC, Cleary PA, Lachin JM, Molitch ME, et al. <span class="citation-title">Renal outcomes in patients with type 1 diabetes and macroalbuminuria</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">2014</span>;<span class="volume">25</span>(10):2342‐50. [MEDLINE: 24925722]<a class="crsref citation-link central-link" data-crsref="9141026" href="" ref="info:x-wiley/crsRef/9141026" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24925722" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Renal+outcomes+in+patients+with+type+1+diabetes+and+macroalbuminuria&author=IH+Boer&author=M+Afkarian&author=TC+Rue&author=PA+Cleary&author=JM+Lachin&author=ME+Molitch&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0331"> <div class="citation-journal">Boer IH, Rue TC, Cleary PA, Lachin JM, Molitch ME, Steffes MW, et al. <span class="citation-title">Long‐term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort</span>. <span class="citation"> Archives of Internal Medicine </span><span class="pubYear">2011</span>;<span class="volume">171</span>(5):412‐20. [MEDLINE: 21403038]<a class="crsref citation-link central-link" data-crsref="9141027" href="" ref="info:x-wiley/crsRef/9141027" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21403038" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+renal+outcomes+of+patients+with+type+1+diabetes+mellitus+and+microalbuminuria:+an+analysis+of+the+Diabetes+Control+and+Complications+Trial/Epidemiology+of+Diabetes+Interventions+and+Complications+cohort+&author=IH+Boer&author=TC+Rue&author=PA+Cleary&author=JM+Lachin&author=ME+Molitch&author=MW+Steffes&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0332"> <div class="citation-journal">Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes M, et al. <span class="citation-title">Effects of intensive diabetes therapy on glomerular filtration rate of type 1 diabetes: results from the DCCT/EDIC [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study] [abstract no: LB‐OR05]</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">2011</span>;<span class="volume">22</span>(Abstracts):2B. <a class="crsref citation-link central-link" data-crsref="9141028" href="" ref="info:x-wiley/crsRef/9141028" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+intensive+diabetes+therapy+on+glomerular+filtration+rate+of+type+1+diabetes:+results+from+the+DCCT/EDIC+[Diabetes+Control+and+Complications+Trial/Epidemiology+of+Diabetes+Interventions+and+Complications+study]+[abstract+no:+LB%E2%80%90OR05]+&author=IH+Boer&author=W+Sun&author=PA+Cleary&author=JM+Lachin&author=ME+Molitch&author=M+Steffes&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0069"> <div class="reference-title-banner"> <h4 class="title">de Boer 2013 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0333"> <div class="citation-journal">Boer IH, Sachs M, Hoofnagle AN, Utzschneider KM, Kahn SE, Kestenbaum B, et al. <span class="citation-title">Paricalcitol does not improve glucose metabolism in patients with stage 3‐4 chronic kidney disease</span>. <span class="citation"> Kidney International </span><span class="pubYear">2013</span>;<span class="volume">83</span>(2):323‐30. [MEDLINE: 22913981]<a class="crsref citation-link central-link" data-crsref="9141030" href="" ref="info:x-wiley/crsRef/9141030" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22913981" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Paricalcitol+does+not+improve+glucose+metabolism+in+patients+with+stage+3%E2%80%904+chronic+kidney+disease+&author=IH+Boer&author=M+Sachs&author=AN+Hoofnagle&author=KM+Utzschneider&author=SE+Kahn&author=B+Kestenbaum&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0070"> <div class="reference-title-banner"> <h4 class="title">DeFronzo 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0334"> <div class="citation-journal">DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, et al. <span class="citation-title">The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2009</span>;<span class="volume">32</span>(9):1649‐55. [MEDLINE: 19478198]<a class="crsref citation-link central-link" data-crsref="9141032" href="" ref="info:x-wiley/crsRef/9141032" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19478198" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+efficacy+and+safety+of+saxagliptin+when+added+to+metformin+therapy+in+patients+with+inadequately+controlled+type+2+diabetes+with+metformin+alone+&author=RA+DeFronzo&author=MN+Hissa&author=AJ+Garber&author=J+LuizGross&author=R+YuyanDuan&author=S+Ravichandran&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0071"> <div class="reference-title-banner"> <h4 class="title">Derosa 2004 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0335"> <div class="citation-journal">Derosa G, Franzetti I, Gadaleta G, Ciccarelli L, Fogari R. <span class="citation-title">Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin</span>. <span class="citation"> Diabetes, Nutrition &amp; Metabolism ‐ Clinical &amp; Experimental </span><span class="pubYear">2004</span>;<span class="volume">17</span>(3):143‐50. [MEDLINE: 15334791]<a class="crsref citation-link central-link" data-crsref="9141034" href="" ref="info:x-wiley/crsRef/9141034" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Metabolic+variations+with+oral+antidiabetic+drugs+in+patients+with+Type+2+diabetes:+comparison+between+glimepiride+and+metformin+&author=G+Derosa&author=I+Franzetti&author=G+Gadaleta&author=L+Ciccarelli&author=R+Fogari&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0072"> <div class="reference-title-banner"> <h4 class="title">Didjurgeit 2002 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0336"> <div class="citation-journal">Didjurgeit U, Kruse J, Schmitz N, Stuckenschneider P, Sawicki PT. <span class="citation-title">A time‐limited, problem‐orientated psychotherapeutic intervention in Type 1 diabetic patients with complications: a randomized controlled trial</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2002</span>;<span class="volume">19</span>(10):814‐21. [MEDLINE: 12358867]<a class="crsref citation-link central-link" data-crsref="9141036" href="" ref="info:x-wiley/crsRef/9141036" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12358867" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+time%E2%80%90limited,+problem%E2%80%90orientated+psychotherapeutic+intervention+in+Type+1+diabetic+patients+with+complications:+a+randomized+controlled+trial+&author=U+Didjurgeit&author=J+Kruse&author=N+Schmitz&author=P+Stuckenschneider&author=PT+Sawicki&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0073"> <div class="reference-title-banner"> <h4 class="title">Di Mauro 2001 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0337"> <div class="citation-journal">Mauro M, Papalia G, Moli R, Nativo B, Nicoletti F, Lunetta M. <span class="citation-title">Effect of octreotide on insulin requirement, hepatic glucose production, growth hormone, glucagon and c‐peptide levels in type 2 diabetic patients with chronic renal failure or normal renal function</span>. <span class="citation"> Diabetes Research &amp; Clinical Practice </span><span class="pubYear">2001</span>;<span class="volume">51</span>(1):45‐50. [MEDLINE: 11137181]<a class="crsref citation-link central-link" data-crsref="9141038" href="" ref="info:x-wiley/crsRef/9141038" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+octreotide+on+insulin+requirement,+hepatic+glucose+production,+growth+hormone,+glucagon+and+c%E2%80%90peptide+levels+in+type+2+diabetic+patients+with+chronic+renal+failure+or+normal+renal+function+&author=M+Mauro&author=G+Papalia&author=R+Moli&author=B+Nativo&author=F+Nicoletti&author=M+Lunetta&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0074"> <div class="reference-title-banner"> <h4 class="title">DNETT Japan 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0338"> <div class="citation-journal">Shikata K, Haneda M, Koya D, Suzuki Y, Tomino Y, Yamada K, et al. <span class="citation-title">Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT‐Japan): rationale and study design</span>. <span class="citation"> Diabetes Research &amp; Clinical Practice </span><span class="pubYear">2010</span>;<span class="volume">87</span>(2):228‐32. [MEDLINE: 19889469]<a class="crsref citation-link central-link" data-crsref="9141040" href="" ref="info:x-wiley/crsRef/9141040" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Diabetic+Nephropathy+Remission+and+Regression+Team+Trial+in+Japan+(DNETT%E2%80%90Japan):+rationale+and+study+design+&author=K+Shikata&author=M+Haneda&author=D+Koya&author=Y+Suzuki&author=Y+Tomino&author=K+Yamada&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0075"> <div class="reference-title-banner"> <h4 class="title">Einhorn 2000 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0339"> <div class="citation-journal">Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. <span class="citation-title">Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo‐controlled study. The Pioglitazone 027 Study Group</span>. <span class="citation"> Clinical Therapeutics </span><span class="pubYear">2000</span>;<span class="volume">22</span>(12):1395‐409. [MEDLINE: 11192132]<a class="crsref citation-link central-link" data-crsref="9141042" href="" ref="info:x-wiley/crsRef/9141042" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11192132" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone+hydrochloride+in+combination+with+metformin+in+the+treatment+of+type+2+diabetes+mellitus:+a+randomized,+placebo%E2%80%90controlled+study.+The+Pioglitazone+027+Study+Group+&author=D+Einhorn&author=M+Rendell&author=J+Rosenzweig&author=JW+Egan&author=AL+Mathisen&author=RL+Schneider&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0076"> <div class="reference-title-banner"> <h4 class="title">Fadini 2016 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0340"> <div class="citation-journal">Fadini GP, Bonora BM, Cappellari R, Menegazzo L, Vedovato M, Iori E, et al. <span class="citation-title">Acute effects of linagliptin on progenitor cells, monocyte phenotypes, and soluble mediators in type 2 diabetes</span>. <span class="citation"> Journal of Clinical Endocrinology &amp; Metabolism </span><span class="pubYear">2016</span>;<span class="volume">101</span>(2):748‐56. [MEDLINE: 26695864]<a class="crsref citation-link central-link" data-crsref="9141044" href="" ref="info:x-wiley/crsRef/9141044" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Acute+effects+of+linagliptin+on+progenitor+cells,+monocyte+phenotypes,+and+soluble+mediators+in+type+2+diabetes+&author=GP+Fadini&author=BM+Bonora&author=R+Cappellari&author=L+Menegazzo&author=M+Vedovato&author=E+Iori&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0077"> <div class="reference-title-banner"> <h4 class="title">Fang 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0341"> <div class="citation-journal">Fang YJ. <span class="citation-title">Observation of treatment effect of pioglitazone in diabetic kidney disease</span>. <span class="citation"> Modern Practical Medicine </span><span class="pubYear">2007</span>;<span class="volume">19</span>(7):555‐6. [CENTRAL: CN‐00783737]<a class="crsref citation-link central-link" data-crsref="9141046" href="" ref="info:x-wiley/crsRef/9141046" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Observation+of+treatment+effect+of+pioglitazone+in+diabetic+kidney+disease&author=YJ+Fang&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0078"> <div class="reference-title-banner"> <h4 class="title">Feldt‐Rasmussen 1986 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0342"> <div class="citation-journal">Feldt‐Rasmussen B, Mathiesen ER, Deckert T. <span class="citation-title">Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin‐dependent diabetes</span>. <span class="citation"> Lancet </span><span class="pubYear">1986</span>;<span class="volume">2</span>(8519):1300‐4. [MEDLINE: 2878175]<a class="crsref citation-link central-link" data-crsref="9141048" href="" ref="info:x-wiley/crsRef/9141048" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2878175" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+two+years+of+strict+metabolic+control+on+progression+of+incipient+nephropathy+in+insulin%E2%80%90dependent+diabetes+&author=B+Feldt%E2%80%90Rasmussen&author=ER+Mathiesen&author=T+Deckert&publication_year=1986&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0343"> <div class="citation-journal">Feldt‐Rasmussen B, Mathiesen ER, Hegedus L, Deckert T. <span class="citation-title">Kidney function during 12 months of strict metabolic control in insulin‐dependent diabetic patients with incipient nephropathy</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">1986</span>;<span class="volume">314</span>(11):665‐70. [MEDLINE: 3513009]<a class="crsref citation-link central-link" data-crsref="9141049" href="" ref="info:x-wiley/crsRef/9141049" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/3513009" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Kidney+function+during+12+months+of+strict+metabolic+control+in+insulin%E2%80%90dependent+diabetic+patients+with+incipient+nephropathy+&author=B+Feldt%E2%80%90Rasmussen&author=ER+Mathiesen&author=L+Hegedus&author=T+Deckert&publication_year=1986&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0079"> <div class="reference-title-banner"> <h4 class="title">Frederich 2012 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0344"> <div class="citation-journal">Frederich R, McNeill R, Berglind N, Fleming D, Chen R. <span class="citation-title">The efficacy and safety of the dipeptidyl peptidase‐4 inhibitor saxagliptin in treatment‐naive patients with type 2 diabetes mellitus: a randomized controlled trial</span>. <span class="citation"> Diabetology &amp; Metabolic Syndrome </span><span class="pubYear">2012</span>;<span class="volume">4</span>(1):36. [MEDLINE: 22828124]<a class="crsref citation-link central-link" data-crsref="9141051" href="" ref="info:x-wiley/crsRef/9141051" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22828124" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+efficacy+and+safety+of+the+dipeptidyl+peptidase%E2%80%904+inhibitor+saxagliptin+in+treatment%E2%80%90naive+patients+with+type+2+diabetes+mellitus:+a+randomized+controlled+trial+&author=R+Frederich&author=R+McNeill&author=N+Berglind&author=D+Fleming&author=R+Chen&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0080"> <div class="reference-title-banner"> <h4 class="title">Gadallah 2000b {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0345"> <div class="citation-journal">Gadallah M, Andrews G, Hanna D, Patel A, Po S, Wooldridge T. <span class="citation-title">Role of metformin in treatment of hypertension in patients with insulin resistance mediated hypertension [abstract]</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">2000</span>;<span class="volume">11</span>(Sept):347A. [CENTRAL: CN‐00583336]<a class="crsref citation-link central-link" data-crsref="9141053" href="" ref="info:x-wiley/crsRef/9141053" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Role+of+metformin+in+treatment+of+hypertension+in+patients+with+insulin+resistance+mediated+hypertension+[abstract]+&author=M+Gadallah&author=G+Andrews&author=D+Hanna&author=A+Patel&author=S+Po&author=T+Wooldridge&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0081"> <div class="reference-title-banner"> <h4 class="title">Gan 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0346"> <div class="citation-journal">Gan JX, Tang FR. <span class="citation-title">Observation of therapeutic effects of rosiglitazone in type2 diabetic nephropathy</span>. <span class="citation"> Chinese Medical Journal of Metallurgical Industry </span><span class="pubYear">2007</span>;<span class="volume">24</span>(1):45‐6. [CENTRAL: CN‐00783735]<a class="crsref citation-link central-link" data-crsref="9141055" href="" ref="info:x-wiley/crsRef/9141055" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Observation+of+therapeutic+effects+of+rosiglitazone+in+type2+diabetic+nephropathy&author=JX+Gan&author=FR+Tang&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0082"> <div class="reference-title-banner"> <h4 class="title">Gao 2006a {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0347"> <div class="citation-journal">Gao XH, HP X. <span class="citation-title">Short‐term improvement effects of pioglitazone combined prostaglandin E1 in diabetic nephropathy</span>. <span class="citation"> Clinical Focus </span><span class="pubYear">2006</span>;<span class="volume">21</span>(20):1497‐8. [CENTRAL: CN‐00784213]<a class="crsref citation-link central-link" data-crsref="9141057" href="" ref="info:x-wiley/crsRef/9141057" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Short%E2%80%90term+improvement+effects+of+pioglitazone+combined+prostaglandin+E1+in+diabetic+nephropathy+&author=XH+Gao&author=X+HP&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0083"> <div class="reference-title-banner"> <h4 class="title">Gao 2007a {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0348"> <div class="citation-journal">Gao L, Yu DM. <span class="citation-title">Effects of rosiglitazone on urinary albumin excretion in patients with early diabetic nephropathy</span>. <span class="citation"> Zhong Guo Man Xing Bing Yu Fang Yu Kong Zhi [Chinese Journal of Prevention and Control of Chronic Non‐communicable Diseases] </span><span class="pubYear">2007</span>;<span class="volume">15</span>(2):126‐8. [CENTRAL: CN‐00783105]<a class="crsref citation-link central-link" data-crsref="9141059" href="" ref="info:x-wiley/crsRef/9141059" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+rosiglitazone+on+urinary+albumin+excretion+in+patients+with+early+diabetic+nephropathy+&author=L+Gao&author=DM+Yu&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0084"> <div class="reference-title-banner"> <h4 class="title">Gao 2007b {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0349"> <div class="citation-journal">Gao MS, Zheng CH, Ke SH. <span class="citation-title">Pioglitazone combined fosinopril in treating 52 patients with type 2 diabetes and microalbuminuria</span>. <span class="citation"> Journal of New Medicine </span><span class="pubYear">2007</span>;<span class="volume">17</span>(3):176‐7. [CENTRAL: CN‐00783869]<a class="crsref citation-link central-link" data-crsref="9141061" href="" ref="info:x-wiley/crsRef/9141061" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone+combined+fosinopril+in+treating+52+patients+with+type+2+diabetes+and+microalbuminuria+&author=MS+Gao&author=CH+Zheng&author=SH+Ke&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0085"> <div class="reference-title-banner"> <h4 class="title">GEMINI 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0350"> <div class="citation-journal">Bakris GL, Bell DS, Fonseca V, Katholi R, McGill J, Phillips R, et al. <span class="citation-title">The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol‐Metoprolol Comparison in Hypertensives (GEMINI) trial</span>. <span class="citation"> Journal of Diabetes &amp; its Complications </span><span class="pubYear">2005</span>;<span class="volume">19</span>(2):74‐9. [MEDLINE: 15745836]<a class="crsref citation-link central-link" data-crsref="9141063" href="" ref="info:x-wiley/crsRef/9141063" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+rationale+and+design+of+the+Glycemic+Effects+in+Diabetes+Mellitus+Carvedilol%E2%80%90Metoprolol+Comparison+in+Hypertensives+(GEMINI)+trial+&author=GL+Bakris&author=DS+Bell&author=V+Fonseca&author=R+Katholi&author=J+McGill&author=R+Phillips&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0351"> <div class="citation-journal">Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli F, Phillips RA, et al. <span class="citation-title">Differential effects of beta‐blockers on albuminuria in patients with type 2 diabetes</span>. <span class="citation"> Hypertension </span><span class="pubYear">2005</span>;<span class="volume">46</span>(6):1309‐15. [MEDLINE: 16286578]<a class="crsref citation-link central-link" data-crsref="9141064" href="" ref="info:x-wiley/crsRef/9141064" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16286578" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Differential+effects+of+beta%E2%80%90blockers+on+albuminuria+in+patients+with+type+2+diabetes&author=GL+Bakris&author=V+Fonseca&author=RE+Katholi&author=JB+McGill&author=F+Messerli&author=RA+Phillips&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0086"> <div class="reference-title-banner"> <h4 class="title">Goicolea 2002 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0352"> <div class="citation-journal">Goicolea I, Fernandez Gonzalez R, Pinies J, Garrido J, Martinez JM, Armenteros S, et al. <span class="citation-title">Effect of antihypertensive combinations on arterial pressure, albuminuria, and glycemic control in patients with type II diabetic nephropathy: a randomized study</span> [Efecto de dos combinaciones antihipertensivas sobre la presion arterial, albuminuria y control glucemico en pacientes con nefropatia diabetica tipo 2: un estudio aleatorizado]. <span class="citation"> Nefrologia </span><span class="pubYear">2002</span>;<span class="volume">22</span>(2):170‐8. [MEDLINE: 12085418]<a class="crsref citation-link central-link" data-crsref="9141066" href="" ref="info:x-wiley/crsRef/9141066" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12085418" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+antihypertensive+combinations+on+arterial+pressure,+albuminuria,+and+glycemic+control+in+patients+with+type+II+diabetic+nephropathy:+a+randomized+study+&author=I+Goicolea&author=R+FernandezGonzalez&author=J+Pinies&author=J+Garrido&author=JM+Martinez&author=S+Armenteros&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0087"> <div class="reference-title-banner"> <h4 class="title">He 2004 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0353"> <div class="citation-journal">He JP, Zhao Q, Yuan WS, Zeng WX. <span class="citation-title">Observation of therapeutic effects of pioglitazone in early diabetic nephropathy</span>. <span class="citation"> Journal of Practical Medicine </span><span class="pubYear">2004</span>;<span class="volume">20</span>(6):704‐5. [CENTRAL: CN‐00783733]<a class="crsref citation-link central-link" data-crsref="9141068" href="" ref="info:x-wiley/crsRef/9141068" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Observation+of+therapeutic+effects+of+pioglitazone+in+early+diabetic+nephropathy&author=JP+He&author=Q+Zhao&author=WS+Yuan&author=WX+Zeng&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0088"> <div class="reference-title-banner"> <h4 class="title">Hollander 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0354"> <div class="citation-journal">Hollander P, Li J, Allen E, Chen R, CV181‐013 Investigators. <span class="citation-title">Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone</span>. <span class="citation"> Journal of Clinical Endocrinology &amp; Metabolism </span><span class="pubYear">2009</span>;<span class="volume">94</span>(12):4810‐9. [MEDLINE: 19864452]<a class="crsref citation-link central-link" data-crsref="9141070" href="" ref="info:x-wiley/crsRef/9141070" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Saxagliptin+added+to+a+thiazolidinedione+improves+glycemic+control+in+patients+with+type+2+diabetes+and+inadequate+control+on+thiazolidinedione+alone+&author=P+Hollander&author=J+Li&author=E+Allen&author=R+Chen&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0089"> <div class="reference-title-banner"> <h4 class="title">Holman 1983 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0355"> <div class="citation-journal">Holman RR, Dornan TL, Mayon‐White V, Howard‐Williams J, Orde‐Peckar C, Jenkins L, et al. <span class="citation-title">Prevention of deterioration of renal and sensory‐nerve function by more intensive management of insulin‐dependent diabetic patients. A two‐year randomised prospective study</span>. <span class="citation"> Lancet </span><span class="pubYear">1983</span>;<span class="volume">1</span>(8318):204‐8. [MEDLINE: 6130244]<a class="crsref citation-link central-link" data-crsref="9141072" href="" ref="info:x-wiley/crsRef/9141072" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/6130244" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Prevention+of+deterioration+of+renal+and+sensory%E2%80%90nerve+function+by+more+intensive+management+of+insulin%E2%80%90dependent+diabetic+patients.+A+two%E2%80%90year+randomised+prospective+study+&author=RR+Holman&author=TL+Dornan&author=V+Mayon%E2%80%90White&author=J+Howard%E2%80%90Williams&author=C+Orde%E2%80%90Peckar&author=L+Jenkins&publication_year=1983&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0090"> <div class="reference-title-banner"> <h4 class="title">Hu 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0356"> <div class="citation-journal">Hu ZY, Zhao JW. <span class="citation-title">Effect of rosiglitazone on serum CRP and plasma PAI‐1 in patients with early type 2 diabetic nephropathy</span>. <span class="citation"> Central Plains Medical Journal </span><span class="pubYear">2007</span>;<span class="volume">34</span>(20):27‐8. [CENTRAL: CN‐00783022]<a class="crsref citation-link central-link" data-crsref="9141074" href="" ref="info:x-wiley/crsRef/9141074" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+rosiglitazone+on+serum+CRP+and+plasma+PAI%E2%80%901+in+patients+with+early+type+2+diabetic+nephropathy+&author=ZY+Hu&author=JW+Zhao&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0091"> <div class="reference-title-banner"> <h4 class="title">Hu 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0357"> <div class="citation-journal">Hu YY, Ye SD, Zhao LL, Zheng M, Chen Y. <span class="citation-title">Hydrochloride pioglitazone decreases urinary TGF‐beta1 excretion in type 2 diabetics</span>. <span class="citation"> European Journal of Clinical Investigation </span><span class="pubYear">2010</span>;<span class="volume">40</span>(7):571‐4. [MEDLINE: 20482594]<a class="crsref citation-link central-link" data-crsref="9141076" href="" ref="info:x-wiley/crsRef/9141076" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20482594" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Hydrochloride+pioglitazone+decreases+urinary+TGF%E2%80%90beta1+excretion+in+type+2+diabetics&author=YY+Hu&author=SD+Ye&author=LL+Zhao&author=M+Zheng&author=Y+Chen&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0358"> <div class="citation-journal">Hu YY, Ye SD, Zhao LL, Zheng M, Wu FZ, Chen Y. <span class="citation-title">Hydrochloride pioglitazone decreases urinary cytokines excretion in type 2 diabetes</span>. <span class="citation"> Clinical Endocrinology </span><span class="pubYear">2010</span>;<span class="volume">73</span>(6):739‐43. [MEDLINE: 20874769]<a class="crsref citation-link central-link" data-crsref="9141077" href="" ref="info:x-wiley/crsRef/9141077" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20874769" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Hydrochloride+pioglitazone+decreases+urinary+cytokines+excretion+in+type+2+diabetes&author=YY+Hu&author=SD+Ye&author=LL+Zhao&author=M+Zheng&author=FZ+Wu&author=Y+Chen&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0092"> <div class="reference-title-banner"> <h4 class="title">Huang 2004 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0359"> <div class="citation-journal">Huang H, Liu PY. <span class="citation-title">Observation of therapeutic effects of rosiglitazone in diabetic nephropathy</span>. <span class="citation"> Acta Medicinae Sinica </span><span class="pubYear">2004</span>;<span class="volume">17</span>(3):324‐5. [CENTRAL: CN‐00783734]<a class="crsref citation-link central-link" data-crsref="9141079" href="" ref="info:x-wiley/crsRef/9141079" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Observation+of+therapeutic+effects+of+rosiglitazone+in+diabetic+nephropathy&author=H+Huang&author=PY+Liu&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0093"> <div class="reference-title-banner"> <h4 class="title">Huang 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0360"> <div class="citation-journal">Huang XX, Zhang JE, Li XF, Li T. <span class="citation-title">Effect of rosiglitazone on urinary monocyte chemoattractant protein‐1 in patients with diabetic nephropathy</span>. <span class="citation"> Journal of Yunyang Medical College </span><span class="pubYear">2006</span>;<span class="volume">25</span>(4):211‐3. [CENTRAL: CN‐00783023]<a class="crsref citation-link central-link" data-crsref="9141081" href="" ref="info:x-wiley/crsRef/9141081" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+rosiglitazone+on+urinary+monocyte+chemoattractant+protein%E2%80%901+in+patients+with+diabetic+nephropathy+&author=XX+Huang&author=JE+Zhang&author=XF+Li&author=T+Li&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0094"> <div class="reference-title-banner"> <h4 class="title">Huang 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0361"> <div class="citation-journal">Huang YY, Liu JH. <span class="citation-title">Effects of pioglitazone on changes of haemorrheology and insulin resistance in patients with early diabetic nephropathy</span>. <span class="citation"> IMHGN ‐ International Medicine &amp; Health Guidance News </span><span class="pubYear">2007</span>;<span class="volume">13</span>(7):51‐4. [CENTRAL: CN‐00783093]<a class="crsref citation-link central-link" data-crsref="9141083" href="" ref="info:x-wiley/crsRef/9141083" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+pioglitazone+on+changes+of+haemorrheology+and+insulin+resistance+in+patients+with+early+diabetic+nephropathy+&author=YY+Huang&author=JH+Liu&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0095"> <div class="reference-title-banner"> <h4 class="title">Imano 1998 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0362"> <div class="citation-journal">Imano E, Kanda T, Nakatani Y, Nishida T, Arai K, Motomura M, et al. <span class="citation-title">Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1998</span>;<span class="volume">21</span>(12):2135‐9. [MEDLINE: 9839106]<a class="crsref citation-link central-link" data-crsref="9141085" href="" ref="info:x-wiley/crsRef/9141085" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9839106" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+troglitazone+on+microalbuminuria+in+patients+with+incipient+diabetic+nephropathy&author=E+Imano&author=T+Kanda&author=Y+Nakatani&author=T+Nishida&author=K+Arai&author=M+Motomura&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0096"> <div class="reference-title-banner"> <h4 class="title">Inagaki 2014 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0363"> <div class="citation-journal">Inagaki N, Kondo K, Yoshinari T, Ishii M, Sakai M, Kuki H, et al. <span class="citation-title">Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment</span>. <span class="citation"> Clinical Drug Investigation </span><span class="pubYear">2014</span>;<span class="volume">34</span>(10):731‐42. [MEDLINE: 25200141]<a class="crsref citation-link central-link" data-crsref="9141087" href="" ref="info:x-wiley/crsRef/9141087" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25200141" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pharmacokinetic+and+pharmacodynamic+profiles+of+canagliflozin+in+Japanese+patients+with+type+2+diabetes+mellitus+and+moderate+renal+impairment+&author=N+Inagaki&author=K+Kondo&author=T+Yoshinari&author=M+Ishii&author=M+Sakai&author=H+Kuki&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0097"> <div class="reference-title-banner"> <h4 class="title">Jerums 1987 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0364"> <div class="citation-journal">Jerums G, Murray RM, Seeman E, Cooper ME, Edgley S, Marwick K, et al. <span class="citation-title">Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: a two‐year controlled study</span>. <span class="citation"> Diabetes Research &amp; Clinical Practice </span><span class="pubYear">1987</span>;<span class="volume">3</span>(2):71‐80. [MEDLINE: 3552537]<a class="crsref citation-link central-link" data-crsref="9141089" href="" ref="info:x-wiley/crsRef/9141089" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Lack+of+effect+of+gliclazide+on+early+diabetic+nephropathy+and+retinopathy:+a+two%E2%80%90year+controlled+study+&author=G+Jerums&author=RM+Murray&author=E+Seeman&author=ME+Cooper&author=S+Edgley&author=K+Marwick&publication_year=1987&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0098"> <div class="reference-title-banner"> <h4 class="title">Kadhim 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0365"> <div class="citation-journal">Kadhim HM, Ismail SH, Hussein KI, Bakir IH, Sahib AS, Khalaf BH, et al. <span class="citation-title">Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin</span>. <span class="citation"> Journal of Pineal Research </span><span class="pubYear">2006</span>;<span class="volume">41</span>(2):189‐93. [MEDLINE: 16879326]<a class="crsref citation-link central-link" data-crsref="9141091" href="" ref="info:x-wiley/crsRef/9141091" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16879326" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+melatonin+and+zinc+on+lipid+profile+and+renal+function+in+type+2+diabetic+patients+poorly+controlled+with+metformin+&author=HM+Kadhim&author=SH+Ismail&author=KI+Hussein&author=IH+Bakir&author=AS+Sahib&author=BH+Khalaf&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0099"> <div class="reference-title-banner"> <h4 class="title">Kadowaki 2014 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0366"> <div class="citation-journal">Kadowaki T, Haneda M, Inagaki N, Terauchi Y, Taniguchi A, Koiwai K, et al. <span class="citation-title">Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12‐week, double‐blind, placebo‐controlled, phase II trial</span>. <span class="citation"> Advances in Therapy </span><span class="pubYear">2014</span>;<span class="volume">31</span>(6):621‐38. [MEDLINE: 24958326]<a class="crsref citation-link central-link" data-crsref="9141093" href="" ref="info:x-wiley/crsRef/9141093" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24958326" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Empagliflozin+monotherapy+in+Japanese+patients+with+type+2+diabetes+mellitus:+a+randomized,+12%E2%80%90week,+double%E2%80%90blind,+placebo%E2%80%90controlled,+phase+II+trial+&author=T+Kadowaki&author=M+Haneda&author=N+Inagaki&author=Y+Terauchi&author=A+Taniguchi&author=K+Koiwai&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0100"> <div class="reference-title-banner"> <h4 class="title">Karalliedde 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0367"> <div class="citation-journal">Karalliedde J, Buckingham R, Starkie M, Lorand D, Stewart M, Viberti G, et al. <span class="citation-title">Effect of various diuretic treatments on rosiglitazone‐induced fluid retention</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">2006</span>;<span class="volume">17</span>(12):3482‐90. [MEDLINE: 17093067]<a class="crsref citation-link central-link" data-crsref="9141095" href="" ref="info:x-wiley/crsRef/9141095" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17093067" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+various+diuretic+treatments+on+rosiglitazone%E2%80%90induced+fluid+retention&author=J+Karalliedde&author=R+Buckingham&author=M+Starkie&author=D+Lorand&author=M+Stewart&author=G+Viberti&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0101"> <div class="reference-title-banner"> <h4 class="title">Katavetin 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0368"> <div class="citation-journal">Katavetin P, Eiam‐Ong S, Suwanwalaikorn S. <span class="citation-title">Pioglitazone reduces urinary protein and urinary transforming growth factor‐beta excretion in patients with type 2 diabetes and overt nephropathy</span>. <span class="citation"> Journal of the Medical Association of Thailand </span><span class="pubYear">2006</span>;<span class="volume">89</span>(2):170‐7. [MEDLINE: 16579002]<a class="crsref citation-link central-link" data-crsref="9141097" href="" ref="info:x-wiley/crsRef/9141097" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16579002" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone+reduces+urinary+protein+and+urinary+transforming+growth+factor%E2%80%90beta+excretion+in+patients+with+type+2+diabetes+and+overt+nephropathy+&author=P+Katavetin&author=S+Eiam%E2%80%90Ong&author=S+Suwanwalaikorn&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0102"> <div class="reference-title-banner"> <h4 class="title">Kim 2003 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0369"> <div class="citation-journal">Do J, Cho K, Park J, Yoon K, Cho D, Kim Y. <span class="citation-title">Local and systemic effects of neutral pH, low GDP dialysate in CAPD patients [abstract no: SA‐FC202]</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">2002</span>;<span class="volume">13</span>(September, Program &amp; Abstracts):41A. [CENTRAL: CN‐00445121]<a class="crsref citation-link central-link" data-crsref="9141099" href="" ref="info:x-wiley/crsRef/9141099" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Local+and+systemic+effects+of+neutral+pH,+low+GDP+dialysate+in+CAPD+patients+[abstract+no:+SA%E2%80%90FC202]+&author=J+Do&author=K+Cho&author=J+Park&author=K+Yoon&author=D+Cho&author=Y+Kim&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0370"> <div class="citation-journal">Park J, Do J, Kim Y, Kim T, Yoon K, Park S. <span class="citation-title">The effect of low GDPs solution on peritoneal fibrosis markers [abstract no: SA‐PO333]</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">2004</span>;<span class="volume">15</span>(Oct):374A. [CENTRAL: CN‐00583515]<a class="crsref citation-link central-link" data-crsref="9141100" href="" ref="info:x-wiley/crsRef/9141100" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+effect+of+low+GDPs+solution+on+peritoneal+fibrosis+markers+[abstract+no:+SA%E2%80%90PO333]&author=J+Park&author=J+Do&author=Y+Kim&author=T+Kim&author=K+Yoon&author=S+Park&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0103"> <div class="reference-title-banner"> <h4 class="title">Kirk 1999 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0371"> <div class="citation-journal">Kirk JK, Pearce KA, Michielutte R, Summerson JH. <span class="citation-title">Troglitazone or metformin in combination with sulfonylureas for patients with type 2 diabetes?</span>. <span class="citation"> Journal of Family Practice </span><span class="pubYear">1999</span>;<span class="volume">48</span>(11):879‐82. [MEDLINE: 10907625]<a class="crsref citation-link central-link" data-crsref="9141102" href="" ref="info:x-wiley/crsRef/9141102" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10907625" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Troglitazone+or+metformin+in+combination+with+sulfonylureas+for+patients+with+type+2+diabetes?+&author=JK+Kirk&author=KA+Pearce&author=R+Michielutte&author=JH+Summerson&publication_year=1999&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0104"> <div class="reference-title-banner"> <h4 class="title">KUMAMOTO 1995 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0372"> <div class="citation-journal">Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. <span class="citation-title">Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non‐insulin‐dependent diabetes mellitus: a randomized prospective 6‐year study</span>. <span class="citation"> Diabetes Research &amp; Clinical Practice </span><span class="pubYear">1995</span>;<span class="volume">28</span>(2):103‐17. [MEDLINE: 7587918]<a class="crsref citation-link central-link" data-crsref="9141104" href="" ref="info:x-wiley/crsRef/9141104" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensive+insulin+therapy+prevents+the+progression+of+diabetic+microvascular+complications+in+Japanese+patients+with+non%E2%80%90insulin%E2%80%90dependent+diabetes+mellitus:+a+randomized+prospective+6%E2%80%90year+study+&author=Y+Ohkubo&author=H+Kishikawa&author=E+Araki&author=T+Miyata&author=S+Isami&author=S+Motoyoshi&publication_year=1995&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0373"> <div class="citation-journal">Shichiri M, Kishikawa H, Ohkubo Y, Wake N. <span class="citation-title">Long‐term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2000</span>;<span class="volume">23 Suppl 2</span>:B21‐9. [MEDLINE: 10860187]<a class="crsref citation-link central-link" data-crsref="9141105" href="" ref="info:x-wiley/crsRef/9141105" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10860187" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+results+of+the+Kumamoto+Study+on+optimal+diabetes+control+in+type+2+diabetic+patients+&author=M+Shichiri&author=H+Kishikawa&author=Y+Ohkubo&author=N+Wake&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0374"> <div class="citation-journal">Wake N, Hisashige A, Katayama T, Kishikawa H, Ohkubo Y, Sakai M, et al. <span class="citation-title">Cost‐effectiveness of intensive insulin therapy for type 2 diabetes: a 10‐year follow‐up of the Kumamoto study</span>. <span class="citation"> Diabetes Research &amp; Clinical Practice </span><span class="pubYear">2000</span>;<span class="volume">48</span>(3):201‐10. [MEDLINE: 10802159]<a class="crsref citation-link central-link" data-crsref="9141106" href="" ref="info:x-wiley/crsRef/9141106" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cost%E2%80%90effectiveness+of+intensive+insulin+therapy+for+type+2+diabetes:+a+10%E2%80%90year+follow%E2%80%90up+of+the+Kumamoto+study+&author=N+Wake&author=A+Hisashige&author=T+Katayama&author=H+Kishikawa&author=Y+Ohkubo&author=M+Sakai&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0105"> <div class="reference-title-banner"> <h4 class="title">Lebovitz 2001 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0375"> <div class="citation-journal">Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI, Rosiglitazone Clinical Trials Study Group. <span class="citation-title">Rosiglitazone monotherapy is effective in patients with type 2 diabetes.[Erratum appears in J Clin Endocrinol Metab. 2002 Feb;2(1):iv.], [Erratum appears in J Clin Endocrinol Metab 2001 Apr;86(4):1659]</span>. <span class="citation"> Journal of Clinical Endocrinology &amp; Metabolism </span><span class="pubYear">2001</span>;<span class="volume">86</span>(1):280‐8. [MEDLINE: 11232013]<a class="crsref citation-link central-link" data-crsref="9141108" href="" ref="info:x-wiley/crsRef/9141108" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rosiglitazone+monotherapy+is+effective+in+patients+with+type+2+diabetes.[Erratum+appears+in+J+Clin+Endocrinol+Metab.+2002+Feb;2(1):iv.],+[Erratum+appears+in+J+Clin+Endocrinol+Metab+2001+Apr;86(4):1659]+&author=HE+Lebovitz&author=JF+Dole&author=R+Patwardhan&author=EB+Rappaport&author=MI+Freed&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0106"> <div class="reference-title-banner"> <h4 class="title">Leslie 2008 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0376"> <div class="citation-journal">Leslie B, Tang W, Tang W, List JF. <span class="citation-title">Renal effects of the sodium‐glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin (BMS‐512148) in patients with type 2 diabetes mellitus (T2DM) [abstract no: TH‐PO1022]</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">2008</span>;<span class="volume">19</span>(Abstracts Issue):341A. <a class="crsref citation-link central-link" data-crsref="9141110" href="" ref="info:x-wiley/crsRef/9141110" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Renal+effects+of+the+sodium%E2%80%90glucose+cotransporter+2+(SGLT2)+inhibitor+dapagliflozin+(BMS%E2%80%90512148)+in+patients+with+type+2+diabetes+mellitus+(T2DM)+[abstract+no:+TH%E2%80%90PO1022]+&author=B+Leslie&author=W+Tang&author=W+Tang&author=JF+List&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0107"> <div class="reference-title-banner"> <h4 class="title">Li 2004a {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0377"> <div class="citation-journal">Li X, Duan BH, Wang YW, Feng K, Yang YZ. <span class="citation-title">Observation of effect of rosiglitazone in type 2 diabetes with trace urinary protein</span>. <span class="citation"> Zhong Guo Wu Zhen Xue Za Zhi [Chinese Journal of Misdiagnostics] </span><span class="pubYear">2004</span>;<span class="volume">4</span>(9):1432. [CENTRAL: CN‐00783727]<a class="crsref citation-link central-link" data-crsref="9141112" href="" ref="info:x-wiley/crsRef/9141112" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Observation+of+effect+of+rosiglitazone+in+type+2+diabetes+with+trace+urinary+protein&author=X+Li&author=BH+Duan&author=YW+Wang&author=K+Feng&author=YZ+Yang&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0108"> <div class="reference-title-banner"> <h4 class="title">Li 2006e {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0378"> <div class="citation-journal">Li ZL. <span class="citation-title">Effects of pioglitazone on microalbuminuria of early diabetic nephropathy</span>. <span class="citation"> Journal of Medical Forum </span><span class="pubYear">2006</span>;<span class="volume">27</span>(9):31‐3. [CENTRAL: CN‐00783094]<a class="crsref citation-link central-link" data-crsref="9141114" href="" ref="info:x-wiley/crsRef/9141114" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+pioglitazone+on+microalbuminuria+of+early+diabetic+nephropathy&author=ZL+Li&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0109"> <div class="reference-title-banner"> <h4 class="title">Li 2008f {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0379"> <div class="citation-journal">Li B, Ba HJ, Yun L, Wang SG, Zhao SZ, Yue ZW. <span class="citation-title">Therapeutic effect of captopril combined with rosiglitazone on early diabetic nephropathy</span>. <span class="citation"> Chinese Journal of Difficult &amp; Complicated Cases </span><span class="pubYear">2008</span>;<span class="volume">7</span>(2):80‐2. [CENTRAL: CN‐00784501]<a class="crsref citation-link central-link" data-crsref="9141116" href="" ref="info:x-wiley/crsRef/9141116" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Therapeutic+effect+of+captopril+combined+with+rosiglitazone+on+early+diabetic+nephropathy&author=B+Li&author=HJ+Ba&author=L+Yun&author=SG+Wang&author=SZ+Zhao&author=ZW+Yue&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0110"> <div class="reference-title-banner"> <h4 class="title">Li 2008g {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0380"> <div class="citation-journal">Li YL, Wang SJ, Li JZ. <span class="citation-title">Rosiglitazone affect type 2 diabetic nephropathy</span>. <span class="citation"> Zhong Guo Chang Kuang Yi Xue [Chinese Medicine of Factory and Mine] </span><span class="pubYear">2008</span>;<span class="volume">21</span>(1):58‐9. [CENTRAL: CN‐00784162]<a class="crsref citation-link central-link" data-crsref="9141118" href="" ref="info:x-wiley/crsRef/9141118" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rosiglitazone+affect+type+2+diabetic+nephropathy&author=YL+Li&author=SJ+Wang&author=JZ+Li&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0111"> <div class="reference-title-banner"> <h4 class="title">Lu 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0381"> <div class="citation-journal">Lu WH, Shi BY, Zhang XT, Wei DG, Liu WD, Duan PZ. <span class="citation-title">Significance of intensive glycemic control on early diabetic nephropathy patients with microalbuminuria</span>. <span class="citation"> Academic Journal of Xi'an Jiaotong University </span><span class="pubYear">2010</span>;<span class="volume">22</span>(2):135‐8. [EMBASE: 2010319798]<a class="crsref citation-link central-link" data-crsref="9141120" href="" ref="info:x-wiley/crsRef/9141120" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Significance+of+intensive+glycemic+control+on+early+diabetic+nephropathy+patients+with+microalbuminuria+&author=WH+Lu&author=BY+Shi&author=XT+Zhang&author=DG+Wei&author=WD+Liu&author=PZ+Duan&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0112"> <div class="reference-title-banner"> <h4 class="title">Matthews 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0382"> <div class="citation-journal">Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, et al. <span class="citation-title">Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2005</span>;<span class="volume">48</span>(6):1093‐104. [MEDLINE: 15889234]<a class="crsref citation-link central-link" data-crsref="9141122" href="" ref="info:x-wiley/crsRef/9141122" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15889234" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+efficacy+and+tolerability+of+add%E2%80%90on+pioglitazone+therapy+to+failing+monotherapy+compared+with+addition+of+gliclazide+or+metformin+in+patients+with+type+2+diabetes+&author=B+Charbonnel&author=G+Schernthaner&author=P+Brunetti&author=DR+Matthews&author=R+Urquhart&author=MH+Tan&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0383"> <div class="citation-journal">Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. <span class="citation-title">Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study</span>. <span class="citation"> Diabetes/Metabolism Research Reviews </span><span class="pubYear">2005</span>;<span class="volume">21</span>(2):167‐74. [MEDLINE: 15386821]<a class="crsref citation-link central-link" data-crsref="9141123" href="" ref="info:x-wiley/crsRef/9141123" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+therapy+with+addition+of+pioglitazone+to+metformin+compared+with+the+addition+of+gliclazide+to+metformin+in+patients+with+type+2+diabetes:+a+randomized,+comparative+study+&author=DR+Matthews&author=BH+Charbonnel&author=M+Hanefeld&author=P+Brunetti&author=G+Schernthaner&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0113"> <div class="reference-title-banner"> <h4 class="title">MEMO 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0384"> <div class="citation-journal">Crasto W, Jarvis J, Khunti K, Skinner TC, Gray LJ, Brela J, et al. <span class="citation-title">Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) study</span>. <span class="citation"> Diabetes Research &amp; Clinical Practice </span><span class="pubYear">2011</span>;<span class="volume">93</span>(3):328‐36. [MEDLINE: 21640424]<a class="crsref citation-link central-link" data-crsref="9141125" href="" ref="info:x-wiley/crsRef/9141125" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Multifactorial+intervention+in+individuals+with+type+2+diabetes+and+microalbuminuria:+the+Microalbuminuria+Education+and+Medication+Optimisation+(MEMO)+study+&author=W+Crasto&author=J+Jarvis&author=K+Khunti&author=TC+Skinner&author=LJ+Gray&author=J+Brela&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0385"> <div class="citation-journal">Crasto W, Khunti K, Jarvis Kay J, Skinner TC, Gray LJ, Brela J, et al. <span class="citation-title">Impact of intensive multi‐factorial intervention on novel markers of inflammation and vascular stiffness [abstract no: P446]</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2011</span>;<span class="volume">28</span>(Suppl 1):166. [EMBASE: 70631246]<a class="crsref citation-link central-link" data-crsref="9141126" href="" ref="info:x-wiley/crsRef/9141126" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Impact+of+intensive+multi%E2%80%90factorial+intervention+on+novel+markers+of+inflammation+and+vascular+stiffness+[abstract+no:+P446]+&author=W+Crasto&author=K+Khunti&author=J+JarvisKay&author=TC+Skinner&author=LJ+Gray&author=J+Brela&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0386"> <div class="citation-journal">Crasto WA, Jarvis J, Brela J, Daly H, Gray LJ, Troughton J, et al. <span class="citation-title">Interim analysis of the effects of a multifactorial intervention in people with Type 2 diabetes and microalbuminuria after twelve months [abstract no: P410]</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2009</span>;<span class="volume">26</span>(Suppl 1):160. [EMBASE: 70342536]<a class="crsref citation-link central-link" data-crsref="9141127" href="" ref="info:x-wiley/crsRef/9141127" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Interim+analysis+of+the+effects+of+a+multifactorial+intervention+in+people+with+Type+2+diabetes+and+microalbuminuria+after+twelve+months+[abstract+no:+P410]+&author=WA+Crasto&author=J+Jarvis&author=J+Brela&author=H+Daly&author=LJ+Gray&author=J+Troughton&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0114"> <div class="reference-title-banner"> <h4 class="title">Miyazaki 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0387"> <div class="citation-journal">Miyazaki Y, Cersosimo E, Triplitt C, DeFronzo RA. <span class="citation-title">Rosiglitazone decreases albuminuria in type 2 diabetic patients</span>. <span class="citation"> Kidney International </span><span class="pubYear">2007</span>;<span class="volume">72</span>(11):1367‐73. [MEDLINE: 17805239]<a class="crsref citation-link central-link" data-crsref="9141129" href="" ref="info:x-wiley/crsRef/9141129" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17805239" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rosiglitazone+decreases+albuminuria+in+type+2+diabetic+patients&author=Y+Miyazaki&author=E+Cersosimo&author=C+Triplitt&author=RA+DeFronzo&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0115"> <div class="reference-title-banner"> <h4 class="title">Nakamura 2000b {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0388"> <div class="citation-journal">Nakamura T, Ushiyama C, Shimada N, Hayashi K, Ebihara I, Koide H. <span class="citation-title">Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin‐1 and albumin excretion in diabetes patients</span>. <span class="citation"> Journal of Diabetes &amp; its Complications </span><span class="pubYear">2000</span>;<span class="volume">14</span>(5):250‐4. [MEDLINE: 11113686]<a class="crsref citation-link central-link" data-crsref="9141131" href="" ref="info:x-wiley/crsRef/9141131" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparative+effects+of+pioglitazone,+glibenclamide,+and+voglibose+on+urinary+endothelin%E2%80%901+and+albumin+excretion+in+diabetes+patients+&author=T+Nakamura&author=C+Ushiyama&author=N+Shimada&author=K+Hayashi&author=I+Ebihara&author=H+Koide&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0116"> <div class="reference-title-banner"> <h4 class="title">Nakamura 2001b {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0389"> <div class="citation-journal">Nakamura T, Ushiyama C, Suzuki S, Shimada N, Sekizuka K, Ebihara L, et al. <span class="citation-title">Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2001</span>;<span class="volume">18</span>(4):308‐13. [MEDLINE: 11437862]<a class="crsref citation-link central-link" data-crsref="9141133" href="" ref="info:x-wiley/crsRef/9141133" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11437862" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+troglitazone+on+urinary+albumin+excretion+and+serum+type+IV+collagen+concentrations+in+Type+2+diabetic+patients+with+microalbuminuria+or+macroalbuminuria+&author=T+Nakamura&author=C+Ushiyama&author=S+Suzuki&author=N+Shimada&author=K+Sekizuka&author=L+Ebihara&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0117"> <div class="reference-title-banner"> <h4 class="title">Nakamura 2004 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0390"> <div class="citation-journal">Nakamura T, Matsuda T, Kawagoe Y, Ogawa H, Takahashi Y, Sekizuka K, et al. <span class="citation-title">Effect of pioglitazone on carotid intima‐media thickness and arterial stiffness in type 2 diabetic nephropathy patients</span>. <span class="citation"> Metabolism: Clinical &amp; Experimental </span><span class="pubYear">2004</span>;<span class="volume">53</span>(10):1382‐6. [MEDLINE: 15375799]<a class="crsref citation-link central-link" data-crsref="9141135" href="" ref="info:x-wiley/crsRef/9141135" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+pioglitazone+on+carotid+intima%E2%80%90media+thickness+and+arterial+stiffness+in+type+2+diabetic+nephropathy+patients+&author=T+Nakamura&author=T+Matsuda&author=Y+Kawagoe&author=H+Ogawa&author=Y+Takahashi&author=K+Sekizuka&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0118"> <div class="reference-title-banner"> <h4 class="title">Nakamura 2006a {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0391"> <div class="citation-journal">Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Koide H. <span class="citation-title">Effect of pioglitazone on urinary liver‐type fatty acid‐binding protein concentrations in diabetes patients with microalbuminuria</span>. <span class="citation"> Diabetes/Metabolism Research Reviews </span><span class="pubYear">2006</span>;<span class="volume">22</span>(5):385‐9. [MEDLINE: 16506273]<a class="crsref citation-link central-link" data-crsref="9141137" href="" ref="info:x-wiley/crsRef/9141137" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+pioglitazone+on+urinary+liver%E2%80%90type+fatty+acid%E2%80%90binding+protein+concentrations+in+diabetes+patients+with+microalbuminuria+&author=T+Nakamura&author=T+Sugaya&author=Y+Kawagoe&author=Y+Ueda&author=H+Koide&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0119"> <div class="reference-title-banner"> <h4 class="title">NCT00708981 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0392"> <div class="citation-other">Fogelfeld L, Stroger JH. <span class="citation-title">Combined diabetes‐renal multifactorial intervention in patients with advanced diabetic nephropathy (ADN)</span>. www.clinicaltrials.gov/ct2/show/NCT00708981 (first received 3 July 2008). <a class="crsref citation-link central-link" data-crsref="9141139" href="" ref="info:x-wiley/crsRef/9141139" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0120"> <div class="reference-title-banner"> <h4 class="title">NCT01245166 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0393"> <div class="citation-other">NCT01245166. <span class="citation-title">A phase III randomized, double‐blind, parallel‐group study to evaluate the efficacy and safety of acarmet (metformin HCl 500 mg plus acarbose 50 mg tablets) versus acarbose alone in subjects with type 2 diabetes mellitus</span>. www.clinicaltrials.gov/ct2/show/NCT01245166 (first received 22 November 2010). <a class="crsref citation-link central-link" data-crsref="9141141" href="" ref="info:x-wiley/crsRef/9141141" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0121"> <div class="reference-title-banner"> <h4 class="title">Nishimura 2015 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0394"> <div class="citation-journal">Jinnouchi H, Nozaki K, Watase H, Omiya H, Sakai S, Samukawa Y. <span class="citation-title">Impact of reduced renal function on the glucose‐lowering effects of luseogliflozin, a selective SGLT2 inhibitor, assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus</span>. <span class="citation"> Advances in Therapy </span><span class="pubYear">2016</span>;<span class="volume">33</span>(3):460‐79. [MEDLINE: 26846284]<a class="crsref citation-link central-link" data-crsref="9141143" href="" ref="info:x-wiley/crsRef/9141143" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26846284" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Impact+of+reduced+renal+function+on+the+glucose%E2%80%90lowering+effects+of+luseogliflozin,+a+selective+SGLT2+inhibitor,+assessed+by+continuous+glucose+monitoring+in+Japanese+patients+with+type+2+diabetes+mellitus+&author=H+Jinnouchi&author=K+Nozaki&author=H+Watase&author=H+Omiya&author=S+Sakai&author=Y+Samukawa&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0395"> <div class="citation-journal">Nishimura R, Osonoi T, Kanada S, Jinnouchi H, Sugio K, Omiya H, et al. <span class="citation-title">Effects of luseogliflozin, a sodium‐glucose co‐transporter 2 inhibitor, on 24‐h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double‐blind, placebo‐controlled, crossover study</span>. <span class="citation"> Diabetes, Obesity &amp; Metabolism </span><span class="pubYear">2015</span>;<span class="volume">17</span>(8):800‐4. [MEDLINE: 25930989]<a class="crsref citation-link central-link" data-crsref="9141144" href="" ref="info:x-wiley/crsRef/9141144" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25930989" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+luseogliflozin,+a+sodium%E2%80%90glucose+co%E2%80%90transporter+2+inhibitor,+on+24%E2%80%90h+glucose+variability+assessed+by+continuous+glucose+monitoring+in+Japanese+patients+with+type+2+diabetes+mellitus:+a+randomized,+double%E2%80%90blind,+placebo%E2%80%90controlled,+crossover+study+&author=R+Nishimura&author=T+Osonoi&author=S+Kanada&author=H+Jinnouchi&author=K+Sugio&author=H+Omiya&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0122"> <div class="reference-title-banner"> <h4 class="title">OSLO 1986 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0396"> <div class="citation-journal">Dahl‐Jorgensen K, Brinchmann‐Hansen O, Hanssen KF, Ganes T, Kierulf P, Smeland E, et al. <span class="citation-title">Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study</span>. <span class="citation"> British Medical Journal Clinical Research Ed </span><span class="pubYear">1986</span>;<span class="volume">293</span>(6556):1195‐9. [MEDLINE: 3096429]<a class="crsref citation-link central-link" data-crsref="9141146" href="" ref="info:x-wiley/crsRef/9141146" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/3096429" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+near+normoglycaemia+for+two+years+on+progression+of+early+diabetic+retinopathy,+nephropathy,+and+neuropathy:+the+Oslo+study+&author=K+Dahl%E2%80%90Jorgensen&author=O+Brinchmann%E2%80%90Hansen&author=KF+Hanssen&author=T+Ganes&author=P+Kierulf&author=E+Smeland&publication_year=1986&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0397"> <div class="citation-journal">Dahl‐Jorgensen K, Hanssen KF, Kierulf P, Bjoro T, Sandvik L, Aagenaes O. <span class="citation-title">Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin‐dependent diabetes mellitus. The Oslo Study</span>. <span class="citation"> Acta Endocrinologica </span><span class="pubYear">1988</span>;<span class="volume">117</span>(1):19‐25. [MEDLINE: 3289293]<a class="crsref citation-link central-link" data-crsref="9141147" href="" ref="info:x-wiley/crsRef/9141147" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/3289293" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Reduction+of+urinary+albumin+excretion+after+4+years+of+continuous+subcutaneous+insulin+infusion+in+insulin%E2%80%90dependent+diabetes+mellitus.+The+Oslo+Study+&author=K+Dahl%E2%80%90Jorgensen&author=KF+Hanssen&author=P+Kierulf&author=T+Bjoro&author=L+Sandvik&author=O+Aagenaes&publication_year=1988&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0123"> <div class="reference-title-banner"> <h4 class="title">Ostman 1998 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0398"> <div class="citation-journal">Ostman J, Asplund K, Bystedt T, Dahlof B, Jern S, Kjellstrom T, et al. <span class="citation-title">Comparison of effects of quinapril and metoprolol on glycaemic control, serum lipids, blood pressure, albuminuria and quality of life in non‐insulin‐dependent diabetes mellitus patients with hypertension. Swedish Quinapril Group</span>. <span class="citation"> Journal of Internal Medicine </span><span class="pubYear">1998</span>;<span class="volume">244</span>(2):95‐107. [MEDLINE: 10095796]<a class="crsref citation-link central-link" data-crsref="9141149" href="" ref="info:x-wiley/crsRef/9141149" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10095796" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparison+of+effects+of+quinapril+and+metoprolol+on+glycaemic+control,+serum+lipids,+blood+pressure,+albuminuria+and+quality+of+life+in+non%E2%80%90insulin%E2%80%90dependent+diabetes+mellitus+patients+with+hypertension.+Swedish+Quinapril+Group+&author=J+Ostman&author=K+Asplund&author=T+Bystedt&author=B+Dahlof&author=S+Jern&author=T+Kjellstrom&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0124"> <div class="reference-title-banner"> <h4 class="title">Pan 2012 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0399"> <div class="citation-journal">Pan CY, Yang W, Tou C, Gause‐Nilsson I, Zhao J. <span class="citation-title">Efficacy and safety of saxagliptin in drug‐naive Asian patients with type 2 diabetes mellitus: a randomized controlled trial</span>. <span class="citation"> Diabetes/Metabolism Research Reviews </span><span class="pubYear">2012</span>;<span class="volume">28</span>(3):268‐75. [MEDLINE: 22081481]<a class="crsref citation-link central-link" data-crsref="9141151" href="" ref="info:x-wiley/crsRef/9141151" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+saxagliptin+in+drug%E2%80%90naive+Asian+patients+with+type+2+diabetes+mellitus:+a+randomized+controlled+trial+&author=CY+Pan&author=W+Yang&author=C+Tou&author=I+Gause%E2%80%90Nilsson&author=J+Zhao&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0125"> <div class="reference-title-banner"> <h4 class="title">Petrica 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0400"> <div class="citation-journal">Petrica L, Petrica M, Vlad A, Dragos Jianu C, Gluhovschi G, Ianculescu C, et al. <span class="citation-title">Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial</span>. <span class="citation"> Wiener Klinische Wochenschrift </span><span class="pubYear">2009</span>;<span class="volume">121</span>(23‐24):765‐75. [MEDLINE: 20047115]<a class="crsref citation-link central-link" data-crsref="9141153" href="" ref="info:x-wiley/crsRef/9141153" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20047115" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Nephro%E2%80%90+and+neuroprotective+effects+of+rosiglitazone+versus+glimepiride+in+normoalbuminuric+patients+with+type+2+diabetes+mellitus:+a+randomized+controlled+trial+&author=L+Petrica&author=M+Petrica&author=A+Vlad&author=C+DragosJianu&author=G+Gluhovschi&author=C+Ianculescu&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0126"> <div class="reference-title-banner"> <h4 class="title">Pistrosch 2004 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0401"> <div class="citation-journal">Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. <span class="citation-title">In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2004</span>;<span class="volume">27</span>(2):484‐90. [MEDLINE: 14747233]<a class="crsref citation-link central-link" data-crsref="9141155" href="" ref="info:x-wiley/crsRef/9141155" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/14747233" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=In+type+2+diabetes,+rosiglitazone+therapy+for+insulin+resistance+ameliorates+endothelial+dysfunction+independent+of+glucose+control+&author=F+Pistrosch&author=J+Passauer&author=S+Fischer&author=K+Fuecker&author=M+Hanefeld&author=P+Gross&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0127"> <div class="reference-title-banner"> <h4 class="title">Pistrosch 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0402"> <div class="citation-journal">Pistrosch F, Herbrig K, Kindel B, Passauer J, Fischer S, Gross P. <span class="citation-title">Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients</span>. <span class="citation"> Diabetes </span><span class="pubYear">2005</span>;<span class="volume">54</span>(7):2206‐11. [MEDLINE: 15983223]<a class="crsref citation-link central-link" data-crsref="9141157" href="" ref="info:x-wiley/crsRef/9141157" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15983223" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rosiglitazone+improves+glomerular+hyperfiltration,+renal+endothelial+dysfunction,+and+microalbuminuria+of+incipient+diabetic+nephropathy+in+patients+&author=F+Pistrosch&author=K+Herbrig&author=B+Kindel&author=J+Passauer&author=S+Fischer&author=P+Gross&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0128"> <div class="reference-title-banner"> <h4 class="title">Pistrosch 2012 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0403"> <div class="citation-journal">Pistrosch F, Passauer J, Herbrig K, Schwanebeck U, Gross P, Bornstein SR. <span class="citation-title">Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy</span>. <span class="citation"> Hormone &amp; Metabolic Research </span><span class="pubYear">2012</span>;<span class="volume">44</span>(12):914‐8. [MEDLINE: 22723267]<a class="crsref citation-link central-link" data-crsref="9141159" href="" ref="info:x-wiley/crsRef/9141159" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+thiazolidinedione+treatment+on+proteinuria+and+renal+hemodynamic+in+type+2+diabetic+patients+with+overt+nephropathy+&author=F+Pistrosch&author=J+Passauer&author=K+Herbrig&author=U+Schwanebeck&author=P+Gross&author=SR+Bornstein&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0129"> <div class="reference-title-banner"> <h4 class="title">PIVIT 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0404"> <div class="citation-journal">Weinrauch LA, Sun J, Gleason RE, Boden GH, Creech RH, Dailey G, et al. <span class="citation-title">Pulsatile intermittent intravenous insulin therapy for attenuation of retinopathy and nephropathy in type 1 diabetes mellitus</span>. <span class="citation"> Metabolism: Clinical &amp; Experimental </span><span class="pubYear">2010</span>;<span class="volume">59</span>(10):1429‐34. [MEDLINE: 20189608]<a class="crsref citation-link central-link" data-crsref="9141161" href="" ref="info:x-wiley/crsRef/9141161" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pulsatile+intermittent+intravenous+insulin+therapy+for+attenuation+of+retinopathy+and+nephropathy+in+type+1+diabetes+mellitus+&author=LA+Weinrauch&author=J+Sun&author=RE+Gleason&author=GH+Boden&author=RH+Creech&author=G+Dailey&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0130"> <div class="reference-title-banner"> <h4 class="title">Pomerleau 1993 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0405"> <div class="citation-journal">Pomerleau J, Verdy M, Garrel DR, Nadeau MH. <span class="citation-title">Effect of protein intake on glycaemic control and renal function in type 2 (non‐insulin‐dependent) diabetes mellitus</span>. <span class="citation"> Diabetologia </span><span class="pubYear">1993</span>;<span class="volume">36</span>(9):829‐34. [MEDLINE: 8405754]<a class="crsref citation-link central-link" data-crsref="9141163" href="" ref="info:x-wiley/crsRef/9141163" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8405754" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+protein+intake+on+glycaemic+control+and+renal+function+in+type+2+(non%E2%80%90insulin%E2%80%90dependent)+diabetes+mellitus+&author=J+Pomerleau&author=M+Verdy&author=DR+Garrel&author=MH+Nadeau&publication_year=1993&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0131"> <div class="reference-title-banner"> <h4 class="title">QUARTET 2004 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0406"> <div class="citation-journal">Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, et al. <span class="citation-title">Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2005</span>;<span class="volume">48</span>(6):1093‐104. [MEDLINE: 15889234]<a class="crsref citation-link central-link" data-crsref="9141165" href="" ref="info:x-wiley/crsRef/9141165" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15889234" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+efficacy+and+tolerability+of+add%E2%80%90on+pioglitazone+therapy+to+failing+monotherapy+compared+with+addition+of+gliclazide+or+metformin+in+patients+with+type+2+diabetes+&author=B+Charbonnel&author=G+Schernthaner&author=P+Brunetti&author=DR+Matthews&author=R+Urquhart&author=MH+Tan&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0407"> <div class="citation-journal">Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P, QUARTET Study Group. <span class="citation-title">A long‐term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double‐blind, parallel‐group comparison trial</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2005</span>;<span class="volume">22</span>(4):399‐405. [MEDLINE: 15787663]<a class="crsref citation-link central-link" data-crsref="9141166" href="" ref="info:x-wiley/crsRef/9141166" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15787663" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+long%E2%80%90term+comparison+of+pioglitazone+and+gliclazide+in+patients+with+Type+2+diabetes+mellitus:+a+randomized,+double%E2%80%90blind,+parallel%E2%80%90group+comparison+trial+&author=BH+Charbonnel&author=DR+Matthews&author=G+Schernthaner&author=M+Hanefeld&author=P+Brunetti&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0408"> <div class="citation-journal">Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH, QUARTET Study Group. <span class="citation-title">One‐year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2004</span>;<span class="volume">27</span>(1):141‐7. [MEDLINE: 14693980]<a class="crsref citation-link central-link" data-crsref="9141167" href="" ref="info:x-wiley/crsRef/9141167" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/14693980" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=One%E2%80%90year+glycemic+control+with+a+sulfonylurea+plus+pioglitazone+versus+a+sulfonylurea+plus+metformin+in+patients+with+type+2+diabetes+&author=M+Hanefeld&author=P+Brunetti&author=GH+Schernthaner&author=DR+Matthews&author=BH+Charbonnel&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0409"> <div class="citation-journal">Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P, Quartet [corrected] Study Group. <span class="citation-title">Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double‐blind, randomized trial.[Erratum appears in J Clin Endocrinol Metab. 2005 Feb;90(2):746]</span>. <span class="citation"> Journal of Clinical Endocrinology &amp; Metabolism </span><span class="pubYear">2004</span>;<span class="volume">89</span>(12):6068‐76. [MEDLINE: 15579760]<a class="crsref citation-link central-link" data-crsref="9141168" href="" ref="info:x-wiley/crsRef/9141168" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+pioglitazone+versus+metformin+in+patients+with+type+2+diabetes+mellitus:+a+double%E2%80%90blind,+randomized+trial.[Erratum+appears+in+J+Clin+Endocrinol+Metab.+2005+Feb;90(2):746]+&author=G+Schernthaner&author=DR+Matthews&author=B+Charbonnel&author=M+Hanefeld&author=P+Brunetti&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0132"> <div class="reference-title-banner"> <h4 class="title">Reinhard 2013 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0410"> <div class="citation-journal">Reinhard M, Frystyk J, Jespersen B, Bjerre M, Christiansen JS, Flyvbjerg A, et al. <span class="citation-title">Effect of hyperinsulinemia during hemodialysis on the insulin‐like growth factor system and inflammatory biomarkers: a randomized open‐label crossover study</span>. <span class="citation"> BMC Nephrology </span><span class="pubYear">2013</span>;<span class="volume">14</span>:80. [MEDLINE: 23557110]<a class="crsref citation-link central-link" data-crsref="9141170" href="" ref="info:x-wiley/crsRef/9141170" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23557110" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+hyperinsulinemia+during+hemodialysis+on+the+insulin%E2%80%90like+growth+factor+system+and+inflammatory+biomarkers:+a+randomized+open%E2%80%90label+crossover+study+&author=M+Reinhard&author=J+Frystyk&author=B+Jespersen&author=M+Bjerre&author=JS+Christiansen&author=A+Flyvbjerg&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0133"> <div class="reference-title-banner"> <h4 class="title">Rosenstock 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0411"> <div class="citation-journal">Rosenstock J, Aguilar‐Salinas C, Klein E, Nepal S, List J, Chen R, et al. <span class="citation-title">Effect of saxagliptin monotherapy in treatment‐naive patients with type 2 diabetes</span>. <span class="citation"> Current Medical Research &amp; Opinion </span><span class="pubYear">2009</span>;<span class="volume">25</span>(10):2401‐11. [MEDLINE: 19650754]<a class="crsref citation-link central-link" data-crsref="9141172" href="" ref="info:x-wiley/crsRef/9141172" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+saxagliptin+monotherapy+in+treatment%E2%80%90naive+patients+with+type+2+diabetes&author=J+Rosenstock&author=C+Aguilar%E2%80%90Salinas&author=E+Klein&author=S+Nepal&author=J+List&author=R+Chen&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0134"> <div class="reference-title-banner"> <h4 class="title">SDIS 1988 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0412"> <div class="citation-journal">Jensen‐Urstad K, Reichard P, Jensen‐Urstad M. <span class="citation-title">Decreased heart rate variability in patients with type 1 diabetes mellitus is related to arterial wall stiffness</span>. <span class="citation"> Journal of Internal Medicine </span><span class="pubYear">1999</span>;<span class="volume">245</span>(1):57‐61. [MEDLINE: 10095817]<a class="crsref citation-link central-link" data-crsref="9141174" href="" ref="info:x-wiley/crsRef/9141174" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10095817" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Decreased+heart+rate+variability+in+patients+with+type+1+diabetes+mellitus+is+related+to+arterial+wall+stiffness+&author=K+Jensen%E2%80%90Urstad&author=P+Reichard&author=M+Jensen%E2%80%90Urstad&publication_year=1999&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0413"> <div class="citation-journal">Johansson J, Reichard P, Jensen‐Urstad K, Rosfors S, Jensen‐Urstad M. <span class="citation-title">Influence of glucose control, lipoproteins, and haemostasis function on brachial endothelial reactivity and carotid intima‐media area, stiffness and diameter in Type 1 diabetes mellitus patients</span>. <span class="citation"> European Journal of Clinical Investigation </span><span class="pubYear">2003</span>;<span class="volume">33</span>(6):472‐9. [MEDLINE: 12795643]<a class="crsref citation-link central-link" data-crsref="9141175" href="" ref="info:x-wiley/crsRef/9141175" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12795643" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Influence+of+glucose+control,+lipoproteins,+and+haemostasis+function+on+brachial+endothelial+reactivity+and+carotid+intima%E2%80%90media+area,+stiffness+and+diameter+in+Type+1+diabetes+mellitus+patients+&author=J+Johansson&author=P+Reichard&author=K+Jensen%E2%80%90Urstad&author=S+Rosfors&author=M+Jensen%E2%80%90Urstad&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0414"> <div class="citation-journal">Rathsman B, Jensen‐Urstad K, Nystrom T. <span class="citation-title">Intensified insulin treatment is associated with improvement in skin microcirculation and ischaemic foot ulcer in patients with type 1 diabetes mellitus: a long‐term follow‐up study</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2014</span>;<span class="volume">57</span>(8):1703‐10. [MEDLINE: 24802206]<a class="crsref citation-link central-link" data-crsref="9141176" href="" ref="info:x-wiley/crsRef/9141176" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24802206" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensified+insulin+treatment+is+associated+with+improvement+in+skin+microcirculation+and+ischaemic+foot+ulcer+in+patients+with+type+1+diabetes+mellitus:+a+long%E2%80%90term+follow%E2%80%90up+study+&author=B+Rathsman&author=K+Jensen%E2%80%90Urstad&author=T+Nystrom&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0424"> <div class="citation-journal">Reichard P. <span class="citation-title">Risk factors for progression of microvascular complications in the Stockholm Diabetes Intervention Study (SDIS)</span>. <span class="citation"> Diabetes Research &amp; Clinical Practice </span><span class="pubYear">1992</span>;<span class="volume">16</span>(2):151‐6. [MEDLINE: 1600854]<a class="crsref citation-link central-link" data-crsref="9141186" href="" ref="info:x-wiley/crsRef/9141186" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Risk+factors+for+progression+of+microvascular+complications+in+the+Stockholm+Diabetes+Intervention+Study+(SDIS)+&author=P+Reichard&publication_year=1992&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0415"> <div class="citation-journal">Reichard P, Berglund B, Britz A, Cars I, Nilsson BY, Rosenqvist U. <span class="citation-title">Intensified conventional insulin treatment retards the microvascular complications of insulin‐dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years</span>. <span class="citation"> Journal of Internal Medicine </span><span class="pubYear">1991</span>;<span class="volume">230</span>(2):101‐8. [MEDLINE: 1865159]<a class="crsref citation-link central-link" data-crsref="9141177" href="" ref="info:x-wiley/crsRef/9141177" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/1865159" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensified+conventional+insulin+treatment+retards+the+microvascular+complications+of+insulin%E2%80%90dependent+diabetes+mellitus+(IDDM):+the+Stockholm+Diabetes+Intervention+Study+(SDIS)+after+5+years+&author=P+Reichard&author=B+Berglund&author=A+Britz&author=I+Cars&author=BY+Nilsson&author=U+Rosenqvist&publication_year=1991&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0416"> <div class="citation-journal">Reichard P, Britz A, Carlsson P, Cars I, Lindblad L, Nilsson BY, et al. <span class="citation-title">Metabolic control and complications over 3 years in patients with insulin dependent diabetes (IDDM): the Stockholm Diabetes Intervention Study (SDIS)</span>. <span class="citation"> Journal of Internal Medicine </span><span class="pubYear">1990</span>;<span class="volume">228</span>(5):511‐7. [MEDLINE: 2254723]<a class="crsref citation-link central-link" data-crsref="9141178" href="" ref="info:x-wiley/crsRef/9141178" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2254723" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Metabolic+control+and+complications+over+3+years+in+patients+with+insulin+dependent+diabetes+(IDDM):+the+Stockholm+Diabetes+Intervention+Study+(SDIS)+&author=P+Reichard&author=A+Britz&author=P+Carlsson&author=I+Cars&author=L+Lindblad&author=BY+Nilsson&publication_year=1990&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0417"> <div class="citation-journal">Reichard P, Britz A, Cars I, Nilsson BY, Sobocinsky‐Olsson B, Rosenqvist U. <span class="citation-title">The Stockholm Diabetes Intervention Study (SDIS): 18 months' results</span>. <span class="citation"> Acta Medica Scandinavica </span><span class="pubYear">1988</span>;<span class="volume">224</span>(2):115‐22. [MEDLINE: 3048052]<a class="crsref citation-link central-link" data-crsref="9141179" href="" ref="info:x-wiley/crsRef/9141179" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/3048052" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+Stockholm+Diabetes+Intervention+Study+(SDIS):+18+months'+results&author=P+Reichard&author=A+Britz&author=I+Cars&author=BY+Nilsson&author=B+Sobocinsky‐Olsson&author=U+Rosenqvist&publication_year=1988&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0418"> <div class="citation-journal">Reichard P, Jensen‐Urstad K, Ericsson M, Jensen‐Urstad M, Lindblad LE. <span class="citation-title">Autonomic neuropathy‐‐a complication less pronounced in patients with Type 1 diabetes mellitus who have lower blood glucose levels</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2000</span>;<span class="volume">17</span>(12):860‐6. [MEDLINE: 11168329]<a class="crsref citation-link central-link" data-crsref="9141180" href="" ref="info:x-wiley/crsRef/9141180" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11168329" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Autonomic+neuropathy%E2%80%90%E2%80%90a+complication+less+pronounced+in+patients+with+Type+1+diabetes+mellitus+who+have+lower+blood+glucose+levels+&author=P+Reichard&author=K+Jensen%E2%80%90Urstad&author=M+Ericsson&author=M+Jensen%E2%80%90Urstad&author=LE+Lindblad&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0419"> <div class="citation-journal">Reichard P, Nilsson BY, Rosenqvist U. <span class="citation-title">The effect of long‐term intensified insulin treatment on the development of microvascular complications of diabetes mellitus</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">1993</span>;<span class="volume">329</span>(5):304‐9. [MEDLINE: 8147960]<a class="crsref citation-link central-link" data-crsref="9141181" href="" ref="info:x-wiley/crsRef/9141181" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8147960" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+effect+of+long%E2%80%90term+intensified+insulin+treatment+on+the+development+of+microvascular+complications+of+diabetes+mellitus+&author=P+Reichard&author=BY+Nilsson&author=U+Rosenqvist&publication_year=1993&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0421"> <div class="citation-journal">Reichard P, Pihl M. <span class="citation-title">Mortality and treatment side‐effects during long‐term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study</span>. <span class="citation"> Diabetes </span><span class="pubYear">1994</span>;<span class="volume">43</span>(2):313‐7. [MEDLINE: 8288056]<a class="crsref citation-link central-link" data-crsref="9141183" href="" ref="info:x-wiley/crsRef/9141183" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8288056" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Mortality+and+treatment+side%E2%80%90effects+during+long%E2%80%90term+intensified+conventional+insulin+treatment+in+the+Stockholm+Diabetes+Intervention+Study+&author=P+Reichard&author=M+Pihl&publication_year=1994&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0420"> <div class="citation-journal">Reichard P, Pihl M, Rosenqvist U, Sule J. <span class="citation-title">Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10‐year follow up</span>. <span class="citation"> Diabetologia </span><span class="pubYear">1996</span>;<span class="volume">39</span>(12):1483‐8. [MEDLINE: 8960830]<a class="crsref citation-link central-link" data-crsref="9141182" href="" ref="info:x-wiley/crsRef/9141182" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8960830" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Complications+in+IDDM+are+caused+by+elevated+blood+glucose+level:+the+Stockholm+Diabetes+Intervention+Study+(SDIS)+at+10%E2%80%90year+follow+up+&author=P+Reichard&author=M+Pihl&author=U+Rosenqvist&author=J+Sule&publication_year=1996&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0422"> <div class="citation-journal">Reichard P, Rosenqvist U. <span class="citation-title">Nephropathy is delayed by intensified insulin treatment in patients with insulin‐dependent diabetes mellitus and retinopathy</span>. <span class="citation"> Journal of Internal Medicine </span><span class="pubYear">1989</span>;<span class="volume">226</span>(2):81‐7. [MEDLINE: 2671247]<a class="crsref citation-link central-link" data-crsref="9141184" href="" ref="info:x-wiley/crsRef/9141184" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2671247" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Nephropathy+is+delayed+by+intensified+insulin+treatment+in+patients+with+insulin%E2%80%90dependent+diabetes+mellitus+and+retinopathy+&author=P+Reichard&author=U+Rosenqvist&publication_year=1989&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0423"> <div class="citation-journal">Reichard P, Toomingas B, Rosenqvist U. <span class="citation-title">Changes in conceptions and attitudes during five years of intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study (SDIS)</span>. <span class="citation"> Diabetes Educator </span><span class="pubYear">1994</span>;<span class="volume">20</span>(6):503‐8. [MEDLINE: 7851263]<a class="crsref citation-link central-link" data-crsref="9141185" href="" ref="info:x-wiley/crsRef/9141185" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/7851263" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Changes+in+conceptions+and+attitudes+during+five+years+of+intensified+conventional+insulin+treatment+in+the+Stockholm+Diabetes+Intervention+Study+(SDIS)+&author=P+Reichard&author=B+Toomingas&author=U+Rosenqvist&publication_year=1994&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0135"> <div class="reference-title-banner"> <h4 class="title">Seino 2015 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0425"> <div class="citation-journal">Seino Y, Inagaki N, Haneda M, Kaku K, Sasaki T, Fukatsu A, et al. <span class="citation-title">Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus</span>. <span class="citation"> Journal of Diabetes Investigation </span><span class="pubYear">2015</span>;<span class="volume">6</span>(4):443‐53. [MEDLINE: 26221523]<a class="crsref citation-link central-link" data-crsref="9141188" href="" ref="info:x-wiley/crsRef/9141188" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26221523" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+luseogliflozin+added+to+various+oral+antidiabetic+drugs+in+Japanese+patients+with+type+2+diabetes+mellitus+&author=Y+Seino&author=N+Inagaki&author=M+Haneda&author=K+Kaku&author=T+Sasaki&author=A+Fukatsu&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0136"> <div class="reference-title-banner"> <h4 class="title">SESTA R 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0426"> <div class="citation-journal">Herz M, Gaspari F, Perico N, Viberti G, Urbanowska T, Rabbia M, et al. <span class="citation-title">Effects of high dose aleglitazar on renal function in patients with type 2 diabetes</span>. <span class="citation"> International Journal of Cardiology </span><span class="pubYear">2011</span>;<span class="volume">151</span>(2):136‐42. [MEDLINE: 20837369]<a class="crsref citation-link central-link" data-crsref="9141190" href="" ref="info:x-wiley/crsRef/9141190" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20837369" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+high+dose+aleglitazar+on+renal+function+in+patients+with+type+2+diabetes&author=M+Herz&author=F+Gaspari&author=N+Perico&author=G+Viberti&author=T+Urbanowska&author=M+Rabbia&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0137"> <div class="reference-title-banner"> <h4 class="title">Shata'er 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0427"> <div class="citation-journal">Shata'er R. <span class="citation-title">Rosiglitazone in urinary protein of diabetic nephropathy</span>. <span class="citation"> Chinese Medicine Clinical Research ‐ Chinese Magazine of Clinical Medicinal Professional Research </span><span class="pubYear">2007</span>;<span class="volume">13</span>(15):2162‐3. [CENTRAL: CN‐00784163]<a class="crsref citation-link central-link" data-crsref="9141192" href="" ref="info:x-wiley/crsRef/9141192" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rosiglitazone+in+urinary+protein+of+diabetic+nephropathy&author=R+Shata'er&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0138"> <div class="reference-title-banner"> <h4 class="title">SPEAD‐A 2013 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0428"> <div class="citation-journal">Katakami N, Mita T, Yoshii H, Onuma T, Kaneto H, Osonoi T, et al. <span class="citation-title">Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP‐4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD‐A)</span>. <span class="citation"> Journal of Atherosclerosis &amp; Thrombosis </span><span class="pubYear">2013</span>;<span class="volume">20</span>(12):893‐902. [MEDLINE: 23965491]<a class="crsref citation-link central-link" data-crsref="9141194" href="" ref="info:x-wiley/crsRef/9141194" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rationale,+design,+and+baseline+characteristics+of+a+trial+for+the+prevention+of+diabetic+atherosclerosis+using+a+DPP%E2%80%904+inhibitor:+the+Study+of+Preventive+Effects+of+Alogliptin+on+Diabetic+Atherosclerosis+(SPEAD%E2%80%90A)+&author=N+Katakami&author=T+Mita&author=H+Yoshii&author=T+Onuma&author=H+Kaneto&author=T+Osonoi&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0139"> <div class="reference-title-banner"> <h4 class="title">Stein 2014 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0429"> <div class="citation-journal">Stein P, Berg JK, Morrow L, Polidori D, Artis E, Rusch S, et al. <span class="citation-title">Canagliflozin, a sodium glucose co‐transporter 2 inhibitor, reduces post‐meal glucose excursion in patients with type 2 diabetes by a non‐renal mechanism: results of a randomized trial</span>. <span class="citation"> Metabolism: Clinical &amp; Experimental </span><span class="pubYear">2014</span>;<span class="volume">63</span>(10):1296‐303. [MEDLINE: 25110280]<a class="crsref citation-link central-link" data-crsref="9141196" href="" ref="info:x-wiley/crsRef/9141196" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Canagliflozin,+a+sodium+glucose+co%E2%80%90transporter+2+inhibitor,+reduces+post%E2%80%90meal+glucose+excursion+in+patients+with+type+2+diabetes+by+a+non%E2%80%90renal+mechanism:+results+of+a+randomized+trial+&author=P+Stein&author=JK+Berg&author=L+Morrow&author=D+Polidori&author=E+Artis&author=S+Rusch&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0140"> <div class="reference-title-banner"> <h4 class="title">STENO‐2 1999 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0430"> <div class="citation-journal">Gaede P, Lund‐Andersen H, Parving HH, Pedersen O. <span class="citation-title">Effect of a multifactorial intervention on mortality in type 2 diabetes</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2008</span>;<span class="volume">358</span>(6):580‐91. [MEDLINE: 18256393]<a class="crsref citation-link central-link" data-crsref="9141198" href="" ref="info:x-wiley/crsRef/9141198" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18256393" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+a+multifactorial+intervention+on+mortality+in+type+2+diabetes&author=P+Gaede&author=H+Lund%E2%80%90Andersen&author=HH+Parving&author=O+Pedersen&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0431"> <div class="citation-journal">Gaede P, Parving H, Pedersen O. <span class="citation-title">Multifactorial intervention in patients with type 2 diabetes: long‐term effects on mortality and vascular complications [abstract no: SA‐FC042]</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">2007</span>;<span class="volume">18</span>(Abstracts):43A. [CENTRAL: CN‐00740461]<a class="crsref citation-link central-link" data-crsref="9141199" href="" ref="info:x-wiley/crsRef/9141199" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Multifactorial+intervention+in+patients+with+type+2+diabetes:+long%E2%80%90term+effects+on+mortality+and+vascular+complications+[abstract+no:+SA%E2%80%90FC042]+&author=P+Gaede&author=H+Parving&author=O+Pedersen&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0432"> <div class="citation-journal">Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, et al. <span class="citation-title">Cost‐effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno‐2 study</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2008</span>;<span class="volume">31</span>(8):1510‐5. [MEDLINE: 18443195]<a class="crsref citation-link central-link" data-crsref="9141200" href="" ref="info:x-wiley/crsRef/9141200" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18443195" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cost%E2%80%90effectiveness+of+intensified+versus+conventional+multifactorial+intervention+in+type+2+diabetes:+results+and+projections+from+the+Steno%E2%80%902+study+&author=P+Gaede&author=WJ+Valentine&author=AJ+Palmer&author=DM+Tucker&author=M+Lammert&author=HH+Parving&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0433"> <div class="citation-journal">Gaede P, Vedel P, Larsen N, Jensen G, Parving HH, Pedersen O. <span class="citation-title">The STENO‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: F‐FC031]</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">2002</span>;<span class="volume">13</span>(September, Program &amp; Abstracts):72A. [CENTRAL: CN‐00445410]<a class="crsref citation-link central-link" data-crsref="9141201" href="" ref="info:x-wiley/crsRef/9141201" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+STENO%E2%80%902+study:+intensified+multifactorial+intervention+reduces+the+risk+of+cardiovascular+disease+in+patients+with+type+2+diabetes+and+microalbuminuria+[abstract+no:+F%E2%80%90FC031]+&author=P+Gaede&author=P+Vedel&author=N+Larsen&author=G+Jensen&author=HH+Parving&author=O+Pedersen&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0434"> <div class="citation-other">Gaede P, Vedel P, Larsen N, Jensen G, Parving HH, Pedersen O. <span class="citation-title">The Steno‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with Type 2 diabetes and microalbuminuria [abstract no: 181]</span>. 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2002 Sep 1‐5; Budapest, Hungary. <span class="pubYear">2002</span>. <a class="crsref citation-link central-link" data-crsref="9141202" href="" ref="info:x-wiley/crsRef/9141202" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+Steno%E2%80%902+study:+intensified+multifactorial+intervention+reduces+the+risk+of+cardiovascular+disease+in+patients+with+Type+2+diabetes+and+microalbuminuria+[abstract+no:+181]+&author=P+Gaede&author=P+Vedel&author=N+Larsen&author=G+Jensen&author=HH+Parving&author=O+Pedersen&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0435"> <div class="citation-journal">Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. <span class="citation-title">Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2003</span>;<span class="volume">348</span>(5):383‐93. [MEDLINE: 12556541]<a class="crsref citation-link central-link" data-crsref="9141203" href="" ref="info:x-wiley/crsRef/9141203" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12556541" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Multifactorial+intervention+and+cardiovascular+disease+in+patients+with+type+2+diabetes&author=P+Gaede&author=P+Vedel&author=N+Larsen&author=GV+Jensen&author=HH+Parving&author=O+Pedersen&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0436"> <div class="citation-journal">Gaede P, Vedel P, Obel J, Parving HH, Pedersen O. <span class="citation-title">Intensive multifactorial intervention in NIDDM patients with persistent microalbuminuria [abstract]</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">1996</span>;<span class="volume">7</span>(9):1357. [CENTRAL: CN‐00445411]<a class="crsref citation-link central-link" data-crsref="9141204" href="" ref="info:x-wiley/crsRef/9141204" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensive+multifactorial+intervention+in+NIDDM+patients+with+persistent+microalbuminuria+[abstract]+&author=P+Gaede&author=P+Vedel&author=J+Obel&author=HH+Parving&author=O+Pedersen&publication_year=1996&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0437"> <div class="citation-journal">Gaede P, Vedel P, Parving HH, Pedersen O. <span class="citation-title">Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study</span>. <span class="citation"> Lancet </span><span class="pubYear">1999</span>;<span class="volume">353</span>(9153):617‐22. [MEDLINE: 10030326]<a class="crsref citation-link central-link" data-crsref="9141205" href="" ref="info:x-wiley/crsRef/9141205" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10030326" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensified+multifactorial+intervention+in+patients+with+type+2+diabetes+mellitus+and+microalbuminuria:+the+Steno+type+2+randomised+study+&author=P+Gaede&author=P+Vedel&author=HH+Parving&author=O+Pedersen&publication_year=1999&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0438"> <div class="citation-journal">Gaede PH, Jepsen PV, Parving HH, Pedersen OB. <span class="citation-title">Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno‐2 study</span> [Intensiveret multifaktoriel intervention hos patienter med type 2‐diabetes mellitus og mikroalbuminuri: Steno‐2‐studiet]. <span class="citation"> Ugeskrift for Laeger </span><span class="pubYear">1999</span>;<span class="volume">161</span>(30):4277‐85. [MEDLINE: 10439688]<a class="crsref citation-link central-link" data-crsref="9141206" href="" ref="info:x-wiley/crsRef/9141206" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10439688" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensified+multifactorial+intervention+in+patients+with+type+2+diabetes+mellitus+and+microalbuminuria:+the+Steno%E2%80%902+study+&author=PH+Gaede&author=PV+Jepsen&author=HH+Parving&author=OB+Pedersen&publication_year=1999&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0439"> <div class="citation-journal">Oellgaard J, Gaede P, Rossing P, Persson F, Parving HH, Pedersen O. <span class="citation-title">Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long‐term renal benefits Kidney Int. 2017;91:982‐988.[Erratum appears in Kidney Int. 2017 May;91(5):1257; PMID: 28407880]</span>. <span class="citation"> Kidney International </span><span class="pubYear">2017</span>;<span class="volume">91</span>(4):982‐8. [MEDLINE: 28187983]<a class="crsref citation-link central-link" data-crsref="9141207" href="" ref="info:x-wiley/crsRef/9141207" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/28187983" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensified+multifactorial+intervention+in+type+2+diabetics+with+microalbuminuria+leads+to+long%E2%80%90term+renal+benefits+Kidney+Int.+2017;91:982%E2%80%90988.[Erratum+appears+in+Kidney+Int.+2017+May;91(5):1257;+PMID:+28407880]+&author=J+Oellgaard&author=P+Gaede&author=P+Rossing&author=F+Persson&author=HH+Parving&author=O+Pedersen&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0141"> <div class="reference-title-banner"> <h4 class="title">Strojek 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0440"> <div class="citation-journal">Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. <span class="citation-title">Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trial</span>. <span class="citation"> Diabetes, Obesity &amp; Metabolism </span><span class="pubYear">2011</span>;<span class="volume">13</span>(10):928‐38. [MEDLINE: 21672123]<a class="crsref citation-link central-link" data-crsref="9141209" href="" ref="info:x-wiley/crsRef/9141209" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21672123" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+dapagliflozin+in+patients+with+type+2+diabetes+who+have+inadequate+glycaemic+control+with+glimepiride:+a+randomized,+24%E2%80%90week,+double%E2%80%90blind,+placebo%E2%80%90controlled+trial+&author=K+Strojek&author=KH+Yoon&author=V+Hruba&author=M+Elze&author=AM+Langkilde&author=S+Parikh&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0142"> <div class="reference-title-banner"> <h4 class="title">Su 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0441"> <div class="citation-journal">Su RT, Hang XJ. <span class="citation-title">Pioglitazone affects the urinary protein extracting rate in early diabetic nephropathy</span>. <span class="citation"> Youjiang Medical Journal </span><span class="pubYear">2006</span>;<span class="volume">34</span>(6):593‐4. [CENTRAL: CN‐00783868]<a class="crsref citation-link central-link" data-crsref="9141211" href="" ref="info:x-wiley/crsRef/9141211" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone+affects+the+urinary+protein+extracting+rate+in+early+diabetic+nephropathy&author=RT+Su&author=XJ+Hang&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0143"> <div class="reference-title-banner"> <h4 class="title">Sun 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0442"> <div class="citation-journal">Sun Z, Ren X, Jin H, Gong Y, Li l, Zhang L. <span class="citation-title">Effect of pioglitazone on serum advanced glycosylation end product peptide and monocyte chemoattractant protein‐1 in type 2 diabetic patients</span>. <span class="citation"> Jiangsu Medical Journal </span><span class="pubYear">2006</span>;<span class="volume">32</span>(2):101‐3. [CENTRAL: CN‐00783008]<a class="crsref citation-link central-link" data-crsref="9141213" href="" ref="info:x-wiley/crsRef/9141213" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+pioglitazone+on+serum+advanced+glycosylation+end+product+peptide+and+monocyte+chemoattractant+protein%E2%80%901+in+type+2+diabetic+patients+&author=Z+Sun&author=X+Ren&author=H+Jin&author=Y+Gong&author=l+Li&author=L+Zhang&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0144"> <div class="reference-title-banner"> <h4 class="title">Tan 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0443"> <div class="citation-journal">Tan YH, Zheng W. <span class="citation-title">Observation of therapeutic effect of rosiglitazone in type 2 diabetes with nephropathy</span>. <span class="citation"> Journal of Modern Clinical Medical Bioengineering </span><span class="pubYear">2006</span>;<span class="volume">12</span>(2):176‐8. [CENTRAL: CN‐00783732]<a class="crsref citation-link central-link" data-crsref="9141215" href="" ref="info:x-wiley/crsRef/9141215" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Observation+of+therapeutic+effect+of+rosiglitazone+in+type+2+diabetes+with+nephropathy&author=YH+Tan&author=W+Zheng&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0145"> <div class="reference-title-banner"> <h4 class="title">Tang 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0444"> <div class="citation-journal">Tang GJ, Zhu GD, Xie NR. <span class="citation-title">Treatment effect of rosiglitazone in type 2 diabetic nephropathy</span>. <span class="citation"> Clinical Medicine </span><span class="pubYear">2007</span>;<span class="volume">27</span>(7):47‐8. [CENTRAL: CN‐00784585]<a class="crsref citation-link central-link" data-crsref="9141217" href="" ref="info:x-wiley/crsRef/9141217" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Treatment+effect+of+rosiglitazone+in+type+2+diabetic+nephropathy&author=GJ+Tang&author=GD+Zhu&author=NR+Xie&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0146"> <div class="reference-title-banner"> <h4 class="title">Thrasher 2012 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0445"> <div class="citation-journal">Thrasher J, Daniels K, Patel S, Whetteckey J. <span class="citation-title">Black/African American patients with type 2 diabetes mellitus: study design and baseline patient characteristics from a randomized clinical trial of linagliptin</span>. <span class="citation"> Expert Opinion on Pharmacotherapy </span><span class="pubYear">2012</span>;<span class="volume">13</span>(17):2443‐52. [MEDLINE: 23134211]<a class="crsref citation-link central-link" data-crsref="9141219" href="" ref="info:x-wiley/crsRef/9141219" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23134211" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Black/African+American+patients+with+type+2+diabetes+mellitus:+study+design+and+baseline+patient+characteristics+from+a+randomized+clinical+trial+of+linagliptin+&author=J+Thrasher&author=K+Daniels&author=S+Patel&author=J+Whetteckey&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0147"> <div class="reference-title-banner"> <h4 class="title">UKPDS 1991 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0446"> <div class="citation-journal">Turner R, Cull C, Holman R. <span class="citation-title">United Kingdom Prospective Diabetes Study 17: a 9‐year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non‐insulin‐dependent diabetes mellitus</span>. <span class="citation"> Annals of Internal Medicine </span><span class="pubYear">1996</span>;<span class="volume">124</span>(1 Pt 2):136‐45. [MEDLINE: 8554206]<a class="crsref citation-link central-link" data-crsref="9141221" href="" ref="info:x-wiley/crsRef/9141221" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8554206" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=United+Kingdom+Prospective+Diabetes+Study+17:+a+9%E2%80%90year+update+of+a+randomized,+controlled+trial+on+the+effect+of+improved+metabolic+control+on+complications+in+non%E2%80%90insulin%E2%80%90dependent+diabetes+mellitus+&author=R+Turner&author=C+Cull&author=R+Holman&publication_year=1996&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0148"> <div class="reference-title-banner"> <h4 class="title">UKPDS‐HD 1998 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0447"> <div class="citation-journal"><span class="citation-title">Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group</span>. <span class="citation"> BMJ </span><span class="pubYear">1998</span>;<span class="volume">317</span>(7160):713‐20. [MEDLINE: 9732338]<a class="crsref citation-link central-link" data-crsref="9141223" href="" ref="info:x-wiley/crsRef/9141223" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9732338" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0448"> <div class="citation-journal"><span class="citation-title">Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.[Erratum appears in BMJ 1999 Jan 2;318(7175):29.]</span>. <span class="citation"> BMJ </span><span class="pubYear">1998</span>;<span class="volume">317</span>(7160):703‐13. [MEDLINE: 9732337]<a class="crsref citation-link central-link" data-crsref="9141224" href="" ref="info:x-wiley/crsRef/9141224" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9732337" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0149"> <div class="reference-title-banner"> <h4 class="title">VA‐CSDM 1992 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0449"> <div class="citation-journal">Abraira C, Colwell J, Nuttall F, Sawin CT, Henderson W, Comstock JP, et al. <span class="citation-title">Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes</span>. <span class="citation"> Archives of Internal Medicine </span><span class="pubYear">1997</span>;<span class="volume">157</span>(2):181‐8. [MEDLINE: 9009975]<a class="crsref citation-link central-link" data-crsref="9141226" href="" ref="info:x-wiley/crsRef/9141226" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9009975" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cardiovascular+events+and+correlates+in+the+Veterans+Affairs+Diabetes+Feasibility+Trial.+Veterans+Affairs+Cooperative+Study+on+Glycemic+Control+and+Complications+in+Type+II+Diabetes+&author=C+Abraira&author=J+Colwell&author=F+Nuttall&author=CT+Sawin&author=W+Henderson&author=JP+Comstock&publication_year=1997&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0450"> <div class="citation-journal">Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, et al. <span class="citation-title">Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1995</span>;<span class="volume">18</span>(8):1113‐23. [MEDLINE: 7587846]<a class="crsref citation-link central-link" data-crsref="9141227" href="" ref="info:x-wiley/crsRef/9141227" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/7587846" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Veterans+Affairs+Cooperative+Study+on+glycemic+control+and+complications+in+type+II+diabetes+(VA+CSDM).+Results+of+the+feasibility+trial.+Veterans+Affairs+Cooperative+Study+in+Type+II+Diabetes+&author=C+Abraira&author=JA+Colwell&author=FQ+Nuttall&author=CT+Sawin&author=NJ+Nagel&author=JP+Comstock&publication_year=1995&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0451"> <div class="citation-journal">Abraira C, Emanuele N, Colwell J, Henderson W, Comstock J, Levin S, et al. <span class="citation-title">Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM)</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1992</span>;<span class="volume">15</span>(11):1560‐71. [MEDLINE: 1308130]<a class="crsref citation-link central-link" data-crsref="9141228" href="" ref="info:x-wiley/crsRef/9141228" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/1308130" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Glycemic+control+and+complications+in+type+II+diabetes.+Design+of+a+feasibility+trial.+VA+CS+Group+(CSDM)+&author=C+Abraira&author=N+Emanuele&author=J+Colwell&author=W+Henderson&author=J+Comstock&author=S+Levin&publication_year=1992&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0452"> <div class="citation-journal">Abraira C, Henderson WG, Colwell JA, Nuttall FQ, Comstock JP, Emanuele NV, et al. <span class="citation-title">Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM)</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1998</span>;<span class="volume">21</span>(4):574‐9. [MEDLINE: 9571345]<a class="crsref citation-link central-link" data-crsref="9141229" href="" ref="info:x-wiley/crsRef/9141229" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9571345" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Response+to+intensive+therapy+steps+and+to+glipizide+dose+in+combination+with+insulin+in+type+2+diabetes.+VA+feasibility+study+on+glycemic+control+and+complications+(VA+CSDM)+&author=C+Abraira&author=WG+Henderson&author=JA+Colwell&author=FQ+Nuttall&author=JP+Comstock&author=NV+Emanuele&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0453"> <div class="citation-journal">Abraira C, McGuire DK. <span class="citation-title">Intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans affairs (VA CSDM) feasibility trial</span>. <span class="citation"> American Heart Journal </span><span class="pubYear">1999</span>;<span class="volume">138</span>(5 Pt 1):S360‐5. [MEDLINE: 10539798]<a class="crsref citation-link central-link" data-crsref="9141230" href="" ref="info:x-wiley/crsRef/9141230" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10539798" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensive+insulin+therapy+in+patients+with+type+2+diabetes:+implications+of+the+Veterans+affairs+(VA+CSDM)+feasibility+trial+&author=C+Abraira&author=DK+McGuire&publication_year=1999&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0454"> <div class="citation-journal">Agrawal L, Emanuele NV, Abraira C, Henderson WG, Levin SR, Sawin CT, et al. <span class="citation-title">Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM)</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1998</span>;<span class="volume">21</span>(4):510‐5. [MEDLINE: 9571333]<a class="crsref citation-link central-link" data-crsref="9141231" href="" ref="info:x-wiley/crsRef/9141231" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9571333" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Ethnic+differences+in+the+glycemic+response+to+exogenous+insulin+treatment+in+the+Veterans+Affairs+Cooperative+Study+in+Type+2+Diabetes+Mellitus+(VA+CSDM)+&author=L+Agrawal&author=NV+Emanuele&author=C+Abraira&author=WG+Henderson&author=SR+Levin&author=CT+Sawin&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0455"> <div class="citation-journal">Azad N, Emanuele NV, Abraira C, Henderson WG, Colwell J, Levin SR, et al. <span class="citation-title">The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM)</span>. <span class="citation"> Journal of Diabetes &amp; its Complications </span><span class="pubYear">1999</span>;<span class="volume">13</span>(5‐6):307‐13. [MEDLINE: 10765007]<a class="crsref citation-link central-link" data-crsref="9141232" href="" ref="info:x-wiley/crsRef/9141232" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+effects+of+intensive+glycemic+control+on+neuropathy+in+the+VA+cooperative+study+on+type+II+diabetes+mellitus+(VA+CSDM)+&author=N+Azad&author=NV+Emanuele&author=C+Abraira&author=WG+Henderson&author=J+Colwell&author=SR+Levin&publication_year=1999&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0456"> <div class="citation-journal">Emanuele N, Azad N, Abraira C, Henderson W, Colwell J, Levin S, et al. <span class="citation-title">Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus</span>. <span class="citation"> Archives of Internal Medicine </span><span class="pubYear">1998</span>;<span class="volume">158</span>(22):2485‐90. [MEDLINE: 9855387]<a class="crsref citation-link central-link" data-crsref="9141233" href="" ref="info:x-wiley/crsRef/9141233" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9855387" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+intensive+glycemic+control+on+fibrinogen,+lipids,+and+lipoproteins:+Veterans+Affairs+Cooperative+Study+in+Type+II+Diabetes+Mellitus+&author=N+Emanuele&author=N+Azad&author=C+Abraira&author=W+Henderson&author=J+Colwell&author=S+Levin&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0457"> <div class="citation-journal">Emanuele N, Klein R, Abraira C, Colwell J, Comstock J, Henderson WG, et al. <span class="citation-title">Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1996</span>;<span class="volume">19</span>(12):1375‐81. [MEDLINE: 8941467]<a class="crsref citation-link central-link" data-crsref="9141234" href="" ref="info:x-wiley/crsRef/9141234" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8941467" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Evaluations+of+retinopathy+in+the+VA+Cooperative+Study+on+Glycemic+Control+and+Complications+in+Type+II+Diabetes+(VA+CSDM).+A+feasibility+study+&author=N+Emanuele&author=R+Klein&author=C+Abraira&author=J+Colwell&author=J+Comstock&author=WG+Henderson&publication_year=1996&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0458"> <div class="citation-journal">Levin SR, Coburn JW, Abraira C, Henderson WG, Colwell JA, Emanuele NV, et al. <span class="citation-title">Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2000</span>;<span class="volume">23</span>(10):1478‐85. [MEDLINE: 11023140]<a class="crsref citation-link central-link" data-crsref="9141235" href="" ref="info:x-wiley/crsRef/9141235" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11023140" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+intensive+glycemic+control+on+microalbuminuria+in+type+2+diabetes.+Veterans+Affairs+Cooperative+Study+on+Glycemic+Control+and+Complications+in+Type+2+Diabetes+Feasibility+Trial+Investigators+&author=SR+Levin&author=JW+Coburn&author=C+Abraira&author=WG+Henderson&author=JA+Colwell&author=NV+Emanuele&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0459"> <div class="citation-journal">Pitale S, Kernan‐Schroeder D, Emanuele N, Sawin C, Sacks J, Abraira C, et al. <span class="citation-title">Health‐related quality of life in the VA Feasibility Study on glycemic control and complications in type 2 diabetes mellitus</span>. <span class="citation"> Journal of Diabetes &amp; its Complications </span><span class="pubYear">2005</span>;<span class="volume">19</span>(4):207‐11. [MEDLINE: 15993354]<a class="crsref citation-link central-link" data-crsref="9141236" href="" ref="info:x-wiley/crsRef/9141236" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Health%E2%80%90related+quality+of+life+in+the+VA+Feasibility+Study+on+glycemic+control+and+complications+in+type+2+diabetes+mellitus+&author=S+Pitale&author=D+Kernan%E2%80%90Schroeder&author=N+Emanuele&author=C+Sawin&author=J+Sacks&author=C+Abraira&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0460"> <div class="citation-journal">Pitale SU, Abraira C, Emanuele NV, McCarren M, Henderson WG, Pacold I, et al. <span class="citation-title">Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM)</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2000</span>;<span class="volume">23</span>(9):1316‐20. [MEDLINE: 10977025]<a class="crsref citation-link central-link" data-crsref="9141237" href="" ref="info:x-wiley/crsRef/9141237" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10977025" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Two+years+of+intensive+glycemic+control+and+left+ventricular+function+in+the+Veterans+Affairs+Cooperative+Study+in+Type+2+Diabetes+Mellitus+(VA+CSDM)+&author=SU+Pitale&author=C+Abraira&author=NV+Emanuele&author=M+McCarren&author=WG+Henderson&author=I+Pacold&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0150"> <div class="reference-title-banner"> <h4 class="title">Viswanathan 1990 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0461"> <div class="citation-journal">Viswanathan M, Snehalatha C, Mohan V, Ramachandran A, Mohan R. <span class="citation-title">Comparative study of monocomponent insulins and conventional insulins on the course of diabetic nephropathy. A follow‐up study</span>. <span class="citation"> Journal of the Association of Physicians of India </span><span class="pubYear">1990</span>;<span class="volume">38</span>(11):833‐4. [MEDLINE: 2152550]<a class="crsref citation-link central-link" data-crsref="9141239" href="" ref="info:x-wiley/crsRef/9141239" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2152550" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparative+study+of+monocomponent+insulins+and+conventional+insulins+on+the+course+of+diabetic+nephropathy.+A+follow%E2%80%90up+study+&author=M+Viswanathan&author=C+Snehalatha&author=V+Mohan&author=A+Ramachandran&author=R+Mohan&publication_year=1990&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0151"> <div class="reference-title-banner"> <h4 class="title">Vos 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0462"> <div class="citation-journal">Vos FE, Manning PJ, Sutherland WH, Schollum JB, Walker RJ. <span class="citation-title">Anti‐inflammatory effect of an insulin infusion in patients on maintenance haemodialysis: a randomized controlled pilot study</span>. <span class="citation"> Nephrology </span><span class="pubYear">2011</span>;<span class="volume">16</span>(1):68‐75. [MEDLINE: 21175981]<a class="crsref citation-link central-link" data-crsref="9141241" href="" ref="info:x-wiley/crsRef/9141241" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21175981" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Anti%E2%80%90inflammatory+effect+of+an+insulin+infusion+in+patients+on+maintenance+haemodialysis:+a+randomized+controlled+pilot+study+&author=FE+Vos&author=PJ+Manning&author=WH+Sutherland&author=JB+Schollum&author=RJ+Walker&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0463"> <div class="citation-journal">Vos FE, Manning PJ, Sutherland WHF, Schollum J, Walker RJ. <span class="citation-title">Does insulin have an anti‐inflammatory effect in patients with end‐stage renal disease on haemodialysis?</span>. <span class="citation"> Nephrology </span><span class="pubYear">2009</span>;<span class="volume">14</span>(Suppl 1):A4. <a class="crsref citation-link central-link" data-crsref="9141242" href="" ref="info:x-wiley/crsRef/9141242" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Does+insulin+have+an+anti%E2%80%90inflammatory+effect+in+patients+with+end%E2%80%90stage+renal+disease+on+haemodialysis?+&author=FE+Vos&author=PJ+Manning&author=WHF+Sutherland&author=J+Schollum&author=RJ+Walker&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0152"> <div class="reference-title-banner"> <h4 class="title">Wang 2004 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0464"> <div class="citation-journal">Wang L. <span class="citation-title">Renal protecting effects of pioglitazone in diabetic nephropathy</span>. <span class="citation"> Clinical Medicine </span><span class="pubYear">2004</span>;<span class="volume">24</span>(6):13‐4. [CENTRAL: CN‐00784118]<a class="crsref citation-link central-link" data-crsref="9141244" href="" ref="info:x-wiley/crsRef/9141244" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Renal+protecting+effects+of+pioglitazone+in+diabetic+nephropathy&author=L+Wang&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0153"> <div class="reference-title-banner"> <h4 class="title">Wang 2005b {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0465"> <div class="citation-journal">Wang XQ, Chen JY, Wang YH, Chen JF, Wu G, Jin Y. <span class="citation-title">Rosiglitazone affects albuminuria in type 2 diabetes</span>. <span class="citation"> Journal of Postgraduates of Medicine </span><span class="pubYear">2005</span>;<span class="volume">28</span>(11A):36‐7. [CENTRAL: CN‐00784160]<a class="crsref citation-link central-link" data-crsref="9141246" href="" ref="info:x-wiley/crsRef/9141246" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rosiglitazone+affects+albuminuria+in+type+2+diabetes&author=XQ+Wang&author=JY+Chen&author=YH+Wang&author=JF+Chen&author=G+Wu&author=Y+Jin&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0154"> <div class="reference-title-banner"> <h4 class="title">Wang 2005c {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0466"> <div class="citation-journal">Wang YW, Duan BH, Feng K, Zhang XL. <span class="citation-title">Effects of rosiglitazone in type 2 diabetic nephropathy</span>. <span class="citation"> Clinical Medicine of China </span><span class="pubYear">2005</span>;<span class="volume">21</span>(8):711‐2. [CENTRAL: CN‐00783103]<a class="crsref citation-link central-link" data-crsref="9141248" href="" ref="info:x-wiley/crsRef/9141248" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+rosiglitazone+in+type+2+diabetic+nephropathy&author=YW+Wang&author=BH+Duan&author=K+Feng&author=XL+Zhang&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0467"> <div class="citation-journal">Wang YW, Duan BH, Feng K, Zhang XL. <span class="citation-title">Rosiglitazone affects urinary protein excretory rate and C‐reactive protein in diabetic nephropathy</span>. <span class="citation"> Zhong Guo Wu Zhen Xue Za Zhi [Chinese Journal of Misdiagnostics] </span><span class="pubYear">2005</span>;<span class="volume">5</span>(4):692‐4. [CENTRAL: CN‐00784161]<a class="crsref citation-link central-link" data-crsref="9141249" href="" ref="info:x-wiley/crsRef/9141249" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rosiglitazone+affects+urinary+protein+excretory+rate+and+C%E2%80%90reactive+protein+in+diabetic+nephropathy+&author=YW+Wang&author=BH+Duan&author=K+Feng&author=XL+Zhang&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0155"> <div class="reference-title-banner"> <h4 class="title">Wang 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0468"> <div class="citation-journal">Wang JG. <span class="citation-title">Twenty‐two cases diagnosed with diabetic nephropathy treated with pioglitazone combined prostaglandin</span>. <span class="citation"> Zheng Zhou Da Xue Xue Bao (Yi Xue Ban) [Journal of Zhengzhou University (Medical Science)] </span><span class="pubYear">2006</span>;<span class="volume">41</span>(4):808‐9. <a class="crsref citation-link central-link" data-crsref="9141251" href="" ref="info:x-wiley/crsRef/9141251" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Twenty%E2%80%90two+cases+diagnosed+with+diabetic+nephropathy+treated+with+pioglitazone+combined+prostaglandin+&author=JG+Wang&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0156"> <div class="reference-title-banner"> <h4 class="title">Wang 2008e {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0469"> <div class="citation-journal">Wang XH. <span class="citation-title">Effect of rosiglitazone in early stage of diabetic nephropathy</span>. <span class="citation"> Journal of Clinical and Experimental Medicine </span><span class="pubYear">2008</span>;<span class="volume">7</span>(2):95‐6. [CENTRAL: CN‐00783020]<a class="crsref citation-link central-link" data-crsref="9141253" href="" ref="info:x-wiley/crsRef/9141253" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+rosiglitazone+in+early+stage+of+diabetic+nephropathy&author=XH+Wang&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0157"> <div class="reference-title-banner"> <h4 class="title">Wiseman 1985 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0470"> <div class="citation-journal">Wiseman MJ, Saunders AJ, Keen H, Viberti G. <span class="citation-title">Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin‐dependent diabetes</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">1985</span>;<span class="volume">312</span>(10):617‐21. [MEDLINE: 3883162]<a class="crsref citation-link central-link" data-crsref="9141255" href="" ref="info:x-wiley/crsRef/9141255" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/3883162" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+blood+glucose+control+on+increased+glomerular+filtration+rate+and+kidney+size+in+insulin%E2%80%90dependent+diabetes+&author=MJ+Wiseman&author=AJ+Saunders&author=H+Keen&author=G+Viberti&publication_year=1985&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0158"> <div class="reference-title-banner"> <h4 class="title">Xu 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0471"> <div class="citation-journal">Xu FJ, Yu FL, Yu FQ, Gu QX, Li Q. <span class="citation-title">Observation of trace urinary protein and C‐reactive protein level of pioglitazone treating early diabetic nephropathy</span>. <span class="citation"> Chongqin Medicine Journal </span><span class="pubYear">2005</span>;<span class="volume">34</span>(1):56‐7. [CENTRAL: CN‐00783736]<a class="crsref citation-link central-link" data-crsref="9141257" href="" ref="info:x-wiley/crsRef/9141257" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Observation+of+trace+urinary+protein+and+C%E2%80%90reactive+protein+level+of+pioglitazone+treating+early+diabetic+nephropathy+&author=FJ+Xu&author=FL+Yu&author=FQ+Yu&author=QX+Gu&author=Q+Li&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0159"> <div class="reference-title-banner"> <h4 class="title">Yang 2011a {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0472"> <div class="citation-journal">Yang W, Pan CY, Tou C, Zhao J, Gause‐Nilsson I. <span class="citation-title">Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial</span>. <span class="citation"> Diabetes Research &amp; Clinical Practice </span><span class="pubYear">2011</span>;<span class="volume">94</span>(2):217‐24. [MEDLINE: 21871686]<a class="crsref citation-link central-link" data-crsref="9141259" href="" ref="info:x-wiley/crsRef/9141259" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+saxagliptin+added+to+metformin+in+Asian+people+with+type+2+diabetes+mellitus:+a+randomized+controlled+trial+&author=W+Yang&author=CY+Pan&author=C+Tou&author=J+Zhao&author=I+Gause%E2%80%90Nilsson&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0160"> <div class="reference-title-banner"> <h4 class="title">Yokoyama 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0473"> <div class="citation-journal">Yokoyama H, Inoue T, Node K. <span class="citation-title">Effect of insulin‐unstimulated diabetic therapy with miglitol on serum cystatin C level and its clinical significance</span>. <span class="citation"> Diabetes Research &amp; Clinical Practice </span><span class="pubYear">2009</span>;<span class="volume">83</span>(1):77‐82. [MEDLINE: 19027977]<a class="crsref citation-link central-link" data-crsref="9141261" href="" ref="info:x-wiley/crsRef/9141261" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+insulin%E2%80%90unstimulated+diabetic+therapy+with+miglitol+on+serum+cystatin+C+level+and+its+clinical+significance+&author=H+Yokoyama&author=T+Inoue&author=K+Node&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0161"> <div class="reference-title-banner"> <h4 class="title">Zhang 2007c {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0474"> <div class="citation-journal">Zhang JD. <span class="citation-title">Clinical observation of treatment effect of enalapril combined rosiglitazone in early stage diabetic nephropathy</span>. <span class="citation"> Zhong Guo Yi Yuan Yao Xue Za Zhi [Chinese Journal of Hospital Pharmacy] </span><span class="pubYear">2007</span>;<span class="volume">27</span>(10):1432‐4. [CENTRAL: CN‐00782589]<a class="crsref citation-link central-link" data-crsref="9141263" href="" ref="info:x-wiley/crsRef/9141263" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Clinical+observation+of+treatment+effect+of+enalapril+combined+rosiglitazone+in+early+stage+diabetic+nephropathy+&author=JD+Zhang&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0162"> <div class="reference-title-banner"> <h4 class="title">Zhang 2012a {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0475"> <div class="citation-journal">Zhang H, Zhang X, Hu C, Lu W. <span class="citation-title">Exenatide reduces urinary transforming growth factor‐beta1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria</span>. <span class="citation"> Kidney &amp; Blood Pressure Research </span><span class="pubYear">2012</span>;<span class="volume">35</span>(6):483‐8. [MEDLINE: 22687869]<a class="crsref citation-link central-link" data-crsref="9141265" href="" ref="info:x-wiley/crsRef/9141265" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22687869" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Exenatide+reduces+urinary+transforming+growth+factor%E2%80%90beta1+and+type+IV+collagen+excretion+in+patients+with+type+2+diabetes+and+microalbuminuria+&author=H+Zhang&author=X+Zhang&author=C+Hu&author=W+Lu&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0163"> <div class="reference-title-banner"> <h4 class="title">Zhao 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0476"> <div class="citation-journal">Zhao ZG, Liu J, Hou YL. <span class="citation-title">Effect of rosiglitazone in microalbuminuria in type 2 diabetic nephropathy</span>. <span class="citation"> Clinical Focus </span><span class="pubYear">2007</span>;<span class="volume">22</span>(14):1037‐8. [CENTRAL: CN‐00783021]<a class="crsref citation-link central-link" data-crsref="9141267" href="" ref="info:x-wiley/crsRef/9141267" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+rosiglitazone+in+microalbuminuria+in+type+2+diabetic+nephropathy&author=ZG+Zhao&author=J+Liu&author=YL+Hou&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0164"> <div class="reference-title-banner"> <h4 class="title">Zheng 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0477"> <div class="citation-journal">Zheng W. <span class="citation-title">The clinical observation of benazepril combined with rosiglitazone in patients with diabetic nephropathy</span>. <span class="citation"> Academic Journal of GuangZhou Medical College </span><span class="pubYear">2006</span>;<span class="volume">34</span>(6):36‐8. [CENTRAL: CN‐00784331]<a class="crsref citation-link central-link" data-crsref="9141269" href="" ref="info:x-wiley/crsRef/9141269" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+clinical+observation+of+benazepril+combined+with+rosiglitazone+in+patients+with+diabetic+nephropathy+&author=W+Zheng&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0165"> <div class="reference-title-banner"> <h4 class="title">Zhou 2003 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0478"> <div class="citation-journal">Zhou GY, Su XS, Liu Y, Li DT. <span class="citation-title">Renal protection effects of rosiglitazone in diabetic nephropathy</span>. <span class="citation"> Liaoning Pharmacy and Clinical Remedies </span><span class="pubYear">2003</span>;<span class="volume">6</span>(2):72‐3. [CENTRAL: CN‐00784119]<a class="crsref citation-link central-link" data-crsref="9141271" href="" ref="info:x-wiley/crsRef/9141271" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Renal+protection+effects+of+rosiglitazone+in+diabetic+nephropathy&author=GY+Zhou&author=XS+Su&author=Y+Liu&author=DT+Li&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0166"> <div class="reference-title-banner"> <h4 class="title">Zhou 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0479"> <div class="citation-journal">Zhou DY, Sheng CQ. <span class="citation-title">Observation of treatment effect of rosiglitazone combined irbesartan</span>. <span class="citation"> Zhong Guo Man Xing Bing Yu Fang Yu Kong Zhi [Chinese Journal of Prevention and Control of Chronic Non‐communicable Diseases] </span><span class="pubYear">2007</span>;<span class="volume">15</span>(5):480‐1. [CENTRAL: CN‐00783738]<a class="crsref citation-link central-link" data-crsref="9141273" href="" ref="info:x-wiley/crsRef/9141273" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Observation+of+treatment+effect+of+rosiglitazone+combined+irbesartan&author=DY+Zhou&author=CQ+Sheng&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0167"> <div class="reference-title-banner"> <h4 class="title">Zhu 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0480"> <div class="citation-journal">Zhu K, Yang BY, Jin Y, Liu W. <span class="citation-title">Metformin treatment of early diabetic nephropathy</span>. <span class="citation"> JiLin Medical Journal </span><span class="pubYear">2007</span>;<span class="volume">28</span>(17):1845‐6. [CENTRAL: CN‐00783630]<a class="crsref citation-link central-link" data-crsref="9141275" href="" ref="info:x-wiley/crsRef/9141275" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Metformin+treatment+of+early+diabetic+nephropathy&author=K+Zhu&author=BY+Yang&author=Y+Jin&author=W+Liu&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011798-bbs2-0168"> <div class="reference-title-banner"> <h4 class="title">Zou 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0481"> <div class="citation-journal">Zou XB, Zhou YH. <span class="citation-title">Observation of curative effect of rosiglitazone on delaying progression of type 2 diabetic nephropathy</span>. <span class="citation"> China Pharmacy </span><span class="pubYear">2005</span>;<span class="volume">16</span>(12):931‐3. [CENTRAL: CN‐00783726]<a class="crsref citation-link central-link" data-crsref="9141277" href="" ref="info:x-wiley/crsRef/9141277" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Observation+of+curative+effect+of+rosiglitazone+on+delaying+progression+of+type+2+diabetic+nephropathy+&author=XB+Zou&author=YH+Zhou&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD011798-bbs1-0003"> <h3 class="title">References to studies awaiting assessment</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD011798-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0004">ongoing studies</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0005">additional references</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0006">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD011798-bbs2-0169"> <div class="reference-title-banner"> <h4 class="title">AWARD‐7 2017 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0482"> <div class="citation-journal">Tuttle KR, Lakshmanan MC, Gross JL, Rayner B, Busch RS, Woodward DB, et al. <span class="citation-title">Comparable glycaemic control with once weekly dulaglutide versus insulin glargine, both combined with lispro, in type 2 diabetes and chronic kidney disease (AWARD‐7) [abstract]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2017</span>;<span class="volume">60</span>(1 Suppl 1):S3. [EMBASE: 618051873]<a class="crsref citation-link central-link" data-crsref="9141279" href="" ref="info:x-wiley/crsRef/9141279" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparable+glycaemic+control+with+once+weekly+dulaglutide+versus+insulin+glargine,+both+combined+with+lispro,+in+type+2+diabetes+and+chronic+kidney+disease+(AWARD%E2%80%907)+[abstract]+&author=KR+Tuttle&author=MC+Lakshmanan&author=JL+Gross&author=B+Rayner&author=RS+Busch&author=DB+Woodward&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD011798-bbs2-0170"> <div class="reference-title-banner"> <h4 class="title">Chacra 2017 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0483"> <div class="citation-journal">Chacra A, Gantz I, Mendizabal G, Durlach L, O'Neill EA, Zimmer Z, et al. <span class="citation-title">A randomised, double‐blind, trial of the safety and efficacy of omarigliptin (a once‐weekly DPP‐4 inhibitor) in subjects with type 2 diabetes and renal impairment</span>. <span class="citation"> International Journal of Clinical Practice </span><span class="pubYear">2017</span>;<span class="volume">71</span>(6):1. [MEDLINE: 28449320]<a class="crsref citation-link central-link" data-crsref="9141281" href="" ref="info:x-wiley/crsRef/9141281" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+randomised,+double%E2%80%90blind,+trial+of+the+safety+and+efficacy+of+omarigliptin+(a+once%E2%80%90weekly+DPP%E2%80%904+inhibitor)+in+subjects+with+type+2+diabetes+and+renal+impairment+&author=A+Chacra&author=I+Gantz&author=G+Mendizabal&author=L+Durlach&author=EA+O'Neill&author=Z+Zimmer&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD011798-bbs2-0171"> <div class="reference-title-banner"> <h4 class="title">Chan 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0484"> <div class="citation-journal">Chan D, Watts G, Irish A, Dogra G. <span class="citation-title">Effect of rosiglitazone on arterial function and stiffness in patients with stage 3 to 4 chronic kidney disease [abstract no: 127]</span>. <span class="citation"> Nephrology </span><span class="pubYear">2008</span>;<span class="volume">13</span>(Suppl 3):A133. <a class="crsref citation-link central-link" data-crsref="9141283" href="" ref="info:x-wiley/crsRef/9141283" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+rosiglitazone+on+arterial+function+and+stiffness+in+patients+with+stage+3+to+4+chronic+kidney+disease+[abstract+no:+127]+&author=D+Chan&author=G+Watts&author=A+Irish&author=G+Dogra&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0485"> <div class="citation-other">Chan D, Watts G, Irish A, Dogra G. <span class="citation-title">Rosiglitazone improves inflammation and in vivo marker of endothelial function but not arterial function and stiffness in patients with stage 3 ‐ 4 chronic kidney disease [abstract no: SA181]</span>. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. <span class="pubYear">2009</span>. <a class="crsref citation-link central-link" data-crsref="9141284" href="" ref="info:x-wiley/crsRef/9141284" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rosiglitazone+improves+inflammation+and+in+vivo+marker+of+endothelial+function+but+not+arterial+function+and+stiffness+in+patients+with+stage+3+%E2%80%90+4+chronic+kidney+disease+[abstract+no:+SA181]+&author=D+Chan&author=G+Watts&author=A+Irish&author=G+Dogra&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0486"> <div class="citation-journal">Chan D, Watts G, Irish A, Dogra G. <span class="citation-title">Rosiglitazone lowers insulin resistance, inflammation and von Willebrand factor in patients with stage 1‐4 chronic kidney disease [abstract no: 126]</span>. <span class="citation"> Nephrology </span><span class="pubYear">2008</span>;<span class="volume">13</span>(Suppl 3):A132‐3. <a class="crsref citation-link central-link" data-crsref="9141285" href="" ref="info:x-wiley/crsRef/9141285" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rosiglitazone+lowers+insulin+resistance,+inflammation+and+von+Willebrand+factor+in+patients+with+stage+1%E2%80%904+chronic+kidney+disease+[abstract+no:+126]+&author=D+Chan&author=G+Watts&author=A+Irish&author=G+Dogra&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0487"> <div class="citation-journal">Chan D, Watts G, Irish A, Dogra G. <span class="citation-title">Safety and tolerability of rosiglitazone in stage 3‐4 chronic kidney disease [abstract no: 125]</span>. <span class="citation"> Nephrology </span><span class="pubYear">2008</span>;<span class="volume">13</span>(Suppl 3):A132. <a class="crsref citation-link central-link" data-crsref="9141286" href="" ref="info:x-wiley/crsRef/9141286" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Safety+and+tolerability+of+rosiglitazone+in+stage+3%E2%80%904+chronic+kidney+disease+[abstract+no:+125]+&author=D+Chan&author=G+Watts&author=A+Irish&author=G+Dogra&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0488"> <div class="citation-journal">Chan D, Watts G, Irish A, Lim E, Dogra G. <span class="citation-title">Impact of rosiglitazone on markers of bone metabolism in chronic kidney disease [abstract no: 060]</span>. <span class="citation"> Nephrology </span><span class="pubYear">2010</span>;<span class="volume">15</span>(Suppl 4):42. [EMBASE: 70467064]<a class="crsref citation-link central-link" data-crsref="9141287" href="" ref="info:x-wiley/crsRef/9141287" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20377770" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Impact+of+rosiglitazone+on+markers+of+bone+metabolism+in+chronic+kidney+disease+[abstract+no:+060]+&author=D+Chan&author=G+Watts&author=A+Irish&author=E+Lim&author=G+Dogra&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0489"> <div class="citation-journal">Chan DT, Watts GF, Irish AB, Dogra GK. <span class="citation-title">Rosiglitazone does not improve vascular function in subjects with chronic kidney disease</span>. <span class="citation"> Nephrology Dialysis Transplantation </span><span class="pubYear">2011</span>;<span class="volume">26</span>(11):3543‐9. [MEDLINE: 21378155]<a class="crsref citation-link central-link" data-crsref="9141288" href="" ref="info:x-wiley/crsRef/9141288" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rosiglitazone+does+not+improve+vascular+function+in+subjects+with+chronic+kidney+disease&author=DT+Chan&author=GF+Watts&author=AB+Irish&author=GK+Dogra&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD011798-bbs2-0172"> <div class="reference-title-banner"> <h4 class="title">DEVOTE 2017 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0490"> <div class="citation-journal">Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. <span class="citation-title">Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) ‐ DEVOTE 1</span>. <span class="citation"> American Heart Journal </span><span class="pubYear">2016</span>;<span class="volume">179</span>:175‐83. [MEDLINE: 27595693]<a class="crsref citation-link central-link" data-crsref="9141290" href="" ref="info:x-wiley/crsRef/9141290" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27595693" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Design+of+DEVOTE+(Trial+Comparing+Cardiovascular+Safety+of+Insulin+Degludec+vs+Insulin+Glargine+in+Patients+With+Type+2+Diabetes+at+High+Risk+of+Cardiovascular+Events)+%E2%80%90+DEVOTE+1+&author=SP+Marso&author=DK+McGuire&author=B+Zinman&author=NR+Poulter&author=SS+Emerson&author=TR+Pieber&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0491"> <div class="citation-journal">Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. <span class="citation-title">Efficacy and safety of degludec versus glargine in type 2 diabetes</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2017</span>;<span class="volume">377</span>(8):723‐32. [MEDLINE: 28605603]<a class="crsref citation-link central-link" data-crsref="9141291" href="" ref="info:x-wiley/crsRef/9141291" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/28605603" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+degludec+versus+glargine+in+type+2+diabetes&author=SP+Marso&author=DK+McGuire&author=B+Zinman&author=NR+Poulter&author=SS+Emerson&author=TR+Pieber&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0492"> <div class="citation-journal">Pieber TR, Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, et al. <span class="citation-title">DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2018</span>;<span class="volume">61</span>(1):58‐65. [MEDLINE: 28913543]<a class="crsref citation-link central-link" data-crsref="9141292" href="" ref="info:x-wiley/crsRef/9141292" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/28913543" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=DEVOTE+3:+temporal+relationships+between+severe+hypoglycaemia,+cardiovascular+outcomes+and+mortality+&author=TR+Pieber&author=SP+Marso&author=DK+McGuire&author=B+Zinman&author=NR+Poulter&author=SS+Emerson&publication_year=2018&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0493"> <div class="citation-journal">Zinman B, Marso SP, Poulter NR, Emerson SS, Pieber TR, Pratley RE, et al. <span class="citation-title">Day‐to‐day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2018</span>;<span class="volume">61</span>(1):48‐57. [MEDLINE: 28913575]<a class="crsref citation-link central-link" data-crsref="9141293" href="" ref="info:x-wiley/crsRef/9141293" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/28913575" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Day%E2%80%90to%E2%80%90day+fasting+glycaemic+variability+in+DEVOTE:+associations+with+severe+hypoglycaemia+and+cardiovascular+outcomes+(DEVOTE+2)+&author=B+Zinman&author=SP+Marso&author=NR+Poulter&author=SS+Emerson&author=TR+Pieber&author=RE+Pratley&publication_year=2018&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD011798-bbs2-0173"> <div class="reference-title-banner"> <h4 class="title">EXAMINE 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0494"> <div class="citation-journal">Cavender MA, White WB, Jarolim P, Bakris GL, Cushman WC, Kupfer S, et al. <span class="citation-title">Serial measurement of high‐sensitivity troponin i and cardiovascular outcomes in patients with type 2 diabetes mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care)</span>. <span class="citation"> Circulation </span><span class="pubYear">2017</span>;<span class="volume">135</span>(20):1911‐21. [MEDLINE: 28246236]<a class="crsref citation-link central-link" data-crsref="9141295" href="" ref="info:x-wiley/crsRef/9141295" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/28246236" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Serial+measurement+of+high%E2%80%90sensitivity+troponin+i+and+cardiovascular+outcomes+in+patients+with+type+2+diabetes+mellitus+in+the+EXAMINE+Trial+(Examination+of+Cardiovascular+Outcomes+With+Alogliptin+Versus+Standard+of+Care)+&author=MA+Cavender&author=WB+White&author=P+Jarolim&author=GL+Bakris&author=WC+Cushman&author=S+Kupfer&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0495"> <div class="citation-journal">White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, et al. <span class="citation-title">EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome</span>. <span class="citation"> American Heart Journal </span><span class="pubYear">2011</span>;<span class="volume">162</span>(4):620‐6. [MEDLINE: 21982652]<a class="crsref citation-link central-link" data-crsref="9141296" href="" ref="info:x-wiley/crsRef/9141296" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21982652" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=EXamination+of+cArdiovascular+outcoMes+with+alogliptIN+versus+standard+of+carE+in+patients+with+type+2+diabetes+mellitus+and+acute+coronary+syndrome+(EXAMINE):+a+cardiovascular+safety+study+of+the+dipeptidyl+peptidase+4+inhibitor+alogliptin+in+patients+with+type+2+diabetes+with+acute+coronary+syndrome+&author=WB+White&author=GL+Bakris&author=RM+Bergenstal&author=CP+Cannon&author=WC+Cushman&author=P+Fleck&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0496"> <div class="citation-journal">White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. <span class="citation-title">Alogliptin after acute coronary syndrome in patients with type 2 diabetes</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2013</span>;<span class="volume">369</span>(14):1327‐35. [MEDLINE: 23992602]<a class="crsref citation-link central-link" data-crsref="9141297" href="" ref="info:x-wiley/crsRef/9141297" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23992602" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Alogliptin+after+acute+coronary+syndrome+in+patients+with+type+2+diabetes&author=WB+White&author=CP+Cannon&author=SR+Heller&author=SE+Nissen&author=RM+Bergenstal&author=GL+Bakris&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0497"> <div class="citation-journal">White WB, Kupfer S, Zannad F, Mehta CR, Wilson CA, Lei L, et al. <span class="citation-title">Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2016</span>;<span class="volume">39</span>(7):1267‐73. [MEDLINE: 27289121]<a class="crsref citation-link central-link" data-crsref="9141298" href="" ref="info:x-wiley/crsRef/9141298" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27289121" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cardiovascular+mortality+in+patients+with+type+2+diabetes+and+recent+acute+coronary+syndromes+from+the+EXAMINE+trial+&author=WB+White&author=S+Kupfer&author=F+Zannad&author=CR+Mehta&author=CA+Wilson&author=L+Lei&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0498"> <div class="citation-journal">Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, et al. <span class="citation-title">Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double‐blind trial</span>. <span class="citation"> Lancet </span><span class="pubYear">2015</span>;<span class="volume">385</span>(9982):2067‐76. [MEDLINE: 25765696]<a class="crsref citation-link central-link" data-crsref="9141299" href="" ref="info:x-wiley/crsRef/9141299" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25765696" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Heart+failure+and+mortality+outcomes+in+patients+with+type+2+diabetes+taking+alogliptin+versus+placebo+in+EXAMINE:+a+multicentre,+randomised,+double%E2%80%90blind+trial+&author=F+Zannad&author=CP+Cannon&author=WC+Cushman&author=GL+Bakris&author=V+Menon&author=AT+Perez&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD011798-bbs2-0174"> <div class="reference-title-banner"> <h4 class="title">LEADER 2017 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0499"> <div class="citation-journal">Daniels GH, Hegedus L, Marso SP, Nauck MA, Zinman B, Bergenstal RM, et al. <span class="citation-title">LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations</span>. <span class="citation"> Diabetes, Obesity &amp; Metabolism </span><span class="pubYear">2015</span>;<span class="volume">17</span>(5):477‐86. [MEDLINE: 25656058]<a class="crsref citation-link central-link" data-crsref="9141301" href="" ref="info:x-wiley/crsRef/9141301" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25656058" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=LEADER+2:+baseline+calcitonin+in+9340+people+with+type+2+diabetes+enrolled+in+the+Liraglutide+Effect+and+Action+in+Diabetes:+Evaluation+of+cardiovascular+outcome+Results+(LEADER)+trial:+preliminary+observations+&author=GH+Daniels&author=L+Hegedus&author=SP+Marso&author=MA+Nauck&author=B+Zinman&author=RM+Bergenstal&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0500"> <div class="citation-journal">Mann J, Nauck M, Jacob S, Ludemann J, Brown‐Frandsen K, Rieck M, et al. <span class="citation-title">Liraglutide and renal outcomes in type 2 diabetes: Results of the LEADER trial [abstract]</span>. <span class="citation"> Internist </span><span class="pubYear">2017</span>;<span class="volume">58</span>(Suppl 1):S8. [EMBASE: 615632528]<a class="crsref citation-link central-link" data-crsref="9141302" href="" ref="info:x-wiley/crsRef/9141302" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+and+renal+outcomes+in+type+2+diabetes:+Results+of+the+LEADER+trial+[abstract]&author=J+Mann&author=M+Nauck&author=S+Jacob&author=J+Ludemann&author=K+Brown%E2%80%90Frandsen&author=M+Rieck&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0501"> <div class="citation-journal">Mann JF, Frandsen KB, Daniels G, Kristensen P, Nauck M, Nissen S, et al. <span class="citation-title">Liraglutide and renal outcomes in type 2 diabetes: results of the LEADER trial [abstract no: HI‐OR01]</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">2016</span>;<span class="volume">27</span>(Abstract Suppl):1B. <a class="crsref citation-link central-link" data-crsref="9141303" href="" ref="info:x-wiley/crsRef/9141303" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+and+renal+outcomes+in+type+2+diabetes:+results+of+the+LEADER+trial+[abstract+no:+HI%E2%80%90OR01]+&author=JF+Mann&author=KB+Frandsen&author=G+Daniels&author=P+Kristensen&author=M+Nauck&author=S+Nissen&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0502"> <div class="citation-journal">Mann JF, Orsted DD, Brown‐Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al. <span class="citation-title">Liraglutide and renal outcomes in type 2 diabetes</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2017</span>;<span class="volume">377</span>(9):839‐48. [MEDLINE: 28854085]<a class="crsref citation-link central-link" data-crsref="9141304" href="" ref="info:x-wiley/crsRef/9141304" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/28854085" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+and+renal+outcomes+in+type+2+diabetes&author=JF+Mann&author=DD+Orsted&author=K+Brown%E2%80%90Frandsen&author=SP+Marso&author=NR+Poulter&author=S+Rasmussen&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0503"> <div class="citation-journal">Marso SP, Daniels GH, Brown‐Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. <span class="citation-title">Liraglutide and cardiovascular outcomes in type 2 diabetes</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2016</span>;<span class="volume">375</span>(4):311‐22. [MEDLINE: 27295427]<a class="crsref citation-link central-link" data-crsref="9141305" href="" ref="info:x-wiley/crsRef/9141305" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27295427" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+and+cardiovascular+outcomes+in+type+2+diabetes&author=SP+Marso&author=GH+Daniels&author=K+Brown%E2%80%90Frandsen&author=P+Kristensen&author=JF+Mann&author=MA+Nauck&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0504"> <div class="citation-journal">Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, et al. <span class="citation-title">Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial</span>. <span class="citation"> American Heart Journal </span><span class="pubYear">2013</span>;<span class="volume">166</span>(5):823‐30. [MEDLINE: 24176437]<a class="crsref citation-link central-link" data-crsref="9141306" href="" ref="info:x-wiley/crsRef/9141306" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24176437" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Design+of+the+liraglutide+effect+and+action+in+diabetes:+evaluation+of+cardiovascular+outcome+results+(LEADER)+trial+&author=SP+Marso&author=NR+Poulter&author=SE+Nissen&author=MA+Nauck&author=B+Zinman&author=GH+Daniels&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0505"> <div class="citation-journal">Petrie JR, Marso SP, Bain SC, Franek E, Jacob S, Masmiquel L, et al. <span class="citation-title">LEADER‐4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial</span>. <span class="citation"> Journal of Hypertension </span><span class="pubYear">2016</span>;<span class="volume">34</span>(6):1140‐50. [MEDLINE: 26855018]<a class="crsref citation-link central-link" data-crsref="9141307" href="" ref="info:x-wiley/crsRef/9141307" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26855018" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=LEADER%E2%80%904:+blood+pressure+control+in+patients+with+type+2+diabetes+and+high+cardiovascular+risk:+baseline+data+from+the+LEADER+randomized+trial+&author=JR+Petrie&author=SP+Marso&author=SC+Bain&author=E+Franek&author=S+Jacob&author=L+Masmiquel&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0506"> <div class="citation-journal">Poulter N, Mann JF, Brown‐Frandsen K, Daniels GH, Kristensen P, Nauck MA, et al. <span class="citation-title">Liraglutide and renal outcomes in Type 2 diabetes: Results of the 'liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results' (LEADER) trial [abstract]</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2017</span>;<span class="volume">34</span>(Suppl 1):23‐4. [EMBASE: 614841222]<a class="crsref citation-link central-link" data-crsref="9141308" href="" ref="info:x-wiley/crsRef/9141308" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+and+renal+outcomes+in+Type+2+diabetes:+Results+of+the+'liraglutide+effect+and+action+in+diabetes:+Evaluation+of+cardiovascular+outcome+results'+(LEADER)+trial+[abstract]+&author=N+Poulter&author=JF+Mann&author=K+Brown‐Frandsen&author=GH+Daniels&author=P+Kristensen&author=MA+Nauck&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0507"> <div class="citation-journal">Rutten GE, Tack CJ, Pieber TR, Comlekci A, Orsted DD, Baeres FM, et al. <span class="citation-title">LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ</span>. <span class="citation"> Diabetology &amp; metabolic syndrome </span><span class="pubYear">2016</span>;<span class="volume">8</span>:37. [MEDLINE: 27274772]<a class="crsref citation-link central-link" data-crsref="9141309" href="" ref="info:x-wiley/crsRef/9141309" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27274772" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=LEADER+7:+cardiovascular+risk+profiles+of+US+and+European+participants+in+the+LEADER+diabetes+trial+differ+&author=GE+Rutten&author=CJ+Tack&author=TR+Pieber&author=A+Comlekci&author=DD+Orsted&author=FM+Baeres&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0508"> <div class="citation-journal">Satman I, R Rea R, Eriksson M, Mosenzon O, Pratley R, M Baeres M, et al. <span class="citation-title">LEADER‐6: Baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes population</span>. <span class="citation"> Journal of Diabetes &amp; its Complications </span><span class="pubYear">2016</span>;<span class="volume">30</span>(8):1631‐9. [MEDLINE: 27320184]<a class="crsref citation-link central-link" data-crsref="9141310" href="" ref="info:x-wiley/crsRef/9141310" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=LEADER%E2%80%906:+Baseline+renal+function+and+associated+factors+in+a+high+cardiovascular+risk+type+2+diabetes+population+&author=I+Satman&author=+RReaR&author=M+Eriksson&author=O+Mosenzon&author=R+Pratley&author=+MBaeresM&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0509"> <div class="citation-journal">Sesti G, Mann JF, Brown Frandsen K, Daniels G, Kristensen P, Nauck M, et al. <span class="citation-title">Liraglutide and renal outcomes in type 2 diabetes: Results of the LEADER trial [abstract]</span>. <span class="citation"> High Blood Pressure and Cardiovascular Prevention </span><span class="pubYear">2017</span>;<span class="volume">24</span>(2):206. [EMBASE: 616801212]<a class="crsref citation-link central-link" data-crsref="9141311" href="" ref="info:x-wiley/crsRef/9141311" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+and+renal+outcomes+in+type+2+diabetes:+Results+of+the+LEADER+trial+[abstract]&author=G+Sesti&author=JF+Mann&author=K+BrownFrandsen&author=G+Daniels&author=P+Kristensen&author=M+Nauck&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0510"> <div class="citation-journal">Steinberg WM, Buse JB, Ghorbani ML, Orsted DD, Nauck MA, LEADER Study Committee, et al. <span class="citation-title">Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: results from the LEADER randomized trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2017</span>;<span class="volume">40</span>(7):966‐72. [MEDLINE: 28476871]<a class="crsref citation-link central-link" data-crsref="9141312" href="" ref="info:x-wiley/crsRef/9141312" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/28476871" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Amylase,+lipase,+and+acute+pancreatitis+in+people+with+type+2+diabetes+treated+with+liraglutide:+results+from+the+LEADER+randomized+trial+&author=WM+Steinberg&author=JB+Buse&author=ML+Ghorbani&author=DD+Orsted&author=MA+Nauck&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0511"> <div class="citation-journal">Steinberg WM, Nauck MA, Zinman B, Daniels GH, Bergenstal RM, Mann JF, et al. <span class="citation-title">LEADER 3‐‐lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial</span>. <span class="citation"> Pancreas </span><span class="pubYear">2014</span>;<span class="volume">43</span>(8):1223‐31. [MEDLINE: 25275271]<a class="crsref citation-link central-link" data-crsref="9141313" href="" ref="info:x-wiley/crsRef/9141313" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25275271" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=LEADER+3%E2%80%90%E2%80%90lipase+and+amylase+activity+in+subjects+with+type+2+diabetes:+baseline+data+from+over+9000+subjects+in+the+LEADER+Trial+&author=WM+Steinberg&author=MA+Nauck&author=B+Zinman&author=GH+Daniels&author=RM+Bergenstal&author=JF+Mann&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD011798-bbs2-0175"> <div class="reference-title-banner"> <h4 class="title">Li 2012b {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0512"> <div class="citation-journal">Li Y, Xie QH, You HZ, Tian J, Hao CM, Lin SY, et al. <span class="citation-title">Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients‐‐a randomized crossover trial</span>. <span class="citation"> Peritoneal Dialysis International </span><span class="pubYear">2012</span>;<span class="volume">32</span>(5):507‐15. [MEDLINE: 22383630]<a class="crsref citation-link central-link" data-crsref="9141315" href="" ref="info:x-wiley/crsRef/9141315" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22383630" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Twelve+weeks+of+pioglitazone+therapy+significantly+attenuates+dysmetabolism+and+reduces+inflammation+in+continuous+ambulatory+peritoneal+dialysis+patients%E2%80%90%E2%80%90a+randomized+crossover+trial+&author=Y+Li&author=QH+Xie&author=HZ+You&author=J+Tian&author=CM+Hao&author=SY+Lin&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD011798-bbs2-0176"> <div class="reference-title-banner"> <h4 class="title">MARLINA‐T2D 2015 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0513"> <div class="citation-journal">Groop PH, Cooper ME, Perkovic V, Hocher B, Kanasaki K, Haneda M, et al. <span class="citation-title">Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA‐T2D trial</span>. <span class="citation"> Diabetes, Obesity &amp; Metabolism </span><span class="pubYear">2017</span>;<span class="volume">19</span>(11):1610‐9. [MEDLINE: 28636754]<a class="crsref citation-link central-link" data-crsref="9141317" href="" ref="info:x-wiley/crsRef/9141317" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/28636754" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Linagliptin+and+its+effects+on+hyperglycaemia+and+albuminuria+in+patients+with+type+2+diabetes+and+renal+dysfunction:+the+randomized+MARLINA%E2%80%90T2D+trial+&author=PH+Groop&author=ME+Cooper&author=V+Perkovic&author=B+Hocher&author=K+Kanasaki&author=M+Haneda&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0514"> <div class="citation-journal">Groop PH, Cooper ME, Perkovic V, Sharma K, Schernthaner G, Haneda M, et al. <span class="citation-title">Dipeptidyl peptidase‐4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA‐T2DTM trial</span>. <span class="citation"> Diabetes &amp; Vascular Disease Research </span><span class="pubYear">2015</span>;<span class="volume">12</span>(6):455‐62. [MEDLINE: 26224765]<a class="crsref citation-link central-link" data-crsref="9141318" href="" ref="info:x-wiley/crsRef/9141318" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26224765" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Dipeptidyl+peptidase%E2%80%904+inhibition+with+linagliptin+and+effects+on+hyperglycaemia+and+albuminuria+in+patients+with+type+2+diabetes+and+renal+dysfunction:+Rationale+and+design+of+the+MARLINA%E2%80%90T2DTM+trial+&author=PH+Groop&author=ME+Cooper&author=V+Perkovic&author=K+Sharma&author=G+Schernthaner&author=M+Haneda&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0515"> <div class="citation-journal">Schernthaner G, Groop P, Cooper ME, Perkovic V, Hocher B, Kanasaki K, et al. <span class="citation-title">Effects of linagliptin on glycaemic control and albuminuria in type 2 diabetes: The MARLINA‐T2DTM trial [abstract]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2016</span>;<span class="volume">59</span>(1 Suppl 1):S360. [EMBASE: 612313287]<a class="crsref citation-link central-link" data-crsref="9141319" href="" ref="info:x-wiley/crsRef/9141319" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+linagliptin+on+glycaemic+control+and+albuminuria+in+type+2+diabetes:+The+MARLINA%E2%80%90T2DTM+trial+[abstract]+&author=G+Schernthaner&author=P+Groop&author=ME+Cooper&author=V+Perkovic&author=B+Hocher&author=K+Kanasaki&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0516"> <div class="citation-journal">Schernthaner G, Groop P‐H, Cooper ME, Perkovic V, Hocher B, Kanasaki K, et al. <span class="citation-title">Effects of linagliptin on glycaemic control and albuminuria in type 2 diabetes‐the MARLINA‐T2DTM trial [abstract]</span>. <span class="citation"> Nephrology </span><span class="pubYear">2016</span>;<span class="volume">21</span>(Suppl 2):60. [EMBASE: 612313048]<a class="crsref citation-link central-link" data-crsref="9141320" href="" ref="info:x-wiley/crsRef/9141320" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27004749" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+linagliptin+on+glycaemic+control+and+albuminuria+in+type+2+diabetes%E2%80%90the+MARLINA%E2%80%90T2DTM+trial+[abstract]+&author=G+Schernthaner&author=P%E2%80%90H+Groop&author=ME+Cooper&author=V+Perkovic&author=B+Hocher&author=K+Kanasaki&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD011798-bbs2-0177"> <div class="reference-title-banner"> <h4 class="title">NCT00846716 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0517"> <div class="citation-other">Kashiwagi A, Maegawa H. <span class="citation-title">Exploratory study to investigate the suppressive effect of oral anti‐diabetic drug (tzd) on progression of diabetic nephropathy on Japanese type 2 diabetic patients</span>. www.clinicaltrials.gov/ct2/show/NCT00846716 (first received 19 February 2009). <a class="crsref citation-link central-link" data-crsref="9141322" href="" ref="info:x-wiley/crsRef/9141322" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD011798-bbs2-0178"> <div class="reference-title-banner"> <h4 class="title">Neff 2016 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0518"> <div class="citation-journal">Neff KJ, Tobin LM, Hogan AE, Docherty NG, Roux CW, O'Shea D. <span class="citation-title">The effect of low dose liraglutide on renal inflammation in type 2 diabetic kidney disease: a randomised controlled study [abstract]</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2016</span>;<span class="volume">33</span>(Suppl 1):64. [EMBASE: 72230717]<a class="crsref citation-link central-link" data-crsref="9141324" href="" ref="info:x-wiley/crsRef/9141324" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+effect+of+low+dose+liraglutide+on+renal+inflammation+in+type+2+diabetic+kidney+disease:+a+randomised+controlled+study+[abstract]+&author=KJ+Neff&author=LM+Tobin&author=AE+Hogan&author=NG+Docherty&author=CW+Roux&author=D+O'Shea&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD011798-bbs2-0179"> <div class="reference-title-banner"> <h4 class="title">Ott 2016 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0519"> <div class="citation-journal">Ott C, Kistner I, Keller M, Friedrich S, Willam C, Bramlage P, et al. <span class="citation-title">Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2016</span>;<span class="volume">59</span>(12):2579‐87. [MEDLINE: 27586249]<a class="crsref citation-link central-link" data-crsref="9141326" href="" ref="info:x-wiley/crsRef/9141326" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27586249" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+linagliptin+on+renal+endothelial+function+in+patients+with+type+2+diabetes:+a+randomised+clinical+trial+&author=C+Ott&author=I+Kistner&author=M+Keller&author=S+Friedrich&author=C+Willam&author=P+Bramlage&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0520"> <div class="citation-journal">Schmieder RE, Friedrich S, Kistner I, Ott C. <span class="citation-title">Effects of linagliptin on early alterations of renal endothelial function in patients with type‐2 diabetes [abstract]</span>. <span class="citation"> Nephrology Dialysis Transplantation </span><span class="pubYear">2015</span>;<span class="volume">30</span>(Suppl 3):iii11. [EMBASE: 72206303]<a class="crsref citation-link central-link" data-crsref="9141327" href="" ref="info:x-wiley/crsRef/9141327" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+linagliptin+on+early+alterations+of+renal+endothelial+function+in+patients+with+type%E2%80%902+diabetes+[abstract]+&author=RE+Schmieder&author=S+Friedrich&author=I+Kistner&author=C+Ott&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD011798-bbs2-0180"> <div class="reference-title-banner"> <h4 class="title">SUSTAIN‐6 2016 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0521"> <div class="citation-journal">Consoli A, Bain SC, Davies M, Lingvay I, Bergan EQ, Hansen O, et al. <span class="citation-title">Semaglutide provides sustained reductions in body weight over 2 years in subjects with type 2 diabetes (SUSTAIN 6) [abstract]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2017</span>;<span class="volume">60</span>(1 Suppl 1):S4. [EMBASE: 618051943]<a class="crsref citation-link central-link" data-crsref="9141329" href="" ref="info:x-wiley/crsRef/9141329" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Semaglutide+provides+sustained+reductions+in+body+weight+over+2+years+in+subjects+with+type+2+diabetes+(SUSTAIN+6)+[abstract]+&author=A+Consoli&author=SC+Bain&author=M+Davies&author=I+Lingvay&author=EQ+Bergan&author=O+Hansen&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0522"> <div class="citation-journal">Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. <span class="citation-title">Semaglutide and cardiovascular outcomes in patients with type 2 diabetes</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2016</span>;<span class="volume">375</span>(19):1834‐44. [MEDLINE: 27633186]<a class="crsref citation-link central-link" data-crsref="9141330" href="" ref="info:x-wiley/crsRef/9141330" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27633186" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Semaglutide+and+cardiovascular+outcomes+in+patients+with+type+2+diabetes&author=SP+Marso&author=SC+Bain&author=A+Consoli&author=FG+Eliaschewitz&author=E+Jodar&author=LA+Leiter&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0523"> <div class="citation-journal">Sanyal AJ, Hansen M, Linder M, Newsome PN. <span class="citation-title">Effect of semaglutide on alanine aminotransferase in subjects with type 2 diabetes and high cardiovascular risk [abstract]</span>. <span class="citation"> Hepatology </span><span class="pubYear">2017</span>;<span class="volume">66</span>(Suppl 1):1175A. [EMBASE: 618937026]<a class="crsref citation-link central-link" data-crsref="9141331" href="" ref="info:x-wiley/crsRef/9141331" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+semaglutide+on+alanine+aminotransferase+in+subjects+with+type+2+diabetes+and+high+cardiovascular+risk+[abstract]+&author=AJ+Sanyal&author=M+Hansen&author=M+Linder&author=PN+Newsome&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD011798-bbs2-0181"> <div class="reference-title-banner"> <h4 class="title">von Scholten 2017 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0524"> <div class="citation-journal">Scholten BJ, Persson F, Rosenlund S, Hovind P, Faber J, Hansen TW, et al. <span class="citation-title">The effect of liraglutide on renal function: a randomized clinical trial</span>. <span class="citation"> Diabetes, Obesity &amp; Metabolism </span><span class="pubYear">2017</span>;<span class="volume">19</span>(2):239‐47. [MEDLINE: 27753201]<a class="crsref citation-link central-link" data-crsref="9141333" href="" ref="info:x-wiley/crsRef/9141333" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27753201" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+effect+of+liraglutide+on+renal+function:+a+randomized+clinical+trial&author=BJ+Scholten&author=F+Persson&author=S+Rosenlund&author=P+Hovind&author=J+Faber&author=TW+Hansen&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD011798-bbs2-0182"> <div class="reference-title-banner"> <h4 class="title">Xie 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0525"> <div class="citation-journal">Xie XR, Jiang HY. <span class="citation-title">Rosiglitazone's effect to trace urinary protein and C‐reactive protein in patients with diabetic nephropathy</span>. <span class="citation"> Chinese Journal of Postgraduate Medicine </span><span class="pubYear">2006</span>;<span class="volume">29</span>(11A):55‐6. [CENTRAL: CN‐00784164]<a class="crsref citation-link central-link" data-crsref="9141335" href="" ref="info:x-wiley/crsRef/9141335" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rosiglitazone's+effect+to+trace+urinary+protein+and+C‐reactive+protein+in+patients+with+diabetic+nephropathy+&author=XR+Xie&author=HY+Jiang&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD011798-bbs1-0004"> <h3 class="title">References to ongoing studies</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD011798-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0003">studies awaiting assessment</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0005">additional references</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0006">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD011798-bbs2-0183"> <div class="reference-title-banner"> <h4 class="title">CARMELINA 2017 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0526"> <div class="citation-journal">Perkovic V, Rosenstock J, MacGuire DK. <span class="citation-title">CARMELINA trial baseline characteristics: A cardiovascular and renal microvascular outcome trial with linagliptin in patients with type 2 diabetes at high vascular risk [abstract]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2017</span>;<span class="volume">60</span>(1 Suppl 1):S357. [EMBASE: 618052704]<a class="crsref citation-link central-link" data-crsref="9141337" href="" ref="info:x-wiley/crsRef/9141337" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=CARMELINA+trial+baseline+characteristics:+A+cardiovascular+and+renal+microvascular+outcome+trial+with+linagliptin+in+patients+with+type+2+diabetes+at+high+vascular+risk+[abstract]+&author=V+Perkovic&author=J+Rosenstock&author=DK+MacGuire&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011798-bib-0527"> <div class="citation-journal">Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Kahn SE, Marx N, et al. <span class="citation-title">CARMELINA trial baseline characteristics: A cardiovascular and renal microvascular outcome trial with linagliptin in patients with type 2 diabetes at high vascular risk [abstract]</span>. <span class="citation"> Diabetes </span><span class="pubYear">2017</span>;<span class="volume">66</span>(Suppl 1):A344. [EMBASE: 616960820]<a class="crsref citation-link central-link" data-crsref="9141338" href="" ref="info:x-wiley/crsRef/9141338" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=CARMELINA+trial+baseline+characteristics:+A+cardiovascular+and+renal+microvascular+outcome+trial+with+linagliptin+in+patients+with+type+2+diabetes+at+high+vascular+risk+[abstract]+&author=J+Rosenstock&author=V+Perkovic&author=JH+Alexander&author=ME+Cooper&author=SE+Kahn&author=N+Marx&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD011798-bbs2-0184"> <div class="reference-title-banner"> <h4 class="title">NCT02547935 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0528"> <div class="citation-other">NCT02547935. <span class="citation-title">A study to evaluate the effect of dapagliflozin with and without saxagliptin on albuminuria, and to investigate the effect of dapagliflozin and saxagliptin on hba1c in patients with type 2 diabetes and CKD3</span>. www.clinicaltrials.gov/ct2/show/NCT02547935 (first received 14 September 2015). <a class="crsref citation-link central-link" data-crsref="9141340" href="" ref="info:x-wiley/crsRef/9141340" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD011798-bbs2-0185"> <div class="reference-title-banner"> <h4 class="title">NCT02608177 {published data only} </h4> </div> <div class="bibliography-section" id="CD011798-bib-0529"> <div class="citation-other">Boer I. <span class="citation-title">Continuous glucose monitoring to assess glycemia in chronic kidney disease ‐ changing glucose management (CANDY‐CANE)</span>. www.clinicaltrials.gov/ct2/show/NCT02608177 (first received 18 November 2015). <a class="crsref citation-link central-link" data-crsref="9141342" href="" ref="info:x-wiley/crsRef/9141342" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD011798-bbs1-0005"> <h3 class="title">Additional references</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD011798-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0003">studies awaiting assessment</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0004">ongoing studies</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0006">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0186"> <div class="reference-title-banner"> <h4 class="title">ADA 2017</h4> </div> <div class="bibliography-section" id="CD011798-bib-0530"> <div class="citation-journal">American Diabetes Association. <span class="citation-title">Standards of medical care in diabetes‐‐2017</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2017</span>;<span class="volume">40</span>(Suppl 1):S1‐135. [MEDLINE: 24357209] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27979885" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0187"> <div class="reference-title-banner"> <h4 class="title">ADVANCE Group 2008</h4> </div> <div class="bibliography-section" id="CD011798-bib-0531"> <div class="citation-journal">ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. <span class="citation-title">Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2008</span>;<span class="volume">358</span>(24):2560‐72. [MEDLINE: 18539916] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18539916" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensive+blood+glucose+control+and+vascular+outcomes+in+patients+with+type+2+diabetes&author=A+Patel&author=S+MacMahon&author=J+Chalmers&author=B+Neal&author=L+Billot&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0188"> <div class="reference-title-banner"> <h4 class="title">ALECARDIO 2013</h4> </div> <div class="bibliography-section" id="CD011798-bib-0532"> <div class="citation-other">Nainggolan L. <span class="citation-title">ALECARDIO trial halted for safety</span>. Medscape: News and Perspective: www.medscape.com/viewarticle/793304 July 10, 2013. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0189"> <div class="reference-title-banner"> <h4 class="title">Andrianesis 2016</h4> </div> <div class="bibliography-section" id="CD011798-bib-0533"> <div class="citation-other">Andrianesis V, Glykofridi S, Doupis J. <span class="citation-title">The renal effects of SGLT2 inhibitors and a mini‐review of the literature</span>. Therapeutic Advances in Endocrinology &amp; Metabolism<span class="pubYear">2016</span>; Vol. 7, issue 5‐6:212‐28. [MEDLINE: 28203358] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+renal+effects+of+SGLT2+inhibitors+and+a+mini%E2%80%90review+of+the+literature&author=V+Andrianesis&author=S+Glykofridi&author=J+Doupis&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0190"> <div class="reference-title-banner"> <h4 class="title">ANZDATA 2008</h4> </div> <div class="bibliography-section" id="CD011798-bib-0534"> <div class="citation-other">McDonald S, Excell L, Dent H. <span class="citation-title">ANZDATA 32nd Annual Report. 2009 Report: Data to 2008. Chapter 2: New patients commencing treatment in 2008</span>. www.anzdata.org.au/anzdata/AnzdataReport/32ndReport/Ch02.pdf (accessed 9 August 2018). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0191"> <div class="reference-title-banner"> <h4 class="title">Bennett 1983</h4> </div> <div class="bibliography-section" id="CD011798-bib-0535"> <div class="citation-journal">Bennett WM, Aronoff GR, Morrison G, Golper TA, Pulliam J, Wolfson M, et al. <span class="citation-title">Drug prescribing in renal failure: dosing guidelines for adults</span>. <span class="citation"> American Journal of Kidney Diseases </span><span class="pubYear">1983</span>;<span class="volume">3</span>(3):155‐93. [MEDLINE: 6356890] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/6356890" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Drug+prescribing+in+renal+failure:+dosing+guidelines+for+adults&author=WM+Bennett&author=GR+Aronoff&author=G+Morrison&author=TA+Golper&author=J+Pulliam&author=M+Wolfson&publication_year=1983&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0192"> <div class="reference-title-banner"> <h4 class="title">Chadban 2003</h4> </div> <div class="bibliography-section" id="CD011798-bib-0536"> <div class="citation-journal">Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn, TA, et al. <span class="citation-title">Prevalence of kidney damage in Australian adults: the AusDiab kidney study</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">2003</span>;<span class="volume">14</span>(7 Suppl 2):S131‐8. [MEDLINE: 12819318] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12819318" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Prevalence+of+kidney+damage+in+Australian+adults:+the+AusDiab+kidney+study&author=SJ+Chadban&author=EM+Briganti&author=PG+Kerr&author=DW+Dunstan&author=+Welborn&author=+TA&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0193"> <div class="reference-title-banner"> <h4 class="title">Chadban 2010</h4> </div> <div class="bibliography-section" id="CD011798-bib-0537"> <div class="citation-journal">Chadban S, Howell M, Twigg S, Thomas M, Jerums G, Cass A, et al. <span class="citation-title">The CARI Guidelines. Prevention and management of chronic kidney disease in type 2 diabetes</span>. <span class="citation"> Nephrology </span><span class="pubYear">2010</span>;<span class="volume">15 Suppl 1</span>:S162‐94. [MEDLINE: 20591029] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20591029" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+CARI+Guidelines.+Prevention+and+management+of+chronic+kidney+disease+in+type+2+diabetes+&author=S+Chadban&author=M+Howell&author=S+Twigg&author=M+Thomas&author=G+Jerums&author=A+Cass&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0194"> <div class="reference-title-banner"> <h4 class="title">Charpentier 2000</h4> </div> <div class="bibliography-section" id="CD011798-bib-0538"> <div class="citation-journal">Charpentier G, Riveline JP, Varroud‐Vial M. <span class="citation-title">Management of drugs affecting blood glucose in diabetic patients with renal failure</span>. <span class="citation"> Diabetes &amp; Metabolism </span><span class="pubYear">2000</span>;<span class="volume">26 Suppl 4</span>:73‐85. [MEDLINE: 10922977] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10922977" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Management+of+drugs+affecting+blood+glucose+in+diabetic+patients+with+renal+failure&author=G+Charpentier&author=JP+Riveline&author=M+Varroud%E2%80%90Vial&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0195"> <div class="reference-title-banner"> <h4 class="title">Cheng 2014</h4> </div> <div class="bibliography-section" id="CD011798-bib-0539"> <div class="citation-journal">Cheng D, Fei Y, Liu Y, Li J, Chen Y, Wang X, et al. <span class="citation-title">Efficacy and safety of dipeptidyl peptidase‐4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta‐analysis</span>. <span class="citation"> PLoS ONE (Electronic Resource] </span><span class="pubYear">2014</span>;<span class="volume">9</span>(10):e111543. [MEDLINE: 25360775] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+dipeptidyl+peptidase%E2%80%904+inhibitors+in+type+2+diabetes+mellitus+patients+with+moderate+to+severe+renal+impairment:+a+systematic+review+and+meta%E2%80%90analysis+&author=D+Cheng&author=Y+Fei&author=Y+Liu&author=J+Li&author=Y+Chen&author=X+Wang&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0196"> <div class="reference-title-banner"> <h4 class="title">Collins 2007</h4> </div> <div class="bibliography-section" id="CD011798-bib-0540"> <div class="citation-journal">Collins AJ, Kasiske B, Herzog C, Chavers B, Foley R, Gilbertson D, et al. <span class="citation-title">Excerpts from the United States Renal Data System 2006 Annual Data Report</span>. <span class="citation"> American Journal of Kidney Diseases </span><span class="pubYear">2007</span>;<span class="volume">49</span>(1 Suppl 1):A6‐7, S6‐296. [MEDLINE: 17189040] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Excerpts+from+the+United+States+Renal+Data+System+2006+Annual+Data+Report&author=AJ+Collins&author=B+Kasiske&author=C+Herzog&author=B+Chavers&author=R+Foley&author=D+Gilbertson&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0197"> <div class="reference-title-banner"> <h4 class="title">Collins 2008</h4> </div> <div class="bibliography-section" id="CD011798-bib-0541"> <div class="citation-journal">Collins AJ, Foley R, Herzog C, Chavers B, Gilbertson D, Ishani A, et al. <span class="citation-title">Excerpts from the United States Renal Data System 2007 Annual Data Report</span>. <span class="citation"> American Journal of Kidney Diseases </span><span class="pubYear">2008</span>;<span class="volume">51</span>(1 Suppl 1):S1‐320. [MEDLINE: 18086389] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Excerpts+from+the+United+States+Renal+Data+System+2007+Annual+Data+Report&author=AJ+Collins&author=R+Foley&author=C+Herzog&author=B+Chavers&author=D+Gilbertson&author=A+Ishani&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0198"> <div class="reference-title-banner"> <h4 class="title">CONTROL Group 2009</h4> </div> <div class="bibliography-section" id="CD011798-bib-0542"> <div class="citation-journal">Control Group, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, et al. <span class="citation-title">Intensive glucose control and macrovascular outcomes in type 2diabetes.[Erratum appears in Diabetologia. 2009 Nov;52(1):2470 Note: Control Group [added]]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2009</span>;<span class="volume">52</span>(11):2288‐98. [MEDLINE: 19655124] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19655124" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensive+glucose+control+and+macrovascular+outcomes+in+type+2diabetes.[Erratum+appears+in+Diabetologia.+2009+Nov;52(1):2470+Note:+Control+Group+[added]]+&author=FM+Turnbull&author=C+Abraira&author=RJ+Anderson&author=RP+Byington&author=JP+Chalmers&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0199"> <div class="reference-title-banner"> <h4 class="title">Coresh 2003</h4> </div> <div class="bibliography-section" id="CD011798-bib-0543"> <div class="citation-journal">Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. <span class="citation-title">Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey</span>. <span class="citation"> American Journal of Kidney Diseases </span><span class="pubYear">2003</span>;<span class="volume">41</span>(1):1‐12. [MEDLINE: 12500213] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12500213" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Prevalence+of+chronic+kidney+disease+and+decreased+kidney+function+in+the+adult+US+population:+Third+National+Health+and+Nutrition+Examination+Survey+&author=J+Coresh&author=BC+Astor&author=T+Greene&author=G+Eknoyan&author=AS+Levey&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0200"> <div class="reference-title-banner"> <h4 class="title">DCCT Group 1993</h4> </div> <div class="bibliography-section" id="CD011798-bib-0544"> <div class="citation-journal">Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, et al. <span class="citation-title">The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">1993</span>;<span class="volume">329</span>(14):977‐86. [MEDLINE: 8366922] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8366922" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+effect+of+intensive+treatment+of+diabetes+on+the+development+and+progression+of+long%E2%80%90term+complications+in+insulin%E2%80%90dependent+diabetes+mellitus+&author=DM+Nathan&author=S+Genuth&author=J+Lachin&author=P+Cleary&author=O+Crofford&publication_year=1993&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0201"> <div class="reference-title-banner"> <h4 class="title">DCCT Group 1995</h4> </div> <div class="bibliography-section" id="CD011798-bib-0545"> <div class="citation-journal">Anonymous. <span class="citation-title">Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group</span>. <span class="citation"> Kidney International </span><span class="pubYear">1995</span>;<span class="volume">47</span>(6):1703‐20. [MEDLINE: 7643540] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/7643540" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+intensive+therapy+on+the+development+and+progression+of+diabetic+nephropathy+in+the+Diabetes+Control+and+Complications+Trial.+The+Diabetes+Control+and+Complications+(DCCT)+Research+Group+&author=+Anonymous&publication_year=1995&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0202"> <div class="reference-title-banner"> <h4 class="title">Duckworth 2009</h4> </div> <div class="bibliography-section" id="CD011798-bib-0546"> <div class="citation-journal">Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. <span class="citation-title">Glucose control and vascular complications in veterans with type 2 diabetes.[Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1028], [Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1024‐5; PMID: 19726779]</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2009</span>;<span class="volume">360</span>(2):129‐39. [MEDLINE: 19092145] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19092145" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Glucose+control+and+vascular+complications+in+veterans+with+type+2+diabetes.[Erratum+appears+in+N+Engl+J+Med.+2009+Sep+3;361(10):1028],+[Erratum+appears+in+N+Engl+J+Med.+2009+Sep+3;361(10):1024%E2%80%905;+PMID:+19726779]+&author=W+Duckworth&author=C+Abraira&author=T+Moritz&author=D+Reda&author=N+Emanuele&author=PD+Reaven&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0203"> <div class="reference-title-banner"> <h4 class="title">Elashoff 2011</h4> </div> <div class="bibliography-section" id="CD011798-bib-0547"> <div class="citation-journal">Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. <span class="citation-title">Pancreatitis, pancreatic, and thyroid cancer with glucagon‐like peptide‐1‐based therapies</span>. <span class="citation"> Gastroenterology </span><span class="pubYear">2011</span>;<span class="volume">141</span>(1):150‐6. [MEDLINE: 21334333] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21334333" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pancreatitis,+pancreatic,+and+thyroid+cancer+with+glucagon%E2%80%90like+peptide%E2%80%901%E2%80%90based+therapies&author=M+Elashoff&author=AV+Matveyenko&author=B+Gier&author=R+Elashoff&author=PC+Butler&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0204"> <div class="reference-title-banner"> <h4 class="title">ERBP 2015</h4> </div> <div class="bibliography-section" id="CD011798-bib-0548"> <div class="citation-journal">Guideline Development Group. <span class="citation-title">Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR &lt;45 mL/min)</span>. <span class="citation"> Nephrology Dialysis Transplantation </span><span class="pubYear">2015</span>;<span class="volume">30 Suppl 2</span>:ii1‐11142. [MEDLINE: 25940656] <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0205"> <div class="reference-title-banner"> <h4 class="title">FDA 2000</h4> </div> <div class="bibliography-section" id="CD011798-bib-0549"> <div class="citation-other">US Food, Drug Administration. <span class="citation-title">Rezulin from the market</span>. www.nfb.org/Images/nfb/Publications/vod/vsum0003.htm 21 March 2000. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0206"> <div class="reference-title-banner"> <h4 class="title">Feldt‐Rasmussen 2006</h4> </div> <div class="bibliography-section" id="CD011798-bib-0550"> <div class="citation-journal">Feldt‐Rasmussen B. <span class="citation-title">Is there a need to optimize glycemic control in hemodialyzed diabetic patients?</span>. <span class="citation"> Kidney International </span><span class="pubYear">2006</span>;<span class="volume">70</span>(8):1392‐4. [MEDLINE: 17024163] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17024163" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Is+there+a+need+to+optimize+glycemic+control+in+hemodialyzed+diabetic+patients?&author=B+Feldt%E2%80%90Rasmussen&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0207"> <div class="reference-title-banner"> <h4 class="title">GRADE 2008</h4> </div> <div class="bibliography-section" id="CD011798-bib-0551"> <div class="citation-journal">Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. <span class="citation-title">GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</span>. <span class="citation"> BMJ </span><span class="pubYear">2008</span>;<span class="volume">336</span>(7650):924‐6. [MEDLINE: 18436948] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18436948" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=GRADE:+an+emerging+consensus+on+rating+quality+of+evidence+and+strength+of+recommendations&author=GH+Guyatt&author=AD+Oxman&author=GE+Vist&author=R+Kunz&author=Y+Falck%E2%80%90Ytter&author=P+Alonso%E2%80%90Coello&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0208"> <div class="reference-title-banner"> <h4 class="title">Higgins 2003</h4> </div> <div class="bibliography-section" id="CD011798-bib-0552"> <div class="citation-journal">Higgins JP, Thompson SG, Deeks JJ, Altman DG. <span class="citation-title">Measuring inconsistency in meta‐analyses</span>. <span class="citation"> BMJ </span><span class="pubYear">2003</span>;<span class="volume">327</span>(7414):557‐60. [MEDLINE: 12958120] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12958120" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Measuring+inconsistency+in+meta%E2%80%90analyses&author=JP+Higgins&author=SG+Thompson&author=JJ+Deeks&author=DG+Altman&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0209"> <div class="reference-title-banner"> <h4 class="title">Higgins 2011</h4> </div> <div class="bibliography-section" id="CD011798-bib-0553"> <div class="citation-other">Higgins JP, Green S (editors). <span class="citation-title">Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</span>. Available from www.cochrane‐handbook.org. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0210"> <div class="reference-title-banner"> <h4 class="title">Holman 2008</h4> </div> <div class="bibliography-section" id="CD011798-bib-0554"> <div class="citation-journal">Holman R, Paul SK, Bethel A, Matthews DR, Neil HA. <span class="citation-title">10‐year follow‐up of intensive glucose control in type 2 diabetes</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2008</span>;<span class="volume">359</span>(15):1577‐89. [MEDLINE: 18784090] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18784090" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=10%E2%80%90year+follow%E2%80%90up+of+intensive+glucose+control+in+type+2+diabetes&author=R+Holman&author=SK+Paul&author=A+Bethel&author=DR+Matthews&author=HA+Neil&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0211"> <div class="reference-title-banner"> <h4 class="title">Howse 2016</h4> </div> <div class="bibliography-section" id="CD011798-bib-0555"> <div class="citation-journal">Howse PM, Chibrikova LN, Twells LK, Barrett BJ, Gamble JM. <span class="citation-title">Safety and efficacy of incretin‐based therapies in patients with type 2 diabetes mellitus and CKD: a systematic review and meta‐analysis</span>. <span class="citation"> American Journal of Kidney Diseases </span><span class="pubYear">2016</span>;<span class="volume">68</span>(5):733‐42. [MEDLINE: 27528374] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27528374" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Safety+and+efficacy+of+incretin%E2%80%90based+therapies+in+patients+with+type+2+diabetes+mellitus+and+CKD:+a+systematic+review+and+meta%E2%80%90analysis+&author=PM+Howse&author=LN+Chibrikova&author=LK+Twells&author=BJ+Barrett&author=JM+Gamble&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0212"> <div class="reference-title-banner"> <h4 class="title">IDF 2013</h4> </div> <div class="bibliography-section" id="CD011798-bib-0556"> <div class="citation-other">International Diabetes Federation. <span class="citation-title">IDF Diabetes Atlas. 6th edition. 2013</span>. www.idf.org/component/attachments/attachments.html?id=813&amp;task=download (accessed 9 August 2018). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0213"> <div class="reference-title-banner"> <h4 class="title">Inzucchi 2012</h4> </div> <div class="bibliography-section" id="CD011798-bib-0557"> <div class="citation-journal">Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. <span class="citation-title">Management of hyperglycaemia in type 2 diabetes: a patient‐centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).[Erratum appears in Diabetologia. 2013 Mar;56(3):680]</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2012</span>;<span class="volume">55</span>(6):1577‐96. [MEDLINE: 22526604] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22526604" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Management+of+hyperglycaemia+in+type+2+diabetes:+a+patient%E2%80%90centered+approach.+Position+statement+of+the+American+Diabetes+Association+(ADA)+and+the+European+Association+for+the+Study+of+Diabetes+(EASD).[Erratum+appears+in+Diabetologia.+2013+Mar;56(3):680]+&author=SE+Inzucchi&author=RM+Bergenstal&author=JB+Buse&author=M+Diamant&author=E+Ferrannini&author=M+Nauck&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0214"> <div class="reference-title-banner"> <h4 class="title">Ismail‐Beigi 2010</h4> </div> <div class="bibliography-section" id="CD011798-bib-0558"> <div class="citation-journal">Ismail‐Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. <span class="citation-title">Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.[Erratum appears in Lancet. 2010 Oct 30;376(9751):1466]</span>. <span class="citation"> Lancet </span><span class="pubYear">2010</span>;<span class="volume">376</span>(9739):419‐30. [MEDLINE: 20594588] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20594588" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+intensive+treatment+of+hyperglycaemia+on+microvascular+outcomes+in+type+2+diabetes:+an+analysis+of+the+ACCORD+randomised+trial.[Erratum+appears+in+Lancet.+2010+Oct+30;376(9751):1466]+&author=F+Ismail%E2%80%90Beigi&author=T+Craven&author=MA+Banerji&author=J+Basile&author=J+Calles&author=RM+Cohen&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0215"> <div class="reference-title-banner"> <h4 class="title">Jackson 2000</h4> </div> <div class="bibliography-section" id="CD011798-bib-0559"> <div class="citation-journal">Jackson MA, Holland MR, Nicholas J, Lodwick R, Forster D, Macdonald IA. <span class="citation-title">Hemodialysis‐induced hypoglycemia in diabetic patients</span>. <span class="citation"> Clinical Nephrology </span><span class="pubYear">2000</span>;<span class="volume">54</span>(1):30‐4. [MEDLINE: 10939754] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10939754" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Hemodialysis%E2%80%90induced+hypoglycemia+in+diabetic+patients&author=MA+Jackson&author=MR+Holland&author=J+Nicholas&author=R+Lodwick&author=D+Forster&author=IA+Macdonald&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0216"> <div class="reference-title-banner"> <h4 class="title">Jun 2012</h4> </div> <div class="bibliography-section" id="CD011798-bib-0560"> <div class="citation-journal">Jun M, Lo C, Badve SV, Pilmore H, White SL, Hawley C, et al. <span class="citation-title">Glucose lowering therapies for chronic kidney disease and kidney transplantation</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2012</span>, Issue 8. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD009966" target="_blank"><span>10.1002/14651858.CD009966</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23076940" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Glucose+lowering+therapies+for+chronic+kidney+disease+and+kidney+transplantation&author=M+Jun&author=C+Lo&author=SV+Badve&author=H+Pilmore&author=SL+White&author=C+Hawley&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0217"> <div class="reference-title-banner"> <h4 class="title">KDIGO 2011</h4> </div> <div class="bibliography-section" id="CD011798-bib-0561"> <div class="citation-journal">Levey AS, Jong PE, Coresh J, Nahas M, Astor BC, Matsushita K, et al. <span class="citation-title">The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report.[Erratum appears in Kidney Int. 2011 Nov;80(9):1000], [Erratum appears in Kidney Int. 2011 Nov 1;80(9):1000; PMID: 30036909]</span>. <span class="citation"> Kidney International </span><span class="pubYear">2011</span>;<span class="volume">80</span>(1):17‐28. [MEDLINE: 21150873] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21150873" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+definition,+classification,+and+prognosis+of+chronic+kidney+disease:+a+KDIGO+Controversies+Conference+report.[Erratum+appears+in+Kidney+Int.+2011+Nov;80(9):1000],+[Erratum+appears+in+Kidney+Int.+2011+Nov+1;80(9):1000;+PMID:+30036909]+&author=AS+Levey&author=PE+Jong&author=J+Coresh&author=M+Nahas&author=BC+Astor&author=K+Matsushita&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0218"> <div class="reference-title-banner"> <h4 class="title">KDOQI 2002</h4> </div> <div class="bibliography-section" id="CD011798-bib-0562"> <div class="citation-journal">National Kidney Foundation. <span class="citation-title">K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification</span>. <span class="citation"> American Journal of Kidney Diseases </span><span class="pubYear">2002</span>;<span class="volume">39</span>(2 Suppl 1):S1‐266. [MEDLINE: 11904577] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11904577" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0219"> <div class="reference-title-banner"> <h4 class="title">KDOQI 2012</h4> </div> <div class="bibliography-section" id="CD011798-bib-0563"> <div class="citation-journal">National Kidney Foundation. <span class="citation-title">KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update.[Erratum appears in Am J Kidney Dis. 2013 Jun;61(6):1049]</span>. <span class="citation"> American Journal of Kidney Diseases </span><span class="pubYear">2012</span>;<span class="volume">60</span>(5):850‐86. [MEDLINE: 23067652] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23067652" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0220"> <div class="reference-title-banner"> <h4 class="title">Kobayashi 2000</h4> </div> <div class="bibliography-section" id="CD011798-bib-0564"> <div class="citation-journal">Kobayashi S, Maejima S, Ikeda T, Nagase M. <span class="citation-title">Impact of dialysis therapy on insulin resistance in end‐stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis</span>. <span class="citation"> Nephrology Dialysis Transplantation </span><span class="pubYear">2000</span>;<span class="volume">15</span>(1):65‐70. [MEDLINE: 10607769] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Impact+of+dialysis+therapy+on+insulin+resistance+in+end%E2%80%90stage+renal+disease:+comparison+of+haemodialysis+and+continuous+ambulatory+peritoneal+dialysis+&author=S+Kobayashi&author=S+Maejima&author=T+Ikeda&author=M+Nagase&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0221"> <div class="reference-title-banner"> <h4 class="title">Levin 2000</h4> </div> <div class="bibliography-section" id="CD011798-bib-0565"> <div class="citation-journal">Levin SR, Coburn JW, Abraira C, Henderson WG, Colwell JA, Emanuele NV, et al. <span class="citation-title">Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2000</span>;<span class="volume">23</span>(10):1478‐85. [MEDLINE: 11023140] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11023140" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+intensive+glycemic+control+on+microalbuminuria+in+type+2+diabetes.+Veterans+Affairs+Cooperative+Study+on+Glycemic+Control+and+Complications+in+Type+2+Diabetes+Feasibility+Trial+Investigators+&author=SR+Levin&author=JW+Coburn&author=C+Abraira&author=WG+Henderson&author=JA+Colwell&author=NV+Emanuele&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0222"> <div class="reference-title-banner"> <h4 class="title">Lo 2017</h4> </div> <div class="bibliography-section" id="CD011798-bib-0566"> <div class="citation-journal">Lo C, Jun M, Badve S V, Pilmore H, White S L, Hawley C, et al. <span class="citation-title">Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2017</span>, Issue 2. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD009966.pub2" target="_blank"><span>10.1002/14651858.CD009966.pub2</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Glucose%E2%80%90lowering+agents+for+treating+pre%E2%80%90existing+and+new%E2%80%90onset+diabetes+in+kidney+transplant+recipients+&author=C+Lo&author=M+Jun&author=SV+Badve&author=H+Pilmore&author=SL+White&author=C+Hawley&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0223"> <div class="reference-title-banner"> <h4 class="title">Loipl 2005</h4> </div> <div class="bibliography-section" id="CD011798-bib-0567"> <div class="citation-journal">Loipl J, Schmekal B, Biesenbach G. <span class="citation-title">Long‐term impact of chronic hemodialysis on glycemic control and serum lipids in insulin‐treated type 2 diabetic patients</span>. <span class="citation"> Renal Failure </span><span class="pubYear">2005</span>;<span class="volume">27</span>(3):305‐8. [MEDLINE: 15957547] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15957547" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+impact+of+chronic+hemodialysis+on+glycemic+control+and+serum+lipids+in+insulin%E2%80%90treated+type+2+diabetic+patients+&author=J+Loipl&author=B+Schmekal&author=G+Biesenbach&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0224"> <div class="reference-title-banner"> <h4 class="title">Moen 2009</h4> </div> <div class="bibliography-section" id="CD011798-bib-0568"> <div class="citation-journal">Moen MF, Zhan M, Hsu VD, Walker LD, Einhorn LM, Seliger SL, et al. <span class="citation-title">Frequency of hypoglycemia and its significance in chronic kidney disease</span>. <span class="citation"> Clinical Journal of the American Society of Nephrology: CJASN </span><span class="pubYear">2009</span>;<span class="volume">4</span>(6):1121‐7. [MEDLINE: 19423569] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19423569" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Frequency+of+hypoglycemia+and+its+significance+in+chronic+kidney+disease&author=MF+Moen&author=M+Zhan&author=VD+Hsu&author=LD+Walker&author=LM+Einhorn&author=SL+Seliger&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0225"> <div class="reference-title-banner"> <h4 class="title">Morioka 2001</h4> </div> <div class="bibliography-section" id="CD011798-bib-0569"> <div class="citation-journal">Morioka T, Emoto M, Tabata T, Shoji T, Tahara H, Kishimoto H, et al. <span class="citation-title">Glycemic control is a predictor of survival for diabetic patients on hemodialysis</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2001</span>;<span class="volume">24</span>(5):909‐13. [MEDLINE: 11347753] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11347753" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Glycemic+control+is+a+predictor+of+survival+for+diabetic+patients+on+hemodialysis&author=T+Morioka&author=M+Emoto&author=T+Tabata&author=T+Shoji&author=H+Tahara&author=H+Kishimoto&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0226"> <div class="reference-title-banner"> <h4 class="title">Nathan 2005</h4> </div> <div class="bibliography-section" id="CD011798-bib-0570"> <div class="citation-journal">Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. <span class="citation-title">Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2005</span>;<span class="volume">353</span>(25):2643‐53. [MEDLINE: 16371630] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16371630" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensive+diabetes+treatment+and+cardiovascular+disease+in+patients+with+type+1+diabetes&author=DM+Nathan&author=PA+Cleary&author=JY+Backlund&author=SM+Genuth&author=JM+Lachin&author=TJ+Orchard&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0227"> <div class="reference-title-banner"> <h4 class="title">Ohkubo 1995</h4> </div> <div class="bibliography-section" id="CD011798-bib-0571"> <div class="citation-journal">Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. <span class="citation-title">Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non‐insulin‐dependent diabetes mellitus: a randomized prospective 6‐year study</span>. <span class="citation"> Diabetes Research &amp; Clinical Practice </span><span class="pubYear">1995</span>;<span class="volume">28</span>(2):103‐17. [MEDLINE: 7587918] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensive+insulin+therapy+prevents+the+progression+of+diabetic+microvascular+complications+in+Japanese+patients+with+non%E2%80%90insulin%E2%80%90dependent+diabetes+mellitus:+a+randomized+prospective+6%E2%80%90year+study+&author=Y+Ohkubo&author=H+Kishikawa&author=E+Araki&author=T+Miyata&author=S+Isami&author=S+Motoyoshi&publication_year=1995&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0228"> <div class="reference-title-banner"> <h4 class="title">Oomichi 2006</h4> </div> <div class="bibliography-section" id="CD011798-bib-0572"> <div class="citation-journal">Oomichi T, Emoto M, Tabata T, Morioka T, Tsujimoto Y, Tahara H, et al. <span class="citation-title">Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7‐year observational study</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2006</span>;<span class="volume">29</span>(7):1496‐500. [MEDLINE: 16801568] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16801568" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Impact+of+glycemic+control+on+survival+of+diabetic+patients+on+chronic+regular+hemodialysis:+a+7%E2%80%90year+observational+study+&author=T+Oomichi&author=M+Emoto&author=T+Tabata&author=T+Morioka&author=Y+Tsujimoto&author=H+Tahara&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0229"> <div class="reference-title-banner"> <h4 class="title">Orme 2017</h4> </div> <div class="bibliography-section" id="CD011798-bib-0573"> <div class="citation-journal">Orme ME, Nguyen H, Lu JY, Thomas SA. <span class="citation-title">Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP‐1 receptor agonists: a network meta‐analysis of placebo‐controlled and active‐comparator trials</span>. <span class="citation"> Diabetes, Metabolic Syndrome &amp; Obesity Targets &amp; Therapy </span><span class="pubYear">2017</span>;<span class="volume">10</span>:111‐22. [MEDLINE: 28435304] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparative+effectiveness+of+glycemic+control+in+patients+with+type+2+diabetes+treated+with+GLP%E2%80%901+receptor+agonists:+a+network+meta%E2%80%90analysis+of+placebo%E2%80%90controlled+and+active%E2%80%90comparator+trials+&author=ME+Orme&author=H+Nguyen&author=JY+Lu&author=SA+Thomas&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0230"> <div class="reference-title-banner"> <h4 class="title">Patel 2016</h4> </div> <div class="bibliography-section" id="CD011798-bib-0574"> <div class="citation-other">Patel S, Gohel K, Patel BG. <span class="citation-title">A systematic review on effect of canagliflozin in special population</span>. Current Diabetes Reviews<span class="pubYear">2016</span>; Vol. 12, issue 3:211‐22. [MEDLINE: 26084476] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+systematic+review+on+effect+of+canagliflozin+in+special+population&author=S+Patel&author=K+Gohel&author=BG+Patel&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0231"> <div class="reference-title-banner"> <h4 class="title">Perkovic 2007</h4> </div> <div class="bibliography-section" id="CD011798-bib-0575"> <div class="citation-journal">Perkovic V, Ninomiya T, Arima H, Gallagher M, Jardine M, Cass A, et al. <span class="citation-title">Chronic kidney disease, cardiovascular events, and the effects of perindopril‐based blood pressure lowering: Data from the PROGRESS Study</span>. <span class="citation"> Journal of the American Society of Nephrology </span><span class="pubYear">2007</span>;<span class="volume">18</span>(10):2766‐72. [MEDLINE: 17804673] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17804673" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Chronic+kidney+disease,+cardiovascular+events,+and+the+effects+of+perindopril%E2%80%90based+blood+pressure+lowering:+Data+from+the+PROGRESS+Study+&author=V+Perkovic&author=T+Ninomiya&author=H+Arima&author=M+Gallagher&author=M+Jardine&author=A+Cass&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0232"> <div class="reference-title-banner"> <h4 class="title">Perkovic 2013</h4> </div> <div class="bibliography-section" id="CD011798-bib-0576"> <div class="citation-journal">Perkovic V, Heerspink HL, Chalmers J, Woodward M, Jun M, Li Q, et al. <span class="citation-title">Intensive glucose control improves kidney outcomes in patients with type 2 diabetes</span>. <span class="citation"> Kidney International </span><span class="pubYear">2013</span>;<span class="volume">83</span>(3):517‐23. [MEDLINE: 23302714] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23302714" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensive+glucose+control+improves+kidney+outcomes+in+patients+with+type+2+diabetes&author=V+Perkovic&author=HL+Heerspink&author=J+Chalmers&author=M+Woodward&author=M+Jun&author=Q+Li&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0233"> <div class="reference-title-banner"> <h4 class="title">Radbill 2008</h4> </div> <div class="bibliography-section" id="CD011798-bib-0577"> <div class="citation-journal">Radbill B, Murphy B, LeRoith D. <span class="citation-title">Rationale and strategies for early detection and management of diabetic kidney disease</span>. <span class="citation"> Mayo Clinic Proceedings </span><span class="pubYear">2008</span>;<span class="volume">83</span>(12):1373‐81. [MEDLINE: 19046557] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19046557" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rationale+and+strategies+for+early+detection+and+management+of+diabetic+kidney+disease&author=B+Radbill&author=B+Murphy&author=D+LeRoith&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0234"> <div class="reference-title-banner"> <h4 class="title">Rave 2001</h4> </div> <div class="bibliography-section" id="CD011798-bib-0578"> <div class="citation-journal">Rave K, Heise T, Pfutzner A, Heinemann L, Sawicki PT. <span class="citation-title">Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2001</span>;<span class="volume">24</span>(5):886‐90. [MEDLINE: 11347749] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11347749" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Impact+of+diabetic+nephropathy+on+pharmacodynamic+and+pharmacokinetic+properties+of+insulin+in+type+1+diabetic+patients+&author=K+Rave&author=T+Heise&author=A+Pfutzner&author=L+Heinemann&author=PT+Sawicki&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0235"> <div class="reference-title-banner"> <h4 class="title">Rehman 2017</h4> </div> <div class="bibliography-section" id="CD011798-bib-0579"> <div class="citation-journal">Rehman MB, Tudrej BV, Soustre J, Buisson M, Archambault P, Pouchain D, et al. <span class="citation-title">Efficacy and safety of DPP‐4 inhibitors in patients with type 2 diabetes: Meta‐analysis of placebo‐controlled randomized clinical trials</span>. <span class="citation"> Diabetes &amp; Metabolism </span><span class="pubYear">2017</span>;<span class="volume">43</span>(1):48‐58. [MEDLINE: 27745828] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27745828" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+DPP%E2%80%904+inhibitors+in+patients+with+type+2+diabetes:+Meta%E2%80%90analysis+of+placebo%E2%80%90controlled+randomized+clinical+trials+&author=MB+Rehman&author=BV+Tudrej&author=J+Soustre&author=M+Buisson&author=P+Archambault&author=D+Pouchain&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0236"> <div class="reference-title-banner"> <h4 class="title">Ruanpeng 2016</h4> </div> <div class="bibliography-section" id="CD011798-bib-0580"> <div class="citation-journal">Ruanpeng D, Ungprasert P, Sangtian J, Harindhanavudhi T. <span class="citation-title">Sodium glucose co‐transporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A systemic review and meta‐analysis [abstract]</span>. <span class="citation"> Diabetes </span><span class="pubYear">2016</span>;<span class="volume">65</span>(Suppl 1):A288. [EMBASE: 620237755] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Sodium+glucose+co%E2%80%90transporter+2+(SGLT2)+inhibitors+and+fracture+risk+in+patients+with+type+2+diabetes+mellitus:+A+systemic+review+and+meta%E2%80%90analysis+[abstract]+&author=D+Ruanpeng&author=P+Ungprasert&author=J+Sangtian&author=T+Harindhanavudhi&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0237"> <div class="reference-title-banner"> <h4 class="title">Scheen 2015</h4> </div> <div class="bibliography-section" id="CD011798-bib-0581"> <div class="citation-other">Scheen AJ. <span class="citation-title">Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease</span>. Clinical Pharmacokinetics<span class="pubYear">2015</span>; Vol. 54, issue 7:691‐708. [MEDLINE: 25805666] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pharmacokinetics,+pharmacodynamics+and+clinical+use+of+SGLT2+inhibitors+in+patients+with+type+2+diabetes+mellitus+and+chronic+kidney+disease+&author=AJ+Scheen&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0238"> <div class="reference-title-banner"> <h4 class="title">Schünemann 2011a</h4> </div> <div class="bibliography-section" id="CD011798-bib-0582"> <div class="citation-other">Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. <span class="citation-title">Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</span>. Available from www.cochrane‐handbook.org. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0239"> <div class="reference-title-banner"> <h4 class="title">Schünemann 2011b</h4> </div> <div class="bibliography-section" id="CD011798-bib-0583"> <div class="citation-other">Schünemann HJ, Oxman AD, Higgins JP, Deeks JJ, Glasziou P, Guyatt GH. <span class="citation-title">Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</span>. Available from www.cochrane‐handbook.org. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0240"> <div class="reference-title-banner"> <h4 class="title">Shurraw 2010</h4> </div> <div class="bibliography-section" id="CD011798-bib-0584"> <div class="citation-journal">Shurraw S, Majumdar SR, Thadhani R, Wiebe N, Tonelli M, Alberta Kidney Disease Network. <span class="citation-title">Glycemic control and the risk of death in 1,484 patients receiving maintenance hemodialysis</span>. <span class="citation"> American Journal of Kidney Diseases </span><span class="pubYear">2010</span>;<span class="volume">55</span>(5):875‐84. [MEDLINE: 20346561] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20346561" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Glycemic+control+and+the+risk+of+death+in+1,484+patients+receiving+maintenance+hemodialysis&author=S+Shurraw&author=SR+Majumdar&author=R+Thadhani&author=N+Wiebe&author=M+Tonelli&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0241"> <div class="reference-title-banner"> <h4 class="title">Shurraw 2011</h4> </div> <div class="bibliography-section" id="CD011798-bib-0585"> <div class="citation-journal">Shurraw S, Hemmelgarn B, Lin M, Majumdar SR, Klarenbach S, Manns B, et al. <span class="citation-title">Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population‐based cohort study</span>. <span class="citation"> Archives of Internal Medicine </span><span class="pubYear">2011</span>;<span class="volume">171</span>(21):1920‐6. [MEDLINE: 22123800] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22123800" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Association+between+glycemic+control+and+adverse+outcomes+in+people+with+diabetes+mellitus+and+chronic+kidney+disease:+a+population%E2%80%90based+cohort+study+&author=S+Shurraw&author=B+Hemmelgarn&author=M+Lin&author=SR+Majumdar&author=S+Klarenbach&author=B+Manns&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0242"> <div class="reference-title-banner"> <h4 class="title">Shyangdan 2016</h4> </div> <div class="bibliography-section" id="CD011798-bib-0586"> <div class="citation-other">Shyangdan DS, Uthman OA, Waugh N. <span class="citation-title">SGLT‐2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta‐analysis</span>. BMJ Open<span class="pubYear">2016</span>; Vol. 6, issue 2:e009417. [MEDLINE: 26911584] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=SGLT%E2%80%902+receptor+inhibitors+for+treating+patients+with+type+2+diabetes+mellitus:+a+systematic+review+and+network+meta%E2%80%90analysis+&author=DS+Shyangdan&author=OA+Uthman&author=N+Waugh&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0243"> <div class="reference-title-banner"> <h4 class="title">Singh‐Franco 2016</h4> </div> <div class="bibliography-section" id="CD011798-bib-0587"> <div class="citation-journal">Singh‐Franco D, Harrington C, Tellez‐Corrales E. <span class="citation-title">An updated systematic review and meta‐analysis on the efficacy and tolerability of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes with moderate to severe chronic kidney disease</span>. <span class="citation"> SAGE Open Medicine </span><span class="pubYear">2016</span>;<span class="volume">4</span>:2050312116659090. [MEDLINE: 27516879] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27516879" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=An+updated+systematic+review+and+meta%E2%80%90analysis+on+the+efficacy+and+tolerability+of+dipeptidyl+peptidase%E2%80%904+inhibitors+in+patients+with+type+2+diabetes+with+moderate+to+severe+chronic+kidney+disease+&author=D+Singh%E2%80%90Franco&author=C+Harrington&author=E+Tellez%E2%80%90Corrales&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0244"> <div class="reference-title-banner"> <h4 class="title">Storgaard 2016</h4> </div> <div class="bibliography-section" id="CD011798-bib-0588"> <div class="citation-other">Storgaard H, Gluud LL, Bennett C, Grondahl MF, Christensen MB, Knop FK, et al. <span class="citation-title">Benefits and harms of sodium‐glucose co‐transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta‐analysis</span>. PLoS ONE (Electronic Resource]<span class="pubYear">2016</span>; Vol. 11, issue 11:e0166125. [MEDLINE: 27835680] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Benefits+and+harms+of+sodium%E2%80%90glucose+co%E2%80%90transporter+2+inhibitors+in+patients+with+type+2+diabetes:+a+systematic+review+and+meta%E2%80%90analysis+&author=H+Storgaard&author=LL+Gluud&author=C+Bennett&author=MF+Grondahl&author=MB+Christensen&author=FK+Knop&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0245"> <div class="reference-title-banner"> <h4 class="title">Tuttle 2014</h4> </div> <div class="bibliography-section" id="CD011798-bib-0589"> <div class="citation-journal">Tuttle KR, Bakris GL, Bilous RW, Chiang JL, Boer IH, Goldstein‐Fuchs J, et al. <span class="citation-title">Diabetic kidney disease: a report from an ADA Consensus Conference</span>. <span class="citation"> American Journal of Kidney Diseases </span><span class="pubYear">2014</span>;<span class="volume">64</span>(4):510‐33. [MEDLINE: 25257325] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25257325" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Diabetic+kidney+disease:+a+report+from+an+ADA+Consensus+Conference&author=KR+Tuttle&author=GL+Bakris&author=RW+Bilous&author=JL+Chiang&author=IH+Boer&author=J+Goldstein%E2%80%90Fuchs&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0246"> <div class="reference-title-banner"> <h4 class="title">UKPDS 33 1998</h4> </div> <div class="bibliography-section" id="CD011798-bib-0590"> <div class="citation-journal">Anonynous. <span class="citation-title">Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.[Erratum appears in Lancet 1999 Aug 14;354(9178):602]</span>. <span class="citation"> Lancet </span><span class="pubYear">1998</span>;<span class="volume">352</span>(9131):857‐53. [MEDLINE: 9742976] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensive+blood%E2%80%90glucose+control+with+sulphonylureas+or+insulin+compared+with+conventional+treatment+and+risk+of+complications+in+patients+with+type+2+diabetes+(UKPDS+33).+UK+Prospective+Diabetes+Study+(UKPDS)+Group.[Erratum+appears+in+Lancet+1999+Aug+14;354(9178):602]+&author=+Anonynous&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0247"> <div class="reference-title-banner"> <h4 class="title">UKPDS 34 1998</h4> </div> <div class="bibliography-section" id="CD011798-bib-0591"> <div class="citation-journal">Anonymous. <span class="citation-title">Effect of intensive blood‐glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.[Erratum appears in Lancet 1998 Nov 7;352(9139):1558]</span>. <span class="citation"> Lancet </span><span class="pubYear">1998</span>;<span class="volume">352</span>(9131):854‐65. [MEDLINE: 9742977] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9742977" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+intensive+blood%E2%80%90glucose+control+with+metformin+on+complications+in+overweight+patients+with+type+2+diabetes+(UKPDS+34).+UK+Prospective+Diabetes+Study+(UKPDS)+Group.[Erratum+appears+in+Lancet+1998+Nov+7;352(9139):1558]+&author=+Anonymous&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0248"> <div class="reference-title-banner"> <h4 class="title">Vallon 2007</h4> </div> <div class="bibliography-section" id="CD011798-bib-0592"> <div class="citation-journal">Vallon V, Thomson SC. <span class="citation-title">Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2007</span>;<span class="volume">60</span>(2):215‐25. [MEDLINE: 27878313] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Targeting+renal+glucose+reabsorption+to+treat+hyperglycaemia:+the+pleiotropic+effects+of+SGLT2+inhibition+&author=V+Vallon&author=SC+Thomson&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0249"> <div class="reference-title-banner"> <h4 class="title">Walker 2017</h4> </div> <div class="bibliography-section" id="CD011798-bib-0593"> <div class="citation-journal">Walker SR, Komenda P, Khojah S, Al‐Tuwaijri W, MacDonald K, Hiebert B, et al. <span class="citation-title">Dipeptidyl peptidase‐4 inhibitors in chronic kidney disease: a systematic review of randomized clinical trials</span>. <span class="citation"> Nephron </span><span class="pubYear">2017</span>;<span class="volume">136</span>(2):85‐94. [MEDLINE: 28178698] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/28178698" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Dipeptidyl+peptidase%E2%80%904+inhibitors+in+chronic+kidney+disease:+a+systematic+review+of+randomized+clinical+trials+&author=SR+Walker&author=P+Komenda&author=S+Khojah&author=W+Al%E2%80%90Tuwaijri&author=K+MacDonald&author=B+Hiebert&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0250"> <div class="reference-title-banner"> <h4 class="title">Williams 2006</h4> </div> <div class="bibliography-section" id="CD011798-bib-0594"> <div class="citation-journal">Williams ME, Lacson EJ, Teng M, Ofsthun N, Lazarus JM. <span class="citation-title">Hemodialyzed type I and type II diabetic patients in the US: characteristics, glycemic control, and survival</span>. <span class="citation"> Kidney International </span><span class="pubYear">2006</span>;<span class="volume">70</span>(8):1503‐9. [MEDLINE: 16941022] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16941022" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Hemodialyzed+type+I+and+type+II+diabetic+patients+in+the+US:+characteristics,+glycemic+control,+and+survival+&author=ME+Williams&author=EJ+Lacson&author=M+Teng&author=N+Ofsthun&author=JM+Lazarus&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0251"> <div class="reference-title-banner"> <h4 class="title">Wu 1997</h4> </div> <div class="bibliography-section" id="CD011798-bib-0595"> <div class="citation-journal">Wu MS, Yu CC, Yang CW, Wu CH, Haung JY, Hong JJ, et al. <span class="citation-title">Poor pre‐dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis</span>. <span class="citation"> Nephrology Dialysis Transplantation </span><span class="pubYear">1997</span>;<span class="volume">12</span>(10):2105‐10. [MEDLINE: 9351073] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Poor+pre%E2%80%90dialysis+glycaemic+control+is+a+predictor+of+mortality+in+type+II+diabetic+patients+on+maintenance+haemodialysis+&author=MS+Wu&author=CC+Yu&author=CW+Yang&author=CH+Wu&author=JY+Haung&author=JJ+Hong&publication_year=1997&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0252"> <div class="reference-title-banner"> <h4 class="title">Wu 2016</h4> </div> <div class="bibliography-section" id="CD011798-bib-0596"> <div class="citation-other">Wu JH, Foote C, Blomster J, Toyama T, Perkovic V, Sundstrom J, et al. <span class="citation-title">Effects of sodium‐glucose cotransporter‐2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta‐analysis.[Erratum appears in Lancet Diabetes Endocrinol. 2016 Sep;4(9):e9; PMID: 27174817]</span>. The Lancet Diabetes &amp; Endocrinology<span class="pubYear">2016</span>; Vol. 4, issue 5:411‐9. [MEDLINE: 27009625] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+sodium%E2%80%90glucose+cotransporter%E2%80%902+inhibitors+on+cardiovascular+events,+death,+and+major+safety+outcomes+in+adults+with+type+2+diabetes:+a+systematic+review+and+meta%E2%80%90analysis.[Erratum+appears+in+Lancet+Diabetes+Endocrinol.+2016+Sep;4(9):e9;+PMID:+27174817]+&author=JH+Wu&author=C+Foote&author=J+Blomster&author=T+Toyama&author=V+Perkovic&author=J+Sundstrom&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0253"> <div class="reference-title-banner"> <h4 class="title">Xu 2017</h4> </div> <div class="bibliography-section" id="CD011798-bib-0597"> <div class="citation-journal">Xu S, Zhang X, Tang L, Zhang F, Tong N. <span class="citation-title">Cardiovascular effects of dipeptidyl peptidase‐4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta‐analysis and systematic review</span>. <span class="citation"> Postgraduate Medicine </span><span class="pubYear">2017</span>;<span class="volume">129</span>(2):205‐15. [MEDLINE: 27813442] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27813442" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cardiovascular+effects+of+dipeptidyl+peptidase%E2%80%904+inhibitor+in+diabetic+patients+with+and+without+established+cardiovascular+disease:+a+meta%E2%80%90analysis+and+systematic+review+&author=S+Xu&author=X+Zhang&author=L+Tang&author=F+Zhang&author=N+Tong&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0254"> <div class="reference-title-banner"> <h4 class="title">Zaccardi 2016</h4> </div> <div class="bibliography-section" id="CD011798-bib-0598"> <div class="citation-other">Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. <span class="citation-title">Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis</span>. Diabetes, Obesity &amp; Metabolism<span class="pubYear">2016</span>; Vol. 18, issue 8:783‐94. [MEDLINE: 27059700] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+sodium%E2%80%90glucose+co%E2%80%90transporter%E2%80%902+inhibitors+in+type+2+diabetes+mellitus:+systematic+review+and+network+meta%E2%80%90analysis+&author=F+Zaccardi&author=DR+Webb&author=ZZ+Htike&author=D+Youssef&author=K+Khunti&author=MJ+Davies&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0255"> <div class="reference-title-banner"> <h4 class="title">Zanoli 2015</h4> </div> <div class="bibliography-section" id="CD011798-bib-0599"> <div class="citation-other">Zanoli L, Granata A, Lentini P, Rastelli S, Fatuzzo P, Rapisarda F, et al. <span class="citation-title">Sodium‐glucose linked transporter‐2 inhibitors in chronic kidney disease</span>. Thescientificworldjournal<span class="pubYear">2015</span>; Vol. 2015:317507. [MEDLINE: 25785281] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Sodium%E2%80%90glucose+linked+transporter%E2%80%902+inhibitors+in+chronic+kidney+disease&author=L+Zanoli&author=A+Granata&author=P+Lentini&author=S+Rastelli&author=P+Fatuzzo&author=F+Rapisarda&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011798-bbs2-0256"> <div class="reference-title-banner"> <h4 class="title">Zoungas 2017</h4> </div> <div class="bibliography-section" id="CD011798-bib-0600"> <div class="citation-journal">Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, et al. <span class="citation-title">Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta‐analysis of individual participant data from randomised controlled trials</span>. <span class="citation"> The Lancet Diabetes and Endocrinology </span><span class="pubYear">2017</span>;<span class="volume">5</span>(6):431‐7. [MEDLINE: 28365411] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/28365411" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+intensive+glucose+control+on+microvascular+outcomes+in+patients+with+type+2+diabetes:+a+meta%E2%80%90analysis+of+individual+participant+data+from+randomised+controlled+trials+&author=S+Zoungas&author=H+Arima&author=HC+Gerstein&author=RR+Holman&author=M+Woodward&author=P+Reaven&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD011798-bbs1-0006"> <h3 class="title">References to other published versions of this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD011798-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0003">studies awaiting assessment</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0004">ongoing studies</a></li> <li><a class="jump-to" href="#CD011798-bbs1-0005">additional references</a></li> </ul> </div> </div> <div class="bibliographies references_otherVersions" id="CD011798-bbs2-0257"> <div class="reference-title-banner"> <h4 class="title">Lo 2015</h4> </div> <div class="bibliography-section" id="CD011798-bib-0601"> <div class="citation-journal">Lo C, Toyama T, Hirakawa Y, Jun M, Cass A, Hawley C, et al. <span class="citation-title">Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2015</span>, Issue 8. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD011798" target="_blank"><span>10.1002/14651858.CD011798</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25927091" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Insulin+and+glucose%E2%80%90lowering+agents+for+treating+people+with+diabetes+and+chronic+kidney+disease+&author=C+Lo&author=T+Toyama&author=Y+Hirakawa&author=M+Jun&author=A+Cass&author=C+Hawley&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> </section> <section class="characteristicStudies" id="characteristicStudies"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title"> Characteristics of studies <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="characteristicIncludedStudiesContent" lang=""> <div class="section-header" id="CD011798-sec2-0020"> <h3 class="title">Characteristics of included studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD011798-sec2-0021" class="jump-to">excluded studies</a></li> <li><a href="#CD011798-sec2-0022" class="jump-to">awaiting classification</a></li> <li><a href="#CD011798-sec2-0023" class="jump-to">ongoing studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Abe 2007 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0019"> <li> <p>Study design: open‐label parallel RCT</p> </li> <li> <p>Study time frame: not reported</p> </li> <li> <p>Duration of follow‐up: 12 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0020"> <li> <p>Country: Japan</p> </li> <li> <p>Setting: single centre</p> </li> <li> <p>Inclusion criteria: HD patients with type 2 DM untreated with insulin; unstable glycaemic control ≥ 7.0% after 12 consecutive weeks of daily administration of 0.9 mg voglibose </p> </li> <li> <p>Number: treatment group (16); control group (15)</p> </li> <li> <p>Mean age ± SEM (years): treatment group (70.1 ± 5.1); control group (65.6 ± 2.8)</p> </li> <li> <p>Sex (M/F): treatment group (9/7); control group (9/6)</p> </li> <li> <p>Exclusion criteria: deranged liver function; decompensated congestive heart failure; infectious disease; thyroid disease; malignant tumour; treatment with steroids </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0021"> <li> <p>Pioglitazone: 30 mg for 12 weeks</p> </li> <li> <p> Voglibose: 0.9 mg for 12 weeks</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0022"> <li> <p>Voglibose: 0.9 mg for 12 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0023"> <li> <p>HbA1c and plasma glucose levels</p> </li> <li> <p>Insulin resistance via HOMA‐IR</p> </li> <li> <p>Hb</p> </li> <li> <p>AST, ALT, creatinine phosphokinase, total cholesterol, HDL, triglyceride</p> </li> <li> <p>Mean corpuscular volume, mean HbA1c, body weight before and after dialysis, BMI, CTR by chest X‐ray and predialysis SBP and DBP </p> </li> <li> <p>Safety variables and adverse events</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0024"> <li> <p>Funding source: not reported</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A computer generated list was used</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open‐label study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open‐label study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No people dropped out</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were not available on a clinical trials database</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest and funding source were not reported</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Abe 2008a </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0025"> <li> <p>Study design: open‐label, parallel RCT</p> </li> <li> <p>Study time frame: not reported</p> </li> <li> <p>Duration of follow‐up: 24 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0026"> <li> <p>Country: Japan</p> </li> <li> <p>Setting: single centre</p> </li> <li> <p>Inclusion criteria: HD patients with type 2 DM; poor glycaemic control (HbA1c &gt; 6.5% (48 mmol/mol) over previous 3 months); hypertension; not receiving insulin therapy </p> </li> <li> <p>Number: treatment group (20); control group (20)</p> </li> <li> <p>Mean age ± SEM (years): treatment group (71.1 ± 7.1); control group (68.8 ± 5.8)</p> </li> <li> <p>Sex (M/F): treatment group (12/8); control group (12/8)</p> </li> <li> <p>Exclusion criteria: abnormal liver function at baseline; congestive heart failure; ischaemic heart disease; thyroid disease or malignant tumours; under steroid treatment </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0027"> <li> <p>Pioglitazone: 30 mg over 24 weeks</p> </li> <li> <p>Conventional oral antidiabetic agents for 24 weeks</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0028"> <li> <p>Conventional oral antidiabetic agents for 24 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0029"> <li> <p>HbA1c and plasma glucose levels</p> </li> <li> <p>Insulin resistance via HOMA‐IR</p> </li> <li> <p>Hb</p> </li> <li> <p>AST, ALT, creatinine phosphokinase, total cholesterol, HDL, triglyceride</p> </li> <li> <p>Body weight before and after dialysis</p> </li> <li> <p>BMI</p> </li> <li> <p>CTR by chest X‐ray</p> </li> <li> <p>Predialysis SBP and DBP</p> </li> <li> <p>Safety assessments and serious adverse events</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0030"> <li> <p>Further data required for meta‐analysis was not available from the authors</p> </li> <li> <p>Funding source: not reported</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study was described as randomised, method of randomisation was not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open‐label study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open‐label study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No patients dropped out in either group</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were not available on a clinical trials database</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest and funding source were not reported</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Abe 2010 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0031"> <li> <p>Study design: open‐label parallel RCT</p> </li> <li> <p>Study time frame: not reported</p> </li> <li> <p>Duration of follow‐up: 24 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0032"> <li> <p>Country: Japan</p> </li> <li> <p>Setting: single centre</p> </li> <li> <p>Inclusion criteria: HD patients with type 2 DM; poor glycaemic control (HbA1c ≥ 6.5% (48 mmol/mol) after 8 weeks on oral voglibose therapy of 0.9 mg daily </p> </li> <li> <p>Number: treatment group (18); control group (18)</p> </li> <li> <p>Mean age ± SD (years)<b>:</b> treatment group (67.0 ± 9.2). control group (66.0 ± 9.0) </p> </li> <li> <p>Sex (M/F): treatment group (11/7); control group (11/7)</p> </li> <li> <p>Exclusion criteria: deranged liver function at baseline; decompensated congestive heart failure; infectious disease; thyroid disease; malignant tumour; treatment with steroids </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0033"> <li> <p>Oral mitiglinide: started with 5 mg 3 times/d before each meal. This dose was increased up to 10 mg 3 times/d if target HbA1c values &lt; 6.5% (48 mmol were not reached after 12 weeks). Elderly HD patients (&gt; 75 years) initially received 2.5 mg 3 times/d. The dose was escalated to 5 mg 3 times/d at week 12, if necessary. Voglibose: dose was reduced from 0.9 to 0.6 mg/d if necessary to avoid hypoglycaemia. On the other hand, if the physician judged that mitiglinide 5 mg 3 times/d presented a safety problem, its dose could be reduced to 2.5 mg 3 times/d or 2.5 mg 2 times/d in elderly patients. Treated for 24 weeks </p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0034"> <li> <p>Voglibose: 0.9 mg/d for 24 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0035"> <li> <p>HbA1c, GA and plasma glucose levels were measured as the criteria for glycaemic control</p> </li> <li> <p>Insulin resistance was assessed using HOMA‐IR</p> </li> <li> <p>Plasma insulin</p> </li> <li> <p>Levels of Hb, total bilirubin, AST, ALT, lactate dehydrogenase, alkaline phosphatase, g‐GTP, total cholesterol, HDL and triglycerides </p> </li> <li> <p>Body weight before and after dialysis</p> </li> <li> <p>BMI</p> </li> <li> <p>CTR determined by radiographic examination of the chest</p> </li> <li> <p>Predialysis SBP and DBP</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0036"> <li> <p>Funding source: "The author states that Kissei Pharmaceutical had no involvement the preparation/approval of the paper. However, Kissei Pharmaceutical have paid for the FastTrack prioritization of the manuscript and they are the developers of mitiglinide." </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A computer‐generated list was used for randomisation.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open‐label study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open‐label study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No patients dropped out in either arm</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were not available on a clinical trials database</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No conflicts of interest</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Abe 2010a </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0037"> <li> <p>Study design: open‐label, parallel RCT</p> </li> <li> <p>Study time frame: June 2007 to October 2009</p> </li> <li> <p>Duration of follow‐up: 96 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0038"> <li> <p>Country: Japan</p> </li> <li> <p>Setting: single centre</p> </li> <li> <p>Inclusion criteria: HD with type 2 DM; clinically stable on maintenance HD for ≥ 12 months; ability to tolerate a 4 hr HD session with a blood flow rate of 200 mL/min; poor glycaemic control defined as a HbA1c &gt; 7.0% (53 mmol/mol) after 12 consecutive weeks of daily administration of conventional antidiabetic agents; </p> </li> <li> <p>Number (randomised/analysed): treatment group (31/30); control group (32/30)</p> </li> <li> <p>Mean age ± SD (years)<b>:</b> treatment group: (65.2 ± 12.1); control group (67.2 ± 9.4) </p> </li> <li> <p>Sex (M/F): treatment group (21/10); control group (22/10)</p> </li> <li> <p>Exclusion criteria: cirrhosis or liver dysfunction at baseline; History of heart failure (both SBP and DBP), MI, or symptomatic coronary artery disease; significant aortic or mitral valve disease; NYHA class III or IV cardiac status); thyroid disease or malignancy; history of GI or other major bleeding within the last 6 months; treatment with steroids; receiving thiazolidinedione or insulin therapy at enrolment </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0039"> <li> <p>Pioglitazone: 15 to 30 mg/d plus their other therapy at the time, including oral antidiabetic agents. All patients received advice on diet and exercise. The dose of antidiabetic agents, including pioglitazone, was adjusted as judged by the investigators to achieve a glycaemic target of HbA1c &lt; 7.0% (53 mmol/mol) </p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0040"> <li> <p>Conventional oral antidiabetic agents (not insulin). All patients received advice on diet and exercise. The dose of antidiabetic agents was adjusted as judged by the investigators to achieve a glycaemic target of HbA1c &lt; 7.0% (53 mmol/mol) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0041"> <li> <p>Glycaemic control: HbA1c, GA, and plasma fasting glucose levels</p> </li> <li> <p>Insulin resistance was assessed using the HOMA‐IR</p> </li> <li> <p>Plasma immunoreactive insulin</p> </li> <li> <p>Levels of serum iron, transferrin saturation and ferritin</p> </li> <li> <p>Hb</p> </li> <li> <p>Total cholesterol, HDL, triglyceride, plasma albumin, albumin‐corrected serum calcium, and serum phosphorus </p> </li> <li> <p>High‐sensitivity CRP</p> </li> <li> <p>iPTH</p> </li> <li> <p>Measurement of arterial blood pH and bicarbonate concentration</p> </li> <li> <p>Body weight before and after dialysis, interdialytic weight gain</p> </li> <li> <p>BMI</p> </li> <li> <p>CTR by chest X‐ray</p> </li> <li> <p>Predialysis SBP and DBP</p> </li> <li> <p>High‐molecular‐weight adiponectin and TNF‐a and IL‐6</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0042"> <li> <p>Funding source: "The authors state no conflict of interest and have received no payment in preparation of this manuscript." </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study was described as randomised, method of randomisation was not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open‐label study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open‐label study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low dropout rate with 3.2% of intervention group and 6.3% of control group dropping out </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were not available on a clinical trials database</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No conflict of interest reported</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Abe 2016 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0043"> <li> <p>Study design: open‐label, parallel RCT</p> </li> <li> <p>Study time frame: June 2014 to October 2015</p> </li> <li> <p>Duration of follow‐up: 24 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0044"> <li> <p>Country: Japan</p> </li> <li> <p>Setting: multicentre (4)</p> </li> <li> <p>Inclusion criteria: HD patients with type 2 DM; aged ≥ 20 years and ≤ 80 years; HD duration &gt; 6 months at enrolment; poor glycaemic control defined as a GA level exceeding 20.0% after 8 consecutive weeks of daily administration of conventional therapy (dietary therapy alone, oral antidiabetic agents and/or insulin) </p> </li> <li> <p>Number: treatment group (42); control group (42)</p> </li> <li> <p>Mean age ± SD (years): treatment group (66.9 ± 9.4); control group (66.3 ± 9.4)</p> </li> <li> <p>Sex (M/F): treatment group (27/14); control group (28/13)</p> </li> <li> <p>Exclusion criteria: history of severe heart failure, angina, MI or stroke within the past 6 months; presence of infectious disease, liver dysfunction, thyroid disease, malignant tumours, or treatment with steroids or immunosuppressants; current hospitalisation; treatment with any DPP‐4 inhibitor within the past 6 months </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Both groups</p> <p> <ul id="CD011798-lst1-0045"> <li> <p>Before randomisation, patients received fixed doses of conventional antidiabetic drugs (oral hypoglycaemic agents and/or insulin) for 8 weeks, and these drugs were continued during the 24‐week treatment period. If the GA remained ≥20.0% after 12 weeks of treatment in either group, the dose(s) of other antidiabetic drugs could be increased </p> </li> </ul> </p> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0046"> <li> <p>Oral saxagliptin: 2.5 mg/d</p> </li> <li> <p>Continued their regular medications, such as antihypertensive drugs, ESA, phosphate binders and lipid lowering agents, during the study period </p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0047"> <li> <p>Continued their regular medications, such as antihypertensive drugs, ESA, phosphate binders and lipid lowering agents, during the study period. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0048"> <li> <p>Change in GA</p> </li> <li> <p>Changes in vital signs and laboratory/biochemical tests during the study, and safety. GA and HbA1c levels were measured as indices of glycaemic control </p> </li> <li> <p>Postprandial plasma glucose levels</p> </li> <li> <p>Vital signs: body weight, interdialytic weight gain, BMI, CTR on chest X‐ray, and predialysis SBP and DBP </p> </li> <li> <p>Hb</p> </li> <li> <p>AST, ALT, lactate dehydrogenase, alkaline phosphatase, c‐glutamyl transpeptidase, total cholesterol, HDL, triglyceride, total protein, and albumin concentrations </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0049"> <li> <p>Funding source: "Publication of this report was financially supported by a grant from Kyowa Hakko Kirin Co. Ltd. No financial support was received for implementation of this study.) Medical writing support was provided by Dr. Nicholas D. Smith (Edanz Group Ltd.) and Elsevier/ELMCOMTM. Kyowa Hakko Kirin Co. Ltd. was not involved in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication." </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study was described as randomised, method of randomisation was not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The randomisation of subjects was monitored by an independent investigator with no previous knowledge of the subjects </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open‐label study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open‐label study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low dropout rate with 2.3% of each group dropping out</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All outcomes reported. The prespecified outcomes were available on a clinical trials database </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"MA has received honoraria from Kyowa Hakko Kirin Co. Ltd. The other authors have no conflict of interest to declare" </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">AleNephro 2014 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0050"> <li> <p>Study design: phase IIb, double‐blind, parallel RCT</p> </li> <li> <p>Recruitment period: 27 May 2010 to 13 May 2011</p> </li> <li> <p>Duration of follow‐up: 60 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0051"> <li> <p>Countries: 13 countries (Europe, South America, Asia, Australia)</p> </li> <li> <p>Setting: international (62 sites)</p> </li> <li> <p>Inclusion criteria: aged ≥ 18 years; diagnosis of type 2 DM and moderately impaired kidney function (CKD stage 3, as defined by eGFR MDRD ≥ 30 and &lt; 60 mL/min/1.73 m<sup>2</sup>); naive to the use of oral antihyperglycaemic agents or on monotherapy or combination therapy with no more than 2 antihyperglycaemic medications; HbA1c 6.5% to 10% (48‐86 mmol/mol); FBG ≤ 13.3 mmol/L; UACR ≤ 3000 μg/mg; BMI from 25.0 kg/m<sup>2</sup> (Asian patients: from 23.0 kg/m<sup>2</sup>) to 35.0 kg/m<sup>2</sup> </p> </li> <li> <p>Number (randomised/analysed): treatment group (150/149); control group (152/148)</p> </li> <li> <p>Mean age ± SD (years): treatment group (66.9 ± 8.0); control group (68.2 ± 7.6)</p> </li> <li> <p>Sex (M/F): treatment group (75/74); control group (70/78)</p> </li> <li> <p>Exclusion criteria: known diagnosis of kidney disease (except DKD); Congestive heart failure NYHA class II to IV; known macular oedema or impaired liver function (ALT or AST &gt; 3 times the ULN); currently on, or had previously received, the following treatments: thiazolidinedione or insulin (with the exception of emergency cases, in which insulin was given for &lt; 7 consecutive days), or medications interfering with measurement of creatinine (e.g. cimetidine, trimethoprim, probenecid, sulphonamides, procaine or thiazolsulfone); treatment with fibrates in the 3 months; chronic therapy with NSAID (with the exception of prophylactic stable low‐dose aspirin) 1 month prior to screening; or changes in antihypertensive therapy in the last 3 months or in statins in the last month before screening or likely to require changes during the study </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0052"> <li> <p>Patients received a once‐daily dose of 150 μg aleglitazar tablets and placebo capsules matching pioglitazone capsules, for 52 weeks, added to pre‐existing antihyperglycaemic therapy and/or diet and exercise </p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0053"> <li> <p>Patients received a once‐daily dose of 45 mg pioglitazone capsules and placebo tablets matching aleglitazar tablets, for 52 weeks, added to pre‐existing antihyperglycaemic therapy and/or diet and exercise </p> </li> </ul> </p> <p>Both groups</p> <p> <ul id="CD011798-lst1-0054"> <li> <p>2‐week screening period prior to treatment</p> </li> <li> <p>After termination of treatment, patients were followed for 8 weeks, with visits in Weeks 4 and 8 to evaluate reversibility of kidney effects </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0055"> <li> <p>Changes in eGFR following 52 weeks of daily treatment with 150 μg aleglitazar and 8 weeks of follow‐up observation after the last study medication, in comparison with 45 mg pioglitazone </p> </li> <li> <p>Percentage and absolute change from baseline in eGFR and lipid profiles at end of treatment </p> </li> <li> <p>Change from baseline to end of treatment and after 8 weeks of follow‐up in additional kidney parameters, and time to first occurrence of any component of the triple‐composite kidney endpoint (ESKD, confirmed doubling of SCr from baseline, (confirmed at least 4 weeks later) or confirmed increase in SCr of 50% (confirmed within 1 week and leading to discontinuation of treatment)), or the double‐composite kidney endpoint (ESRD or any doubling of SCr from baseline) </p> </li> <li> <p>Safety endpoints: adverse events, clinical laboratory tests, ECG, vital signs, physical examination, peripheral oedema, and cardiovascular symptoms including events </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0056"> <li> <p>Funding source: "The AleNephro study was funded by F. Hoffmann‐La Roche AG"</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“At the baseline visit, patients were randomly assigned (via an interactive voice‐response system) in a 1:1 ratio to receive orally either 150 μg aleglitazar tablets and placebo capsules matching pioglitazone capsules, or 45 mg pioglitazone capsules and placebo tablets matching aleglitazar tablets. The patient randomisation numbers were generated by Roche and maintained by an unblinded statistician. The investigator or designee entered the case report form number (CRF; patient number) on the electronic CRF (given to a patient at visit 2 at the time of randomisation) and entered the corresponding randomisation number for allocation to the treatment groups in the appropriate place on each patient’s eCRF." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"The patient randomisation numbers were allocated sequentially in the order in which the patients were enrolled according to the specification document agreed with the randomisation company (S‐Clinica). The password‐protected and/or encrypted electronic master randomisation list was kept in a central repository by the Roche Biometrics and Drug Safety Departments. No open key to the code was available at the study centre, to the Roche monitors, project statisticians, or to the project team at Roche.” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Patients, study site personnel and sponsor were all blinded to treatment assignment</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Patients, study site personnel and sponsor were all blinded to treatment assignment</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>21.3% dropped out from the aleglitazar group and 22.4% dropped out from the pioglitazone group </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were available on a clinical trials database was available and reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest were present. The sponsor F. Hoffmann‐La Roche contributed to dosing, data collection, statistical analysis and interpretation of data in collaboration with the investigators. Authors were either employees of F. Hoffmann‐La Roche or serve as advisors to the company, or have received speaker honoraria, consulting fees, research grants from the company </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Arjona Ferreira 2013 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0057"> <li> <p>Study design: double‐blind, parallel RCT</p> </li> <li> <p>Study time frame: not reported</p> </li> <li> <p>Duration of follow‐up: 54 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0058"> <li> <p>Countries: multinational (number of countries not reported)</p> </li> <li> <p>Setting: multicentre (number of centres not reported)</p> </li> <li> <p>Inclusion criteria: patients with type 2 DM; moderate to severe chronic kidney insufficiency (eGFR &lt; 50 mL/min/1.73 m<sup>2</sup> using the MDRD equation); not on dialysis and unlikely to require dialysis for the duration of the study; HbA1c 7.0 to ≥ 9.0%, and were ≥ 30 years of age at the screening visit </p> </li> <li> <p>Number: treatment group (211); control group (212)</p> </li> <li> <p>Mean age ± SD (years)<b>:</b> treatment group (64.8 ± 10.6); control group (64.3 ± 9.2) </p> </li> <li> <p>Sex (M/F): treatment group (80/55); control group (78/64)</p> </li> <li> <p>Exclusion criteria: taking insulin within 12 weeks of the screening visit; type 1 DM; history of ketoacidosis, AKI, kidney transplant or liver disease; recent (within 3 months) cardiovascular event; hepatic transaminase levels ≥ 2 times the ULN; thyroid stimulating hormone outside the reference range; triglycerides &gt; 6.78 mmol/L; met one of the following prespecified glycaemic criteria: visit 2, FBG &gt; 14.44 mmol/L, unlikely to improve with diet/exercise; visit 3, FBG &gt; 13.89 mmol/L consistently (i.e. measurement repeated and confirmed within 7 days); visit 4, FBG &gt; 13.33 mmol/L consistently; and visit 5, finger‐stick glucose &gt; 13.33 or &lt; 6.67 mmol/L </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0059"> <li> <p>Patients with moderate kidney insufficiency received 50 mg/d of sitagliptin (2 x 25 mg tablets). The dose of sitagliptin was reduced from 50 mg/d to 25 mg/d for patients whose kidney status changed from moderate to severe </p> </li> <li> <p>Patients with severe kidney insufficiency received 25 mg/d of sitagliptin (1 x 25 mg tablet) </p> </li> <li> <p>After maximally titrating the matching placebo to glipizide, patients had insulin rescue therapy initiated, with the regimen and dose determined by investigator, if they met the following criteria: confirmed FBG &gt; 13.33 mmol/L any time from randomisation to week 6; confirmed FBG &gt; 12.22 mmol/L from week 6 to 12; confirmed FBG &gt; 11.11 mmol/L from week 12 to 24; and confirmed HbA1c &gt; 8% after week 24. Once insulin rescue therapy was initiated, patients continued to take blinded sitagliptin or matching placebo, but discontinued the matching placebo to glipizide. </p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0060"> <li> <p>Glipizide was administered at a starting dose of 2.5 mg/d, prior to the morning meal, and electively titrated to a maximum of 20 mg/d as considered appropriate by the investigator based on the patient’s glycaemic control. The dose of glipizide could also be reduced or interrupted to prevent hypoglycaemia. Patients received a placebo for sitagliptin. After maximally titrating glipizide, patients had insulin rescue therapy initiated, with the regimen and dose determined by investigator, if they met the following criteria: confirmed FBG &gt; 13.33 mmol/L any time from randomisation to week 6; confirmed FBG &gt; 12.22 mmol/L from week 6 to 12; confirmed FBG &gt; 11.11 mmol/L from week 12 to 24; and confirmed HbA1c &gt; 8% after week 24. Once insulin rescue therapy was initiated, patients continued to take blinded sitagliptin or matching placebo, but discontinued blinded glipizide </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0061"> <li> <p>Change from baseline in HbA1c at week 54</p> </li> <li> <p>FBG, fasting serum insulin and proinsulin, and plasma lipid profiles (total cholesterol, LDL, HDL, non–HDL‐cholesterol, triglycerides) </p> </li> <li> <p>Homeostasis model assessment–B‐cell function, HOMA‐IR, proinsulin/insulin ratio were calculated from fasting measurements of FBG, insulin, and proinsulin </p> </li> <li> <p>Proportion of individuals whose HbA1c values met glycaemic goals (&lt; 7.0% as primary; &lt; 6.5% as secondary) at week 54 </p> </li> <li> <p>Post hoc analysis evaluated the effect of sitagliptin versus glipizide on a composite end point consisting of glycaemic control (reduction in HbA1c &gt; 0.5%), no body weight gain, and no hypoglycaemia </p> </li> <li> <p>Adverse events, physical examination and vital signs, and ECG</p> </li> <li> <p>Laboratory safety studies included serum chemistry, haematology, and urinalysis</p> </li> <li> <p>Hypoglycaemia were considered of special interest</p> </li> <li> <p>Events of hypoglycaemia requiring (non‐medical) assistance of others, requiring medical intervention, or exhibiting markedly depressed level of consciousness, loss of consciousness, or seizure were considered severe </p> </li> <li> <p>Change in body weight and GI adverse events (nausea, vomiting, diarrhoea, and abdominal pain) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0062"> <li> <p>The study included a 1‐week screening period, a diet/exercise and oral glucose‐lowering agent wash‐off period of up to 14 weeks, a 2‐week, single‐blind placebo run‐in period, and a 54‐week, double‐blind treatment period. </p> </li> <li> <p>At screening, patients not taking glucose‐lowering agents for ≥ 12 weeks with an HbA1c of 7–9% directly entered the single‐blind placebo run‐in period and those with an HbA1c &gt; 9% entered a 6‐week diet and exercise period. Patients taking oral glucose‐lowering agents with an HbA1c of 7–9% entered an 8‐week drug wash‐off and diet and exercise period (those taking thiazolidinediones underwent a 10‐week wash‐off period), and those with an HbA1c of 6.5 to &lt; 7% entered an 8–12‐week drug wash‐off and diet and exercise period (those on thiazolidinediones underwent a 10–14‐week wash‐off period). Patients received diet and exercise counselling throughout the study, consistent with American Diabetes Association recommendations and appropriate for their kidney insufficiency status. Following the placebo run‐in, eligible patients were randomised (1:1) using a computer‐generated randomisation schedule to receive sitagliptin or glipizide and their matching placebo. </p> </li> <li> <p>Data from one study site (3 patients) were considered potentially unreliable due to lack of compliance with Good Clinical Practice and excluded from all analyses. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Patients were randomised (1:1) using a computer‐generated randomisation schedule to receive sitagliptin or glipizide. Randomization was stratified based on: 1) kidney insufficiency status (moderate or severe), 2) history of cardiovascular disease (yes or no), and 3) history of heart failure (yes or no)". </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Sitagliptin and glipizide matching placebos were used to maintain blinding</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The study was described as double‐blind, but the methods to ensure blinding of outcome assessment were not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>22.3% of the sitagliptin group and 19.8% of the glipizide group dropped out</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were available on a clinical trials database. All outcomes were reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: The study was sponsored by Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., Whitehouse Station, NJ, the manufacturer of sitagliptin. J.C.A.F., H.G., G.T.G., C.M.S., K.D.K., and B.J.G. are employees of Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., and may have stock or stock options in the company. N.B. has served on the National Diabetes Advisory Board. M.M. is a consultant for Association Diabete Risque Vasculaire, serves on the Merck global advisory board and the French subsidiary advisory board, and is a speaker for Merck, Sanofi, Novo Nordisk, Servier, and Abbott Diagnostics. No other potential conflicts of interest relevant to this. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Arjona Ferreira 2013a </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0063"> <li> <p>Study design: double‐blind, parallel RCT</p> </li> <li> <p>Study time frame: not reported</p> </li> <li> <p>Duration of follow‐up: 54 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0064"> <li> <p>Countries: 13 (countries not reported)</p> </li> <li> <p>Setting: multicentre (3 sites)</p> </li> <li> <p>Inclusion criteria: patients with type 2 DM on HD or PD for at least 6 months; ≥ 30 years; patients on monotherapy or low‐dose combination therapy with oral antihyperglycaemic agents could participate if their treatment regimen could be discontinued during the run‐in period </p> </li> <li> <p>Number: treatment group (64); control group (65)</p> </li> <li> <p>Mean age ± SD (years)<b>:</b> treatment group (60.5 ± 9.1); control group (58.5 ± 9.9) </p> </li> <li> <p>Sex (M/F): treatment group (40/24); control group (37/28)</p> </li> <li> <p>Exclusion criteria: on insulin therapy within 12 weeks of the screening visit; type 1 DM or a history of ketoacidosis; AKI; kidney transplant; liver disease; recent (within 6 months) cardiovascular event; hepatic transaminase levels ≥ 2 times the ULN; repeated FBG &gt; 13.3 mmol/L, or triglyceride &gt; 6.7 mmol/L </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0065"> <li> <p>Sitagliptin 25 mg daily and a glipizide placebo pill. Glipizide placebo was initiated at 2.5 mg daily and progressively titrated in 2‐week intervals to a potential maximum dose of 10 mg twice daily. In general, uptitration of glipizide placebo was to occur if the prior week’s fasting and preprandial glucose measurements were ≥ 6.7 mmol/L and there were no episodes of hypoglycaemia. However, investigators were allowed to increase the dose of glipizide placebo as considered appropriate, deviating from the parameters outlined above. Downtitration, including interruption of treatment, could occur if a patient had unexplained hypoglycaemia documented by fingerstick glucose level &lt; 3.9 mmol/L or at the clinical judgment of the investigator, to reduce the risk of hypoglycaemia. Treatment adherence was assessed by patient query at prespecified visits throughout the study. Glycaemic rescue therapy (i.e. insulin) was available after randomisation for patients whose glipizide placebo tablets had been uptitrated to the maximum tolerated dose and who met predefined glycaemic parameters as follows: confirmed FBG &gt; 13.33 mmol/L at any time after randomisation (day 1) until week 6, confirmed FBG &gt; 12.2 mmol/L after week 6 through week 12, confirmed FBG &gt; 11.1 mmol/L after week 12 through week 24, and confirmed HbA1c &gt; 8% (64 mmol/mol) after week 24. Prior to initiating rescue therapy, patients were to undergo efficacy and safety measurements and procedures. Investigators were responsible for the management of insulin therapy. </p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0066"> <li> <p>Glipizide initiated at 2.5 mg daily and progressively titrated in 2‐week intervals to a potential maximum dose of 10 mg twice daily and a sitagliptin placebo pill. In general, uptitration of glipizide was to occur if the prior week’s fasting and preprandial glucose measurements were ≥ 6.67mmol/L and there were no episodes of hypoglycaemia. However, investigators were allowed to increase the dose of glipizide as considered appropriate, deviating from the parameters outlined above. Downtitration, including interruption of treatment, could occur if a patient had unexplained hypoglycaemia documented by fingerstick glucose level &lt; 3.89 mmol/L or at the clinical judgment of the investigator, to reduce the risk of hypoglycaemia. Treatment adherence was assessed by patient query at prespecified visits throughout the study. Glycaemic rescue therapy (i.e. insulin) was available after randomisation for patients whose glipizide tablets had been uptitrated to the maximum tolerated dose and who met predefined glycaemic parameters as follows: confirmed FBG &gt; 13.3 mmol/L at any time after randomisation (day 1) until week 6, confirmed FBG &gt; 12.2 mmol/L after week 6 through week 12, confirmed FBG &gt; 11.1 mmol/L after week 12 through week 24, and confirmed HbA1c &gt; 8% (64 mmol/mol) after week 24. Prior to initiating rescue therapy, patients were to undergo efficacy and safety measurements and procedures. Investigators were responsible for the management of insulin therapy </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0067"> <li> <p>Change in HbA1c, tolerability ‐ vital signs, electrocardiograms, blood chemistry, haematology, and urinalysis </p> </li> <li> <p>Incidence of symptomatic hypoglycaemia</p> </li> <li> <p>FBG, fasting serum insulin and proinsulin, and plasma lipid profiles (total cholesterol, LDL cholesterol, HDL and triglycerides) </p> </li> <li> <p>Homeostasis model assessment of B‐cell function, HOMA‐IR, and proinsulin to insulin ratio were calculated from fasting measurements of glucose, insulin, and/or proinsulin </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0068"> <li> <p>At the screening visit, patients not on antihyperglycaemic therapy for 12 weeks or longer with an HbA1c level of 7% to 9% (53 to 75 mmol/mol) directly entered a 2‐week, single‐blind, placebo run‐in period. Patients not on therapy with an HbA1c level &gt; 9% (75 mmol/mol) entered a 6‐week diet and exercise period. Patients on an oral antihyperglycaemic regimen with an HbA1c level of 7%‐9% entered an 8‐week drug washout and diet and exercise period; those using thiazolidinediones underwent a 10‐week washout period. Patients on an oral antihyperglycaemic regimen with an HbA1c level of 6.5% to &lt; 7% (48 to &lt;53 mmol/mol) entered an 8‐ to 12‐week drug washout and diet and exercise period; those using thiazolidinediones underwent a 10‐ to 14‐week washout period. Patients received counselling throughout the study on diet and exercise consistent with American Diabetes Association recommendations and appropriate for patients with ESKD on dialysis therapy. Following the diet and exercise and washout period, patients with an HbA1c level of 7% to 9% (53 to 75 mmol/mol) entered the 2‐week placebo run‐in period. </p> </li> <li> <p>Funding source: "The study was sponsored by Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co. Inc., the manufacturer of sitagliptin." </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Patients were “randomly assigned 1:1, using a computer‐generated randomisation schedule, to receive sitagliptin, 25 mg daily or glipizide”. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Sitagliptin or glipizide placebo pills were used to maintain blinding”.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Large dropout rates for both groups ‐ 26.6% for the sitagliptin group and 30.8% for the glipizide group </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were available on a clinical trials database and all outcomes were reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1) The study was underpowered. From the report: “Due to enrolment challenges, the sample size was revised from 150 (original design) to 125. The following calculations were based on the revised sample size. Assuming 10% of patients discontinued without a post randomisation measurement, the study had 76% power to detect a true difference of 0.40% in the within‐group mean reduction in HbA1c level from baseline, using a standard deviation of 1.1%”. However, 28.7% of cohort discontinued. </p> <p>2) Conflict of interest: The study was sponsored by Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co. Inc., the manufacturer of </p> <p>sitagliptin. Doctors Arjona Ferreira, Xu, Golm, Davies, Kaufman, and Goldstein and Mr Gonzalez are employees of Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co. Inc., and may have stock or stock options in the company. Dr Sloan has served on an advisory board for sitagliptin and has been a speaker and consultant for Merck Sharp &amp; Dohme Corp. The other authors declare that they have no other relevant financial interests. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Baldwin 2012 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0069"> <li> <p>Study design: parallel RCT</p> </li> <li> <p>Study time frame: June 2009 to June 2011</p> </li> <li> <p>Duration of follow‐up: 6 days</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0070"> <li> <p>Country: USA</p> </li> <li> <p>Setting: multicentre (3 sites)</p> </li> <li> <p>Inclusion criteria: patients with type 2 DM &gt; 1 year of duration; &gt; 18 years; eGFR ≤ 45 mL/min/1.73 m<sup>2</sup>; at least one hospital blood glucose level &gt; 10 mmol/L; if on insulin, outpatient dose ≥ 0.5 U/kg </p> </li> <li> <p>Number: treatment group (57); control group (50)</p> </li> <li> <p>Mean age ± SD (years)<b>:</b> treatment group (63.7 ± 13.0); control group (65.3 ± 10.6) </p> </li> <li> <p>Sex (M/F): treatment group (28/29); control group (20/30)</p> </li> <li> <p>Exclusion criteria: type 1 DM; pregnancy; chronic dialysis; solid‐organ transplant within the past 12 months; steroid therapy &gt; 7.5 mg/d of prednisolone or equivalent medication; known hypopituitarism or adrenal insufficiency; known hypoglycaemia unawareness; length of stay &lt; 48 h; severe liver disease </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Both groups</p> <p> <ul id="CD011798-lst1-0071"> <li> <p>All oral antidiabetic agents were stopped on hospital admission</p> </li> </ul> </p> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0072"> <li> <p>SC insulin: 0.25 U/kg, half the dose given as glargine and half the dose as glulisine 3 times/d equally </p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0073"> <li> <p>SC insulin: 0.5 U/Kg, half the dose glargine and half the dose as glulisine 3 times/d equally </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0074"> <li> <p>Percentage of BGL within the range of 5.6 to 10 mmol/L, and the percentage of subjects experiencing a hypoglycaemic event defined as a blood glucose &lt; 3.9 mmol/L </p> </li> <li> <p>Hypoglycaemic events were further separated into moderate hypoglycaemia (2.8 to 3.8 mmol/L) and severe hypoglycaemia (&lt; 2.8 mmol/L) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0075"> <li> <p>Funding source: "This study was sponsored by an investigator‐initiated grant from sanofi‐aventis." </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The method of random sequence generation was not reported. All the paper reports was: “Eligible patients gave informed consent and were randomised 1:1 into two protocol groups by a research pharmacist”. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>There were no drop‐outs in each group, and all subjects were analysed in the groups to which they were randomised </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were available on a clinical trials database and all outcomes were reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No conflicts of interest were reported</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Barnett 2013 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0076"> <li> <p>Study design: phase 3, parallel RCT</p> </li> <li> <p>Study time frame: 10 March 2010 to 22 June 2011</p> </li> <li> <p>Duration of follow‐up: 24 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0077"> <li> <p>Countries: Australia, Canada, Denmark, the Netherlands; Sweden</p> </li> <li> <p>Setting: multinational (33 clinics)</p> </li> <li> <p>Inclusion criteria: Men and women ≥ 70 years with type 2 DM; had insufficient glycaemic control (HbA1c ≥ 7.0%; 53 mmol/mol); receiving stable doses of metformin, sulphonylureas, or basal insulin, or combinations of these drugs, for at least 8 weeks </p> </li> <li> <p>Number (randomised/analysed): treatment group (162/146); control group (79/74)</p> </li> <li> <p>Mean age ± SD (years): treatment group (74.9 ± 4.4); control group (74.9 ± 4.2)</p> </li> <li> <p>Sex (M/F): treatment group (116/46); control group (49/30)</p> </li> <li> <p>36 patients had an eGFR &lt; 60 included in the analysis</p> </li> <li> <p>Exclusion criteria: FBG &gt; 13·3 mmol/L; impaired hepatic function (ALT, AST, or ALP &gt; 3 times the ULN); MI, stroke, or TIA within 3 months before the study; previous bariatric surgery; present treatment with rapid‐acting or premixed insulin or systemic steroids; treatment within the previous 3 months with a thiazolidinedione, α‐glucosidase inhibitor, meglitinide, GLP1 analogue, DPP‐4 inhibitor, or anti‐obesity drug </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Both groups</p> <p> <ul id="CD011798-lst1-0078"> <li> <p>After screening, eligible patients underwent a 2 week, open‐label, placebo run‐in period. Patients were then randomised </p> </li> <li> <p>Maintained existing glucose‐lowering treatment throughout the study</p> </li> </ul> </p> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0079"> <li> <p>Oral linagliptin: 5 mg once/d for 24 weeks</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0080"> <li> <p>Oral placebo: once/d for 24 weeks</p> </li> </ul> </p> <p>Other information</p> <p> <ul id="CD011798-lst1-0081"> <li> <p>Doses of background treatments were maintained for the first 12 weeks of randomised treatment, after which dose adjustments were permitted. Rescue medication for hyperglycaemia (confirmed glucose level: fasting &gt;13·3 mmol/L in weeks 1–12, &gt; 11·1 mmol/L in weeks 13–24; or random test &gt; 22·2 mmol/L; two or more measurements on different days, one done after an overnight fast) was permitted during randomised treatment </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0082"> <li> <p>Change in HbA1c from baseline to week 24</p> </li> <li> <p>Proportion of patients achieving HbA1c &lt; 7.0% (53 mmol/mol) after 24 weeks</p> </li> <li> <p>Proportion of patients with a 0·5% or greater reduction in HbA1c after 24 weeks</p> </li> <li> <p>Change in HbA1c from baseline over time</p> </li> <li> <p>Change in FBG from baseline at week 24</p> </li> <li> <p>Change in FBG from baseline over time, and use of rescue therapy</p> </li> <li> <p>Incidence and intensity of adverse events (including adverse changes noted during physical examinations or 12‐lead ECGs) </p> </li> <li> <p>Withdrawals because of adverse events; hypoglycaemia; cardiovascular events; and changes in vital signs, laboratory variables, and background treatment </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0083"> <li> <p>The proportion of patients achieving other levels of HbA1c (&lt; 7.5% (58 mmol/mol) , &lt; 8.0% (64 mmol/mol), &lt; 8.5%) was analysed post hoc </p> </li> <li> <p>Funding source: Boehringer Ingelheim</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Computer‐generated randomisation lists were produced by the sponsor...”</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“...allocation concealed using a central interactive voice–web response system”.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Linagliptin and placebo tablets were identical in appearance, and investigators and patients were masked to treatment assignment throughout the study” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Linagliptin and placebo tablets were identical in appearance, and investigators and patients were masked to treatment assignment throughout the study”. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16/162 (9.9%) linagliptin; 5/79 (6.3%) placebo dropped out</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were available on a clinical trials database and all outcomes were reported. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflict of interest: This study was sponsored by Boehringer Ingelheim. The sponsor was involved in study design, and data collection, review, and analysis. All authors were employees of Boehringer Ingelheim except the first author who has received honoraria for lecture and advisory work for the company. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Bellante 2016 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0084"> <li> <p>Study design: prospective RCT</p> </li> <li> <p>Study time frame: not reported</p> </li> <li> <p>Duration of follow‐up: 52 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0085"> <li> <p>Country: Italy</p> </li> <li> <p>Setting single centre</p> </li> <li> <p>Inclusion criteria: patients with type 2 DM and CKD stage 3B, 4‐5 and 5D</p> </li> <li> <p>Number: treatment group (32); control group (17)</p> </li> <li> <p>Mean age ± SD: 73 ± 8 years</p> </li> <li> <p>Sex (M/F): not reported</p> </li> <li> <p>Exclusion criteria: not reported</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0086"> <li> <p>Sitagliptin: dose not reported</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0087"> <li> <p>Insulin: dose not reported</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0088"> <li> <p>Effects on circulating endothelial progenitor cells</p> </li> <li> <p>Effects on endothelial progenitor cells functional properties</p> </li> <li> <p>BMI, BP, lipids, eGFR and HbA1c</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0089"> <li> <p>Abstract‐only publication</p> </li> <li> <p>Funding source: not reported</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation was not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"The same trained operators, blind to the clinical status of each subject, performed the tests throughout the entire study." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No dropouts were reported.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were not available on a clinical trials database.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Chan 2008a </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0090"> <li> <p>Study design: parallel RCT</p> </li> <li> <p>Study time frame: not reported</p> </li> <li> <p>Duration of follow‐up: 54 weeks</p> </li> <li> <p>54‐week, multinational, randomised, double‐blind, parallel‐group study that included a 12‐week, double‐blind, placebo‐controlled phase and a 42‐week, double‐blind, continuation phase during which all patients were eligible for active therapy (either continued treatment with sitagliptin or treatment with glipizide for those initially randomised to placebo). </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0091"> <li> <p>Countries: Australia; Chile; Colombia; Hong Kong; Hungary; Malaysia; Mexico; New Zealand; Philippines; Spain; USA </p> </li> <li> <p>Setting: multinational (30 sites)</p> </li> <li> <p>Inclusion criteria: Patients ≥ 18 years with type 2 DM and kidney insufficiency; not on oral antihyperglycaemic agents or washed off these agents during the run‐in period; patients on insulin monotherapy were also allowed to participate in this study </p> </li> <li> <p>Number: treatment group (65); control group (26)</p> </li> <li> <p>Mean age ± SD (years): treatment group (68.9 ± 9.8); control group (65.3 ± 9.7)</p> </li> <li> <p>Sex (M/F): treatment group (31/34); control group (16/10)</p> </li> <li> <p>Exclusion criteria: type 1 diabetes (or a history of ketoacidosis); AKI; history of kidney transplant; liver disease; recent (within 6 months) cardiovascular event; hepatic transaminase or creatine phosphokinase levels ≥ two times the ULN; repeated FBG &gt;15 mmol/L or triglycerides &gt; 6.8 mmol/L </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0092"> <li> <p>Sitagliptin for 12 weeks. Patients with CrCl ≥ 30 to &lt; 50 mL/min received once‐daily sitagliptin 50 mg; patients with CrCl &lt; 30 mL/min inclusive of those on dialysis received once‐daily sitagliptin 25 mg. If estimated CrCl decreased to &lt; 30 mL/min during the study, patients were instructed to down titrate their dose for the remainder of the study. </p> </li> <li> <p>From week 12, patients received glipizide placebo for 42 weeks</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0093"> <li> <p>Placebo: for 12 weeks</p> </li> <li> <p>From week 12 patients were eligible for active treatment with glipizide initiated at a dose of 5 mg/d and progressively titrated in 2‐week intervals to a maximum dose of 10 mg twice daily. Initiation and uptitration of glipizide placebo were to occur if the FBG was &gt; 7.2 mmol/L and if considered clinically appropriate by the investigator </p> </li> </ul> </p> <p>Other information</p> <p> <ul id="CD011798-lst1-0094"> <li> <p>Both groups</p> <ul id="CD011798-lst2-0003"> <li> <p>Patients received counselling on exercise and diet consistent with American Diabetes Association recommendations and appropriate for patients with kidney insufficiency throughout the study </p> </li> </ul> </li> <li> <p>Treatment group</p> <ul id="CD011798-lst2-0004"> <li> <p>If the investigator considered a patient to be at significantly increased risk for hypoglycaemia, the investigator could either withhold glipizide placebo altogether, initiate dosing at the lower dose of 2.5 mg/day, or, for those patients already receiving glipizide placebo tablets, either withhold uptitration of glipizide placebo or down titrate the glipizide placebo dose. To avoid the potentially increased risk of hypoglycaemia episodes with co‐administered insulin and glipizide, patients who entered the study on insulin therapy were ineligible to initiate glipizide/glipizide placebo upon entry into the continuation phase. Open‐label glycaemic rescue therapy was available throughout the study. For glycaemic rescue, patients on insulin had their insulin dose uptitrated, while patients not on insulin initiated either an open‐label sulphonylurea or insulin therapy (at the discretion of the investigator). To avoid accidental treatment with two sulphonylurea agents or treatment with the combination of insulin and a sulphonylurea, patients who had undergone glycaemic rescue during the first 12 weeks of the study were ineligible to initiate double‐blind glipizide/glipizide placebo upon entry into the 42‐week continuation phase. Similarly, patients requiring glycaemic rescue therapy during the 42‐week continuation phase were to discontinue their blinded, glipizide/glipizide placebo tablets before rescue treatment was added </p> </li> </ul> </li> </ul> <ul id="CD011798-lst1-0095"> <li> <p>Control group</p> <ul id="CD011798-lst2-0005"> <li> <p>If the investigator considered a patient to be at significantly increased risk for hypoglycaemia, the investigator could either withhold glipizide altogether, initiate dosing at the lower dose of 2.5 mg/day, or, for those patients already receiving glipizide tablets, either withhold uptitration of glipizide or down titrate the glipizide dose. To avoid the potentially increased risk of hypoglycaemia episodes with co‐administered insulin and glipizide, patients who entered the study on insulin therapy were ineligible to initiate glipizide/glipizide placebo upon entry into the continuation phase. Open‐label glycaemic rescue therapy was available throughout the study. For glycaemic rescue, patients on insulin had their insulin dose uptitrated, while patients not on insulin initiated either an open‐label sulphonylurea or insulin therapy (at the discretion of the investigator). To avoid accidental treatment with two sulphonylurea agents or treatment with the combination of insulin and a sulphonylurea, patients who had undergone glycaemic rescue during the first 12 weeks of the study were ineligible to initiate double‐blind glipizide/glipizide placebo upon entry into the 42‐week continuation phase. Similarly, patients requiring glycaemic rescue therapy during the 42‐week continuation phase were to discontinue their blinded, glipizide/glipizide placebo tablets before rescue treatment was added. </p> </li> </ul> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0096"> <li> <p>Glycaemic and lipid assessments included the change from baseline in HbA1c, FBG and the per cent change from baseline in plasma lipids (total cholesterol, low density lipoprotein cholesterol (LDL‐C), HDL cholesterol (HDL‐C) and triglycerides) </p> </li> <li> <p>Physical examinations, vital signs and ECGs collected at specified study visits</p> </li> <li> <p>Blood chemistry, haematology, urinalysis and urine microalbumin/creatinine ratio</p> </li> <li> <p>Events of hypoglycaemia were considered of special interest</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0097"> <li> <p>Funding source: Merck &amp; Co., Inc</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Following the placebo run‐in period, patients underwent baseline measurements and were randomised to receive once‐daily administration of sitagliptin or placebo in a 2 : 1 ratio using a computer‐generated randomisation schedule”. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Following the placebo run‐in period, patients underwent baseline measurements and were randomised to receive once‐daily administration of sitagliptin or placebo in a 2 : 1 ratio using a computer‐generated randomisation schedule” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Patients received placebo tablets. Also described as a 54‐week, multinational, randomised, double‐blind, parallel‐group study </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>study described as a 54‐week, multinational, randomised, double‐blind, parallel‐group study, but the method of outcome assessment blinding was not described in the report </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>29.2% 19/65 dropped out in the sitagliptin group.</p> <p>23.1% 6/26 dropped out in the placebo/gliclazide group.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were available on a clinical trials database and all outcomes were reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflict of interest: This study was sponsored by Merck &amp; Co., Inc, Whitehouse Station, NJ, USA, who make sitagliptin </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Diez 1987 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0098"> <li> <p>Study design: parallel RCT</p> </li> <li> <p>Study time frame: not reported</p> </li> <li> <p>Duration of follow‐up: 9 months</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0099"> <li> <p>Country: Spain</p> </li> <li> <p>Setting multicentre (2)</p> </li> <li> <p>Inclusion criteria: DM patients on CAPD</p> </li> <li> <p>Number: treatment group 1 (13); treatment group 2 (6)</p> </li> <li> <p>Mean age ± SD (years): not reported</p> </li> <li> <p>Sex (M/F): not reported</p> </li> <li> <p>Exclusion criteria: not reported</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group 1</p> <p> <ul id="CD011798-lst1-0100"> <li> <p>SC insulin</p> </li> </ul> </p> <p>Treatment group 2</p> <p> <ul id="CD011798-lst1-0101"> <li> <p>IP insulin</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0102"> <li> <p>Metabolic control</p> </li> <li> <p>Peritonitis</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0103"> <li> <p>Abstract‐only publications</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study was described as randomised, method of randomisation was not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No drop‐outs reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were not available on a clinical trials database available ‐ inadequate information </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">EMPA‐REG BP 2015 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0104"> <li> <p>Study design: phase 3, parallel RCT</p> </li> <li> <p>Study time frame: June 2011 to July 2012</p> </li> <li> <p>Duration of follow‐up: 14 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0105"> <li> <p>Countries: Europe, Middle East and North America</p> </li> <li> <p>Setting: multinational (number of centres not reported)</p> </li> <li> <p>Inclusion criteria: patients aged ≥ 18 years, BMI ≤ 45 kg/m<sup>2</sup>, type 2 DM and hypertension (SBP 130 to 159 mmHg; DBP 80 to 99 mmHg); HbA1c ≥ 7.0 to ≤ 10.0% (≥ 53 to ≤ 86 mmol/mol); required to receive up to two antihypertensive medications at a stable dose for ≥ 4 weeks at screening and throughout a 2‐week, open‐label, placebo run‐in period; for treatment of type 2 DM, patients were required to be on a diet and exercise regimen and be drug naive (no oral antidiabetes therapy, GLP‐1 analogue, or insulin for ≥ 12 weeks (or ≥ 16 weeks for pioglitazone) prior to randomisation) or pretreated with any oral antidiabetes therapy, GLP‐1 analogue, or insulin for ≥ 12 weeks prior to randomisation; antidiabetes therapy doses were to have remained unchanged for ≥ 12 weeks (or ≥ 16 weeks for pioglitazone) prior to randomisation or, for insulin, the dose was not to have been changed within 12 weeks prior to randomisation by &gt; 10% from the dose at randomisation </p> </li> <li> <p>Number: treatment group 1 (276); treatment group 2 (276); control group (271)</p> <ul id="CD011798-lst2-0006"> <li> <p>45 patients had eGFR &lt; 60 mL/min at baseline</p> </li> <li> <p>Treatment group 1 (13); treatment group 2 (21); control group (11)</p> </li> </ul> </li> <li> <p>Mean age ± SD (years): treatment group 1 (60.6 ± 8.5); treatment group 2 (59.9 ± 9.7); control group (60.3 ± 8.8) </p> </li> <li> <p>Sex (M/F)<b>:</b> treatment group 1 (171/105); treatment group 2 (156/120); control group (168/103) </p> </li> <li> <p>Exclusion criteria: uncontrolled hyperglycaemia (plasma glucose &gt; 13.3 mmol/L after an overnight fast during the run‐in period);SBP ≥ 160 mmHg and/or DBP ≥ 100 mmHg during the run‐in period; known/suspected secondary hypertension; history/evidence of hypertensive retinopathy or hypertensive encephalopathy; kidney impairment (eGFR &lt; 60 mL/min/1.73 m<sup>2</sup>; indication of liver disease (serum ALT, AST, or ALP &gt; three times the ULN) during screening/run‐in period; acute coronary syndrome, stroke, or TIA within 3 months of consent.; use of anti‐obesity drugs within 3 months of consent or bariatric surgery within 2 years; any uncontrolled endocrine disorder except type 2 DM </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>All groups</p> <p> <ul id="CD011798-lst1-0106"> <li> <p>2‐week, open‐label, placebo run‐in, patients were then randomised (1:1:1)</p> </li> <li> <p>Patients continued their antihypertensive and antidiabetes background therapy throughout the study at an unchanged dose and regimen, if possible </p> </li> </ul> </p> <p>Treatment group 1</p> <p> <ul id="CD011798-lst1-0107"> <li> <p>Empagliflozin: 10 mg daily for 12 weeks</p> </li> </ul> </p> <p>Treatment group 2</p> <p> <ul id="CD011798-lst1-0108"> <li> <p>Empagliflozin: 25 mg daily for 12 weeks</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0109"> <li> <p>Placebo for 12 weeks</p> </li> </ul> </p> <p>Other information</p> <p> <ul id="CD011798-lst1-0110"> <li> <p>Changes in antihypertensive medication could be initiated if a patient had a mean SBP ≥ 160 mmHg and/or a mean DBP ≥ 100 mmHg at a clinic visit </p> </li> <li> <p>Rescue medication for hyperglycaemia could be initiated at the discretion of the investigator if, after an overnight fast, a patient had plasma glucose &gt; 13.3 mmol/L during the first 12 weeks of treatment or &gt; 11.1 mmol/L during the follow‐up period </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0111"> <li> <p>Change from baseline in HbA1c at week 12</p> </li> <li> <p>Change from baseline in mean 24 h SBP at week 12</p> </li> <li> <p>Change from baseline in mean 24 h DBP at week 12, both measured via ABPM</p> </li> <li> <p>Changes from baseline in FBG body weight, daytime and night‐time mean SBP and DBP, and mean seated office SBP and DBP </p> </li> <li> <p>Use of rescue medication</p> </li> <li> <p>Adverse events of special interest included confirmed hypoglycaemic adverse events (plasma glucose ≤ 3.9 mmol/L and/or assistance required), </p> </li> <li> <p>Adverse events consistent with UTI (based on a prospectively defined search of 70 preferred terms), </p> </li> <li> <p>Adverse events consistent with genital infection (based on a prospectively defined search of 89 preferred terms) </p> </li> <li> <p>Adverse events consistent with volume depletion (based on 8 preferred terms)</p> </li> <li> <p>The change from baseline in the proportion of patients with a positive orthostatic BP test at week 12 was analysed </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0112"> <li> <p>Interested in patients with eGFR &lt; 60 for this systematic review</p> </li> <li> <p>Funding source: Boehringer Ingelheim and Eli Lilly</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomisation was undertaken using a computer‐generated, pseudo‐random sequence and an interactive voice and web response system. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomisation was undertaken using a computer‐generated, pseudo‐random sequence and an interactive voice and web response system. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Patients were randomised (1:1:1) to receive 10 mg empagliflozin o.d., 25mg empagliflozin o.d., or placebo double blind for 12 weeks.” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study labelled as double blind, but the methodology for blinding was not reported.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11/276 (4.0%) Empagliflozin 10 mg d; 11/277 (4.0%) Empagliflozin 25 mg d; 16/272 (5.9%) placebo discontinued. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were available on a clinical trials database and all major outcomes were reported. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: This study was funded by Boehringer Ingelheim and Eli Lilly who developed Empagliflozin. All but one of the authors works for Boehringer Ingelheim or on behalf of Boehringer Ingelheim. The remaining author has received consulting fees/payments for lectures and support for travel to meetings from Boehringer Ingelheim. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">EMPA‐REG OUTCOME 2013 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0113"> <li> <p>Study design: phase 3, parallel RCT</p> </li> <li> <p>Study time frame: July 2010 to April 2015</p> </li> <li> <p>Duration of follow‐up: 192 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0114"> <li> <p>Countries: 42, including North America, Australia, New Zealand, Latin America, Europe, Africa, Asia </p> </li> <li> <p>Setting: multinational (590 sites)</p> </li> <li> <p>Inclusion criteria: adults ≥18 years with type 2 DM; BMI ≤ 45 kg/m<sup>2</sup>; eGFR ≥ 30 mL/min/1.73 m<sup>2</sup> (MDRD); established CVD; no glucose‐lowering agents for at least 12 weeks before randomisation and had a HbA1c ≥ 7.0% and ≤ 9.0%, or had received stable glucose‐lowering therapy for at least 12 weeks before randomisation and had a HbA1c ≥ 7.0% and ≤ 10.0% </p> </li> <li> <p>Number (randomised/analysed): treatment group 1 (2345/2264); treatment group 2 (2342/2279); control group (2333/2266) </p> <ul id="CD011798-lst2-0007"> <li> <p>eGFR &lt; 60: treatment groups (1212); control group (607)</p> </li> </ul> </li> <li> <p>Mean age ± SD (years): treatment groups (67.1 ± 7.6); control group (67.1 ± 8.2).</p> </li> <li> <p>Sex (M/F)<b>:</b> treatment groups (816/396); control group (418/189) </p> </li> <li> <p>Exclusion criteria: uncontrolled hyperglycaemia with glucose &gt; 13.3 mmol/L after an overnight fast during placebo run‐in; indication of liver disease, ALT, AST, or ALP &gt; 3 x ULN during screening or run‐in phase); planned cardiac surgery or angioplasty within 3 months; eGFR &lt; 30 mL/min/1.73 m<sup>2</sup> (according to the MDRD equation) at screening or during run‐in phase; bariatric surgery within the past 2 years and other GI surgeries that induce chronic malabsorption; blood dyscrasias or any disorders causing haemolysis or unstable RBC; medical history of cancer (except for BCC) and/or treatment for cancer within the last 5 years; contraindications to background therapy according to the local label; treatment with anti‐obesity drugs 3 months prior to informed consent or any other treatment at time of screening leading to unstable body weight; treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent; any uncontrolled endocrine disorder except type 2 DM; pre‐menopausal women (last menstruation ≤ 1 year prior to informed consent) who were nursing, pregnant, or of child‐bearing potential and were not practicing an acceptable method of birth control, or did not plan to continue using this method throughout the study, or did not agree to submit to periodic pregnancy testing during the study; alcohol or drug abuse within 3 months of informed consent that would interfere with study participation or any ongoing condition leading to reduced compliance with study procedures or study drug intake. Intake of an investigational drug in another study within 30 days prior to intake of study medication in this study or participating in another study involving an investigational drug and/or follow‐up; any clinical condition that would jeopardize patient safety while participating in this clinical study (in Canada, this included current genito‐urinal infection or genito‐urinal infection within 2 weeks prior to informed consent); acute coronary syndrome, stroke, or TIA within 2 months prior to informed consent. In South Africa: BP &gt; 160/100 mmHg at screening </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0115"> <li> <p>Empagliflozin: dose of 10 mg or 25 mg</p> </li> <li> <p>Standard care</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0116"> <li> <p>Placebo</p> </li> <li> <p>Standard care</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0117"> <li> <p>Composite of three major adverse cardiovascular events (3‐point MACE), which was defined as the first occurrence of death from cardiovascular causes, nonfatal MI, or nonfatal stroke. </p> </li> <li> <p>A composite of the primary outcome plus hospitalisation for unstable angina (4‐point MACE) </p> </li> <li> <p>A composite microvascular outcome that included the first occurrence of any of the following: the initiation of retinal photocoagulation, vitreous haemorrhage, diabetes‐related blindness, or incident or worsening nephropathy </p> </li> <li> <p>Kidney microvascular outcomes include</p> <ul id="CD011798-lst2-0008"> <li> <p>Incident or worsening nephropathy, defined as progression to macroalbuminuria (UACR &gt; 300 mg/g </p> </li> <li> <p>A doubling of the SCR accompanied by an eGFR of ≤ 45 mL/min/1.73 m<sup>2</sup>, as calculated by the MDRD formula </p> </li> <li> <p>The initiation of RRT</p> </li> <li> <p>Death from kidney disease.</p> </li> <li> <p>A composite of incident or worsening kidney disease or death from cardiovascular causes, the individual components of incident or worsening kidney disease, and incident albuminuria (UACR ≥ 30) in patients with a normal albumin level (UACR &lt; 30) at baseline </p> </li> </ul> </li> <li> <p>Assessed on the basis of adverse events that occurred during treatment or within 7 days after the last dose of a study drug. Adverse events of special interest included confirmed hypoglycaemic adverse events (plasma glucose level, ≤ 3.9 mmol/L or an event requiring assistance), and adverse events reflecting UTI, genital infection, volume depletion, AKI, bone fracture, diabetic ketoacidosis, and thromboembolic events </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0118"> <li> <p>Interested in patients with eGFR &lt; 60 for this systematic review</p> </li> <li> <p>Funding source: Boehringer Ingelheim and Eli Lilly</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Randomization was performed with the use of a computer‐generated random‐sequence and interactive voice‐ and Web‐response system and was stratified according to the glycated haemoglobin level at screening (&lt;8.5% or ≥8.5%), body mass index at randomisation (&lt;30 or ≥30), renal function at screening (eGFR, 30 to 59 mL, 60 to 89 mL, or ≥90 mL per minute per 1.73 m<sup>2</sup>), and geographic region (North America [plus Australia and New Zealand], Latin America, Europe, Africa, or Asia)”. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Randomization was performed with the use of a computer‐generated random‐sequence and interactive voice‐ and Web‐response system and was stratified according to the glycated haemoglobin level at screening (&lt;8.5% or ≥8.5%), body mass index at randomisation (&lt;30 or ≥30), renal function at screening (eGFR, 30 to 59 mL, 60 to 89 mL, or ≥90 mL per minute per 1.73 m2), and geographic region (North America [plus Australia and New Zealand], Latin America, Europe, Africa, or Asia)”. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Patients meeting the inclusion criteria were then randomly assigned in a 1:1:1 ratio to receive either 10 mg or 25 mg of empagliflozin or placebo once daily”. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study reported to be double‐blind, but the methodology for blinding was not reported.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>81/2345 (3.5%) Empagliflozin 10 mg; 63/2342 (2.7%) Empagliflozin 25 mg ; 67/2333 (2.9%) Placebo discontinued. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were available on a clinical trials database and all major outcomes were reported. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: The study was supported by the manufacturers of Empagliflozin, Boehringer Ingelheim and Eli Lilly. Six of the authors were employees of Boehringer Ingelheim, and 3 of them either received consulting fees from Eli Lilly or research grants from Boehringer Ingelheim and/or Eli Lilly were on the advisory board of both companies. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">EMPA‐REG RENAL 2014 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0119"> <li> <p>Study design: phase 3, parallel RCT</p> </li> <li> <p>Study time frame: 3 September 2010 to 26 July 2012</p> </li> <li> <p>Duration of follow‐up: 55 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0120"> <li> <p>Countries: 15 (Canada, France, Hong Kong, India, Malaysia, Philippines, Poland, Portugal, Russia, Slovakia, South Africa, Spain, Netherlands, UK, USA) </p> </li> <li> <p>Setting: multinational (127 centres)</p> </li> <li> <p>Inclusion criteria: patients aged ≥ years with type 2 DM; BMI ≥ 45 kg/m<sup>2</sup>; HbA1c of 7% to 10%; eGFR; MDRD) &lt; 90 mL/min/1.73 m<sup>2</sup>; if receiving antidiabetes drugs (excluding SGLT2 inhibitors) were required to be on an unchanged dose (or, for insulin, within 10% of the dose at randomisation) or the maximum tolerated dose (or maximum dose according to local label) for 12 weeks or longer before randomisation </p> </li> <li> <p>Number: patients stratified according to CKD stage</p> <ul id="CD011798-lst2-0009"> <li> <p>CKD stage 2: treatment group 1 (98); treatment group 2 (97); control group (95)</p> </li> <li> <p>CKD stage 3: treatment group (188); control group (187)</p> </li> <li> <p>CKD stage 4: treatment group (37); control group (37)</p> </li> </ul> </li> <li> <p>Mean age ± SD (years)</p> <ul id="CD011798-lst2-0010"> <li> <p>CKD stage 2: treatment group 1 (63.2 ± 8.5); treatment group 2 (62.0 ± 8.4); control group (62.6 ± 8.1) </p> </li> <li> <p>CKD stage 3: treatment group (64.6 ± 8.9); control group (65.1 ± 8.2)</p> </li> <li> <p>CKD stage 4: treatment group (65.4 ± 10.2); control group (62.9 ± 11.9)</p> </li> </ul> </li> <li> <p>Sex (M/F)</p> <ul id="CD011798-lst2-0011"> <li> <p>CKD stage 2: treatment group 1 (60/38); treatment group 2 (61/36); control group (56/39)</p> </li> <li> <p>CKD stage 3: treatment group (107/80); control group (106/81)</p> </li> <li> <p>CKD stage 4: treatment group (21/16); control group (19/18)</p> </li> </ul> </li> <li> <p>Exclusion criteria: uncontrolled hyperglycaemia (glucose level &gt; 13·3 mmol/L after an overnight fast); kidney transplant; eGFR &lt; 15 mL/min/1·73 m<sup>2</sup>; requirement for chronic or acute dialysis; history of acute coronary syndrome, stroke, or TIA within 3 months of screening; liver disease; cancer within the past 5 years; GI surgery in the past 2 years; treatment with anti‐obesity drugs within 3 months of screening or any intervention leading to unstable bodyweight at screening </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>CKD stage 2 (1:1:1)</p> <p> <ul id="CD011798-lst1-0121"> <li> <p>Oral empagliflozin 10 mg or 25 mg once/d</p> </li> <li> <p>Oral placebo: once /d</p> </li> </ul> </p> <p>CKD stage 3 (1:1)</p> <p> <ul id="CD011798-lst1-0122"> <li> <p>Oral empagliflozin: 25 mg once/d</p> </li> <li> <p>Oral placebo: once/d</p> </li> </ul> </p> <p>CKD stage 4 (1:1)</p> <p> <ul id="CD011798-lst1-0123"> <li> <p>Oral empagliflozin: 25 mg once/d</p> </li> <li> <p>Oral placebo: once/day</p> </li> </ul> </p> <p>All groups</p> <p> <ul id="CD011798-lst1-0124"> <li> <p>All treatments for 52 weeks</p> </li> <li> <p>Rescue therapy was to be started if, between weeks 1 and 12, a patient had a confirmed glucose level greater than 13·3 mmol/L after an overnight fast, or between weeks 12 and 24, a patient had a confirmed glucose level greater than 11·1 mmol/L after an overnight fast. The rescue medication given was at the discretion of the investigator, in accordance with local prescribing information </p> </li> <li> <p>Adjustment of background antidiabetes medication between weeks 24 and 52 was not deemed rescue medication. Patients continued their background antidiabetes medication unchanged for the first 24 weeks; thereafter, it could be altered by the investigator to control glucose values and HbA1c according to clinical judgment </p> </li> <li> <p>Patients received diet and exercise counselling throughout the study.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0125"> <li> <p>Change from baseline in HbA1c at week 24</p> </li> <li> <p>Change from baseline in HbA1c at week 52</p> </li> <li> <p>Proportion of patients with HbA1c ≥ 7.0% (53 mmol/mol) or greater at baseline who had HbA1c &lt; 7.0% (53 mmol/mol) at week 24 </p> </li> <li> <p>Changes from baseline at weeks 24 and 52 in FBG, bodyweight, and SBP and DBP</p> </li> <li> <p>Proportion of patients with &gt; 5% reduction in bodyweight at week 24</p> </li> <li> <p>Proportion of patients with uncontrolled BP at baseline (SBP ≥ 130 mmHg or DBP ≥ 80 mmHg) who had controlled BP (SBP &lt; 130 mmHg and DBP &lt; 80 mmHg) at week 24 </p> </li> <li> <p>Proportion of patients using rescue medication up to week 24</p> </li> <li> <p>Vital signs, clinical laboratory values, and adverse events</p> </li> <li> <p>Confirmed hypoglycaemic adverse events (plasma glucose ≤3·9 mmol/L or needing assistance)</p> </li> <li> <p>UTI</p> </li> <li> <p>Genital infection</p> </li> <li> <p>Volume depletion</p> </li> <li> <p>Bone fractures</p> </li> <li> <p>eGFR and UACR</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0126"> <li> <p>Interested in patients with eGFR &lt; 60 for this systematic review</p> </li> <li> <p>Funding source: Boehringer Ingelheim and Eli Lilly</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Randomisation was done by the study sponsor via an interactive response system using a computer‐generated random sequence, and was stratified by degree of renal impairment”. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Treatment allocation during the treatment period was masked from patients, investigators, and those involved in analysing study data. Access to the randomisation code was limited to non‐study team functions including a randomisation operator, a person trained to generate the randomisation scheme, supply staff responsible for packaging and labelling, an independent statistician to verify the randomisation scheme, a system operator for clinical data systems to do the technical aspects of uploading the randomisation scheme, a dedicated contract research organisation responsible for the interactive voice and internet‐based response system, and a dedicated contract research organisation supporting the Data Monitoring Committee”. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Treatment allocation during the treatment period was masked from patients, investigators, and those involved in analysing trial data. Access to the randomisation code was limited to non‐trial team functions including a randomisation operator, a person trained to generate the randomisation scheme, supply staff responsible for packaging and labelling, an independent statistician to verify the randomisation scheme, a system operator for clinical data systems to do the technical aspects of uploading the randomisation scheme, a dedicated contract research organisation responsible for the interactive voice and internet‐based response system, and a dedicated contract research organisation supporting the Data Monitoring Committee” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Treatment allocation during the treatment period was masked from patients, investigators, and those involved in analysing trial data. Access to the randomisation code was limited to non‐trial team functions including a randomisation operator, a person trained to generate the randomisation scheme, supply staff responsible for packaging and labelling, an independent statistician to verify the randomisation scheme, a system operator for clinical data systems to do the technical aspects of uploading the randomisation scheme, a dedicated contract research organisation responsible for the interactive voice and internet‐based response system, and a dedicated contract research organisation supporting the Data Monitoring Committee” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stage 3: Empagliflozin 25 mg 23/188 12.2%; Placebo 21/187 7.3% discontinued.</p> <p>Stage 4: Empagliflozin 25 mg 11/37 29.7%; Placebo 12/37 32.4% discontinued</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were available on a clinical trials database and all major outcomes were reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: Boehringer Ingelheim was involved in study design, data collection, and data analysis. Eli Lilly cosponsored the study, but was not involved in study design, data collection, or data analysis. All authors, except 2 were employees of Boehringer Ingelheim the maker of empagliflozin. The other 2 authors had received honoraria from Boehringer Ingelheim for lectures and advisory work/consultancy </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">GUARD 2017 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0127"> <li> <p>Study design: parallel RCT</p> </li> <li> <p>Study time frame: October 2013 to January 2015</p> </li> <li> <p>Duration of follow‐up: 12 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0128"> <li> <p>Country: South Korea</p> </li> <li> <p>Setting: multicentre (number centres not reported)</p> </li> <li> <p>Inclusion criteria: patients with type 2 DM; HbA1c 7‐11%; moderate (eGFR: 30‐59 mL/min/1.73 m<sup>2</sup>) to severe (eGFR: 15‐29 mL/min/1.73 m<sup>2</sup>) kidney impairment (MDRD) </p> </li> <li> <p>Number: treatment group (64); control group (66)</p> </li> <li> <p>Mean age ± SD (years): treatment group (61.7 ± 7.9); control group (62.3 ± 9.0)</p> </li> <li> <p>Sex (M/F)<b>:</b> treatment group (38/26); control group (38/28) </p> </li> <li> <p>Exclusion criteria: ESKD; kidney transplant; hepatic cirrhosis or CVDs diagnosed within 6 months; uncontrolled thyroid dysfunction requiring medication; diabetic ketoacidosis; BMI &gt; 40 kg/m<sup>2</sup>; total bilirubin &gt; 1.5 × ULN and ALT/AST (ALT/AST) &gt; 2.5 × ULN; using strong cytochrome P450‐3A4 (CYP3A4) inducers, glucagon‐like peptide‐1 (GLP‐1)mimetics, or other agents affecting blood glucose </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0129"> <li> <p>Gemigliptin: 50 mg/d</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0130"> <li> <p>Placebo</p> </li> </ul> </p> <p>Both groups</p> <p> <ul id="CD011798-lst1-0131"> <li> <p>As background medications, only insulin and/or sulphonylureas were allowed, if prescribed for more than 6 weeks before screening. Other drugs affecting blood glucose level were prohibited during the study unless they were indicated as a rescue therapy, which was regarded as a protocol violation </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0132"> <li> <p>HbA1c change at week 12.</p> </li> <li> <p>Changes in body weight, eGFR, UACR, FBG, GA, fructosamine, fasting serum C‐peptide, HOMA of beta cell function, HOMA‐IR, and fasting lipid parameters at Week 12 </p> </li> <li> <p>Adverse events</p> </li> <li> <p>Changes in vital signs</p> </li> <li> <p>Laboratory abnormalities</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0133"> <li> <p>Funding source: LG Life Sciences</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1:1 ratio by severity of kidney impairment and the type of background antidiabetic agents, using the interactive web response system for randomisation </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1:1 ratio by severity of kidney impairment and the type of background antidiabetic agents, using the interactive web response system for randomisation </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"The double‐blind approach was maintained by providing matching placebo, labelling each study drug with a kit number, disclosing the randomisation code only to authorized personnel (statistician, IWRS manager and randomisation manager) when necessary, and by not disclosing individual data to the investigator or other study‐related personnel during or before the time of this interim analysis" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"The double‐blind approach was maintained by providing matching placebo, labelling each study drug with a kit number, disclosing the randomisation code only to authorized personnel (statistician, IWRS manager and randomisation manager) when necessary, and by not disclosing individual data to the investigator or other study‐related personnel during or before the time of this interim analysis" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No missing outcome data</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were available on a clinical trials database. All major outcomes reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: 2 of the authors are employed by LG Life Sciences who manufacture gemigliptin </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Haneda 2016 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0134"> <li> <p>Study design: parallel RCT</p> </li> <li> <p>Study time frame: not reported</p> </li> <li> <p>Duration of follow‐up: 24 and 52 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0135"> <li> <p>Country: Japan</p> </li> <li> <p>Setting: multicentre (number of centres not reported)</p> </li> <li> <p>Inclusion criteria: patients with type 2 DM with eGFR ≥ 30 to &lt; 60 mL/min/1.73 m<sup>2</sup> at weeks ‐ 4 or ‐ 2, who were receiving diet/exercise therapy only or were being treated with 1 or 2 OHAs at a fixed dose for 48 weeks before study entry (Week ‐4) were eligible </p> </li> <li> <p>Number: treatment group (95) control group (50)</p> </li> <li> <p>Mean age ± SD (years)<b>:</b> treatment group (67.9 ± 8.9); control group (68.4 ± 8.9) </p> </li> <li> <p>Sex (M/F)<b>:</b> treatment group (72/23); control group (39/11) </p> </li> <li> <p>Exclusion criteria: kidney disease accompanied with severe proteinuria; a history of dialysis within 1 year of study entry; at risk of developing ESKD before study completion </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0136"> <li> <p>Luseogliflozin: 2.5 mg/d for 24 weeks</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0137"> <li> <p>Placebo for 24 weeks</p> </li> </ul> </p> <p>Other information</p> <p> <ul id="CD011798-lst1-0138"> <li> <p>After 24 weeks, in the open‐label phase, 2.5 or 5 mg/d luseogliflozin was administered to all patients for 28 weeks, regardless of their assigned treatment in the initial double‐blind phase </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0139"> <li> <p>Changes in HbA1c, FBG, and body weight from baseline to week 52.</p> </li> <li> <p>Changes in GA, fasting insulin levels, CRP levels, intact proinsulin levels, HOMA‐R, and HOMA‐β </p> </li> <li> <p>Abnormal changes in laboratory values and vital signs</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0140"> <li> <p>This publication reported and pooled 3 studies. This table summarises data from Study 1 (TS071‐03‐04) which was original research reported by the authors and the only time this data has been reported in the literature. The other 2 studies are described in <a href="references#CD011798-bbs2-0135">Seino 2015</a> </p> </li> <li> <p>Funding source: Taisho Pharmaceuticals</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study was described as randomised, method of randomisation was not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“The allocations were implemented at the individual central registration office”.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Patients were either given 2.5 mg/d luseogliflozin or placebo</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The study was reported to be placebo‐controlled, randomised and double‐blinded, but the method of blinding was not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The discontinuation rate was not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were not available on a clinical trials database and it was unclear what the major outcomes were for the original study </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The sponsor of the study and maker of luseogliflozin, Taisho Pharmaceuticals collected the study data and monitored the study sites. All authors are either employed by Taisho Pharmaceutical or have received advisory board consulting fees, lectures fees, research support and grants from Taisho Pharmaceuticals </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Idorn 2013 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0141"> <li> <p>Study design: parallel RCT</p> </li> <li> <p>Study time frame: not reported</p> </li> <li> <p>Duration of follow‐up: 12 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0142"> <li> <p>Country: Denmark</p> </li> <li> <p>Setting: multicentre (2 centres)</p> </li> <li> <p>Inclusion criteria: 2 groups of patients ‐ ESKD (Group 1) and normal kidney function (Group 2) </p> <ul id="CD011798-lst2-0012"> <li> <p>Group 1: Patients aged 18 to 85 years receiving chronic HD or PD; type 2 DM diagnosed at least 3 months prior to screening; preserved beta‐cell function as evaluated by a glucagon test </p> </li> <li> <p>Group 2: Patients aged 18 to 85 years with normal kidney function (SCr &lt; 105 µmol/L for men and &lt; 90 µmol/L for women); type 2 DM diagnosed at least 3 months prior to screening; HbA1c &gt; 6.5% (&gt; 48 mmol/mol); preserved beta‐cell function as evaluated by a glucagon test </p> </li> </ul> </li> <li> <p>Number (randomised/analysed)</p> <ul id="CD011798-lst2-0013"> <li> <p>Group 1: treatment group (14/10); control group (10/10)</p> </li> <li> <p>Group 2: treatment group (11/10); control group (12/10)</p> </li> </ul> </li> <li> <p>Mean age ± SE (years)</p> <ul id="CD011798-lst2-0014"> <li> <p>Group 1: treatment group (68.3 ± 3.1); control group (65.9 ± 4.4)</p> </li> <li> <p>Group 2: treatment group (60.7 ± 3.2); control group (63.1 ± 2.1)</p> </li> </ul> </li> <li> <p>Sex (M/F)</p> <ul id="CD011798-lst2-0015"> <li> <p>Group 1: treatment group (8/2); control group (9/1)</p> </li> <li> <p>Group 2: treatment group (7/3); control group (8/2)</p> </li> </ul> </li> <li> <p>Exclusion criteria: type 1 DM; chronic pancreatitis or previous acute pancreatitis; known or suspected hypersensitivity to trial product(s) or related products; treatment with oral glucocorticoids, calcineurin inhibitors; dipeptidyl peptidase 4 inhibitors or other drugs, which in the investigator’s opinion could interfere with glucose or lipid metabolism 90 days prior to screening; cancer (except BCC or squamous cell skin cancer) or any other clinically significant disorder, which in the investigator’s opinion could interfere with the results of the trial; inflammatory bowel disease; cardiac disease defined as heart failure (NYHA Class III–IV) and/or diagnosis of unstable angina pectoris and/or myocardial infarction within the last 6 months; BMI ≤18.5 or ≥ 50.0 kg/m<sup>2</sup>; women of childbearing potential who are pregnant, breastfeeding, intend to become pregnant or not using adequate contraceptive methods; clinical signs of diabetic gastroparesis; impaired liver function (ALT &gt; twice upper reference level); use of any investigational product 90 days prior to this trial; known or suspected abuse of alcohol or narcotics; screening plasma calcitonin ≥ 50 ng/L; personal or family history of medullary thyroid carcinoma or a personal history of multiple endocrine neoplasia type 2 </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0143"> <li> <p>SC Liraglutide: 0.6 mg once/d for 12 weeks. All participants were requested to inject the medicine in the abdomen before breakfast. </p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0144"> <li> <p>Placebo: once/d for 12 weeks. All participants were requested to inject the medicine in the abdomen before breakfast </p> </li> </ul> </p> <p>Other information</p> <p> <ul id="CD011798-lst1-0145"> <li> <p>Depending on glycaemic control and adverse effects, dose was escalated by up to 0.6 mg/week to a maximum 1.8 mg </p> </li> <li> <p>Doses of baseline antidiabetic medication were individually adjusted in parallel with study medication according to prespecified treatment goals. To minimize risk of hypoglycaemia, basal insulin dose reduced by 20‐50% at randomisation and suIphonylureas were paused, while metformin was continued in unchanged doses </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0146"> <li> <p>Dose corrected trough concentration of liraglutide in plasma at the final study visit (week 12) </p> </li> <li> <p>Severe adverse events, Adverse effects, glycaemic control, change in baseline insulin, body weight, hypoglycaemic episodes (divided into minor blood glucose &lt; 3.1 mmol/L and no need assistance) and major (blood glucose &lt; 3.1 mmol/L and requiring assistance from third person) </p> </li> <li> <p>Cardiovascular parameters: heart rate, BP, and prohormone brain natriuretic peptide concentration in plasma </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0147"> <li> <p>Only Group 1 (ESKD patients) was included in this systematic review</p> </li> <li> <p>Funding source: Novo Nordisk</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Patients and control subjects were assigned to receive either liraglutide or pIacebo according to a computer‐generated randomisation list provided by Novo Nordisk”. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Patients and control subjects were assigned to receive either liraglutide or pIacebo according to a computer‐generated randomisation list provided by Novo Nordisk”. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Participants, Investigators, and healthcare staff were blinded for the allocated treatment and remained so until the last patient’s last visit”. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Participants, Investigators, and healthcare staff were blinded for the allocated treatment and remained so until the last patient’s last visit”. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5/14 35% liraglutide group; 0/10 0% control group discontinued for the ESKD group.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were available on a clinical trials database and major outcomes were reported. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: Novo Nordisk sponsored the study although the company did not participate in writing the protocol, collection, analysis and interpretation of data or writing the manuscript. All authors have either received research support, are on the advisory board, or hold shares with Novo Nordisk. </p> <p>Study was mildly underpowered: Based on the primary end point and with a liraglutide trough value of 20 000 pmol/L during steady state and standard deviation estimated to be 8000 pmol/L in people with normal kidney function, 10 completers in each liraglutide treatment arm and an α = 0.05 would enable the investigators to detect a difference of 10,600 pmol/L with a power of 80% (1‐ β = 0.80) using a 2 sample Student t‐test. In the ESKD arm, 9 patients completed the study. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Ito 2011a </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0148"> <li> <p>Study design: parallel, open‐label RCT</p> </li> <li> <p>Study time frame: not reported</p> </li> <li> <p>Duration of follow‐up: 24 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0149"> <li> <p>Country: Japan</p> </li> <li> <p>Setting: multicentre (number of centres not reported).</p> </li> <li> <p>Inclusion criteria: patients with type 2 DM patients undergoing regular HD; poor glycaemic control which was defined as HbA1c level &gt; 7.0% and/or a GA level exceeding 21.0% after 8 consecutive weeks of daily administration of conventional therapy (dietary therapy alone or mitiglinide and/or voglibose); none were receiving insulin treatment </p> </li> <li> <p>Number: treatment group (30); control group (21)</p> </li> <li> <p>Mean age ± SEM (years)<b>:</b> treatment group (67 ± 2); control group (68 ± 2). </p> </li> <li> <p>Sex (M/F): treatment group (21/9); control group (14/7)</p> </li> <li> <p>Exclusion criteria: infectious disease; thyroid disease; malignant tumours; treatment with steroids </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Both groups</p> <p> <ul id="CD011798-lst1-0150"> <li> <p>An eight week observation period first for all subjects before randomisation where a fixed dose of conventional anti‐diabetic agents (mitiglinide and/or voglibose) was administered orally </p> </li> </ul> </p> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0151"> <li> <p>Continued conventional therapy at the same dose</p> </li> <li> <p>Oral vildagliptin: 50 mg once/d. Thereafter, if 8 weeks of continuous vildagliptin administration did not result in the target HbA1c value (&lt;7.0% or &lt;53 mmol/mol) or GA value (&lt;21.0%), the vildagliptin dose was increased to 100 mg daily from week 8. On the other hand, if the physician judged that vildagliptin 50 mg daily presented a safety problem, the dose was reduced to 25 mg once daily. Patients continued their regular medications, such as antihypertensives, recombinant human erythropoietin, phosphate binders and lipid‐lowering agents, during the study period </p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0152"> <li> <p>Conventional oral antidiabetic agents alone (no vildagliptin). However, 9 patients in the control group took additional anti‐diabetic agents for treatment. Patients continued their regular medications, such as antihypertensives, recombinant human erythropoietin, phosphate binders and lipid‐lowering agents, during the study period </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0153"> <li> <p>HbA1c and GA levels were measured once monthly as indices of glycaemic control</p> </li> <li> <p>Postprandial plasma glucose levels were measured 3 times/wk</p> </li> <li> <p>Hb</p> </li> <li> <p>Total bilirubin, AST, ALT, LDH, ALP, γ‐glutamyl transpeptidase, total cholesterol, HDL, triglyceride, total protein and albumin </p> </li> <li> <p>Body weight before and after dialysis to assess the interdialytic weight gain, BMI</p> </li> <li> <p>Cardiothoracic ratio</p> </li> <li> <p>Predialysis SBP and DBP</p> </li> <li> <p>Safety events/adverse events</p> </li> <li> <p>Serious adverse events were defined as medical events that resulted in death, hospitalisation or significant disability or incapacity. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0154"> <li> <p>Funding source: not reported</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported. The text just says: “subjects were then randomly split into two groups”.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open‐label study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open‐label study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None of the treatment group but 9/30 30% control group discontinued.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were not available on a clinical trials database.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>There were no conflicts of interest</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Jin 2007 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0155"> <li> <p>Study design: parallel RCT</p> </li> <li> <p>Study time frame: not reported</p> </li> <li> <p>Duration of follow‐up: 12 months</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0156"> <li> <p>Country: China</p> </li> <li> <p>Setting: single centre</p> </li> <li> <p>Inclusion criteria: patients with type 2 diabetic kidney disease; 42 and 80 years; SCr 150–420 µM, presence of CKD stage 3 (GFR 30 ‐ 59 mL/min/1.73 m<sup>2</sup>) or stage 4 (GFR 15 ‐ 29 mL/min/1.73 m<sup>2</sup>). Nephropathy was defined clinically by the presence on two occasions of a ratio of urinary albumin (mg/L) to urinary creatinine (g/L) from a first morning specimen of at least 300, or a 24‐hour urinary protein excretion value ≥ 500 mg on two consecutive determinations, by the presence of diabetic retinopathy, and by the absence of any clinical or laboratory evidence of other kidney or renal tract disease </p> </li> <li> <p>Number</p> <ul id="CD011798-lst2-0016"> <li> <p>CKD stage 3: treatment group (15); control group (15)</p> </li> <li> <p>CKD stage 4: treatment group (15); control group (15)</p> </li> </ul> </li> <li> <p>Mean age ± SD (years)</p> <ul id="CD011798-lst2-0017"> <li> <p>CKD stage 3: treatment group (52.87 ± 12.47); control group (51.6 ±(11.19)</p> </li> <li> <p>CKD stage 4: treatment group (52.67 ± 12.5); control group (50.53 ± 11.67)</p> </li> </ul> </li> <li> <p>Sex (M/F)</p> <ul id="CD011798-lst2-0018"> <li> <p>CKD stage 3: treatment group (8/7); control group (8/7)</p> </li> <li> <p>CKD stage 4: treatment group (8/7); control group (8/7)</p> </li> </ul> </li> <li> <p>Exclusion criteria: clinical or laboratory evidence of nondiabetic kidney disease; diagnosis of type 1 DM; abnormal liver function; heart disease </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0157"> <li> <p>Pioglitazone: 30 mg/d was given as an add‐on medication</p> </li> <li> <p>Oral losartan: 100 mg daily</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0158"> <li> <p>Oral losartan: 100 mg daily</p> </li> </ul> </p> <p>Both groups</p> <p> <ul id="CD011798-lst1-0159"> <li> <p>All patients received a low‐protein diet (protein content 0.6 g/kg/d) and conventional insulin therapy. Throughout the 12‐month study period, the patients with hypertension received conventional antihypertensive therapies, except ACEi </p> </li> <li> <p>Mixed human insulin (70/30) was administered twice daily at a dosage of 0.2 U/kg and was adjusted to achieve a FBG level ≤ 8.5 mM without occurrence of severe or frequent hypoglycaemia </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0160"> <li> <p>BP</p> </li> <li> <p>Fasting glucose</p> </li> <li> <p>HbA1c</p> </li> <li> <p>SCr</p> </li> <li> <p>24‐hour urinary protein excretion</p> </li> <li> <p>Endogenous CrCl</p> </li> <li> <p>GFR</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0161"> <li> <p>Funding source: not reported</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Block randomisation with stratification for stage of CKD, method of randomisation was not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No patients discontinued.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were not available on a clinical trials database</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest were not reported.</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Kaku 2014 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0162"> <li> <p>Study design: parallel RCT</p> </li> <li> <p>Study time frame: not reported</p> </li> <li> <p>Duration of follow‐up: 24 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0163"> <li> <p>Country: Japan</p> </li> <li> <p>Setting: multicentre (number of centres not reported)</p> </li> <li> <p>Inclusion criteria: patients aged ≥ 20 years; confirmed diagnosis of T2 DM; drug‐naive (never received medical treatment for DM or received treatment for &lt; 30 days after diagnosis, and during the 30‐day period before screening did not receive oral antidiabetic agents for &gt; 3 consecutive or &gt; 7 non‐consecutive days, or were previously treated for DM but not within 6 weeks of enrolment), OR receiving ongoing treatment for DM within 6 weeks of enrolment (not drug‐naive) </p> </li> </ul> <ul id="CD011798-lst1-0164"> <li> <p>Number: treatment group 1 (86); treatment group 2 (88); control group (87)</p> <ul id="CD011798-lst2-0019"> <li> <p>72 patients had an eGFR &lt; 60 mL/min/1.73 m<sup>2</sup> </p> </li> </ul> </li> <li> <p>Mean age ± SD (years)<b>:</b> treatment group 1 (58.6 ± 10.4); treatment group 2 (57.5 ± 9.3); control group (60.4 ± 9.7) </p> </li> <li> <p>Sex (M/F)<b>:</b> treatment group 1 (50/36); treatment group 2 (53/35); control group (52/35) </p> </li> <li> <p>Exclusion criteria: type 1 DM; FBG &gt; 13.3mmol/L; pregnant or breastfeeding women; creatinine kinase &gt;3× ULN; eGFR &lt; 45 mL/min or a SCR &gt;133 μmol/L for men and &gt;124 μmol/L for women; Severe hepatic insufficiency and/or significant abnormal liver function (AST &gt;3 ×ULN and/or ALT &gt;3 × ULN). </p> </li> <li> <p>NYHA class IV congestive heart failure; unstable or acute congestive heart failure.</p> </li> <li> <p>Treatment with thiazolidinediones &lt; 6months before enrolment.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0165"> <li> <p>The study included a 2‐week screening period, and a 4‐week, single‐blind, placebo lead‐in period </p> </li> <li> <p>These patients would undergo a washout period before study treatments</p> <ul id="CD011798-lst2-0020"> <li> <p>At enrolment, HbA1c values ≥ 6.5% (48 mmol/mol) and ≤ 10% (86 mmol/mol) were required for patients defined as drug‐naive, and HbA1c values ≤ 8% (64 mmol/mol) were required for patients with ongoing treatment. At 1 week before randomisation, HbA1c was required to be ≥ 6.5% (48 mmol/mol) and ≤ 10% (86 mmol/mol) for all patients </p> </li> </ul> </li> </ul> </p> <p>Treatment group 1</p> <p> <ul id="CD011798-lst1-0166"> <li> <p>Oral dapagliflozin: 5 mg once/d for 24 weeks</p> </li> </ul> </p> <p>Treatment group 2</p> <p> <ul id="CD011798-lst1-0167"> <li> <p>Oral dapagliflozin: 10 mg once/d for 24 weeks</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0168"> <li> <p>Oral placebo: once/d for 24 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0169"> <li> <p>Change in mean HbA1c from baseline to week 24</p> </li> <li> <p>Change from baseline to week 24 in FBG and body weight.</p> </li> <li> <p>Change from baseline to week 24 in total body weight in patients with baseline BMI ≥ 25 kg/m<sup>2</sup>; fasting insulin and C‐peptide levels; seated SBP </p> </li> <li> <p>SBP overall and in patients with baseline seated SBP ≥ 130mmHg</p> </li> <li> <p>Fasting lipids (total cholesterol, LDL cholesterol, HDL cholesterol, free fatty acid and triglyceride levels) </p> </li> <li> <p>Proportion of patients achieving a therapeutic glycaemic response (defined as HbA1c &lt; 7% [53 mmol/mol]) after 24 weeks in patients with baseline HbA1c ≥ 7% (53 mmol/mol) </p> </li> <li> <p>Proportion of patients discontinued for lack of efficacy or rescued for failing to maintain FBG below prespecified rescue criteria after 24 weeks </p> </li> <li> <p>Evaluated based on reported adverse events (AEs), laboratory values, ECG, heart rate, BP, hypoglycaemic events, calculated CrCl, eGFR and physical examination findings. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0170"> <li> <p>Funding source: AstraZeneca and Bristol‐Myers Squibb</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study was described as randomised, method of randomisation was not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reported to be double blind, but method of blinding of participants and personnel was not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reported to be double blind, but method of blinding of participants and personnel was not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8/87 (9.1%) of placebo group, 5/86 (5.8%) of dapagliflozin 5 mg group and 9/88 (10.2%) of dapagliflozin 10 mg group discontinued </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were not available on a clinical trials database</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: The study was funded by AstraZeneca and Bristol‐Myers Squibb the manufacturers of Dapagliflozin. All authors except 3 either received research funding from the sponsoring companies or were employees and share‐holders </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Kohan 2014 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0171"> <li> <p>Study design: parallel RCT</p> </li> <li> <p>Study time frame: not reported</p> </li> <li> <p>Duration of follow‐up: 104 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0172"> <li> <p>Countries: USA, Argentina, Canada, India, Mexico, Peru, Italy, Australia, France, Spain, Denmark, Puerto Rico, Singapore </p> </li> <li> <p>Setting: multinational (111 sites)</p> </li> <li> <p>Inclusion criteria: Male and female patients ≥18 years with type 2 DM and inadequate glycaemic control defined as HbA1c ≥ 7.0% (53 mmol/mol) and ≤ 11.0% (97 mmol/mol); eGFR values of 30 to 59 mL/min per 1.73 m<sup>2</sup>; BMI ≤ 45.0 kg/m<sup>2</sup>. </p> </li> <li> <p>Number: treatment group 1 (83); treatment group 2 (85); control group (84)</p> </li> <li> <p>Mean age ± SD (years): treatment group 1 (66 ± 8.9); treatment group 2 (68 ± 7.7); control group (67 ± 8.6) </p> </li> <li> <p>Sex (M/F): treatment group 1 (55/28); treatment group 2 (56/29); control group (53/31)</p> </li> <li> <p>Exclusion criteria: AST or ALT &gt; 3.0 times the ULN; serum total bilirubin &gt; 2.8 mmol/L; history of diabetes insipidus or diabetic ketoacidosis or hyperosmolar nonketotic coma; uncontrolled hypertension defined as SBP ≥ 180 mmHg and/or DBP ≥110 mmHg, or specified cardiovascular/vascular diseases within 6 months of enrolment visit; kidney exclusion criteria included the need for HD or RRT, history of rapidly progressing kidney disease, lupus nephritis, renal or systemic vasculitis, renal artery stenosis, kidney transplant; hepatic disease </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Both groups</p> <p> <ul id="CD011798-lst1-0173"> <li> <p>A 7‐day lead‐in period included diet and exercise counselling, which continued throughout the study </p> </li> <li> <p>Original pre‐enrolment antidiabetic regimen</p> </li> </ul> </p> <p>Treatment group 1</p> <p> <ul id="CD011798-lst1-0174"> <li> <p>Dapagliflozin: 5 mg/d</p> </li> </ul> </p> <p>Treatment group 2</p> <p> <ul id="CD011798-lst1-0175"> <li> <p>Dapagliflozin: 10 mg/d</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0176"> <li> <p>Placebo</p> </li> </ul> </p> <p>Other information</p> <p> <ul id="CD011798-lst1-0177"> <li> <p>During the first 24 weeks (short‐term period), patients received rescue medication (any approved antidiabetic agent except metformin) if FBG &gt; 15 mmol/L (weeks 4–6), &gt; 13.3 mmol/L (weeks 6–12), or &gt; 11.1 mmol/L (weeks 12–24) </p> </li> <li> <p>Patients completing the first 24 weeks were eligible to continue into an additional 28‐week (long‐term) period and were eligible to receive rescue medication if HbA1c &gt; 8.0% (64 mmol/mol) </p> </li> <li> <p>Patients completing the first 52 weeks (the short‐term plus long‐term periods) were eligible to continue into the extension period (an additional 52 weeks) and received rescue medication if HbA1c &gt; 7.5% (58 mmol/mol) (weeks 52–76) and &gt; 7.0% (53 mmol/mol) (weeks 76–104) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0178"> <li> <p>Change from baseline in HbA1c with each dose of dapagliflozin versus placebo at 24 weeks </p> </li> <li> <p>Change from baseline in FBG and weight for each dose of dapagliflozin versus placebo at 24 weeks </p> </li> <li> <p>Change from baseline in eGFR (MDRD) and CrCl (Cockcroft and Gault method) for each dapagliflozin dose versus placebo at 52 weeks. </p> </li> <li> <p>Serious and non serious adverse events</p> </li> <li> <p>Discontinuations owing to adverse events, hypoglycaemia, laboratory abnormalities, ECG, and vital signs (seated BP and heart rate) </p> </li> <li> <p>UACR and urinary protein:creatinine</p> </li> <li> <p>UTI and genital infection</p> </li> <li> <p>All safety analyses included data after glycaemic rescue</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0179"> <li> <p>Funding source: Bristol‐Myers Squibb and AstraZeneca</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“On day 1, patients were randomised in a double‐blind manner to either placebo, dapagliflozin 5‐mg, or dapagliflozin 10‐mg daily, in addition to their original pre‐enrollment antidiabetic regimen.” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The study was labelled as double blind but does not describe how patients were blinded or if they were given placebo medications. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The study was labelled as double blind but does not describe how assessment was blinded</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High rates of discontinuation by the end of the study.</p> <p>Dropout rates:</p> <p>At 24 weeks: 5 mg dapagliflozin 11/83 (13.3%); 10 mg dapagliflozin 16/85 (18.8%); Placebo 22/84 (26.2%) </p> <p>At 52 weeks: 5 mg dapagliflozin 19/83 (22.9%); 10 mg dapagliflozin; 21/85 (24.7%); Placebo 30/84 (35.7%) </p> <p>At 104 weeks: 5 mg dapagliflozin 38/83 (45.8%); 10 mg dapagliflozin 34/85 (40.0%); Placebo 41/84 (48.8%) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>There was an error in the study flow diagram ‐ authors missed counting one patient</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: All the authors declared no competing interests. Bristol‐Myers Squibb and AstraZeneca‐supported the study </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Kothny 2015 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0180"> <li> <p>Study design: parallel RCT</p> </li> <li> <p>Study time frame: not reported</p> </li> <li> <p>Duration of follow‐up: 24 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0181"> <li> <p>Countries: Brazil, USA</p> </li> <li> <p>Setting: multinational (87 centres)</p> </li> <li> <p>Inclusion criteria: patients aged 18 to 85 years, BMI 18 to 42 kg/m<sup>2</sup>; HbA1c 6.5–10.0% (48–86 mmol/mol); type 2 DM either untreated (no glucose‐lowering medication in the past 8 weeks) or treated with a stable dose of sulphonylureas, thiazolidinedione, meglitinide or insulin, as monotherapy or in combination (for at least 4 weeks); Severe kidney impairment (eGFR (MDRD) &lt; 30 mL/min/1.73 m<sup>2</sup>) </p> </li> <li> <p>Number (randomised/analysed): treatment group 1 (83/81), treatment group 2 (65/63)</p> </li> <li> <p>Mean age ± SD (years): treatment group 1 (66.7 ± 8.8); treatment group 2 (66.9 ± 9.6)</p> </li> <li> <p>Sex (M/F): treatment group 1 (42/41); treatment group 2 (29/36)</p> </li> <li> <p>Exclusion criteria: history of kidney transplant; significant cardiovascular history within 6 months; liver disease; abnormal liver function tests (ALT &gt;2 × ULN, AST &gt; 2 × ULN, or total bilirubin &gt; 2× ULN and/or direct bilirubin &gt; ULN); any treatment that is contraindicated (i.e. metformin) in the severe CKD population </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Both groups</p> <p> <ul id="CD011798-lst1-0182"> <li> <p>Patients continued their initial background treatment throughout the study.</p> </li> <li> <p>2‐ week, single‐blind, placebo run‐in period</p> </li> </ul> </p> <p>Treatment group 1</p> <p> <ul id="CD011798-lst1-0183"> <li> <p>Vildagliptin: 50 mg once/d for 24 weeks</p> </li> </ul> </p> <p>Treatment group 2</p> <p> <ul id="CD011798-lst1-0184"> <li> <p>Sitagliptin: 25 mg once/d for 24 weeks</p> </li> </ul> </p> <p>Other information</p> <p> <ul id="CD011798-lst1-0185"> <li> <p>Both medications were used at the doses recommended in the label for patients with severe kidney impairment </p> </li> <li> <p>Rescue medication (insulin addition or intensification) could be administered on or after week 4 if FBG was &gt; 15 mmol/L, after week 8 if FBG &gt;13.3 mmol/L, and after week 16 if FBG &gt;12.2 mmol/L </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0186"> <li> <p>HbA1c</p> </li> <li> <p>FBG</p> </li> <li> <p>An analysis of responder rate was also performed to assess the percentage of patients achieving HbA1c ≤6.5% (48 mmol/mol) and &lt; 7.0% (53 mmol/mol). </p> </li> <li> <p>Routine biochemistry laboratory assessments</p> </li> <li> <p>Safety, tolerability and all treatment emergent adverse events</p> </li> <li> <p>Hypoglycaemia was defined as symptoms suggestive of low blood glucose confirmed by a self‐monitored blood glucose measurement &lt; 3.1 mmol/L plasma glucose equivalent. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0187"> <li> <p>The initial protocol excluded patients undergoing any dialysis, but it was subsequently amended to remove this restriction to facilitate recruitment </p> </li> <li> <p>Nearly two‐thirds of the patients were white, more than 20% were black and about 12% were Hispanic/Latino </p> </li> <li> <p>Funding source: Novartis Pharma AG</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Eligible patients were randomised using interactive voice response technology (IVRS) to receive either vildagliptin (50 mg once daily) or sitagliptin (25 mg once daily)” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“IVRS assigned a randomisation number to the patient, which was used to link the patient to a treatment arm and to specify unique medication numbers for the first package of study drug to be dispensed to the patient” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Patients, investigator staff, persons performing the assessments and data analysts remained blinded to the identity of the treatment from the time of randomisation until database lock” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Patients, investigator staff, persons performing the assessments and data analysts remained blinded to the identity of the treatment from the time of randomisation until database lock” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>19/83 (22.9%) of the vildagliptin group and 12/65 (18.5%) of the sitagliptin group discontinued </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were available on a clinical trials database and major outcomes were reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: This study was funded by Novartis Pharma AG, Basel, Switzerland. The sponsor was involved in study design, and collection, analysis and interpretation of data. Four of the authors are employed by and have shares with Novartis. The remaining authors are involved in clinical trials with Novartis. Novartis makes vildagliptin </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Laakso 2015 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0188"> <li> <p>Study design: parallel RCT</p> </li> <li> <p>Study time frame: 17 March 2010 and 18 June 2012</p> </li> <li> <p>Duration of follow‐up: 12 weeks followed by a 40‐week, active‐controlled extension</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0189"> <li> <p>Countries: 9 countries including Finland, USA, UK, Germany, Australia</p> </li> <li> <p>Setting: multinational (52 outpatient clinics)</p> </li> <li> <p>Inclusion criteria: adults ≥ 18 years with type 2 DM; eGFR &lt; 60 mL/min; HbA1c ≥ 7.0% to ≤ 10% (53 mmol/mol to 86 mmol/mol); BMI ≤ 45 kg/m<sup>2</sup> </p> </li> <li> <p>Number (randomised/completed week 12/completed week 52): treatment group (113/110/95); control group (122/114/90) </p> </li> <li> <p>Mean age ± SD: 66.6 ± 9.3 years (data not provided for each group)</p> </li> <li> <p>Sex (M/F): 149/86 (data not provided for each group)</p> </li> <li> <p>Exclusion criteria: MI; stroke or TIA within 3 months prior to informed consent.; kidney impairment requiring dialysis; bariatric surgery; impaired hepatic function; treatment with glitazones; GLP‐1 analogues; DPP‐4 inhibitors; treatment with anti‐obesity drugs; treatment with sulphonylureas; glinides and metformin 8 weeks prior to informed consent </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0190"> <li> <p>Linagliptin: 5 mg/d for 52 weeks</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0191"> <li> <p>Placebo for 12 weeks</p> </li> <li> <p>After 12 weeks placebo patients were then switched to glimepiride 1–4 mg/d, with double blinding maintained using a double dummy design, and treatments continued until week 52. Glimepiride could be up‐titrated in 1‐mg increments from a 1‐mg starting dose to a maximum of 4 mg at 4‐week intervals during the first 12 weeks of the extension if patients’ self‐monitored FBG values were &gt; 6.1 mmol/L </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0192"> <li> <p>HbA1c: change from baseline to week 12 in the full‐analysis set</p> </li> <li> <p>Change in HbA1c over time</p> </li> <li> <p>FBG: change from baseline to week 12</p> </li> <li> <p>FBG: change from baseline over time</p> </li> <li> <p>Percentage of patients with HbA1c &lt; 7.0% (53 mmol/mol) at week 12 and week 52</p> </li> <li> <p>Percentage of patients with HbA1c &lt; 6.5% (48 mmol/mol) at week 12 and week 52</p> </li> <li> <p>Percentage of patients who have a HbA1c lowering by at least 0.5% (5 mmol/mol) at week 12 and week 52 </p> </li> <li> <p>Plasma concentration of linagliptin at trough from baseline over time</p> </li> <li> <p>Adverse events</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0193"> <li> <p>Funding source: Boehringer Ingelheim Pharma GmbH &amp; Co</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study was described as randomised, method of randomisation was not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Patients “were randomised 1:1 to double‐blind treatment with linagliptin 5 mg/day or placebo for 12 weeks; placebo patients were then switched to glimepiride 1–4 mg/day, with double blinding maintained using a double dummy design, and treatments continued until week 52.” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study was reported to be double‐blind although the methodology of blinding of outcome assessment was not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk of attrition bias at week 12: 3/113 linagliptin (2.7%) and 8/122 placebo (6.6%) discontinued by week 12. </p> <p>High risk of attrition bias at week 52: 18/113 linagliptin (15.9%) and 32/122 (26.2%) placebo/glimepiride discontinued by week 52 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were available on a clinical trials database and major outcomes were reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: This study was sponsored by Boehringer Ingelheim (BI) Pharma GmbH &amp; Co. KG, the manufacturer of linagliptin. Authors have either served on the scientific advisory board, received grants or research support and/or received speaker honoraria from BI, or are employees of BI </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">LANTERN 2015 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0194"> <li> <p>Study design: parallel RCT</p> </li> <li> <p>Study time frame: January 2011 and November 2012</p> </li> <li> <p>Duration of follow‐up: 24 weeks with open‐label 28 week extension</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0195"> <li> <p>Country: Japan</p> </li> <li> <p>Setting: multicentre (67 institutions)</p> </li> <li> <p>Inclusion criteria: patients aged 20–74 years; Diagnosed with type 2 DM ≥ 12 weeks before providing informed consent were eligible if they: </p> <ul id="CD011798-lst2-0021"> <li> <p>Currently on diet/exercise therapy alone or in combination with an alpha‐glucosidase inhibitor, a sulphonylureas, or pioglitazone in a constant dosing regimen </p> </li> <li> <p>Poor glycaemic control despite treatment, defined as a glycated haemoglobin (HbA1c) of 6.9–8.9% (52 to 74 mmol/mol), a change in HbA1c of ≤ 1.0% (11 mmol/mol) between visits 1 and 2, and a FBG concentration of ≥6.99 mmol/L for patients using a sulphonylureas </p> </li> <li> <p>BMI of 20.0–45.0 kg/m<sup>2.</sup> </p> </li> <li> <p>Mild (eGFR ≥ 60 to &lt; 90 mL/min/1.73m<sup>2</sup>) or moderate CKD (eGFR ≥30 to &lt;60 mL/min/1.73m<sup>2</sup>) </p> </li> </ul> </li> <li> <p>Number: treatment group (119); control group (46)</p> <ul id="CD011798-lst2-0022"> <li> <p>81 patients had an eGFR &lt; 60 mL/min/1.73 m<sup>2</sup>: treatment group (58); control group (230) </p> </li> </ul> </li> <li> <p>Mean age ± SD (years): treatment group (63.9 ± 6.59); control group (65.7 ± 6.93)</p> </li> <li> <p>Sex (M/F): treatment group (92/26); control group (36/10)</p> </li> <li> <p>Exclusion criteria: type 1 DM; proliferative diabetic retinopathy; treatment with insulin within 12 weeks before visit 1; currently using or scheduled to start dialysis; history of clinically significant kidney disease (e.g. renovascular occlusive disease, nephrectomy and/or kidney transplant) or complications of severe kidney disease (e.g. nephrotic syndrome and/or glomerular nephritis); renal tubular dysfunction (e.g. Fanconi syndrome and interstitial nephritis); dysuria caused by a neurogenic bladder or benign prostatic hypertrophy, symptomatic UTI or symptomatic genital infection at visit 1; chronic disease that required the continuous use of adrenocortical steroids, immunosuppressants or loop diuretic; history of cerebral vascular attack, unstable angina, MI, vascular intervention or heart failure (NYHA Class III–IV) within 12 weeks before visit 1, or presence of heart failure or cerebral vascular disease deemed likely to interfere with treatment or evaluation of safety of this study; heart failure or a history of heart failure if treated with pioglitazone; unstable psychiatric disorder; women wishing to become pregnant, were pregnant or were lactating; males or premenopausal females who could not use contraception; severe infection; perioperative or serious trauma; drug addiction or alcohol abuse; presence of a malignant tumour; history of allergy to SGLT2 inhibitor; history of treatment with ipragliflozin; participation in another clinical study, post‐marketing study or medical device study within 12 weeks before providing written informed consent; patients who were unable or unwilling to adhere to study procedures, including attending the hospital or following the instructions for drug administration </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Both groups</p> <p> <ul id="CD011798-lst1-0196"> <li> <p>The study consisted of a 4‐week screening period, a 2‐week run‐in period in which all patients received placebo </p> </li> <li> <p>Patients continued their diet/exercise therapy</p> </li> <li> <p>Patients who had used an oral hypoglycaemic agent for ≥ 12 weeks before the start of the study were permitted to continue the drug at the same dose throughout the study; changes in the dosing regimen or switching to an alternative drug were prohibited </p> </li> <li> <p>Concomitant use of hypoglycaemic agents other than an alpha‐‐glucosidase inhibitor, a sulphonylureas, or pioglitazone was prohibited </p> </li> </ul> </p> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0197"> <li> <p>Ipragliflozin: 50 mg once/d before breakfast for 24 weeks</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0198"> <li> <p>Placebo once daily before breakfast for 24 weeks</p> </li> </ul> </p> <p>Other information</p> <p> <ul id="CD011798-lst1-0199"> <li> <p>At week 24, the ipragliflozin dose to be used in treatment period 2 could be increased to 100 mg in patients who met the following criteria: an HbA1c level of ≥ 7.4% (57 mmol/mol) at week 20 for patients whose HbA1c level was ≥ 7.4% (57 mmol/mol) at week 0; an HbA1c level of ≥ 6.9% (52 mmol/mol) at week 20 for patients whose HbA1c level was &lt; 7.4% (57 mmol/mol) at week 0; and a willingness to use a higher dose. The dose could be reduced to 50mg if there were possible safety concerns, but the dose could not be increased again after the dose reduction. Other patients continued 50 mg ipragliflozin in treatment period 2 </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0200"> <li> <p>HbA1c</p> </li> <li> <p>FBG</p> </li> <li> <p>Fasting serum insulin</p> </li> <li> <p>Leptin and adiponectin levels</p> </li> <li> <p>Body weight and waist circumference</p> </li> <li> <p>Treatment‐emergent adverse events, vital signs, laboratory variables, 12‐lead ECG and eGFR </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0201"> <li> <p>Funding source: Astellas Pharma Inc. and Kotobuki Pharmaceutical Co., Ltd</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported. Text says: “At the end of the run‐in period, patients were randomised at a 2:1 ratio to receive 50mg ipragliflozin or placebo. Randomization was performed after stratifying patients according to RI severity”. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Patients received placebo or ipragliflozin</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study labelled as double‐blind however methodology of blinding of outcome assessment was but not reported. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low rate of discontinuation from the study</p> <p>For the whole cohort 12/119 10.1% treatment group and 4/46 8.7% control group discontinued</p> <p>For those patients with an eGFR &lt; 60 6/58 10.3% treatment group and 3/23 13.0% control group discontinued </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were available on a clinical trials database and major outcomes were reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: ipragliflozin (ASP1941) was developed by Astellas Pharma Inc. and Kotobuki Pharmaceutical Co., Ltd. Authors were either consultants and received consulting fees/honoraria from Astellas or were employees of Astellas Pharma Inc., Tokyo, Japan </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Leiter 2014 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0202"> <li> <p>Study design: phase 3, parallel RCT</p> </li> <li> <p>Study time frame: 7 May 2010 and 30 May 2012</p> </li> <li> <p>Duration of follow‐up: 52 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0203"> <li> <p>Country: 15 countries (countries not reported)</p> </li> <li> <p>Setting: multinational (134 centres)</p> </li> <li> <p>Inclusion criteria: male and non‐pregnant, non‐lactating female patients ≥18 years of age with historical diagnoses of type 2 DM; baseline HbA1c between 7.0 and 10.0% (53–86 mmol/mol); BMI between 20 and 45 kg/m<sup>2</sup>; fasting C‐peptide level of ≥ 0.8 ng/mL (0.26 nmol/L); GFR ≥ 15 to &lt; 90 mL/min/1.73 m<sup>2</sup>; HB ≥ 10 g/dL for male patients and ≥ 9 g/dL for female patients; normal levels of thyroid‐stimulating hormone or clinically euthyroid </p> </li> <li> <p>Number: treatment group 1 (254); treatment group 2 (253)</p> <ul id="CD011798-lst2-0023"> <li> <p>239 patients had an eGFR &lt; 60 mL/min/1.73 m<sup>2</sup> </p> </li> </ul> </li> <li> <p>Mean age ± SD (years): treatment group 1 (63.2 ± 8.37); treatment group 2 (63.5 ± 9.02) </p> </li> <li> <p>Sex (M/F): treatment group 1 (136/113); treatment group 2 (130/116)</p> </li> <li> <p>Exclusion criteria: malignant disease (except squamous cell or BCC); history of diabetic gastroparesis; current ongoing symptomatic biliary disease or history of pancreatitis; significant GI surgery or surgeries thought to significantly affect upper GI function; recent clinically significant cardiovascular and/or cerebrovascular disease; history of HIV infection, and acute symptomatic hepatitis B or C infection </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Both groups</p> <p> <ul id="CD011798-lst1-0204"> <li> <p>All patients continued to receive their prescribed oral antihyperglycaemic medication regimen (metformin, thiazolidinedione, sulphonylureas, or any combination of these oral antihyperglycaemic medications) for the duration of the study with the exception of patients with GFR &lt; 60 mL/min/1.73 m<sup>2</sup>, who were washed off their background metformin </p> </li> <li> <p>Instructions for down‐titration of sulphonylureas were also provided to avoid hypoglycaemia</p> </li> </ul> </p> <p>Treatment group 1</p> <p> <ul id="CD011798-lst1-0205"> <li> <p>SC albiglutide: 30 mg once/wk (with treatment‐masked up‐titration, if needed, to 50 mg weekly) </p> </li> </ul> </p> <p>Treatment group 2</p> <p> <ul id="CD011798-lst1-0206"> <li> <p>Sitagliptin: dosed based on the eGFR value at randomisation per the sitagliptin package insert </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0207"> <li> <p>Change in HbA1c from baseline at week 26</p> </li> <li> <p>HbA1c</p> </li> <li> <p>FBG</p> </li> <li> <p>Body weight</p> </li> <li> <p>Proportion of patients who met prespecified HbA1c treatment targets</p> </li> <li> <p>Time to hyperglycaemic rescue</p> </li> <li> <p>Population pharmacokinetics of albiglutide</p> </li> <li> <p>Adverse and severe adverse events (clinical laboratory parameters, vital sign measurements, ECG readings, and physical examinations) </p> </li> <li> <p>Immunogenicity</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0208"> <li> <p>We are interested in the 239 patients with an eGFR &lt; 60 mL/min/1.73 m<sup>2</sup> in this systematic review </p> </li> <li> <p>Funding source: GlaxoSmithKline</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“An interactive voice response system was used for the blinded randomisation, which was based on a sequestered fixed randomisation schedule” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“An interactive voice response system was used for the blinded randomisation, which was based on a sequestered fixed randomisation schedule” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Albiglutide and matching placebo was supplied as a fixed‐dose (30 or 50 mg) pen injector system, which was injected subcutaneously into the abdomen. Sitagliptin and matching placebo were provided as overcoated tablets or capsules" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Although the study was described as double‐blind the method by which outcome assessment was blinded was not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High rate of discontinuation, especially in the sitagliptin group</p> <p>51/254 (20.1%) of the albiglutide and 68/253 (26.9%) of the sitagliptin group discontinued</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were available on a clinical trials database and major outcomes were reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: This study was sponsored by GlaxoSmithKline who manufactures albiglutide. All authors except one are employees and share‐holders of GlaxoSmithKline. The remaining author has received research funding from GlaxoSmithKline. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Lewin 2012 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0209"> <li> <p>Study design: phase 3, parallel RCT</p> </li> <li> <p>Study time frame: December 2008 to January 2010</p> </li> <li> <p>Duration of follow‐up: 19 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0210"> <li> <p>Countries: Asia (India, Japan), Europe (Hungary, Poland, Russia), North America (USA), and South America (Argentina). </p> </li> <li> <p>Setting: multinational (45 centres)</p> </li> <li> <p>Inclusion criteria: 18 to 80 years; diagnosis of type 2 DM; BMI of ≤ 40 kg/m<sup>2</sup>; received either sulphonylurea monotherapy or sulphonylurea plus 1 additional glucose‐lowering agent; all agents, including sulphonylurea, were required to have remained unchanged for 10 weeks prior to enrolment; sulphonylurea dose had to be at least half the maximum dose (or less if documented as the maximum tolerated dose for ≥ 12 weeks).HbA1c ≥ 7.0% (53 mmol/L) to ≤ 9.0% (75 mmol/mol) for patients undergoing washout and ≥ 7.5% (58 mmol/mol) to ≤ 10.0% (86 mmol/mol) for patients on sulphonylurea monotherapy </p> </li> <li> <p>Number: treatment group (161); control group (84)</p> <ul id="CD011798-lst2-0024"> <li> <p>6.9% of population (17) had an eGFR &lt; 60 mL/min/1.73 m<sup>2</sup> </p> </li> </ul> </li> <li> <p>Mean age ± SD (years): treatment group (57.2 ± 9.8); control group (56.2 ± 10.2)</p> </li> <li> <p>Sex (M/F): treatment group (77/84); control group (52/32)</p> </li> <li> <p>Exclusion criteria: previous treatment with thiazolidinedione, GLP‐1 analogues, long‐term daily use of insulin or anti‐obesity drugs in the previous 3 months; treatment with systemic corticosteroids or a change in dosage of thyroid hormones in the previous 6 weeks; experience of a MI, stroke, or TIA in the previous 6 months; unstable or acute congestive heart failure; kidney failure, severe kidney impairment, or impaired hepatic function (defined as elevated serum levels of either ALT, AST or ALP &gt; 3‐fold the ULN, or elevated serum total bilirubin levels &gt; 3‐fold ULN; hypersensitivity or allergy to linagliptin or its excipients, the prescribed sulphonylurea drug, or placebo; history of alcohol or drug abuse in the previous 3 months; hereditary galactose intolerance; premenopausal women who were nursing or pregnant </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Run‐in period</p> <p> <ul id="CD011798-lst1-0211"> <li> <p>Patients taking 1 oral glucose‐lowering agent in addition to sulphonylureas at screening underwent a 4‐week drug washout period followed by a 2‐week placebo run‐in period, whereas patients on sulphonylurea monotherapy were entered directly into the 2‐week placebo run‐in </p> </li> </ul> </p> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0212"> <li> <p>Linagliptin: 5 mg once daily for 18 weeks</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0213"> <li> <p>Placebo for 18 weeks</p> </li> </ul> </p> <p>Both groups</p> <p> <ul id="CD011798-lst1-0214"> <li> <p>The background sulphonylurea therapy was administered at an unchanged dosage throughout the entire study duration (including the washout and placebo run‐in periods), with the exception that down‐titration of sulphonylurea was permitted for safety reasons </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0215"> <li> <p>Change in HbA1c from baseline to week 18</p> </li> <li> <p>Mean change in FBG from baseline</p> </li> <li> <p>Mean change from baseline in HbA1c and FBG over time</p> </li> <li> <p>Proportion of patients achieving a reduction in HbA1c ≥ 0.5% (5 mmol/mol)</p> </li> <li> <p>Proportion of patients achieving HbA1c &lt; 7% (53 mmol/mol)</p> </li> <li> <p>Mean change in body weight from baseline</p> </li> <li> <p>Proportion of patients requiring rescue therapy or discontinuing due to lack of efficacy</p> </li> <li> <p>Tolerability data were collected at every visit and included incidence of AE, serious AEs, discontinuation due to AEs, 12‐lead ECG, vital signs, and clinical laboratory parameters. </p> </li> <li> <p>Hypoglycaemic episodes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0216"> <li> <p>Funding source: Boehringer Ingelheim</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Patients were randomised using the interactive voice response system (IVRS; Almac Clinical Technologies, Yardley, Pennsylvania) to ensure that the investigator did not know to which of the 2 treatment groups the next patient would belong” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Patients were randomised using the interactive voice response system (IVRS; Almac Clinical Technologies, Yardley, Pennsylvania) to ensure that the investigator did not know to which of the 2 treatment groups the next patient would belong” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The study was labelled as double‐blind. Patients were given either linagliptin or placebo </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Although the study was labelled as double‐blind, the method through which outcome assessment was blinded was not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10/161 (6.21%) in the linagliptin plus sulphonylurea group versus 7/84 (1.19%) in the sulphonylurea group discontinued </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were available on a clinical trials database and major outcomes were reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: The study was initiated and supported by Boehringer Ingelheim, the manufacturer of linagliptin. Boehringer Ingelheim financially supported the medical writing and editorial assistance. Authors were either employees of Boehringer Ingelheim or received honoraria for attending meetings, consultancy fees, speaker fees and/or travel grants from Boehringer Ingelheim </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">LIRA‐RENAL 2016 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0217"> <li> <p>Study design: parallel RCT</p> </li> <li> <p>Study time frame: June 2012 to August 2013</p> </li> <li> <p>Duration of follow‐up: 26 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0218"> <li> <p>Countries: France (4 sites), Poland (8 sites), Russian Federation (15 sites), Ukraine (6 sites), UK (9 sites), USA (36 sites) </p> </li> <li> <p>Inclusion criteria: 18 to 80 years, previously diagnosed with type 2 DM.HbA1c 7% to 10% (53 to 86 mmol/mmol inclusive); on stable diabetes treatment for &gt; 90 days before screening; the following background diabetes treatments were allowed: monotherapy or dual‐therapy combinations of metformin and/or sulphonylurea and/or pioglitazone, monotherapy with basal or premix insulin, or any combination of basal or premix insulin with metformin and/or pioglitazone; moderate CKD (eGFR 30 to 59 mL/min/1.73 m<sup>2</sup>) &gt; 90 days before screening (confirmed at screening); BMl of 25 to 45 kg/m<sup>2</sup> (inclusive). </p> </li> <li> <p>Number: treatment group (140); control group (139)</p> </li> <li> <p>Mean age ± SD (years): treatment group (68 ± 8.3); control group (66.3 ± 8.0)</p> </li> <li> <p>Sex (M/F): treatment group (75/65); control group (65/72)</p> </li> <li> <p>Exclusion criteria: hypoglycaemic unawareness and/or recurrent severe hypoglycaemia as judged by the investigator; impaired liver function (ALT ≥ 2.5 x ULN; history of chronic pancreatitis or idiopathic acute pancreatitis; NYHA Functional Classification IV heart failure; episode of unstable angina, acute coronary event, cerebral stroke/TIA, or other significant cardiovascular event within the past 180 days; SBP ≥ 180 mmHg or a DBP ≥ 100 mmHg; screening calcitonin value ≥ 50 ng/L; personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0219"> <li> <p>Liraglutide: initiated at 0.6 mg/d with subsequent weekly dose escalations of 0.6 mg/d until the maintenance dose of 1.8 mg/d was reached. Dose escalation could be extended for up to 4 weeks in case of GI adverse effects </p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0220"> <li> <p>Placebo: initiated at 0.6 mg/d with subsequent weekly dose escalations of 0.6 mg/d until the maintenance dose of 1.8 mg/d was reached. Dose escalation could be extended for up to 4 weeks in case of GI adverse effects </p> </li> </ul> </p> <p>Both groups</p> <p> <ul id="CD011798-lst1-0221"> <li> <p>If the patient was on insulin with an HbA1c ≤ 8% (64 mmol/mol) at screening, the pretrial insulin dose was reduced by 20% at day 0 and kept fixed until the liraglutide/placebo dose escalation was complete. Titration to pretrial insulin dose was allowed at the discretion of the investigators. Patients were to maintain their background diabetes medications during the study and were allowed to dose reduce insulin or sulphonylureas doses if hypoglycaemic episodes occurred </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0222"> <li> <p>Change in HbA1c from baseline to week 26. Responder end points at week 26 for HbA1c &lt; 7.0% (&lt; 53 mmol/mol) and HbA1c &lt; 7.0% (&lt; 53 mmol/mol) with no hypoglycaemic episodes were determined </p> </li> <li> <p>Change from baseline to week 26 in FBG, body weight, BMI, SBP and DBP, fasting lipids, and selected cardiovascular bio markers, total prescribed daily insulin dose </p> </li> <li> <p>Adverse events, change from baseline in eGFR , UACR, amylase, lipase and pulse rate</p> </li> <li> <p>Hypoglycaemic episodes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0223"> <li> <p>Funding source: Novo Nordisk</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomised using a sponsor‐provided telephone or Web‐based randomisation system.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomised using a sponsor‐provided telephone or Web‐based randomisation system.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Trial site personnel, patients, and the sponsor remained blinded until trial completion”.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Trial site personnel, patients, and the sponsor remained blinded until trial completion”.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Discontinuation rates were moderately high: 35/140 (25%) from the liraglutide group versus 34/137 (24.8%) in the control group </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were available on a clinical trials database and major outcomes were reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: The study was sponsored by Novo Nordisk who developed and sells liraglutide. All authors have either been on the advisory panel for Novo Nordisk, received research support or educational grants from Novo Nordisk or work for Novo Nordisk </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Lukashevich 2011 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0224"> <li> <p>Study design: parallel RCT</p> </li> <li> <p>Study time frame: not reported</p> </li> <li> <p>Duration of follow‐up: 52‐week clinical study – 24 weeks with extension to 1 year</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0225"> <li> <p>Country: international (countries not reported)</p> </li> <li> <p>Setting: multicentre (108 sites)</p> </li> <li> <p>Inclusion criteria: Adults aged 18 to 85 years with type 2 DM; moderate or severe CKD (eGFR by the MDRD formula ≥ 30 to &lt; 50 mL/min/1.73 m<sup>2</sup> and &lt; 30 mL/min/1.73 m<sup>2</sup>, respectively) either untreated (no therapy in previous 8 weeks) or treated with an sulphonylurea, alpha glucosidase inhibitor, thiazolidinedione, insulin, meglitinide or a combination of agents was permitted provided that their dosages were stable for the previous 4 weeks; HbA1C was between 6.5% (48 mmol/mol) and 10% (86 mmol/mol); BMI was between 18 and 42 kg/m<sup>2</sup> </p> </li> <li> <p>Number (randomised)</p> <ul id="CD011798-lst2-0025"> <li> <p>Moderate CKD: treatment group (165); control group (129)</p> </li> <li> <p>Severe CKD: treatment group (124); control group (97)</p> </li> </ul> </li> <li> <p>Mean age ± SD (years)</p> <ul id="CD011798-lst2-0026"> <li> <p>Moderate CKD: treatment group (67.7 ± 8.8); control group (69.7 ± 7.3)</p> </li> <li> <p>Severe CKD: treatment group (64.1 ± 9.2); control group (64.5 ± 10.8)</p> </li> </ul> </li> <li> <p>Sex (M/F)</p> <ul id="CD011798-lst2-0027"> <li> <p>Moderate CKD: treatment group (96/69); control group (80/49)</p> </li> <li> <p>Severe CKD: treatment group (65/59); control group (44/53)</p> </li> </ul> </li> <li> <p>Exclusion criteria: FBG ≥15 mmol/L; history of kidney transplant; significant cardiovascular history within 6 months; active liver disease or abnormal liver tests (ALT, AST or bilirubin 2× ULN) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Run‐in period</p> <p> <ul id="CD011798-lst1-0226"> <li> <p>2‐week single‐blind, placebo run‐in period</p> </li> </ul> </p> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0227"> <li> <p>Vildagliptin: 50 mg once/d</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0228"> <li> <p>Placebo once daily</p> </li> </ul> </p> <p>Both group</p> <p> <ul id="CD011798-lst1-0229"> <li> <p>Rescue medication (insulin addition or intensification) was administered after Week 4 if the FBG was 15 mmol/L, at Week 8 if the FBG was 13.3 mmol/L and at Week 16, if the FBG was 12.2 mmol/L. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0230"> <li> <p>FBG and HbA1c</p> </li> <li> <p>Percentage of patients achieving HbA1c &lt; 7.0%</p> </li> <li> <p>Adverse events</p> </li> <li> <p>Particular attention was paid to safety areas considered to be of potential concern for DPP‐4 inhibitors (i.e. hepatic, infections, skin, pancreatitis) as well as oedema and cardiovascular safety, which were considered of interest in this renally impaired population and which were previously analysed in patients with normal kidney function or mild CKD. </p> </li> <li> <p>Hypoglycaemia was defined as symptoms suggestive of low blood glucose confirmed by self‐monitored blood glucose measurement &lt; 3.1 mmol/L plasma glucose equivalent </p> </li> <li> <p>Severe hypoglycaemia was defined as any episode requiring assistance of another party (whether or not a confirmatory self‐monitoring blood glucose measure was available) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0231"> <li> <p>The initial protocol excluded patients undergoing any dialysis, but this was subsequently amended to remove that restriction </p> </li> <li> <p>Funding source: Novartis</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study was described as randomised, method of randomisation was not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“The investigators and patients remained blinded to the identity of the treatment”.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“The investigators and patients remained blinded to the identity of the treatment”.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High rate of discontinuation across both treatment groups in those with moderate CKD (52/165 (31.5%) from the vildagliptin group and 40/129 (31.0%) from the placebo group) and severe CKD (41/124 (33.1%) from the vildagliptin group and 41/97 (42.3%) from the placebo group). </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were not available on a clinical trials database</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"P.‐H. G. has served on advisory boards for Novartis, Boehringer Ingelheim and Cebix, has received honoraria for speaking engagements from Novartis, Boehringer Ingelheim, Novo‐Nordisk, Eli Lilly, Genzyme and MSD Finland and received research support from Eli Lilly. V. L., Q. S., A. S.and W. K. are employed by and own shares in Novartis." </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">McGill 2013 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0232"> <li> <p>Study design: parallel RCT</p> </li> <li> <p>Study time frame: not reported</p> </li> <li> <p>Duration of follow‐up: 52‐week double‐blind treatment period, and a 1‐week follow‐up period </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0233"> <li> <p>Countries: international (Australia, Hong Kong, Israel, New Zealand, Ukraine, USA)</p> </li> <li> <p>Setting: multicentre (53 sites)</p> </li> <li> <p>Inclusion criteria: women (non‐fertile or using a medically approved birth control method) and men aged 18 to 80 years; previously diagnosed with type 2 DM, who were treated with glucose‐lowering agents, including insulin, sulphonylureas, glinides, pioglitazone, and alpha‐glucosidase inhibitors; existing glucose‐lowering therapy must have remained unchanged for ≥ 8 weeks before study entry; severe CKD (CKD stage 4/5) at screening, having an eGFR &lt; 30 mL/min/1.73 m<sup>2</sup> (while not receiving chronic dialysis); HbA1c &gt; 7 and ≤ 10% (&gt; 53 and ≤ 86 mmol/mol); BMI ≤ 45 kg/m<sup>2</sup> </p> </li> <li> <p>Number (randomised/completed): treatment group (68/49); control group (65/48)</p> </li> <li> <p>Mean age ± SD (years): treatment group (64.0 ± 10.9); control group (64.9 ± 9.6)</p> </li> <li> <p>Sex (M/F): treatment group (45/23); control group (35/30)</p> </li> <li> <p>Exclusion criteria: MI, stroke, or TIA within the previous 6 months; any requirement for acute dialysis within the previous 3 months; kidney transplantation; impaired hepatic function; use of any other DPP‐4 inhibitor or anti‐obesity drug within the previous 3 months </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Run‐in period</p> <p> <ul id="CD011798-lst1-0234"> <li> <p>2‐week, open‐label placebo run‐in period</p> </li> </ul> </p> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0235"> <li> <p>Linagliptin: 5 mg/d in addition to their glucose‐lowering background therapy for 52 weeks. To assess the glucose‐lowering effect of adding linagliptin, stable doses of existing background therapy were maintained </p> </li> <li> <p>During the first 12 weeks of treatment (unless dose adjustment was required for safety reasons) </p> </li> <li> <p>During the following 40‐week treatment period, background therapy could be adjusted according to glucose parameters </p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0236"> <li> <p>Placebo in addition to their glucose‐lowering background therapy for 52 weeks</p> </li> </ul> </p> <p>Both groups</p> <p> <ul id="CD011798-lst1-0237"> <li> <p>Rescue therapy (any changes in treatment or doses of glucose‐lowering background therapy during weeks 1–12 and/or addition of insulin during weeks 1–52) could be initiated based on failure to meet prespecified glycaemic response criteria: a confirmed FBG level &gt; 13.3 mmol/L during weeks 1–12, a confirmed FBG level &gt; 11.1 mmol/L during weeks 12–52, or a randomly determined glucose level &gt; 22.2 mmol/L at any time. Patients who failed to meet these criteria despite rescue therapy were discontinued from the study </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0238"> <li> <p>Change from baseline to week 12 in HbA1c</p> </li> <li> <p>Changes from baseline to week 52 in HbA1c, FBG, glucose‐lowering background therapy, and body weight </p> </li> <li> <p>Frequency and intensity of AEs, withdrawals because of AEs, physical examinations, 12‐lead electrocardiograms, vital signs, and clinical laboratory assessments throughout the 52 weeks </p> <ul id="CD011798-lst2-0028"> <li> <p>Hypoglycaemic events and severe hypoglycaemic episodes</p> </li> <li> <p>Treatment‐emergent fatal events and suspected cardiovascular events (cardiovascular death, stroke, MI, and hospitalisation for unstable angina. </p> </li> </ul> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0239"> <li> <p>Stratified by HbA1c and glucose‐lowering background therapy</p> </li> <li> <p>Funding source: Boehringer Ingelheim</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study was described as randomised, method of randomisation was not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Study investigators and participants were blinded to treatment assignment for the duration of the study and to results of interim analyses” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Study investigators and participants were blinded to treatment assignment for the duration of the study and to results of interim analyses” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Moderately large discontinuation rate across both groups: 19/68 (27.9%) of the linagliptin group and 17/65 (26.2%) of the placebo group </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were not available on a clinical trials database</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The study was sponsored by Boehringer Ingelheim. Authors were either employees of Boehringer Ingelheim or have spoken for or served as a consultant for Boehringer Ingelheim </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Mohideen 2005 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0240"> <li> <p>Study design: open‐label, parallel RCT</p> </li> <li> <p>Study time frame: not reported</p> </li> <li> <p>Duration of follow‐up: 6 months</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0241"> <li> <p>Country: USA</p> </li> <li> <p>Setting: single centre</p> </li> <li> <p>Inclusion criteria: men and women ≥ 18 years; physician‐diagnosed diabetes mellitus type 2; ESKD treated with either HD or PD; treated with insulin or a sulphonylureas or if not taking insulin, had HbA1c &gt; 7% </p> </li> <li> <p>Number: treatment group (6); control group (6)</p> </li> <li> <p>Mean age ± SD (years): treatment group (58.8 ± 6.2); control group (52.0 ± 5.5)</p> </li> <li> <p>Sex (M/F): treatment group (2/4); control group (2/4)</p> </li> <li> <p>Exclusion criteria: known liver disease or cirrhosis; ALT or AST &gt; 3 times ULN; congestive heart failure or cardiomyopathy; sensitivity to troglitazone or components of troglitazone </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0242"> <li> <p>Troglitazone: started on 200 mg/d and titrated to a maximum dose 600 mg/d</p> </li> <li> <p>Continuing previous diabetes medications (insulin or sulphonylureas)</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0243"> <li> <p>Continued to receive their current diabetes medication regimen (insulin or sulphonylureas)</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0244"> <li> <p>HbA1c levels</p> </li> <li> <p>Blood glucose profiles (blood glucose values were averaged for the week prior to study visit) </p> </li> <li> <p>Insulin and sulphonylureas dosage</p> </li> <li> <p>Safety measures</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0245"> <li> <p>Control subjects were eligible to “cross‐over” into the troglitazone treatment group after completing 6 months of the protocol </p> </li> <li> <p>Written to authors to get first phase data on 6th February 2017 to include in the meta‐analysis. No data available </p> </li> <li> <p>Funding source: Pfizer</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Eligible subjects were randomised to either with troglitazone or without troglitazone (control) group using a table of random numbers assigned by an independent investigator” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Eligible subjects were randomised to either with troglitazone or without troglitazone (control) group using a table of random numbers assigned by an independent investigator”. But for second phase, subjects were given the option of crossing over into the Troglitazone arm. This give a risk of selection bias. The risk is removed if we analyse first phase data only as per the protocol </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open‐label study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open‐label study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3/6 (50%) of the troglitazone arm and 1/6 (16.7%) of the control arm discontinued</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were not available on a clinical trials database</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: The study was supported in part by Pfizer, Inc</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Mori 2016 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0246"> <li> <p>Study design: open‐label, parallel RCT</p> </li> <li> <p>Study time frame: 6 July 2012 to 8 July 2014</p> </li> <li> <p>Duration of follow‐up: 12 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0247"> <li> <p>Country: Japan</p> </li> <li> <p>Setting: multicentre (15 sites)</p> </li> <li> <p>Inclusion criteria: men and women with type 2 DM undergoing stable maintenance HD, aged ≥ 20 years; HbA1c level ≥ 4.6% (27 mmol/mol) and ≤ 10% (86 mmol/mol) or a GA level ≥ 18% and ≤ 30%; GA level was adopted as an inclusion criterion because HbA1c level is often underestimated in this population as a result of renal anaemia and/or the use of ESA </p> </li> <li> <p>Number: treatment group 1 (38); treatment group 2 (40)</p> </li> <li> <p>Mean age ± SD (years): treatment group 1 (69.2 ± 9.5); treatment group 2 (66.7 ± 9.5)</p> </li> <li> <p>Sex (M/F): treatment group 1 (31/7); treatment group 2 (30/10)</p> </li> <li> <p>Exclusion criteria: treatment with any type of insulin; impaired hepatic function (AST ≥ 100 IU/L or ALT ≥ 100 IU/L); malignant tumours; untreated diabetic retinopathy </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group 1</p> <p> <ul id="CD011798-lst1-0248"> <li> <p>Linagliptin: 5 mg/d</p> </li> </ul> </p> <p>Treatment group 2</p> <p> <ul id="CD011798-lst1-0249"> <li> <p>Voglibose 0.2 mg 3 times/d</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0250"> <li> <p>Change in HbA1c level between baseline and week 12.</p> </li> <li> <p>Changes in GA and casual plasma glucose levels between baseline and week 12</p> </li> <li> <p>Adverse events, clinical laboratory tests</p> </li> <li> <p>Hypoglycaemia episodes: defined as any hypoglycaemia symptoms or a casual blood glucose level &lt; 2.8 mmol/L as evaluated by finger‐stick blood testing </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0251"> <li> <p>Funding source: KM, ME, TS and MI received unrestricted research grants from Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Co., Astellas Pharma, Asahi Kasei Pharm Corporation, Kyowa Hakko Kirin Co., Chugai Pharmaceutical Co., Teijin Pharma, Takeda Pharmaceutical Company, and Ono Pharmaceutical Co </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open‐label study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open‐label study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>There was higher discontinuation in voglibose compared to the linagliptin group: 6/38 (15.8%) in the voglibose group and 3/40 (7.5 %) in the linagliptin group. Data were analysed using the full analysis set with the last observation carried forward </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Prespecified outcomes were available on a public database and were reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The authors received unrestricted research grants from Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Co., Astellas Pharma, Asahi Kasei Pharm Corporation, Kyowa Hakko Kirin Co., Chugai Pharmaceutical Co., Teijin Pharma, Takeda Pharmaceutical Company, and Ono Pharmaceutical Co. All but one of the authors received honorarium for lecturing from Nippon Boehringer Ingelheim. Takeda produces voglibose, and Nippon Boehringer Ingelheim linagliptin </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Nakamura 2001 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0252"> <li> <p>Study design: parallel RCT</p> </li> <li> <p>Study time frame: not reported</p> </li> <li> <p>Duration of follow‐up: 3 months</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0253"> <li> <p>Country: Japan</p> </li> <li> <p>Setting: not reported</p> </li> <li> <p>Inclusion criteria: dialysis patients with type 2 DM, dyslipidaemia without lipid lowering drugs </p> </li> <li> <p>Number: treatment group (10); control group (10)</p> </li> <li> <p>Mean age: 54.5 years (age not reported for each group)</p> </li> <li> <p>Sex (M/F): 12/8 (sex not reported for each group)</p> </li> <li> <p>Exclusion criteria: not reported</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0254"> <li> <p>Pioglitazone: 30 mg/d</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0255"> <li> <p>Placebo</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0256"> <li> <p>HbA1c levels</p> </li> <li> <p>Fasting serum triglyceride levels</p> </li> <li> <p>Fasting HDL cholesterol levels</p> </li> <li> <p>Fasting total cholesterol levels</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0257"> <li> <p>Written to authors for data for inclusion in the meta‐analysis. No data available</p> </li> <li> <p>Funding source: not reported</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study was described as randomised, method of randomisation was not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Patients were given a placebo tablet</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No patients discontinued</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were not available on a clinical trials database</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest were not reported</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Nowicki 2011 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0258"> <li> <p>Study design: parallel RCT</p> </li> <li> <p>Study time frame: January 2008 to March 2010</p> </li> <li> <p>Duration of follow‐up: 52 weeks; 12‐week double‐blind treatment period followed by a 40‐week double‐blind controlled extension with continuation of treatment </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0259"> <li> <p>Country: international (countries not reported)</p> </li> <li> <p>Setting: multicentre (number of sites not reported)</p> </li> <li> <p>Inclusion criteria: adults with a diagnosis of type 2 DM; CrCl &lt; 50 mL ⁄ min within the past 3 months; inadequate glycaemic control (HbA1c 7% to 11% [53 to 97 mmol/mol]).C‐peptide ≥ 0.33 nmol/L </p> </li> <li> <p>Number (randomised/completed week 12): treatment group (85/61); control group (85/68)</p> </li> <li> <p>Mean age ± SD (years): treatment group (66.8 ± 8.3); control group (66.2 ± 9.1)</p> </li> <li> <p>Sex (M/F): treatment group (32/53); control group (41/44)</p> </li> <li> <p>Exclusion criteria: current or anticipated need for PD or expected kidney transplant within 3 months after enrolment; AST, ALT and ⁄ or total bilirubin &gt; 1.5 times ULN; creatine kinase ≥ 3 times ULN; treatment with metformin within 4 weeks before enrolment; previous or current treatment with any DPP‐4 inhibitor or GLP‐1 agonist </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Run‐in period</p> <p> <ul id="CD011798-lst1-0260"> <li> <p>2‐week, single‐blind, placebo lead‐in period</p> </li> </ul> </p> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0261"> <li> <p>Oral saxagliptin: 2.5 mg once/d taken immediately before or with a meal</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0262"> <li> <p>Oral placebo: once/d taken immediately before or with a meal</p> </li> </ul> </p> <p>Both groups</p> <p> <ul id="CD011798-lst1-0263"> <li> <p>For patients with ESKD receiving HD, study medication was taken after completion of the HD treatment on the days that scheduled HD treatment occurred, with the exception of week 12 when patients took one dose for pharmacokinetic (PK) sampling and a second dose after HD treatment </p> </li> <li> <p> Patients were provided with a glucometer and diary, and instructed to monitor their plasma glucose at least every other day throughout the study, and record plasma glucose values and information about any hypoglycaemic events in their diaries </p> </li> <li> <p>Counselling on dietary and lifestyle modifications was provided according to usual clinical practice during the lead‐in period, and reinforced at all subsequent visits </p> </li> <li> <p>Oral antihyperglycaemic drugs and/or insulin therapy present at enrolment were continued throughout the study; discontinuation or down titration of these medications was allowed only if needed to prevent hypoglycaemia </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0264"> <li> <p>Absolute HbA1c change from baseline to week 12</p> </li> <li> <p>Assessment of efficacy at 52 weeks using absolute change from baseline in HbA1c and FBG and changes from baseline in the type and ⁄ or daily doses of background oral glucose‐lowering therapy and insulin. </p> </li> <li> <p>AEs, treatment‐related AEs, AEs leading to discontinuation of study medication and serious AEs </p> </li> <li> <p>Laboratory values, including estimated glomerular filtration rate using the Cockcroft‐Gault and MDRD equations and the urinary albumin:creatinine ratio </p> </li> <li> <p>Electrocardiograms, measurement of body weight and vital signs and physical examinations were performed at predetermined intervals, incidence of doubling of SCr concentration and shifts in CKD category, including progression to ESKD </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0265"> <li> <p>Patients were stratified based on degree of CKD (moderate, severe or ESKD), and randomised (1:1) </p> </li> <li> <p>Patients were to be discontinued from the study if they did not meet progressively stringent glycaemic control criteria. These prespecified glycaemic goals included confirmed FBG &gt; 15.0 mmol/L at weeks 2 or 4; &gt; 13.3 mmol/L at weeks 6 or 9 and &gt; 12.2 mmol/L at week 12. Study discontinuation criteria also included confirmed lymphopenia (≤ 400 cells/μL), thrombocytopenia (&lt; 75,000 cells/μL) or clinical symptoms of poorly controlled DM. Glycaemic parameters were assessed at each visit to determine if criteria for discontinuation were met </p> </li> <li> <p>Funding source: "This study was funded, designed and supervised by scientists at Bristol‐Myers Squibb and AstraZeneca." </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Using CrCl estimated by the Cockcroft‐Gault equation (23), patients were stratified by degree of renal impairment: moderate (CrCl ≥ 30 and &lt; 50 mL ⁄ min), severe (CrCl &lt; 30 mL ⁄ min and not receiving dialysis) or end‐stage renal disease (ESRD) on haemodialysis at baseline. Patients were randomised 1 : 1 via an interactive voice response system in balanced blocks within each renal impairment category to once‐daily double‐blind treatment with saxagliptin 2.5 mg or placebo” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Using CrCl estimated by the Cockcroft‐Gault equation (23), patients were stratified by degree of renal impairment: moderate (CrCl ≥30 and &lt; 50 mL ⁄ min), severe (CrCl &lt; 30 mL ⁄ min and not receiving dialysis) or end‐stage renal disease (ESRD) on haemodialysis at baseline. Patients were randomised 1 : 1 via an interactive voice response system in balanced blocks within each renal impirment category to once‐daily double‐blind treatment with saxagliptin 2.5 mg or placebo”. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Blinding was ensured using a single‐dummy technique”.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study labelled as a double‐blind study. Otherwise, method of blinding was not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>There was high discontinuation in both groups: 43/85 (50.6%) in the saxagliptin group and 35/85 (41.2%) in the control group </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were available on a clinical trials database and major outcomes were reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: The study was funded, designed and supervised by scientists at Bristol‐Myers Squibb and AstraZeneca. Three of the authors were employees of Astra Zeneca, the maker of saxagliptin. Two of the authors are either study investigators for Astra Zeneca or have received speaking honoraria. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Pfutzner 2011 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0266"> <li> <p>Study design: phase 2, parallel RCT</p> </li> <li> <p>Study time frame: not reported</p> </li> <li> <p>Duration of follow‐up: 6 months</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0267"> <li> <p>Country: Germany</p> </li> <li> <p>Setting: multicentre (12 sites)</p> </li> <li> <p>Inclusion criteria: patients with type 2 DM (WHO criteria); HbA1c ≥ 48 mmol/mol (6.5%); persistent albuminuria (≥ 30 mg/g (3.39 mg/mmol) in at least 2 out of 3 consecutive morning spot urine samples) and who were receiving stable RAS‐blocking treatment </p> </li> <li> <p>Number (randomised/completed): treatment group (20/15); control group (19/11)</p> </li> <li> <p>Mean age ± SD (years): treatment group (68.9 ± 6.8); control group (69.6 ± 9.4)</p> </li> <li> <p>Sex (M/F): treatment group (14/6); control group (13/6)</p> </li> <li> <p>Exclusion criteria: diagnosis of clinical heart failure; eGFR ≤ 30 mL/min/1.73 m<sup>2</sup> </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0268"> <li> <p>Pioglitazone: 1 x 30 mg/d at breakfast for 6 months. Advice for insulin dosage adaptation and choice of insulin was at the discretion of the investigator. At the discretion of the investigator, the initial insulin dose was reduced by 10% at the randomisation visit. Insulin was titrated to target a FBG level of 4.44 to 6.67 mmol/L. Patients were allowed to use any further concomitant medications that they required as far as they did not belong to those representing exclusion criteria. If medically acceptable, all concomitant medications had to be kept constant during the investigation. </p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0269"> <li> <p>Placebo for 6 months</p> </li> </ul> </p> <p>Both groups</p> <p> <ul id="CD011798-lst1-0270"> <li> <p>Advice for insulin dosage adaptation and choice of insulin was at the discretion of the investigator. At the discretion of the investigator, the initial insulin dose was reduced by 10% at the randomisation visit. Insulin was titrated to target a FBG level of 4.44 – 6.67 mmol/L. Patients were allowed to use any further concomitant medications that they required as far as they did not belong to those representing exclusion criteria. If medically acceptable, all concomitant medications had to be kept constant during the investigation. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0271"> <li> <p>The change in the daily insulin dose (basal and prandial) after 6 months of treatment with either pioglitazone or placebo given in addition to insulin. The total daily insulin dose was defined as the mean of the daily insulin dose on 3 consecutive days before the respective visits </p> </li> <li> <p>The number of patients with a reduction of the daily insulin dose of ≥ 30%</p> </li> <li> <p>Laboratory parameters such as HbA1c, glucose, C‐peptide, intact proinsulin, adiponectin, relaxin, fetuin A, carbonyl protein, angiotensin, high‐sensitivity CRP, calcification markers (MPO, matrix Gla protein), lipids (cholesterol, HDL, LDL, triglycerides), matrix metallopeptidase 9 (MMP‐9), monocyte chemotactic protein‐1 (MCP‐1), soluble E‐selectin, oxidized LDL (ox LDL), PIO in serum, iPTH, and N‐terminal fragment of pro‐brain natriuretic peptide (NT‐proBNP) </p> </li> <li> <p>Laboratory efficacy parameters were measured using blood collected prior to dialysis at visit 2 (baseline), visit 5 (12 weeks later), and visit 7 (6 months later) </p> </li> <li> <p>The influence of the treatment on cardiac function was furthermore evaluated as the change in the ultrafiltrate volumes during the course of the study. Another objective was the safety surveillance including assessment of adverse events (AE) and safety laboratory parameters. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0272"> <li> <p>Funding source: The study was sponsored by TAKEDA Pharma GmbH, Aachen, Germany</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study was described as randomised, method of randomisation was not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“After written informed consent was obtained from each participant, patients were randomised to either receive an additional treatment with pioglitazone (1 x 30 mg/day at breakfast) or placebo for 6 months”. </p> <p>Also the study was reported to be a double‐blind study.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>There was greater discontinuation in the control group compared to the pioglitazone group: 4/19 (21.1%) pioglitazone versus 6/17 (35.3%) control group. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were not available on a clinical trials database</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: The study was sponsored by TAKEDA Pharma GmbH, Aachen, Germany.</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Ruggenenti 2003a </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0273"> <li> <p>Study design: cross‐over RCT</p> </li> <li> <p>Study time frame: not reported</p> </li> <li> <p>Duration of follow‐up: two 10 hour periods separated by a 2‐week washout period</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0274"> <li> <p>Country: Italy</p> </li> <li> <p>Setting: single centre</p> </li> <li> <p>Inclusion criteria: type 2 DM; continued treatment with oral antidiabetic argents and/or insulin for at least 1 year; SCr &lt; 176.8 µmol/L and an albuminuria persistently ≥ 200 µg/min in 2 of 3 urinary collections for at least 6 months were asked to submit within 2 weeks three consecutive timed overnight urine collections for the centralised measurement of UAER ≥ 200 µg/min in 2 of the 3 urinary samples entered the study </p> </li> <li> <p>Number: 11</p> </li> <li> <p>Median age (range): 59.3 years (42 to 72)</p> </li> <li> <p>Sex (M/F): 7/4</p> </li> <li> <p>Exclusion criteria: any evidence of nondiabetic kidney disease; renovascular disease; urinary tract obstruction; incomplete bladder voiding; UTI; stroke, acute MI or unstable angina in the last 6 months; severe liver or haematological disease; collagen vascular disease; cancer; treatment with cimetidine; steroidal or NSAIDs over the last 2 months; any condition that in the investigator's judgement might prevent study completion or affect data interpretation were not included; pregnancy or childbearing potential </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0275"> <li> <p>After an insulin clamp to maintain BGL between 4.44 to 6.66 mmol/L for 2 hours, baseline bloods were done and subjects were then given insulin lispro. Five minutes after insulin administration, subjects were given a standard meal made of pasta, turkey, bread, fresh tomatoes, an apple, and olive oil, containing 692 kcal (54.2% CHO, 17.l4% proteins and 28.4% lipids), with the broad aim to achieve postprandial BGL &gt; 13.88 mmol/L after the SC injection of a standard dose (0.1 U/kg) of regular insulin. Patients voided at the beginning of the meal and six consecutive 1 hour urine collections were made for postprandial evaluations. Blood was sampled at the beginning and end of each postprandial urine collection. Urine and plasma samples were collected for the measurement of inulin, PAH and albumin which were used to calculate GFR. At completion of the clearance studies, patients were discharged and asked to continue their previous antidiabetic and antihypertensive therapy. No change was introduced in diet or pharmacological treatments. 2 weeks later, they attended the clinical research centre for a second clearance study, and given regular SC insulin half an hour before the meal, with exactly the same procedure as described previously. </p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0276"> <li> <p>Same procedure as in active arm, except regular insulin given half an hour before the meal, and 2 weeks later, given insulin lispro. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0277"> <li> <p>The percent change in postprandial GFR achieved by lispro versus regular insulin – 2 and 4 hour change in GFR </p> </li> <li> <p>Albumin concentration</p> </li> <li> <p>Amino acid plasma concentration</p> </li> <li> <p>Inulin and PAH clearance samples.</p> </li> <li> <p>Blood glucose and plasma amino acid areas under the curve, mean GFR, renal plasma flow, filtration fraction, renal vascular resistance, albumin fractional clearances </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0278"> <li> <p>Funding source: sponsored partially by Eli Lilly Florence Italy</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study was described as randomised, method of randomisation was not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>There were no discontinuations</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were not available on a clinical trials database</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: The study was sponsored partially by Eli Lilly Florence Italy</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">SAVOR‐TIMI 53 2011 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0279"> <li> <p>Study design: parallel RCT</p> </li> <li> <p>Study time frame: May 2010 to December 2011</p> </li> <li> <p>Duration of follow‐up: median duration 2.1 years</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0280"> <li> <p>Country: 26 countries (included Europe, Russia, South‐east Asia, China, South and North America, Israel, Australia) </p> </li> <li> <p>Setting: multicentre (788 sites)</p> </li> <li> <p>Inclusion criteria: documented type 2 DM; HbA1c from 6.5% to 12.0%; history of established CVD or multiple risk factors for vascular disease; eGFR was determined according to the MDRD formula </p> </li> <li> <p>Number: treatment group (8280); control group (8212)</p> <ul id="CD011798-lst2-0029"> <li> <p>2576 patients had an eGFR &lt; 50 mL/min/1.73 m<sup>2</sup>: treatment group (1294); control group (1282) </p> </li> </ul> </li> <li> <p>Mean age ± SD (years): treatment group (65.1 ± 8.5); control group (65.0 ± 8.6)</p> </li> <li> <p>Sex (M/F): treatment group (5512/2768); control group (5525/2687)</p> </li> <li> <p>Exclusion criteria: currently receiving or had received within the previous 6 months an incretin‐based therapy; ESKD and undergoing long‐term dialysis; undergone a kidney transplant; SCr level &gt; 6.0 mg/dL (530 μmol/L) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0281"> <li> <p>Saxagliptin: 5 mg/d (or 2.5 mg/d in patients with an eGFR ≤ 50 mL/min)</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0282"> <li> <p>Placebo</p> </li> </ul> </p> <p>Both groups</p> <p> <ul id="CD011798-lst1-0283"> <li> <p>All other therapy for the management of the patient’s diabetes and CVD ‐ including adding, discontinuing, or changing the dose of concomitant anti hyperglycaemic drugs ‐ was at the discretion of the responsible physician </p> </li> <li> <p>Concomitant use of other DPP‐4 inhibitors or glucagon‐like peptide 1 agonists was not allowed </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0284"> <li> <p>A composite of cardiovascular death, nonfatal MI, or nonfatal ischaemic stroke</p> </li> <li> <p>The primary composite end point plus hospitalisation for heart failure, coronary revascularization, or unstable angina </p> </li> <li> <p>Hypoglycaemic events, pancreatitis, thrombocytopenia, lymphocytopenia, infections, cancers, hypersensitivity or skin reactions, bone fractures, kidney abnormality and liver abnormalities. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0285"> <li> <p>For this systematic review, we are interested in those patients with an eGFR &lt; 60 mL/min/1.73 m<sup>2</sup> </p> </li> <li> <p>Written to authors for further data for patients with an eGFR &lt; 50 for the meta‐analysis. No further data available </p> </li> <li> <p>Funding source: AstraZeneca and Bristol‐Myers Squibb</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Patients were randomised via a central computerized telephone or Web‐based system in blocks of 4, with stratification according to the qualifying CVD state and kidney function </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Patients were randomised via a central computerized telephone or Web‐based system in blocks of 4, with stratification according to the qualifying CVD state and kidney function </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"Saxagliptin or placebo was administered in a blinded fashion until the end of the follow‐up period" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"No member of the study delivery team at AstraZeneca or BMS or representative, personnel at study centres or any clinical research organisation (CRO) handling data will have access to the randomisation scheme during the conduct of the study" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low rate of attrition:‐ 202/8280 (2.4%) in the Saxagliptin group; 214/8212 (2.6%) in the placebo group </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were available on a clinical trials database and all major outcomes were reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: The study was sponsored by AstraZeneca and Bristol‐Myers Squibb and designed by the TIMI Study Group and Hadassah Medical Organization in conjunction with the sponsors, who provided monitoring support and donated the drug. All authors except one author either received grant support, consulting fees and/or lecture fees from AstraZeneca and Bristol‐Myers Squibb or are employees of AstraZeneca or Bristol‐Myers Squibb </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Scarpioni 1994 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0286"> <li> <p>Study design: cross‐over RCT</p> </li> <li> <p>Study time frame: not reported</p> </li> <li> <p>Duration of follow‐up: not reported</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0287"> <li> <p>Country: Italy</p> </li> <li> <p>Setting: single centre</p> </li> <li> <p>Inclusion criteria: insulin‐dependent patients with DM receiving CAPD</p> </li> <li> <p>Number: 6</p> </li> <li> <p>Mean age ± SD: 52.4 ± 5.2 years</p> </li> <li> <p>Sex (M/F): 5/1</p> </li> <li> <p>Exclusion criteria: not reported</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0288"> <li> <p>IP insulin: 4 injections of regular insulin in every dialysis bag immediately before the IP infusion of the last 200mL of dialysate </p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0289"> <li> <p>SC insulin: 3 daily injections of regular insulin at 7:00/12:00/17:00 and 1 injection of mixture of regular and intermediate acting insulin at 21:00 </p> </li> </ul> </p> <p>Both groups</p> <p> <ul id="CD011798-lst1-0290"> <li> <p>Isocaloric diet ( 126 kJ/kg body weight plus 33.6 kJ/kg from the dialysate) containing, as a percentage of the total calories, 20% from proteins (1.4 g/kg body weight), 50% from carbohydrates and 30% from fats, divided in four meals taken immediately after the exchanges. Also patients received tolrestat (aldose‐reductase inhibitor) and nifedipine or an ACEi </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0291"> <li> <p>Blood glucose, free insulin, lactate, glycerol, β ‐hydroxybutyrate at each hour following treatment </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0292"> <li> <p>Funding source: not reported</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study was described as randomised, method of randomisation was not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No discontinuations occurred</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were not available on a clinical trials database. All outcomes were reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No washout period documented, therefore potential for carryover effect. No conflicts of interest documented </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">TECOS 2013 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0293"> <li> <p>Study design: parallel RCT</p> </li> <li> <p>Study time frame: December 2008 to July 2012</p> </li> <li> <p>Duration of follow‐up: median follow‐up 3.0 years</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0294"> <li> <p>Country: 38 countries (Europe, North and South America, Asia, Oceania and Israel)</p> </li> <li> <p>Setting: multicentre (673 sites)</p> </li> <li> <p>Inclusion criteria: Type 2 DM with established CVD, defined as a history of major coronary artery disease, ischaemic cerebrovascular disease, or atherosclerotic peripheral arterial disease; at least 50 years of age; HbA1c of 6.5 to 8.0% when treated with stable doses of one or two oral antihyperglycaemic agents (metformin, pioglitazone, or sulphonylureas) or insulin (with or without metformin) </p> </li> <li> <p>Number: treatment group (); control group ()</p> <ul id="CD011798-lst2-0030"> <li> <p>eGFR &lt; 60 mL/min/1.73m<sup>2</sup>: treatment group (1667); control group (1657) </p> </li> </ul> </li> <li> <p>Mean age ± SD: 68.8 ± 7.9 years (not reported for groups)</p> </li> <li> <p>Sex (M/F): 2060/1263 (not reported for groups)</p> </li> <li> <p>Exclusion criteria: taken a DPP‐4 inhibitor, glucagon‐like peptide‐1 receptor agonist, or thiazolidinedione (other than pioglitazone) during the preceding 3 months; history of two or more episodes of severe hypoglycaemia (defined as requiring third party assistance) during the preceding 12 months; eGFR &lt; 30 mL/min/1.73 m<sup>2</sup> at baseline </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0295"> <li> <p>Sitagliptin: 100 mg/d (or 50 mg/d if the baseline eGFR was ≥ 30 and &lt; 50 mL/min/1.73 m<sup>2</sup>) </p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0296"> <li> <p>Placebo</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0297"> <li> <p>Composite cardiovascular outcome" defined as the first confirmed event of cardiovascular death, nonfatal MI, nonfatal stroke, or hospitalisation for unstable angina </p> </li> <li> <p>The secondary composite cardiovascular outcome was the first confirmed event of cardiovascular death, nonfatal MI, or nonfatal stroke. Other secondary outcomes included the occurrence of the individual components of the primary composite cardiovascular outcome, fatal and nonfatal MI, fatal and nonfatal stroke, death from any cause, and hospitalisation for heart failure </p> </li> <li> <p>Changes in the glycated haemoglobin level and the eGFR, initiation of additional antihyperglycaemic agents or long‐term insulin therapy, and frequency of severe hypoglycaemia, adverse events, severe hypoglycaemia, and expected diabetes‐related complications. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0298"> <li> <p>Written to authors for further data for the subgroup analysis for those patients with an eGFR &lt; 60. Authors reported that data not available currently as they will publish the subgroup analysis. </p> </li> <li> <p>Funding source: Merck</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"An interactive voice‐response system assigned the study medication in a double‐blind manner, blocked within each site" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"An interactive voice‐response system assigned the study medication in a double‐blind manner, blocked within each site" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"An interactive voice‐response system assigned the study medication in a double‐blind manner, blocked within each site" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"A clinical events committee (CEC), blinded to treatment allocation and independent of the sponsor, will adjudicate events including cardiovascular‐related death, non‐fatal MI, nonfatal stroke, unstable angina requiring hospitalization, congestive heart failure requiring hospitalization, and acute pancreatitis" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low rate of discontinuation for the whole population (not just eGFR &lt; 60) in both sitagliptin arm (360/7332; 4.9%) and placebo arm (434/7339; 5.9%) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were available on a clinical trials database and all major outcomes were reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: The study was supported by Merck, the manufacturer of sitagliptin. All authors except 2, either received research grants, consulting fees, travel reimbursements and/or speaker fees from Merck or were employees of Merck with shares in the company </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Wong 2005 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0299"> <li> <p>Study design: open‐label, parallel RCT</p> </li> <li> <p>Study time frame: 2001 to 2002</p> </li> <li> <p>Duration of follow‐up: 24 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0300"> <li> <p>Country: Hong Kong</p> </li> <li> <p>Setting: single centre</p> </li> <li> <p>Inclusion criteria: insulin‐treated patients with type 2 DM; on CAPD therapy; stable glycaemic control (defined as HbA1c &lt; 8% while insulin dosage is maintained at the same dose in the past 6 weeks) </p> </li> <li> <p>Number: treatment group 1 (26); treatment group 2 (26)</p> </li> <li> <p>Mean age ± SD (years): treatment group 1 (62.9 ± 7.3); treatment group 2 (61.6 ± 9.7)</p> </li> <li> <p>Sex (M/F): not reported</p> </li> <li> <p>Exclusion criteria: deranged liver function at baseline (ALT level &gt; 2.5 times ULN); decompensated congestive heart failure </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0301"> <li> <p>Rosiglitazone: 4 mg daily</p> </li> <li> <p>Insulin: intermediate acting insulin. Insulin dosage was reduced by 10% at the start of the study to minimize the risk for hypoglycaemia </p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0302"> <li> <p>Insulin alone: intermediate acting insulin</p> </li> </ul> </p> <p>Both groups</p> <p> <ul id="CD011798-lst1-0303"> <li> <p>PD prescription was kept unchanged during the study period except during episodes of fluid overload as a temporary change. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0304"> <li> <p>Change in insulin dosage at the end of the study compared with baseline dosage</p> </li> <li> <p>Change in C‐peptide, HbA1c, lipid, and high‐sensitivity CRP levels and adverse events</p> </li> <li> <p>Adverse events: defined as liver function derangement, fluid overload, and need for blood transfusion </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0305"> <li> <p>Funding source: GLaxoSmithKline</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A computer generalized list was used for randomisation</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"Investigators were unaware of the randomisation schedule when recruiting patients"</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"investigators and patients were not blinded during the follow‐up period"</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"investigators and patients were not blinded during the follow‐up period"</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No discontinuations were reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were available on a clinical trials database</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: Rosiglitazone was provided by GLaxoSmithKline UK, with no other funding involved </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Yale 2013 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0306"> <li> <p>Study design: phase 3, parallel RCT</p> </li> <li> <p>Study time frame: not reported</p> </li> <li> <p>Duration of follow‐up: 52 weeks (26‐week core period and a 26‐week extension)</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0307"> <li> <p>Country: 19 countries</p> </li> <li> <p>Setting: multicentre (89 sites)</p> </li> <li> <p>Inclusion criteria: patients with type 2 DM aged ≥ 25 years; HbA1c ≥ 7.0% (53 mmol/mol) and ≤ 10.5% (91 mmol/mol); eGFR ≥30 and &lt;50 mL/min/1.73 m<sup>2</sup>: either not on glucose‐lowering therapy or were on stable glucose‐lowering therapy monotherapy or combination therapy with any approved agent </p> </li> <li> <p>Number: treatment group 1 (89); treatment group 2 (90); control group (90)</p> </li> <li> <p>Mean age ± SD (years): treatment group 1 (67.9 ± 8.2); treatment group 2 (69.5 ± 8.2); control group (68.2 ± 8.4) </p> </li> <li> <p>Sex (M/F): treatment group 1 (48/41); treatment group 2 (58/32); control group (57/33)</p> </li> <li> <p>Exclusion criteria: repeated FBG &gt; 15.0 mmol/L (270 mg/dL) during the pretreatment phase; history of type 1 DM; kidney disease that required immunosuppressive therapy, dialysis or transplant; nephrotic syndrome or inflammatory kidney disease; MI, unstable angina, revascularization procedure or cerebrovascular accident within 3 months prior to screening </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group 1</p> <p> <ul id="CD011798-lst1-0308"> <li> <p>Canagliflozin: 300 mg</p> </li> </ul> </p> <p>Treatment group 2</p> <p> <ul id="CD011798-lst1-0309"> <li> <p>Canagliflozin: 100 mg</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0310"> <li> <p>Placebo</p> </li> </ul> </p> <p>All groups</p> <p> <ul id="CD011798-lst1-0311"> <li> <p>During the double blind treatment period, glycaemic rescue therapy (up‐titration of current antihypertensive agents or step‐wise addition of oral or non‐oral antihypertensive agents) was initiated if protocol‐specified glycaemic criteria were met. Patients were to remain on their stable glucose‐lowering regimens through completion of the 52‐week period unless glycaemic rescue criteria were met </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0312"> <li> <p>Change from baseline in HbA1c, FBG and SBP, and percent change from baseline in body weight and fasting plasma lipids </p> </li> <li> <p>AE reports, safety laboratory tests, vital sign measurements, physical examinations and 12‐lead electrocardiograms </p> </li> <li> <p>Selected AEs of interest, including genital mycotic infections, UTI and AEs related to osmotic diuresis and volume depletion, hypoglycaemia episode, were assessed </p> </li> <li> <p>Measures of kidney function, including eGFR, SCr, (BUN) and UACR were also assessed</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0313"> <li> <p>Funding source: Janssen</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>An Interactive Voice Response System/Interactive Web Response System was used for randomisation </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>An Interactive Voice Response System/Interactive Web Response System was used for randomisation </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Patients received canagliflozin at 100 or 300 mg or placebo</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study was labelled as a double‐blind placebo controlled study, but the methodology for the blinding of outcome assessment was not described </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>23/90 (25.6%) from the canagliflozin 100 mg; 13/89 (14.6%) from the canagliflozin 300 mg group; and 26/90 (28.9%) from the placebo group did not complete the study </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All major outcomes were reported and the prespecified outcomes were available on a clinical trials database </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: All authors except one are either employees of Janssen or have received research support, served on the advisory panels for, and/or served as a lecturer for Janssen or Johnson and Johnson. Janssen, a division of Johnson and Johnson markets canagliflozin </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Yki‐Järvinen 2013 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0314"> <li> <p>Study design: parallel RCT</p> </li> <li> <p>Study time frame: August 2009 to September 2011</p> </li> <li> <p>Duration of follow‐up: 52 weeks</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0315"> <li> <p>Country: 9 countries (Argentina, Belgium, Brazil, Canada, Czech Republic, Finland, Germany, Greece, Italy, Korea, Mexico, the Netherlands, Norway, Peru, Russia, Slovakia, Spain, Taiwan, and the USA) </p> </li> <li> <p>Setting: multicentre (167 sites)</p> </li> <li> <p>Inclusion criteria: ≥ 18 years; diagnosis of type 2 DM; inadequate glycaemic control (HbA1c ≥ 7.0% (53 mmol/mol) to ≤ 10.0% (86 mmol/mol)); BMI of ≤ 45 kg/m<sup>2</sup>; receiving treatment with basal insulin, alone or in combination with metformin and/or pioglitazone, for ≥ 12 weeks.; acceptable basal insulins were insulin glargine, insulin detemir, and neutral protamine Hagedorn insulin; total prescribed insulin dose must not have changed by &gt; 10% of the baseline value during the 12 weeks before randomisation </p> </li> <li> <p>Number (randomised/completed study): treatment group (631/543); control group (630/520)</p> <ul id="CD011798-lst2-0031"> <li> <p>eGFR &lt; 60: 127 participants</p> </li> </ul> </li> <li> <p>Mean age ± SD (years): treatment group (65.8 ± 7.4); control group (68.0 ± 9.1)</p> </li> <li> <p>Sex (M/F): treatment group (33/26); control group (33/35)</p> </li> <li> <p>Exclusion criteria: uncontrolled fasting hyperglycaemia (glucose &gt; 13.3 mmol/L during placebo run in); MI, stroke, or TIA within 6 months before informed consent; impaired hepatic function (either ALT, ASP, or ALP &gt; 3 times ULN); previous gastric bypass surgery; any medical history of cancer (except BCC) in the 5 years before screening; hypersensitivity or allergy to the investigational products; contraindications to metformin or pioglitazone; treatment with rosiglitazone, sulphonylureas, glucagon‐like peptide 1 analogs, DPP‐4 inhibitors, or anti‐obesity drugs within the 3 months before informed consent; history of alcohol or drug abuse in the previous 3 months; current treatment with systemic steroids or change in dosage of thyroid hormones within 6 weeks before informed consent; premenopausal women who were nursing, pregnant, or not practicing an acceptable method of birth control </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Run‐in period</p> <p> <ul id="CD011798-lst1-0316"> <li> <p>Patients underwent a 2‐week, open‐label placebo run‐in period to confirm their eligibility after the initial screening and to exclude those who were non‐adherent </p> </li> </ul> </p> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0317"> <li> <p>Linagliptin: 5 mg once/d for 52 weeks</p> </li> <li> <p>Basal insulin</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0318"> <li> <p>Placebo: 52 weeks</p> </li> <li> <p>Basal insulin</p> </li> </ul> </p> <p>Both groups</p> <p> <ul id="CD011798-lst1-0319"> <li> <p>During the first 24 weeks of treatment, the doses of basal insulin (within 10% of baseline dose) and oral glucose‐lowering agents were kept unchanged. After week 24, adjustments to the dose of basal insulin (but not oral glucose‐lowering agents) were allowed according to the medical judgment of the investigator, with a treatment target for FBG of 6.1 mmol/L </p> </li> <li> <p>Rescue therapy could be initiated during randomised treatment if a patient met the following criteria: confirmed FBG (after overnight fast) &gt; 13.3 mmol/L during the first 12 weeks, FBG &gt; 11.1 mmol/L from weeks 12 to 24, or FBG &gt; 10.0 mmol/L or HbA1c &gt; 8.0% (64 mmol/mol) after week 24. For initiation of rescue medication, these criteria had to be confirmed by two measurements on separate days. Patients were withdrawn from the study if the FBG remained above this threshold despite rescue therapy </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0320"> <li> <p>Change from baseline in HbA1c after 24 weeks of treatment</p> </li> <li> <p>Changes from baseline in HbA1c and FBG with time, change from baseline in FBG after 52 weeks of treatment, the proportion of patients achieving HbA1c &lt; 7% (53 mmol/mol), the proportion of patients achieving ≥ 0.5% (5.5 mmol/mol) reduction in HbA1c, and the change from baseline in mean basal insulin dose after 52 weeks of treatment, use of rescue medication and mean change in body weight to the end of treatment </p> </li> <li> <p>The frequency and intensity of AEs, including hypoglycaemia and clinically relevant new or worsening findings in physical examination, 12‐lead electrocardiogram, vital signs, lipid parameters, and clinical laboratory assessments </p> </li> <li> <p>Also treatment‐emergent fatal events and suspected events of stroke or cardiac ischaemia (including MI), hospitalisation for heart failure, stent thrombosis, and revascularization procedures </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0321"> <li> <p>As part of the unique study design, after the 24‐week period, free insulin titration was allowed up to at least week 52 at the investigators’ discretion </p> </li> <li> <p>Funding source: Boehringer Ingelheim</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Treatment assignment was determined by computer‐generated random sequence with an interactive voice response system” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Treatment assignment was determined by computer‐generated random sequence with an interactive voice response system” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The study was reported to be double‐blind, and patients received placebo medication if they were not prescribed linagliptin </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>88/631 (13.9%) of the linagliptin group and 110/630 (17.5%) of the control group discontinued</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The prespecified outcomes were available on a clinical trials database and major outcomes were reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: The study was sponsored by Boehringer Ingelheim. Authors either received research support, received consulting fees and/or served on scientific advisory committee and received honoraria, or were employees of Boehringer Ingelheim </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Zambrowicz 2015 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0322"> <li> <p>Study design: parallel RCT</p> </li> <li> <p>Study time frame: 31 October 2012 to 14 August 2013</p> </li> <li> <p>Duration of follow‐up: 7 days</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0323"> <li> <p>Country: USA</p> </li> <li> <p>Setting: single centre</p> </li> <li> <p>Inclusion criteria: patients with type 2 DM; moderate to severe CKD (defined by an eGFR &lt; 60 mL/min/1.73 m<sup>2</sup>) </p> </li> <li> <p>Number: treatment group (16); control group (15)</p> </li> <li> <p>Mean age ± SD (years): treatment group (64.8 ± 8.53); control group (68.1 ± 7.33)</p> </li> <li> <p>Sex (M/F): treatment group (8/8); control group (9/6)</p> </li> <li> <p>Exclusion criteria: Type 1 DM; diabetes due to a pancreatic disorder; secondary diabetes (e.g. from Acromegaly or Cushing's disease); received a kidney allograft; expecting to require dialysis or undergo kidney transplantation within 3 months of Day 1; active hepatic disease; history of MI or stable angina or coronary revascularisation within 6 months prior to start of study; clinically significant arrhythmia; congestive heart failure; uncontrolled hypertension; history of 2 or more emergency or doctor visits due to hypoglycaemia within 6 months of study or hypoglycaemia unawareness; history of alcohol or illicit drug use; any bowel condition affecting gastric emptying or malabsorptive disorder or bowel resection; history of active infection within 2 weeks of recruitment; history of major surgery within 6 months of recruitment or imminent surgery during study; history of malignancy within 5 years of recruitment; pregnant; previous reaction to SGLT2 inhibitor; previous exposure to LX4211 </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0324"> <li> <p>LX4211 400 mg/d</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0325"> <li> <p>Placebo</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0326"> <li> <p>Effect of LX4211 therapy on post‐prandial glucose levels, measured as the change from baseline to day 7 </p> </li> <li> <p>Tolerability, pharmacodynamic effects on FBG and GLP‐1 levels from baseline to day 7, and pharmacokinetics effects of single and multiple doses. including 24‐hour urine glucose excretion, BP, mean finger‐stick BGL, fractional excretion of calcium and phosphate, serum uric acid levels and fractional excretion of uric acid, fasting triglyceride levels, tumour necrosis factor α levels, leptin levels, and exogenous insulin dose </p> </li> <li> <p>Monitoring of AEs, clinical laboratory tests (chemistry, haematology, lipid profile, and urinalysis), vital signs (BP, heart rate, respiratory rate, and oral temperature), 12‐lead electrocardiograms, physical examinations, and BGL </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0327"> <li> <p>Funding source: Lexicon Pharmaceuticals</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study was described as randomised, method of randomisation was not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information to permit judgement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants received LX4211 or placebo. study also described as double blind</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Although the study was described as double blind, the methodology behind outcome assessment blinding was not described </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Only 1 patient 1/16 (6.3%) of the LX4211 group discontinued. No patients discontinued from the placebo arm </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Protocol available. All major outcomes reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Conflicts of interest: All authors were employees of Lexicon Pharmaceuticals who funded the study and was responsible for the study design, interpretation of the data, writing of the manuscript, and the decision to submit the manuscript </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ABPM ‐ ambulatory blood pressure monitoring; AE ‐ adverse event/s; AKI ‐ acute kidney injury; ALT ‐ alanine aminotransferase; ALP ‐ alkaline phosphatase; AST ‐ aspartate aminotransferase; BCC ‐ basal cell carcinoma; BGL ‐ blood glucose level/s; BMI ‐ body mass index; BP ‐ blood pressure; BUN ‐ blood urea nitrogen; CAPD ‐ continuous ambulatory peritoneal dialysis; CrCl ‐ creatinine clearance; CRP ‐ C‐reactive protein; CTR ‐ cardiothoracic ratio; CVD ‐ cardiovascular disease; DBP ‐ diastolic blood pressure; DKD ‐ diabetic kidney disease; DM ‐ diabetes mellitus; eGFR ‐ estimated glomerular filtration rate; ESA ‐ erythropoietin stimulating agent/s; ESKD ‐ end‐stage kidney disease; FBG ‐ fasting blood glucose; GI ‐ gastrointestinal; GA ‐ glycated albumin; Hb ‐ haemoglobin; HbA1c ‐ haemoglobin A1c (glycated); HD ‐ haemodialysis; HDL ‐ high‐density lipoprotein; HIV ‐ human immunodeficiency virus; HOMA‐IR ‐ homeostasis model assessment for insulin resistance; IP ‐ intraperitoneal; iPTH ‐ intact parathyroid hormone; LDH ‐ lactate dehydrogenase; LDL ‐ low‐density lipoprotein; MDRD ‐ Modification of Diet in Renal Disease; M/F ‐ male/female; MI ‐ myocardial infarction; NYHA ‐ New York Heart Association; NSAID ‐ nonsteroidal anti‐inflammatory drugs; PAH ‐ paraminohippuric acid; PD ‐ peritoneal dialysis; RBC ‐ red blood cell/s; RCT‐ randomised controlled trial; RRT ‐ renal replacement therapy; SBP ‐ systolic blood pressure; SC‐ subcutaneous; SCr ‐ serum creatinine; SD ‐ standard deviation; SEM ‐ standard error of the mean; TIA ‐ transient ischaemic attack; UACR ‐ urinary albumin/creatinine ratio; UAER ‐ urinary albumin excretion ratio; ULN ‐ upper limit of normal; UTI ‐ urinary tract infection </p> </div> </div> </p> </section> <section class="characteristicsOfExcludedStudies" lang=""> <div class="section-header" id="CD011798-sec2-0021"> <h3 class="title">Characteristics of excluded studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD011798-sec2-0020" class="jump-to">included studies</a></li> <li><a href="#CD011798-sec2-0022" class="jump-to">awaiting classification</a></li> <li><a href="#CD011798-sec2-0023" class="jump-to">ongoing studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reason for exclusion</p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0045">ACCORD 2007</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: comparing intensive versus less intensive glucose targets</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0046">ADOPT 2011</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0047">ADVANCE 2001</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: comparing intensive versus less intensive glucose targets</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0048">Agarwal 2005</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Inadequate information: data for subgroup of patients with an eGFR &lt; 60 not available from authors </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0049">Aljabri 2004</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0050">Amador‐Licona 2000</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0051">Aoki 1995</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: insulin is not being used as glucose‐lowering agent</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0052">APRIME 2011</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0053">Bakris 2006</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0054">Bangstad 1992</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0055">BARI 2D 2011</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: not comparing specific glucose‐lowering agents but comparing insulin sensitiser versus insulin provision therapy </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0056">Barnett 1984</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: intervention was not a glucose‐lowering agent</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0057">CANTATA‐SU 2016</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0058">Cao 2005</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0059">Chacra 2009</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0060">Chen 2004b</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0061">Chen 2006h</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0062">Christensen 1986</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0063">Christensen 2001c</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: intervention was not a glucose‐lowering agent</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0064">Chu 2006</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: intervention was not a glucose‐lowering agent</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0065">Ciavarella 1985</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0066">Dailey 2000</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: insulin is not being used as glucose‐lowering agent</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0067">Davidson 2007</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0068">DCCT 1986</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0069">de Boer 2013</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: intervention was not a glucose‐lowering agent.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0070">DeFronzo 2009</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0071">Derosa 2004</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0073">Di Mauro 2001</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: intervention was not a glucose lowering‐agent</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0072">Didjurgeit 2002</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: intervention was not a glucose‐lowering agent</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0074">DNETT Japan 2010</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: intervention was not a glucose‐lowering agent</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0075">Einhorn 2000</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0076">Fadini 2016</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No relevant outcomes (looks at progenitor cells and monocyte phenotypes)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0077">Fang 2007</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0078">Feldt‐Rasmussen 1986</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0079">Frederich 2012</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0080">Gadallah 2000b</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0081">Gan 2007</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0082">Gao 2006a</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0083">Gao 2007a</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0084">Gao 2007b</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0085">GEMINI 2005</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: intervention was not a glucose‐lowering agent</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0086">Goicolea 2002</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: intervention was not a glucose‐lowering agent</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0087">He 2004</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0088">Hollander 2009</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0089">Holman 1983</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0090">Hu 2007</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0091">Hu 2010</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0092">Huang 2004</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0093">Huang 2006</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0094">Huang 2007</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0095">Imano 1998</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0096">Inagaki 2014</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No relevant outcomes (pharmacokinetic and pharmacodynamic study)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0097">Jerums 1987</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0098">Kadhim 2006</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: intervention was not a glucose‐lowering agent</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0099">Kadowaki 2014</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0100">Karalliedde 2006</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: intervention was not a glucose‐lowering agent</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0101">Katavetin 2006</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Inadequate information: unable to get information about patients with an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0102">Kim 2003</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0103">Kirk 1999</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0104">KUMAMOTO 1995</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0105">Lebovitz 2001</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0106">Leslie 2008</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0107">Li 2004a</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0108">Li 2006e</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0109">Li 2008f</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0110">Li 2008g</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0111">Lu 2010</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: intervention was not a glucose‐lowering agent</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0112">Matthews 2005</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0113">MEMO 2011</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: intervention was not a glucose‐lowering agent</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0114">Miyazaki 2007</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0115">Nakamura 2000b</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0116">Nakamura 2001b</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0117">Nakamura 2004</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0118">Nakamura 2006a</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0119">NCT00708981</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: intervention was not a glucose‐lowering agent</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0120">NCT01245166</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0121">Nishimura 2015</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0122">OSLO 1986</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0123">Ostman 1998</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: intervention was not a glucose‐lowering agent</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0124">Pan 2012</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0125">Petrica 2009</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0126">Pistrosch 2004</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0127">Pistrosch 2005</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0128">Pistrosch 2012</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0129">PIVIT 2010</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: insulin was not being used as a glucose‐lowering agent</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0130">Pomerleau 1993</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: intervention was not a glucose‐lowering agent</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0131">QUARTET 2004</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0132">Reinhard 2013</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: intervention looking at bioactive IGF‐I and inflammatory biomarkers</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0133">Rosenstock 2009</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0134">SDIS 1988</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0135">Seino 2015</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Inadequate information: unable to get information about patients with an eGFR &lt; 60 from authors </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0136">SESTA R 2011</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0137">Shata'er 2007</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0138">SPEAD‐A 2013</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0139">Stein 2014</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0140">STENO‐2 1999</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: intervention was not a glucose‐lowering agent</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0141">Strojek 2011</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0142">Su 2006</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0143">Sun 2006</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0144">Tan 2006</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0145">Tang 2007</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0146">Thrasher 2012</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0147">UKPDS 1991</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention ‐ examining "more intensive" versus "less intensive" glucose targets</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0148">UKPDS‐HD 1998</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: examining "more intensive" versus "less intensive" glucose targets</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0149">VA‐CSDM 1992</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong intervention: examining "more intensive" versus "less intensive" glucose targets</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0150">Viswanathan 1990</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Inadequate information: unable to get information about patients with an eGFR &lt; 60 from authors </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0151">Vos 2011</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0152">Wang 2004</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0153">Wang 2005b</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0154">Wang 2005c</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0155">Wang 2006</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0156">Wang 2008e</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0157">Wiseman 1985</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0158">Xu 2005</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0159">Yang 2011a</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0160">Yokoyama 2009</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No relevant outcomes (serum cystatin C levels)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0161">Zhang 2007c</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0162">Zhang 2012a</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: not in patients with diabetes and an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0163">Zhao 2007</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0164">Zheng 2006</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0165">Zhou 2003</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0166">Zhou 2007</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0167">Zhu 2007</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011798-bbs2-0168">Zou 2005</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Wrong study population: no information concerning whether patients had an eGFR &lt; 60</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>eGFR ‐ estimated glomerular filtration rate</p> </div> </div> </p> </section> <section class="characteristicsOfAwaitingStudies" lang=""> <div class="section-header" id="CD011798-sec2-0022"> <h3 class="title">Characteristics of studies awaiting assessment [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD011798-sec2-0020" class="jump-to">included studies</a></li> <li><a href="#CD011798-sec2-0021" class="jump-to">excluded studies</a></li> <li><a href="#CD011798-sec2-0023" class="jump-to">ongoing studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">AWARD‐7 2017 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open‐label, parallel RCT over 26 weeks</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0328"> <li> <p>Number: 576 patients</p> </li> <li> <p>Inclusion criteria: men and non‐pregnant women aged ≥18 years; HbA1c ≥7.5% (58 mmol/mol) and ≤ 10.5% (91 mmol/mol); type 2 DM on insulin or insulin + oral glucose‐lowering medications; participants with presumed DKD with or without hypertensive nephrosclerosis diagnosed with moderate or severe CKD with eGFR of ≥15 to &lt;60 mL/min/1.73 m<sup>2</sup>; able and willing to perform multiple daily injections; BMI between 23 and 45 kg/m<sup>2</sup> </p> </li> <li> <p>Exclusion criteria: stage 5 CKD as defined by eGFR &lt; 15 mL/min/1.73 m<sup>2</sup> OR having required dialysis; rapidly progressing kidney dysfunction likely to require RRT; history of a transplanted organ, type 1 DM; at screening a SBP of ≥ 150 mmHg or a DBP of ≥ 90 mmHg with or without antihypertensive medication; an episode of ketoacidosis or hyperosmolar state/coma in the past 6 months or a history of severe hypoglycaemia in the past 3 months prior to the screening visit; cardiovascular conditions within 12 weeks prior to randomisation: acute MI, NYHA class III or class IV heart failure, or cerebrovascular accident (stroke); acute or chronic hepatitis; signs and symptoms of chronic or acute pancreatitis, or were in the past diagnosed with pancreatitis; serum calcitonin ≥ 35 pg/mL at screening visit; self or family history of medullary C‐cell hyperplasia, focal hyperplasia, or carcinoma; known history of untreated proliferative retinopathy </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Treatment group 1</p> <p> <ul id="CD011798-lst1-0329"> <li> <p>Insulin glargine</p> </li> </ul> </p> <p> Treatment group 1</p> <p> <ul id="CD011798-lst1-0330"> <li> <p>Dulaglutide: 0.75 mg and 1.5 mg</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0331"> <li> <p>Change from baseline in HbA1c</p> </li> <li> <p>Percentage of participants whose HbA1c was &lt; 7.0% (53 mmol/mol)</p> </li> <li> <p>Percentage of participants whose HbA1c was &lt; 8.0% (64 mmol/mol)</p> </li> <li> <p>Change from baseline in 8‐Point SMPG</p> </li> <li> <p>Change from baseline in mean daily Insulin Lispro dose</p> </li> <li> <p>Percentage of participants with estimated average glucose &lt; 8.5 mmol/L.</p> </li> <li> <p>Change from baseline in SCr</p> </li> <li> <p>Change from baseline in eGFR</p> </li> <li> <p>Change from baseline in estimated CrCl</p> </li> <li> <p>Change from baseline in UACR</p> </li> <li> <p>Percentage of participants with self‐reported hypoglycaemic events</p> </li> <li> <p>Rate of hypoglycaemic event</p> </li> <li> <p>Change from baseline in FBG</p> </li> <li> <p>Change from baseline in body weight</p> </li> <li> <p>Percentage of participants with allergic/hypersensitivity reactions</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0332"> <li> <p>Awaiting full publication. More information is required from the authors</p> </li> </ul> </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Chacra 2017 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>This was a randomised, placebo‐controlled, parallel‐group, double‐blind, multicentre, multinational study. Study duration was up to 69 weeks, including a 1‐week screening period, an 8‐week “wash‐off” period (for patients on oral glucose‐lowering agents at screening), a 2‐week single‐blind placebo run‐in period, a 54‐week double‐blind treatment period consisting of a 24‐week placebo‐controlled period (Phase A) and a 30‐week active‐controlled period (Phase B) and a post‐trial phone follow‐up 28 days after final dose </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0333"> <li> <p>Number: 213 patients</p> </li> <li> <p>Setting: multinational; 109 centres in Australia, North America, Europe, Asia, Israel and Russia </p> </li> <li> <p>Inclusion criteria: male or female ≥ 30 years with type 2 DM; moderate kidney impairment (eGFR ≥ 30 to &lt; 60 mL/min/1.73 m<sup>2</sup>) or severe CKD (eGFR &lt; 30 mL/min/1.73 m<sup>2</sup>), as determined by the MDRD formula, or ESKD on dialysis for at least 6 months; eligible patients were either (1) not on a glucose lowering agent (naive or off therapy for ≥ 12 weeks) with HbA1c ≥ 7.0% (53 mmol/mol) and ≤ 10.0% (86 mmol/mol); (2) on a single oral glucose lowering agent or low‐dose dual oral combination glucose lowering agents (i.e. at ≤ 50% of maximum labelled dose of each agent) with an HbA1c of ≥ 6.5% (48 mmol/mol) and ≤ 9.0% (75 mmol/mol); or (3) on a stable insulin regimen, at a dose of at least 15 U/d, for ≥ 10 weeks, with no oral glucose lowering agent and HbA1c ≥ 7.5% (58 mmol/mol) and ≤ 10.0% (86 mmol/mol) and FBG &gt; 7.22 mmol/L, subjects on oral glucose lowering agents therapy had their medication discontinued (“washed‐off”) </p> </li> <li> <p>Exclusion criteria: type 1 DM; history of ketoacidosis; C‐peptide level &lt; 0.7 ng/mL; active liver disease; significant CVD; a haematological disorder; a history of malignancy; treated with any incretin mimetic or thiazolidinedione within the prior 12 weeks of screening, or with omarigliptin at any time prior to signing informed consent </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0334"> <li> <p>Omarigliptin</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0335"> <li> <p>Matching placebo.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0336"> <li> <p>Changes from baseline in HbA1c and FBG</p> </li> <li> <p>Percentages of subjects at HbA1c goal of &lt;7.0% (53 mmol/mol)</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Chan 2011 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomised double‐blind placebo‐controlled study over 8 weeks</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0337"> <li> <p>Country: Australia</p> </li> <li> <p>Setting: multi‐centre, from the Perth Renal Units</p> </li> <li> <p>Inclusion criteria: CKD stages 3 and 4 (eGFR 20 to 60 mL/min/1.73 m<sup>2</sup> by the MDRD equation; 18 to 75 years; non‐diabetic and non‐insulin requiring type 2 DM patients; patients who were current smokers, and on antiplatelet and antihypertensive agents were included </p> </li> <li> <p>Number: treatment group (36); control group (35)</p> <ul id="CD011798-lst2-0032"> <li> <p>16 patients had both DM and CKD (eGFR &lt; 60 mL/min/1.73 m<sup>2</sup>) </p> </li> </ul> </li> <li> <p>Mean age ± SD (years)<b>:</b> treatment group (62 ± 10); control group (62 ± 10) </p> </li> <li> <p>Sex (M/F)<b>:</b> treatment group (24/11); control group (26/9) </p> </li> <li> <p>Exclusion criteria: Type 1 DM; nephrotic‐range proteinuria; liver enzymes &gt; 2 times ULN; alcohol consumption &gt; 3 standard drinks/d; cardiovascular event or unstable CVD; symptomatic or NYHA Stage 3 or 4 heart failure; Hb &lt; 100 g/L; significant psychiatric disorder; active infection or inflammation; pregnancy or planning a pregnancy; currently receiving a glucagon‐like peptide‐1 analogue for glycaemic control of type 2 DM at screening </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0338"> <li> <p>Rosiglitazone: 4 mg/d</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0339"> <li> <p>Matching placebo</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0340"> <li> <p>Endothelial function as assessed by post‐ischaemic flow mediated dilatation of the brachial artery </p> </li> <li> <p>Systemic arterial compliance as assessed by small artery compliance (C1) and large artery compliance (C2) </p> </li> <li> <p>Arterial stiffness as assessed by augmentation index</p> </li> <li> <p>Pulse wave velocity</p> </li> <li> <p>Insulin resistance as measured by the HOMA score</p> </li> <li> <p>Lipid and lipoprotein profile (cholesterol, triglycerides, low‐density lipoprotein cholesterol (LDL‐C), high‐density lipoprotein cholesterol (HDL‐C), apolipoprotein B and A‐I) adipocytokine (adiponectin); in vivo markers of inflammation; high‐sensitivity CRP, high‐sensitivity interleukin 6 and endothelial function; 24 hour ambulatory BP monitoring </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Awaiting data from authors for patients with an eGFR &lt; 60 mL/min/1.73m<sup>2</sup> and with DM </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">DEVOTE 2017 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Multinational, treat‐to‐target, randomised, double‐blind, active comparator–controlled cardiovascular outcomes trial </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0341"> <li> <p>Country: 20 countries in North America, South America, Europe, Asia, and South Africa</p> </li> <li> <p>Setting: multicentre (438 sites)</p> </li> <li> <p>Inclusion criteria: type 2 DM treated with ≥ 1 oral or injectable antihyperglycaemic therapy, HbA1c ≥ 7.0% (53 mmol/mol) or HbA1c &lt; 7.0%, if treated with ≥ 20 U/d of basal insulin; 2 cohorts were eligible for recruitment into the trial: </p> <ul id="CD011798-lst2-0033"> <li> <p>Prior CVD or history of moderate CKD cohort:</p> <ul id="CD011798-lst3-0001"> <li> <p>≥ 50 years and had a history of CVD or moderate CKD. Prior CVD was defined by any 1 of the following: MI; stroke or TIA (TIA); coronary, carotid, or peripheral revascularization; &gt; 50% diameter stenosis found on angiography or other imaging modality of the coronary, carotid, or lower extremity arteries; history of symptomatic coronary heart disease documented by positive non‐invasive stress test or unstable angina pectoris with ECG changes; asymptomatic cardiac ischaemia; NYHA class II to III congestive heart failure; OR </p> </li> </ul> </li> <li> <p>Moderate CKD (stage 3) defined as eGFR 30 to 59 mL/min per 1.73 m<sup>2</sup> using the CKD‐EPI equation </p> </li> </ul> </li> <li> <p>No prior CVD cohort:</p> <ul id="CD011798-lst2-0034"> <li> <p>≥ 60 years and did not have a history of CVD; OR</p> </li> <li> <p>Moderate CKD but did have at least one of the following: microalbuminuria or proteinuria; hypertension with left ventricular hypertrophy; left ventricular systolic and diastolic dysfunction as defined by the investigator; or an abnormal ankle‐brachial index of &lt; 0.9 </p> </li> </ul> </li> <li> <p>Number: treatment group (2701); control group (2679)</p> <ul id="CD011798-lst2-0035"> <li> <p>eGFR &lt; 60 mL/min/1.73 m<sup>2</sup>: treatment group (772); control group (793) </p> </li> </ul> </li> <li> <p>Exclusion criteria: acute coronary or cerebrovascular event in the previous 60 days; planned coronary, carotid or peripheral artery revascularization; chronic heart failure NYHA class IV.; current HD or PD or eGFR &lt; 30 mL/min per 1.73 m<sup>2</sup> per CKD‐EPI; end‐stage liver disease, defined as the presence of acute or chronic liver disease and recent history of 1 or more of the following: ascites, encephalopathy, variceal bleeding, bilirubin ≥ 34.2 mmol/L; albumin ≤ 3.5 g/dL, prothrombin time ≥ 4 s prolonged, international normalized ratio ≥ 1.7 or prior liver transplant; known or suspected hypersensitivity to trial products or related products; female of child‐bearing potential who is pregnant, breastfeeding or intends to become pregnant, or is not using adequate contraceptive methods as required by local law or practice; expected simultaneous participation in any other clinical trial of an investigational medicinal product; receipt of any investigational medicinal product within 30 days before randomisation </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Treatment group 1</p> <p> <ul id="CD011798-lst1-0342"> <li> <p>Insulin degludec: 100 U/mL</p> </li> </ul> </p> <p>Treatment group 2</p> <p> <ul id="CD011798-lst1-0343"> <li> <p>Insulin glargine: 100 U/mL</p> </li> </ul> </p> <p>Identical 100 U/mL, 10 mL vials</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0344"> <li> <p>Time from randomisation to the first occurrence of a 3‐component MACE consisting of cardiovascular death, nonfatal MI, or nonfatal stroke </p> </li> <li> <p>Severe hypoglycaemia, defined according to contemporary ADA criteria, as an episode requiring assistance from another person or an episode temporally associated with an accident, convulsion, or death </p> </li> <li> <p>Time from randomisation to all‐cause death, the frequency of serious adverse events, and the frequency of adverse events leading to discontinuation of the investigational product. </p> </li> <li> <p>The change from baseline to the final assessment of HbA1c, FBG, BP, pulse rate, lipid profile, weight, BMI, eGFR, as well as basal and bolus insulin dose at the end of the trial </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Information for the subgroup of patients with an eGFR &lt; 60 mL/min/1.73 m<sup>2</sup> is required from the authors </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">EXAMINE 2011 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Multicenter, prospective, randomised, double‐blind trial over 4.75 years</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0345"> <li> <p>Country: 49 countries in North America, South America, Europe, Asia, and South Africa</p> </li> <li> <p>Setting: multicentre (898 sites)</p> </li> <li> <p>Inclusion criteria: diagnosis of type 2 DM; receiving monotherapy or combination antidiabetic therapy with a glycosylated haemoglobin level between 6.5% and 11.0%, inclusive, at screening (between 7.0 and 11.0%, inclusive, if the participant's antidiabetic regimen includes insulin); diagnosis of acute coronary syndrome within 15 to 90 days prior to randomisation </p> </li> <li> <p>Number: treatment group (2701); control group (2679)</p> <ul id="CD011798-lst2-0036"> <li> <p>eGFR &lt; 60 mL/min/1.73 m<sup>2</sup>: treatment group (772); control group (793) </p> </li> </ul> </li> <li> <p>Median age: treatment group (61.0); control group (61.0)</p> </li> <li> <p>Sex (M/F): treatment group (1828/873); control group (1823/856)</p> </li> <li> <p>Exclusion criteria: signs of type 1 DM; currently receiving a glucagon‐like peptide‐1 analogue for glycaemic control of type 2 DM at screening; received a dipeptidyl peptidase‐4 inhibitor for either more than 14 days total or within the 3 months prior to screening </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0346"> <li> <p>Oral alogliptin: 25 mg once/d for participants with normal or mildly impaired kidney function as defined by eGFR ≥ 60 mL/min) </p> </li> <li> <p>Oral alogliptin 12.5 mg once/d for participants with moderately impaired kidney function (eGFR ≥ 30 and &lt; 60 mL/min) </p> </li> <li> <p>Oral alogliptin 6.25 mg once/d for participants with severely impaired kidney function or ESKD (eGFR &lt; 30 mL/min) </p> </li> <li> <p>Participants continued to receive standard care for CVD and DM according to regional guidelines. </p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0347"> <li> <p>Oral alogliptin placebo matching tablets: once/d</p> </li> <li> <p>Participants continued to receive standard care for CVD and DM according to regional guidelines. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0348"> <li> <p>Composite of death from cardiovascular causes, nonfatal MI, or nonfatal stroke</p> </li> <li> <p>Primary composite outcome with the addition of urgent revascularization due to unstable angina within 24 hours after hospital admission </p> </li> <li> <p>Death from cardiovascular causes and death from any cause</p> </li> <li> <p>Angioedema, hypoglycaemia, pancreatitis, cancer, and the results of laboratory testing</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Further data for those patients with an eGFR &lt; 60 mL/min/1.73 m<sup>2</sup> were not available at the moment but will be published </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">LEADER 2017 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Multicenter, randomised double‐blind, placebo‐controlled trial with a median follow‐up of 3.8 years </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0349"> <li> <p>Countries: 32 countries</p> </li> <li> <p>Setting: Multi‐national (410 sites)</p> </li> <li> <p>Inclusion criteria: patients with type 2 DM who had HbA1c of 7.0% or more if they either had not received drugs for this condition previously or had been treated with one or more oral antihyperglycaemic agents or insulin (human neutral protamine Hagedorn, long‐acting analogue, or premixed) or a combination of these agents; aged ≥ 50 years with at least one cardiovascular coexisting condition (coronary heart disease, cerebrovascular disease, peripheral vascular disease, CKD of stage 3 or greater, or chronic heart failure of NYHA class II or III); OR age ≥ 60 years with at least one cardiovascular risk factor, as determined by the investigator (microalbuminuria or proteinuria, hypertension and left ventricular hypertrophy, left ventricular systolic or diastolic dysfunction, or an ankle–brachial index (the ratio of the SBP at the ankle to the SBP in the arm) of less than 0.9) </p> </li> <li> <p>Number: 9340; 2158 patients had an eGFR &lt; 60 mL/min/1.73 m<sup>2</sup> </p> </li> <li> <p>Exclusion criteria: type 1 DM; use of GLP‐1–receptor agonists, dipeptidyl peptidase 4 (DPP‐4) inhibitors, pramlintide, or rapid‐acting insulin; familial or personal history of multiple endocrine neoplasia type 2 or medullary thyroid cancer; acute coronary or cerebrovascular event within 14 days before screening and randomisation </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0350"> <li> <p>Liraglutide</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0351"> <li> <p>Placebo</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0352"> <li> <p>Composite outcome in the time‐to‐event analysis of the first occurrence of death from cardiovascular causes, nonfatal (including silent) MI, or nonfatal stroke </p> </li> <li> <p>An expanded composite cardiovascular outcome (death from cardiovascular causes, nonfatal MI, nonfatal stroke, coronary revascularization, or hospitalisations for unstable angina pectoris or heart failure) </p> </li> <li> <p>Death from any cause</p> </li> <li> <p>A composite kidney and retinal microvascular outcome (nephropathy defined as the new onset of macroalbuminuria or a doubling of the SCr level and an eGFR of ≤ 45 mL/min/1.73 m<sup>2</sup>), the need for continuous RRT, or death from kidney disease; retinopathy defined as the need for retinal photocoagulation or treatment with intravitreal agents, vitreous haemorrhage, or the onset of diabetes‐related blindness) </p> </li> <li> <p>HbA1c</p> </li> <li> <p>Neoplasms</p> </li> <li> <p>Pancreatitis</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Li 2012b </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomised cross‐over trial. Randomly assigned to receive either oral pioglitazone 15 mg once daily or no pioglitazone for 12 weeks then, after a 4‐week washout, the patients were switched to the alternative regimen </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0353"> <li> <p>Country: China</p> </li> <li> <p>Setting: single centre</p> </li> <li> <p>Inclusion criteria: &gt; 20 years; DM (HbA1c &gt; 10% (86 mmol/mol)) or no diagnosis of DM; never received glitazones; serum triglyceride (&gt; 1.8 mmol/L); &gt; 1 month of treatment of regular continuous ambulatory PD </p> </li> <li> <p>Number: 36</p> </li> <li> <p>Mean age ± SD: 64 ± 11 years</p> </li> <li> <p>Sex (M/F): 12/24</p> </li> <li> <p>Exclusion criteria: not reported</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0354"> <li> <p>Oral pioglitazone 15 mg once daily for 12 weeks, and then after a washout period of 4 weeks, they received no pioglitazone for 12 weeks. </p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0355"> <li> <p>No pioglitazone for 12 weeks, and then after a washout period of 4 weeks, they received pioglitazone for 12 weeks </p> </li> </ul> </p> <p>Both groups</p> <p> <ul id="CD011798-lst1-0356"> <li> <p>Food intake was recorded in a continuous self‐completed 3‐day food diary every 6 weeks</p> </li> <li> <p>All patients were under the direction of a dietitian and were instructed to eat a low‐lipid diet and to take more exercise </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0357"> <li> <p>Change in serum triglycerides</p> </li> <li> <p>Changes in serum cholesterol, LDL, HDL, HOMA‐IR, adipocytokines, and CRP</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Awaiting reply to authors for patients with both DM and on PD (n = 10). Wrote to the authors on 6/2/17 </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">MARLINA‐T2D 2015 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomised, double‐blind parallel group trial</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0358"> <li> <p>Inclusion criteria: diagnosis of type 2 DM; HbA1c between 6.5 and 10% (48 and 86 mmol/mol); current therapy with ACEi or ARB at stable dose for 10 weeks; UACR 30‐3000 mg/g creatinine 3.39‐339 mg/mmol to documented in the previous 12 months or detected at screening; eGFR &gt; 30 mL/min; 18 and 80 years </p> </li> <li> <p>Exclusion criteria: dual or triple blockade of the RAS; uncontrolled hyperglycaemia; MAP &gt; 110 mmHg; known hypersensitivity or allergy to the investigational product, or their excipients (including matching placebos); treatment with a glitazone within 6 months prior to informed consent; treatment with a DPP‐4 inhibitor, a glucagon‐like peptide‐1 agonist, a sodium/glucose co‐transporter 2 inhibitor, a dopamine‐agonist, a bile‐acid sequestrant a short acting (prandial) insulin or premixed insulin within 10 weeks prior to informed consent; treatment with anti‐obesity drugs 10 weeks prior to informed consent; alcohol or drug abuse within 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake in the opinion of the investigator; current treatment with systemic steroids (glucocorticoids) at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent; participation in another trial with an investigational drug within 2 months prior to informed consent </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0359"> <li> <p>Linagliptin: 5 mg/d</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0360"> <li> <p>Matching placebo</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Change from baseline in HbA1c at 24 weeks</p> <p>Time weighted average of percentage change from baseline in UACR at 24 weeks</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Information for the subgroup of patients with an eGFR &lt; 60 mL/min/1.73 m<sup>2</sup> is required from the authors </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT00846716 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomised, open‐label parallel group trial of pioglitazone added on to a sulphonylurea or biguanide versus a sulphonylurea or biguanide </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0361"> <li> <p>Inclusion criteria: Type 2 DM; HbA1c &lt; 8.0%(64 mmol/mol); creatinine &lt; 300 mg/g (33.9 mg/mmol) of urinary albumin level; concomitant therapy with sulphonylurea and/or biguanide; untreated hypertension and hypertension treated with ARB or ACEi </p> </li> <li> <p>Exclusion criteria: history of heart failure and concomitant heart failure; history of administration of thiazolidinedione agent; severe hepatic dysfunction with more than 3 times higher than ULN range of GOT, GPT or rGPT; severe kidney dysfunction creatinine &gt; 221 μmol/L; history of AE with thiazolidinedione agent; insulin treatment; concomitant UTI </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Treatment group 1</p> <p> <ul id="CD011798-lst1-0362"> <li> <p>Pioglitazone</p> </li> <li> <p>Sulphonylurea or biguanide</p> </li> </ul> </p> <p>Treatment group 2</p> <p> <ul id="CD011798-lst1-0363"> <li> <p>Sulphonylurea or biguanide</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0364"> <li> <p>Onset or progression of DKD</p> </li> <li> <p>Progression of DM; change in HbA1c; change in UACR change in GFR; change in cystatin C </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years. The study is not published. Written to authors 3 March 2017. Awaiting response. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Neff 2016 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RCT</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0365"> <li> <p>Inclusion criteria: type 2 DM with a HbA1c of 42‐75 mmol/mol (6‐9% DCCT); Male or female aged &gt; 30 years; negative pregnancy test at screening (women of child bearing potential only); BMI ≥ 25 kg/m<sup>2</sup> on a RAS antagonist, at a stable dose, for at least 8 weeks before inclusion into the study; established microalbuminuria; eGFR ≥ 30 mL/min/1.73m<sup>2</sup> MDRD formula. </p> </li> <li> <p>Exclusion criteria: any cognitive impediment that preclude the patient from giving free and informed consent; DPP‐4 inhibitors or thiazolidinedione treatment; stage 4‐5 CKD, defined as an eGFR ≤ 30 mL/min/1.73m<sup>2</sup>; used a GLP‐1 agent in the last 6 months; female patients of child bearing potential who are pregnant, breastfeeding, or unwilling to practice an acceptable barrier and/or hormonal method of contraception or abstinence during participation in the study; previous pancreatitis; hypersensitivity to Glucagon‐like peptide‐1 analogues; proliferative diabetic retinopathy; any other contraindications, as per the summary of product characteristics for liraglutide; any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the dosing requirements.; on current treatment with an investigational drug or participation in another clinical trial; use of an investigational drug within 4 weeks or 5 half‐lives, whichever is longer, preceding the first dose of investigational medicinal product </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0366"> <li> <p>Liraglutide: 0.6 mg/d</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0367"> <li> <p>Standard diabetes care including renin angiotensin aldosterone inhibitor or antagonist</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0368"> <li> <p>Monocyte chemoattractant protein‐1:creatinine ratio in urine up to 26 weeks</p> </li> <li> <p>UACR up to 26 weeks; other bio markers including sCD163 in serum</p> </li> <li> <p>Safety in all participants as measured by adverse event rate</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Further details are required from the authors. The complete manuscript has not been published yet. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Ott 2016 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Double‐blind, parallel‐group, investigator‐initiated RCT</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0369"> <li> <p>Inclusion criteria: Type 2 DM; males and females (female participants had to have a negative pregnancy test before and during the study period); aged 18 and 65 years </p> </li> <li> <p>Exclusion criteria: use of insulin, thiazolidinedione or DPP‐4 inhibitor within the last 3 months or use of any other oral glucose‐lowering drug that could not be discontinued for the study period; HbA1c &gt; 10% (86 mmol/mol); UACR &gt; 11.3 mg/mmol (&gt; 100 mg/g); eGFR &lt; 45 mL/min/1.73m<sup>2</sup>; cardio‐ and cerebrovascular event within the previous 6 months </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0370"> <li> <p>Linagliptin: 5 mg/d</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0371"> <li> <p>Placebo</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The primary objective was to assess endothelial function of the renal vasculature, by constant‐infusion input clearance and UACR, both before and after blockade of nitric oxide synthase with NG‐monomethyl‐L‐arginine </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Further details regarding the subpopulation of patient with an eGFR &lt; 60 mL/min/1.73m<sup>2</sup> are required from the authors </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">SUSTAIN‐6 2016 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Multi‐national, double‐blind, placebo‐controlled, parallel‐group RCT</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0372"> <li> <p>Country: 20 countries</p> </li> <li> <p>Setting: multinational (230 sites)</p> </li> <li> <p>Inclusion criteria: patients with type 2 DM and a HbA1c ≥ 7% were eligible if they had not been treated with a glucose‐lowering agent or had been treated with no more than 2 oral antihyperglycaemic agents, with or without basal or premixed insulin; aged ≥ 50 years with established CVD (previous cardiovascular, cerebrovascular, or peripheral vascular disease), chronic heart failure (NYHA class II or III), or CKD of stage 3 or higher OR aged ≥ 60 years with at least one cardiovascular risk factor </p> </li> <li> <p>Number: 3297 randomised; 2358 patients had an eGFR &lt; 60 mL/min/1.73m<sup>2</sup> </p> </li> <li> <p>Exclusion criteria: treatment with a DPP‐4 inhibitor within 30 days before screening or with a glycogen‐like peptide‐1 receptor agonist or insulin other than basal or premixed within 90 days before screening; history of an acute coronary or cerebrovascular event within 90 days before randomisation; planned revascularization of a coronary, carotid, or peripheral artery; long‐term dialysis </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0373"> <li> <p>Semaglutide: 0.5 mg or 1.0 mg once/week for 104 weeks</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0374"> <li> <p>Placebo</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0375"> <li> <p>First occurrence of death from cardiovascular causes, nonfatal MI (including silent), or nonfatal stroke </p> </li> <li> <p>First occurrence of an expanded composite cardiovascular outcome (death from cardiovascular causes, nonfatal MI, nonfatal stroke, revascularization (coronary or peripheral), and hospitalisation for unstable angina or heart failure), an additional composite outcome (death from all causes, nonfatal MI, or nonfatal stroke), the individual components of the composite outcomes, retinopathy complications, and new or worsening nephropathy. </p> </li> <li> <p>Serious and non serious adverse events and hypoglycaemic episodes, which were defined as severe (according to ADA criteria 6) or as confirmed on analysis of plasma glucose (with symptomatic hypoglycaemia defined as &lt; 56 mg/dL (3.1 mmol/L </p> </li> <li> <p>Neoplasm and pancreatitis events</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Further details regarding the subpopulation of patient with an eGFR &lt; 60 mL/min/1.73m<sup>2</sup> are required from the authors </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">von Scholten 2017 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Double‐blind, placebo‐controlled, cross‐over RCT running for 28 weeks.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0376"> <li> <p>Country: Denmark</p> </li> <li> <p>Setting: single centre</p> </li> <li> <p>Inclusion criteria: patients with type 2 DM (WHO criteria); HbA1c ≥ 48 mmol/mol (6.5%); persistent albuminuria (≥ 30 mg/g creatinine (3.39 mg/mmol) in at least 2 out of 3 consecutive morning spot urine samples) and who were receiving stable RAS‐blocking treatment </p> </li> <li> <p>Number (randomised/completed): 32/27</p> </li> <li> <p>Mean age ± SD: 65 ± 7 years</p> </li> <li> <p>Sex (M/F): 22/5</p> </li> <li> <p>Exclusion criteria: diagnosis of clinical heart failure; eGFR ≤ 30 mL/min/1.73 m<sup>2</sup> </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0377"> <li> <p>Liraglutide</p> </li> <li> <p>Standard therapy</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0378"> <li> <p>Placebo</p> </li> <li> <p>standard therapy</p> </li> </ul> </p> <p>After 12 weeks of treatment, patients underwent a 4‐week washout period prior to crossing over to the other treatment group for 12 weeks. Participants attended a baseline examination visit and were instructed in SC injection of the study drug. Participants were treated with liraglutide/placebo 0.6 mg/d for 7 days, escalated to 1.2 mg/d for 7 days and lastly to 1.8 mg/d for the remaining 10 weeks or matching placebo </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0379"> <li> <p>Change in UAER after 12 weeks of liraglutide treatment compared with placebo treatment</p> </li> <li> <p>The effect of liraglutide treatment on measured GFR (51Cr‐EDTA) and RAS hormones in plasma (renin, renin activity, angiotensin II and aldosterone) </p> </li> <li> <p>24‐hour SBP, 24‐hour DBP, 24‐hour heart rate and fractional albumin clearance</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Written to authors for the subgroup analysis for those patients with an eGFR &lt; 60. There were 11 patients with an eGFR &lt; 60. We are awaiting reply from authors for the sub‐analysis </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Xie 2006 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No details available</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No details available</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No details available</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No details available</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unable to obtain a copy of the study</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ACEi ‐ angiotensin‐converting enzyme inhibitor; ADA ‐ American Diabetes Association; AE ‐ adverse event/s; ARB ‐ angiotensin receptor blocker; BMI ‐ body mass index; BP ‐ blood pressure; CKD ‐ chronic kidney disease; CKD‐EPI ‐ CKD‐Epidemiology Collaboration; CrCl ‐ creatinine clearance; CRP ‐ C‐reactive protein; CVD ‐ cardiovascular disease; DBP ‐ diastolic blood pressure; DKD ‐ diabetic kidney disease; DM ‐ diabetes mellitus; DPP‐4 ‐ dipeptidyl‐peptidase 4; ECG ‐ electrocardiogram; (e)GFR ‐ (estimated) glomerular filtration rate; ESKD ‐ end‐stage kidney disease; FBG ‐ fasting blood glucose; GOT ‐ glutamic oxaloacetic transaminase; GPT ‐ glutamic pyruvic transaminase; Hb ‐ haemoglobin; HbA1c ‐ haemoglobin A1c (glycated); HD ‐ haemodialysis; HOMA ‐ homoeostasis model assessment; MACE ‐ Major Adverse Cardiac Events; MAP ‐ mean arterial pressure; MI ‐ myocardial infarction; NYHA ‐ New York Heart Association; PD ‐ peritoneal dialysis; RAS ‐ renin‐angiotensin system; RCT ‐ randomised controlled trial; RRT ‐ renal replacement therapy; SBP ‐ systolic blood pressure; SCr ‐ serum creatinine; SMPG ‐ self‐monitored plasma glucose; UACR ‐ urinary albumin‐creatinine ratio; UAER ‐ urinary albumin excretion rate; ULN ‐ upper limit of normal; UTI ‐ urinary tract infection </p> </div> </div> </p> </section> <section class="characteristicsOfOngoingStudies" lang=""> <div class="section-header" id="CD011798-sec2-0023"> <h3 class="title">Characteristics of ongoing studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD011798-sec2-0020" class="jump-to">included studies</a></li> <li><a href="#CD011798-sec2-0021" class="jump-to">excluded studies</a></li> <li><a href="#CD011798-sec2-0022" class="jump-to">awaiting classification</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">CARMELINA 2017 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Cardiovascular and renal microvascular outcome study with linagliptin in patients with type 2 diabetes mellitus (CARMELINA) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Parallel group, double‐blind RCT</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Inclusion criteria</p> <p> <ul id="CD011798-lst1-0380"> <li> <p>Type 2 DM</p> </li> <li> <p>Male or female patients who are drug‐naive or pre‐treated with any antidiabetic background medication, excluding treatment with glycogen‐like peptide‐1 receptor agonists, DPP‐4 inhibitors or sodium‐glucose co‐transporter‐2 inhibitors if ≥ consecutive 7 days </p> </li> <li> <p>Stable antidiabetic background medication (unchanged daily dose) for at least 8 weeks prior to randomisation. If insulin is part of the background therapy, the average daily insulin dose should not have changed by more than 10% within the 8 weeks prior to randomisation compared with the daily insulin dose at randomisation </p> </li> <li> <p>HbA1c of ≥ 6.5% (48 mmol/mol) and ≤ 10.0% (86 mmol/mol) at visit 1 (screening)</p> </li> <li> <p>Age ≥ 18 years at visit 1(screening); for Japan only: age ≥ 20 years at visit 1</p> </li> <li> <p>BMI ≤ 45 kg/m<sup>2</sup> at visit 1 (screening) </p> </li> <li> <p>Signed and dated written informed consent by date of visit 1(screening) in accordance with Good Clinical Practice and local legislation prior to any study related procedure </p> </li> <li> <p>High risk of cardiovascular events defined by: 1) albuminuria (micro or macro) and previous macrovascular disease and/or 2) impaired kidney function with albuminuria </p> </li> </ul> </p> <p>Exclusion criteria</p> <p> <ul id="CD011798-lst1-0381"> <li> <p>Type 1 DM</p> </li> <li> <p>Treatment (≥ 7 consecutive days) with glycogen‐like peptide‐1 receptor agonists, other DPP‐4 inhibitors or sodium‐glucose co‐transporter‐2 inhibitors prior to informed consent. Note: This also includes clinical trials where these glucose‐lowering agents have been provided to the patient </p> </li> <li> <p>Active liver disease or impaired hepatic function, defined by serum levels of either ALT, AST, or ALP ≥ 3 x ULN as determined at visit 1 </p> </li> <li> <p>eGFR &lt; 15 mL/min/1.73 m<sup>2</sup> (severe CKD or ESKD, MDRD formula), as determined during screening at Visit 1 and/or the need for maintenance dialysis </p> </li> <li> <p>Any previous (or planned within next 12 months) bariatric surgery (open or laparoscopic) or intervention (gastric sleeve) </p> </li> <li> <p>Pre‐planned coronary artery revascularisation or any previous ≤ 2 months prior informed consent </p> </li> <li> <p>Known hypersensitivity or allergy to the investigational products or its excipients</p> </li> <li> <p>Any previous or current alcohol or drug abuse that would interfere with trial participation in the opinion of the investigator </p> </li> <li> <p>Participation in another trial with an investigational drug ongoing or within 2 months prior to visit 1 (screening) </p> </li> <li> <p>Pre‐menopausal women (last menstruation = 1 year prior to informed consent) who are nursing or pregnant, are of child‐bearing potential and were not practicing an acceptable method of birth control (acceptable methods of birth control include tubal ligation, transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, sexual abstinence (if allowed by local authorities), double barrier method and vasectomised partner) or do not plan to continue using acceptable method of birth control throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial </p> </li> <li> <p>Patients considered unreliable by the investigator concerning the requirements for follow up during the study and/or compliance with study drug administration, have a life expectancy less than 5 years for non‐cardiovascular causes, or have cancer other than non‐melanoma skin cancer within last 3 years, or has any other condition than mentioned which in the opinion of the investigator, would not allow safe participation in the study </p> </li> <li> <p>Acute coronary syndrome, diagnosed ≤ 2 months prior to visit 1 (screening).</p> </li> <li> <p>Stroke or TIA ≤ 3 months prior to visit 1 (screening)</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Treatment group</p> <p> <ul id="CD011798-lst1-0382"> <li> <p>Linagliptin</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0383"> <li> <p>Placebo</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0384"> <li> <p>Time to the first occurrence of any of the following by adjudication confirmed components of the primary composite endpoint (3‐point MACE): cardiovascular death, non‐fatal MI, or non‐fatal stroke (time frame: 54 months) </p> </li> <li> <p>Time to the first occurrence of any of the following by adjudication confirmed components: composite kidney endpoint (death due to kidney disease, sustained ESKD, sustained decrease of 40% or more in eGFR) (time frame: 54 months) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>July 10 2013</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Boehringer Ingelheim</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT02547935 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>An exploratory phase II/III, randomised, double‐blind, placebo controlled, parallel design study to evaluate the efficacy, safety and pharmacodynamics of dapagliflozin and dapagliflozin in combination with saxagliptin in CKD patients with type 2 diabetes mellitus and albuminuria treated With ACEi or ARB </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Double‐blind randomised parallel group trial.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Inclusion criteria</p> <p> <ul id="CD011798-lst1-0385"> <li> <p>Provision of informed consent prior to any study specific procedures</p> </li> <li> <p>Female or male aged ≥ 18 years</p> </li> <li> <p>History of type 2 DM for more than 12 months</p> </li> <li> <p>HbA1c ≥ 7.0% (53 mmol/mol) and ≤11.0% (97 mmol/mol)</p> </li> <li> <p>Stable antidiabetic treatment during the last 12 weeks up to randomisation</p> </li> <li> <p>eGFR 25 to 75 mL/min/1.73 m<sup>2</sup>, inclusive </p> </li> <li> <p>Micro or macroalbuminuria (UACR 30 to 3500 mg/g (3.39 to 395.5 mg/mmol))</p> </li> <li> <p>Treatment with ACEi or an ARB for at least 3 months prior to screening</p> </li> <li> <p>BMI between 20 and 45 kg/m<sup>2</sup> </p> </li> </ul> </p> <p>Exclusion criteria</p> <p> <ul id="CD011798-lst1-0386"> <li> <p>Any of the following cardiovascular/vascular diseases within 3 month prior to signing the consent at Visit 1: MI, cardiac surgery or revascularization, unstable angina, unstable heart failure, NYHA Class III‐IV, TIA or significant cerebrovascular disease unstable or previously undiagnosed arrhythmia </p> </li> <li> <p>Significant hepatic disease, including, but not limited to, chronic active hepatitis and/or severe hepatic insufficiency </p> </li> <li> <p>AST or ALT &gt; 3 x ULN</p> </li> <li> <p>Total bilirubin &gt;2 mg/dL (34.2 μmol/L)</p> </li> <li> <p>History of AKI requiring RRT (dialysis or ultrafiltration) or any biopsy or imaging verifying intercurrent kidney disease other than DKD or DKD with nephrosclerosis. </p> </li> <li> <p>Ongoing treatment with a Sodium‐glucose co‐transporter‐2 inhibitor, glycogen‐like peptide‐1 agonist or DPP‐4 inhibitors </p> </li> <li> <p>Any condition which, in the judgment of the Investigator, may render the patient unable to complete the study or which may pose a significant risk to the patient or patient suspected or with confirmed poor protocol or medication compliance </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Treatment group 1</p> <p> <ul id="CD011798-lst1-0387"> <li> <p>Dapagliflozin: 10 mg/d</p> </li> </ul> </p> <p>Treatment group 2</p> <p> <ul id="CD011798-lst1-0388"> <li> <p>Dapagliflozin: 10 mg/d</p> </li> <li> <p>Saxagliptin 2.5 mg/d</p> </li> </ul> </p> <p>Control group</p> <p> <ul id="CD011798-lst1-0389"> <li> <p>Placebo tablets</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0390"> <li> <p>Change in HbA1c (dapagliflozin 10 mg + saxagliptin 2.5 mg) (time frame: up to 24 weeks of treatment); to compare the mean change from baseline to week 24 in HbA1c between dapagliflozin 10 mg plus saxagliptin 2.5 mg and placebo </p> </li> <li> <p>Percent change in Urine albumin to creatinine ratio (UACR) (dapagliflozin 10 mg + saxagliptin 2.5 mg) (time frame: up to 24 weeks of treatment) </p> </li> <li> <p>Mean percent change from baseline to week 24 in UACR between dapagliflozin 10 mg plus saxagliptin 2.5 mg and placebo </p> </li> <li> <p>Percent change in UACR) (dapagliflozin 10 mg) (time frame: up to 24 weeks of treatment); to compare the mean percent change from baseline to week 24 in UACR between dapagliflozin 10 mg and placebo. </p> </li> </ul> <ul id="CD011798-lst1-0391"> <li> <p>Percent change in total body weight (time frame: up to 24 weeks of treatment); to compare the mean percent change from baseline in total body weight between dapagliflozin 10 mg with and, separately, without saxagliptin 2.5 mg and placebo </p> </li> <li> <p>Change in FBG (time frame: up to 24 weeks of treatment); to compare the mean change from baseline in FBG between dapagliflozin 10 mg with and, separately, without saxagliptin 2.5 mg and placebo </p> </li> <li> <p>Proportion of patients that achieve 30% reduction in UACR (time frame: up to 24 weeks of treatment); to compare the proportion of patients achieving a 30% reduction in UACR between dapagliflozin 10 mg with and, separately, without saxagliptin 2.5 mg and placebo </p> </li> <li> <p>Proportion of patients which achieve HbA1c &lt; 7% (53 mmol/mol) (time frame: up to 24 weeks of treatment); to compare the proportion of patients achieving a reduction in HbA1c &lt;7.0% (53 mmol/mol) between dapagliflozin 10 mg with and, separately, without saxagliptin 2.5 mg and placebo </p> </li> <li> <p>Change in seated SBP (time frame: up to 24 weeks of treatment); to compare the mean change from baseline in seated SBP between dapagliflozin 10 mg with and, separately, without saxagliptin 2.5 mg and placebo </p> </li> <li> <p>Change in HbA1c (time frame: up to 24 weeks of treatment); to compare the mean change from baseline in HbA1c between dapagliflozin 10 mg and placebo </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>September 21, 2015</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>AstraZeneca Clinical Study Information centre: 1‐877‐240‐9479; <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="472e292128352a26332e2829692422293322350726343335263d22292224266924282a">[email&#160;protected]</a></p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Currently recruiting participants.</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT02608177 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Continuous glucose monitoring to assess glycaemia in chronic kidney disease ‐ Changing glucose management (CANDY‐CANE) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventional cross‐over RCT</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Inclusion criteria</p> <p> <ul id="CD011798-lst1-0392"> <li> <p>Type 2 DM</p> </li> <li> <p>eGFR 15 to 59 mL/min/1.73 m<sup>2</sup> </p> </li> <li> <p>HbA1c &lt; 8%</p> </li> <li> <p>Age ≥ 18 years</p> </li> <li> <p>Current use of sulphonylureas</p> </li> </ul> </p> <p>Exclusion criteria</p> <p> <ul id="CD011798-lst1-0393"> <li> <p>BMI &gt; 40 kg/m<sup>2</sup> </p> </li> <li> <p>Actively using continuous glucose monitoring for clinical care</p> </li> <li> <p>ESKD needing dialysis</p> </li> <li> <p>Kidney transplant</p> </li> <li> <p>Pregnant or nursing</p> </li> <li> <p>Unable to provide informed consent</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Linagliptin/glipizide</p> <p> <ul id="CD011798-lst1-0394"> <li> <p>4 weeks of study drug linagliptin followed by 4 weeks of glipizide</p> </li> </ul> </p> <p>Glipizide/linagliptin</p> <p> <ul id="CD011798-lst1-0395"> <li> <p>4 weeks of study drug glipizide followed by 4 weeks linagliptin</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011798-lst1-0396"> <li> <p>Glucose time in range (time frame: 28 days)</p> </li> <li> <p>Glycaemic variability (time frame: 28 days)</p> </li> <li> <p>Hypoglycaemia (time frame: 28 days)</p> </li> <li> <p>Biomarkers of systemic inflammation (time frame: 28 days). Measured by plasma C‐reactive protein </p> </li> <li> <p>Biomarkers of systemic inflammation (time frame: 28 days). Measured by plasma interleukin‐6</p> </li> <li> <p>Biomarkers of oxidative stress (time frame: 28 days). Measured by plasma F2‐isoprostanes</p> </li> <li> <p>Biomarkers of oxidative stress (time frame: 28 days). Measured by urine F2‐isoprostanes</p> </li> <li> <p>Biomarkers of albuminuria (time frame: 28 days). Measured by UACR</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>November 2015</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Ian de Boer, Associate Professor, Medicine/Nephrology, University of Washington</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Currently recruiting participants</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ACEi ‐ angiotensin‐converting enzyme inhibitor; AKI ‐ acute kidney injury; ALT ‐ alanine aminotransferase; ALP ‐ alkaline phosphatase; ARB ‐ angiotensin receptor blocker; AST ‐ aspartate aminotransferase; BMI ‐ body mass index; BP ‐ blood pressure; CKD ‐ chronic kidney disease; DKD ‐ diabetic kidney disease; DM ‐ diabetes mellitus; DPP‐4 ‐ dipeptidyl‐peptidase 4; eGFR ‐ estimated glomerular filtration rate; ESKD ‐ end‐stage kidney disease; HbA1c ‐ haemoglobin A1c (glycated); MDRD ‐ Modification of Diet in Renal Disease; MACE ‐ Major Adverse Cardiac Events; MI ‐ myocardial infarction; NYHA ‐ New York Heart Association; RCT ‐ randomised controlled trial; RRT ‐ renal replacement therapy; SBP ‐ systolic blood pressure; TIA ‐ transient ischaemic attack; UACR ‐ urinary albumin‐creatinine ratio; ULN ‐ upper limit of normal </p> </div> </div> </p> </section> </section> <section class="dataAndAnalyses" id="dataAndAnalyses"> <section class="dataAndAnalyses" lang="en"> <div class="section-header section-collapse-header" id="CD011798-sec1-0011"> <h2 class="title section-collapse-title">Data and analyses<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <div class="table" id="CD011798-tbl-0006"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">SGLT2 inhibitors versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1092</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.29 [‐0.38, ‐0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00101"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-01.png?filename=nCD011798-CMP-001-01.ppt&amp;title=1.1&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%201%20HbA1c.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.1</div> </div> <hr class="top"><img data-id="CD011798-fig-00101" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-01.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 1 HbA1c."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 1 HbA1c.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>855</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.48 [‐0.78, ‐0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00102"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-02.png?filename=nCD011798-CMP-001-02.ppt&amp;title=1.2&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%202%20Fasting%20blood%20glucose.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.2</div> </div> <hr class="top"><img data-id="CD011798-fig-00102" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-02.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 2 Fasting blood glucose."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 2 Fasting blood glucose.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2933</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.78 [0.60, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00103"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-03.png?filename=nCD011798-CMP-001-03.ppt&amp;title=1.3&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%203%20Death%20%28all%20causes%29.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.3</div> </div> <hr class="top"><img data-id="CD011798-fig-00103" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-03.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 3 Death (all causes)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 3 Death (all causes).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 All cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2788</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.78 [0.56, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00104"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-04.png?filename=nCD011798-CMP-001-04.ppt&amp;title=1.4&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%204%20All%20cardiovascular%20death.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.4</div> </div> <hr class="top"><img data-id="CD011798-fig-00104" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-04.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 4 All cardiovascular death."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 4 All cardiovascular death.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2788</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.63 [0.30, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00105"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-05.png?filename=nCD011798-CMP-001-05.ppt&amp;title=1.5&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%205%20Myocardial%20infarction.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.5</div> </div> <hr class="top"><img data-id="CD011798-fig-00105" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-05.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 5 Myocardial infarction."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 5 Myocardial infarction.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2933</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.96 [0.63, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00106"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-06.png?filename=nCD011798-CMP-001-06.ppt&amp;title=1.6&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%206%20Stroke.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.6</div> </div> <hr class="top"><img data-id="CD011798-fig-00106" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-06.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 6 Stroke."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 6 Stroke.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2519</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.59 [0.41, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00107"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-07.png?filename=nCD011798-CMP-001-07.ppt&amp;title=1.7&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%207%20Heart%20failure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.7</div> </div> <hr class="top"><img data-id="CD011798-fig-00107" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-07.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 7 Heart failure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 7 Heart failure.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1029</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.41 [‐1.80, ‐1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00108"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-08.png?filename=nCD011798-CMP-001-08.ppt&amp;title=1.8&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%208%20Weight.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.8</div> </div> <hr class="top"><img data-id="CD011798-fig-00108" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-08.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 8 Weight."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 8 Weight.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 eGFR [mL/min/1.73 m<sup>2</sup>] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>848</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.85 [‐2.76, ‐0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00109"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-09.png?filename=nCD011798-CMP-001-09.ppt&amp;title=1.9&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%209%20eGFR%20%5BmL%2Fmin%2F1.73%20m2%5D.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.9</div> </div> <hr class="top"><img data-id="CD011798-fig-00109" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-09.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 9 eGFR [mL/min/1.73 m2]."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 9 eGFR [mL/min/1.73 m<sup>2</sup>]. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1198</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐4.68 [‐6.69, ‐2.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00110"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-10.png?filename=nCD011798-CMP-001-10.ppt&amp;title=1.10&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2010%20Systolic%20blood%20pressure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.10</div> </div> <hr class="top"><img data-id="CD011798-fig-00110" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-10.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 10 Systolic blood pressure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 10 Systolic blood pressure.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Diastolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1142</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.72 [‐2.77, ‐0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00111"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-11.png?filename=nCD011798-CMP-001-11.ppt&amp;title=1.11&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2011%20Diastolic%20blood%20pressure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.11</div> </div> <hr class="top"><img data-id="CD011798-fig-00111" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-11.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 11 Diastolic blood pressure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 11 Diastolic blood pressure.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 Serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>848</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.82 [1.45, 6.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00112"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-12.png?filename=nCD011798-CMP-001-12.ppt&amp;title=1.12&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2012%20Serum%20creatinine.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.12</div> </div> <hr class="top"><img data-id="CD011798-fig-00112" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-12.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 12 Serum creatinine."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 12 Serum creatinine.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 Urinary albumin/creatinine ratio <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1153</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐8.14 [‐14.51, ‐1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00113"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-13.png?filename=nCD011798-CMP-001-13.ppt&amp;title=1.13&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2013%20Urinary%20albumin%2Fcreatinine%20ratio.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.13</div> </div> <hr class="top"><img data-id="CD011798-fig-00113" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-13.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 13 Urinary albumin/creatinine ratio."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 13 Urinary albumin/creatinine ratio. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">14 Serum potassium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2443</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.01 [‐0.05, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00114"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-14.png?filename=nCD011798-CMP-001-14.ppt&amp;title=1.14&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2014%20Serum%20potassium.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.14</div> </div> <hr class="top"><img data-id="CD011798-fig-00114" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-14.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 14 Serum potassium."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 14 Serum potassium.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">15 Total cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>529</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.09 [‐0.05, 0.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00115"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-15.png?filename=nCD011798-CMP-001-15.ppt&amp;title=1.15&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2015%20Total%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.15</div> </div> <hr class="top"><img data-id="CD011798-fig-00115" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-15.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 15 Total cholesterol."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 15 Total cholesterol.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">16 HDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>918</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.04 [0.01, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00116"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-16.png?filename=nCD011798-CMP-001-16.ppt&amp;title=1.16&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2016%20HDL%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.16</div> </div> <hr class="top"><img data-id="CD011798-fig-00116" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-16.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 16 HDL cholesterol."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 16 HDL cholesterol.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">17 LDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>917</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.04 [‐0.06, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00117"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-17.png?filename=nCD011798-CMP-001-17.ppt&amp;title=1.17&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2017%20LDL%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.17</div> </div> <hr class="top"><img data-id="CD011798-fig-00117" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-17.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 17 LDL cholesterol."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 17 LDL cholesterol.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">18 Triglyceride <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>918</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.01 [‐0.11, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00118"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-18.png?filename=nCD011798-CMP-001-18.ppt&amp;title=1.18&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2018%20Triglyceride.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.18</div> </div> <hr class="top"><img data-id="CD011798-fig-00118" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-18.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 18 Triglyceride."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 18 Triglyceride.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">19 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3086</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.88 [0.73, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00119"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-19.png?filename=nCD011798-CMP-001-19.ppt&amp;title=1.19&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2019%20Hypoglycaemia.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.19</div> </div> <hr class="top"><img data-id="CD011798-fig-00119" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-19.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 19 Hypoglycaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 19 Hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">20 Discontinuation of medication due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>917</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.86 [0.56, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00120"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-20.png?filename=nCD011798-CMP-001-20.ppt&amp;title=1.20&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2020%20Discontinuation%20of%20medication%20due%20to%20adverse%20events.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.20</div> </div> <hr class="top"><img data-id="CD011798-fig-00120" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-20.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 20 Discontinuation of medication due to adverse events."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 20 Discontinuation of medication due to adverse events. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">21 End‐stage kidney disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>700</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.71 [0.10, 4.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00121"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-21.png?filename=nCD011798-CMP-001-21.ppt&amp;title=1.21&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2021%20End%E2%80%90stage%20kidney%20disease.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.21</div> </div> <hr class="top"><img data-id="CD011798-fig-00121" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-21.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 21 End‐stage kidney disease."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 21 End‐stage kidney disease.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">22 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2788</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.58 [0.42, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00122"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-22.png?filename=nCD011798-CMP-001-22.ppt&amp;title=1.22&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2022%20Hyperkalaemia.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.22</div> </div> <hr class="top"><img data-id="CD011798-fig-00122" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-22.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 22 Hyperkalaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 22 Hyperkalaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">23 Hypoglycaemia requiring third party assistance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>845</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.47 [0.17, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00123"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-23.png?filename=nCD011798-CMP-001-23.ppt&amp;title=1.23&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2023%20Hypoglycaemia%20requiring%20third%20party%20assistance.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.23</div> </div> <hr class="top"><img data-id="CD011798-fig-00123" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-23.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 23 Hypoglycaemia requiring third party assistance."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 23 Hypoglycaemia requiring third party assistance. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">24 Hypovolaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3005</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.07 [0.63, 1.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00124"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-24.png?filename=nCD011798-CMP-001-24.ppt&amp;title=1.24&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2024%20Hypovolaemia.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.24</div> </div> <hr class="top"><img data-id="CD011798-fig-00124" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-24.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 24 Hypovolaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 24 Hypovolaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">25 Fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2860</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.81 [0.31, 2.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00125"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-25.png?filename=nCD011798-CMP-001-25.ppt&amp;title=1.25&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2025%20Fracture.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.25</div> </div> <hr class="top"><img data-id="CD011798-fig-00125" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-25.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 25 Fracture."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 25 Fracture.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">26 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00126"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-26.png?filename=nCD011798-CMP-001-26.ppt&amp;title=1.26&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2026%20Diarrhoea.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.26</div> </div> <hr class="top"><img data-id="CD011798-fig-00126" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-26.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 26 Diarrhoea."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 26 Diarrhoea.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">27 Diabetic ketoacidosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1962</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.00 [0.09, 11.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00127"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-27.png?filename=nCD011798-CMP-001-27.ppt&amp;title=1.27&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2027%20Diabetic%20ketoacidosis.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.27</div> </div> <hr class="top"><img data-id="CD011798-fig-00127" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-27.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 27 Diabetic ketoacidosis."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 27 Diabetic ketoacidosis.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">28 Upper respiratory tract infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>593</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.79 [0.43, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00128"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-28.png?filename=nCD011798-CMP-001-28.ppt&amp;title=1.28&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2028%20Upper%20respiratory%20tract%20infection.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.28</div> </div> <hr class="top"><img data-id="CD011798-fig-00128" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-28.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 28 Upper respiratory tract infection."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 28 Upper respiratory tract infection.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">29 Urinary tract infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3086</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.09 [0.82, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00129"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-29.png?filename=nCD011798-CMP-001-29.ppt&amp;title=1.29&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2029%20Urinary%20tract%20infection.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.29</div> </div> <hr class="top"><img data-id="CD011798-fig-00129" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-29.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 29 Urinary tract infection."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 29 Urinary tract infection.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">30 Genital infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3086</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.50 [1.52, 4.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00130"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-30.png?filename=nCD011798-CMP-001-30.ppt&amp;title=1.30&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2030%20Genital%20infection.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.30</div> </div> <hr class="top"><img data-id="CD011798-fig-00130" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-30.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 30 Genital infection."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 30 Genital infection.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">31 Acute kidney injury <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2788</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.78 [0.61, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00131"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-31.png?filename=nCD011798-CMP-001-31.ppt&amp;title=1.31&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2031%20Acute%20kidney%20injury.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.31</div> </div> <hr class="top"><img data-id="CD011798-fig-00131" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-31.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 31 Acute kidney injury."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 31 Acute kidney injury.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">32 Doubling of serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>700</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.96 [0.49, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00132"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-32.png?filename=nCD011798-CMP-001-32.ppt&amp;title=1.32&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2032%20Doubling%20of%20serum%20creatinine.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.32</div> </div> <hr class="top"><img data-id="CD011798-fig-00132" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-32.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 32 Doubling of serum creatinine."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 32 Doubling of serum creatinine.</p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD011798-tbl-0007"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 2.</span>&nbsp;<span class="table-title">DPP‐4 inhibitors versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>867</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.62 [‐0.85, ‐0.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00201"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-01.png?filename=nCD011798-CMP-002-01.ppt&amp;title=2.1&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%201%20HbA1c.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.1</div> </div> <hr class="top"><img data-id="CD011798-fig-00201" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-01.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 1 HbA1c."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 1 HbA1c.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>589</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.47 [‐1.08, 0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00202"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-02.png?filename=nCD011798-CMP-002-02.ppt&amp;title=2.2&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%202%20Fasting%20blood%20glucose.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.2</div> </div> <hr class="top"><img data-id="CD011798-fig-00202" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-02.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 2 Fasting blood glucose."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 2 Fasting blood glucose.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4211</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.89 [0.75, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00203"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-03.png?filename=nCD011798-CMP-002-03.ppt&amp;title=2.3&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%203%20Death%20%28all%20causes%29.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.3</div> </div> <hr class="top"><img data-id="CD011798-fig-00203" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-03.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 3 Death (all causes)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 3 Death (all causes).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 All cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5897</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.93 [0.77, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00204"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-04.png?filename=nCD011798-CMP-002-04.ppt&amp;title=2.4&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%204%20All%20cardiovascular%20death.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.4</div> </div> <hr class="top"><img data-id="CD011798-fig-00204" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-04.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 4 All cardiovascular death."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 4 All cardiovascular death.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6121</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.08 [0.88, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00205"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-05.png?filename=nCD011798-CMP-002-05.ppt&amp;title=2.5&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%205%20Myocardial%20infarction.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.5</div> </div> <hr class="top"><img data-id="CD011798-fig-00205" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-05.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 5 Myocardial infarction."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 5 Myocardial infarction.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6030</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.92 [0.69, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00206"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-06.png?filename=nCD011798-CMP-002-06.ppt&amp;title=2.6&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%206%20Stroke.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.6</div> </div> <hr class="top"><img data-id="CD011798-fig-00206" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-06.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 6 Stroke."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 6 Stroke.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6115</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.18 [0.98, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00207"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-07.png?filename=nCD011798-CMP-002-07.ppt&amp;title=2.7&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%207%20Heart%20failure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.7</div> </div> <hr class="top"><img data-id="CD011798-fig-00207" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-07.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 7 Heart failure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 7 Heart failure.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>210</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.16 [‐0.58, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00208"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-08.png?filename=nCD011798-CMP-002-08.ppt&amp;title=2.8&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%208%20Weight.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.8</div> </div> <hr class="top"><img data-id="CD011798-fig-00208" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-08.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 8 Weight."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 8 Weight.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 eGFR [mL/min/1.73 m<sup>2</sup>] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00209"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-09.png?filename=nCD011798-CMP-002-09.ppt&amp;title=2.9&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%209%20eGFR%20%5BmL%2Fmin%2F1.73%20m2%5D.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.9</div> </div> <hr class="top"><img data-id="CD011798-fig-00209" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-09.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 9 eGFR [mL/min/1.73 m2]."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 9 eGFR [mL/min/1.73 m<sup>2</sup>]. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00210"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-10.png?filename=nCD011798-CMP-002-10.ppt&amp;title=2.10&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2010%20Serum%20creatinine.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.10</div> </div> <hr class="top"><img data-id="CD011798-fig-00210" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-10.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 10 Serum creatinine."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 10 Serum creatinine.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Urinary albumin/creatinine ratio <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00211"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-11.png?filename=nCD011798-CMP-002-11.ppt&amp;title=2.11&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2011%20Urinary%20albumin%2Fcreatinine%20ratio.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.11</div> </div> <hr class="top"><img data-id="CD011798-fig-00211" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-11.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 11 Urinary albumin/creatinine ratio."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 11 Urinary albumin/creatinine ratio. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 Total cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00212"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-12.png?filename=nCD011798-CMP-002-12.ppt&amp;title=2.12&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2012%20Total%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.12</div> </div> <hr class="top"><img data-id="CD011798-fig-00212" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-12.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 12 Total cholesterol."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 12 Total cholesterol.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 LDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00213"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-13.png?filename=nCD011798-CMP-002-13.ppt&amp;title=2.13&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2013%20LDL%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.13</div> </div> <hr class="top"><img data-id="CD011798-fig-00213" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-13.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 13 LDL cholesterol."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 13 LDL cholesterol.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">14 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1443</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.07 [0.80, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00214"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-14.png?filename=nCD011798-CMP-002-14.ppt&amp;title=2.14&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2014%20Hypoglycaemia.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.14</div> </div> <hr class="top"><img data-id="CD011798-fig-00214" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-14.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 14 Hypoglycaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 14 Hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">15 Discontinuation of medication due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1257</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.94 [0.61, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00215"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-15.png?filename=nCD011798-CMP-002-15.ppt&amp;title=2.15&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2015%20Discontinuation%20of%20medication%20due%20to%20adverse%20events.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.15</div> </div> <hr class="top"><img data-id="CD011798-fig-00215" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-15.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 15 Discontinuation of medication due to adverse events."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 15 Discontinuation of medication due to adverse events. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">16 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>502</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.30 [0.81, 2.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00216"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-16.png?filename=nCD011798-CMP-002-16.ppt&amp;title=2.16&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2016%20Hyperkalaemia.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.16</div> </div> <hr class="top"><img data-id="CD011798-fig-00216" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-16.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 16 Hyperkalaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 16 Hyperkalaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">17 Hypoglycaemia requiring third party assistance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3383</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.72 [0.25, 2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00217"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-17.png?filename=nCD011798-CMP-002-17.ppt&amp;title=2.17&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2017%20Hypoglycaemia%20requiring%20third%20party%20assistance.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.17</div> </div> <hr class="top"><img data-id="CD011798-fig-00217" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-17.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 17 Hypoglycaemia requiring third party assistance."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 17 Hypoglycaemia requiring third party assistance. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">18 New or worsening retinopathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00218"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-18.png?filename=nCD011798-CMP-002-18.ppt&amp;title=2.18&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2018%20New%20or%20worsening%20retinopathy.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.18</div> </div> <hr class="top"><img data-id="CD011798-fig-00218" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-18.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 18 New or worsening retinopathy."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 18 New or worsening retinopathy.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">19 Peripheral oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>763</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.84 [0.58, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00219"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-19.png?filename=nCD011798-CMP-002-19.ppt&amp;title=2.19&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2019%20Peripheral%20oedema.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.19</div> </div> <hr class="top"><img data-id="CD011798-fig-00219" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-19.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 19 Peripheral oedema."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 19 Peripheral oedema.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">20 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>502</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.39 [0.80, 2.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00220"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-20.png?filename=nCD011798-CMP-002-20.ppt&amp;title=2.20&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2020%20Diarrhoea.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.20</div> </div> <hr class="top"><img data-id="CD011798-fig-00220" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-20.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 20 Diarrhoea."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 20 Diarrhoea.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">21 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>224</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.79 [0.09, 6.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00221"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-21.png?filename=nCD011798-CMP-002-21.ppt&amp;title=2.21&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2021%20Constipation.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.21</div> </div> <hr class="top"><img data-id="CD011798-fig-00221" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-21.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 21 Constipation."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 21 Constipation.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">22 Malignancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00222"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-22.png?filename=nCD011798-CMP-002-22.ppt&amp;title=2.22&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2022%20Malignancy.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.22</div> </div> <hr class="top"><img data-id="CD011798-fig-00222" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-22.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 22 Malignancy."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 22 Malignancy.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">23 Pancreatic cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00223"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-23.png?filename=nCD011798-CMP-002-23.ppt&amp;title=2.23&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2023%20Pancreatic%20cancer.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.23</div> </div> <hr class="top"><img data-id="CD011798-fig-00223" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-23.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 23 Pancreatic cancer."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 23 Pancreatic cancer.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">24 Pancreatitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3693</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.99 [0.14, 7.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00224"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-24.png?filename=nCD011798-CMP-002-24.ppt&amp;title=2.24&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2024%20Pancreatitis.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.24</div> </div> <hr class="top"><img data-id="CD011798-fig-00224" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-24.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 24 Pancreatitis."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 24 Pancreatitis.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">25 Liver impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>451</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.42 [0.26, 7.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00225"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-25.png?filename=nCD011798-CMP-002-25.ppt&amp;title=2.25&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2025%20Liver%20impairment.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.25</div> </div> <hr class="top"><img data-id="CD011798-fig-00225" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-25.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 25 Liver impairment."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 25 Liver impairment.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">26 Upper respiratory tract infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>593</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.63 [0.38, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00226"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-26.png?filename=nCD011798-CMP-002-26.ppt&amp;title=2.26&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2026%20Upper%20respiratory%20tract%20infection.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.26</div> </div> <hr class="top"><img data-id="CD011798-fig-00226" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-26.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 26 Upper respiratory tract infection."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 26 Upper respiratory tract infection.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">27 Cellulitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00227"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-27.png?filename=nCD011798-CMP-002-27.ppt&amp;title=2.27&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2027%20Cellulitis.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.27</div> </div> <hr class="top"><img data-id="CD011798-fig-00227" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-27.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 27 Cellulitis."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 27 Cellulitis.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">28 Urinary tract infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>763</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.82 [0.50, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00228"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-28.png?filename=nCD011798-CMP-002-28.ppt&amp;title=2.28&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2028%20Urinary%20tract%20infection.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.28</div> </div> <hr class="top"><img data-id="CD011798-fig-00228" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-28.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 28 Urinary tract infection."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 28 Urinary tract infection.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">29 Acute kidney injury <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00229"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-29.png?filename=nCD011798-CMP-002-29.ppt&amp;title=2.29&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2029%20Acute%20kidney%20injury.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.29</div> </div> <hr class="top"><img data-id="CD011798-fig-00229" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-29.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 29 Acute kidney injury."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 29 Acute kidney injury.</p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD011798-tbl-0008"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 3.</span>&nbsp;<span class="table-title">GLP‐1 agonists versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>283</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.53 [‐1.01, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00301"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-01.png?filename=nCD011798-CMP-003-01.ppt&amp;title=3.1&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%201%20HbA1c.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.1</div> </div> <hr class="top"><img data-id="CD011798-fig-00301" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-01.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 1 HbA1c."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 1 HbA1c.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00302"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-02.png?filename=nCD011798-CMP-003-02.ppt&amp;title=3.2&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%202%20Fasting%20blood%20glucose.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.2</div> </div> <hr class="top"><img data-id="CD011798-fig-00302" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-02.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 2 Fasting blood glucose."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 2 Fasting blood glucose.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>301</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.91 [0.44, 34.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00303"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-03.png?filename=nCD011798-CMP-003-03.ppt&amp;title=3.3&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%203%20Death%20%28all%20causes%29.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.3</div> </div> <hr class="top"><img data-id="CD011798-fig-00303" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-03.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 3 Death (all causes)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 3 Death (all causes).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00304"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-04.png?filename=nCD011798-CMP-003-04.ppt&amp;title=3.4&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%204%20Myocardial%20infarction.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.4</div> </div> <hr class="top"><img data-id="CD011798-fig-00304" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-04.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 4 Myocardial infarction."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 4 Myocardial infarction.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00305"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-05.png?filename=nCD011798-CMP-003-05.ppt&amp;title=3.5&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%205%20Heart%20failure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.5</div> </div> <hr class="top"><img data-id="CD011798-fig-00305" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-05.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 5 Heart failure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 5 Heart failure.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00306"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-06.png?filename=nCD011798-CMP-003-06.ppt&amp;title=3.6&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%206%20Weight.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.6</div> </div> <hr class="top"><img data-id="CD011798-fig-00306" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-06.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 6 Weight."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 6 Weight.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00307"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-07.png?filename=nCD011798-CMP-003-07.ppt&amp;title=3.7&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%207%20Systolic%20blood%20pressure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.7</div> </div> <hr class="top"><img data-id="CD011798-fig-00307" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-07.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 7 Systolic blood pressure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 7 Systolic blood pressure.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Diastolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00308"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-08.png?filename=nCD011798-CMP-003-08.ppt&amp;title=3.8&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%208%20Diastolic%20blood%20pressure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.8</div> </div> <hr class="top"><img data-id="CD011798-fig-00308" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-08.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 8 Diastolic blood pressure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 8 Diastolic blood pressure.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00309"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-09.png?filename=nCD011798-CMP-003-09.ppt&amp;title=3.9&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%209%20Serum%20creatinine.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.9</div> </div> <hr class="top"><img data-id="CD011798-fig-00309" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-09.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 9 Serum creatinine."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 9 Serum creatinine.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Total cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00310"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-10.png?filename=nCD011798-CMP-003-10.ppt&amp;title=3.10&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%2010%20Total%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.10</div> </div> <hr class="top"><img data-id="CD011798-fig-00310" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-10.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 10 Total cholesterol."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 10 Total cholesterol.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 HDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00311"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-11.png?filename=nCD011798-CMP-003-11.ppt&amp;title=3.11&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%2011%20HDL%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.11</div> </div> <hr class="top"><img data-id="CD011798-fig-00311" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-11.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 11 HDL cholesterol."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 11 HDL cholesterol.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 LDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00312"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-12.png?filename=nCD011798-CMP-003-12.ppt&amp;title=3.12&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%2012%20LDL%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.12</div> </div> <hr class="top"><img data-id="CD011798-fig-00312" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-12.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 12 LDL cholesterol."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 12 LDL cholesterol.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 Triglyceride <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00313"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-13.png?filename=nCD011798-CMP-003-13.ppt&amp;title=3.13&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%2013%20Triglyceride.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.13</div> </div> <hr class="top"><img data-id="CD011798-fig-00313" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-13.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 13 Triglyceride."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 13 Triglyceride.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">14 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00314"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-14.png?filename=nCD011798-CMP-003-14.ppt&amp;title=3.14&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%2014%20Hypoglycaemia.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.14</div> </div> <hr class="top"><img data-id="CD011798-fig-00314" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-14.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 14 Hypoglycaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 14 Hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">15 Discontinuation of medication due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00315"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-15.png?filename=nCD011798-CMP-003-15.ppt&amp;title=3.15&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%2015%20Discontinuation%20of%20medication%20due%20to%20adverse%20events.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.15</div> </div> <hr class="top"><img data-id="CD011798-fig-00315" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-15.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 15 Discontinuation of medication due to adverse events."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 15 Discontinuation of medication due to adverse events. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">16 Gastrointestinal disorders <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00316"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-16.png?filename=nCD011798-CMP-003-16.ppt&amp;title=3.16&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%2016%20Gastrointestinal%20disorders.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.16</div> </div> <hr class="top"><img data-id="CD011798-fig-00316" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-16.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 16 Gastrointestinal disorders."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 16 Gastrointestinal disorders.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">17 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00317"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-17.png?filename=nCD011798-CMP-003-17.ppt&amp;title=3.17&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%2017%20Vomiting.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.17</div> </div> <hr class="top"><img data-id="CD011798-fig-00317" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-17.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 17 Vomiting."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 17 Vomiting.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">18 Pancreatitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00318"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-18.png?filename=nCD011798-CMP-003-18.ppt&amp;title=3.18&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%2018%20Pancreatitis.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.18</div> </div> <hr class="top"><img data-id="CD011798-fig-00318" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-18.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 18 Pancreatitis."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 18 Pancreatitis.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">19 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00319"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-19.png?filename=nCD011798-CMP-003-19.ppt&amp;title=3.19&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%2019%20Nausea.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.19</div> </div> <hr class="top"><img data-id="CD011798-fig-00319" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-19.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 19 Nausea."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 19 Nausea.</p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD011798-tbl-0009"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 4.</span>&nbsp;<span class="table-title">Glitazone versus placebo/control</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>88</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.41 [‐1.15, 0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00401"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-01.png?filename=nCD011798-CMP-004-01.ppt&amp;title=4.1&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%201%20HbA1c.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.1</div> </div> <hr class="top"><img data-id="CD011798-fig-00401" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-01.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 1 HbA1c."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 1 HbA1c.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00402"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-02.png?filename=nCD011798-CMP-004-02.ppt&amp;title=4.2&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%202%20Fasting%20blood%20glucose.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.2</div> </div> <hr class="top"><img data-id="CD011798-fig-00402" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-02.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 2 Fasting blood glucose."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 2 Fasting blood glucose.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00403"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-03.png?filename=nCD011798-CMP-004-03.ppt&amp;title=4.3&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%203%20Death%20%28all%20causes%29.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.3</div> </div> <hr class="top"><img data-id="CD011798-fig-00403" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-03.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 3 Death (all causes)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 3 Death (all causes).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>123</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.34 [0.01, 8.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00404"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-04.png?filename=nCD011798-CMP-004-04.ppt&amp;title=4.4&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%204%20Heart%20failure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.4</div> </div> <hr class="top"><img data-id="CD011798-fig-00404" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-04.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 4 Heart failure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 4 Heart failure.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00405"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-05.png?filename=nCD011798-CMP-004-05.ppt&amp;title=4.5&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%205%20Systolic%20blood%20pressure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.5</div> </div> <hr class="top"><img data-id="CD011798-fig-00405" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-05.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 5 Systolic blood pressure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 5 Systolic blood pressure.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Diastolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00406"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-06.png?filename=nCD011798-CMP-004-06.ppt&amp;title=4.6&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%206%20Diastolic%20blood%20pressure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.6</div> </div> <hr class="top"><img data-id="CD011798-fig-00406" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-06.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 6 Diastolic blood pressure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 6 Diastolic blood pressure.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Total cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>72</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.60 [‐0.02, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00407"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-07.png?filename=nCD011798-CMP-004-07.ppt&amp;title=4.7&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%207%20Total%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.7</div> </div> <hr class="top"><img data-id="CD011798-fig-00407" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-07.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 7 Total cholesterol."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 7 Total cholesterol.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 HDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>72</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.07 [‐0.25, 0.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00408"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-08.png?filename=nCD011798-CMP-004-08.ppt&amp;title=4.8&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%208%20HDL%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.8</div> </div> <hr class="top"><img data-id="CD011798-fig-00408" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-08.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 8 HDL cholesterol."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 8 HDL cholesterol.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 LDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>72</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.39 [‐0.60, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00409"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-09.png?filename=nCD011798-CMP-004-09.ppt&amp;title=4.9&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%209%20LDL%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.9</div> </div> <hr class="top"><img data-id="CD011798-fig-00409" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-09.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 9 LDL cholesterol."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 9 LDL cholesterol.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Triglyceride <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>72</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.34 [‐2.99, 2.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00410"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-10.png?filename=nCD011798-CMP-004-10.ppt&amp;title=4.10&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%2010%20Triglyceride.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.10</div> </div> <hr class="top"><img data-id="CD011798-fig-00410" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-10.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 10 Triglyceride."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 10 Triglyceride.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00411"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-11.png?filename=nCD011798-CMP-004-11.ppt&amp;title=4.11&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%2011%20Hypoglycaemia.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.11</div> </div> <hr class="top"><img data-id="CD011798-fig-00411" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-11.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 11 Hypoglycaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 11 Hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 Hypoglycaemia requiring third party assistance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00412"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-12.png?filename=nCD011798-CMP-004-12.ppt&amp;title=4.12&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%2012%20Hypoglycaemia%20requiring%20third%20party%20assistance.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.12</div> </div> <hr class="top"><img data-id="CD011798-fig-00412" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-12.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 12 Hypoglycaemia requiring third party assistance."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 12 Hypoglycaemia requiring third party assistance. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 Peripheral oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>134</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.05 [0.33, 28.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00413"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-13.png?filename=nCD011798-CMP-004-13.ppt&amp;title=4.13&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%2013%20Peripheral%20oedema.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.13</div> </div> <hr class="top"><img data-id="CD011798-fig-00413" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-13.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 13 Peripheral oedema."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 13 Peripheral oedema.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">14 Fluid overload <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00414"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-14.png?filename=nCD011798-CMP-004-14.ppt&amp;title=4.14&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%2014%20Fluid%20overload.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.14</div> </div> <hr class="top"><img data-id="CD011798-fig-00414" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-14.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 14 Fluid overload."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 14 Fluid overload.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">15 Fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00415"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-15.png?filename=nCD011798-CMP-004-15.ppt&amp;title=4.15&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%2015%20Fracture.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.15</div> </div> <hr class="top"><img data-id="CD011798-fig-00415" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-15.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 15 Fracture."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 15 Fracture.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">16 Gastrointestinal disorders <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00416"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-16.png?filename=nCD011798-CMP-004-16.ppt&amp;title=4.16&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%2016%20Gastrointestinal%20disorders.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.16</div> </div> <hr class="top"><img data-id="CD011798-fig-00416" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-16.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 16 Gastrointestinal disorders."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 16 Gastrointestinal disorders.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">17 Liver impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00417"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-17.png?filename=nCD011798-CMP-004-17.ppt&amp;title=4.17&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%2017%20Liver%20impairment.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.17</div> </div> <hr class="top"><img data-id="CD011798-fig-00417" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-17.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 17 Liver impairment."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 17 Liver impairment.</p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD011798-tbl-0010"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 5.</span>&nbsp;<span class="table-title">Glinides versus placebo/control</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00501"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-005-01.png?filename=nCD011798-CMP-005-01.ppt&amp;title=5.1&amp;caption=Comparison%205%20Glinides%20versus%20placebo%2Fcontrol%2C%20Outcome%201%20Hypoglycaemia.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 5.1</div> </div> <hr class="top"><img data-id="CD011798-fig-00501" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-005-01.png" alt="Comparison 5 Glinides versus placebo/control, Outcome 1 Hypoglycaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 5 Glinides versus placebo/control, Outcome 1 Hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Hypoglycaemia requiring third party assistance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00502"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-005-02.png?filename=nCD011798-CMP-005-02.ppt&amp;title=5.2&amp;caption=Comparison%205%20Glinides%20versus%20placebo%2Fcontrol%2C%20Outcome%202%20Hypoglycaemia%20requiring%20third%20party%20assistance.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 5.2</div> </div> <hr class="top"><img data-id="CD011798-fig-00502" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-005-02.png" alt="Comparison 5 Glinides versus placebo/control, Outcome 2 Hypoglycaemia requiring third party assistance."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 5 Glinides versus placebo/control, Outcome 2 Hypoglycaemia requiring third party assistance. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Peripheral oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00503"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-005-03.png?filename=nCD011798-CMP-005-03.ppt&amp;title=5.3&amp;caption=Comparison%205%20Glinides%20versus%20placebo%2Fcontrol%2C%20Outcome%203%20Peripheral%20oedema.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 5.3</div> </div> <hr class="top"><img data-id="CD011798-fig-00503" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-005-03.png" alt="Comparison 5 Glinides versus placebo/control, Outcome 3 Peripheral oedema."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 5 Glinides versus placebo/control, Outcome 3 Peripheral oedema.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Liver impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00504"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-005-04.png?filename=nCD011798-CMP-005-04.ppt&amp;title=5.4&amp;caption=Comparison%205%20Glinides%20versus%20placebo%2Fcontrol%2C%20Outcome%204%20Liver%20impairment.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 5.4</div> </div> <hr class="top"><img data-id="CD011798-fig-00504" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-005-04.png" alt="Comparison 5 Glinides versus placebo/control, Outcome 4 Liver impairment."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 5 Glinides versus placebo/control, Outcome 4 Liver impairment.</p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD011798-tbl-0011"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 6.</span>&nbsp;<span class="table-title">Sitagliptin versus glipizide</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>398</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.05 [‐0.39, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00601"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-01.png?filename=nCD011798-CMP-006-01.ppt&amp;title=6.1&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%201%20HbA1c.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.1</div> </div> <hr class="top"><img data-id="CD011798-fig-00601" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-01.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 1 HbA1c."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 1 HbA1c.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>397</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.36 [‐0.10, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00602"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-02.png?filename=nCD011798-CMP-006-02.ppt&amp;title=6.2&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%202%20Fasting%20blood%20glucose.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.2</div> </div> <hr class="top"><img data-id="CD011798-fig-00602" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-02.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 2 Fasting blood glucose."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 2 Fasting blood glucose.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>551</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.55 [0.22, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00603"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-03.png?filename=nCD011798-CMP-006-03.ppt&amp;title=6.3&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%203%20Death%20%28all%20causes%29.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.3</div> </div> <hr class="top"><img data-id="CD011798-fig-00603" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-03.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 3 Death (all causes)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 3 Death (all causes).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00604"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-04.png?filename=nCD011798-CMP-006-04.ppt&amp;title=6.4&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%204%20Myocardial%20infarction.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.4</div> </div> <hr class="top"><img data-id="CD011798-fig-00604" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-04.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 4 Myocardial infarction."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 4 Myocardial infarction.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00605"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-05.png?filename=nCD011798-CMP-006-05.ppt&amp;title=6.5&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%205%20Stroke.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.5</div> </div> <hr class="top"><img data-id="CD011798-fig-00605" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-05.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 5 Stroke."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 5 Stroke.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Total cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00606"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-06.png?filename=nCD011798-CMP-006-06.ppt&amp;title=6.6&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%206%20Total%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.6</div> </div> <hr class="top"><img data-id="CD011798-fig-00606" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-06.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 6 Total cholesterol."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 6 Total cholesterol.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 HDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00607"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-07.png?filename=nCD011798-CMP-006-07.ppt&amp;title=6.7&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%207%20HDL%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.7</div> </div> <hr class="top"><img data-id="CD011798-fig-00607" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-07.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 7 HDL cholesterol."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 7 HDL cholesterol.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 LDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00608"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-08.png?filename=nCD011798-CMP-006-08.ppt&amp;title=6.8&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%208%20LDL%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.8</div> </div> <hr class="top"><img data-id="CD011798-fig-00608" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-08.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 8 LDL cholesterol."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 8 LDL cholesterol.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Triglyceride <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00609"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-09.png?filename=nCD011798-CMP-006-09.ppt&amp;title=6.9&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%209%20Triglyceride.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.9</div> </div> <hr class="top"><img data-id="CD011798-fig-00609" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-09.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 9 Triglyceride."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 9 Triglyceride.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>551</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.40 [0.23, 0.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00610"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-10.png?filename=nCD011798-CMP-006-10.ppt&amp;title=6.10&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2010%20Hypoglycaemia.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.10</div> </div> <hr class="top"><img data-id="CD011798-fig-00610" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-10.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 10 Hypoglycaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 10 Hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Discontinuation of medication due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>551</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.93 [0.54, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00611"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-11.png?filename=nCD011798-CMP-006-11.ppt&amp;title=6.11&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2011%20Discontinuation%20of%20medication%20due%20to%20adverse%20events.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.11</div> </div> <hr class="top"><img data-id="CD011798-fig-00611" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-11.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 11 Discontinuation of medication due to adverse events."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 11 Discontinuation of medication due to adverse events. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 Hypoglycaemia requiring third party assistance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>551</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.35 [0.09, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00612"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-12.png?filename=nCD011798-CMP-006-12.ppt&amp;title=6.12&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2012%20Hypoglycaemia%20requiring%20third%20party%20assistance.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.12</div> </div> <hr class="top"><img data-id="CD011798-fig-00612" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-12.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 12 Hypoglycaemia requiring third party assistance."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 12 Hypoglycaemia requiring third party assistance. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 Peripheral oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>551</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.71 [0.11, 4.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00613"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-13.png?filename=nCD011798-CMP-006-13.ppt&amp;title=6.13&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2013%20Peripheral%20oedema.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.13</div> </div> <hr class="top"><img data-id="CD011798-fig-00613" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-13.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 13 Peripheral oedema."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 13 Peripheral oedema.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">14 Fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00614"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-14.png?filename=nCD011798-CMP-006-14.ppt&amp;title=6.14&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2014%20Fracture.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.14</div> </div> <hr class="top"><img data-id="CD011798-fig-00614" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-14.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 14 Fracture."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 14 Fracture.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">15 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00615"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-15.png?filename=nCD011798-CMP-006-15.ppt&amp;title=6.15&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2015%20Vomiting.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.15</div> </div> <hr class="top"><img data-id="CD011798-fig-00615" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-15.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 15 Vomiting."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 15 Vomiting.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">16 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>551</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.79 [0.39, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00616"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-16.png?filename=nCD011798-CMP-006-16.ppt&amp;title=6.16&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2016%20Diarrhoea.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.16</div> </div> <hr class="top"><img data-id="CD011798-fig-00616" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-16.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 16 Diarrhoea."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 16 Diarrhoea.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">17 Malignancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00617"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-17.png?filename=nCD011798-CMP-006-17.ppt&amp;title=6.17&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2017%20Malignancy.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.17</div> </div> <hr class="top"><img data-id="CD011798-fig-00617" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-17.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 17 Malignancy."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 17 Malignancy.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">18 Pancreatic cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00618"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-18.png?filename=nCD011798-CMP-006-18.ppt&amp;title=6.18&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2018%20Pancreatic%20cancer.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.18</div> </div> <hr class="top"><img data-id="CD011798-fig-00618" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-18.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 18 Pancreatic cancer."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 18 Pancreatic cancer.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">19 Upper respiratory tract infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>551</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.60 [0.31, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00619"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-19.png?filename=nCD011798-CMP-006-19.ppt&amp;title=6.19&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2019%20Upper%20respiratory%20tract%20infection.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.19</div> </div> <hr class="top"><img data-id="CD011798-fig-00619" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-19.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 19 Upper respiratory tract infection."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 19 Upper respiratory tract infection.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">20 Urinary tract infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>551</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.29 [0.24, 6.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00620"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-20.png?filename=nCD011798-CMP-006-20.ppt&amp;title=6.20&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2020%20Urinary%20tract%20infection.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.20</div> </div> <hr class="top"><img data-id="CD011798-fig-00620" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-20.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 20 Urinary tract infection."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 20 Urinary tract infection.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">21 Cellulitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00621"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-21.png?filename=nCD011798-CMP-006-21.ppt&amp;title=6.21&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2021%20Cellulitis.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.21</div> </div> <hr class="top"><img data-id="CD011798-fig-00621" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-21.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 21 Cellulitis."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 21 Cellulitis.</p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD011798-tbl-0012"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 7.</span>&nbsp;<span class="table-title">Vildagliptin versus sitagliptin</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00701"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-007-01.png?filename=nCD011798-CMP-007-01.ppt&amp;title=7.1&amp;caption=Comparison%207%20Vildagliptin%20versus%20sitagliptin%2C%20Outcome%201%20HbA1c.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 7.1</div> </div> <hr class="top"><img data-id="CD011798-fig-00701" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-01.png" alt="Comparison 7 Vildagliptin versus sitagliptin, Outcome 1 HbA1c."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 7 Vildagliptin versus sitagliptin, Outcome 1 HbA1c.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00702"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-007-02.png?filename=nCD011798-CMP-007-02.ppt&amp;title=7.2&amp;caption=Comparison%207%20Vildagliptin%20versus%20sitagliptin%2C%20Outcome%202%20Fasting%20blood%20glucose.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 7.2</div> </div> <hr class="top"><img data-id="CD011798-fig-00702" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-02.png" alt="Comparison 7 Vildagliptin versus sitagliptin, Outcome 2 Fasting blood glucose."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 7 Vildagliptin versus sitagliptin, Outcome 2 Fasting blood glucose.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00703"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-007-03.png?filename=nCD011798-CMP-007-03.ppt&amp;title=7.3&amp;caption=Comparison%207%20Vildagliptin%20versus%20sitagliptin%2C%20Outcome%203%20Death%20%28all%20causes%29.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 7.3</div> </div> <hr class="top"><img data-id="CD011798-fig-00703" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-03.png" alt="Comparison 7 Vildagliptin versus sitagliptin, Outcome 3 Death (all causes)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 7 Vildagliptin versus sitagliptin, Outcome 3 Death (all causes).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00704"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-007-04.png?filename=nCD011798-CMP-007-04.ppt&amp;title=7.4&amp;caption=Comparison%207%20Vildagliptin%20versus%20sitagliptin%2C%20Outcome%204%20Hypoglycaemia.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 7.4</div> </div> <hr class="top"><img data-id="CD011798-fig-00704" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-04.png" alt="Comparison 7 Vildagliptin versus sitagliptin, Outcome 4 Hypoglycaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 7 Vildagliptin versus sitagliptin, Outcome 4 Hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Discontinuation of medication due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00705"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-007-05.png?filename=nCD011798-CMP-007-05.ppt&amp;title=7.5&amp;caption=Comparison%207%20Vildagliptin%20versus%20sitagliptin%2C%20Outcome%205%20Discontinuation%20of%20medication%20due%20to%20adverse%20events.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 7.5</div> </div> <hr class="top"><img data-id="CD011798-fig-00705" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-05.png" alt="Comparison 7 Vildagliptin versus sitagliptin, Outcome 5 Discontinuation of medication due to adverse events."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 7 Vildagliptin versus sitagliptin, Outcome 5 Discontinuation of medication due to adverse events. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Peripheral oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00706"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-007-06.png?filename=nCD011798-CMP-007-06.ppt&amp;title=7.6&amp;caption=Comparison%207%20Vildagliptin%20versus%20sitagliptin%2C%20Outcome%206%20Peripheral%20oedema.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 7.6</div> </div> <hr class="top"><img data-id="CD011798-fig-00706" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-06.png" alt="Comparison 7 Vildagliptin versus sitagliptin, Outcome 6 Peripheral oedema."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 7 Vildagliptin versus sitagliptin, Outcome 6 Peripheral oedema.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Pancreatitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00707"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-007-07.png?filename=nCD011798-CMP-007-07.ppt&amp;title=7.7&amp;caption=Comparison%207%20Vildagliptin%20versus%20sitagliptin%2C%20Outcome%207%20Pancreatitis.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 7.7</div> </div> <hr class="top"><img data-id="CD011798-fig-00707" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-07.png" alt="Comparison 7 Vildagliptin versus sitagliptin, Outcome 7 Pancreatitis."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 7 Vildagliptin versus sitagliptin, Outcome 7 Pancreatitis.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Liver impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00708"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-007-08.png?filename=nCD011798-CMP-007-08.ppt&amp;title=7.8&amp;caption=Comparison%207%20Vildagliptin%20versus%20sitagliptin%2C%20Outcome%208%20Liver%20impairment.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 7.8</div> </div> <hr class="top"><img data-id="CD011798-fig-00708" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-08.png" alt="Comparison 7 Vildagliptin versus sitagliptin, Outcome 8 Liver impairment."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 7 Vildagliptin versus sitagliptin, Outcome 8 Liver impairment.</p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD011798-tbl-0013"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 8.</span>&nbsp;<span class="table-title">Albiglutide versus sitagliptin</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00801"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-008-01.png?filename=nCD011798-CMP-008-01.ppt&amp;title=8.1&amp;caption=Comparison%208%20Albiglutide%20versus%20sitagliptin%2C%20Outcome%201%20HbA1c.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 8.1</div> </div> <hr class="top"><img data-id="CD011798-fig-00801" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-008-01.png" alt="Comparison 8 Albiglutide versus sitagliptin, Outcome 1 HbA1c."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 8 Albiglutide versus sitagliptin, Outcome 1 HbA1c.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00802"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-008-02.png?filename=nCD011798-CMP-008-02.ppt&amp;title=8.2&amp;caption=Comparison%208%20Albiglutide%20versus%20sitagliptin%2C%20Outcome%202%20Fasting%20blood%20glucose.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 8.2</div> </div> <hr class="top"><img data-id="CD011798-fig-00802" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-008-02.png" alt="Comparison 8 Albiglutide versus sitagliptin, Outcome 2 Fasting blood glucose."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 8 Albiglutide versus sitagliptin, Outcome 2 Fasting blood glucose.</p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD011798-tbl-0014"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 9.</span>&nbsp;<span class="table-title">Aleglitazar versus pioglitazone</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00901"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-01.png?filename=nCD011798-CMP-009-01.ppt&amp;title=9.1&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%201%20HbA1c.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 9.1</div> </div> <hr class="top"><img data-id="CD011798-fig-00901" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-01.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 1 HbA1c."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 1 HbA1c.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00902"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-02.png?filename=nCD011798-CMP-009-02.ppt&amp;title=9.2&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%202%20Fasting%20blood%20glucose.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 9.2</div> </div> <hr class="top"><img data-id="CD011798-fig-00902" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-02.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 2 Fasting blood glucose."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 2 Fasting blood glucose.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00903"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-03.png?filename=nCD011798-CMP-009-03.ppt&amp;title=9.3&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%203%20Heart%20failure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 9.3</div> </div> <hr class="top"><img data-id="CD011798-fig-00903" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-03.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 3 Heart failure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 3 Heart failure.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00904"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-04.png?filename=nCD011798-CMP-009-04.ppt&amp;title=9.4&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%204%20Death%20%28all%20causes%29.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 9.4</div> </div> <hr class="top"><img data-id="CD011798-fig-00904" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-04.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 4 Death (all causes)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 4 Death (all causes).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 All cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00905"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-05.png?filename=nCD011798-CMP-009-05.ppt&amp;title=9.5&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%205%20All%20cardiovascular%20death.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 9.5</div> </div> <hr class="top"><img data-id="CD011798-fig-00905" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-05.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 5 All cardiovascular death."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 5 All cardiovascular death.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00906"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-06.png?filename=nCD011798-CMP-009-06.ppt&amp;title=9.6&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%206%20Myocardial%20infarction.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 9.6</div> </div> <hr class="top"><img data-id="CD011798-fig-00906" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-06.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 6 Myocardial infarction."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 6 Myocardial infarction.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00907"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-07.png?filename=nCD011798-CMP-009-07.ppt&amp;title=9.7&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%207%20Stroke.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 9.7</div> </div> <hr class="top"><img data-id="CD011798-fig-00907" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-07.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 7 Stroke."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 7 Stroke.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00908"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-08.png?filename=nCD011798-CMP-009-08.ppt&amp;title=9.8&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%208%20Weight.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 9.8</div> </div> <hr class="top"><img data-id="CD011798-fig-00908" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-08.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 8 Weight."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 8 Weight.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 eGFR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00909"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-09.png?filename=nCD011798-CMP-009-09.ppt&amp;title=9.9&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%209%20eGFR.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 9.9</div> </div> <hr class="top"><img data-id="CD011798-fig-00909" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-09.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 9 eGFR."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 9 eGFR.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00910"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-10.png?filename=nCD011798-CMP-009-10.ppt&amp;title=9.10&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%2010%20Systolic%20blood%20pressure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 9.10</div> </div> <hr class="top"><img data-id="CD011798-fig-00910" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-10.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 10 Systolic blood pressure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 10 Systolic blood pressure.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Diastolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00911"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-11.png?filename=nCD011798-CMP-009-11.ppt&amp;title=9.11&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%2011%20Diastolic%20blood%20pressure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 9.11</div> </div> <hr class="top"><img data-id="CD011798-fig-00911" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-11.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 11 Diastolic blood pressure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 11 Diastolic blood pressure.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 Serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00912"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-12.png?filename=nCD011798-CMP-009-12.ppt&amp;title=9.12&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%2012%20Serum%20creatinine.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 9.12</div> </div> <hr class="top"><img data-id="CD011798-fig-00912" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-12.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 12 Serum creatinine."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 12 Serum creatinine.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00913"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-13.png?filename=nCD011798-CMP-009-13.ppt&amp;title=9.13&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%2013%20Hypoglycaemia.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 9.13</div> </div> <hr class="top"><img data-id="CD011798-fig-00913" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-13.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 13 Hypoglycaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 13 Hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">14 Hypoglycaemia requiring third party assistance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00914"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-14.png?filename=nCD011798-CMP-009-14.ppt&amp;title=9.14&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%2014%20Hypoglycaemia%20requiring%20third%20party%20assistance.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 9.14</div> </div> <hr class="top"><img data-id="CD011798-fig-00914" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-14.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 14 Hypoglycaemia requiring third party assistance."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 14 Hypoglycaemia requiring third party assistance. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">15 Peripheral oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00915"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-15.png?filename=nCD011798-CMP-009-15.ppt&amp;title=9.15&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%2015%20Peripheral%20oedema.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 9.15</div> </div> <hr class="top"><img data-id="CD011798-fig-00915" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-15.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 15 Peripheral oedema."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 15 Peripheral oedema.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">16 Fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00916"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-16.png?filename=nCD011798-CMP-009-16.ppt&amp;title=9.16&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%2016%20Fracture.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 9.16</div> </div> <hr class="top"><img data-id="CD011798-fig-00916" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-16.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 16 Fracture."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 16 Fracture.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">17 Malignancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-00917"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-17.png?filename=nCD011798-CMP-009-17.ppt&amp;title=9.17&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%2017%20Malignancy.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 9.17</div> </div> <hr class="top"><img data-id="CD011798-fig-00917" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-17.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 17 Malignancy."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 17 Malignancy.</p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD011798-tbl-0015"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 10.</span>&nbsp;<span class="table-title">Insulin glulisine and glargine 0.5 versus 0.25 U/kg/d</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Hypoglycaemia &lt; 3.89 mmol/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-01001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-010-01.png?filename=nCD011798-CMP-010-01.ppt&amp;title=10.1&amp;caption=Comparison%2010%20Insulin%20glulisine%20and%20glargine%200.5%20versus%200.25%20U%2Fkg%2Fd%2C%20Outcome%201%20Hypoglycaemia%20%3C%203.89%20mmol%2FL.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 10.1</div> </div> <hr class="top"><img data-id="CD011798-fig-01001" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-010-01.png" alt="Comparison 10 Insulin glulisine and glargine 0.5 versus 0.25 U/kg/d, Outcome 1 Hypoglycaemia < 3.89 mmol/L."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 10 Insulin glulisine and glargine 0.5 versus 0.25 U/kg/d, Outcome 1 Hypoglycaemia &lt; 3.89 mmol/L. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Hypoglycaemia &lt; 2.78 mmol/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011798-fig-01002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-010-02.png?filename=nCD011798-CMP-010-02.ppt&amp;title=10.2&amp;caption=Comparison%2010%20Insulin%20glulisine%20and%20glargine%200.5%20versus%200.25%20U%2Fkg%2Fd%2C%20Outcome%202%20Hypoglycaemia%20%3C%202.78%20mmol%2FL.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 10.2</div> </div> <hr class="top"><img data-id="CD011798-fig-01002" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-010-02.png" alt="Comparison 10 Insulin glulisine and glargine 0.5 versus 0.25 U/kg/d, Outcome 2 Hypoglycaemia < 2.78 mmol/L."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 10 Insulin glulisine and glargine 0.5 versus 0.25 U/kg/d, Outcome 2 Hypoglycaemia &lt; 2.78 mmol/L. </p> </div> </div> </div> </td> </tr> </tbody> </table> </div> </section> </section> <div class="figures-list"> <div class="figure" id="CD011798-fig-0001"> <img data-id="CD011798-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-AFig-FIG01.png" alt="Study flow diagram."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p> Study flow diagram.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/full#CD011798-fig-0001" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-AFig-FIG01.png?filename=nCD011798-AFig-FIG01.ppt&amp;title=1&amp;caption=Study%20flow%20diagram.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-AFig-FIG01.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-0002"><img data-id="CD011798-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-AFig-FIG02.png" alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/full#CD011798-fig-0002" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-AFig-FIG02.png?filename=nCD011798-AFig-FIG02.ppt&amp;title=2&amp;caption=Risk%20of%20bias%20graph%3A%20review%20authors%27%20judgements%20about%20each%20risk%20of%20bias%20item%20presented%20as%20percentages%20across%20all%20included%20studies.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-AFig-FIG02.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-0003"><img data-id="CD011798-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-AFig-FIG03.png" alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/full#CD011798-fig-0003" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-AFig-FIG03.png?filename=nCD011798-AFig-FIG03.ppt&amp;title=3&amp;caption=Risk%20of%20bias%20summary%3A%20review%20authors%27%20judgements%20about%20each%20risk%20of%20bias%20item%20for%20each%20included%20study.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-AFig-FIG03.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00101"><img data-id="CD011798-fig-00101" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-01.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 1 HbA1c."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 1 HbA1c.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00101" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-01.png?filename=nCD011798-CMP-001-01.ppt&amp;title=1.1&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%201%20HbA1c.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00102"><img data-id="CD011798-fig-00102" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-02.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 2 Fasting blood glucose."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 2 Fasting blood glucose.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00102" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-02.png?filename=nCD011798-CMP-001-02.ppt&amp;title=1.2&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%202%20Fasting%20blood%20glucose.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00103"><img data-id="CD011798-fig-00103" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-03.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 3 Death (all causes)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 3 Death (all causes).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00103" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-03.png?filename=nCD011798-CMP-001-03.ppt&amp;title=1.3&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%203%20Death%20%28all%20causes%29.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00104"><img data-id="CD011798-fig-00104" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-04.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 4 All cardiovascular death."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 4 All cardiovascular death.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00104" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-04.png?filename=nCD011798-CMP-001-04.ppt&amp;title=1.4&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%204%20All%20cardiovascular%20death.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00105"><img data-id="CD011798-fig-00105" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-05.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 5 Myocardial infarction."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 5 Myocardial infarction.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00105" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-05.png?filename=nCD011798-CMP-001-05.ppt&amp;title=1.5&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%205%20Myocardial%20infarction.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-05.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00106"><img data-id="CD011798-fig-00106" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-06.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 6 Stroke."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 6 Stroke.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00106" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-06.png?filename=nCD011798-CMP-001-06.ppt&amp;title=1.6&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%206%20Stroke.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-06.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00107"><img data-id="CD011798-fig-00107" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-07.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 7 Heart failure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 7 Heart failure.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00107" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-07.png?filename=nCD011798-CMP-001-07.ppt&amp;title=1.7&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%207%20Heart%20failure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-07.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00108"><img data-id="CD011798-fig-00108" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-08.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 8 Weight."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 8 Weight.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00108" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-08.png?filename=nCD011798-CMP-001-08.ppt&amp;title=1.8&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%208%20Weight.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-08.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00109"><img data-id="CD011798-fig-00109" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-09.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 9 eGFR [mL/min/1.73 m2]."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 9 eGFR [mL/min/1.73 m<sup>2</sup>]. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00109" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-09.png?filename=nCD011798-CMP-001-09.ppt&amp;title=1.9&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%209%20eGFR%20%5BmL%2Fmin%2F1.73%20m2%5D.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-09.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00110"><img data-id="CD011798-fig-00110" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-10.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 10 Systolic blood pressure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 10 Systolic blood pressure.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00110" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-10.png?filename=nCD011798-CMP-001-10.ppt&amp;title=1.10&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2010%20Systolic%20blood%20pressure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-10.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00111"><img data-id="CD011798-fig-00111" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-11.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 11 Diastolic blood pressure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 11 Diastolic blood pressure.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00111" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-11.png?filename=nCD011798-CMP-001-11.ppt&amp;title=1.11&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2011%20Diastolic%20blood%20pressure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-11.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00112"><img data-id="CD011798-fig-00112" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-12.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 12 Serum creatinine."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 12 Serum creatinine.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00112" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-12.png?filename=nCD011798-CMP-001-12.ppt&amp;title=1.12&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2012%20Serum%20creatinine.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-12.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00113"><img data-id="CD011798-fig-00113" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-13.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 13 Urinary albumin/creatinine ratio."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 13 Urinary albumin/creatinine ratio. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00113" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-13.png?filename=nCD011798-CMP-001-13.ppt&amp;title=1.13&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2013%20Urinary%20albumin%2Fcreatinine%20ratio.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-13.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00114"><img data-id="CD011798-fig-00114" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-14.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 14 Serum potassium."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 14 Serum potassium.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00114" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-14.png?filename=nCD011798-CMP-001-14.ppt&amp;title=1.14&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2014%20Serum%20potassium.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-14.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00115"><img data-id="CD011798-fig-00115" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-15.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 15 Total cholesterol."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 15 Total cholesterol.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00115" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-15.png?filename=nCD011798-CMP-001-15.ppt&amp;title=1.15&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2015%20Total%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-15.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00116"><img data-id="CD011798-fig-00116" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-16.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 16 HDL cholesterol."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 16 HDL cholesterol.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00116" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-16.png?filename=nCD011798-CMP-001-16.ppt&amp;title=1.16&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2016%20HDL%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-16.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00117"><img data-id="CD011798-fig-00117" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-17.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 17 LDL cholesterol."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 17 LDL cholesterol.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00117" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-17.png?filename=nCD011798-CMP-001-17.ppt&amp;title=1.17&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2017%20LDL%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-17.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00118"><img data-id="CD011798-fig-00118" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-18.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 18 Triglyceride."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 18 Triglyceride.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00118" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-18.png?filename=nCD011798-CMP-001-18.ppt&amp;title=1.18&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2018%20Triglyceride.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-18.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00119"><img data-id="CD011798-fig-00119" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-19.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 19 Hypoglycaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 19 Hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00119" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-19.png?filename=nCD011798-CMP-001-19.ppt&amp;title=1.19&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2019%20Hypoglycaemia.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-19.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00120"><img data-id="CD011798-fig-00120" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-20.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 20 Discontinuation of medication due to adverse events."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 20 Discontinuation of medication due to adverse events. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00120" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-20.png?filename=nCD011798-CMP-001-20.ppt&amp;title=1.20&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2020%20Discontinuation%20of%20medication%20due%20to%20adverse%20events.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-20.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00121"><img data-id="CD011798-fig-00121" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-21.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 21 End‐stage kidney disease."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 21 End‐stage kidney disease.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00121" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-21.png?filename=nCD011798-CMP-001-21.ppt&amp;title=1.21&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2021%20End%E2%80%90stage%20kidney%20disease.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-21.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00122"><img data-id="CD011798-fig-00122" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-22.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 22 Hyperkalaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 22 Hyperkalaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00122" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-22.png?filename=nCD011798-CMP-001-22.ppt&amp;title=1.22&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2022%20Hyperkalaemia.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-22.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00123"><img data-id="CD011798-fig-00123" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-23.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 23 Hypoglycaemia requiring third party assistance."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 23 Hypoglycaemia requiring third party assistance. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00123" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-23.png?filename=nCD011798-CMP-001-23.ppt&amp;title=1.23&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2023%20Hypoglycaemia%20requiring%20third%20party%20assistance.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-23.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00124"><img data-id="CD011798-fig-00124" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-24.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 24 Hypovolaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 24 Hypovolaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00124" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-24.png?filename=nCD011798-CMP-001-24.ppt&amp;title=1.24&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2024%20Hypovolaemia.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-24.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00125"><img data-id="CD011798-fig-00125" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-25.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 25 Fracture."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 25 Fracture.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00125" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-25.png?filename=nCD011798-CMP-001-25.ppt&amp;title=1.25&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2025%20Fracture.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-25.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00126"><img data-id="CD011798-fig-00126" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-26.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 26 Diarrhoea."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 26 Diarrhoea.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00126" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-26.png?filename=nCD011798-CMP-001-26.ppt&amp;title=1.26&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2026%20Diarrhoea.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-26.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00127"><img data-id="CD011798-fig-00127" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-27.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 27 Diabetic ketoacidosis."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 27 Diabetic ketoacidosis.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00127" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-27.png?filename=nCD011798-CMP-001-27.ppt&amp;title=1.27&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2027%20Diabetic%20ketoacidosis.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-27.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00128"><img data-id="CD011798-fig-00128" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-28.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 28 Upper respiratory tract infection."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 28 Upper respiratory tract infection.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00128" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-28.png?filename=nCD011798-CMP-001-28.ppt&amp;title=1.28&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2028%20Upper%20respiratory%20tract%20infection.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-28.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00129"><img data-id="CD011798-fig-00129" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-29.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 29 Urinary tract infection."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 29 Urinary tract infection.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00129" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-29.png?filename=nCD011798-CMP-001-29.ppt&amp;title=1.29&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2029%20Urinary%20tract%20infection.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-29.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00130"><img data-id="CD011798-fig-00130" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-30.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 30 Genital infection."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 30 Genital infection.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00130" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-30.png?filename=nCD011798-CMP-001-30.ppt&amp;title=1.30&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2030%20Genital%20infection.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-30.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00131"><img data-id="CD011798-fig-00131" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-31.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 31 Acute kidney injury."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 31 Acute kidney injury.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00131" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-31.png?filename=nCD011798-CMP-001-31.ppt&amp;title=1.31&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2031%20Acute%20kidney%20injury.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-31.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00132"><img data-id="CD011798-fig-00132" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-32.png" alt="Comparison 1 SGLT2 inhibitors versus placebo, Outcome 32 Doubling of serum creatinine."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1 SGLT2 inhibitors versus placebo, Outcome 32 Doubling of serum creatinine.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00132" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-001-32.png?filename=nCD011798-CMP-001-32.ppt&amp;title=1.32&amp;caption=Comparison%201%20SGLT2%20inhibitors%20versus%20placebo%2C%20Outcome%2032%20Doubling%20of%20serum%20creatinine.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-001-32.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00201"><img data-id="CD011798-fig-00201" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-01.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 1 HbA1c."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 1 HbA1c.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00201" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-01.png?filename=nCD011798-CMP-002-01.ppt&amp;title=2.1&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%201%20HbA1c.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00202"><img data-id="CD011798-fig-00202" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-02.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 2 Fasting blood glucose."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 2 Fasting blood glucose.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00202" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-02.png?filename=nCD011798-CMP-002-02.ppt&amp;title=2.2&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%202%20Fasting%20blood%20glucose.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00203"><img data-id="CD011798-fig-00203" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-03.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 3 Death (all causes)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 3 Death (all causes).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00203" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-03.png?filename=nCD011798-CMP-002-03.ppt&amp;title=2.3&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%203%20Death%20%28all%20causes%29.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00204"><img data-id="CD011798-fig-00204" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-04.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 4 All cardiovascular death."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 4 All cardiovascular death.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00204" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-04.png?filename=nCD011798-CMP-002-04.ppt&amp;title=2.4&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%204%20All%20cardiovascular%20death.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00205"><img data-id="CD011798-fig-00205" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-05.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 5 Myocardial infarction."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 5 Myocardial infarction.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00205" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-05.png?filename=nCD011798-CMP-002-05.ppt&amp;title=2.5&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%205%20Myocardial%20infarction.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-05.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00206"><img data-id="CD011798-fig-00206" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-06.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 6 Stroke."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 6 Stroke.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00206" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-06.png?filename=nCD011798-CMP-002-06.ppt&amp;title=2.6&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%206%20Stroke.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-06.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00207"><img data-id="CD011798-fig-00207" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-07.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 7 Heart failure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 7 Heart failure.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00207" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-07.png?filename=nCD011798-CMP-002-07.ppt&amp;title=2.7&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%207%20Heart%20failure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-07.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00208"><img data-id="CD011798-fig-00208" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-08.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 8 Weight."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 8 Weight.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00208" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-08.png?filename=nCD011798-CMP-002-08.ppt&amp;title=2.8&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%208%20Weight.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-08.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00209"><img data-id="CD011798-fig-00209" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-09.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 9 eGFR [mL/min/1.73 m2]."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 9 eGFR [mL/min/1.73 m<sup>2</sup>]. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00209" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-09.png?filename=nCD011798-CMP-002-09.ppt&amp;title=2.9&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%209%20eGFR%20%5BmL%2Fmin%2F1.73%20m2%5D.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-09.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00210"><img data-id="CD011798-fig-00210" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-10.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 10 Serum creatinine."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 10 Serum creatinine.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00210" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-10.png?filename=nCD011798-CMP-002-10.ppt&amp;title=2.10&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2010%20Serum%20creatinine.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-10.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00211"><img data-id="CD011798-fig-00211" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-11.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 11 Urinary albumin/creatinine ratio."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 11 Urinary albumin/creatinine ratio. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00211" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-11.png?filename=nCD011798-CMP-002-11.ppt&amp;title=2.11&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2011%20Urinary%20albumin%2Fcreatinine%20ratio.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-11.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00212"><img data-id="CD011798-fig-00212" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-12.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 12 Total cholesterol."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 12 Total cholesterol.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00212" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-12.png?filename=nCD011798-CMP-002-12.ppt&amp;title=2.12&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2012%20Total%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-12.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00213"><img data-id="CD011798-fig-00213" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-13.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 13 LDL cholesterol."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 13 LDL cholesterol.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00213" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-13.png?filename=nCD011798-CMP-002-13.ppt&amp;title=2.13&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2013%20LDL%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-13.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00214"><img data-id="CD011798-fig-00214" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-14.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 14 Hypoglycaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 14 Hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00214" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-14.png?filename=nCD011798-CMP-002-14.ppt&amp;title=2.14&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2014%20Hypoglycaemia.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-14.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00215"><img data-id="CD011798-fig-00215" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-15.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 15 Discontinuation of medication due to adverse events."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 15 Discontinuation of medication due to adverse events. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00215" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-15.png?filename=nCD011798-CMP-002-15.ppt&amp;title=2.15&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2015%20Discontinuation%20of%20medication%20due%20to%20adverse%20events.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-15.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00216"><img data-id="CD011798-fig-00216" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-16.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 16 Hyperkalaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 16 Hyperkalaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00216" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-16.png?filename=nCD011798-CMP-002-16.ppt&amp;title=2.16&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2016%20Hyperkalaemia.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-16.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00217"><img data-id="CD011798-fig-00217" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-17.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 17 Hypoglycaemia requiring third party assistance."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 17 Hypoglycaemia requiring third party assistance. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00217" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-17.png?filename=nCD011798-CMP-002-17.ppt&amp;title=2.17&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2017%20Hypoglycaemia%20requiring%20third%20party%20assistance.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-17.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00218"><img data-id="CD011798-fig-00218" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-18.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 18 New or worsening retinopathy."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 18 New or worsening retinopathy.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00218" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-18.png?filename=nCD011798-CMP-002-18.ppt&amp;title=2.18&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2018%20New%20or%20worsening%20retinopathy.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-18.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00219"><img data-id="CD011798-fig-00219" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-19.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 19 Peripheral oedema."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 19 Peripheral oedema.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00219" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-19.png?filename=nCD011798-CMP-002-19.ppt&amp;title=2.19&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2019%20Peripheral%20oedema.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-19.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00220"><img data-id="CD011798-fig-00220" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-20.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 20 Diarrhoea."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 20 Diarrhoea.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00220" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-20.png?filename=nCD011798-CMP-002-20.ppt&amp;title=2.20&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2020%20Diarrhoea.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-20.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00221"><img data-id="CD011798-fig-00221" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-21.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 21 Constipation."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 21 Constipation.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00221" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-21.png?filename=nCD011798-CMP-002-21.ppt&amp;title=2.21&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2021%20Constipation.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-21.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00222"><img data-id="CD011798-fig-00222" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-22.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 22 Malignancy."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 22 Malignancy.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00222" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-22.png?filename=nCD011798-CMP-002-22.ppt&amp;title=2.22&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2022%20Malignancy.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-22.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00223"><img data-id="CD011798-fig-00223" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-23.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 23 Pancreatic cancer."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 23 Pancreatic cancer.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00223" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-23.png?filename=nCD011798-CMP-002-23.ppt&amp;title=2.23&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2023%20Pancreatic%20cancer.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-23.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00224"><img data-id="CD011798-fig-00224" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-24.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 24 Pancreatitis."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 24 Pancreatitis.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00224" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-24.png?filename=nCD011798-CMP-002-24.ppt&amp;title=2.24&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2024%20Pancreatitis.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-24.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00225"><img data-id="CD011798-fig-00225" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-25.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 25 Liver impairment."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.25</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 25 Liver impairment.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00225" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-25.png?filename=nCD011798-CMP-002-25.ppt&amp;title=2.25&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2025%20Liver%20impairment.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-25.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00226"><img data-id="CD011798-fig-00226" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-26.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 26 Upper respiratory tract infection."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.26</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 26 Upper respiratory tract infection.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00226" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-26.png?filename=nCD011798-CMP-002-26.ppt&amp;title=2.26&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2026%20Upper%20respiratory%20tract%20infection.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-26.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00227"><img data-id="CD011798-fig-00227" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-27.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 27 Cellulitis."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.27</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 27 Cellulitis.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00227" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-27.png?filename=nCD011798-CMP-002-27.ppt&amp;title=2.27&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2027%20Cellulitis.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-27.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00228"><img data-id="CD011798-fig-00228" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-28.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 28 Urinary tract infection."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.28</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 28 Urinary tract infection.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00228" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-28.png?filename=nCD011798-CMP-002-28.ppt&amp;title=2.28&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2028%20Urinary%20tract%20infection.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-28.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00229"><img data-id="CD011798-fig-00229" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-29.png" alt="Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 29 Acute kidney injury."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.29</div> <div class="figure-caption"> <p>Comparison 2 DPP‐4 inhibitors versus placebo, Outcome 29 Acute kidney injury.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00229" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-002-29.png?filename=nCD011798-CMP-002-29.ppt&amp;title=2.29&amp;caption=Comparison%202%20DPP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%2029%20Acute%20kidney%20injury.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-002-29.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00301"><img data-id="CD011798-fig-00301" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-01.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 1 HbA1c."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 1 HbA1c.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00301" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-01.png?filename=nCD011798-CMP-003-01.ppt&amp;title=3.1&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%201%20HbA1c.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00302"><img data-id="CD011798-fig-00302" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-02.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 2 Fasting blood glucose."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 2 Fasting blood glucose.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00302" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-02.png?filename=nCD011798-CMP-003-02.ppt&amp;title=3.2&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%202%20Fasting%20blood%20glucose.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00303"><img data-id="CD011798-fig-00303" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-03.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 3 Death (all causes)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 3 Death (all causes).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00303" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-03.png?filename=nCD011798-CMP-003-03.ppt&amp;title=3.3&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%203%20Death%20%28all%20causes%29.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00304"><img data-id="CD011798-fig-00304" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-04.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 4 Myocardial infarction."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 4 Myocardial infarction.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00304" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-04.png?filename=nCD011798-CMP-003-04.ppt&amp;title=3.4&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%204%20Myocardial%20infarction.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00305"><img data-id="CD011798-fig-00305" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-05.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 5 Heart failure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 5 Heart failure.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00305" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-05.png?filename=nCD011798-CMP-003-05.ppt&amp;title=3.5&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%205%20Heart%20failure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-05.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00306"><img data-id="CD011798-fig-00306" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-06.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 6 Weight."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 6 Weight.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00306" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-06.png?filename=nCD011798-CMP-003-06.ppt&amp;title=3.6&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%206%20Weight.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-06.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00307"><img data-id="CD011798-fig-00307" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-07.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 7 Systolic blood pressure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 7 Systolic blood pressure.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00307" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-07.png?filename=nCD011798-CMP-003-07.ppt&amp;title=3.7&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%207%20Systolic%20blood%20pressure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-07.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00308"><img data-id="CD011798-fig-00308" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-08.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 8 Diastolic blood pressure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 8 Diastolic blood pressure.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00308" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-08.png?filename=nCD011798-CMP-003-08.ppt&amp;title=3.8&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%208%20Diastolic%20blood%20pressure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-08.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00309"><img data-id="CD011798-fig-00309" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-09.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 9 Serum creatinine."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 9 Serum creatinine.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00309" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-09.png?filename=nCD011798-CMP-003-09.ppt&amp;title=3.9&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%209%20Serum%20creatinine.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-09.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00310"><img data-id="CD011798-fig-00310" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-10.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 10 Total cholesterol."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 10 Total cholesterol.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00310" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-10.png?filename=nCD011798-CMP-003-10.ppt&amp;title=3.10&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%2010%20Total%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-10.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00311"><img data-id="CD011798-fig-00311" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-11.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 11 HDL cholesterol."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 11 HDL cholesterol.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00311" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-11.png?filename=nCD011798-CMP-003-11.ppt&amp;title=3.11&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%2011%20HDL%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-11.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00312"><img data-id="CD011798-fig-00312" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-12.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 12 LDL cholesterol."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 12 LDL cholesterol.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00312" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-12.png?filename=nCD011798-CMP-003-12.ppt&amp;title=3.12&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%2012%20LDL%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-12.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00313"><img data-id="CD011798-fig-00313" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-13.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 13 Triglyceride."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 13 Triglyceride.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00313" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-13.png?filename=nCD011798-CMP-003-13.ppt&amp;title=3.13&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%2013%20Triglyceride.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-13.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00314"><img data-id="CD011798-fig-00314" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-14.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 14 Hypoglycaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 14 Hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00314" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-14.png?filename=nCD011798-CMP-003-14.ppt&amp;title=3.14&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%2014%20Hypoglycaemia.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-14.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00315"><img data-id="CD011798-fig-00315" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-15.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 15 Discontinuation of medication due to adverse events."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 15 Discontinuation of medication due to adverse events. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00315" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-15.png?filename=nCD011798-CMP-003-15.ppt&amp;title=3.15&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%2015%20Discontinuation%20of%20medication%20due%20to%20adverse%20events.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-15.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00316"><img data-id="CD011798-fig-00316" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-16.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 16 Gastrointestinal disorders."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 16 Gastrointestinal disorders.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00316" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-16.png?filename=nCD011798-CMP-003-16.ppt&amp;title=3.16&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%2016%20Gastrointestinal%20disorders.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-16.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00317"><img data-id="CD011798-fig-00317" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-17.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 17 Vomiting."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 17 Vomiting.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00317" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-17.png?filename=nCD011798-CMP-003-17.ppt&amp;title=3.17&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%2017%20Vomiting.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-17.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00318"><img data-id="CD011798-fig-00318" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-18.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 18 Pancreatitis."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 18 Pancreatitis.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00318" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-18.png?filename=nCD011798-CMP-003-18.ppt&amp;title=3.18&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%2018%20Pancreatitis.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-18.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00319"><img data-id="CD011798-fig-00319" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-19.png" alt="Comparison 3 GLP‐1 agonists versus placebo, Outcome 19 Nausea."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.19</div> <div class="figure-caption"> <p>Comparison 3 GLP‐1 agonists versus placebo, Outcome 19 Nausea.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00319" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-003-19.png?filename=nCD011798-CMP-003-19.ppt&amp;title=3.19&amp;caption=Comparison%203%20GLP%E2%80%901%20agonists%20versus%20placebo%2C%20Outcome%2019%20Nausea.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-003-19.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00401"><img data-id="CD011798-fig-00401" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-01.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 1 HbA1c."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 1 HbA1c.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00401" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-01.png?filename=nCD011798-CMP-004-01.ppt&amp;title=4.1&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%201%20HbA1c.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00402"><img data-id="CD011798-fig-00402" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-02.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 2 Fasting blood glucose."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 2 Fasting blood glucose.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00402" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-02.png?filename=nCD011798-CMP-004-02.ppt&amp;title=4.2&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%202%20Fasting%20blood%20glucose.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00403"><img data-id="CD011798-fig-00403" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-03.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 3 Death (all causes)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 3 Death (all causes).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00403" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-03.png?filename=nCD011798-CMP-004-03.ppt&amp;title=4.3&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%203%20Death%20%28all%20causes%29.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00404"><img data-id="CD011798-fig-00404" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-04.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 4 Heart failure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 4 Heart failure.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00404" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-04.png?filename=nCD011798-CMP-004-04.ppt&amp;title=4.4&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%204%20Heart%20failure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00405"><img data-id="CD011798-fig-00405" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-05.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 5 Systolic blood pressure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 5 Systolic blood pressure.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00405" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-05.png?filename=nCD011798-CMP-004-05.ppt&amp;title=4.5&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%205%20Systolic%20blood%20pressure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-05.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00406"><img data-id="CD011798-fig-00406" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-06.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 6 Diastolic blood pressure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 6 Diastolic blood pressure.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00406" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-06.png?filename=nCD011798-CMP-004-06.ppt&amp;title=4.6&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%206%20Diastolic%20blood%20pressure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-06.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00407"><img data-id="CD011798-fig-00407" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-07.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 7 Total cholesterol."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 7 Total cholesterol.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00407" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-07.png?filename=nCD011798-CMP-004-07.ppt&amp;title=4.7&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%207%20Total%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-07.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00408"><img data-id="CD011798-fig-00408" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-08.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 8 HDL cholesterol."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 8 HDL cholesterol.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00408" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-08.png?filename=nCD011798-CMP-004-08.ppt&amp;title=4.8&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%208%20HDL%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-08.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00409"><img data-id="CD011798-fig-00409" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-09.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 9 LDL cholesterol."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 9 LDL cholesterol.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00409" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-09.png?filename=nCD011798-CMP-004-09.ppt&amp;title=4.9&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%209%20LDL%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-09.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00410"><img data-id="CD011798-fig-00410" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-10.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 10 Triglyceride."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 10 Triglyceride.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00410" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-10.png?filename=nCD011798-CMP-004-10.ppt&amp;title=4.10&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%2010%20Triglyceride.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-10.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00411"><img data-id="CD011798-fig-00411" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-11.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 11 Hypoglycaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 11 Hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00411" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-11.png?filename=nCD011798-CMP-004-11.ppt&amp;title=4.11&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%2011%20Hypoglycaemia.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-11.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00412"><img data-id="CD011798-fig-00412" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-12.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 12 Hypoglycaemia requiring third party assistance."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 12 Hypoglycaemia requiring third party assistance. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00412" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-12.png?filename=nCD011798-CMP-004-12.ppt&amp;title=4.12&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%2012%20Hypoglycaemia%20requiring%20third%20party%20assistance.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-12.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00413"><img data-id="CD011798-fig-00413" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-13.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 13 Peripheral oedema."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 13 Peripheral oedema.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00413" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-13.png?filename=nCD011798-CMP-004-13.ppt&amp;title=4.13&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%2013%20Peripheral%20oedema.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-13.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00414"><img data-id="CD011798-fig-00414" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-14.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 14 Fluid overload."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 14 Fluid overload.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00414" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-14.png?filename=nCD011798-CMP-004-14.ppt&amp;title=4.14&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%2014%20Fluid%20overload.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-14.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00415"><img data-id="CD011798-fig-00415" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-15.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 15 Fracture."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 15 Fracture.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00415" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-15.png?filename=nCD011798-CMP-004-15.ppt&amp;title=4.15&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%2015%20Fracture.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-15.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00416"><img data-id="CD011798-fig-00416" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-16.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 16 Gastrointestinal disorders."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 16 Gastrointestinal disorders.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00416" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-16.png?filename=nCD011798-CMP-004-16.ppt&amp;title=4.16&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%2016%20Gastrointestinal%20disorders.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-16.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00417"><img data-id="CD011798-fig-00417" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-17.png" alt="Comparison 4 Glitazone versus placebo/control, Outcome 17 Liver impairment."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.17</div> <div class="figure-caption"> <p>Comparison 4 Glitazone versus placebo/control, Outcome 17 Liver impairment.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00417" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-004-17.png?filename=nCD011798-CMP-004-17.ppt&amp;title=4.17&amp;caption=Comparison%204%20Glitazone%20versus%20placebo%2Fcontrol%2C%20Outcome%2017%20Liver%20impairment.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-004-17.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00501"><img data-id="CD011798-fig-00501" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-005-01.png" alt="Comparison 5 Glinides versus placebo/control, Outcome 1 Hypoglycaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Glinides versus placebo/control, Outcome 1 Hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00501" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-005-01.png?filename=nCD011798-CMP-005-01.ppt&amp;title=5.1&amp;caption=Comparison%205%20Glinides%20versus%20placebo%2Fcontrol%2C%20Outcome%201%20Hypoglycaemia.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-005-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00502"><img data-id="CD011798-fig-00502" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-005-02.png" alt="Comparison 5 Glinides versus placebo/control, Outcome 2 Hypoglycaemia requiring third party assistance."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Glinides versus placebo/control, Outcome 2 Hypoglycaemia requiring third party assistance. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00502" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-005-02.png?filename=nCD011798-CMP-005-02.ppt&amp;title=5.2&amp;caption=Comparison%205%20Glinides%20versus%20placebo%2Fcontrol%2C%20Outcome%202%20Hypoglycaemia%20requiring%20third%20party%20assistance.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-005-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00503"><img data-id="CD011798-fig-00503" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-005-03.png" alt="Comparison 5 Glinides versus placebo/control, Outcome 3 Peripheral oedema."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Glinides versus placebo/control, Outcome 3 Peripheral oedema.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00503" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-005-03.png?filename=nCD011798-CMP-005-03.ppt&amp;title=5.3&amp;caption=Comparison%205%20Glinides%20versus%20placebo%2Fcontrol%2C%20Outcome%203%20Peripheral%20oedema.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-005-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00504"><img data-id="CD011798-fig-00504" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-005-04.png" alt="Comparison 5 Glinides versus placebo/control, Outcome 4 Liver impairment."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Glinides versus placebo/control, Outcome 4 Liver impairment.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00504" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-005-04.png?filename=nCD011798-CMP-005-04.ppt&amp;title=5.4&amp;caption=Comparison%205%20Glinides%20versus%20placebo%2Fcontrol%2C%20Outcome%204%20Liver%20impairment.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-005-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00601"><img data-id="CD011798-fig-00601" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-01.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 1 HbA1c."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 1 HbA1c.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00601" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-01.png?filename=nCD011798-CMP-006-01.ppt&amp;title=6.1&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%201%20HbA1c.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00602"><img data-id="CD011798-fig-00602" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-02.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 2 Fasting blood glucose."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 2 Fasting blood glucose.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00602" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-02.png?filename=nCD011798-CMP-006-02.ppt&amp;title=6.2&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%202%20Fasting%20blood%20glucose.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00603"><img data-id="CD011798-fig-00603" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-03.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 3 Death (all causes)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 3 Death (all causes).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00603" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-03.png?filename=nCD011798-CMP-006-03.ppt&amp;title=6.3&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%203%20Death%20%28all%20causes%29.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00604"><img data-id="CD011798-fig-00604" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-04.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 4 Myocardial infarction."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 4 Myocardial infarction.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00604" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-04.png?filename=nCD011798-CMP-006-04.ppt&amp;title=6.4&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%204%20Myocardial%20infarction.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00605"><img data-id="CD011798-fig-00605" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-05.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 5 Stroke."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 5 Stroke.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00605" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-05.png?filename=nCD011798-CMP-006-05.ppt&amp;title=6.5&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%205%20Stroke.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-05.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00606"><img data-id="CD011798-fig-00606" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-06.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 6 Total cholesterol."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 6 Total cholesterol.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00606" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-06.png?filename=nCD011798-CMP-006-06.ppt&amp;title=6.6&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%206%20Total%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-06.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00607"><img data-id="CD011798-fig-00607" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-07.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 7 HDL cholesterol."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 7 HDL cholesterol.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00607" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-07.png?filename=nCD011798-CMP-006-07.ppt&amp;title=6.7&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%207%20HDL%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-07.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00608"><img data-id="CD011798-fig-00608" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-08.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 8 LDL cholesterol."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 8 LDL cholesterol.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00608" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-08.png?filename=nCD011798-CMP-006-08.ppt&amp;title=6.8&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%208%20LDL%20cholesterol.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-08.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00609"><img data-id="CD011798-fig-00609" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-09.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 9 Triglyceride."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 9 Triglyceride.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00609" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-09.png?filename=nCD011798-CMP-006-09.ppt&amp;title=6.9&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%209%20Triglyceride.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-09.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00610"><img data-id="CD011798-fig-00610" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-10.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 10 Hypoglycaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 10 Hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00610" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-10.png?filename=nCD011798-CMP-006-10.ppt&amp;title=6.10&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2010%20Hypoglycaemia.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-10.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00611"><img data-id="CD011798-fig-00611" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-11.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 11 Discontinuation of medication due to adverse events."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 11 Discontinuation of medication due to adverse events. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00611" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-11.png?filename=nCD011798-CMP-006-11.ppt&amp;title=6.11&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2011%20Discontinuation%20of%20medication%20due%20to%20adverse%20events.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-11.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00612"><img data-id="CD011798-fig-00612" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-12.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 12 Hypoglycaemia requiring third party assistance."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.12</div> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 12 Hypoglycaemia requiring third party assistance. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00612" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-12.png?filename=nCD011798-CMP-006-12.ppt&amp;title=6.12&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2012%20Hypoglycaemia%20requiring%20third%20party%20assistance.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-12.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00613"><img data-id="CD011798-fig-00613" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-13.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 13 Peripheral oedema."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.13</div> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 13 Peripheral oedema.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00613" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-13.png?filename=nCD011798-CMP-006-13.ppt&amp;title=6.13&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2013%20Peripheral%20oedema.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-13.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00614"><img data-id="CD011798-fig-00614" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-14.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 14 Fracture."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.14</div> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 14 Fracture.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00614" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-14.png?filename=nCD011798-CMP-006-14.ppt&amp;title=6.14&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2014%20Fracture.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-14.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00615"><img data-id="CD011798-fig-00615" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-15.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 15 Vomiting."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.15</div> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 15 Vomiting.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00615" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-15.png?filename=nCD011798-CMP-006-15.ppt&amp;title=6.15&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2015%20Vomiting.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-15.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00616"><img data-id="CD011798-fig-00616" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-16.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 16 Diarrhoea."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.16</div> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 16 Diarrhoea.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00616" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-16.png?filename=nCD011798-CMP-006-16.ppt&amp;title=6.16&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2016%20Diarrhoea.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-16.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00617"><img data-id="CD011798-fig-00617" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-17.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 17 Malignancy."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.17</div> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 17 Malignancy.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00617" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-17.png?filename=nCD011798-CMP-006-17.ppt&amp;title=6.17&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2017%20Malignancy.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-17.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00618"><img data-id="CD011798-fig-00618" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-18.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 18 Pancreatic cancer."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.18</div> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 18 Pancreatic cancer.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00618" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-18.png?filename=nCD011798-CMP-006-18.ppt&amp;title=6.18&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2018%20Pancreatic%20cancer.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-18.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00619"><img data-id="CD011798-fig-00619" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-19.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 19 Upper respiratory tract infection."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.19</div> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 19 Upper respiratory tract infection.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00619" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-19.png?filename=nCD011798-CMP-006-19.ppt&amp;title=6.19&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2019%20Upper%20respiratory%20tract%20infection.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-19.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00620"><img data-id="CD011798-fig-00620" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-20.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 20 Urinary tract infection."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.20</div> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 20 Urinary tract infection.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00620" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-20.png?filename=nCD011798-CMP-006-20.ppt&amp;title=6.20&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2020%20Urinary%20tract%20infection.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-20.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00621"><img data-id="CD011798-fig-00621" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-21.png" alt="Comparison 6 Sitagliptin versus glipizide, Outcome 21 Cellulitis."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.21</div> <div class="figure-caption"> <p>Comparison 6 Sitagliptin versus glipizide, Outcome 21 Cellulitis.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00621" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-006-21.png?filename=nCD011798-CMP-006-21.ppt&amp;title=6.21&amp;caption=Comparison%206%20Sitagliptin%20versus%20glipizide%2C%20Outcome%2021%20Cellulitis.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-006-21.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00701"><img data-id="CD011798-fig-00701" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-01.png" alt="Comparison 7 Vildagliptin versus sitagliptin, Outcome 1 HbA1c."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Vildagliptin versus sitagliptin, Outcome 1 HbA1c.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00701" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-007-01.png?filename=nCD011798-CMP-007-01.ppt&amp;title=7.1&amp;caption=Comparison%207%20Vildagliptin%20versus%20sitagliptin%2C%20Outcome%201%20HbA1c.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00702"><img data-id="CD011798-fig-00702" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-02.png" alt="Comparison 7 Vildagliptin versus sitagliptin, Outcome 2 Fasting blood glucose."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Vildagliptin versus sitagliptin, Outcome 2 Fasting blood glucose.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00702" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-007-02.png?filename=nCD011798-CMP-007-02.ppt&amp;title=7.2&amp;caption=Comparison%207%20Vildagliptin%20versus%20sitagliptin%2C%20Outcome%202%20Fasting%20blood%20glucose.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00703"><img data-id="CD011798-fig-00703" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-03.png" alt="Comparison 7 Vildagliptin versus sitagliptin, Outcome 3 Death (all causes)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Vildagliptin versus sitagliptin, Outcome 3 Death (all causes).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00703" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-007-03.png?filename=nCD011798-CMP-007-03.ppt&amp;title=7.3&amp;caption=Comparison%207%20Vildagliptin%20versus%20sitagliptin%2C%20Outcome%203%20Death%20%28all%20causes%29.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00704"><img data-id="CD011798-fig-00704" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-04.png" alt="Comparison 7 Vildagliptin versus sitagliptin, Outcome 4 Hypoglycaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Vildagliptin versus sitagliptin, Outcome 4 Hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00704" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-007-04.png?filename=nCD011798-CMP-007-04.ppt&amp;title=7.4&amp;caption=Comparison%207%20Vildagliptin%20versus%20sitagliptin%2C%20Outcome%204%20Hypoglycaemia.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00705"><img data-id="CD011798-fig-00705" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-05.png" alt="Comparison 7 Vildagliptin versus sitagliptin, Outcome 5 Discontinuation of medication due to adverse events."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Vildagliptin versus sitagliptin, Outcome 5 Discontinuation of medication due to adverse events. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00705" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-007-05.png?filename=nCD011798-CMP-007-05.ppt&amp;title=7.5&amp;caption=Comparison%207%20Vildagliptin%20versus%20sitagliptin%2C%20Outcome%205%20Discontinuation%20of%20medication%20due%20to%20adverse%20events.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-05.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00706"><img data-id="CD011798-fig-00706" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-06.png" alt="Comparison 7 Vildagliptin versus sitagliptin, Outcome 6 Peripheral oedema."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 Vildagliptin versus sitagliptin, Outcome 6 Peripheral oedema.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00706" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-007-06.png?filename=nCD011798-CMP-007-06.ppt&amp;title=7.6&amp;caption=Comparison%207%20Vildagliptin%20versus%20sitagliptin%2C%20Outcome%206%20Peripheral%20oedema.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-06.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00707"><img data-id="CD011798-fig-00707" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-07.png" alt="Comparison 7 Vildagliptin versus sitagliptin, Outcome 7 Pancreatitis."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7 Vildagliptin versus sitagliptin, Outcome 7 Pancreatitis.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00707" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-007-07.png?filename=nCD011798-CMP-007-07.ppt&amp;title=7.7&amp;caption=Comparison%207%20Vildagliptin%20versus%20sitagliptin%2C%20Outcome%207%20Pancreatitis.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-07.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00708"><img data-id="CD011798-fig-00708" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-08.png" alt="Comparison 7 Vildagliptin versus sitagliptin, Outcome 8 Liver impairment."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7 Vildagliptin versus sitagliptin, Outcome 8 Liver impairment.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00708" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-007-08.png?filename=nCD011798-CMP-007-08.ppt&amp;title=7.8&amp;caption=Comparison%207%20Vildagliptin%20versus%20sitagliptin%2C%20Outcome%208%20Liver%20impairment.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-007-08.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00801"><img data-id="CD011798-fig-00801" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-008-01.png" alt="Comparison 8 Albiglutide versus sitagliptin, Outcome 1 HbA1c."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Albiglutide versus sitagliptin, Outcome 1 HbA1c.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00801" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-008-01.png?filename=nCD011798-CMP-008-01.ppt&amp;title=8.1&amp;caption=Comparison%208%20Albiglutide%20versus%20sitagliptin%2C%20Outcome%201%20HbA1c.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-008-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00802"><img data-id="CD011798-fig-00802" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-008-02.png" alt="Comparison 8 Albiglutide versus sitagliptin, Outcome 2 Fasting blood glucose."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Albiglutide versus sitagliptin, Outcome 2 Fasting blood glucose.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00802" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-008-02.png?filename=nCD011798-CMP-008-02.ppt&amp;title=8.2&amp;caption=Comparison%208%20Albiglutide%20versus%20sitagliptin%2C%20Outcome%202%20Fasting%20blood%20glucose.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-008-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00901"><img data-id="CD011798-fig-00901" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-01.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 1 HbA1c."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 1 HbA1c.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00901" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-01.png?filename=nCD011798-CMP-009-01.ppt&amp;title=9.1&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%201%20HbA1c.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00902"><img data-id="CD011798-fig-00902" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-02.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 2 Fasting blood glucose."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 2 Fasting blood glucose.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00902" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-02.png?filename=nCD011798-CMP-009-02.ppt&amp;title=9.2&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%202%20Fasting%20blood%20glucose.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00903"><img data-id="CD011798-fig-00903" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-03.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 3 Heart failure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 3 Heart failure.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00903" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-03.png?filename=nCD011798-CMP-009-03.ppt&amp;title=9.3&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%203%20Heart%20failure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00904"><img data-id="CD011798-fig-00904" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-04.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 4 Death (all causes)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 4 Death (all causes).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00904" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-04.png?filename=nCD011798-CMP-009-04.ppt&amp;title=9.4&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%204%20Death%20%28all%20causes%29.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00905"><img data-id="CD011798-fig-00905" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-05.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 5 All cardiovascular death."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 5 All cardiovascular death.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00905" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-05.png?filename=nCD011798-CMP-009-05.ppt&amp;title=9.5&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%205%20All%20cardiovascular%20death.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-05.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00906"><img data-id="CD011798-fig-00906" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-06.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 6 Myocardial infarction."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 6 Myocardial infarction.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00906" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-06.png?filename=nCD011798-CMP-009-06.ppt&amp;title=9.6&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%206%20Myocardial%20infarction.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-06.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00907"><img data-id="CD011798-fig-00907" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-07.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 7 Stroke."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.7</div> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 7 Stroke.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00907" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-07.png?filename=nCD011798-CMP-009-07.ppt&amp;title=9.7&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%207%20Stroke.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-07.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00908"><img data-id="CD011798-fig-00908" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-08.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 8 Weight."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.8</div> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 8 Weight.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00908" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-08.png?filename=nCD011798-CMP-009-08.ppt&amp;title=9.8&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%208%20Weight.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-08.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00909"><img data-id="CD011798-fig-00909" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-09.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 9 eGFR."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.9</div> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 9 eGFR.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00909" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-09.png?filename=nCD011798-CMP-009-09.ppt&amp;title=9.9&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%209%20eGFR.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-09.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00910"><img data-id="CD011798-fig-00910" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-10.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 10 Systolic blood pressure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.10</div> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 10 Systolic blood pressure.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00910" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-10.png?filename=nCD011798-CMP-009-10.ppt&amp;title=9.10&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%2010%20Systolic%20blood%20pressure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-10.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00911"><img data-id="CD011798-fig-00911" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-11.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 11 Diastolic blood pressure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.11</div> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 11 Diastolic blood pressure.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00911" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-11.png?filename=nCD011798-CMP-009-11.ppt&amp;title=9.11&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%2011%20Diastolic%20blood%20pressure.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-11.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00912"><img data-id="CD011798-fig-00912" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-12.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 12 Serum creatinine."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.12</div> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 12 Serum creatinine.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00912" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-12.png?filename=nCD011798-CMP-009-12.ppt&amp;title=9.12&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%2012%20Serum%20creatinine.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-12.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00913"><img data-id="CD011798-fig-00913" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-13.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 13 Hypoglycaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.13</div> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 13 Hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00913" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-13.png?filename=nCD011798-CMP-009-13.ppt&amp;title=9.13&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%2013%20Hypoglycaemia.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-13.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00914"><img data-id="CD011798-fig-00914" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-14.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 14 Hypoglycaemia requiring third party assistance."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.14</div> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 14 Hypoglycaemia requiring third party assistance. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00914" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-14.png?filename=nCD011798-CMP-009-14.ppt&amp;title=9.14&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%2014%20Hypoglycaemia%20requiring%20third%20party%20assistance.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-14.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00915"><img data-id="CD011798-fig-00915" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-15.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 15 Peripheral oedema."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.15</div> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 15 Peripheral oedema.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00915" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-15.png?filename=nCD011798-CMP-009-15.ppt&amp;title=9.15&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%2015%20Peripheral%20oedema.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-15.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00916"><img data-id="CD011798-fig-00916" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-16.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 16 Fracture."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.16</div> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 16 Fracture.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00916" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-16.png?filename=nCD011798-CMP-009-16.ppt&amp;title=9.16&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%2016%20Fracture.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-16.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-00917"><img data-id="CD011798-fig-00917" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-17.png" alt="Comparison 9 Aleglitazar versus pioglitazone, Outcome 17 Malignancy."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.17</div> <div class="figure-caption"> <p>Comparison 9 Aleglitazar versus pioglitazone, Outcome 17 Malignancy.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-00917" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-009-17.png?filename=nCD011798-CMP-009-17.ppt&amp;title=9.17&amp;caption=Comparison%209%20Aleglitazar%20versus%20pioglitazone%2C%20Outcome%2017%20Malignancy.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-009-17.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-01001"><img data-id="CD011798-fig-01001" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-010-01.png" alt="Comparison 10 Insulin glulisine and glargine 0.5 versus 0.25 U/kg/d, Outcome 1 Hypoglycaemia < 3.89 mmol/L."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Insulin glulisine and glargine 0.5 versus 0.25 U/kg/d, Outcome 1 Hypoglycaemia &lt; 3.89 mmol/L. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-01001" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-010-01.png?filename=nCD011798-CMP-010-01.ppt&amp;title=10.1&amp;caption=Comparison%2010%20Insulin%20glulisine%20and%20glargine%200.5%20versus%200.25%20U%2Fkg%2Fd%2C%20Outcome%201%20Hypoglycaemia%20%3C%203.89%20mmol%2FL.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-010-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD011798-fig-01002"><img data-id="CD011798-fig-01002" src="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-010-02.png" alt="Comparison 10 Insulin glulisine and glargine 0.5 versus 0.25 U/kg/d, Outcome 2 Hypoglycaemia < 2.78 mmol/L."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Insulin glulisine and glargine 0.5 versus 0.25 U/kg/d, Outcome 2 Hypoglycaemia &lt; 2.78 mmol/L. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-fig-01002" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/ppt/CDSR/CD011798/image_n/nCD011798-CMP-010-02.png?filename=nCD011798-CMP-010-02.ppt&amp;title=10.2&amp;caption=Comparison%2010%20Insulin%20glulisine%20and%20glargine%200.5%20versus%200.25%20U%2Fkg%2Fd%2C%20Outcome%202%20Hypoglycaemia%20%3C%202.78%20mmol%2FL.&amp;citation=Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose%E2%80%90lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews 2018, 9. Art. No.: CD011798. DOI: http://dx.doi.org/10.1002/14651858.CD011798.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011798.pub2/media/CDSR/CD011798/image_n/nCD011798-CMP-010-02.png">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD011798-tbl-0001" class="summary-of-findings framed"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span>&nbsp;<span class="table-title">SGLT2 inhibitors versus placebo for treating people with diabetes and chronic kidney disease (CKD)</span></div> <tbody> <tr class="separated"> <td align="left" valign="top" colspan="6" rowspan="1" bgcolor="#ffffff"> <p><b>SGLT2 inhibitors versus placebo for treating people with diabetes and CKD</b> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="6" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> people with diabetes and CKD<br> <b>Intervention:</b> SGLT2 inhibitors<br> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Effect estimate (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>No. of participants<br> (studies)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with placebo</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with SGLT2 inhibitors</b> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HbA1c (%)</p> <p>HbA1c (mmol/mol)</p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>The mean HbA1c was 0.29% lower (0.19 to 0.38 lower) with SGLT2 inhibitors compared to placebo </p> <p>The mean HbA1c was 3.2 mmol/mol lower (2.2 to 4.2 lower) with SGLT2 inhibitors compared to placebo </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>MD ‐0.29 (‐0.38 to ‐0.19)</p> <p>MD ‐3.2 (‐4.2 to ‐2.2)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1092 (7)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕⊝<br> MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>FBG (mmol/L)</p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>The mean FBG was 0.48 mmol/L lower (0.19 to 0.78 lower) with SGLT2 inhibitors compared to placebo </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>MD ‐0.48</p> <p>(‐0.78 to ‐0.19)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>855 (5)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕⊝<br> MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Death (all causes)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>78 per 1,000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>61 per 1,000<br> (47 to 79) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 0.78<br> (0.60 to 1.02) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2933 (5)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> VERY LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All cardiovascular death</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>52 per 1,000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>40 per 1,000<br> (29 to 57) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 0.78<br> (0.56 to 1.10) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2788 (4)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br> LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Weight (kg)</p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>Weight was 1.41 kg lower (1.02 to 1.8 lower) with SGLT2 inhibitor compared to placebo</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>MD ‐1.41</p> <p>(‐1.8 to ‐1.02)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1029 (5)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br> LOW <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>eGFR (mL/min/1.73 m<sup>2</sup>) </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>The mean eGFR was 1.85 mL/min/1.73 m<sup>2</sup> lower (0.94 to 2.76 lower) with SGLT2 inhibitors compared to placebo </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>MD ‐1.85</p> <p>(‐2.76 to ‐0.94)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>848 (4)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕⊝<br> MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Hypoglycaemia</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>118 per 1,000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>104 per 1,000<br> (86 to 126) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 0.88<br> (0.73 to 1.07) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3086 (7)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br> LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Discontinuation of medication due to adverse events</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>105 per 1,000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>90 per 1,000<br> (59 to 138) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 0.86<br> (0.56 to 1.32) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>917 (4)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> VERY LOW <sup>1 3 4</sup> </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br> <br> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>MD</b>: mean difference </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b><br> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> All studies had funding bias and/or attrition bias </p> <p><sup>2</sup> Effect is beneficial or harmful but confidence interval is wide and crosses 1 </p> <p><sup>3</sup> Moderate heterogeneity in effect </p> <p><sup>4</sup> Wide CI and the effect shows appreciable benefit and harm </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span>&nbsp;<span class="table-title">SGLT2 inhibitors versus placebo for treating people with diabetes and chronic kidney disease (CKD)</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/full#CD011798-tbl-0001" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD011798-tbl-0002" class="summary-of-findings framed"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span>&nbsp;<span class="table-title">DPP‐4 inhibitors versus placebo for treating people with diabetes and chronic kidney disease (CKD)</span></div> <tbody> <tr class="separated"> <td align="left" valign="top" colspan="6" rowspan="1" bgcolor="#ffffff"> <p><b>DPP‐4 inhibitors versus placebo for treating people with diabetes and CKD</b> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="6" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> people with diabetes and CKD<br> <b>Intervention:</b> DPP‐4 inhibitors<br> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Effect estimate (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>No. of participants<br> (studies)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with placebo</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with DPP‐4 inhibitors</b> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HbA1c (%)</p> <p>HbA1c (mmol/mol)</p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>The mean HbA1c was 0.62% lower (0.39 to 0.62 lower) with DPP‐4 inhibitors compared to placebo </p> <p>The mean HbA1c was 6.8 mmol/mol lower (4.3 to 9.3 lower) with DPP‐4 inhibitors compared to placebo </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>MD ‐0.62 (‐0.85 to ‐0.39)</p> <p>MD ‐6.8 (‐9.3 to ‐4.3)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>867 (7)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br> LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>FBG (mmol/L)</p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>The mean FBG was 0.47 mmol/L lower (1.08 lower to 0.15 higher) with DPP‐4 inhibitors compared to placebo </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>MD ‐0.47</p> <p>(‐1.08 to 0.15)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>589 (4)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br> LOW <sup>3 4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Death (all causes)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>108 per 1,000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>96 per 1,000<br> (81 to 115) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 0.89<br> (0.75 to 1.07) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4211 (6)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br> LOW <sup>1 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All cardiovascular death</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>77 per 1,000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>71 per 1,000<br> (59 to 85) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 0.93</p> <p>(0.77 to 1.11)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5897 (2)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕⊝<br> MODERATE <sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Weight (kg)</p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>The mean weight was 0.16 kg higher (0.58 lower to 0.9 higher) with DPP‐4 inhibitors compared to placebo </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>MD 0.16</p> <p>(‐0.58 to 0.9)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>210 (2)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕⊝<br> MODERATE <sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>eGFR (mL/min/1.73 m<sup>2</sup>) </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>The mean eGFR was 1.99 mL/min/1.73 m<sup>2</sup> lower (0.49 to 3.49 lower) with DPP‐4 inhibitors compared to placebo </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>MD ‐1.99</p> <p>(‐3.49 to ‐0.49)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>130 (1)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> VERY LOW <sup>5 6</sup> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Hypoglycaemia</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>229 per 1,000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>245 per 1,000<br> (183 to 325) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 1.07<br> (0.80 to 1.42) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1443 (11)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> VERY LOW <sup>2 3 7</sup> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Discontinuation of medication due to adverse events</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>65 per 1,000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>61 per 1,000<br> (40 to 94) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 0.94<br> (0.61 to 1.45) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1257 (7)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> VERY LOW <sup>1 8</sup> </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br> <br> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>MD</b>: mean difference; <b>HbA1c</b>: haemoglobin A1c (glycated); <b>FBG</b>: fasting blood glucose; <b>eGFR</b>: estimated glomerular filtration rate </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b><br> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> All studies had funding bias, and the majority had attrition bias </p> <p><sup>2</sup> Moderate heterogeneity in results </p> <p><sup>3</sup> Effect had appreciable benefit or harm but the confidence interval crossed 1 </p> <p><sup>4</sup> All studies had risk of funding bias and attrition bias </p> <p><sup>5</sup> All studies had a risk of funding bias </p> <p><sup>6</sup> Only 1 study reported this outcome </p> <p><sup>7</sup> Majority of studies had funding bias and/or attrition bias </p> <p><sup>8</sup> Wide confidence interval with appreciable benefit and harm </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span>&nbsp;<span class="table-title">DPP‐4 inhibitors versus placebo for treating people with diabetes and chronic kidney disease (CKD)</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/full#CD011798-tbl-0002" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD011798-tbl-0003" class="summary-of-findings framed"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span>&nbsp;<span class="table-title">GLP‐1 agonists versus placebo for treating people with diabetes and chronic kidney disease (CKD)</span></div> <tbody> <tr class="separated"> <td align="left" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GLP‐1 agonists versus to placebo for treating people with diabetes and CKD</b> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> people with diabetes and CKD<br> <b>Intervention:</b> GLP‐1 agonists<br> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Effect estimate (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>No. of participants<br> (studies)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with placebo</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with GLP‐1 agonists</b> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HbA1c (%)</p> <p>HbA1c (mmol/mol)</p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>The mean HbA1c was 0.53% lower (0.06 to 1.01 lower) with GLP‐1 agonists compared to placebo </p> <p>The mean HbA1c was 5.8 mmol/mol lower (0.7 to 11.0 lower) with GLP‐1 agonists compared to placebo </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>MD ‐0.53 (‐1.01 to ‐0.06)</p> <p>MD ‐5.8 (‐11.0 to ‐0.7)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>283 (2)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕⊝<br> MODERATE <sup>1</sup> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>FBG (mmol/L)</p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>The mean FBG was 1.08 mmol/L lower (0.45 to 1.71 lower) with GLP‐1 agonists compared to placebo </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>MD ‐1.08 (‐1.71 to ‐0.45)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>231 (1)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Death (all causes)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>7 per 1,000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>27 per 1,000<br> (3 to 235) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 3.91<br> (0.44 to 34.58) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>301 (2)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All cardiovascular death</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Weight (kg)</p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>‐</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>303 (2)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝</p> <p>LOW <sup>1 3</sup> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>On qualitative synthesis of results from two studies (total of 303 participants), liraglutide reduced body weight to a greater extent compared to the control group in people with an eGFR &lt; 60 mL/min/1.73 m<sup>2</sup>, including patients receiving HD. </p> <p>In one study in patients with ESKD receiving HD (24 participants), liraglutide resulted in a 2.20 kg loss of weight (‐3.87 to 0.53; P = 0.01) compared to placebo. However, weight (mean ± SE) was reduced insignificantly compared to before the treatment (91.1 ± 4.9 to 88.7 ± 5.2 kg, P= 0.22). In another study, in patients with an eGFR 30 to &lt; 60 mL/min/1.73 m<sup>2</sup> both liraglutide and placebo exhibited gradual weight reduction (279 participants). The patients in the liraglutide group had a greater reduction in body weight compared to placebo (‐2.41 and ‐1.09 kg respectively) with an estimated treatment different of ‐1.32 kg (95% CI ‐2.24 to ‐0.4; P = 0.0052). </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>eGFR (mL/min/1.73 m<sup>2</sup>) </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>‐</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>279 (1)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br> LOW <sup>1 4</sup> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Only one study reported eGFR. In this study, the mean observed changes in eGFR (MDRD) from baseline to week 26 was ‐0.35 mL/min/1.73 m<sup>2</sup> in the GLP‐1 group and +0.37 mL/min/1.73 m<sup>2</sup> in the placebo group; the estimated treatment effect was not significant (P = 0.36). The other study occurred in HD. </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Hypoglycaemia</p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>‐</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>303 (2)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br> LOW <sup>1 3</sup> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>In one study in patients with an eGFR of 30 to &lt; 60 mL/min/1.73 m<sup>2</sup> (279 participants) liraglutide resulted in an equivalent risk of hypoglycaemia to placebo (0.79; 0.51 to 1.21; P = 0.28). In the other study (24 participants) with ESKD on HD, the number of episodes of hypoglycaemia did not differ between those receiving liraglutide and those receiving placebo. </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Discontinuation of medication due to adverse events</p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>‐</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>303 (2)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br> LOW <sup>1 2</sup> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>In one study in patients with ESKD comparing liraglutide to placebo, there were no discontinuations due to adverse events in the liraglutide or placebo group (24 participants). In another study, in patients with an eGFR 30 to &lt; 60 mL/min/1.73 m<sup>2</sup>, (279 participants) liraglutide resulted in a 4.65 times higher risk of discontinuation due to adverse events compared to placebo (4.65; 1.62 to 13.31; P = 0.004) </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br> <br> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>MD</b>: mean difference; ; <b>HbA1c</b>: haemoglobin A1c (glycated); <b>FBG</b>: fasting blood glucose; <b>eGFR</b>: estimated glomerular filtration rate; <b>ESKD</b>: end‐stage kidney disease; <b>HD</b>: haemodialysis </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b><br> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> All had risk of attrition bias and funding bias </p> <p><sup>2</sup> Effect had appreciable benefit or harm but the confidence interval crossed 1 </p> <p><sup>3</sup> Narrative/qualitative synthesis was conducted. Estimates were not precise </p> <p><sup>4</sup>Downgraded one point because only one study reported eGFR, and therefore there is a likelihood of publication bias </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span>&nbsp;<span class="table-title">GLP‐1 agonists versus placebo for treating people with diabetes and chronic kidney disease (CKD)</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/full#CD011798-tbl-0003" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD011798-tbl-0004" class="summary-of-findings framed"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span>&nbsp;<span class="table-title">Glitazone versus placebo for treating people with diabetes and chronic kidney disease (CKD)</span></div> <tbody> <tr class="separated"> <td align="left" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Glitazone versus placebo for treating people with diabetes and CKD</b> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> people with diabetes and CKD<br> <b>Intervention:</b> glitazone<br> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Effect estimate (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>No. of participants<br> (studies)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with placebo</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with glitazone</b> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HbA1c (%)</p> <p>HbA1c (mmol/mol)</p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>The mean HbA1c was 0.41% lower (1.15 lower to 0.32 higher) with glitazone agonists compared to placebo </p> <p>The mean HbA1c was 4.5 mmol/mol lower (12.6 lower to 3.5 higher) with glitazone agonists compared to placebo </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>MD ‐0.41 (‐1.15 to 0.32)</p> <p>MD ‐4.5 (‐12.6 to 3.5)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>88 (2)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> VERY LOW <sup>1 2 3</sup> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>FBG (mmol/L)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>‐</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>‐</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>233 (5)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> VERY LOW<sup>5 6</sup> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Qualitative synthesis of studies showed that glitazones, particularly pioglitazone lowered FBG compared to placebo in patients with an eGFR &lt; 60 mL/min/1.73 m<sup>2</sup>, including patients on HD. </p> <p>Two studies (total of 71 participants) in people with HD reported that pioglitazone lowered FBG at the end of the study compared to the start, and also lower than in placebo group (both P &lt; 0.05). Similarly another study (39 participants) in HD patients reported that pioglitazone reduced the FBG by 2.91 mmol/L (‐5.44 to ‐0.38 mmol/L); P = 0.02 compared to placebo. </p> <p>Conversely another study in HD patients (63 participants) reported that pioglitazone resulted in a lower FBG (mean ± SD) at the end of the study compared to the start (7.72 ± 2.50 versus 6.89 ± 2.67 mmol/L P &lt; 0.05), but this was not statistically lower than placebo (6.89 ± 2.67 versus 7.33 ± 2.56 mmol/L, P &gt; 0.05). </p> <p>One study of people with earlier stages of CKD (60 participants) showed that in people with stage 3 CKD who were treated with pioglitazone‐losartan, there were higher rates of decline in blood glucose values compared with people treated with losartan only. This difference was significant after 12 months ( change (mean ± SD) after 12 months –22.7 ± 6.9% for pioglitazone‐losartan therapy as compared with –15.1 ± 6.3% for losartan alone; P &lt; 0.01). Larger reductions in FBG concentrations were observed for people in this study with stage 4 CKD after 12 months of the combined as compared with the single‐drug treatment (i.e. –22.9 ± 8.9% versus –17.6 ± 5.9%; P = 0.07), but the difference was not significant. </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Death (all causes)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>77 per 1,000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>38 per 1,000<br> (4 to 398) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 0.50<br> (0.05 to 5.18) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>52<br> (1 RCT) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> VERY LOW <sup>1 4</sup> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All cardiovascular death</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Weight (kg)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>222 (5)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> VERY LOW<sup>5 6</sup> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>From qualitative synthesis of data from 3 studies (total of 110 participants), pioglitazone did not result in a significant increase of dry weight compared to placebo in patients receiving HD (<a href="./references#CD011798-bbs2-0001">Abe 2007</a>; <a href="./references#CD011798-bbs2-0002">Abe 2008a</a>; <a href="./references#CD011798-bbs2-0036">Pfutzner 2011</a>) or a significant increase of body weight compared to placebo in patients with an eGFR 15 to &lt; 60 mL/min/1.73 m<sup>2</sup> (<a href="./references#CD011798-bbs2-0021">Jin 2007</a>: 60 participants). </p> <p>Conversely, in patients receiving PD (<a href="./references#CD011798-bbs2-0041">Wong 2005</a>: 52 participants), rosiglitazone resulted in more weight gain (mean ± SD) compared to placebo (2.0% ± 5.6% versus control, ‐0.8% ± 4.4%; P = 0.049). </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>eGFR (mL/min/1.73 m<sup>2</sup>) </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Hypoglycaemia</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>59 per 1,000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>56 per 1,000<br> (9 to 358) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 0.95<br> (0.15 to 6.08) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>70<br> (2 RCTs) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> VERY LOW <sup>1 4</sup> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Discontinuation of medication due to adverse events</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>0 per 1,000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>0 per 1,000<br> (0 to 0) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>not estimable</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>63<br> (1 RCT) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> VERY LOW <sup>4 5</sup> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br> <br> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>MD</b>: mean difference; <b>HbA1c</b>: haemoglobin A1c (glycated); <b>FBG</b>: fasting blood glucose; <b>eGFR</b>: estimated glomerular filtration rate; <b>HD</b>: haemodialysis; <b>CKD</b>: chronic kidney disease </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b><br> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of attrition and funding bias </p> <p><sup>2</sup> Substantial heterogeneity </p> <p><sup>3</sup> CI is wide and effect shows appreciable benefit and harm </p> <p><sup>4</sup> Only 1 study had data for this outcome </p> <p><sup>5</sup> Risk of selection, performance and detection bias </p> <p><sup>6</sup> Narrative/qualitative synthesis was conducted. Estimates were not precise </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span>&nbsp;<span class="table-title">Glitazone versus placebo for treating people with diabetes and chronic kidney disease (CKD)</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/full#CD011798-tbl-0004" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD011798-tbl-0005" class="summary-of-findings framed"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span>&nbsp;<span class="table-title">Sitagliptin versus glipizide for treating people with diabetes and chronic kidney disease (CKD)</span></div> <tbody> <tr class="separated"> <td align="left" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Sitagliptin versus glipizide for treating people with diabetes and CKD</b> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> people with diabetes and CKD<br> <b>Intervention:</b> sitagliptin<br> <b>Comparison:</b> glipizide </p> </td> </tr> <tr class="table-header separated"> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Effect estimate (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>No. of participants<br> (studies)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with glipizide</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with sitagliptin</b> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HbA1c (%)</p> <p>HbA1c (mmol/mol)</p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>The mean HbA1c was 0.05% lower (0.39 lower to 0.29 higher) with glipizide compared to sitagliptin </p> <p>The mean HbA1c was 0.6 mmol/mol lower (4.3 lower to 3.2 higher) with glipizide compared to sitagliptin </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>MD ‐0.05 (‐0.39 to 0.29)</p> <p>MD ‐0.6 (‐4.3 to 3.2)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>398 (2)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br> LOW <sup>1 2</sup> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>FBG (mmol/L)</p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>Mean FBG was 0.36 mmol/L higher (0.1 lower to 0.82 higher) with glipizide compared to sitagliptin </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>MD 0.36 (‐0.1 to 0.82)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>397 (2)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br> LOW <sup>1 3</sup> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Death (all causes)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>47 per 1,000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>26 per 1,000<br> (10 to 64) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 0.55<br> (0.22 to 1.36) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>551 (2)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> VERY LOW <sup>1 4</sup> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All cardiovascular death</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Weight (kg)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>‐</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>‐</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>552 (2)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br> LOW <sup>1 5</sup> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>In one study in people with an eGFR &lt; 50 mL/min/1.73 m<sup>2</sup> but not on dialysis (423 participants) sitagliptin resulted in a reduction in body weight (‐0.6 kg) compared to glipizide where the body weight increased (1.2 kg), resulting in a statistically significant (P &lt; 0.001) between‐group difference of ‐1.8 kg. </p> <p>Conversely in another study in people with ESKD on dialysis (129 participants), sitagliptin had a similar effect to glipizide on weight ‐1.00 kg (‐2.80 to 0.80) P = 0.28. </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>eGFR (mL/min/1.73 m<sup>2</sup>) </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>552 (2)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br> LOW <sup>1 5</sup> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>One study (423 participants) occurred in patients with an eGFR &lt; 50 mL/min/1.73 m<sup>2</sup> and not on dialysis. There were similar reductions from baseline in eGFR observed in the sitagliptin and glipizide groups (sitagliptin, 23.9 mL/min/1.73 m<sup>2</sup>; glipizide, 23.3 mL/min/1.73 m<sup>2</sup>). Similarly in another study (129 participants) which occurred in patients receiving dialysis, there were no meaningful differences in changes from baseline in eGFR, SCr, UACR between sitagliptin and glipizide. </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Hypoglycaemia</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>155 per 1,000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>62 per 1,000<br> (36 to 107) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 0.40<br> (0.23 to 0.69) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>551 (2)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕⊝<br> MODERATE <sup>1</sup> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Discontinuation of medication due to adverse events</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>90 per 1,000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>84 per 1,000<br> (49 to 144) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 0.93<br> (0.54 to 1.60) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>551 (2)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> VERY LOW <sup>1 4</sup> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br> <br> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>MD</b>: mean difference; <b>HbA1c</b>: haemoglobin A1c (glycated); <b>FBG</b>: fasting blood glucose; <b>eGFR</b>: estimated glomerular filtration rate; <b>ESKD</b>: end‐stage kidney disease; <b>SCr</b>: serum creatinine; <b>UACR</b>: urinary albumin/creatinine ratio </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b><br> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Both studies had funding bias and attrition bias </p> <p><sup>2</sup> Heterogeneity in results </p> <p><sup>3</sup> Effect has either benefit or harm with a confidence interval that crosses 1 </p> <p><sup>4</sup> Effect has both appreciable benefit and harm with a wide confidence interval that crosses 1 </p> <p><sup>5</sup> Narrative/Qualitative synthesis was conducted. Estimates were not precise </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span>&nbsp;<span class="table-title">Sitagliptin versus glipizide for treating people with diabetes and chronic kidney disease (CKD)</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/full#CD011798-tbl-0005" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD011798-tbl-0006" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">SGLT2 inhibitors versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1092</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.29 [‐0.38, ‐0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>855</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.48 [‐0.78, ‐0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2933</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.78 [0.60, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 All cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2788</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.78 [0.56, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2788</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.63 [0.30, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2933</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.96 [0.63, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2519</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.59 [0.41, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1029</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.41 [‐1.80, ‐1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 eGFR [mL/min/1.73 m<sup>2</sup>] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>848</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.85 [‐2.76, ‐0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1198</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐4.68 [‐6.69, ‐2.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Diastolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1142</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.72 [‐2.77, ‐0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 Serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>848</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.82 [1.45, 6.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 Urinary albumin/creatinine ratio <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1153</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐8.14 [‐14.51, ‐1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">14 Serum potassium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2443</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.01 [‐0.05, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">15 Total cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>529</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.09 [‐0.05, 0.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">16 HDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>918</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.04 [0.01, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">17 LDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>917</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.04 [‐0.06, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">18 Triglyceride <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>918</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.01 [‐0.11, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">19 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3086</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.88 [0.73, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">20 Discontinuation of medication due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>917</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.86 [0.56, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">21 End‐stage kidney disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>700</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.71 [0.10, 4.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">22 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2788</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.58 [0.42, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">23 Hypoglycaemia requiring third party assistance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>845</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.47 [0.17, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">24 Hypovolaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3005</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.07 [0.63, 1.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">25 Fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2860</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.81 [0.31, 2.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">26 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">27 Diabetic ketoacidosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1962</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.00 [0.09, 11.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">28 Upper respiratory tract infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>593</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.79 [0.43, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">29 Urinary tract infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3086</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.09 [0.82, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">30 Genital infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3086</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.50 [1.52, 4.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">31 Acute kidney injury <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2788</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.78 [0.61, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">32 Doubling of serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>700</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.96 [0.49, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">SGLT2 inhibitors versus placebo</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-tbl-0006" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD011798-tbl-0007" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 2.</span>&nbsp;<span class="table-title">DPP‐4 inhibitors versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>867</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.62 [‐0.85, ‐0.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>589</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.47 [‐1.08, 0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4211</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.89 [0.75, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 All cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5897</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.93 [0.77, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6121</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.08 [0.88, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6030</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.92 [0.69, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6115</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.18 [0.98, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>210</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.16 [‐0.58, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 eGFR [mL/min/1.73 m<sup>2</sup>] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Urinary albumin/creatinine ratio <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 Total cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 LDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">14 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1443</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.07 [0.80, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">15 Discontinuation of medication due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1257</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.94 [0.61, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">16 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>502</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.30 [0.81, 2.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">17 Hypoglycaemia requiring third party assistance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3383</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.72 [0.25, 2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">18 New or worsening retinopathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">19 Peripheral oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>763</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.84 [0.58, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">20 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>502</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.39 [0.80, 2.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">21 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>224</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.79 [0.09, 6.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">22 Malignancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">23 Pancreatic cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">24 Pancreatitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3693</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.99 [0.14, 7.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">25 Liver impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>451</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.42 [0.26, 7.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">26 Upper respiratory tract infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>593</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.63 [0.38, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">27 Cellulitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">28 Urinary tract infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>763</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.82 [0.50, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">29 Acute kidney injury <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span>&nbsp;<span class="table-title">DPP‐4 inhibitors versus placebo</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-tbl-0007" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD011798-tbl-0008" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 3.</span>&nbsp;<span class="table-title">GLP‐1 agonists versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>283</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.53 [‐1.01, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>301</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.91 [0.44, 34.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Diastolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Total cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 HDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 LDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 Triglyceride <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">14 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">15 Discontinuation of medication due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">16 Gastrointestinal disorders <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">17 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">18 Pancreatitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">19 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span>&nbsp;<span class="table-title">GLP‐1 agonists versus placebo</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-tbl-0008" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD011798-tbl-0009" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 4.</span>&nbsp;<span class="table-title">Glitazone versus placebo/control</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>88</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.41 [‐1.15, 0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>123</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.34 [0.01, 8.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Diastolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Total cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>72</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.60 [‐0.02, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 HDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>72</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.07 [‐0.25, 0.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 LDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>72</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.39 [‐0.60, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Triglyceride <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>72</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.34 [‐2.99, 2.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 Hypoglycaemia requiring third party assistance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 Peripheral oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>134</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.05 [0.33, 28.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">14 Fluid overload <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">15 Fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">16 Gastrointestinal disorders <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">17 Liver impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span>&nbsp;<span class="table-title">Glitazone versus placebo/control</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-tbl-0009" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD011798-tbl-0010" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 5.</span>&nbsp;<span class="table-title">Glinides versus placebo/control</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Hypoglycaemia requiring third party assistance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Peripheral oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Liver impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span>&nbsp;<span class="table-title">Glinides versus placebo/control</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-tbl-0010" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD011798-tbl-0011" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 6.</span>&nbsp;<span class="table-title">Sitagliptin versus glipizide</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>398</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.05 [‐0.39, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>397</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.36 [‐0.10, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>551</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.55 [0.22, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Total cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 HDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 LDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Triglyceride <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>551</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.40 [0.23, 0.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Discontinuation of medication due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>551</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.93 [0.54, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 Hypoglycaemia requiring third party assistance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>551</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.35 [0.09, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 Peripheral oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>551</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.71 [0.11, 4.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">14 Fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">15 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">16 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>551</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.79 [0.39, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">17 Malignancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">18 Pancreatic cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">19 Upper respiratory tract infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>551</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.60 [0.31, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">20 Urinary tract infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>551</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.29 [0.24, 6.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">21 Cellulitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span>&nbsp;<span class="table-title">Sitagliptin versus glipizide</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-tbl-0011" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD011798-tbl-0012" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 7.</span>&nbsp;<span class="table-title">Vildagliptin versus sitagliptin</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Discontinuation of medication due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Peripheral oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Pancreatitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Liver impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span>&nbsp;<span class="table-title">Vildagliptin versus sitagliptin</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-tbl-0012" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD011798-tbl-0013" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 8.</span>&nbsp;<span class="table-title">Albiglutide versus sitagliptin</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span>&nbsp;<span class="table-title">Albiglutide versus sitagliptin</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-tbl-0013" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD011798-tbl-0014" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 9.</span>&nbsp;<span class="table-title">Aleglitazar versus pioglitazone</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 All cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 eGFR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Diastolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 Serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">14 Hypoglycaemia requiring third party assistance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">15 Peripheral oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">16 Fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">17 Malignancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span>&nbsp;<span class="table-title">Aleglitazar versus pioglitazone</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-tbl-0014" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD011798-tbl-0015" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 10.</span>&nbsp;<span class="table-title">Insulin glulisine and glargine 0.5 versus 0.25 U/kg/d</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Hypoglycaemia &lt; 3.89 mmol/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Hypoglycaemia &lt; 2.78 mmol/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span>&nbsp;<span class="table-title">Insulin glulisine and glargine 0.5 versus 0.25 U/kg/d</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011798.pub2/references#CD011798-tbl-0015" class="tableList">Navigate to table in Review</a></div> </div> </div> <section class="translation-notes-modal" style="display: none" data-modal-title="Translation notes" data-modal-class="translation-notes" data-ok-btn-selector=".ok-btn"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011798-note-1205">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011798-note-1212">Español</a> </li> <li class="section-language"> <a class="" href="fr#CD011798-note-1210">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD011798-note-1208">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011798-note-1211">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD011798-note-1207">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD011798-note-1206">Русский</a> </li> <li class="section-language"> <a class="" href="zh#CD011798-note-1209">简体中文</a> </li> <li class="section-language"> <a class="" href="za#CD011798-note-1213">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" id="citeProcText" data-load-error="Unable to load citation data"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a href="#" class="addthis_button_citeulike at300b btn btn-link">CiteULike</a></li> <li><a href="#" class="addthis_button_mendeley at300b btn btn-link">Mendeley</a></li> <li><a href="#" class="citation-btn-refworks at300b btn btn-link" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <h4>Copy or download citation</h4> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button type="button" class="btn btn-link">Plain text</button></li> <li class="citation-option" data-option="endnote"><button type="button" class="btn btn-link">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button type="button" class="btn btn-link">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button type="button" class="btn btn-link">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button type="button" class="btn btn-link">BibteX</button></li> </nav> <div class="citation-content"> <pre id="citationContent" tabindex="0" data-load-error="Unable to load citation data"></pre> </div> <div class="clearfix"> <form class="download-citation-form" method="GET" target="citation-download-iframe" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=citation-citeproc&p_p_cacheability=cacheLevelPage&p_p_col_id=column-1&p_p_col_count=1"> <input type="hidden" id="siteId" name="siteId" value="" /> <input type="hidden" id="downloadType" name="downloadType" value="" /> <input type="hidden" id="style" name="style" value="" /> <input type="hidden" id="articleId" name="articleId" value="" /> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay" /><input name="p_p_lifecycle" type="hidden" value="2" /><input name="p_p_state" type="hidden" value="normal" /><input name="p_p_mode" type="hidden" value="view" /><input name="p_p_resource_id" type="hidden" value="citation-download" /><input name="p_p_cacheability" type="hidden" value="cacheLevelPage" /><input name="p_p_col_id" type="hidden" value="column-1" /><input name="p_p_col_count" type="hidden" value="1" /> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withAbstract"> <input class="checkbox" type="checkbox" name="withAbstract" /> <span class="checkbox-label">Include abstract</span> </label> </div> </form> <iframe title="Citation download frame" name="citation-download-iframe" src="" style="display: none; visibility: hidden" aria-hidden="true"></iframe> </div> </div> </div> </div> <div class="print-modal" style="display: none;" data-modal-title="Print this review"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input title="Select/deselect all" type="checkbox" class="print-options-select-all" checked="checked" /> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i class="fa fa-print" aria-hidden="true"></i> Print</button> </div> </div> <div class="download-stats-data-modal" style="display: none;" data-modal-title="Download statistical data"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <p> Downloaded data can only be viewed using <a class="external" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/tools/review-production-tools/revman-5" target="_blank">Review Manager software.</a> </p> <p> Please note that: <ul> <li>data are only available for Cochrane Reviews that contain one or more forest plots; and</li> <li>data in the downloaded RevMan file are editable and therefore the review data can be amended without warning.</li> </ul> </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input type="hidden" name="content-disposition" value="attachment" /> <input type="hidden" name="mime-type" value="application/octet-stream" /> <p class="print-options-controls"> <input type="checkbox" class="download-stats-data-toc-check-box" aria-label="I agree to these terms and conditions" /> <span class="checkbox-label" aria-hidden="true">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i class="fa fa-download" aria-hidden="true"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" style="display:none;" data-modal-title="Share this review"> <div class="add-this"> <div class="addthis_toolbox addthis_default_style addthis_32x32_style"> <nav class="stacked-nav-list"> <li> <a href="#" class="addthis_button_twitter at300b" title="Tweet">Twitter</a> </li> <li> <a href="#" class="addthis_button_mendeley at300b" target="_blank" title="Mendeley">Mendeley</a> </li> <li> <a href="#" class="addthis_button_facebook at300b" title="Facebook">Facebook</a> </li> <li> <a href="#" class="addthis_button_linkedin at300b" target="_blank" title="LinkedIn">LinkedIn</a> </li> <li> <a href="#" class="addthis_button_email at300b" target="_blank" title="Email">Email</a> </li> <li> <a href="#" class="addthis_button_whatsapp at300b" target="_blank" title="WhatsApp">WhatsApp</a> </li> <li class="clearfix"> <a href="#" class="addthis_button_more btn primary pull-right" target="_blank" title="View more"> <i class="fa fa-plus" aria-hidden="true"></i> View more</a> </li> </ul> </div> </div> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button type="button" class="btn btn-link" id="figureOptionBtn">Figures</button></li> <li class="table-options-btn-container"><button type="button" class="btn btn-link" id="tableOptionBtn">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div id="figureThumbnails" class="figure-thumbnails is-visible"></div> <div id="tableThumbnails" class="table-thumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a href="#" class="figure-viewer-menu-toggle"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-table-show-text="Show table list" data-table-hide-text="Hide table list" data-figure-show-text="Show thumbnails" data-figure-hide-text="Hide thumbnails">Hide thumbnails</span> </a> <a href="#" class="figure-viewer-zoomin"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a href="#" class="figure-viewer-zoomout"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a href="#" class="figure-viewer-nav previous"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a href="#" class="figure-viewer-nav next"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_  portlet-static portlet-static-end kaleo-designer-portlet " id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a title="Cochrane logo" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/">
<img class="footer-logo logo-part-1" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/footer-logo-part-1.png" alt="Cochrane logo" /> <img class="footer-logo logo-part-2" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/footer-logo-part-2.png" alt="" /> </a> </div> <nav class="footer-links"> <ul class="root"> <li class="footer-item"> <a class="footer-item-link" href="/about-cochrane1">About Cochrane</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/evidence" target="_blank">Cochrane.org</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us" target="_blank">Who we are</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NJYXT5SPMNYXG4DTMFYGKLUQPJUB/" target="_blank">Get involved</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX665WNWTYE63PMNYXG4DTMFYGKLUQPJUB/" target="_blank">Consumer Network</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us/our-funders-and-partners" target="_blank">Partners</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYXZ5DQPF4XT7LNF3SX8Z5IPJRX63JPN73GH/" target="_blank">Colloquium</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/news" target="_blank">In the news</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/publications">Publications</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="/library">Cochrane Library</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/" target="_blank">Library Homepage</a> </li> <li class="footer-item"> <a class="footer-item-link" href="cdsr/about-cdsr" target="_blank">Cochrane Reviews (CDSR)</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/central" target="_blank">Trials (CENTRAL)</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/cca/about" target="_blank">Cochrane Clinical Answers</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/about/cochrane-library-app" target="_blank">Cochrane Library App</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/cdsr/journal-club" target="_blank">Journal Club</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/about/podcasts" target="_blank">Podcasts</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/community">Community</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/" target="_blank">Community</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MF3GG4DJMVYGG55DNB3GC5UFF3YYE3D/" target="_blank">Archie log-in</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/PS3GC4LPNFYGPLUDN7SXR6UBN3TT655TMH/" target="_blank">Training and support</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/NWTYI4DQMS3T6Z5QMNVHEZLPMVYG86UH/" target="_blank">Methods</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/help" target="_blank">Software</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/news/jobs" target="_blank">Jobs and opportunities</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/contact-us">Contact Us</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/contact" target="_blank">General enquiries</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/help/contact-us" target="_blank">Cochrane Library support</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/organizational-info/people/central-executive-team/chief-executive-officers-office/team" target="_blank">Chief Executive Officer</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/organizational-info/people/central-executive-team/editorial-methods/team" target="_blank">Editor in Chief</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us/our-global-community" target="_blank">Cochrane groups</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/media" target="_blank">Media</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/accessibility" target="_blank">Accessibility</a> </li> </ul> </li> </ul> </nav> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/advertisers">Advertisers & Agents</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NB4XELUYNFXGK8JPMNYXN/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NB4XELUYNFXGK8JPMNYXN/community/support/cochrane-library">Help & Support</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/terms-and-conditions">Terms & Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright &copy; 2000 - 2020 by <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUYNFXGK8JPMNYXN/" class="">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br /> Review our <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUYNFXGK8JPMNYXN/en-gb/privacy"><strong>Privacy Policy</strong></a> </p> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MW4T675JNSTYTLUDN7XB/"><img class="logo" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/en-US_wiley-footer-logo.png" alt="Wiley logo" /></a> </div> </div> <span class="wiley-semi-circle"></span> </div> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" style="display: none" data-modal-title="Feature in English only" data-modal-class="english-only-modal"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script src="/cochrane-theme/vendor/ie9.js?t=1581422282000" type="text/javascript"></script> <!--<![endif]--> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/js/theme.js?t=1581422282000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX67DFN34C66UFMFTGG7LCMVYGG55N/cochrane/checkout.js"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX67DFN34C66UFMFTGG7LCMVYGG55N/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MN3G865UNWRYE43NMNTG6LUDPJYYG65TMWUC655TMH/widget/v2.0/widget.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MRZXE8DIHB4XC63SNWYHPN3PMNXG87LEM33G85UVF3YGK7A/assets/embed.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718249000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718249000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011798\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011798\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011798\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011798\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011798\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011798\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011798\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011798\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011798\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011798\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011798\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011798\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011798\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011798\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011798\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011798\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011798\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011798\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581422282000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a href="#" class="rh-nav-close-btn"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a href="#" class="rh-nav-open-btn"> <span>Review tools & navigation</span> </a> </div> <iframe title="Print frame" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" aria-hidden="true"></iframe> <div class="mobile-navigation"> <div class="close-container"> <a href="#" class="main-nav-back-btn" aria-label="Navigate back"><i class="fa fa-chevron-left"></i></a> <a href="#" class="main-nav-close-btn" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end " id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img id="ymag__null__null" src="/scolaris-search/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_auth=EfT7x5RD&p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=1&p_p_state=normal&p_p_mode=view&_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input type="hidden" name="searchType" value="basic" /> <input type="hidden" name="facetDisplayName" value="" /> <input type="hidden" name="facetQueryTerm" value="" /> <input type="hidden" name="facetQueryField" value="" /> <input type="hidden" name="facetCategory" value="" /> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select title="Search by options" aria-label="Search by options" name="searchBy" class="custom-select-enabled search-type"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" style="display: none;" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=topics-list&p_p_cacheability=cacheLevelPage"> <select class="search-select-topic-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input type="text" size="30" class="field browser-search search-text ui-autocomplete-input" value="" aria-label="Enter search term" id="searchText" name="searchText" placeholder="Search">
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button type="submit" class="searchByBtn" aria-label="Search">
<i class="fa fa-search" aria-hidden="true"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=references&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011798.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011798.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<a href="/en/browse-by-topic" class="btn secondary">Browse </a>
<a href="/en/advanced-search" class="btn secondary advanced-search-button">Advanced search</a>
</div>
<div class="menu-items parent">
<ul>
<li class="nav-root-item parent">
<a href="#" title="Select language" class="language-selection-title-link">
<span class="mobile-nav-language-title">Select your preferred language</span><span class="icon fa fa-caret-down"></span>
<ul class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img id="fdkn__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hr, ja, ko, ms, pl, pt, ru, ta, th, zh, za]"> <a title="Select your preferred language" class="language-select-mobile" href="#"> <i class="fa fa-file-text"></i> English </a> <a title="Select your preferred language" class="language-select-mobile" href="#"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane Review language</h3> <p>Select your preferred language for Cochrane Reviews. You will see translated Review sections in your preferred language. Sections without translation will be in English.</p> <div id="active-content-language" class="dropdown-trigger"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de" class="content-language-selector " data-languagecode="de">Deutsch</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en" class="content-language-selector is-active" data-languagecode="en">English</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es" class="content-language-selector " data-languagecode="es">Español</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa" class="content-language-selector " data-languagecode="fa">فارسی</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr" class="content-language-selector " data-languagecode="fr">Français</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr" class="content-language-selector " data-languagecode="hr">Hrvatski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja" class="content-language-selector " data-languagecode="ja">日本語</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko" class="content-language-selector " data-languagecode="ko">한국어</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms" class="content-language-selector " data-languagecode="ms">Bahasa Malaysia</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl" class="content-language-selector " data-languagecode="pl">Polski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt" class="content-language-selector " data-languagecode="pt">Português</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru" class="content-language-selector " data-languagecode="ru">Русский</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta" class="content-language-selector " data-languagecode="ta">தமிழ்</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th" class="content-language-selector " data-languagecode="th">ภาษาไทย</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh" class="content-language-selector " data-languagecode="zh">简体中文</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=za" class="content-language-selector " data-languagecode="za">繁體中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div id="active-portal-language" class="dropdown-trigger"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a href="/en/cdsr/doi/10.1002/14651858.CD011798.pub2/references/en" class="portal-language-selector is-active" data-portallanguage="en">English</a> <a href="/es/cdsr/doi/10.1002/14651858.CD011798.pub2/references/es" class="portal-language-selector " data-portallanguage="es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</ul>
</a>
</li>
<li class="parent">
<a class="mobile-link signin" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/c/portal/login?p_l_id=20757&redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011798.pub2%2Freferences" data-redirect="false" rel="nofollow">
Sign In
</a>
</li>
</ul>
<div class="menu-items-footer">
<div class="utility-links">
<a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/" class="cochrane-link" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
<div class="basic-login-form-content" style="display: none;" data-modal-title="Sign in">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_  portlet-static portlet-static-end portlet-login " id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img id="dbam__null__null" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/spacer.png" alt="" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;" /> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" class="form sign-in-form " id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm" autocomplete="on"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1583244165670" /> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false" /> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x2f;references" /> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false" /> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value="" /> </div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value="" /> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true" /> <input checked class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onClick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true" /> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button type="submit" class="btn primary">Sign in</button> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/user-registration" target="_blank" class="btn secondary">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </fieldset> </form> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" style="display: none;" data-modal-title="Institutional login">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="obft__null__null" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form method="post" action="/shibboleth" id="institutionLoginForm"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" name="institutionName" id="institutionName" value="" type="text">
</div>
<button class="btn primary" type="submit" name="button">Go</button>
</div>
<div id="institutionLookupErrorDiv" class="message error" style="display:none">
'<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
</div>
</div>
<input type="hidden" id="entityId" name="entityId" value="">
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_  portlet-static portlet-static-end portlet-login " id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img id="joiu__null__null" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/spacer.png" alt="" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;" /> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" class="form sign-in-form " id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm" autocomplete="on"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1583244165674" /> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false" /> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011798&#x2e;pub2&#x2f;references" /> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false" /> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value="" /> </div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value="" /> </div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true" /> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button type="submit" class="btn primary">Sign in</button> </div> </div> </fieldset> </form> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" style="display: none;" data-modal-title="Unlock the potential of Cochrane evidence">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="wpdq__null__null" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form method="post" action="/shibboleth" id="institutionLoginForm"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" name="institutionName" id="institutionName" value="" type="text"> </div> <button class="btn primary" type="submit" name="button">Go</button> </div> <div id="institutionLookupErrorDiv" class="message error" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input type="hidden" id="entityId" name="entityId" value=""> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'> <input type="hidden" name="openlabel" id="openlabel" value='Open access'> </div> </section> </div> </div>  <script>window.urlTitle="/cdsr/doi/10.1002/14651858.CD011798.pub2";addthis_config={pubid:"ra-593597d01cdf9a55",ui_508_compliant:true};addthis_share={url:window.location.href,title:document.title};</script> <script src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-593597d01cdf9a55"></script> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> </body> </html> 